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A B S T R A C T
Background
Researchers have suggested that omega-3 polyunsaturated fatty acids from oily fish (long-chain omega-3 (LCn3), including eicosapen-
taenoic acid (EPA) and docosahexaenoic acid (DHA)), as well as from plants (alpha-linolenic acid (ALA)) benefit cardiovascular health.
Guidelines recommend increasing omega-3-rich foods, and sometimes supplementation, but recent trials have not confirmed this.
Objectives
To assess effects of increased intake of fish- and plant-based omega-3 for all-cause mortality, cardiovascular (CVD) events, adiposity
and lipids.
Search methods
We searched CENTRAL, MEDLINE and Embase to April 2017, plus ClinicalTrials.gov andWorld Health Organization International
Clinical Trials Registry to September 2016, with no language restrictions. We handsearched systematic review references and bibliogra-
phies and contacted authors.
Selection criteria
We included randomised controlled trials (RCTs) that lasted at least 12 months and compared supplementation and/or advice to
increase LCn3 or ALA intake versus usual or lower intake.
Data collection and analysis
Two review authors independently assessed studies for inclusion, extracted data and assessed validity. We performed separate random-
effects meta-analysis for ALA and LCn3 interventions, and assessed dose-response relationships through meta-regression.
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Main results
We included 79 RCTs (112,059 participants) in this review update and found that 25 were at low summary risk of bias. Trials were of
12 to 72 months’ duration and included adults at varying cardiovascular risk, mainly in high-income countries. Most studies assessed
LCn3 supplementation with capsules, but some used LCn3- or ALA-rich or enriched foods or dietary advice compared to placebo or
usual diet.
Meta-analysis and sensitivity analyses suggested little or no effect of increasing LCn3 on all-cause mortality (RR 0.98, 95% CI 0.90
to 1.03, 92,653 participants; 8189 deaths in 39 trials, high-quality evidence), cardiovascular mortality (RR 0.95, 95% CI 0.87 to
1.03, 67,772 participants; 4544 CVD deaths in 25 RCTs), cardiovascular events (RR 0.99, 95% CI 0.94 to 1.04, 90,378 participants;
14,737 people experienced events in 38 trials, high-quality evidence), coronary heart disease (CHD) mortality (RR 0.93, 95% CI
0.79 to 1.09, 73,491 participants; 1596 CHD deaths in 21 RCTs), stroke (RR 1.06, 95% CI 0.96 to 1.16, 89,358 participants; 1822
strokes in 28 trials) or arrhythmia (RR 0.97, 95% CI 0.90 to 1.05, 53,796 participants; 3788 people experienced arrhythmia in 28
RCTs). There was a suggestion that LCn3 reduced CHD events (RR 0.93, 95% CI 0.88 to 0.97, 84,301 participants; 5469 people
experienced CHD events in 28 RCTs); however, this was not maintained in sensitivity analyses - LCn3 probably makes little or no
difference to CHD event risk. All evidence was of moderate GRADE quality, except as noted.
Increasing ALA intake probably makes little or no difference to all-cause mortality (RR 1.01, 95% CI 0.84 to 1.20, 19,327
participants; 459 deaths, 5 RCTs),cardiovascular mortality (RR 0.96, 95% CI 0.74 to 1.25, 18,619 participants; 219 cardiovascular
deaths, 4 RCTs), and it may make little or no difference to CHD events (RR 1.00, 95% CI 0.80 to 1.22, 19,061 participants,
397 CHD events, 4 RCTs, low-quality evidence). However, increased ALA may slightly reduce risk of cardiovascular events (from
4.8% to 4.7%, RR 0.95, 95% CI 0.83 to 1.07, 19,327 participants; 884 CVD events, 5 RCTs, low-quality evidence), and probably
reduces risk of CHD mortality (1.1% to 1.0%, RR 0.95, 95% CI 0.72 to 1.26, 18,353 participants; 193 CHD deaths, 3 RCTs), and
arrhythmia (3.3% to 2.6%, RR 0.79, 95% CI 0.57 to 1.10, 4,837 participants; 141 events, 1 RCT). Effects on stroke are unclear.
Sensitivity analysis retaining only trials at low summary risk of bias moved effect sizes towards the null (RR 1.0) for all LCn3 primary
outcomes except arrhythmias, but for most ALA outcomes, effect sizes moved to suggest protection. LCn3 funnel plots suggested that
adding in missing studies/results would move effect sizes towards null for most primary outcomes. There were no dose or duration
effects in subgrouping or meta-regression.
There was no evidence that increasing LCn3 or ALA altered serious adverse events, adiposity or lipids, although LCn3 slightly reduced
triglycerides and increased HDL. ALA probably reduces HDL (high- or moderate-quality evidence).
Authors’ conclusions
This is the most extensive systematic assessment of effects of omega-3 fats on cardiovascular health to date. Moderate- and high-quality
evidence suggests that increasing EPA and DHA has little or no effect on mortality or cardiovascular health (evidence mainly from
supplement trials). Previous suggestions of benefits from EPA and DHA supplements appear to spring from trials with higher risk of
bias. Low-quality evidence suggests ALA may slightly reduce CVD event risk, CHD mortality and arrhythmia.
P L A I N L A N G U A G E S U M M A R Y
Omega-3 intake for cardiovascular disease
Review question
We reviewed randomised trials (where participants have an equal chance of being assigned to either treatment) examining effects of
increasing fish- and plant-based omega-3 fats on heart and circulatory disease (called cardiovascular diseases, CVD, which include
heart attacks and stroke), fatness and blood fats (lipids, including cholesterol, triglycerides, high-density lipoprotein (HDL - ’good’
cholesterol) and low-density lipoprotein (LDL - ’bad’ cholesterol)).
Background
Omega-3 fats are essential - to stay healthy we must obtain some from food. The main types of omega-3 fats are alpha-linolenic acid
(ALA), a fat found in plant foods, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), both found in fish. There is a
common belief that eating more fish or taking omega-3 supplements reduces our risk of heart disease, stroke and death.
Study characteristics
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The evidence is current to April 2017. The review included 79 trials involving over 112,000 people. These studies assessed effects of
greater omega-3 intake versus lower or no omega-3 intake for heart and circulatory disease. Twenty-five studies were very trustworthy
(well-designed so as not to give biased results). Participants were adults, some with existing illness and some healthy, living in North
America, Europe, Australia and Asia. Participants increased omega-3 fats, or maintained their usual fats for at least a year. Most EPA
and DHA trials provided capsules, few gave oily fish.
Key results
Increasing EPA and DHA has little or no effect on all-cause deaths and cardiovascular events (high-quality evidence) and probably
makes little or no difference to cardiovascular death, coronary deaths or events, stroke, or heart irregularities (moderate-quality evidence,
coronary events are illnesses of the arteries which supply the heart). EPA and DHA slightly reduce serum triglycerides and raise HDL
(high-quality evidence).
Eating more ALA (for example, by increasing walnuts or enriched margarine) probably makes little or no difference to all-cause or
cardiovascular deaths or coronary events but probably slightly reduce cardiovascular events, coronary mortality and heart irregularities
(moderate/low-quality evidence). Effects of ALA on stroke are unclear as the evidence was of very low quality.
There is evidence that taking omega-3 capsules does not reduce heart disease, stroke or death. There is little evidence of effects of eating
fish. Although EPA and DHA reduce triglycerides, supplementary omega-3 fats are probably not useful for preventing or treating heart
and circulatory diseases. However, increasing plant-based ALA may be slightly protective for some heart and circulatory diseases.
3Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
High versus low LCn3 for preventing cardiovascular disease and mortality (primary outcomes)
Patient or population: adults with or without exist ing CVD
Setting: part icipants were living at home for most or all of the durat ion of their trials. Most studies were carried out in high-income economies (World Bank 2018), but four
trials were carried out in upper-m iddle income countries (Argent ina, Iran, Turkey and China). No studies took place in low- or low-middle income countries.
Intervention: higher intake of long-chain omega-3 fats
Comparison: lower intake of long-chain omega-3 fats
The intervent ion was dietary supplementat ion, a provided diet or advice on diet. Supplementat ion may have been in oil or capsule form or as foodstuf f s provided, to be
consumed by mouth (excluding enteral and parenteral feeds and enemas). The foodstuf f s or supplements must have been: oily f ish or f ish oils as a food, oil, made into a
spreading fat or supplementing another food (such as bread or eggs). Ref ined eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) or concentrated f ish or algal oils,
were also accepted
Outcomes Anticipated absolute effects* (95% CI) Relative effect
(95% CI)
of participants
(studies)
Certainty of the evi-
dence
(GRADE)
Comments
Risk with lower LCn3 Risk with higher LCn3
All- cause mortality -
deaths
Assessed with: number
of part icipants dying of
any cause, whether re-
ported as an outcome
or a reason for dropout
Durat ion: range 12 to 72
months
90 per 1,000 88 per 1,000
(83 to 92)
RR 0.98
(0.93 to 1.03)
92,653
(39 RCTs)
⊕⊕⊕⊕
Higha
Meta-analysis and in-
dicat ions of bias sug-
gest risk reduct ion of
less than 2%. Long-
chain omega-3 fat in-
take makes lit t le or no
dif ference to all-cause
mortality
Cardiovascular mortal-
ity - cardiovascular
deaths
Assessed with: deaths
f rom any cardiovascu-
lar cause. Where this
was not available, car-
diac death was used in-
stead where known
69 per 1,000 66 per 1,000
(60 to 71)
RR 0.95
(0.87 to 1.03)
67,772
(25 RCTs)
⊕⊕⊕©
Moderateb
Meta-analysis and in-
dicat ions of bias sug-
gest risk reduct ion of
less than 5%. Long-
chain omega-3 fat in-
take probably makes lit -
t le or no dif ference to
cardiovascular deaths
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Durat ion: range 12 to 72
months
Cardiovascular events
- cardiovascular events
Assessed with: number
of part icipants experi-
encing any cardiovas-
cular event
Durat ion: range 12 to 72
months
165 per 1,000 164 per 1,000
(155 to 172)
RR 0.99
(0.94 to 1.04)
90,378
(38 RCTs)
⊕⊕⊕⊕
Highc
Meta-analysis and in-
dicat ions of bias sug-
gest risk reduct ion of
less than 1%. Long-
chain omega-3 fat in-
take makes lit t le or no
dif ference to risk of car-
diovascular events
Coronary heart disease
mortality - CHD deaths
Assessed with: coro-
nary deaths, or where
these were not re-
ported, IHD death, fatal
MI or cardiac death (in
that order)
Durat ion: range 12 to 72
months
22 per 1,000 21 per 1,000
(18 to 24)
RR 0.93
(0.79 to 1.09)
73,491
(21 RCTs)
⊕⊕⊕©
Moderated
Meta-analysis and in-
dicat ions of bias sug-
gest risk reduct ion of
less than 7%. Long-
chain omega-3 fat in-
take probably makes lit -
t le or no dif ference to
coronary heart mortal-
ity
Coronary heart disease
events - CHD events
Assessed with: num-
ber of part icipants ex-
periencing the f irst
outcome in this list
reported for each
trial: CHD or coronary
events; total MI; acute
coronary syndrome; or
angina (stable and un-
stable)
Durat ion: range 12 to 72
months
68 per 1,000 63 per 1,000
(59 to 65)
RR 0.93
(0.88 to 0.97)
84,301
(28 RCTs)
⊕⊕⊕©
Moderatee
Meta-analysis and in-
dicat ions of bias sug-
gest risk reduct ion of
less than 7%. Long-
chain omega-3 fat in-
take probably makes lit -
t le or no dif ference to
risk of coronary heart
events
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Stroke
Assessed with: number
of part icipants experi-
encing at least one fatal
or non-fatal, ischaemic
or haemorrhagic stroke
Durat ion: range 12 to 72
months
20 per 1,000 21 per 1,000
(19 to 23)
RR 1.06
(0.96 to 1.16)
89,358
(28 RCTs)
⊕⊕⊕©
Moderatef
Meta-analysis and in-
dicat ions of bias sug-
gest increased risk of
less than 6%. Long-
chain omega-3 fat in-
take probably makes lit -
t le or no dif ference to
risk of experiencing a
stroke
Arrhythmias
Assessed with: num-
ber of part icipants ex-
periencing fatal or non-
fatal, new or recur-
rent arrhythmia, includ-
ing atrial f ibrillat ion,
ventricular tachycardia
and ventricular f ibrilla-
t ion
Durat ion: range 12 to 72
months
68 per 1,000 66 per 1,000
(62 to 72)
RR 0.97
(0.90 to 1.05)
53,796
(28 RCTs)
⊕⊕⊕©
Moderateg
Meta-analysis and in-
dicat ions of bias sug-
gest risk reduct ion of
less than 3%. Long-
chain omega-3 fat in-
take probably makes lit -
t le or no dif ference to
risk of arrhythmia
Harms: bleeding
Assessed with: number
of part icipants experi-
encing bleeding events
Durat ion: range 12 to 72
months
8 per 1,000 8 per 1,000
(5 to 11)
RR 1.06
(0.73 to 1.52)
45,562
(8 RCTs)
⊕©©©
Very lowh
The ef fect of long-chain
omega-3 fat intake on
bleeding is unclear as
the evidence is of very
low quality
Harms: pulmonary em-
bolus or DVT
Assessed with: number
of part icipants experi-
encing pulmonary em-
bolus or deep vein
thrombosis
Durat ion: range 18 to 36
5 per 1,000 6 per 1,000
(2 to 18)
RR 1.25
(0.41 to 3.78)
3,011
(4 RCTs)
⊕©©©
Very low i
The ef fect of long-chain
omega-3 fat intake on
pulmonary embolus or
DVT is unclear as the
evidence is of very low
quality
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months
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CHD: coronary heart disease; CI: conf idence interval; DVT : deep vein thrombosis; IHD: ischaemic heart disease; MI: myocardial infarct ion; RCT : randomised controlled trial;
RR: risk rat io.
GRADE Working Group grades of evidence
High certainty: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate certainty: we are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low certainty: our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low certainty: we have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
aAll- cause mortality, LCn3
• Risk of bias: ef fect size moved closer to no ef fect (RR 1.0) when analysis was lim ited to studies at low summary risk of
bias and low risk of compliance bias (adding weight to the suggest ion of lit t le or no ef fect) but did not alter with f ixed-ef fect
meta-analysis or results in the analysis lim ited to larger studies. It was further noted by the WHO NUGAG Subgroup on Diet
and Health that although many of the RCTs had issues with blinding, the tendency for lack of blinding is an overest imation of
ef fect. This is less of a concern for this outcome, as the pooled ef fect was approaching null and not stat ist ically signif icant.
Not downgraded.
• Inconsistency: I2 was < 60% and I2 reduced when analysis was lim ited to studies at low summary risk of bias. This adds
weight to the suggest ion of lit t le or no ef fect. Not downgraded.
• Indirectness: representat ive, generalisable adult populat ion including men and women, including healthy part icipants
and part icipants with CVD risk factors or previous CVD as well as non-CVD health problems. Low- and middle-income
countries were represented but underrepresented. Not downgraded.
• Imprecision: t ight conf idence intervals, very large numbers of part icipants have taken part in RCTs in long-term studies
with consistent results. Given the lack of a stat ist ically signif icant ef fect in this very large set of part icipants, any ef fect
appears too small to be individually relevant. Not downgraded.
• Publication bias: the funnel plot suggested that some small studies with higher numbers of events in the intervent ion
group might be missing. If such missing studies were added back in, the RR would rise. This adds weight to the suggest ion of
lit t le or no ef fect. Not downgraded.
bCardiovascular mortality, LCn3
• Risk of bias: ef fect size moved closer to no ef fect (RR 1.0) when analysis was lim ited to studies at low summary risk of
bias and low risk of compliance bias (adding weight to the suggest ion of lit t le or no ef fect) but did not alter with f ixed-ef fect
meta-analysis or results in the analysis lim ited to larger studies. It was further noted by the WHO NUGAG Subgroup on Diet
and Health that although many of the RCTs had issues with blinding, the tendency for lack of blinding is an overest imation of
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ef fect. This is less of a concern for this outcome, as the pooled ef fect was approaching null and not stat ist ically signif icant.
Not downgraded.
• Inconsistency: I2 was < 60% and I2 reduced when analysis was lim ited to studies at low summary risk of bias. This adds
weight to the suggest ion of lit t le or no ef fect. Not downgraded.
• Indirectness: representat ive, generalisable adult populat ion including men and women, including healthy part icipants
and part icipants with CVD risk factors or previous CVD as well as non-CVD health problems. All studies were conducted in
high-income countries. Not downgraded.
• Imprecision: Although very large numbers of part icipants have taken part in RCTs in long-term studies, with consistent
results, the 95%CI includes the null. Given the lack of a stat ist ically signif icant ef fect in this very large set of part icipants, any
ef fect appears too small to be individually relevant. However, as 95% conf idence intervals do not exclude important benef its
or harms. Downgraded once.
• Publication bias: the funnel plot suggested that some small studies with higher numbers of events in the intervent ion
group might be missing. If such missing studies were added back in, the RR would rise. This adds weight to the suggest ion of
lit t le or no ef fect. Not downgraded.
cCardiovascular events, LCn3
• Risk of bias: ef fect size moved closer to no ef fect (RR 1.0) when analysis was lim ited to studies at low summary risk of
bias and low risk of compliance bias (adding weight to the suggest ion of lit t le or no ef fect) but did not alter with f ixed-ef fect
meta-analysis or results in the analysis lim ited to larger studies. It was further noted by the WHO NUGAG Subgroup on Diet
and Health that although many of the RCTs had issues with blinding, the tendency for lack of blinding is an overest imation of
ef fect. This is less of a concern for this outcome, as the pooled ef fect was approaching null and not stat ist ically signif icant.
Not downgraded.
• Inconsistency: I2 was < 60% and I2 reduced when analysis was lim ited to studies at low summary risk of bias. This adds
weight to the suggest ion of lit t le or no ef fect. Not downgraded.
• Indirectness: representat ive, generalisable adult populat ion including men and women, including healthy part icipants
and part icipants with CVD risk factors or previous CVD as well as non-CVD health problems. Low- and middle-income
countries were represented but underrepresented. Not downgraded.
• Imprecision: very large numbers of part icipants have taken part in RCTs in long-term studies with consistent results.
Given the lack of an important ef fect in this very large set of part icipants, any ef fect appears too small to be individually
relevant. However, as 95% conf idence intervals do not exclude important benef its or harms, we downgraded once.
• Publication bias: the funnel plot suggested that some small studies with higher numbers of events in the intervent ion
group might be missing. If such missing studies were added back in, the RR would rise. This adds weight to the suggest ion of
lit t le or no ef fect. Not downgraded.
d Coronary heart disease mortality, LCn3
• Risk of bias: ef fect size moved closer to no ef fect (RR 1.0) when analysis was lim ited to studies at low summary risk of
bias and low risk of compliance bias (adding weight to the suggest ion of lit t le or no ef fect) but did not alter with f ixed-ef fect
meta-analysis or results in the analysis lim ited to larger studies. It was further noted by the WHO NUGAG Subgroup on Diet
and Health that although many of the RCTs had issues with blinding, the tendency for lack of blinding is an overest imation of
ef fect. This is less of a concern for this outcome, as the pooled ef fect was approaching null and not stat ist ically signif icant.
Not downgraded.
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• Inconsistency: I2 was < 60% and I2 reduced when analysis was lim ited to studies at low summary risk of bias. This adds
weight to the suggest ion of lit t le or no ef fect. Not downgraded.
• Indirectness: representat ive, generalisable adult populat ion including men and women, including healthy part icipants
and part icipants with CVD risk factors or previous CVD as well as non-CVD health problems. All studies were conducted in
high-income countries. Not downgraded.
• Imprecision: very large numbers of part icipants have taken part in RCTs in long-term studies with consistent results.
Given the lack of a stat ist ically signif icant ef fect in this very large set of part icipants, any ef fect appears too small to be
individually relevant. However, as 95% conf idence intervals do not exclude important benef its or harms we downgraded once.
• Publication bias: the funnel plot suggested that some small studies with higher numbers of events in the intervent ion
group might be missing. If such missing studies were added back in the RR would rise. This adds weight to the suggest ion of
lit t le or no ef fect. Not downgraded.
e Coronary heart disease events, LCn3
• Risk of bias: ef fect size moved closer to no ef fect (RR 1.0) when was analysis lim ited to studies at low summary risk of
bias. This adds weight to the suggest ion of lit t le or no ef fect. However, ef fect size did not alter with f ixed-ef fect meta-
analysis or lim it ing to studies at low risk of compliance bias or larger trials. It was further noted by the WHO NUGAG
Subgroup on Diet and Health that there was a signif icant ef fect observed in main analysis but the ef fect moved closer to a
non-signif icant, null ef fect when analysis was lim ited to studies at low summary risk of bias. Downgraded once.
• Inconsistency: I2 was < 60% and I2 reduced when analysis was lim ited to studies at low summary risk of bias. This adds
weight to the suggest ion of lit t le or no ef fect. Not downgraded.
• Indirectness: representat ive, generalisable adult populat ion including men and women, including healthy part icipants
and part icipants with CVD risk factors or previous CVD as well as non-CVD health problems. Low- and middle-income
countries were represented but underrepresented. Not downgraded.
• Imprecision: 95%CI did not include the null. Not downgraded.
• Publication bias: the funnel plot suggested that some small studies with higher numbers of events in the intervent ion
group might be missing. If such missing studies were added back in, the RR would rise. This adds weight to the suggest ion of
lit t le or no ef fect. Not downgraded.
f Stroke, LCn3
• Risk of bias: ef fect size moved closer to no ef fect (RR 1.0) when analysis lim ited to studies at low summary risk of bias
(adding weight to the suggest ion of lit t le or no ef fect), but did not alter with f ixed-ef fect meta-analysis or lim it ing to larger
studies. Lim it ing to studies at low risk of compliance problems resulted in the suggest ion of greater harm. It was further
noted by the WHO NUGAG Subgroup on Diet and Health that although many of the RCTs had issues with blinding, the
tendency for lack of blinding is an overest imation of ef fect. This is less of a concern for this outcome, as the pooled ef fect
was approaching null and not stat ist ically signif icant. Not downgraded.
• Inconsistency: I2 was < 60%. Not downgraded.
• Indirectness: representat ive, generalisable adult populat ion including men and women, including healthy part icipants
and part icipants with CVD risk factors or previous CVD as well as non-CVD health problems. Low- and middle-income
countries were represented but underrepresented. Not downgraded.
• Imprecision: very large numbers of part icipants have taken part in RCTs in long-term studies with consistent results.
Given the lack of a stat ist ically signif icant ef fect in this very large set of part icipants any ef fect appears too small to be
individually relevant. However, as 95%conf idence intervals do not exclude important benef its or harms, we downgraded once.9
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• Publication bias: the funnel plot did not suggest any small study bias. Not downgraded.
g Arrhythmias, LCn3
• Risk of bias: ef fect size remained sim ilar in most sensit ivity analyses, but moved closer to no ef fect (RR 1.01) when
analysis used f ixed-ef fect meta-analysis (adding weight to the suggest ion of lit t le or no ef fect) and suggested harm when
lim ited to studies at low summary risk of bias. Not downgraded.
• Inconsistency: I2 was < 60% and I2 reduced when analysis was lim ited to studies at low summary risk of bias. This adds
weight to the suggest ion of lit t le or no ef fect. Not downgraded.
• Indirectness: representat ive, generalisable adult populat ion including men and women, including healthy part icipants
and part icipants with CVD risk factors or previous CVD as well as non-CVD health problems. Low- and middle-income
countries were represented but underrepresented. Not downgraded.
• Imprecision: As 95% conf idence intervals do not exclude important benef its we downgraded once.
• Publication bias: f unnel plot not interpretable as studies all of a sim ilar size and weight. Not downgraded.
h Bleeding, LCn3
• Risk of bias: ef fect size changed direct ion (f rom harmful to protect ive) when analysis lim ited to studies at low summary
risk of bias. Downgraded once.
• Inconsistency: I2 was < 60%. Not downgraded.
• Indirectness: representat ive, generalisable adult populat ion including men and women, including healthy part icipants
and part icipants with CVD risk factors or previous CVD as well as non-CVD health problems. Low- and middle-income
countries not represented. Not downgraded.
• Imprecision: 95% conf idence intervals do not exclude large and important benef its or harms. Downgraded twice.
• Publication bias: insuf f icient studies for funnel plot. Not downgraded.
i Pulmonary embolus or DVD, LCn3
• Risk of bias: ef fect size suggested greater harm when analysis lim ited to studies at low summary risk of bias.
Downgraded once.
• Inconsistency: I2 was < 60%. Not downgraded.
• Indirectness: representat ive, generalisable adult populat ion including men and women, including healthy part icipants
and part icipants with CVD risk factors or previous CVD as well as non-CVD health problems. Low- and middle-income
countries not represented. Not downgraded.
• Imprecision: 95% conf idence intervals do not exclude large benef its or large harms. Downgraded twice.
• Publication bias: insuf f icient studies for funnel plot. Not downgraded.
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B A C K G R O U N D
Description of the condition
Cardiovascular diseases (CVDs) are disorders of the heart and
blood vessels. They include cerebrovascular disease (including
stroke and transient ischaemic attack), coronary heart disease (in-
cluding heart attack or myocardial infarction and angina), periph-
eral arterial disease (diseases of the blood vessels to the arms and
legs), deep vein thrombosis and pulmonary embolism (blood clots
formed in the legs which can move to the heart and lungs), as well
as rheumatic and congenital heart disease (WHO 2017); these last
two are not discussed in this review. Globally, 31% of all global
deaths are due to CVD, more than from any other cause (WHO
2017). Of the 17.7 million people who died from CVDs in 2015,
7.4 million were due to coronary heart disease and 6.7 million
due to stroke. Of 17 million premature deaths in 2015 caused
by non-communicable diseases, 82% were in low- and middle-
income countries, and 37% were caused by CVDs (WHO 2017).
Description of the intervention
Omega-3 fats (also called 3 or n-3 fats) from fish sources in-
clude eicosapentaenoic acid (EPA, or 20:5), docosahexaenoic acid
(DHA, 22:6) and docosapentaenoic acid (DPA, 22:5), the longer
chain omega-3 fats (LCn3). Alpha-linolenic acid (ALA or α-
linolenic, 18:3) is the shorter chain omega-3 fat found in plants
and grass-fed, which is partially converted to longer chain omega-
3 fatty acids within our bodies. There is some debate about the
effectiveness of this conversion, which may differ depending on
whether it is assessed over the short or long term as well as on
other dietary factors (Li 1999; Pawlosky 2001). For this reason
the effectiveness of ALA may differ from that of the longer chain
omega-3 fats.
Since Bang and colleagues first suggested that the abundance of
omega-3 fatty acids in the diet of the Greenland Inuit people was
responsible for their low mortality from ischaemic heart disease
(Bang 1972; Bang 1976), there has been considerable interest in
the protective role and possible mechanism of action of marine
unsaturated fats. This interest has spread to encompass plant seeds
and oils rich in omega-3 fatty acids, including chia seed, flax (lin-
seed) and rapeseed (canola) oils (Nettleton 1991), their derivatives
(e.g. margarines), purslane leaves (Simopoulos 1992), and nuts
(especially walnuts).
How the intervention might work
Proposed mechanisms for the protective role of omega-3 fats
against cardiovascular diseases include: lowering the blood pres-
sure; altering the lipid profile, especially reduced serum triglyc-
eride concentration; modulating arterial lipoprotein lipase levels;
reducing thrombotic tendency; producing anti-inflammatory ef-
fects and anti-arrhythmic effects; improving vascular endothelial
function and insulin sensitivity; and increasing plaque stability
and paraoxonase levels (Bhatnagar 2003; BNF 1999; Calabresi
2004; Chang 2013; Geelen 2004).
Given that most omega-3 fats are ingested in the form of oily fish
or fish oil (often fish liver) capsules, reports of high levels of various
toxic compounds such as mercury, dioxins and polychlorinated
biphenyls (PCBs) in oily fish and fish oils are concerning (FSA
2000; Liem 1997;MAFF 1998A; USFDA 1995). These are all fat
soluble and accumulate over time in the body, so harms may be
exhibited only after long-term fish consumption or supplemen-
tation with fish oils. Animal intervention studies and human co-
horts who have suffered accidental exposure to dioxins and PCBs
suggest that pre-natal exposure may cause sub-fertility problems,
and adult exposures may lead to an excess of total cancers (JECFA
2001). Human cohorts exposed to high levels of mercury exhibit
neurological problems (USFDA 1995). As many people eat oily
fish once or twice a week or take fish oil supplements, it is im-
portant to explore the potentially harmful effects of fish-associ-
ated omega-3 intake. It is also possible that omega-3 fats them-
selves may exhibit harm, for example through extension of bleed-
ing times or suppression of normal immune responses (USFDA
2000).
Cardiovascular effects of eating more oily fish may differ from
those of taking a fish oil supplement because fish (not fish oil) is a
rich source of nutrients including selenium, iodine, zinc, calcium
and protein. Fish in the diet may also displace a variety of other
foods including sources of saturated or trans fats, so it could alter
CVD in other ways.
Why it is important to do this review
There is a great deal of public belief in the cardiovascular benefits
of omega-3 fats. Analysis of US National Health and Nutrition
Examination Survey data from 2003 to 2008 suggests that in the
USA, adults’ mean long-chain omega-3 intakes were greater from
dietary supplements (0.72 g/d EPA and DHA) than from foods
(0.41 g/d, Papanikolaou 2014). But public health advice differs
across countries. For example, the National Institute for Health
and Clinical Excellence in the UK now encourages fish intake
but discourages supplementation: “people with or at high risk of
CVD should be advised to consume at least 2 portions of fish per
week, including a portion of oily fish”. However, it advises that
omega-3 fatty acid compounds “should not be offered for primary
or secondary prevention of CVD” (NICE 2016). The American
Heart Association (AHA) also “recommends eating fish (particu-
larly fatty fish) at least two times (two servings) a week”. Although
the AHA suggests that omega-3 intake via foods is preferable, the
AHA is more positive about omega-3 supplements: “those with
coronary artery disease may not get enough omega-3 by diet alone.
These people may want to talk to their doctor about supplements.
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And for those with high triglycerides, even larger doses could help”
(AHA 2016). These recommendations are balanced with a warn-
ing about potential excessive bleeding in those taking doses of >
3 g/d omega-3 fatty acids (presumably long-chain omega-3 fats).
Such recommendations, and resulting increasedfish consumption,
have potentially negative long-term consequences for our marine
ecosystems (Brunner 2009).
Epidemiological studies have supported the relationship between
high omega-3 intake and lower cardiovascular disease (CVD) rates
(Ballard-Barbash 1987; Burr 1993; Kris-Etherton 2002). How-
ever, these associations could be due to some other characteristic of
people who choose to eat fish. In many societies eating fish is asso-
ciated with better social status and a health-conscientious life view
(Cade 2007), so eating fish is highly confounded by dietary qual-
ity, socioeconomic status and other markers of healthy lifestyles.
As an example, the global attributable burden of eating a diet low
in seafood omega-3 fats was estimated as 1.1% of global disability-
adjusted life-years (DALYs; 95% CI 0.8 to 1.5), “with 22% of
ischaemic heart disease DALYs attributable to low seafood intake”
(Engell 2013). The data sources are not described, but when the
estimate was derived from RCTs alone, rather than cohort studies
and RCTs combined, the estimated global attributable burden was
much smaller, 0.5% (95% CI−0.5 to 1.4). Information concern-
ing cause and effect is more reliably supplied by intervention trials
in which participants are randomly allocated to receive fish oil or
advice to eat more fish.
Systematic reviews of randomised controlled trials (RCTs) have
had various findings. An earlier version of this review found no
effects for omega-3 fats on all-cause mortality or cardiovascular
outcomes in trials of at least six months’ duration (which in-
cluded > 36,000 participants) (Hooper 2004). SinceHooper 2004
was published, several other systematic reviews have suggested a
lack of effect for omega-3 fats on all-cause mortality or a variety
of CVDs (Campbell 2013; Chowdhury 2012; Khoueiry 2013;
Kotwal 2012; Kwak 2012; Mariani 2013; Rizos 2012; Zheng
2014). However, others have highlighted particular outcomes or
circumstances in which CVD prevention was evident: after heart
surgery (He 2013), for preventing sudden cardiac death (Zhao
2009), for reducing CVDmortality and sudden cardiac death (al-
though with no effect on all-cause mortality) (Trikalinos 2012),
for CVD mortality (Sethi 2016), and for reducing the risk of
stroke in women (albeit with no effect on stroke overall) (Larsson
2012). Kwak 2012 reported marginal effects on cardiovascular
death, though these were lost when a poor-quality trial was re-
moved, and a few others have reported only positive effects in their
abstracts (reductions in cardiovascular events, cardiac death and
coronary events) (Delgado-Lista 2012). These disparate findings
have fuelled both debate and confusion. A recent extensive Agency
for Healthcare Research and Quality review meta-analysed risk
factors extensively but suggested there was only limited RCT data
to assess the effects of omega-3 fats on clinical CVD outcomes
(Balk 2016).
This systematic review and meta-analysis aimed to assess the ev-
idence on the effects of omega-3 fats (long-chain and ALA sep-
arately) on all-cause mortality and CVDs. It also aimed to assess
potentially harmful effects of omega-3 fats or compounds asso-
ciated with consuming long-chain omega-3 fats such as excessive
bleeding. A related review has formally systematically reviewed po-
tential harms such as excessive cancers, rather than simply exam-
ining studies included in this review for cancer outcomes (Hanson
2017b). We assessed mechanisms of action such as lipid and body
weight changes and antiarrhythmic effects as primary or secondary
outcomes in this review, and we have systematically reviewed these
outcomes in a formal way by including trials that assessed adi-
posity, lipids and arrhythmic events even where no CVD events
occurred or were reported. Sister systematic reviews have assessed
anti-inflammatory effects and effects on inflammatory bowel dis-
ease (Thorpe 2017), as well as effects on insulin sensitivity and
glucose metabolism (Brown 2017).
TheWorld Health Organization (WHO) is currently updating its
guidance on polyunsaturated fatty acid intake in adults and chil-
dren. The update and expansion of this review was commissioned
byWHO in order to inform and contribute to the development of
updated WHO recommendations. The results of this review in-
cluding GRADE assessments were discussed and reviewed by the
WHO Nutrition Guidance Expert Advisory Group (NUGAG)
Subgroup on Diet and Health as part of WHO’s guideline devel-
opment process.
O B J E C T I V E S
To assess the effects of increased intake of fish- and plant-based
omega-3 for all-cause mortality, cardiovascular (CVD) events, adi-
posity and lipids.
The primary reviewquestionwas, ’Do long-chain omega-3 (LCn3,
fish-based omega-3 fats) or ALA (plant-based omega-3 fats) fats
alter risk of all-cause mortality, cardiovascular deaths, cardiovas-
cular events, coronary heart disease deaths, coronary heart disease
events, stroke, arrhythmia, adiposity and lipids?’
Secondary questions include the following.
• If omega-3 fatty acids confer protection:
◦ does protection occur equally in those at low and at
high risk of cardiovascular disease?
◦ does protection depend on the dose of omega-3 fats
taken per day?
◦ do effects differ between dietary and supplemental
omega-3 sources?
◦ does protection depend on study summary risk of bias?
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• Is protection or harm stronger with longer trial duration?
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised controlled clinical trials that included
diet advice or dietary supplementation to promote omega-3 fatty
acid intake versus placebo, no supplementation, usual diet or lower
dose omega-3. One of our outcomes had to bemeasured and avail-
able (through publications or contact with authors), and trials had
to follow participants for at least 12 months (52 weeks or 360
days) for mortality and cardiovascular outcomes. For advice trials,
follow-up must have been at least 12 months following advice,
and for trials where participants received food or supplementation,
provision must have continued for at least 12 months). We ac-
cepted randomisation of individuals or of clusters as long as there
were at least six clusters randomised.
Careful work by Browning suggests that supplements of EPA and
DHA equivalent to one weekly portion of oily fish results in 95%
of maximal incorporation by 5 days for EPA in plasma phos-
phatidylcholine (95% CI 0 to 18 days) to 273 days for DHA
into blood mononuclear cells (95% CI 0 to 670 days) (FISH
2012). While this suggests individual variability, on average all
compartments except bloodmononuclear cells had equilibrated by
117 days (both EPA and DHA into plasma phosphatidylcholine,
plasma cholesteryl esters, plasma nonesterified fatty acids, plasma
triglycerides, erythrocytes and platelets). The authors stated “EPA
and DHA reached a maximum in platelets in 3-4 weeks and 1-
2 months, respectively, and in blood mononuclear cells in 6-9
months”. For this reason we chose 12 months as the minimum
duration of intervention, as it allows equilibration of most body
compartments with EPA and DHA as well as time for this change
in body composition to have some effect on cardiovascular risk or
mortality.
In previous reviews of dietary effects on cardiovascular outcomes,
we limited trials to at least two years’ duration (Hooper 2015),
as the proposed mechanism of effects was via LDL cholesterol,
atherosclerosis and its sequelae, and this takes time to develop.
The 4S trial showed separation of the survival curves at around
two years (Scandinavian Simvastatin Survival Study Group 1994).
Potential mechanisms for effects of polyunsaturated fatty acids
(PUFAs) are broader, including what could be rapid effects on
arrhythmias or inflammation, so we decided to include trials of at
least 12 months to ensure we did not miss these effects.
Types of participants
Studies in adults (18 years or older, men and/or women) at any
risk of cardiovascular disease (with or without existing cardiovas-
cular disease) were eligible, including those in participants with
increased risk of cancer, those undergoing or who have undergone
coronary artery bypass grafting or angioplasty, and those with cur-
rent or previous cardiovascular disease, nephritis in systemic lupus
erythematosus, breast cysts, diabetes mellitus, rheumatoid arthri-
tis, multiple sclerosis, psoriasis, hay fever, asthma or ulcerative
colitis. Including these populations allows us to understand both
development and progression of cardiovascular disease (primary
and secondary prevention). We excluded participants who were
pregnant or acutely ill (with acute-stage cancer, undergoing heart
or renal transplantation, with HIV or AIDS, on haemodialysis,
with IgA glomerulonephritis, or any other renal problem except
in diabetes).
Types of interventions
The intervention must have been dietary supplementation, a pro-
vided diet or advice on diet. The foodstuffs or supplements must
have been: oily fish (including mackerel, dogfish, salmon, herring,
trout, tuna, sturgeon, stablefish, anchovy, sprat, coho, capelin, sar-
dines, swordfish, sild, pilchard, brisling,menhaden, bloater, white-
bait, crab and conger eel); fish oils (made from any of the above or
a mixture of fish, or cod liver oil); linseed (flax), canola (rapeseed),
perilla, purslane, mustard seed, candlenut, stillingia or walnut as
a food, capsule, oil, made into a spreading fat or supplementing
another food (such as bread or eggs). For ALA sources the product
consumed had to have an omega-3 fat content of at least 10%
of the total fat content. Refined eicosapentaenoic acid (EPA), do-
cosahexaenoic acid (DHA) or alpha-linolenic acids, or concen-
trated fish or algal oils, were also accepted. Supplementation may
have been in oil or capsule form or as foodstuffs provided to be
consumed by mouth (excluding enteral and parenteral feeds and
enemas).
We excluded studies using multiple risk factor interventions on
lifestyle factors (such as weight reduction, smoking or physical
activity goals), or differential dietary interventions not involving
dietary fats, except where that other intervention was a direct re-
placement for polyunsaturated fats or the effect of diet or supple-
mentation could be separated out from the other interventions.
Studies were eligible if they compared the effect of dietary advice
or supplementation to increase omega-3 fats with the usual diet,
no advice, no supplementation, placebo or lower dose omega-3.
Types of outcome measures
Primary outcomes
Primary outcomes included numbers of participants experiencing:
• all-cause mortality (deaths);
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• cardiovascular mortality (cardiovascular deaths);
• cardiovascular events (cardiovascular events);
• coronary heart disease mortality (CHD deaths);
• coronary heart disease events (CHD events);
• stroke; and
• arrhythmia (atrial fibrillation).
We analysed coronary heart disease using the first of the follow-
ing to be reported: number of participants experiencing CHD or
coronary events, total myocardial infarction (MI), acute coronary
syndrome or angina (stable and unstable). This meant that if tri-
alists reported CHD events, we used these in analysis and ignored
the other outcomes; where trials did not report CHD events but
did report total MI, we used that (and so on). Combined cardio-
vascular events included fatal and non-fatal myocardial infarction,
angina, stroke, heart failure, peripheral arterial disease, sudden
death and non-scheduled cardiovascular interventions - coronary
artery bypass surgery or angioplasty. We included all available out-
comes where we could be sure that the same participant was not
being counted twice.
At the request of WHONUGAG Subgroup on Diet and Health,
we added CHD mortality post hoc as a primary outcome. Data
used were the first of the following list reported: coronary death,
ischaemic heart disease (IHD) death, fatal MI, cardiac death. We
only used cardiac death when no other outcomes in this category
were available, and we ran a sensitivity analysis omitting cardiac
death. The reason for excluding cardiac death in sensitivity anal-
ysis was that it goes slightly outside our area of interest, includ-
ing other causes of death in addition to CHD, such as cardiomy-
opathies and congenital and valvular heart diseases. We wanted to
include cardiac death in the main analysis as we felt that other-
wise we would be missing some important cases of coronary heart
mortality, but we decided to exclude it in sensitivity analysis as we
were potentially including a few outcomes that CHD mortality
did not encompass.
Secondary outcomes
Secondary outcomes included:
• major adverse cerebrovascular or cardiovascular events
(MACCEs) or individual cardiovascular events (total, fatal or
non-fatal MI, sudden cardiac death, angina, heart failure,
revascularisation, peripheral arterial disease or acute coronary
syndrome);
• body weight and other measures of adiposity; and
• lipids (total, LDL or HDL cholesterol and triglycerides).
We defined MACCEs as participants experiencing MI, unstable
angina, stroke or death. We did not consider studies that did not
provide data on all these health events for this outcome.
The review included studies if any of their participants experi-
enced or were assessed for any primary or secondary outcome.
These could have been reported in publications (as outcomes or
reasons for dropout or adverse events), supplied by study authors,
or which clearly happened even if exact numbers were not avail-
able. However, as almost all trials note if a death or cardiovascular
event occurs in a study participant (so ALL trials assess for our
primary outcomes) we only included trials where at least one event
occurred, or where a continuous outcome was measured.
Tertiary outcomes
We extracted the following outcomes where available within in-
cluded studies.
• Blood pressure.
• Serious adverse events (any other reported illnesses).
• Side effects.
• Dropouts.
• Quality of life measures.
• Economic costs.
We originally intended to assess type 2 diabetes diagnoses, mea-
sures of glucose metabolism, cancers, breast cancer, neurocogni-
tive outcomes such as dementia, depression and anxiety within
included studies. However, as part of the larger set of reviews
we formally systematically reviewed effects of omega-3 fats on
type 2 diabetes diagnoses and measures of glucose metabolism
(Brown 2017), cancers including breast cancer (Hanson 2017b),
neurocognitive outcomes such as dementia (Jimoh 2017), irrita-
ble bowel disease (IBD) and inflammatory factors (Thorpe 2017),
depression and anxiety (Hanson 2017a), and functional outcomes
(Abdelhamid 2017), so a partial assessment within this review
would be unhelpful and potentially misleading. For this reason
we exclude these specific outcomes from our reporting of serious
adverse events.
Key outcomes
When the World Health Organization (WHO) Nutrition Guid-
ance Expert Advisory Group (NUGAG) Subgroup on Diet and
Health requested this review update they named the following as
key outcomes to inform their planned dietary guidance.
• All-cause mortality.
• CVD mortality.
• CVD events.
• CHD mortality.
• CHD events.
• Stroke.
• Arrhythmia (atrial fibrillation).
• Serum lipids including total cholesterol (TC), fasting
triglycerides (TG), high-density lipoprotein (HDL) and low-
density lipoprotein (LDL).
• Measures of adiposity (body weight and body mass index).
We were not able to make all of these outcomes into primary
outcomes. However, because WHO NUGAG Subgroup on Diet
and Health will use these outcomes to underpin guidance, we
carried out sensitivity analyses, subgroup analyses and GRADE
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assessment of quality of evidence for them, even when they were
not primary outcomes.
Search methods for identification of studies
Electronic searches
We searched the following electronic databases on 27 April 2017
to identify reports of relevant randomised clinical trials.
• Cochrane Central Register of Controlled Trials
(CENTRAL; 2017; Issue 3) in the Cochrane Library.
• Epub Ahead of Print, In-Process & Other Non-Indexed
Citations, MEDLINE Daily and MEDLINE (Ovid, 1946 to 27
April 2017).
• Embase Classic and Embase (Ovid, 1947 to 2017 week 17).
We applied date limits to the terms from the original strategies
so that the search included only new records, but we did not
apply any date limits to newly added terms. Appendix 1 shows the
MEDLINE search strategy for the original version of this review,
and Appendix 2 shows the updated searches.We de-duplicated the
results against each other. The RCT filter for MEDLINE was the
Cochrane sensitivity and precision-maximising RCT filter, and for
Embase, we applied the terms as recommended in the Cochrane
Handbook for Systematic Reviews of Interventions (Lefebvre 2011).
As we were also running searches for a new systematic review
of the effects of polyunsaturated fats on cardiovascular disease
(Abdelhamid 2018), as well as updating and extending a Cochrane
Review of the effects of omega-6 polyunsaturated fats on health
outcomes (Hooper 2018), we also ran searches for these reviews
using the same RCT filters (Appendix 3). The results of these
searches were de-duplicated against the omega-3 searches, and all
the titles and abstracts assessed as a single set for all three reviews.
We created a dataset of RCTs that lasted at least six months and
compared higher versus lower omega-6, omega-3 or total polyun-
saturated fatty acids (PUFA) in adults. We used this dataset as
the wider study pool from which we selected included studies for
all reviews (Abdelhamid 2018; Abdelhamid 2017; Hooper 2018;
Brown2017;Hanson 2017a;Hanson 2017b; Jimoh2017;Thorpe
2017; Hooper 2004).
We searched two trials registers,
ClinicalTrials.gov (clinicaltrials.gov) and the WHO International
Clinical Trials Registry Platform (ICTRP, www.who.int/ictrp/en)
on 23 September 2016 for registry entries for relevant completed
and ongoing studies.
Searching other resources
We assessed titles and abstracts retrieved during these electronic
searches for relevant RCTs and also relevant systematic reviews.
We handsearched the included studies in all relevant systematic
reviews for new trials and additional publications of included trials.
We contacted authors of all large included studies (at least 100 par-
ticipants) and some smaller trials for further study data, method-
ological details and references to studies not yet identified, includ-
ing published, unpublished or ongoing studies.
Data collection and analysis
Selection of studies
At least two reviewers independently assessed titles and abstracts
resulting from the electronic and bibliographic searches. We com-
bined the search results for this review and two others, Abdelhamid
2018and Hooper 2018, de-duplicating and assessing them at the
same time. We rejected titles and abstracts on initial screen only if
the reviewer could determine from the title and abstract that the
article was not a report of a randomised controlled trial; did not
address omega-3 intake (or total polyunsaturated fat or omega-6
fat for the other two reviews); were exclusively in children or young
adults (less than 18 years old), pregnant women or the critically ill;
were of less than 12 months’ duration; or if the intervention was
multi-factorial and we could not separate out the effect of dietary
fat.
We rejected studies only when it was certain that no primary or
secondary outcome events occurred, and none of the secondary
outcome risk factors were measured. When we could not reject a
title/abstract with certainty, we obtained the full text of the article
for further evaluation. We made attempts to obtain full-text trans-
lations and/or evaluations of all potentially relevant non-English
articles.
We used an in/out form to assess full-text papers and studies for
inclusion (or otherwise) into the review. We contacted the authors
of all potentially included RCTs for further information on trial
methodology and outcomes. Two assessors independently decided
on inclusion of full-text RCTs, resolving any differences by discus-
sion and, when necessary, in consultation with the review team.
Data extraction and management
We designed a data extraction form for this review, which each
of the reviewers tested on a common ’training’ study (SCIMO
1999), and we adapted it as appropriate. We extracted data con-
cerning participants, interventions, and outcomes, as described
above in the selection criteria section. We extracted dichotomous
data from dietary advice studies at the latest point available in
the trial (regardless of the amount of reinforcement of the origi-
nal dietary message), while for supplement studies, we extracted
dichotomous data to the point that supplementation or the trial
ended, whichever was earlier. We extracted continuous data at the
nearest time point to 12 months and also the latest point available
in fixed-term trials, but in studies where participants were followed
up for varying durations (aside from dropouts), we extracted the
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participants’ data from the first time point following the mean
trial duration. We never used data from periods following the end
of a trial in meta-analysis.
We also extracted data on risk of bias, assessed using the Cochrane
’Risk of bias’ tool, along with data on potential effect modifiers,
including existing cardiovascular disease (primary or secondary
prevention), trial duration, intensity of intervention (dietary ad-
vice, diet provided, supplemental foods, supplements (capsules)
and any combination), long-chain omega-3 fats or ALA and dose,
replacement, medications used (including statins, antihyperten-
sive, antiarrhythmic or antithromboticmedication), fatty acid data
(from plasma, platelets or adipose tissue) and smoking status.
For primary and secondary dichotomous outcomes, we extracted
numbers of participants experiencing an outcome and total num-
bers of participants randomised (or in whom the outcome was
assessed where known) for each study arm. For continuous out-
comes, we extracted the number of participants assessed, means
and standard deviations of the final readings in each treatment
arm; we calculated standard deviations from other variance data
where appropriate. Where data were available on both change and
final readings, we used data on change.
Two reviewers independently extracted original reports of trial re-
sults. We resolved differences between reviewers’ results by discus-
sion and, when necessary, in consultation with a third reviewer or
the review team.
Assessment of risk of bias in included studies
Two reviewers independently assessed risk of bias for each included
study, using Cochrane criteria (Higgins 2011), including in the
domains of sequence generation; allocation concealment; blind-
ing of participants and personnel, blinding of outcome assessors;
incomplete outcome data; and selective outcome reporting. Ad-
ditional review-specific criteria included similarity of type and in-
tensity of intervention in both arms (attention) and evidence of
appropriate moderate to high compliance (to establish that the
intervention group were receiving a different intake of omega-3
fats than the control group). Table 1 presents specific details of
how we interpreted these criteria for this review.
We considered a study to be at low risk of attention bias when
participants were given the same amount of time and attention
from study staff and health professionals whether they were in the
intervention or control arms, and at low risk of compliance bias
when adherencewas assessed, results of that assessmentwere clearly
reported for both intervention and control arms, and where most
participants appeared to have taken at least 75% of the intended
PUFA dose.
Summary risk of bias
Schulz 1995 found that poorly concealed allocation was associ-
ated with a 40% greater effect size, so randomisation and allo-
cation concealment are core issues for all trials. Lack of blinding
is associated with bias, though smaller levels of bias than lack of
allocation concealment (Savovic 2012), especially in studies with
objectively measured outcomes (Wood 2008), such as those we
primarily used in our review. Although we originally planned to
assess summary risk of bias for all included trials in the same way
across this review, the omega-3 review and the total PUFA review
(Abdelhamid 2018; Hooper 2018; Hooper 2004), we adopted a
different approach after discussing the different nature of supple-
ment trials compared to dietary advice or food provision trials with
the WHO NUGAG Subgroup on Diet and Health.
We considered supplement or capsule type trials to be at low sum-
mary risk of bias where we judged randomisation, allocation con-
cealment, blinding of participants and personnel, and blinding of
outcome assessors to be adequate. We considered all other trials
to be at moderate or high risk of bias (a single category).
We considered dietary advice or all-food-provided type trials to
be at low summary risk of bias where we judged randomisation,
allocation concealment, and blinding of outcome assessors to be
adequate. We considered all other trials to be at moderate or high
risk of bias (a single category).
Measures of treatment effect
We pooled dichotomous data using risk ratios (RR) to describe
effect sizes and continuous data using mean differences (MD).
Where effectswere described by different but comparablemeasures
or scales in different studies, we combined themusing standardised
mean difference (SMD).
Unit of analysis issues
We considered that we could reduce patient numbers in cluster-
randomised trials to an effective sample size, as described byHauck
1991; however, we identified no such trials. For combined out-
comes (e.g. combined cardiovascular events), we made attempts to
add numbers of individuals experiencing specific outcomes within
studies, but only where we could be certain that wewere not count-
ing individual participants more than once within any one of our
review outcome categories.
For studies with intervention arms providing different omega-3
doses, we combined data for the intervention groups for binary
outcomes and used data on higher dose data versus control for
continuous outcomes. We used arms with different doses sepa-
rately when subgrouping by dose. Where factorial trials ran more
than one intervention included in this review (AlphaOmega - ALA
2010; AlphaOmega - EPA+DHA 2010), we did not pool both
comparisons in the same meta-analysis.
Dealing with missing data
We sought trials registry entries and study protocols to help us as-
sess which studies measured each outcome. Where trials appeared
to have collected - but did not report - data, we wrote to study
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authors to ask for information. We wrote to authors of all studies
that randomised at least 100 participants as well as to those of
many smaller studies (although not to all due to limited resources),
prioritising our efforts on larger studies that would tend to provide
more information to the review. For larger studies where we found
no trials registry entry or protocol, we wrote to study authors to
ask whether they had collected information on any outcomes of
interest that we had not yet located. Where it was clear that data
existed but could not be located to use within the review, we noted
this and assessed the potential effect of this missing data on effect
sizes narratively.
Assessment of heterogeneity
We assessed heterogeneity using the I2 test and assumed it to be
important when I2 was more than 60% (Higgins 2003).
Assessment of reporting biases
We used funnel plots to assess for evidence of bias for primary
outcomeswhere at least 10 studies contributed to themeta-analysis
(Egger 1997).
Data synthesis
Primary measures of interest were effects of dietary advice or sup-
plementation of fish-based (long-chain, LCn3) omega-3 fats, and
alpha linolenic acid (ALA), on primary outcomes. We separated
out effects of LCn3 and ALA in all analyses and thus present two
separate sets of results: one for ALA and one for LCn3.
We combined treatment/control differences in the outcomes
across studies using relative risks (RR) ormeandifferences (MD) in
random-effects meta-analysis. For combined outcomes (e.g. com-
bined cardiovascular events), we made attempts to add numbers
of individuals experiencing specific outcomes within studies, but
only where we were certain that we were not counting individual
participants more than once within any one of our review outcome
categories. However, individuals may have been counted for more
than one of the review outcomes (in separate forest plots).
Subgroup analysis and investigation of heterogeneity
We explored the effects of LCn3 andALA separately on all primary
review outcomes and also on key review outcomes where these
were secondary outcomes in our review and included at least six
studies by subgrouping. The planned subgroup analyses were:
• type of intervention - dietary advice, supplemental foods
(for example margarine fortified with rapeseed, tins of sardines or
oils to use in cooking) provided by the study, supplements
(capsules or oils) provided to take as medicine or any
combination;
• replacement of saturated fatty acids (SFA), mono-
unsaturated fatty acids (MUFA), omega-6 fats, fat mixture,
carbohydrates or sugars, non-fat or no placebo, or unclear, with
LCn3 or ALA;
• primary prevention versus secondary prevention of CVD;
• LCn3 dose: at least 150 mg/d, 250 mg/d, 400 mg/d from all
sources including supplements (above or below each threshold) -
low dose 0.4 g/d to 2.4 g/d, medium dose 2.5 g/d to 4.4 g/d, and
high dose ≥ 4.5 g/d of combined long-chain omega-3 fats,
• ALA dose: higher versus lower levels of intake (≥ 5 g/d
versus < 5 g/d);
• trial duration - studies with medium follow-up (12 to 23
months), medium follow-up (24 to 47 months) and long follow-
up (≥ 48 months);
• statin use (< 50% of control group on statins, ≥ 50% of
control group on statins, use of statins unclear);
• baseline long-chain omega-3 intake, and baseline ALA
intake.
There were insufficient data on baseline omega three intake (or
intake in control groups which could have been used as a proxy)
to subgroup by baseline omega-3 intake.
Meta-regression
We used meta-regression to further explore effects of LCn3 dose,
ALA dose, omega-6 dose, total PUFA dose (looking for evidence
of dose response for each), duration, primary or secondary preven-
tion, food or capsule intervention (food included dietary advice
and supplemental foods), and risk of bias (summary risk of bias low
or moderate to high) on primary outcomes. We performed ran-
dom-effects meta-regression using the STATA command metareg
(Berkley 1995; Sharp 1998): log(e) relative risk versus (dose or pri-
mary/secondary prevention or type of intervention or risk of bias
or duration), weighted by the standard error of the log(e) relative
risk. Where there were no events in one arm, we added 0.1 to the
numbers for both groups (so a trial with 10 people experiencing
stroke in one arm but none in the other arm would be entered
as 10.1 and 0.1). We analysed all included trials (of at least 12
months’ duration) that reported each outcome from this review
and its sister reviews (omega-3 trials from this review, omega-6
trials from the update of Hooper 2018, and total PUFA trials from
Abdelhamid 2018). We carried out meta-regression of each vari-
able singly, then a multivariate meta-regression of the three vari-
ables with lowest P values in single regression for each outcome.
Given that we generally included data from around 35 trials and
there were somemissing data for some trials, we did not run meta-
regressions with more than three variables at one time.
Sensitivity analysis
We carried out sensitivity analyses on all primary outcomes (re-
gardless of the number of included trials) and on key outcomes
that were secondary outcomes in this review.
We used sensitivity analyses to assess robustness of results to:
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• trial quality (removing trials at moderate or high summary
risk of bias);
• study size (retaining only trials that randomised at least 100
participants across all study arms);
• fixed-effect analysis; and
• compliance (retaining only trials where we assessed
compliance as conferring low risk of bias).
We tabulated the type and frequency of side effects and adverse
effects (with the other extracted data on adverse effects) and com-
pared between different studies and designs.
’Summary of findings’ tables
Outcome data were interpreted as follows:
1. Is there an effect? (options were ‘increased risk’, ‘decreased
risk’, or ‘little or no effect’). Our main outcome measure was RR
so we decided on existence of an effect using RR. RR < 8% (RR
< 0.92 or > 1.08) for the highest quality evidence suggested
increased or decreased risk (otherwise little or no effect). The
presence or not of an effect was decided on the RR for the main
analysis and sensitivity analyses.
2. Quality of evidence was assessed using GRADE assessment
(GRADE Working Group 2004) for key outcomes. We used the
five GRADE considerations (risk of bias, consistency of effect,
imprecision, indirectness and publication bias) to assess the
quality of the body of evidence as it related to the studies that
contributed data to the meta-analyses for the prespecified
outcomes. We used methods and recommendations described in
Section 8.5 and Chapter 12 of the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2011), plus
GRADEpro GDT software (GRADEpro GDT 2015). We
justified all decisions to downgrade the quality of studies using
footnotes and made comments to aid reader’s understanding of
the review.
3. Where there was a suggested effect the size of effect was
assessed using the NNT or ARR.
We included three ’Summary of findings’ tables: for effects of LCn3
on primary outcomes, effects of ALA on primary outcomes, and
for key outcomes that were not included in the review primary
outcomes (measures of adiposity and serum lipids).
R E S U L T S
Description of studies
Results of the search
The electronic searches for the full set of reviews (populating the
dataset of all trials that assessed effects of higher versus lower
omega-6, omega-3 or PUFA over at least 6 months) generated
37,810 titles and abstracts, which we de-duplicated to 19,772
hits. We assessed these along with 53 studies previously included
from Hooper 2018 and Hooper 2004, to reassess for inclusion;
986 potentially relevant trials registry entries; and 35 new refer-
ences gained from systematic review reference lists. In total, we
assessed 20,846 titles and abstracts in duplicate to decide whether
to retrieve full texts. We ultimately assessed 2155 full-text reports,
of which 226 were systematic reviews. Two review authors inde-
pendently assessed the remaining 1929 papers for inclusion and
grouped them into studies. Of these, we included 208 RCTs in a
wider set of trials that underpinned the full set of reviews (this re-
view and several others including Abdelhamid 2018; Abdelhamid
2017;Hooper 2018; Brown2017;Hanson 2017a;Hanson 2017b;
Jimoh 2017; Thorpe 2017). This wider set of trials included RCTs
of omega-3, omega-6 or total polyunsaturated fatty acids (PUFA)
interventions with a duration of at least six months (Figure 1) and
comprised 730 reports.
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Figure 1. Study flow diagram.
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Of these 208 RCTs:
• 27 RCTs (51 documents) assessed effects of omega-3 fats
over at least one year but were ongoing (without published
outcome data);
• 102 RCTs (291 documents) did not assess effects of omega-
3 fats or had a duration of less than one year, so we excluded
them; and
• 79 RCTs (388 documents) were eligible for inclusion in this
review.
Of these 79 RCTs, 76 were included in meta-analyses. Three trials
clearly collected relevant data but did not report them in a format
that could be used in meta-analyses (Gill 2012; Ramirez-Ramirez
2013; Reed 2014; Figure 1).
Included studies
The 79 included RCTs randomised 112,059 participants, tripling
the number of participants in the original version of this review
(36,913 participants, some of whom were followed for only six
months). The number of participants in included studies ranged
from 11 to 18,645. Twelve trials randomised at least 1000 par-
ticipants (AlphaOmega - ALA 2010; AlphaOmega - EPA+DHA
2010; AREDS2 2014; DART2 2003; DART 1989; GISSI-HF
2008; GISSI-P 1999; JELIS 2007; Norwegian 1968; OMEGA
2009; ORIGIN 2012; Risk & Prevention 2013; SU.FOL.OM3
2010), of which one was a 2 × 2 factorial trial where both inter-
ventions were included (AlphaOmega - ALA 2010; AlphaOmega
- EPA+DHA 2010). Most of these larger trials assessed effects of
longer chain omega-3 fats, but two studies/arms assessed effects of
ALA (AlphaOmega - ALA 2010; Norwegian 1968).
Participants had cardiovascular disease at baseline in 33 of the
trials (secondary prevention), and the remaining 46 trials were of
primary prevention.
Most studies assessed effects of long-chain omega-3 fats.
• Sixty-two studies increased LCn3 intake using
supplementary capsules or medicinal oils (ADCS 2010;
AFFORD 2013; Ahn 2016; AREDS2 2014; Baldassarre 2006;
Bates 1989; Berson 2004; Brox 2001; Caldwell 2011; Derosa
2016; Deslypere 1992; Doi 2014; DO IT 2010; EPE-A 2014 (as
two different doses); EPIC-1 2008; EPIC-2 2008; EPOCH
2014; Erdogan 2007; FAAT 2005; FORWARD 2013; Franzen
1993; Gill 2012; GISSI-HF 2008; GISSI-P 1999; HARP 1995;
JELIS 2007; Kumar 2012; Kumar 2013; Lorenz-Meyer 1996;
MAPT 2017; MARINA 2011; Mita 2007; NAT2 2013; Nodari
2011 AF; Nodari 2011 HF; Norouzi 2014; Nutristroke 2009;
Nye 1990; OFAMI 2001; OMEGA 2009; OPAL 2010;
ORIGIN 2012; ORL 2013; Özaydin 2011; Proudman 2015;
Puri 2005; Raitt 2005; Ramirez-Ramirez 2013; Reed 2014; Risk
& Prevention 2013; Rossing 1996; Sandhu 2016; SCIMO 1999;
Shinto 2014; SHOT 1996; Sianni 2013; SOFA 2006; Sofi 2010;
SU.FOL.OM3 2010; Tande 2016; WELCOME 2015; Zhang
2017).
• Two trials used supplemented or supplemental foods, such
as enriched margarine or juice to increase LCn3 (AlphaOmega -
EPA+DHA 2010; FOSTAR 2016).
• Four increased LCn3 fats using dietary advice (DART2
2003; DART 1989; DISAF 2003; THIS DIET 2008).
• Three provided some combination of these interventions to
increase LCn3 (DIPP 2015; SMART 2013; Weinstock-Guttman
2005).
Fewer studies assessed the effects of ALA on health outcomes.
• One trial used supplementary capsules or medicinal oils to
increase ALA (Norwegian 1968).
• Six increased ALA using supplemented or supplemental
foods, such as enriched margarine, bread, walnuts or other
enriched food products (AlphaOmega - ALA 2010; Dodin 2005;
FLAX-PAD 2013; HERO 2009; MARGARIN 2002; WAHA
2016).
• One used a combination of these to increase ALA (MENU
2016).
One trial provided an intervention combining LCn3 and ALA as
capsules (DIPP 2015). However, trialists did not state the ALA
dose, so we treated the study as an LCn3 intervention.
Control groups received olive, corn, sunflower oils, other types
of fats (including medium-chain triglycerides and fat replicat-
ing the composition of an average European diet), other ’inert’
or ill-defined substances (liquid paraffin, aluminium hydroxide,
’placebo’ not described), different dietary advice or foods without
the omega-3 enrichment, or no treatment/no placebo.
The main study outcome was cardiovascular in 48 studies. Eigh-
teen studies (19 comparisons) aimed to measure death or car-
diovascular events (AlphaOmega - ALA 2010; AlphaOmega -
EPA+DHA 2010; DART2 2003; DART 1989; Doi 2014; FAAT
2005; FLAX-PAD 2013; GISSI-HF 2008; GISSI-P 1999; JELIS
2007; Norwegian 1968; Nye 1990; OFAMI 2001; OMEGA
2009; ORIGIN 2012; Risk & Prevention 2013; SOFA 2006;
SU.FOL.OM3 2010; THIS DIET 2008).
Thirty studies aimed to measure various cardiovascular risk factors
or progression of cardiovascular health.
• Atrial fibrillation recurrence or sinus rhythm (AFFORD
2013; DISAF 2003; Erdogan 2007; FAAT 2005; FORWARD
2013; Kumar 2012; Kumar 2013; Nodari 2011 AF; Özaydin
2011; Raitt 2005; Sianni 2013).
• Atherosclerosis progression/regression (Ahn 2016; DO IT
2010; HARP 1995; SCIMO 1999).
• Left ventricular function (Nodari 2011 HF).
• CABG graft patency (SHOT 1996).
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• Lipids and other CVD risk factors (Brox 2001; Deslypere
1992; Franzen 1993; MARGARIN 2002).
• Diabetes, insulin or glucose-based outcomes (Derosa 2016;
Rossing 1996).
• Endothelial function or carotid intima-media thickness
(IMT) (Baldassarre 2006; Gill 2012; MARINA 2011; Mita
2007).
• Body weight and adiposity (HERO 2009; MENU 2016;
SMART 2013).
Thirty-one RCTs assessed effects on other health states.
• Cognitive measures (ADCS 2010; EPOCH 2014; MAPT
2017; OPAL 2010; Shinto 2014; WAHA 2016; Zhang 2017).
• Eye health (AREDS2 2014; Berson 2004; NAT2 2013).
• Multiple sclerosis outcomes (Bates 1989;
Weinstock-Guttman 2005).
• Cancer or pre-cancer outcomes (DIPP 2015).
• Bone health (Dodin 2005).
• Liver health (Caldwell 2011; EPE-A 2014; Sofi 2010;
WELCOME 2015).
• Gastrointestinal health (Crohn’s EPIC-1 2008; EPIC-2
2008; Lorenz-Meyer 1996).
• Arthritis outcomes (FOSTAR 2016; Proudman 2015; Reed
2014).
• Functional status (Nutristroke 2009).
• Neurological function after spinal injury or in Huntington’s
disease (Norouzi 2014; Puri 2005).
• Safety outcomes and adverse events (ORL 2013; Tande
2016).
• Breast health (Sandhu 2016).
• Inflammatory markers (Ramirez-Ramirez 2013).
Most studies took place in high-income economies (World
Bank 2018), but four were in upper-middle-income countries:
Argentina (FORWARD 2013), Iran (Norouzi 2014), Turkey
(Özaydin 2011), and China (Zhang 2017). No studies took place
in low- or low-middle income countries.
We identified a further 27 ongoing trials, which we describe in the
table of Characteristics of ongoing studies. At the time of writing
this review, all of these trials were unpublished, and some were
recruiting or delivering interventions or had recently been com-
pleted, and trialists were presumably analysing data and writing
up results. Others appear overdue for publication, and their status
is unclear - they may constitute missing data.
Excluded studies
We read full texts of over 1000 papers, so the full list of excluded
studies is too extensive to add to this review. The main reason for
exclusion of full-text papers was duration of less than 12 months
(this was often unclear in abstracts, so we collected full-text papers
to check).
We initially included several studies into our wider data set (Singh
1992; Singh 1997a; Singh 1997b; Singh 2002), but we later ex-
cluded them due to expressions of concern published by the BMJ
and The Lancet (BMJ 2005; Horton 2005; White 2005). These
expressions of concern followed extensive examination of the con-
duct, results and publication of these studies and questioned the
veracity of data behind several studies published by RB Singh. An-
other trial was retracted and so not included (Matsuyama 2005).
Risk of bias in included studies
We assessed summary risk of bias as low in 25 RCTs (26 com-
parisons: ADCS 2010; AlphaOmega - ALA 2010; AlphaOmega -
EPA+DHA 2010; AREDS2 2014; Berson 2004; Caldwell 2011;
Derosa 2016; EPOCH 2014; FLAX-PAD 2013; FORWARD
2013; FOSTAR 2016; Lorenz-Meyer 1996; MAPT 2017;
MARGARIN 2002; MARINA 2011; NAT2 2013; OMEGA
2009; OPAL 2010; ORIGIN 2012; Proudman 2015; Puri 2005;
Reed 2014; SCIMO 1999; SOFA 2006; SU.FOL.OM3 2010;
WELCOME 2015), and we deemed it to be moderate to high in
the remainder. Our definition of low summary risk of bias is in
the section Assessment of risk of bias in included studies. Figure
2 itemises risk of bias by domain and study.
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Of the 79 RCT arms described in the ’Risk of bias’ summary
(Figure 2), 64 studies described randomisation well enough to
merit an assessment of low risk (the remainder were unclear), and
45 study arms described adequate allocation concealment (the
remaining 34 were unclear).
Blinding
We considered blinding of participants and personnel to be at low
risk of bias in 37 of the 79 comparisons (Figure 2). Lack of blinding
of participants put 22 trials at high risk of bias while the remaining
20 arms were at unclear risk. Blinding of outcome assessors put
trials at low risk of detection bias in 53 studies and at high risk in 6
trials; this aspect was unclear in the remainder. We found that 33
studies were at low risk of both performance and detection bias.
Incomplete outcome data
We found that 53 trials were at low risk of attrition bias, 14 at
high risk, and the remaining 12 at unclear risk.
Selective reporting
We determined that 17 trials had a pre-published trials registry
entry or protocol and reported all planned outcomes appropriately
so were considered at low risk of selective reporting. Twenty-three
trials were at high risk of selective reporting omitting reports on
either pre-stated outcomes or time points. We judged the remain-
ing 39 trials to be at unclear risk of reporting bias as we could not
find any protocol or prospective trial registry entry (often trials
were published prior to trial registration availability).
Other potential sources of bias
We assessed risk of bias from lack of compliance and attention
bias and also noted other sources of bias. We found four studies
to be at high risk of compliance bias (FAAT 2005; HERO 2009;
Proudman 2015; SMART 2013), while 34 studies provided ev-
idence of good compliance, and the remaining 41 studies were
unclear. We noted a high risk of attention bias in three studies
where intervention participants potentially had more dedicated
time for dietary advice or follow-up (DART2 2003; DART 1989;
MARGARIN 2002). Nine trials did not provide enough details to
assess so we considered them to be at unclear risk of attention bias
(Ahn 2016; Erdogan 2007; Gill 2012; Kumar 2012; Kumar 2013;
Risk & Prevention 2013; Sianni 2013; SMART 2013; WAHA
2016), whilewe thought the remaining67were at low risk of atten-
tion bias. We judged three studies to be at high risk of other poten-
tial biases: Ahn 2016 because it is unclear whether it was placebo-
controlled, and there was concern over reported standard devia-
tions, DISAF 2003 because the study stopped early, and Kumar
2013 due to concerns over design. Three studies were at unclear
risk due to insufficient methodological detail being provided (Gill
2012; Sianni 2013; Zhang 2017).
Effects of interventions
See: Summary of findings for the main comparisonHigh versus
low LCn3 for preventing cardiovascular disease and mortality
(primary outcomes); Summary of findings 2 High versus low
ALA omega-3 fats for preventing cardiovascular disease (primary
outcomes); Summary of findings 3High versus low omega-3 fats
for modification of CVD risk factors (adiposity and lipids): key
outcomes
Primary outcomes
See Summary of findings for the main comparison for a GRADE
summary of our evidence on effects of long-chain omega-3 (LCn3)
fats (including eicosapentaenoic acid (EPA), docosahexaenoic acid
(DHA) and docosapentaenoic acid (DPA)) on our primary out-
comes.
Effects of long-chain omega-3 fats on primary health
outcomes
All-cause mortality (LCn3)
High-quality evidence showed little or no effect of LCn3 on all-
cause mortality.
There was little or no effect of increasing long-chain omega-3 fats
on all-causemortality, despite 8189deaths in >92,000participants
(RR 0.98, 95% CI 0.93 to 1.03, I2 = 12%, Analysis 1.1). The
funnel plot suggested that some small studies with higher numbers
of deaths in the intervention group might be missing (Figure 3),
indicating small study bias. If such missing studies were added
back in the RR would rise (towards the null value of 1.0).
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Figure 3. Funnel plot of comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes), outcome: 1.1
Aall-cause mortality (overall) - LCn3.
Sensitivity analyses using fixed-effect meta-analysis did not alter
the lack of effect on all-cause mortality (RR 0.97, 95% CI 0.93
to 1.01, Analysis 1.2). Removing RCTs not at low summary risk
of bias left us with 15 RCTs involving over 33,000 participants,
3059 of whom died, suggesting no effect of LCn3 on mortality
(RR 1.01, 95% CI 0.94 to 1.08, I2 = 0%, Analysis 1.3). This lack
of effect was also evident in sensitivity analyses limited to studies
at low risk of compliance bias and to larger studies (Analysis 1.4).
The lack of effect for LCn3 on mortality did not differ by replace-
ment with mono-unsaturated fatty acids (MUFA), omega-3 fats
or other types of placebo compounds (Analysis 1.6). There was
no suggestion of any dose effect for long-chain omega-3 fats on
mortality (Analysis 1.5), and subgroups with RRs further away
from 1.00 had wider 95% confidence intervals. The lack of effect
did not differ by primary versus secondary prevention (Analysis
1.9) or mode of intervention (dietary advice, supplemental foods,
or capsules, Analysis 1.7). While there was some suggestion of a
small risk reduction in total mortality with LCn3 in studies with
medium to long duration (2 to < 4 years, RR 0.91, 95% CI 0.86
to 0.96) and this subgroup was clearly different from other dura-
tions (test for subgroup differences P = 0.007), the effect was not
evident in shorter (1 to < 2 years) or longer studies (≥ 4 years, RR
1.03, 95% CI 0.98 to 1.09). Because of the lack of effect in longer
studies, we did not assume any duration effects (Analysis 1.8).
As there was no suggestion of any effect of LCn3 fats on all-cause
mortality, we did not carry out meta-regression.
GRADE assessment suggested that the finding of little or no effect
of LCn3 on all-cause mortality was supported by high-quality
evidence (not downgraded, Summary of findings for the main
comparison).
Cardiovascular mortality (LCn3)
Moderate-quality evidence suggests that long-chain omega-3 fat
intake probably makes little or no difference to cardiovascular
deaths.
Twenty-five trials in at least 67,000 participants, 4544 of whom
died of CVD, reported on cardiovascularmortality (RR0.95, 95%
CI 0.87 to 1.03, I2 = 24%, Analysis 1.11). The funnel plot sug-
gested that some smaller studies with more cardiovascular deaths
in the intervention group were missing (some small study bias,
Figure 4) - if this were the case then adding the missing studies
would increase the relative risk towards the null (no effect).
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Figure 4. Funnel plot of comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes), outcome: 1.11
Cardiovascular mortality (overall) - LCn3.
Fixed-effect meta-analysis suggested a 6% reduction in CVDmor-
tality risk (RR 0.94, 95% CI 0.89 to 1.00, Analysis 1.12). How-
ever, sensitivity analyses removing RCTs not at low summary risk
of bias left nine RCTs in over 29,000 participants, 1539 of whom
died, suggesting little or no effect of LCn3 on CVDmortality (RR
0.99, 95%CI 0.90 to 1.09, I2 = 0%, Analysis 1.13). Removing tri-
als not at low risk of compliance bias had a similar effect (Analysis
1.14).
There were no statistically significant differences between sub-
groups and no differential effects by replacement (Analysis 1.16),
mode of intervention (Analysis 1.17), duration (marginally signif-
icant difference between subgroups, P = 0.06; effects seen only in
medium- to long-term trials and not in shorter or longer studies,
Analysis 1.18), primary or secondary prevention (Analysis 1.19),
statin use (Analysis 1.20) or omega-3 dose (Analysis 1.15). There
was no suggestion of a dose-response effect.
Meta-regression to assess effects of LCn3 dose (or alpha-linolenic
acid (ALA), omega-6 or total poly-unsaturated fatty acid (PUFA)
dose), duration, intervention type, primary or secondary preven-
tion and risk of bias (as well as a single multiple regression of the
three factors with the smallest P value) showed no association be-
tween these factors and risk of cardiovascular mortality (all P val-
ues were > 0.60, Table 2). We saw no suggestion of dose-response
or duration effects.
The suggestion of a protective effect disappeared in studies at low
summary risk of bias and at low risk of compliance problems. The
funnel plot suggests that the true risk ratio is higher than the main
estimate, and there was no suggestion of dose or duration effects;
thus we summarised the evidence as showing little or no effect of
LCn3 on CVD mortality. GRADE assessment suggested moder-
ate-quality evidence that long-chain omega-3 fat intake probably
makes little or no difference to cardiovascular deaths (moderate-
quality/certainty evidence, downgraded once for imprecision).
Combined cardiovascular events (LCn3)
High-quality evidence suggests that LCn3 intake makes little or
no difference to risk of cardiovascular events.
There was little or no effect of increasing LCn3 fats on cardiovas-
cular events (RR 0.99, 95% CI 0.94 to 1.04, I2 = 37%, Analysis
1.21). Analyses included 14,737 participants with cardiovascular
events in more than 90,000 participants in 38 trials. The funnel
plot suggested that some smaller studies with more participants
experiencing cardiovascular events in the intervention group were
missing (some small study bias, not shown) - if this were the case
then adding the missing studies would increase the relative risk.
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Sensitivity analyses removing trials at moderate to high risk of bias
left 14 trials, including more than 31,000 participants, 6695 of
whom had CVD events, with no suggestion of any effect of LCn3
fats (RR 1.00, 95% CI 0.96 to 1.05, I2 = 0%, Analysis 1.23).
Sensitivity analyses including studies at low risk of compliance
bias, at low risk of small study bias and using fixed-effect meta-
analysis did not suggest any effect of LCn3 on CVD events (
Analysis 1.22; Analysis 1.24).
In subgroup analysis, therewas no suggestion of a dose-response ef-
fect (Analysis 1.25). Effects did not differ by replacement (Analysis
1.26), baseline CVD risk (Analysis 1.29), type of intervention
(Analysis 1.27), statin use (Analysis 1.30), LCn3 dose (Analysis
1.25) or study duration (Analysis 1.28), and there were no impor-
tant differences between subgroups.
Meta-regression to assess effects of LCn3 dose (or doses of ALA,
omega-6 and total PUFA), duration, intervention type, primary or
secondary prevention and risk of bias (as well as a single multiple
regression of the three factors with the smallest P value) showed no
association between these factors and risk of cardiovascular events
(all P values were ≥ 0.24, Table 3). We saw no suggestion of dose
or duration effects.
GRADE assessment suggested high-quality evidence that LCn3
intake makes little or no difference to risk of cardiovascular events
(high-quality/certainty evidence).
Coronary heart mortality (LCn3)
Moderate-quality evidence suggests that long-chain omega-3 fat
intake probably makes little or no difference to coronary heart
mortality.
There was a suggestion that increasing LCn3 fats reduced the risk
of coronary heart mortality by 7% (RR 0.93, 95% CI 0.79 to
1.09, I2 = 35%) in 21 trials reporting 1596 events in more than
73,000 participants (Analysis 1.31). Sensitivity analyses using a
fixed-effect model suggested a 6% reduction in CHD mortality
(Analysis 1.32).
However, retaining only RCTs at low summary risk of bias, meta-
analysis of seven trials withmore than 16,000 participants and 283
CHDdeaths suggested no effect of LCn3 fats onCHDdeaths (RR
1.00, 95% CI 0.72 to 1.37, I2 = 18%, Analysis 1.33). Sensitivity
analyses retaining only trials with low risk of compliance bias sug-
gested a 5% increase in risk with LCn3, but retaining only larger
trials suggested a 7% reduction (Analysis 1.34). The funnel plot
suggested that some smaller studies with higher RRs were missing
(Figure 5), and if added back these would increase the RR.
Figure 5. Funnel plot of comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes), outcome: 1.31
Coronary heart disease mortality (overall) - LCn3.
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When we added this outcome we had pre-specified that we would
use the first of the following list reported in any trial: coronary
death, ischaemic heart disease (IHD) death, fatal MI and cardiac
death.We used cardiac death only when no other outcomes in this
category were available, and we ran a sensitivity analysis omitting
cardiac death as it potentially includes other causes of death in
addition to CHD, such as cardiomyopathies and congenital and
valvular heart diseases (though numbers are likely to be small).
Omitting cardiac death resulted in a 17% reduction in CHD
deaths with LCn3 (RR 0.83, 95% CI 0.74 to 0.94, I2 = 0%, 16
trials including 65,325 participants, Analysis 1.35).
There were no statistically significant differences between sub-
groups for type of intervention (Analysis 1.38), dose (Analysis
1.36), baselineCVDrisk (Analysis 1.40), statin use (Analysis 1.41)
or baseline coronary artery disease status (Analysis 1.42). There
were important differences between subgroups for study duration,
with no effect in shorter trials (1 to < 2 years), a significant pro-
tective effect of LCn3 fats in medium- to long-term trials (2 to
< 4 years) and an almost statistically significant harmful effect in
long trials (≥ 4 years, Analysis 1.39), so we did not assume any
differential effect by duration. The differences between subgroups
for replacement disappeared when we omitted the ’replacement
unclear’ category (altering the test for subgroup differences to P =
0.46, Analysis 1.37).
Meta-regression to assess effects of LCn3 dose on CHD mortality
found no relationship (P = 0.94, Table 4). Similarly we saw no
relationships between ALA dose, omega-6 dose, total PUFA dose,
duration, intervention type, primary or secondary prevention or
risk of bias and CHD deaths (all P values were > 0.40, Table 4).
Multiple regression of the three factors with the smallest P value
found no factors associated with risk of CHD deaths. We saw no
suggestion of dose or duration effects.
The suggestion of a protective effect disappeared in studies at low
summary risk of bias, the funnel plot suggests that the true risk
ratio is higher than the main estimate, and there was no sugges-
tion of dose or duration effects, so we summarised the evidence by
assuming little or no effect of LCn3 on CHD mortality. GRADE
assessment suggested moderate-quality evidence that long-chain
omega-3 fat intake probably makes little or no difference to coro-
nary heart mortality (moderate-quality/certainty evidence, down-
graded once for imprecision).
Coronary heart disease events (LCn3)
Moderate-quality evidence suggests that long-chain omega-3 fat
intake probably makes little or no difference to risk of coronary
heart events.
The main meta-analysis suggested a 7% reduction in people expe-
riencing CHD events with higher intake of LCn3 fats (RR 0.93,
95% CI 0.88 to 0.97, I2 = 0%, 5469 events, > 84,000 partici-
pants, Analysis 1.43). The funnel plot suggested that some smaller
studies with more cardiovascular deaths in the intervention group
were missing (some small study bias, Figure 6) - if this were the
case then adding the missing studies would increase the relative
risk.
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Figure 6. Funnel plot of comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes), outcome: 1.43
Coronary heart disease events (overall) - LCn3.
Sensitivity analyses using a fixed-effect model did not alter the re-
sults (RR 0.92, 95% CI 0.88 to 0.97, Analysis 1.44). The protec-
tive effect was lost in studies at low summary risk of bias (Analysis
1.45), and the effect was smaller when studies were limited to
those with good compliance and to larger studies (Analysis 1.46).
Removing RCTs not at low summary risk of bias left 12 trials with
more than 30,000 participants, 2228 of whom developed CHD
(RR 0.97, 95% CI 0.90 to 1.05, I2 = 0%, Analysis 1.45).
There were no statistically significant differences between sub-
groups (Analysis 1.47; Analysis 1.48; Analysis 1.49; Analysis 1.50;
Analysis 1.51; Analysis 1.52; Analysis 1.53).
Meta-regression to assess effects of LCn3, ALA, omega-6, total
PUFA dose and duration, intervention type, primary or secondary
prevention, and risk of bias (as well as a single multiple regression
of the three factorswith the smallest P value) showedno association
between these factors and the risk of CHD events (all P values
were > 0.20, Table 5). We saw no suggestion of dose-response or
duration effects.
Because a protective effect was only apparent in studies at higher
risk of bias, we were concerned that the reduction in CHD events
is residual and arises from methodological weaknesses in some of
the studies (there was a marginally significant difference between
the group of studies at low risk of bias, and those at moderate to
high risk of bias, P = 0.09, Analysis 1.45). GRADE assessment sug-
gested moderate-quality evidence that long-chain omega-3 fat in-
take probably makes little or no difference to risk of coronary heart
events (moderate-quality/certainty evidence, downgraded once for
risk of bias).
Stroke (LCn3)
Moderate-quality evidence suggests that long-chain omega-3 fat
intake probablymakes little or no difference to risk of experiencing
a stroke.
There was a suggestion that increasing intake of LCn3 results in a
6% higher risk of stroke (RR 1.06, 95% CI 0.96 to 1.16, I2 = 0%,
1822 reported strokes, Analysis 1.54), and the funnel plot did not
suggest any small study bias (not shown).
Sensitivity analyses removing trials not at low summary risk of bias
left 12 trials with 888 participants experiencing strokes, suggesting
little or no effect of LCn3 fats on stroke (RR 0.98, 95% CI 0.86
to 1.12, I2 = 0%, Analysis 1.56). Using fixed-effect meta-analysis
also suggested a 6% increase in risk (Analysis 1.55), while sensi-
tivity analysis removing trials with risk from poor compliance and
smaller trials suggested there may be harm from increased LCn3
(Analysis 1.57).
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When studies reported stroke type separately, the risk of both
haemorrhagic (RR 1.20, 95% CI 0.85 to 1.69, I2 = 0%, 130 par-
ticipants with events) and ischaemic stroke were increased (RR
1.09, 95%CI 0.89 to 1.33, I2 = 13%, 556 people with events, in 8
trials each, Analysis 1.58). Five trials reported only 40 participants
experiencing transient ischaemic attack (TIA), suggesting a 26%
reduction in risk but with very wide confidence intervals (TIAs
were not included in any other stroke categories, Analysis 1.58).
Subgrouping did not suggest important differences by interven-
tion type, replacement, statin use, trial duration or dose (Analysis
1.59; Analysis 1.60; Analysis 1.61; Analysis 1.62; Analysis 1.64).
There was a suggestion of increased stroke risk in people with
CVD at baseline (RR 1.21, 95% CI 1.05 to 1.40, I2 = 0%, with
differences in effect size between subgroups by primary or sec-
ondary prevention, P = 0.02, Analysis 1.63).
Meta-regression to assess effects of LCn3 dose did not find any
clear dose response on risk of stroke (P = 0.42, Table 6). Univariate
meta-regression suggested that trials of shorter duration showed a
greater effect on reducing stroke (P = 0.012) and that LCn3 fats
may be more protective against stroke in secondary prevention
than primary (P = 0.04, Table 6). There were no clear relationships
between dose of any PUFA type, risk of bias, or use of food or
capsules, and no significant relationships in multivariate meta-
regression.
Given that studies at low summary risk of bias suggested little
or no effect of LCn3 on stroke risk, and there were no dose-re-
sponse or duration relationships, we assumed little or no true ef-
fect. GRADE assessment suggests moderate-quality evidence that
long-chain omega-3 fat intake probably makes little or no differ-
ence to risk of experiencing a stroke (moderate-quality/certainty
evidence, downgraded once for imprecision).
Arrhythmia (LCn3)
Moderate-quality evidence suggests that long-chain omega-3 fat
intake probably makes little or no difference to risk of arrhythmia.
There was no effect of LCn3 fats on incidence of new or recurrent
(fatal and non-fatal) arrhythmias (RR 0.97, 95% CI 0.90 to 1.05,
I2 = 43%, 3788 events in > 53,000 participants, Analysis 1.65).
The funnel plot was not interpretable as studies were clustered
(not shown).
Sensitivity analyses removing trials not at low summary risk of bias
left 10 trials with 1146 events (> 25,000 participants), suggesting
a 10% increase in risk of arrhythmia with increased LCn3 (RR
1.10, 95% CI 0.98 to 1.23, I2 = 0%, Analysis 1.67). Restricting
the analysis to studies at low summary risk of bias removed hetero-
geneity, and there was a statistically significant difference in effect
size between subgroups at low versus moderate to high risk of bias
(P = 0.03, Analysis 1.67). Using fixed-effect methodology did not
alter the apparent lack of effect of LCn3 on arrhythmia (Analysis
1.66), and sensitivity analysis by compliance and study size also
suggested little or no effect of LCn3 on arrhythmia (Analysis 1.68).
Subgrouping by new or recurrent arrhythmias suggested differ-
ences between subgroups, with LCn3 increasing the risk of new ar-
rhythmias and reducing the risk of recurrent arrhythmia (Analysis
1.69). There were also statistically significant differences between
subgroups by fatality, with a suggestion that LCn3 increased the
risk of fatal arrhythmias but reduced the risk of non-fatal arrhyth-
mias (Analysis 1.70). Subgroup analyses by type of intervention,
replacement, baseline CVD risk, statin use, dose and study dura-
tion did not suggest any statistically significant differences between
subgroups (Analysis 1.71; Analysis 1.72; Analysis 1.73; Analysis
1.74; Analysis 1.75; Analysis 1.76).
Meta-regression suggested a marginally significant negative dose-
response relationship with LCn3 fats, such that lower dose was
associated with lower risk of arrhythmia (P = 0.06, Table 7). The
effect remained marginally significant when we controlled for pri-
mary or secondary prevention and study duration (P = 0.09). Be-
cause of the negative direction of this apparent dose-response re-
lationship, we assumed it was likely to be a chance occurrence re-
sulting from running a large number of statistical tests. There was
also a marginally significant relationship for arrhythmia with pri-
mary versus secondary prevention, suggesting greater reduction in
arrhythmia risk in primary prevention (P = 0.07, Table 7). There
were no other suggested relationships.
GRADE assessment suggested moderate-quality evidence that
long-chain omega-3 fat intake probably makes little or no differ-
ence to risk of arrhythmia (moderate-quality/certainty evidence,
downgraded once for imprecision).
Effects of ALA on primary health outcomes
See Summary of findings 2 for a summary of our evidence on
effects of ALA on our primary outcomes.
As there were fewer than 10 studies for all ALA analyses we did
not use funnel plots, though we did run sensitivity analyses and
subgroups. We assessed ALA dose-response and duration effects
in meta-regression of all included LCn3, ALA, omega-6 and total
PUFA trials (but not of ALA trials alone as there were too few
studies to carry out meta-regression with any reliability).
All-cause mortality (ALA)
Moderate-quality evidence suggests that ALA intake probably
makes little or no difference to all-cause mortality.
There was little or no effect of increasing ALA omega-3 fats on all-
cause mortality, with 458 deaths in more than 18,000 participants
involved in four studies (RR 1.01, 95% CI 0.84 to 1.20, I2 = 0%,
Analysis 4.1).
Sensitivity analyses removing RCTs not at low summary risk of
bias left three trials with 375 deaths, again suggesting little or no
effect (RR 1.02, 95% CI 0.72 to 1.45, I2 = 3%, Analysis 4.3).
Using fixed-effect meta-analysis suggested a 6% increase in risk of
all-cause mortality with increased ALA (RR 1.06, 95% CI 0.84
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to 1.34, Analysis 4.2), while limiting the analysis to studies at low
risk of compliance problems showed a 5% increase, and including
only larger trials showed little or no effect (Analysis 4.4).
Subgrouping by ALA dose, trial duration, statin use, replacement,
primary or secondary prevention, or intervention type did not
result in any significant differences between subgroups (Analysis
4.5; Analysis 4.6; Analysis 4.7; Analysis 4.8; Analysis 4.9; Analysis
4.10). As there was no suggestion of effect in any subgroup, we
did not carry out meta-regression.
GRADE assessment suggested that ALA intake probably makes
little or no difference to all-cause mortality (moderate-quality/
certainty evidence, downgraded once for imprecision).
Cardiovascular mortality (ALA)
Moderate-quality evidence suggests that increasing ALA intake
probably has little or no effect on cardiovascular mortality.
Four studies contributed data to this outcome. There was little
or no effect of increasing ALA omega-3 fats on cardiovascular
mortality (RR 0.96, 95%CI 0.74 to 1.25, I2 = 0%, Analysis 4.11),
but confidence intervals were very wide. Analyses included 219
CVD deaths in > 18,000 participants.
Sensitivity analyses using fixed-effect meta-analysis did alter the
lack of effect (RR 0.96, 95% CI 0.74 to 1.25, Analysis 4.12).
Removing studies not at low risk of bias left three trials with 165
cardiovascular deaths, suggesting a 5% reduction of cardiovascu-
lar death risk with higher ALA (RR 0.95, 95% CI 0.70 to 1.28,
Analysis 4.13). Sensitivity analysis by compliance or study size
again suggested 6%and 4% reductions, respectively, inCVDmor-
tality risk (Analysis 4.14).
Subgrouping by ALA dose, study duration, replacement, inter-
vention type, statin use or primary/secondary prevention did not
suggest important differences between subgroups (Analysis 4.15;
Analysis 4.16; Analysis 4.17; Analysis 4.18; Analysis 4.19; Analysis
4.20). Meta-regression to assess for effects of ALA dose on cardio-
vascular mortality did not suggest dose effects (P = 0.91, Table 2).
GRADE assessment suggested that increasing ALA intake proba-
bly has little or no effect on cardiovascular mortality (moderate-
quality/certainty evidence, downgraded once for imprecision).
Cardiovascular events (ALA)
GRADE assessment suggested that increasing ALA intake may
reduce the risk of cardiovascular events by a small amount.
There was a 5% reduction in risk of cardiovascular events in five
trials with increased ALA intake (RR 0.95, 95% CI 0.83 to 1.07,
I2 = 0%, 884 out of > 19,000 participants experienced at least one
cardiovascular event, Analysis 4.21).
Sensitivity analyses removing studies at moderate to high risk of
bias left three trials in which 691 of > 5,000 enrolled participants
experienced at least one cardiovascular event, suggesting a 9%
reduction in risk of CVD events with higher ALA (RR 0.91, 95%
CI 0.79 to 1.04, I2 = 0%, Analysis 4.23). Fixed-effect analysis
suggested a 5% reduction in risk (Analysis 4.22), while studies at
low risk of compliance bias suggested a 10% reduction in risk, and
larger studies a 5% reduction (Analysis 4.24).
Subgrouping by ALA dose, study duration, replacement, inter-
vention type, statin use or primary/secondary prevention did not
suggest significant differences between subgroups (Analysis 4.25;
Analysis 4.26; Analysis 4.27; Analysis 4.28; Analysis 4.29; Analysis
4.30). Meta-regression to assess for effects of ALA dose on cardio-
vascular events did not suggest any dose effects (P = 0.70, Table
3).
GRADE assessment suggested that increasing ALA intake may
reduce the risk of cardiovascular events by a small amount (low-
quality/certainty evidence, downgraded once for risk of bias and
once for imprecision).
Coronary heart disease mortality (ALA)
GRADE assessment suggested that increasing ALA intake proba-
bly reduces the risk of CHD mortality a little.
Three studies reported 193 CHD deaths in > 18,000 participants,
suggesting a 5% reduction in CHDmortality with increased ALA
(RR 0.95, 95% CI 0.72 to 1.26, I2 = 0%, Analysis 4.31).
Sensitivity analyses using fixed-effect meta-analysis did not alter
the effect (RR 0.95, 95% CI 0.72 to 1.26, Analysis 4.32). Studies
at low summary risk of bias suggested a 7% reduction in risk of
CHD mortality (including 2 trials with 4947 participants, RR
0.93, 95% CI 0.67 to 1.30, I2 = 0%, Analysis 4.33), with similar
effects in studies at low risk of compliance bias, or low risk of small
study bias (Analysis 4.34).
Subgrouping by ALA dose, study duration, replacement, interven-
tion type, statin use, primary/secondary prevention or previous
history of coronary artery disease did not suggest important differ-
ences between subgroups (Analysis 4.35; Analysis 4.36; Analysis
4.37; Analysis 4.38; Analysis 4.39; Analysis 4.40; Analysis 4.41).
Meta-regression to assess for effects of ALA dose on CHD deaths
did not suggest any dose effects (P = 0.93, Table 4).
GRADE assessment suggested that increasing ALA intake proba-
bly reduces the risk of CHD mortality a little (moderate-quality/
certainty evidence, downgraded once for imprecision).
Coronary heart disease events (ALA)
Low-quality evidence suggests that ALA intake may make little or
no difference to CHD events.
Three studies contributed data to this outcome, with 396 out of
over 18,000 participants experiencing at least one CHD event.
There was little or no effect on CHD risk with increased ALA (RR
1.00, 95% CI 0.82 to 1.22, I2 = 2%, Analysis 4.42).
Sensitivity analyses using fixed-effect meta-analysis did not alter
the lack of effect (RR 1.00, 95% CI 0.82 to 1.21, Analysis 4.43).
Removing studies not at low summary risk of bias left two stud-
ies with almost 5000 participants, suggesting a 9% reduction in
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risk of a CHD event (RR 0.91, 95% CI 0.71 to 1.15, Analysis
4.44), similar to sensitivity analysis omitting studies with potential
compliance problems (Analysis 4.45), though no effects were seen
when restricting analysis to larger trials (Analysis 4.45).
Subgrouping by ALA dose, study duration, replacement, interven-
tion type, statin use, primary/secondary prevention or previous
history of coronary artery disease did not suggest important differ-
ences between subgroups (Analysis 4.46; Analysis 4.47; Analysis
4.48; Analysis 4.49; Analysis 4.50; Analysis 4.51; Analysis 4.52).
Meta-regression did not suggest that there was a direct relationship
between ALA dose and CHD events (Table 5).
Given the differences in sensitivity analyses, GRADE assessment
suggested that ALA intake may make little or no difference to
CHD events (low-quality/certainty evidence, downgraded once
for risk of bias and once for imprecision).
Stroke (ALA)
The effect of ALA intake on stroke is unclear, as the evidence is of
very low quality.
Five RCTs involved 51 people out of more than 18,000 partici-
pants experiencing a stroke, suggesting a 15% increase in stroke
risk with increased ALA (RR1.15, 95% CI 0.66 to 2.01, I2 = 0%,
Analysis 4.53). Sensitivity analyses removing studies not at low
summary risk of bias left three studies with 27 stroke events and
no suggestion of effect (Analysis 4.55). Using a fixed-effect model
suggested a 23% increased risk of stroke (Analysis 4.54), while
removing studies at high risk of bias due to compliance suggested
a 15% reduction in stroke risk, while larger studies suggested a
15% greater stroke risk (Analysis 4.56).
Subgrouping by ALA dose, study duration, replacement, inter-
vention type, statin use or primary/secondary prevention did not
result in significant differences between subgroups (Analysis 4.57;
Analysis 4.58; Analysis 4.59; Analysis 4.60; Analysis 4.61; Analysis
4.62).When examining data reported by type of stroke, only three
studies reported on 28 ischaemic strokes, with no clear effects, and
no studies reported on haemorrhagic stroke (Analysis 4.63).Meta-
regression did not suggest any relationship between ALA dose and
risk of stroke (Table 6).
The effect of ALA on stroke is unclear as the evidence is of very
low quality (downgraded twice for risk of bias and once for im-
precision).
Arrhythmia (ALA)
Moderate-quality evidence suggested that ALA intake probably
reduces the risk of arrhythmias.
Only one study reported effects of ALA on arrhythmia, with 141
new arrhythmias in 4837 participants, suggesting a 21% reduction
in arrhythmia but with wide confidence intervals (RR 0.79, 95%
CI 0.57 to 1.10, Analysis 4.64). The results were identical when
sensitivity analysis retained only studies at low summary risk of
bias (as we judged the single included study to be at low risk
of bias, Analysis 4.65). As there was only one trial, we did not
carry out further sensitivity analyses or subgrouping. There was
no suggestion of a dose-response relationship between ALA and
arrhythmia risk in meta-regression (P = 0.67, Table 7).
GRADE assessment suggested that ALA intake probably re-
duces the risk of arrhythmias (moderate-quality/certainty evi-
dence, downgraded once for imprecision).
Secondary outcomes
See Summary of findings 3 for a summary of our evidence on
effects of long-chain omega-3 fats and ALA on serum lipids and
measures of adiposity.
Effects of long-chain omega-3 fats (EPA, DHA and DPA) on
secondary health outcomes
We did not carry out sensitivity analyses or subgrouping on sec-
ondary outcomes, except for adiposity and lipids (which were key
outcomes). We did carry out some post hoc sensitivity analyses
to further assess effects of LCn3 on MI, to ascertain whether the
suggested protection was stable to sensitivity analyses.
Major adverse cerebrovascular or cardiovascular events
(LCn3)
Five trials reported on major adverse cerebrovascular or cardiovas-
cular events (MACCEs) in more than 34,000 participants, 4232
of whom suffered from a MACCE, suggesting little or no effect
of LCn3 fats (RR 1.03, 95% CI 0.97 to 1.09, I2 = 0%, Analysis
2.1).
Myocardial infarction (LCn3)
Twenty-three studies (> 72,000 participants) reported on total
(fatal and non-fatal) myocardial infarction (MI). Meta-analyses
suggested that increasing LCn3 fats resulted in a small reduction
in total MI (RR 0.95, 95% CI 0.88 to 1.03, I2 = 0%, 2200 MI
events, Analysis 2.2). This was confirmed in sensitivity analyses
limited to studies without compliance problems and to studies that
randomised at least 100 participants (Analysis 2.4), but analyses
limited to studies at low summary risk of bias suggest little or no
effect of LCn3 on MI (RR 1.03, 95% CI 0.92 to 1.15, I2 = 0%,
> 30,000 participants in 11 trials, and reporting on 1154 people
experiencing at least one MI, Analysis 2.3). This suggests little or
no true effect of LCn3 on MI.
We ran subgroup analyses by fatality at the request of the WHO
NUGAG Subgroup on Diet and Health, finding no significant
difference between fatal and non-fatal MI subgroups (P = 0.23,
Analysis 2.5).
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Sudden cardiac death (LCn3)
There was little or no effect of LCn3 fats on sudden cardiac death
(RR 0.97, 95%CI 0.80 to 1.18, I2 = 38%, 1274 deaths, 14 studies
in > 65,000 people, Analysis 2.6).
Angina (LCn3)
Meta-analysis of 11 studies involving more than 39,000 partic-
ipants, 2418 of whom reported new or worsening angina, sug-
gested little or no effect of increasing LCn3 fats (RR 0.99, 95%
CI 0.92 to 1.07, I2 = 0%, Analysis 2.7).
Heart failure (LCn3)
Meta-analysis suggested a small effect for LCn3 fatty acids on heart
failure diagnosis in 15 trials with 4098 people experiencing events
(RR 0.93, 95% CI 0.85 to 1.03, I2 = 31%, Analysis 2.8). Because
of this suggested effectiveness, we ran a sensitivity analysis limited
to the six studies at low summary risk of bias, which suggested little
effect (RR 0.97, 95% CI 0.89 to 1.06, I2 = 0%, 1809 participants
experiencing heart failure). For this reasonwe concluded that there
was little or no effect of LCn3 on risk of heart failure.
Revascularisation (LCn3)
Meta-analysis suggested little or no effect of LCn3 fats on revas-
cularisation (all types combined, RR 0.98, 95% CI 0.94 to 1.03,
6558participants experiencing revascularisation, I2 =0%,Analysis
2.9). Data on angioplasty alone were similar (RR 0.96, 95% CI
0.74 to 1.24, 215 events), and there were insufficient reported
CABGs to give meaningful results (9 events, Analysis 2.9).
Peripheral arterial disease (LCn3)
Meta-analysis suggested that LCn3 reduced the risk of peripheral
arterial disease (PAD) by 7% (RR 0.93, 95% CI 0.74 to 1.18, I2 =
0%, 282 events in > 49,000 participants, 7 trials, Analysis 2.10).
All relevant studies had randomised at least 100 participants, so
this sensitivity analysis did not alter the effect, but limiting the
analysis to studies at low risk of compliance bias suggested little
or no effect of LCn3 on PAD, and limiting analyses to studies
at low summary risk of bias suggested an increase in PAD with
increased LCn3 (Analysis 2.11; Analysis 2.12). The effect of LCn3
on peripheral arterial disease is unclear - there may be increased,
decreased or no effect.
Acute coronary syndrome (LCn3)
There were limited data on effects of increasing LCn3 fats on acute
coronary syndrome (RR 1.19, 95% CI 0.71 to 2.00, I2 = 0%, 55
events in > 2000 participants, 2 trials, Analysis 2.13).
Body weight, body mass index (BMI) and other measures of
adiposity (LCn3)
Body weight
High-quality evidence shows that LCn3 intake makes little or no
difference to body weight.
Twelve studies, 11 of which were included in meta-analysis, re-
ported on the effect of increasing LCn3 on body weight, suggest-
ing little or no effect in > 15,000 participants (mean difference
(MD)−0.01 kg, 95%CI−0.84 to 0.82, I2 = 49%, Analysis 2.14).
Sensitivity analysis limited to studies at low summary risk of bias,
low risk from compliance, larger trials or fixed-effect analysis (not
shown) did not alter this lack of effect (Analysis 2.15; Analysis
2.16).
Subgroup analysis by intervention type, primary or secondary pre-
vention, statin use and trial durationdidnot suggest important dif-
ferences between subgroups (Analysis 2.19; Analysis 2.20; Analysis
2.21; Analysis 2.22). There was a marginally significant difference
between dose subgroups (P = 0.06, Analysis 2.17) and increased
body weight when participants received very high LCn3 doses (>
4.4 g/d LCn3, MD 1.51 kg, 95% CI 0.28 to 2.75, I2 = 0%, 2
trials including 261 participants, Analysis 2.17). Subgrouping by
replacement suggested differences between subgroups (P < 0.001,
Analysis 2.18, with reduced body weight when LCn3 replaced
saturated fatty acids (SFA) or carbohydrates but increased weight
when LCn3 replaced nil or low LCn3 (Analysis 2.18).
Several studies clearly measured body weight but did not report
it in a useable way (Baldassarre 2006; Caldwell 2011; Deslypere
1992; EPE-A 2014; MARINA 2011; Nutristroke 2009). Body
weight is commonly measured in healthcare settings, so there may
be considerably more missing data than these.
GRADEevidence suggests high-quality evidence that LCn3 intake
makes little or nodifference to bodyweight (high-quality/certainty
evidence).
BMI
High-quality evidence shows that LCn3 intake makes little or no
difference to BMI.
Fourteen trials, 12 of which were included in meta-analysis, re-
ported on BMI, suggesting little or no effect of LCn3 on BMI
(MD 0.04 kg/m2, 95% CI −0.16 to 0.24, I2 = 40%, > 15,000
participants, Analysis 2.23). This lack of effect was also apparent
in sensitivity analyses limited to studies at low summary risk of
bias (Analysis 2.24), with good compliance or with large study size
(Analysis 2.25), as well as fixed-effect analysis (not shown). Sub-
group analyses by primary or secondary prevention, LCn3 dose,
intervention type, statin use and trial duration did not suggest
important differences between subgroups (Analysis 2.26; Analysis
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2.28; Analysis 2.29; Analysis 2.30; Analysis 2.31). There were sig-
nificant differences between subgroups when subgrouped by re-
placement, suggesting lower BMI when LCn3 was replaced by
SFA and carbohydrate, but increased BMI with LCn3 in other
replacements (P = 0.04, Analysis 2.27).
Several studies clearly measured BMI but did not report it in a
useable way (Caldwell 2011; EPE-A 2014; Nutristroke 2009;
Ramirez-Ramirez 2013; Sofi 2010), suggesting that missing data
may be an issue with this outcome.
GRADE evidence suggests high-quality evidence that LCn3 in-
take makes little or no difference to BMI (high-quality/certainty
evidence).
Other measures of adiposity
Few studies reported on other measures of adiposity (percentage
body fat, percentage visceral fat, waist circumference, waist/hip
ratio, abdominal circumference and hip circumference) with some
suggesting higher adiposity and some lower adiposity in groups
with more LCn3 (Analysis 2.32).
Serum lipids (LCn3)
Several studies clearly measured lipids but did not report them in
a way that we could include in our meta-analyses. These generally
included Baldassarre 2006, Gill 2012, Ramirez-Ramirez 2013 and
Reed 2014, plus Ahn 2016, Caldwell 2011, Franzen 1993 and
Rossing 1996, which assessed but did not report triglycerides, and
Franzen 1993, which measured but did not provide useable data
for HDL and LDL cholesterol. For this reason missing data may
potentially bias these outcomes.
Serum total cholesterol
Moderate-quality evidence shows that LCn3 intake probably
makes little or no difference to serum total cholesterol.
Twenty-eight trials provided data on long-term effects of LCn3
fats on serum total cholesterol, suggesting little or no effect inmore
than 37,000 participants (MD −0.01 mmol/L, 95% CI −0.5 to
0.04, I2 = 19%, Analysis 2.33). Sensitivity analyses limited to trials
at low summary risk of bias, low risk of compliance issues, and
larger trials also suggested little or no effect of LCn3 on serum total
cholesterol (Analysis 2.34; Analysis 2.35), but fixed-effect meta-
analysis suggested that LCn3 reduced serum total cholesterol (MD
−0.04 mmol/L, 95% CI−0.06 to−0.02, I2 = 19%, not shown).
Subgrouping by duration did not suggest any differential effects of
LCn3 (Analysis 2.39). There were significant differences between
subgroups by dose but no logical sequence suggesting a true dose-
response effect (P = 0.03, Analysis 2.36). There were also sub-
group differences for replacement and intervention type (Analysis
2.37; Analysis 2.38), with reductions in serum total cholesterol
when supplemental capsules were used and when LCn3 replaced
carbohydrates (Analysis 2.36; Analysis 2.37; Analysis 2.38).
GRADE assessment suggests moderate-quality evidence that
LCn3 intake probably makes little or no difference to serum to-
tal cholesterol (moderate-quality/certainty evidence, downgraded
once for imprecision).
Serum triglycerides
High-quality evidence suggests that LCn3 intake reduces serum
triglycerides in a dose-dependent manner.
LCn3 fats significantly reduced serum triglycerides in > 35,000
participants in 23 trials (MD −0.24 mmol/L, 95% CI −0.31
to −0.16, I2 = 48%, Analysis 2.42). This effect was not lost in
sensitivity analysis excluding studies at moderate to high risk of
bias, those without clear compliance or small studies (Analysis
2.43; Analysis 2.44), or using fixed-effect analysis (not shown).
Subgrouping suggested that the reduction of serum triglycerides
did not differ between subgroups by primary or secondary pre-
vention, statin use, replacement, intervention type or trial dura-
tion ( Analysis 2.46; Analysis 2.47; Analysis 2.48; Analysis 2.49;
Analysis 2.50). There was a suggestion of a dose-response relation-
ship with greater reductions in triglycerides at higher LCn3 doses,
with significant differences between subgroups (P = 0.04, Analysis
2.45).
GRADE evidence suggests high-quality evidence that LCn3 in-
take reduces serum triglycerides in a dose-dependent manner (not
downgraded).
HDL cholesterol
High-quality evidence suggests that LCn3 intake increases HDL
cholesterol a small amount.
Twenty-seven trials including more than 37,000 participants sug-
gested an increase in serumHDL cholesterol with increased LCn3
(MD 0.02 mmol/L, 95% CI 0.00 to 0.04, P = 0.03, I2 = 48%,
Analysis 2.51). There was still a suggestion of a small HDL in-
crease when we limited analysis to the eight studies at low sum-
mary risk of bias (MD 0.03 mmol/L, 95% CI −0.01 to 0.07, I2
= 66%, > 14,000 participants, Analysis 2.52) where heterogene-
ity was very high. Limiting analyses by compliance and study size
(Analysis 2.53) and in fixed-effect analysis (not shown), results
suggested increases in HDL with LCn3. There were no significant
differences between subgroups in any analysis except by duration,
where shorter trials suggested HDL increases, with no effect in
longer trials (P = 0.05, Analysis 2.57). There were no important
differences between other subgroups and no suggestion of a dose-
response relationship (Analysis 2.54; Analysis 2.55; Analysis 2.56;
Analysis 2.58; Analysis 2.59).
GRADE assessment suggests high-quality evidence that LCn3 in-
take increases HDL cholesterol a little (not downgraded).
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LDL cholesterol
GRADE assessment suggests moderate-quality evidence that
LCn3 intake probably makes little or no difference to LDL choles-
terol.
There was little or no effect of increasing LCn3 on serum LDL
cholesterol in over 35,000 participants from 23 trials (MD 0.01
mmol/L, 95% CI −0.01 to 0.03, I2 = 0%, Analysis 2.60). This
lack of effect did not alter in sensitivity analyses limited to trials
at low summary risk of bias, to trials with good evidence of com-
pliance (Analysis 2.61) , larger studies (Analysis 2.62) or in fixed-
effect meta-analysis (not shown). We saw no statistically signifi-
cant differences between subgroups except for with regard to statin
use, where there was an increase in LDL cholesterol in nine trials
where statin use was low (Analysis 2.63; Analysis 2.64; Analysis
2.65; Analysis 2.66; Analysis 2.67; Analysis 2.68).
GRADE assessment suggests moderate-quality evidence that
LCn3 intake probably makes little or no difference to LDL choles-
terol (moderate-quality/certainty evidence, downgraded once for
imprecision).
Effects of ALA on secondary health outcomes
We did not plan any sensitivity or subgroup analyses on secondary
outcomes, except for adiposity and lipids (key outcomes). As fewer
than 10 ALA trials were available for these outcomes, we carried
out only sensitivity analyses.
Major adverse cerebrovascular or cardiovascular events (ALA)
One trial reported on MACCEs in 110 participants, 9 of whom
experienced an event. There were insufficient data to suggest any
effect of ALA on MACCEs (RR 1.12, 95% CI 0.32 to 3.95,
Analysis 5.1).
Myocardial infarction (ALA)
Three studies reported that 333 out of more than 18,000 partic-
ipants experienced a fatal or non-fatal MI, suggesting little or no
effect of ALA on MI (RR 1.00, 95% CI 0.76 to 1.32, I2 = 26%,
Analysis 5.2).
We carried out subgroup analyses by fatality at the request of
the WHO NUGAG Subgroup on Diet and Health, and these
suggested no significant differences between fatal and non-fatal
MI subgroups (P = 0.36, Analysis 5.3).
Sudden cardiac death (ALA)
No studies assessed effects of ALA on sudden cardiac death.
Angina (ALA)
Two trials assessed the effects of increasing ALA on diagnosis of
new or worsening angina (39 of > 13,000 participants experienced
this). There were insufficient data to suggest any effect of ALA on
angina (RR1.41, 95% CI 0.75 to 2.64, I2 = 0%, Analysis 5.4).
Heart failure (ALA)
No studies assessed effects of ALA on heart failure.
Revascularisation (ALA)
Only one trial (3 events in 266 participants) reported on the effects
of increased ALA on revascularisation (RR 0.72, 95% CI 0.07 to
7.84, 3 events, Analysis 5.5) or CABG specifically (RR 0.29, 95%
CI 0.01 to 5.93, 2 events, Analysis 5.5). There were insufficient
data to suggest any effect of ALA on revascularisation.
Peripheral arterial disease (ALA)
Meta-analysis suggested no clear effect of ALA on PAD in a single
study (RR 0.25, 95% CI 0.05 to 1.17, 10 of the > 13,000 par-
ticipants experienced PAD, Analysis 5.6). There were insufficient
data to suggest any effect of ALA on the outcome.
Acute coronary syndrome (ALA)
There were no trials assessing effects of ALA on acute coronary
syndrome.
Body weight, BMI and other measures of adiposity (ALA)
Low-quality evidence suggests that ALA intake may make little
or no difference to BMI, but the effect of LCn3 intake on body
weight is unclear as the evidence is of very low quality.
Four studies reported on the effect of ALA on body weight in
664 participants, suggesting some weight reduction in those tak-
ing more ALA but with extremely high heterogeneity (MD−1.49
kg, 95% CI −4.17 to 1.18, I2 = 73%, Analysis 5.7). Sensitivity
analysis using fixed-effect meta-analysis suggested a slight increase
in body weight with ALA (Analysis 5.8), while no studies were at
low summary risk of bias (Analysis 5.9). Retaining only trials at
low risk for compliance bias or only larger trials suggested weight
reduction with ALA (Analysis 5.10). There were no significant dif-
ferences between subgroups by intervention type, dose, duration,
replacement, statin use, or primary or secondary prevention of
CVD (Analysis 5.11; Analysis 5.12; Analysis 5.13; Analysis 5.14;
Analysis 5.15; Analysis 5.16). GRADE assessment suggests that
the effect of ALA intake on body weight is unclear, as the evidence
is of very low quality (downgraded once each for risk of bias, in-
consistency and imprecision).
Three trials reported on BMI, suggesting a reduction in BMI with
increased ALA (MD −0.42 kg/m2, 95% CI −1.53 to 0.69, I2
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= 65%, 1581 participants, Analysis 5.17), again with high het-
erogeneity. Sensitivity analyses using fixed-effect analysis or only
retaining studies at low summary risk of bias suggested a small in-
crease in BMI with ALA (Analysis 5.18; Analysis 5.19), while lim-
iting to studies at low risk of compliance bias or eliminating smaller
studies suggested a small reduction in BMI with increased ALA
(Analysis 5.20). There were no statistically significant differences
between subgroups differentiated by replacement or statin use
(Analysis 5.23; Analysis 5.25), but there were differences by dose -
subgrouping by dose suggested greater reduction of BMI in studies
giving more ALA (P = 0.03, Analysis 5.21). All included studies
gave supplemental foods (Analysis 5.22). There were greater re-
ductions in BMI in shorter studies (P = 0.02, Analysis 5.24) and
in primary prevention studies (P = 0.03, Analysis 5.26), but the
inclusion of Dodin 2005 in any subgroup tended to differenti-
ate that group from the others. GRADE assessment suggests low-
quality evidence that ALA intake may make little or no difference
to BMI (low-quality/certainty evidence, downgraded once each
for imprecision and inconsistency).
One study reported on visceral adipose tissue, suggesting no clear
effect, but three trials reported on waist circumference.Meta-anal-
ysis of two of these suggested that increasing ALA resulted in re-
duced weight circumference (MD −1.59 cm, 95% CI −3.10 to
−0.07, I2 = 0%, Analysis 5.27). However, the single trial that we
could not include in the meta-analysis due to lack of information
on variance suggested effects in the opposite direction. Sensitivity
analyses (only retaining studies at low summary risk of bias, not
shown) removed all trials.
Serum lipids (ALA)
Serum total cholesterol
Low-quality evidence suggests that ALA intake may make little or
no difference to serum total cholesterol.
Six trials provided data on the long-term effects of ALA on serum
total cholesterol, suggesting that increased ALA intake leads to a
small reduction in total cholesterol, but with high heterogeneity
(MD −0.09 mmol/L, 95% CI −0.23 to 0.05, I2 = 63%, in >
2000 participants, Analysis 5.28). Restricting analyses to studies
at low summary risk of bias suggested no effect of ALA (Analysis
5.30), but fixed-effect analysis suggested that the intervention led
to a reduction (Analysis 5.29), as did sensitivity analyses limited
to studies at low risk of compliance bias or larger studies (Analysis
5.31). All studies provided food supplements (Analysis 5.33), but
subgroup analyses suggested greater reductions in total cholesterol
in shorter duration studies (P = 0.02, Analysis 5.35). Other differ-
ences between subgroups resulted from effects groups where ALA
replacement or statin use was ’unclear’ (Analysis 5.34; Analysis
5.36), or there were no differences (Analysis 5.32; Analysis 5.37).
GRADE assessment suggests low-quality evidence that ALA in-
take may make little or no difference to serum total cholesterol
(downgraded once each for imprecision and inconsistency).
Serum triglycerides
Moderate-quality evidence suggests that ALA intake probably
makes little or no difference to serum triglycerides.
There was little or no effect of ALA on serum triglycerides in 1776
participants in six trials (MD −0.03 mmol/L, 95% CI −0.11
to 0.05, I2 = 0%, Analysis 5.38). There was little or no effect of
ALA in sensitivity analysis removing trials of moderate to high
risk of bias (Analysis 5.40), in fixed-effect meta-analysis (Analysis
5.39), or limiting by compliance bias or study size (Analysis 5.41).
Subgrouping suggested no important differential effects by dose,
duration, replacement, intervention type, statin use, or primary
or secondary prevention (Analysis 5.42; Analysis 5.43; Analysis
5.44; Analysis 5.45; Analysis 5.46; Analysis 5.47). GRADE assess-
ment suggests moderate-quality evidence that ALA intake prob-
ably makes little or no difference to serum triglycerides (down-
graded once for imprecision).
HDL cholesterol
Moderate-quality evidence suggests that ALA probably reduces
HDL cholesterol.
There was little or no effect of ALA on HDL cholesterol in 1776
participants of 6 trials (MD −0.02 mmol/L, 95% CI −0.08 to
0.03, I2 = 53%, Analysis 5.48), although there were reductions
of HDL in both analyses by risk of bias and using fixed-effect
meta-analysis (Analysis 5.49; Analysis 5.50) with similar effects in
studies with good compliance and in larger trials (Analysis 5.51).
A further trial, WAHA 2016, also measured HDL but did not
provide data in a useable format for meta-analysis. There was a
suggestion of greater HDL reduction with greater ALA dose (P =
0.09, Analysis 5.52), but no other subgrouping effects were evi-
dent (Analysis 5.53; Analysis 5.54; Analysis 5.55; Analysis 5.56;
Analysis 5.57). GRADE assessment suggests moderate-quality ev-
idence that ALA probably reduces HDL cholesterol (downgraded
for imprecision).
LDL cholesterol
Low-quality evidence suggests that ALA intake may make little or
no difference to LDL cholesterol.
There was a small reduction of LDL cholesterol with ALA in 2201
participants of 7 trials (MD −0.05 mmol/L, 95% CI −0.15 to
0.04, I2 = 46%, Analysis 5.58), with similar effects in studies with
good compliance and in larger trials (Analysis 5.61). While fixed-
effect analysis suggested marginal statistical significance of this
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reduction (P = 0.06, Analysis 5.59), there were no effects when
we limited analyses to studies at low summary risk of bias (MD
0.02 mmol/L, 95% CI −0.05 to 0.10, I2 = 0%, Analysis 5.60).
Subgrouping suggested no differences in effect by ALA dose or
primary or secondary prevention (Analysis 5.62; Analysis 5.67),
but shorter studies, those with unclear replacement and unclear
statin use suggested reductions in LDL with ALA (Analysis 5.64;
Analysis 5.65; Analysis 5.66). All studies provided supplemental
foods (Analysis 5.63). GRADE assessment suggests low-quality
evidence that ALA intake may make little or no difference to LDL
cholesterol (downgraded once each for risk of bias and impreci-
sion).
Tertiary outcomes
Effects of long-chain omega-3 fats (EPA, DHA and DPA) on
tertiary health outcomes
We extracted these outcomes from studies that we included for
other outcomes, so we did not assess them completely or system-
atically. We did not carry out sensitivity analyses or subgrouping
for these outcomes. We are aware of missing data for some of these
outcomes, including blood pressure in Ramirez-Ramirez 2013.
Blood pressure (LCn3)
Fifteen included trials (> 34,000 participants) contributed data on
effects of LCn3 fats on blood pressure. Meta-analysis suggested
little or no effect of LCn3 on systolic (MD 0.02 mmHg, 95% CI
−0.32 to 0.35, I2 = 0%, Analysis 3.1) or diastolic (MD −0.02
mmHg, 95% CI −0.22 to 0.17, I2 = 0%, Analysis 3.1) blood
pressure in trials of at least one year.
Serious adverse effects (LCn3)
As part of the larger set of reviews we formally systematically
reviewed effects of omega-3 fats on type 2 diabetes diagnoses,
measures of glucose metabolism (Brown 2017), cancers including
breast cancer (Hanson 2017b), neurocognitive outcomes such as
dementia (Jimoh 2017), irritable bowel disease (IBD) and inflam-
matory factors (Thorpe 2017), depression and anxiety (Hanson
2017a), and functional outcomes (Abdelhamid 2017), so we do
not present these outcomes here.
We did collect data on the following potentially important health
outcomes (Analysis 3.2).
• Any serious adverse event (RR 1.05, 95% CI 0.78 to 1.41, I
2 NA, 126 events in > 400 participants in 1 trial).
• Bleeding (RR 1.06, 95% CI 0.73 to 1.52, I2 = 49%, 374
events in > 45,000 participants in 8 trials).
• Gastrointestinal hospitalisation (RR 1.75, 95% CI 0.53 to
5.79, I2 NA, 11 events in 200 participants in 1 trial).
• Pulmonary embolus or DVT (RR 1.25, 95% CI 0.41 to
3.78, I2 = 11%, 18 events in > 3000 participants in 4 trials).
• Progression to advanced age-related macular degeneration
(RR 0.96, 95% CI 0.90 to 1.02, I2 NA, 2049 events in > 4000
participants in 1 trial).
• Thrombophlebitis: no data identified.
• Urolithiasis: no data identified.
Side effects (non-serious, LCn3)
To assess side effects we collected data on the following potential
side effects (Analysis 3.3).
• Withdrawal: the data suggest more participants taking
LCn3 fats dropped out because of side effects (RR 1.16, 95% CI
0.99 to 1.36, I2 = 1%, 620 dropouts in > 16,000 participants, 23
trials).
• Increased abdominal pain or discomfort: data suggest an
association with higher LCn3 (RR 1.10, 95% CI 0.84 to 1.45, I2
= 24%, 303 events in > 14,000 participants, 7 trials).
• Diarrhoea: the data suggested an increased risk with
increased LCn3 (RR 1.15, 95% CI 0.92 to 1.43, I2 = 0%, 284
events in > 2000 participants, 10 trials).
• Nausea: risk increased with LCn3 (RR 1.76, 95% CI 1.25
to 2.48, I2 = 0%, 140 events in > 1000 participants, 6 trials).
• Any gastrointestinal side effect: risk also appeared to
increase with LCn3, albeit with very high heterogeneity (RR
1.12, 95% CI 0.94 to 1.34, I2 = 74%, 2545 events in > 65,000
participants, 29 trials).
• Skin problems, including itching or rashes: these were not
affected by LCn3 in a meta-analysis with high heterogeneity (RR
1.04, 95% CI 0.47 to 2.30, I2 = 72%, 290 events in > 36,000
participants, 8 trials).
• Headache or worsening migraine: there were limited data
on this outcome (RR 0.81, 95% CI 0.48 to 1.36, I2 = 0%, 55
events in 996 participants, 3 trials).
• Reflux: there were limited data (RR 1.42, 95% CI 0.71 to
2.81, I2 NA, 29 events in 202 participants, 1 trial).
• Joint lumbar and muscle pain: one study provided data
suggesting that LCn3 reduced the risk of such pain (RR 0.80,
95% CI 0.64 to 0.99, 324 out of > 18,000 participants
experiencing pain).
• All adverse effects: there was no suggestion that LCn3
increased or decreased all side effects combined in a meta-
analysis with very high heterogeneity (RR 1.01, 95% CI 0.95 to
1.08, I2 = 81%, 9534 people with at least one side effect in >
38,000 participants, 13 trials).
Dropouts (LCn3)
Included studies reported 5515 dropouts over > 31,000 partici-
pants in 30 trials, suggesting no difference in dropout rates be-
tween intervention and control arms (RR 1.02, 95% CI 0.95 to
1.09, I2 = 11%, Analysis 3.4).
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Quality of life, economic costs (LCn3)
We found no data on quality of life outcomes or economic costs.
Effects of ALA on tertiary health outcomes
We extracted these outcomes from studies that we included for
other outcomes, so we did not assess them completely or system-
atically. We did not carry out sensitivity analyses or subgrouping
for these outcomes.
Blood pressure (ALA)
Four included trials (1671participants) contributed data on effects
of ALA on blood pressure. Meta-analysis suggested little or no
effect of ALA on systolic (MD −0.87 mmHg, 95% CI −4.48 to
2.75, I2 = 58%, Analysis 6.1) or diastolic (MD −1.42 mmHg,
95% CI−4.40 to 1.57, I2 = 74%, Analysis 6.1) blood pressure in
trials of at least one year. The heterogeneity in these results reflect
a single trial, FLAX-PAD 2013, that showed large diastolic and
systolic blood pressure effects. The other (larger) trials did not
suggest such effects.
Serious adverse effects (ALA)
As part of the larger set of reviews we formally systematically re-
viewed effects of omega-3 fats on type 2 diabetes diagnoses and
measures of glucose metabolism (Brown 2017), cancers including
breast cancer (Hanson 2017b), neurocognitive outcomes such as
dementia (Jimoh 2017), irritable bowel disease (IBD) and inflam-
matory factors (Thorpe 2017), depression and anxiety (Hanson
2017a), and functional outcomes (Abdelhamid 2017), so we do
not present these outcomes here.
We did collect data on the following potentially important health
outcomes (Analysis 6.2).
• Any serious adverse event: no data identified.
• Bleeding: no data identified.
• Gastrointestinal hospitalisation: no data identified.
• Pulmonary embolus or DVT: only one event was identified
in a single study, so there were insufficient data to assess effects
• Progression to advanced age-related macular degeneration:
no data identified.
• Thrombophlebitis: there were insufficient data to assess
effects (RR 1.59, 95% CI 0.72 to 3.51, I2 NA, 26 events, >
13,000 participants, 1 trial).
• Urolithiasis: there were insufficient data to assess effects
(RR 0.80, 95% CI 0.47 to 1.36, I2 NA, 54 events, > 13,000
participants, 1 trial).
Side effects (non-serious, ALA)
To assess potential side effects, we collected data on the following
(Analysis 6.3).
• Dropouts due to side effects: data suggested that ALA
increased the risk of withdrawal, although there was high
heterogeneity (RR 2.10, 95% CI 0.66 to 6.71, I2 = 62%, 68
events, > 3000 participants, 5 trials).
• Abdominal pain or discomfort: no data identified.
• Diarrhoea: a single study identified 10 participants with
diarrhoea, suggesting a higher risk of diarrhoea with greater ALA
intake (RR 3.82, 95% CI 0.82 to 17.88).
• Nausea: there were insufficient data to assess effects of ALA
(RR 6.29, 95% CI 0.33 to 118.93, I2 NA, 3 events, 110
participants, 1 trial).
• Any gastrointestinal side effect: there were insufficient data
to assess effects of ALA (RR 1.79, 95% CI 0.48 to 6.69, I2 =
69%, 46 events, > 3000 participants, 3 trials). The very high
heterogeneity suggests that gastrointestinal side effects may be
collected in different ways in different trials.
• Skin problems, including itching or rashes: no data
identified.
• Headache or worsening migraine: no data identified.
• Reflux: no data identified.
• All side effects combined: no data identified.
Dropouts (ALA)
Included studies reported 558 dropouts over > 3000 participants
in 6 trials, suggesting slightly higher dropout rates in participants
taking higher ALA (RR 1.08, 95% CI 0.92 to 1.25, I2 = 0%,
Analysis 6.4).
Quality of life, economic costs (ALA)
We found no data on quality of life outcomes or economic costs.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
High versus low ALA omega-3 fats for preventing cardiovascular disease (primary outcomes)
Patient or population: adults with or without exist ing CVD
Setting: part icipants were living at home for most or all of the durat ion of their trials. Most studies were carried out in high-income economies (World Bank 2018), but four
trials were carried out in upper-m iddle income countries (Argent ina, Iran, Turkey and China). No studies took place in low- or low-middle income countries.
Intervention: higher intake of ALA
Comparison: lower intake of ALA
The intervent ion was dietary supplementat ion, a provided diet or advice on diet. Supplementat ion may have been in oil or capsule form or as foodstuf f s provided, to be
consumed by mouth (excluding enteral and parenteral feeds and enemas). The foodstuf f s or supplements must have been: ref ined ALA, linseed (f lax), canola (rapeseed),
perilla, purslane, mustard seed, candlenut, st ill ingia or walnut as a food, oil, made into a spreading fat or supplementing another food (such as bread or eggs). For ALA sources
the product consumed had to have an omega-3 fat content of at least 10% of the total fat content
Outcomes Anticipated absolute effects* (95% CI) Relative effect
(95% CI)
of participants
(studies)
Certainty of the evi-
dence
(GRADE)
Comments
Risk with lower ALA Risk with higher ALA
All- cause mortality -
deaths
Assessed with: number
of part icipants dying of
any cause, whether re-
ported as an outcome
or a reason for dropout
Durat ion: range 12 to 40
months
25 per 1000 25 per 1000
(21 to 29)
RR 1.01
(0.84 to 1.20)
19327
(5 RCTs)
⊕⊕⊕©
Moderatea
Meta-analysis and sen-
sit ivity analyses sug-
gest risk increase of
less than 1%. ALA in-
take probably makes lit -
t le or no dif ference to
all-cause mortality
Cardiovascular mortal-
ity - cardiovascular
deaths
Assessed with: deaths
f rom any cardiovascu-
lar cause. Where this
was not available car-
diac death was used in-
stead where known
12 per 1000 12 per 1000
(9 to 15)
RR 0.96
(0.74 to 1.25)
18619
(4 RCTs)
⊕⊕⊕©
Moderateb
Meta-analysis and sen-
sit ivity analyses sug-
gest risk reduct ion of
less than 5%. ALA in-
take probably makes lit -
t le or no dif ference to
cardiovascular mortal-
ity
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Durat ion: range 12 to 40
months
Cardiovascular events
- cardiovascular events
Assessed with: number
of part icipants experi-
encing any cardiovas-
cular event
Durat ion: range 12 to 40
months
48 per 1000 47 per 1000
(39 to 57)
RR 0.95
(0.83 to 1.07)
19327
(5 RCTs)
⊕⊕©©
Lowc
Meta-analysis and sen-
sit ivity analyses sug-
gest risk reduct ion of
5% to 10%. ALA in-
take may reduce the
risk of cardiovascular
events but by a very
small amount (f rom 4.
8 to 4.7%). One thou-
sand people would need
to consume more ALA
to prevent a single per-
son experiencing a CVD
event (NNT=1000)
Coronary heart mortal-
ity - CHD deaths
Assessed with: Coro-
nary deaths, or where
these were not re-
ported, IHD death, fatal
MI or cardiac death (in
that order)
Durat ion: range 12 to 40
months
11 per 1000 10 per 1000
(8 to 14)
RR 0.95
(0.72 to 1.26)
18353
(3 RCTs)
⊕⊕⊕©
Moderated
Meta-analysis and sen-
sit ivity analyses sug-
gest risk reduct ion of
5% to 8%. ALA intake
probably reduces risk
of CHD mortality but
by a very small amount
(f rom 1.1 to 1.0%). One
thousand people would
need to consume more
ALA to prevent a single
person experiencing a
CHD death (NNT=1000)
Coronary Heart Dis-
ease - CHD events
Assessed with: num-
ber of part icipants ex-
periencing the f irst
outcome in this list
22 per 1000 22 per 1000
(17 to 28)
RR 1.00
(0.82 to 1.22)
19061
(4 RCTs)
⊕⊕©©
Lowe
Meta-analysis and sen-
sit ivity analyses sug-
gest risk reduct ion of
0% to 9%. ALA intake
maymake lit t le or no dif -
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reported for each
trial: CHD or coronary
events; total MI; acute
coronary syndrome; or
angina (stable and un-
stable)
Durat ion: range 12 to 40
months
ference to CHD events
Stroke
Assessed with: number
of part icipants experi-
encing at least one fatal
or non-fatal, ischaemic
or haemorrhagic stroke
Durat ion: range 12 to 40
months
2 per 1000 3 per 1000
(2 to 5)
RR 1.15
(0.66 to 2.01)
19327
(5 RCTs)
⊕©©©
Very lowf
Meta-analysis and sen-
sit ivity analyses sug-
gest risk increase of
−15% to 23%. The ef -
fect of ALA intake on
stroke is unclear as the
evidence is of very low
quality
Arrhythmias - AF, VT,
VF
Assessed with: num-
ber of part icipants ex-
periencing fatal or non-
fatal, new or recur-
rent arrhythmia, includ-
ing atrial f ibrillat ion,
ventricular tachycardia
and ventricular f ibrilla-
t ion
Durat ion: 1 trial of 40
months
33 per 1000 26 per 1000
(19 to 36)
RR 0.79
(0.57 to 1.10)
4837
(1 RCT)
⊕⊕⊕©
Moderateg
Meta-analysis and sen-
sit ivity analyses sug-
gest risk reduct ion of
21%. ALA intake prob-
ably reduces the risk
of arrhythmias a small
amount (f rom 3.3 to 2.
6%). 143 people would
need to consume more
ALA to prevent a single
person experiencing an
arrhythmic event (NNT=
143)
Harms: bleeding
Assessed with: number
of part icipants experi-
encing bleeding events
The ef fect of ALA intake on bleeding is unclear as no studies reported this outcome
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Harms: pulmonary em-
bolus or DVT
Assessed with: number
of part icipants experi-
encing pulmonary em-
bolus or deep vein
thrombosis
Durat ion: range 24
months
3 per 1000 1 per 1000
(0 to 23)
RR 0.32
(0.01 to 7.80)
708
(1 study)
⊕©©©
Very lowh
The ef fect of ALA intake
on pulmonary embolus
or DVT is unclear as the
evidence is of very low
quality
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
ALA: alpha-linolenic acid; CHD: coronary heart disease; CI: conf idence interval; DVT : deep vein thrombosis; IHD: ischaemic heart disease; MI: myocardial infarct ion; RCT :
randomised controlled trial; RR: risk rat io.
GRADE Working Group grades of evidence
High certainty: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate certainty: we are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low certainty: our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low certainty: we have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
a All- cause mortality, ALA
• Risk of bias: there was lit t le or no ef fect in the main meta-analysis or when data were lim ited to RCTs at low summary
risk of bias, low risk of compliance problems or larger trials, though a suggest ion of increased risk of death with f ixed-ef fect
meta-analyses. Not downgraded.
• Inconsistency: I2 was < 60%; not downgraded.
• Indirectness: representat ive, generalisable adult populat ion including men and women, including healthy part icipants
and part icipants with CVD risk factors or previous CVD as well as non-CVD health problems. All studies were conducted in
high-income countries. Not downgraded.
• Imprecision: large numbers of part icipants have taken part in RCTs in long-term studies with consistent results.
However, as 95% conf idence intervals do not exclude important benef its or harms we downgraded once.
• Publication bias: f unnel plot not useful as fewer than 10 trials included. Not downgraded.
b Cardiovascular mortality, ALA
• Risk of bias: there was lit t le or no ef fect in the main analysis, or when data were lim ited to RCTs at low summary risk of
bias, larger trials or f ixed-ef fect meta-analysis, though a small benef it was suggested when studies were lim ited to trials with
low risk of compliance bias. Not downgraded.
• Inconsistency: I2 was < 60%; not downgraded.
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• Indirectness: representat ive, generalisable adult populat ion including men and women, including healthy part icipants
and part icipants with CVD risk factors or previous CVD as well as non-CVD health problems. All studies were conducted in
high-income countries. Not downgraded.
• Imprecision: large numbers of part icipants have taken part in RCTs in long-term studies with consistent results.
However, as 95% conf idence intervals do not exclude important benef its or harms we downgraded once.
• Publication bias: f unnel plot not useful as fewer than 10 trials included. Not downgraded.
c Cardiovascular events, ALA
• Risk of bias: there was a small ef fect in the main analysis, with larger trials and in f ixed-ef fect analysis, and a larger
ef fect when data were lim ited to RCTs at low summary risk of bias or at low risk f rom compliance problems. Downgraded
once.
• Inconsistency: I2 was <60%; not downgraded.
• Indirectness: representat ive, generalisable adult populat ion including men and women, including healthy part icipants
and part icipants with CVD risk factors or previous CVD as well as non-CVD health problems. All studies were conducted in
high-income countries. Not downgraded.
• Imprecision: large numbers of part icipants have taken part in RCTs in long-term studies with consistent results.
However, as 95% conf idence intervals do not exclude important benef its or harms we downgraded once.
• Publication bias: f unnel plot not useful as fewer than 10 trials included. Not downgraded.
d Coronary heart disease mortality, ALA
• Risk of bias: while ALA reduced CHD mortality by 5% in the main analysis, f ixed-ef fect analysis and in larger trials,
lim it ing data to RCTs at low summary risk of bias and low risk of compliance problems resulted in 7%-8% reduct ions. Not
downgraded.
• Inconsistency: I2 was < 60%; not downgraded.
• Indirectness: representat ive, generalisable adult populat ion including men and women, including healthy part icipants
and part icipants with CVD risk factors or previous CVD as well as non-CVD health problems. All studies were conducted in
high-income countries. Not downgraded.
• Imprecision: large numbers of part icipants have taken part in RCTs in long-term studies with consistent results.
However, as 95% conf idence intervals do not exclude important benef its or harms we downgraded. Downgraded once.
• Publication bias: f unnel plot not useful as fewer than 10 trials included. Not downgraded.
e Coronary heart disease events, ALA
• Risk of bias: there was lit t le or no ef fect in the main analyses, in f ixed-ef fect meta-analysis, or in larger studies, but
some risk reduct ion (8 to 9%) when data were lim ited to RCTs at low summary risk of bias or low risk of compliance bias.
Downgraded once.
• Inconsistency: I2 was < 60%; not downgraded.
• Indirectness: representat ive, generalisable adult populat ion including men and women, including healthy part icipants
and part icipants with CVD risk factors or previous CVD as well as non-CVD health problems. All studies were conducted in
high-income countries. Not downgraded.
• Imprecision: large numbers of part icipants have taken part in RCTs in long-term studies with consistent results.
However, as 95% conf idence intervals do not exclude important benef its or harms we downgraded. Downgraded once.
• Publication bias: f unnel plot not useful as fewer than 10 trials included. Not downgraded.
f Stroke, ALA42
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• Risk of bias: the main analysis, f ixed-ef fect analysis, and larger trials suggest increased risk of stroke with more ALA,
but there was lit t le or no ef fect when data were lim ited to RCTs at low summary risk of bias, and a suggest ion of benef it
when lim ited to trials with low risk of compliance problems. Downgraded twice.
• Inconsistency: I2 was < 60%; not downgraded.
• Indirectness: representat ive, generalisable adult populat ion including men and women, including healthy part icipants
and part icipants with CVD risk factors or previous CVD as well as non-CVD health problems. All studies were conducted in
high-income countries. Not downgraded.
• Imprecision: large numbers of part icipants have taken part in RCTs in long-term studies, but only 49 part icipants
experienced strokes. 95% conf idence intervals do not exclude important benef its or harms, downgraded once.
• Publication bias: f unnel plot not useful as fewer than 10 trials included. Not downgraded.
g Arrhythmias, ALA
• Risk of bias: there was a 21% reduct ion in risk of arrhythmia in the main analysis, when data were lim ited to RCTs at low
summary risk of bias, in larger trials and when data were lim ited to trials at low risk f rom compliance. Not downgraded.
• Inconsistency: only one trial, no inconsistency. Not downgraded.
• Indirectness: a single trial, which included adults with previous MI in a high-income country and only assessed new
arrhythmia. Not downgraded.
• Imprecision: large numbers of part icipants have taken part in this long term study. However, as 95% conf idence
intervals do not exclude important benef its or harms we downgraded once.
• Publication bias: f unnel plot not useful as fewer than 10 trials included. Not downgraded.
h Pulmonary embolus or DVD, ALA
• Risk of bias: the single trial was not at low summary risk of bias. Downgraded once.
• Inconsistency: with one trial no inconsistency. Not downgraded.
• Indirectness: healthy men and women, no part icipants with CVD risk factors or previous CVD; low- and middle-income
countries not represented. Not downgraded.
• Imprecision: only one event included in a single trial. Downgraded twice.
• Publication bias: insuf f icient studies for funnel plot. Not downgraded.
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High versus low omega-3 fats for modification of CVD risk factors (adiposity and lipids)
Patient or population: adults with or without exist ing CVD
Setting: part icipants were living at home for most or all of the durat ion of their trials. Most studies were carried out in high-income economies (World Bank 2018), but four
trials were carried out in upper-m iddle income countries. No studies took place in low- or low-middle income countries
Intervention: higher omega-3 intake (LCn3 or ALA)
Comparison: lower omega-3 intake (LCn3 or ALA)
The intervent ion was dietary supplementat ion, a provided diet or advice on diet. Supplementat ion may have been in oil or capsule form or as foodstuf f s provided, to be
consumed by mouth (excluding enteral and parenteral feeds and enemas). The foodstuf f s or supplements must have been: oily f ish; f ish oils; linseed (f lax), canola (rapeseed)
, perilla, purslane, mustard seed, candlenut, st ill ingia or walnut as a food, oil, made into a spreading fat or supplementing another food (such as bread or eggs). For ALA
sources the product consumed had to have an omega-3 fat content of at least 10%of the total fat content. Ref ined eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA)
or alpha-linolenic acids, or concentrated f ish or algal oils, were also accepted
Outcomes
All in trials of 12 to 72
months’ duration
Anticipated absolute effects* (95% CI) of participants
(studies)
Certainty of the evidence
(GRADE)
Comments
Risk with low omega-3 Risk with high omega-3
Measures of adiposity -
LCn3 - Weight, kg
Mean body weight was 81.
2 kg
MD 0.01 kg lower
(0.84 lower to 0.82 higher)
15812
(12 RCTs)
⊕⊕⊕⊕
Higha
LCn3 intake makes lit t le
or no dif ference to body
weight.
Measures of adiposity -
LCn3 - BMI, kg/ m2
Mean BMI was 27.3 kg/ m2 MD 0.04 higher
(0.16 lower to 0.24 higher)
15234
(14 RCTs)
⊕⊕⊕⊕
Highb
LCn3 intake makes lit t le or
no dif ference to BMI.
Serum total cholesterol -
LCn3 - TC, mmol/ L
Mean TC was 5.61 mmol/ L MD 0.01 lower
(0.05 lower to 0.04 higher)
37281
(28 RCTs)
⊕⊕⊕©
Moderatec
LCn3 intake probably makes
lit t le or no dif ference to
serum total cholesterol
Serum triglyceride, fast ing -
LCn3 - TG, mmol/ L
Mean TG was 1.59 mmol/ L MD 0.24 lower
(0.32 lower to 0.17 lower)
35534
(24 RCTs)
⊕⊕⊕⊕
Highd
Increasing LCn3 intake re-
duces serum triglyceride.
Serum high density lipopro-
tein - LCn3 - HDL, mmol/ L
Mean HDL was 1.32 mmol/
L
MD 0.02 higher
(0 to 0.04 higher)
37237
(27 RCTs)
⊕⊕⊕⊕
Highe
Increasing LCn3 intake in-
creases serum HDL.
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Serum low density lipopro-
tein - LCn3 - LDL, mmol/ L
Mean LDL was 3.27 mmol/
L
MD 0.01 higher
(0.01 lower to 0.03 higher)
35035
(23 RCTs)
⊕⊕⊕©
Moderatef
LCn3 intake probably makes
lit t le or no dif ference to
serum LDL
Measures of adiposity - ALA
- Weight, kg
Mean weight was 80.9 kg MD 0.17 higher
(0.61 lower to 0.96 higher)
664
(4 RCTs)
⊕©©©
Very lowg
The ef fect of ALA intake on
body weight is unclear as
the evidence is of very low
quality
Measures of adiposity - ALA
- BMI, kg/ m2
Mean BMI was 27.4 kg/ m2 MD 0.12 higher
(0.06 lower to 0.3 higher)
1581
(3 RCTs)
⊕⊕©©
Lowh
ALA intake may make lit t le
or no dif ference to BMI.
Serum total cholesterol -
ALA - TC, mmol/ L
Mean TC was 5.02 mmol/ L MD 0.09 lower
(0.23 lower to 0.05 higher)
2164
(6 RCTs)
⊕⊕©©
Low i
ALA intake may make lit t le
or no dif ference to serum
total cholesterol (low-qual-
ity/ certainty evidence)
Serum Triglyceride, fast ing
- ALA - TG, mmol/ L
Mean TG was 1.48 mmol/ L MD 0.03 lower
(0.11 lower to 0.05 higher)
1776
(6 RCTs)
⊕⊕⊕©
Moderatej
ALA intake probably makes
lit t le or no dif ference to
serum triglycerides (mod-
erate-quality/ certainty evi-
dence)
Serum high density lipopro-
tein - ALA - HDL, mmol/ L
Mean HDL was 1.49 mmol/
L
MD 0.02 lower
(0.08 lower to 0.03 higher)
1776
(6 RCTs)
⊕⊕⊕©
Moderatek
ALA intake probably re-
duces serum HDL.
Serum low density lipopro-
tein - ALA - LDL, mmol/ L
Mean LDL was 2.88 mmol/
L
MD 0.05 lower
(0.15 lower to 0.04 higher)
2201
(7 RCTs)
⊕⊕©©
Low l
ALA intake may make lit t le
or no dif ference to serum
LDL.
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
BMI: body mass index; CI: conf idence interval; HDL: high-density lipoprotein; LCn3 : long-chain omega-3 fatty acids; LDL: low-density lipoprotein; MD: mean dif ference; RCT :
randomised controlled trial; TC: total cholesterol; TG: t riglycerides.
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GRADE Working Group grades of evidence
High certainty: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate certainty: we are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low certainty: our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low certainty: we have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
a Measures of adiposity, weight, LCn3
• Risk of bias: there was lit t le or no ef fect in the main analysis or in any sensit ivity analysis. Not downgraded.
• Inconsistency: I2 was < 60%; not downgraded.
• Indirectness: representat ive, generalisable adult populat ion including men and women, including healthy part icipants
and part icipants with previous CVD. However, low- and middle-income countries were underrepresented. Not downgraded.
• Imprecision: large numbers of part icipants have taken part in RCTs in long-term studies with consistent results. 95%
conf idence intervals exclude important benef its or harms. Not downgraded.
• Publication bias: f unnel plot was not interpretable, no clear small study bias. However, we are aware of several studies
whose data could not be included; not downgraded.
b Measures of adiposity, BMI, LCn3
• Risk of bias: there was lit t le or no ef fect in the main analysis or in any sensit ivity analysis. Not downgraded.
• Inconsistency: I2 was < 60%; not downgraded.
• Indirectness: representat ive, generalisable adult populat ion including men and women, including healthy part icipants
and part icipants with previous CVD. However, low- and middle-income countries were underrepresented. Not downgraded.
• Imprecision: large numbers of part icipants have taken part in RCTs in long-term studies with consistent results. 95%
conf idence intervals exclude important benef its or harms. Not downgraded.
• Publication bias: f unnel plot was not interpretable, no clear small study bias. However, we are aware of several studies
whose data could not be included. Not downgraded.
c Lipids, serum total cholesterol, LCn3
• Risk of bias: there was lit t le or no ef fect in the main analysis or in any sensit ivity analysis. Not downgraded.
• Inconsistency: I2 was < 60%; not downgraded.
• Indirectness: representat ive, generalisable adult populat ion including men and women, including healthy part icipants
and part icipants with previous CVD. However, low- and middle-income countries were not represented. Not downgraded.
• Imprecision: when we ran f ixed-ef fect analysis, a stat ist ically signif icant ef fect was suggested. The 95%CI included null
but excluded important benef its or harms. Downgraded once..
• Publication bias: f unnel plot was not interpretable, no clear small study bias. However, we are aware of several studies
whose data could not be included; not downgraded.
d Lipids, serum triglycerides, LCn3
• Risk of bias: there was a stat ist ically signif icant ef fect overall and in all sensit ivity analyses, including when data were
lim ited to RCTs at low summary risk of bias. Not downgraded.
• Inconsistency: I2 was < 60%; not downgraded.
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• Indirectness: representat ive, generalisable adult populat ion including men and women, including healthy part icipants
and part icipants with previous CVD. However, low- and middle-income countries were not represented. Not downgraded.
• Imprecision: large numbers of part icipants have taken part in RCTs in long-term studies with consistent results. 95%
conf idence intervals exclude harms. Not downgraded.
• Publication bias: f unnel plot was not interpretable, no clear small study bias. However, we are aware of several studies
whose data could not be included; not downgraded.
e Lipids, HDL, LCn3
• Risk of bias: the suggested increase in HDL with increased LCn3 was apparent in all sensit ivity analyses. Not
downgraded.
• Inconsistency: I2 was < 60%; not downgraded.
• Indirectness: representat ive, generalisable adult populat ion including men and women, including healthy part icipants
and part icipants with previous CVD. However, low- and middle-income countries were not represented. Not downgraded.
• Imprecision: large numbers of part icipants have taken part in RCTs in long-term studies with consistent results. 95%
conf idence intervals exclude harms. Not downgraded.
• Publication bias: f unnel plot was not interpretable, no clear small study bias. However, we are aware of several studies
whose data could not be included; not downgraded.
f Lipids, LDL, LCn3
• Risk of bias: there was lit t le or no ef fect in the main analysis or in any sensit ivity analysis. Not downgraded.
• Inconsistency: I2 was < 60%; not downgraded.
• Indirectness: representat ive, generalisable adult populat ion including men and women, including healthy part icipants
and part icipants with previous CVD. However, low- and middle-income countries were not represented. Not downgraded.
• Imprecision: large numbers of part icipants have taken part in RCTs in long-term studies with consistent results. 95%
conf idence intervals included the null but excluded important benef its or harms. Downgraded once.
• Publication bias: f unnel plot was not interpretable, no clear small study bias. However, we are aware of several studies
whose data could not be included; not downgraded.
g Measures of adiposity, weight, ALA
• Risk of bias: no included trials were at low summary risk of bias. Downgraded once.
• Inconsistency: I2 was > 60%, downgraded once.
• Indirectness: representat ive, generalisable adult populat ion including men and women, including healthy part icipants
and part icipants with previous CVD. However, low- and middle-income countries were not represented. Not downgraded.
• Imprecision: large numbers of part icipants have taken part in RCTs in long-term studies with consistent results. 95%
conf idence intervals include some benef its or harms. Downgraded once.
• Publication bias: f unnel plot was not interpretable, no clear small study bias. However, we are aware of several studies
whose data could not be included; not downgraded.
h Measures of adiposity, BMI, ALA
• Risk of bias: there was lit t le or no ef fect in the main analysis or in any sensit ivity analysis. Not downgraded.
• Inconsistency: I2 was > 60%, downgraded once.
• Indirectness: representat ive, generalisable adult populat ion including men and women, including healthy part icipants
and part icipants with previous CVD. However, low- and middle-income countries were not represented. Not downgraded.
4
7
O
m
e
g
a
-3
fa
tty
a
c
id
s
fo
r
th
e
p
rim
a
ry
a
n
d
se
c
o
n
d
a
r
y
p
re
v
e
n
tio
n
o
f
c
a
rd
io
v
a
sc
u
la
r
d
ise
a
se
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
8
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
• Imprecision: large numbers of part icipants have taken part in RCTs in long-term studies with consistent results. 95%
conf idence intervals include some benef its and harms. Downgraded once.
• Publication bias: f unnel plot was not interpretable, no clear small study bias. However, we are aware of several studies
whose data could not be included; not downgraded.
i Lipids, serum total cholesterol, ALA
• Risk of bias: there was lit t le or no ef fect in the main analysis or in any sensit ivity analysis. Not downgraded.
• Inconsistency: I2 was > 60%. Downgraded once.
• Indirectness: representat ive, generalisable adult populat ion including men and women, including healthy part icipants
and part icipants with previous CVD. However, low- and middle-income countries were not represented. Not downgraded.
• Imprecision: when we ran f ixed-ef fect analysis a stat ist ically signif icant ef fect was suggested, but main analysis
includes some benef its and harms. Downgraded once.
• Publication bias: f unnel plot was not interpretable, no clear small study bias. However, we are aware of several studies
whose data could not be included; not downgraded.
j Lipids, serum triglycerides, ALA
• Risk of bias: there was lit t le or no ef fect in the main analysis or in any sensit ivity analysis. Not downgraded.
• Inconsistency: I2 was < 60%; not downgraded.
• Indirectness: representat ive, generalisable adult populat ion including men and women, including healthy part icipants
and part icipants with previous CVD. However, low- and middle-income countries were not represented. Not downgraded.
• Imprecision: large numbers of part icipants have taken part in RCTs in long-term studies with consistent results. 95%
include benef its and harms. Downgraded once.
• Publication bias: f unnel plot was not interpretable, no clear small study bias. However, we are aware of several studies
whose data could not be included; not downgraded.
k Lipids, HDL, ALA
• Risk of bias: there was a stat ist ically signif icant ef fect with f ixed ef fects analysis and when data were lim ited to RCTs at
low summary risk of bias, but the main analysis and other sensit ivity analyses also suggested reduct ions om HDL. Not
downgraded.
• Inconsistency: I2 was < 60%; not downgraded.
• Indirectness: representat ive, generalisable adult populat ion including men and women, including healthy part icipants
and part icipants with previous CVD. However, low- and middle-income countries were not represented. Not downgraded.
• Imprecision: large numbers of part icipants have taken part in RCTs in long-term studies with consistent results. 95% CI
includes benef its and harms. Downgraded once.
• Publication bias: f unnel plot was not interpretable, no clear small study bias. However, we are aware of several studies
whose data could not be included; not downgraded.
l Lipids, LDL, ALA
• Risk of bias: apparent ef fect altered f rom slight benef it to slight harm when data were lim ited to RCTs at low summary
risk of bias. Downgraded once.
• Inconsistency: I2 was < 60%; not downgraded.
• Indirectness: representat ive, generalisable adult populat ion including men and women, including healthy part icipants
and part icipants with previous CVD. However, low- and middle-income countries were not represented. Not downgraded.
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• Imprecision: when we ran f ixed-ef fect analysis a stat ist ically signif icant ef fect was suggested. For main analysis 95%CI
included benef its and harms. Downgraded once.
• Publication bias: f unnel plot was not interpretable, no clear small study bias. However, we are aware of several studies
whose data could not be included; not downgraded.
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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D I S C U S S I O N
Summary of main results
We included 79 randomised controlled trials (112,059 partici-
pants), of which 25 were at low summary risk of bias (randomi-
sation, allocation concealment, selection and detection bias all at
low risk for supplementation trials; randomisation, allocation con-
cealment and detection bias all at low risk for dietary advice tri-
als). Trials of 12 to 72 months’ duration included adults at vary-
ing levels of cardiovascular risk, mainly in high-income countries.
Most studies assessed LCn3 supplementation with capsules, but
some used LCn3- or ALA-rich or enriched foods or dietary advice
compared to placebo or usual diet.
Pooled trial results suggested there is probably little or no ef-
fect of increasing long-chain omega-3 fats on risk of our primary
outcomes: all-cause mortality, cardiovascular deaths, cardiovas-
cular events, coronary heart disease deaths, coronary heart dis-
ease events, stroke or arrhythmias (moderate and high-quality evi-
dence). For all of these outcomes except arrhythmia, limitingLCn3
analyses to trials at low summary risk of bias moved the effect size
towards 1.0 (the null value) whether initial analyses suggested a
protective effect (for example, for CHD mortality, whose effect
size moved from RR 0.93 to RR 1.00) or a harmful effect (for
example, stroke, whose effect size moved from RR 1.06 to RR
0.98). We found no suggestion of dose response (in subgrouping
or meta-regression), or important effects regardless of sensitivity
analysis, subgrouping or meta-regression. These results apply to
supplemental LCn3 intake. We did not see important differences
in LCn3 trials between those providing oily fish (dietary source) or
EPA/DHA capsules (supplemental source), but as few trials pro-
vided whole fish health effects may differ.
On the other hand we found moderate-quality evidence that in-
creasing ALA probably reduces risk of CHDmortality a very small
amount (from 1.1% to 1.0%) and arrhythmia (from 3.3% to
2.6%), and low-quality evidence that increasing ALA may reduce
risk of CVD events a little (from 4.8% to 4.7%). However, there is
probably little or no effect on all-cause or cardiovascular mortality
or coronary heart disease events (low and moderate-quality evi-
dence), and effects on stroke are unclear. For ALA, limiting anal-
yses to studies at low summary risk of bias tended to reduce the
RR, or increase the suggested protection. Data were more limited
than for LCn3, and there were too few studies for informative fun-
nel plots or subgroup analyses. These suggested benefits of ALA
need to be considered with caution, as effects were small, and few
trials (though often at low summary risk of bias) addressed the
outcomes.
Meta-analyses suggested little or no effect of long-chain omega-
3 fats or ALA intake on secondary outcomes: major adverse
cerebrovascular or cardiovascular events, fatal and/or non-fatal
myocardial infarction, sudden cardiac death, new or worsening
angina, heart failure, revascularisation, peripheral arterial disease
or acute coronary syndrome.
There was no evidence for effects of LCn3 or ALA on measures of
adiposity, but LCn3 did reduce serum triglycerides and increase
HDL cholesterol a little. We did not see these effects in trials of
ALA, and no omega-3 fats altered total or LDL cholesterol in these
long-term trials.Within the included studies we assessed effects on
blood pressure, serious adverse effects, side effects and dropouts.
There was no suggestion that blood pressure or risk of adverse
events such as bleeding differed by LCn3 or ALA intake. Thus,
proposed mechanisms for omega-3 activity, including lowering of
blood pressure, reduced thrombotic tendency and anti-arrhythmic
effects are not apparent in adult humans, but LCn3 does lower
serum triglyceride levels.
The review has provided some answers for its secondary questions.
• If omega-3 fatty acids confer protection:
◦ does protection occur equally in those at low and at
high risk of cardiovascular disease? There is no evidence of
differential effects on mortality or cardiovascular health by
primary or secondary CVD prevention.
◦ does protection depend on the dose of omega-3 fats
taken per day? We ran subgroup analyses for primary and key
outcomes and meta-regression for primary outcomes but found
no evidence of differential effects by LCn3 or ALA dose on any
outcomes except LCn3 on serum triglycerides, where there was a
statistically significant difference between different dose
subgroups and greater effects with higher dose.
◦ do effects differ between dietary and supplemental
omega-3 sources? We assessed this question by looking for
statistically significant differences between subgroups but found
no evidence of differential effects by dietary or supplemental
LCn3 or ALA sources. However, few of the LCn3 trials advised
or gave fish, most gave supplemental fish oils, so our ability to
assess effects of eating more oily whole fish are limited.
◦ does protection depend on study summary risk of bias?
Some analyses suggested a protective effect of LCn3 fats, but
these effects disappeared when analyses were limited to studies at
low summary risk of bias. The stronger studies with higher
internal validity suggested few or no effects of LCn3 on mortality
or CVD outcomes. On the other hand, for most primary
cardiovascular outcomes, ALA trials at low summary risk of bias
suggested greater protection with higher ALA than in the main
analysis (including trials of all levels of summary risk of bias).
• Is protection or harm stronger with longer trial duration? In
subgroup analyses for primary and key outcomes and in meta-
regression for primary outcomes, there was no evidence that
longer trials increased the effect of LCn3 or ALA.
Overall completeness and applicability of
evidence
We searched very carefully to find all studies relevant to this review
and located 79 trials randomising 112,059 participants to higher
and lower omega-3 fats (LCn3 or ALA) for at least 12 months.
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To reduce selection bias, we contacted authors of trials that ap-
peared to have randomised appropriate participants to appropri-
ate intervention and comparator but may not have published rel-
evant outcomes. If trialists had assessed any of our outcomes, we
requested data and included the study. This enabled us to in-
clude several additional trials. We also contacted authors of all in-
cluded trials that randomised at least 100 participants (and most
smaller trials) to request data on any further outcomes (as well as
on methodological issues) that may have been recorded but not
reported. We tried to contact 72 of the 79 included studies (all
except Baldassarre 2006; HERO 2009; Mita 2007; Nutristroke
2009; Özaydin 2011; Shinto 2014; Sofi 2010). This allowed us
to collect useful additional data on outcomes such as deaths and
cardiovascular events that we would not have had access to other-
wise.
We identified 27 trials that appeared to be unpublished at the time
of writing (Characteristics of ongoing studies). We have labelled
these trials as ongoing, although some appear overdue for publi-
cation, and their status is unclear - they may constitute missing
data. We tried to contact authors of all ’overdue’ ongoing studies,
and some stated that publications are forthcoming; others did not
reply.We suspect that if trialists have not published outcomes, it is
likely that any protective health effects did not reach statistical sig-
nificance. Given that existing studies suggest no effects of omega-
3 fats on cardiovascular health outcomes, any missing data may
not affect outcomes greatly; however, for completeness we would
prefer to include all available data.
Post hoc, we followed advice to assess differences in effects be-
tween EPA and DHA within the review. However, most LCn3
trials provided or advised changes resulting in increased intakes
of both EPA and DHA (as in natural fish oil), though in differ-
ent ratios. Only three trials provided data on DHA only (ADCS
2010; Berson 2004; Zhang 2017), and five provided data on EPA
only (Doi 2014; JELIS 2007; Mita 2007; Nye 1990; Puri 2005).
Unfortunately for any single outcome only two or three of these
trials were represented, so our ability to assess differential effects
of the DHA-only and EPA-only interventions was very limited,
and we have not presented these analyses or attempted to draw
any information from them.
Quality of the evidence
Figure 2 displays risk of bias of included studies. Of the 79 RCTs,
25 were at low summary risk of bias (at low risk of selection bias,
performance bias and detection bias, plus low risk of performance
bias in supplemental trials). We assessed the validity of evidence in
meta-analyses by running sensitivity analyses that removed trials
not at low summary risk of bias.When sensitivity analyses removed
LCn3 trials at moderate to high summary risk of bias, effect sizes
moved closer to no effect (RR 1.0) for all primary outcomes except
arrhythmias, where the RR rose to 1.10. Funnel plots for LCn3
trials suggested that there may be missing studies for all primary
outcomes except stroke and arrhythmia, and in all cases adding
such studies back in would move effect sizes closer to no effect
(RR 1.0). This lack of effect in the studies at lowest risk of bias
(with suggestions of effect in studies at moderate to high risk of
bias) was an important finding from this review and supported
our interpretation of lack of effect of long-chain omega-3 fats on
our primary outcomes.
As there were fewer ALA trials, funnel plots were not useful, but
sensitivity analyses retaining only trials at low summary risk of bias
were more variable, often suggesting lower risk of a cardiovascular
outcome.
Potential biases in the review process
Potential adverse effects include cancers and neurological prob-
lems associatedwith polychlorinated biphenyls (PCBs) ormercury
in fish oils, and bleeds associated with reductions in clotting (see
How the intervention might work). Any data on bleeds, including
haemorrhagic stroke, have been collated in this review, though we
did not ask authors specifically for additional data on these out-
comes. Unfortunately there were insufficient data on serious harms
(bleeding and pulmonary embolism or deep vein thrombosis) to
assess these potential harms. We have not collated data on cancers
and neurological problems within this review but have formally
systematically reviewed them elsewhere (Hanson 2017b; Jimoh
2017). This approach is preferable to including data on these out-
comes from within included studies, which would be incomplete
and potentially underpowered to show important effects.
One problem with CVD outcomes is that they are collected to-
gether in a variety of ways, depending on the study. For example,
in assessing CHD mortality, we pre-specified that we would in-
clude the first of the following list reported in any trial: coronary
death, ischaemic heart disease death, fatal myocardial infarction,
cardiac death. Each included trial includes outcome data in its
own way, so we had to adapt to this in our analysis. One way to
get around this problem would be to use individual patient data,
as in one recent meta-analysis that included fewer trials than this
review but was able to formulate their outcome data to match pre-
cisely between trials (Aung 2018). The next section discusses sim-
ilarities and differences between this review and Aung 2018, but
their findings were highly similar. For CHD mortality, our meta-
analytic estimate of effect of LCn3 was RR 0.93, (95% CI 0.79 to
1.09, I2 = 35%) in 21 trials reporting 1596 CHD deaths, while
theirs was RR 0.93 (95% CI 0.83 to 1.03) in 10 trials reporting
2695 CHD deaths.
While we tried hard to locate all available trials and collect addi-
tional outcome data where possible, there was evidence from fun-
nel plots of some small study bias. Some smaller studies showing
increased risk of CVD outcomes with omega-3 fats may be miss-
ing from some of the meta-analyses. If these studies were replaced
they would tend to increase risk ratios. This suggests that there is
some underlying small study bias within the review.
51Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Given that the many LCn3 studies at moderate to high risk of bias
appear to be inflating any protective effects, and that small study
bias is also inflating any protective effects, it is justified to view
with skepticism the occasional suggestion of a protective effect.
Given the very large number of subgroup analyses we carried out,
it is also important to treat the occasional subgroup analysis that
throws up a statistically significant difference between subgroups
very cautiously.
A secondary question asked by this review was about differential
effects of dietary and supplemental LCn3 fats. LCn3 interventions
included dietary advice (advice to eatmore oily fish), supplemental
foods (LCn3 fats incorporated into other foods such as margarine)
and supplements or capsules (by far the greatest proportion of
studies). Dietary fish is likely to have different health effects, as
it may take the place of less healthy foods in the diet (leading
to reduced saturated fat intake, for example) and provides many
nutrients in addition to omega-3 fats (such as protein, selenium,
iodine, calcium, magnesium, etc.). There were only four LCn3
dietary advice trials with event data (DART 1989; DART2 2003;
DISAF 2003; THIS DIET 2008), and two of these also provided
fish oil capsules when participants did not want to eat more fish
(DART1989;DART2 2003).We found no statistically significant
differences between dietary advice subgroups and supplemental
foods or capsule subgroups for primary outcomes. This may mean
that health effects between the two types of intervention are not
different, but It is likely that our analysis was underpowered to see
any such differences if they exist.
Population LCn3 status varies widely across the world, from over
8% of fatty acids in Japan, Scandinavia and other areas with non-
Westernised dietary patterns to less than 4% in North, South and
Central America; Europe; the Middle East; Southeast Asia; and
Africa (Stark 2016).We hypothesised that additional LCn3 might
have greater health effects in people whose usual LCn3 intake
was relatively low, but unfortunately we were not able to ascertain
baseline LCn3 intake or status for most of our included trials.
However, most of the included studies were carried out in areas
of the world with lower LCn3 status, so we would expect to see
effects of increasing LCn3 in most included trials if such effects
exist - the fact that we did not see them suggests that any such
effects may not be important in the populations included in this
review.
Agreements and disagreements with other
studies or reviews
One potential difference between the findings of this review and
some other trials and reviews is our running sensitivity analyses
assessing effects exclusively in studies at low summary risk of bias.
This clarified the lack of effect of LCn3 fats on CHD mortality,
CHD events and heart failure, which otherwise appeared slightly
protective, and on stroke, which otherwise appeared slightly harm-
ful. On the other hand, these sensitivity analyses suggested some
protective effects for ALA (onCVDevents, CHDmortality, CHD
events and arrhythmia), though these were small and evidence
limited.
The effect of LCn3 on arrhythmias was unclear. There was a sug-
gestion that LCn3 was harmful regarding development of new ar-
rhythmia (where trials were not set up with arrhythmia as a pri-
mary outcome), but protective of recurrent arrhythmia. However,
trials at low summary risk of bias suggested harm, and other trials
(at moderate to high risk of bias) suggested benefit. Eight of the 10
included studies at low summary risk of bias were trials assessing
new arrhythmia. It is possible that the apparent difference between
effects on new and recurrent arrhythmia are related to summary
risk of bias.
There was no suggestion that blood pressure or risk of adverse
events such as bleeding differed by LCn3 or ALA intake. This
suggests that possible mechanisms for omega-3 activity, includ-
ing lowering of blood pressure, reduced thrombotic tendency and
anti-arrhythmic effects are not important in most adult humans,
though LCn3 does appear to lower serum triglyceride levels. We
did not systematically review blood pressure data so may have
missed a few long-term studies (though not many) - missing data
from included studies is likely to be a bigger issues. Of the 15 in-
cluded trials that reported blood pressure outcomes, nine reported
numbers of hypertensive participants at baseline, ranging from
5% in MARINA 2011 to 79% of participants in ORIGIN 2012.
Effects did not differ by proportions of hypertensive participants
(I2 was 0% for both systolic and diastolic blood pressure, Analysis
3.1).
Nearly 20 years ago, the GISSI-P 1999 trial suggested that LCn3
had its primary effects in reducing sudden cardiac death. However,
the forest plot clearly shows that subsequent trials have not seen
this effect individually or in aggregate (Analysis 2.6).
The scope of this review is similar to that of the extensive Agency
for Healthcare Research and Quality review (Balk 2016), so we
have compared our results with theirs. Given that our review in-
cluded 79 RCTs randomising more than 112,000 participants,
who experienced over 8000 deaths and upwards of 4000 CVD
deaths, we were surprised to read that Balk and colleagues charac-
terised the body of evidence as having “limited data ... from RCTs
on the effect of n-3 FA on clinical CVD outcomes” (Balk 2016).
This appears to be because the Balk review excluded RCTs of peo-
ple with non-CVD and non-diabetes related diseases at baseline,
while we included them. While Balk 2016 excluded some stud-
ies we included, it did not include any studies providing all-cause
mortality data that we excluded. This meant that in analysing
effects on all-cause mortality, Balk 2016 included 18 RCTs ran-
domising 81,027 participants experiencing 8480 deaths, while we
included 112,059 participants randomised to high or low LCn3 or
ALA experiencing 8648 deaths. Balk 2016 excluded studies that
we included, such as AREDS2 2014, a high-quality trial with 368
deaths in more than 4000 participants with age-related macular
degeneration. This sort of population appeared ideal to us for as-
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sessment of omega-3 fats on primary prevention of CVD, as these
people tend to be elderly but there is no clear reason why omega-3
fats would affect CVD differently in this population than in other
older adults at usual CVD risk.
Despite these slight differences in approach, we obtained very
similar effect estimates to Balk 2016. We meta-analysed effects of
LCn3 and ALA trials, finding an RR for all-cause mortality of 0.98
(95% CI 0.93 to 1.03, I2 = 6%), compared to a pooled RR for
all-cause mortality of 0.97 (95% CI 0.92 to 1.03) in Balk 2016.
While that review seldom pooled their results, we can compare our
results with theirs where they did. Despite our slightly different
inclusion criteria, our results are very comparable (Table 8).
A recent individualmeta-analysis of 10 large trials in almost 78,000
people at high risk of CVD found no associations of LCn3 with
CHD mortality (RR 0.93, 99% CI 0.83 to 1.03), nonfatal MI
(RR 0.97, 99% CI 0.87 to 1.08), CHD events (RR 0.96, 95%
CI 0.90 to 1.01) or major vascular events (RR 0.97, 95% CI
0.93 to 1.01, Aung 2018). Aung 2018 included individual pa-
tient data from the participants of large, long trials (randomising
at least 500 participants and following them for at least one year)
(AlphaOmega - EPA+DHA 2010; AREDS2 2014; DO IT 2010;
GISSI-HF 2008; GISSI-P 1999; JELIS 2007; OMEGA 2009;
ORIGIN 2012; Risk & Prevention 2013; SU.FOL.OM3 2010),
and this review includes all their trials. Their review had the ad-
vantage of being able to ensure that they had complete and equiv-
alent data for all of their key outcomes from all the trials, reducing
the risk of publication bias, but the disadvantage of missing all the
data from many large LCn3 trials such as DART2 2003 DART
1989 FORWARD 2013, MAPT 2017 SHOT 1996 and SOFA
2006 (all LCn3 trials randomising at least 500 participants). It
also missed large trials of LCn3 in lower risk participants such as
OPAL 2010, and large trials of ALA such as MARGARIN 2002,
Norwegian 1968 andWAHA 2016, as well as all the smaller trials.
However, though taking different approaches, the results of this
review and Aung 2018 are also very similar (Table 8). LCn3 has
little or no effect on major cardiovascular outcomes. This review,
Balk 2016 and Aung 2018 addressed the analysis of the data in
slightly different ways, creating sensitivity analyses for each other.
The fact that they came to the same conclusions reassures us that
our conclusions are solidly based.
Our results, suggesting high-quality evidence of no clinically
useful cardiovascular health effects of either LCn3 or ALA, are
consistent with many further high-quality recent systematic re-
views (Campbell 2013; Chowdhury 2012; Enns 2014; He 2013;
Khoueiry 2013; Kotwal 2012; Kwak 2012; Mariani 2013; Rizos
2012; Zheng 2014), and they confirm and expand on the findings
of earlier versions of this review (Hooper 2004; Hooper 2006).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
We found high-quality evidence that long-chain omega-3 fats do
not have important positive or negative effects on mortality or
CVD events and moderate-quality evidence that they have little
or no effect on other measures of cardiovascular health in primary
or secondary prevention. Most evidence on long-chain omega-3
fats came from trials of capsules of fish oil or EPA/DHAmixtures.
While we did not see important differences between trials of sup-
plemental capsules and trials of oily fish, there were few trials of
oily fish.
We found moderate-quality evidence that increasing ALA proba-
bly slightly reduces risk of CHD mortality and arrhythmia, and
may slightly reduce risk ofCVDevents.However, there is probably
little or no effect on all-cause or cardiovascular mortality or coro-
nary heart disease events (low and moderate-quality evidence). Ef-
fects of ALA were very small - 143 people would need to increase
their ALA intake to prevent one person developing arrhythmia,
and 1000 would need to take more ALA to prevent one person
experiencing a CVD event or dying from CHD. Trials of ALA
gave ALA-rich or enriched foods such as walnuts or enriched mar-
garine.
Supplemental long-chain omega-3 fats are probably not useful
for preventing or treating cardiovascular disease, although long-
chain omega-3 fats can help to reduce serum triglycerides and
raise HDL a little. Fish and seafood are nutrient-dense and rich in
a variety of other nutrients (such as vitamin D, calcium, iodine,
selenium) so are useful foods even without cardiovascular benefits.
In light of the evidence in this review it would be appropriate to
review official recommendations supporting supplemental LCn3
fatty acid intake.
ALA is an essential fatty acid, an important part of amixeddiet, and
increasing intakes may be very slightly beneficial for prevention or
treatment of cardiovascular disease.
Implications for research
There are several large ongoing trials of supplemental long-chain
omega-3 fats (see Characteristics of ongoing studies). We suggest
that given the lack of convincing effects suggested for omega-3 fats
in the large number of trials to date, no further trials should be
initiated until the ongoing trials have reported. Further large and
high-quality trials of ALA carried out in lower and higher income
countries and that assess baseline ALA intake and use biomarkers
to assess compliance would be helpful to clarify the cardiovascular
effects of ALA. Similarly trials of dietary fish would be helpful.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
ADCS 2010
Methods Alzheimer’s Disease Cooperative Study (ADCS)
RCT, parallel, (n-3 DHA vs n-6 LA), 18 months
Summary risk of bias: low
Participants Individuals with mild to moderate Alzheimer’s disease
N: 238 intervention, 164 control
Level of risk for CVD: low
Men: 52.9% intervention, 40.2% control
Mean age in years (SD): 76 (9.3) intervention, 76 (7.8) control
Age range: unclear
Smokers: 24.4% intervention, 21.9% control
Hypertension: not reported
Medications taken by at least 50% of those in the control group: cholinesterase inhibitor,
memantine
Medications taken by 20%-49% of those in the control group: none
Medications taken by some, but less than 20% of the control group: none
Location: USA
Ethnicity: not reported
Interventions Type: supplement (capsule)
Comparison: DHA vs omega 6
Intervention: 2 × 1 g algal-derived DHA capsules (Neuromins) per day for a total daily
dose of 2 g, each capsule contain 45% to 55% of DHA and does not contain EPA (950
mg soft-gel capsules which contain approximately 510 mg DHA). Dose: +DHA 1.02 g/
d
Control: 2 × 1 g placebo capsules per day (made up of corn or soy oil)
Compliance: measured by pill counts at every visit
Length of intervention: 18 months
Outcomes Main study outcome: change in the cognitive subscale of the Alzheimer’s Disease Assess-
ment Scale (ADAS-cog) and change in the Clinical Dementia Rating (CDR)
Dropouts: 67 intervention, 40 control (discontinued treatment but included in main
analyses)
Available outcomes:mortality,measures of cognition, baseline& change in plasmaDHA,
adverse events
Response to contact: no data provided
Notes Study funding; quote: “grant UO1-AG10483 from theNational Institute on Aging. The
National Institute on Aging was not otherwise involved in the design and conduct of
the study, or in the analysis of data or preparation of the manuscript”. “The placebo and
DHA study drugs were provided by Martek Biosciences. Martek also provided plasma
and cerebrospinal fluid measurements of fatty acids, as well as partial financial support
for the magnetic resonance imaging sub study. (Martek Biosciences produces nutritional
supplements from cultivated fungi and microalgae). Martek employees participated in
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ADCS 2010 (Continued)
design of the study and in revision of the manuscript, but were not involved in data
management or data analysis.” (Quinn 2010, p. 1910)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was achieved with a cen-
tralised interactive voice response system,
using a block design with a block size of 5
(3 in the DHA group and 2 in the placebo
group
Allocation concealment (selection bias) Low risk Randomisation was achieved with a cen-
tralised interactive voice response system,
using a block design with a block size of 5
(3 in the DHA group and 2 in the placebo
group
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Placebo capsules (made up of corn or soy
oil) were identical in appearance. The ade-
quacy of blinding was assessed by question-
naires completed by caregivers, study coor-
dinators, and site physicians
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The adequacy of blinding was assessed
by questionnaires completed by caregivers,
study coordinators, and site physicians
with results showing no difference between
groups and the majority did not know
Incomplete outcome data (attrition bias)
All outcomes
Low risk Intention-to-treat analysis. At 12 months
data were available for > 80% (ITT analy-
sis)
Selective reporting (reporting bias) Low risk Prospectively registered February 2007,
study started February 2007, completed
May 2009. Primary outcomes were rate of
change in ADAS-Cog11 and CDR-SOB,
which are both reported in main report.
NPI and ADL were secondary outcomes
also reported
Attention Low risk Both study arms had the same follow-up
and care.
Compliance Unclear risk Measured by pill count at every visit. 28%
intervention and 24% control discontin-
ued supplement with a minority discontin-
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ADCS 2010 (Continued)
uing due to adverse events. A further 8%
were excluded for < 80% compliance in
both intervention and control arms
Other bias Low risk None noted
AFFORD 2013
Methods Multi-center study to evaluate the effect of n-3 fatty acids on arrhythmia recurrence in
atrial fibrillation (AFFORD)
RCT, parallel, (n-3 EPA + DHA vs n-6), 12 months
Summary risk of bias: moderate or high
Participants People with symptomatic paroxysmal or persistent AF
N: 165 intervention, 172 control. (analysed, intervention: 153 control: 163)
Level of risk for CVD: high
Men: 69% intervention, 65% control
Mean age in years (SD): 60 (12) intervention, 62 (13) control
Age range: not reported
Smokers: not reported
Hypertension: 45% intervention, 42% control
Medications taken by at least 50% of those in the control group: oral anticoagulant
Medications taken by 20%-49%: beta-blockers, angiotensin-converting enzyme in-
hibitors, angiotensin receptor blockers
Medications taken by some, but < 20%: none
Location: Canada
Ethnicity: not reported
Interventions Type: supplement (fish oil)
Comparison: EPA + DHA vs omega 6 safflower oil
Intervention: 4 × 1 g enteric-coated fish oil capsules/d (1.6 g/d EPA + 0.8 g/d DHA,
Genuine Health, Toronto, Ontario, Canada). Dose: +2.4 g/d EPA + DHA,
Control: 4 ×1 g matching placebo capsules, 4 g/d safflower oil
Compliance: omega-3 index increased in intervention group, but not control, over the
study
Duration of intervention: 6 to 16 months
Outcomes Main study outcome: AF recurrence
Dropouts: 21 intervention, 19 control
Available outcomes: all-cause mortality, stroke, AF recurrence,TIA, CV events, CRP (not
usable)
Response to contact: no
Notes Authors contacted about QoL, resource use and dietary habits
Study funding: Canadian Institutes for Health Research and the Heart and Stroke Foun-
dation of Quebec
Risk of bias
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AFFORD 2013 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “[R]andomised”
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Described as double-blind, but blinding
not described or tested
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk An independent events committee adju-
dicated AF recurrences, bleeding, strokes,
transient ischemic attacks, and deaths, but
unclear if blinded to allocation
Incomplete outcome data (attrition bias)
All outcomes
Low risk Participant flow well described. ITT anal-
ysis
Selective reporting (reporting bias) High risk NCT01235130 registered July 2010, re-
cruitment March 2009-March 2012, fol-
low-up finished December 2012. Results
published 2014, but no data on quality of
life, resource utilisation, or dietary habits
(stated in registry) found
Attention Low risk No problem with attention bias
Compliance Low risk Omega-3 index measured
Other bias Low risk None noted
Ahn 2016
Methods RCT, parallel, (EPA + DHA + statins vs statins), 12 months
Summary risk of bias: moderate to high
Participants Statin treated CAD patients undergoing PCI
N: 38 intervention, 36 control
Level of risk for CVD: high
Men: 63.2% intervention, 72.2% control
Mean age in years (SD): 59.6 (9.1) intervention, 60.7 (0.8) [sic] control
Age range: unclear
Smokers: 36.8% intervention, 58.3% control
Hypertension: 50% in both groups
Medications taken by at least 50% of those in the control group: aspirin, clopidogrel,
ACE inhibitors/ARB, beta-blockers, atorvastatin
Medications taken by 20%-49% of those in the control group: cilostazol
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Ahn 2016 (Continued)
Medications takenby some, but less than 20%of the control group: rosuvastatin, nitrates,
calcium antagonists
Location: South Korea
Ethnicity: not reported
Interventions Type: supplement (capsule)
Comparison: EPA + DHA vs unclear (nil)
Intervention: 3 g of ω-3 PUFA containing 1395 mg of EPA and 1125 mg of DHA per
day. No further details. Dose: +2.52 g/d EPA + DHA
Control: unclear whether control group were given placebo or only statins
Compliance: unclear how it was measured but reported good compliance with no num-
bers
Length of intervention: 12 months
Outcomes Main study outcome: change in atherosclerotic burden
Dropouts: none
Available outcomes: lipids (TG reported as median, IQR so not used), atheroma volume,
neointimal volume index
Response to contact: no
Notes Study funding: the study was supported by clinical research grant from Pusan National
University Hospital
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Simple randomisation was carried out us-
ing random number tables to assign each
participant to the intervention or control
group
Allocation concealment (selection bias) Low risk Participants were assigned randomisation
numbers sequentially on recruitment to the
study, and the randomisation codes were
retained by the clinical research coordinator
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No details
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The personnel responsible for randomisa-
tion as well as those performing labora-
torymeasurements were blinded to the ran-
domisation assignments
Incomplete outcome data (attrition bias)
All outcomes
Low risk No dropouts reported
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Selective reporting (reporting bias) Unclear risk No protocol or trial register entry found
Attention Unclear risk No details
Compliance Unclear risk No details on how it was measured and no
fatty acid levels reported
Other bias High risk It’s unclear whether the study was placebo
controlled or the control group had no in-
tervention. Also, some of the SDs appear
to be incorrectly reported
AlphaOmega - ALA 2010
Methods RCT, (n-3 ALA vs MUFA), 40 months
Summary risk of bias: low
Participants 60-80 year-olds with previous MI
N: 1197 ALA intervention, 1236 control (1212 ALA + EPA/DHA intervention group)
Level of risk for CVD: high
Men: 77.9% intervention, 78.7% control
Mean age in years (SD): 69.0 (5.6) intervention, 68.9 (5.6) control
Age range: 60-80 years
Smokers: 17.4% intervention, 18% control
Hypertension: unclear
Medications taken by at least 50% of those in the control group: lipid lowering medica-
tion, antihypertensives, antithrombotics
Medications taken by 20%-49% of those in the control group: not reported
Medications taken by some, but less than 20% of the control group: antiarrythmic drugs,
antidiabetic drugs
Location: the Netherlands
Ethnicty: not reported
Interventions Type: supplementary margarine
Comparsion: ALA vs MUFA
Intervention 20 g of enriched margarine per day incorporating: 2 g ALA. 8 × 250 g
margarine tubs delivered every 12 weeks. Dose: average achieved +1.9 g/d ALA
Control: 20 g of margarine per day. No additional n-3 PUFAs. Identical margarine (oleic
acid) placebo
Compliance: unused margarine tubs were returned- daily intakes of margarine and n-3
fatty acids were calculated on the basis of the amount unused. Adherence was measured
by levels of fatty acids in plasma cholesteryl esters, margarine and questionnaires. 90.5%
of patients adhered to the protocol and consumed 20.6 (SD 2.8) g of margarine/d
Length of intervention: 40 months
Outcomes Main study outcome: cardiovascular disease events
Dropouts: 91 died, 98 discontinued intervention, 93 died, 93 discontinued control
Available outcomes: deaths, MI, cardiovascular events, ventricular arrhythmia, Incident
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cardiovascular disease
Response to contact: yes (data provided)
Notes The study has 3 intervention arms (ALA margarine, EPA/DHA margarine, mixture of
the two interventions). This table represents the ALA only intervention. Outcome data
is used for the ALA group where reported separately or for the combined (ALA arm,
ALA + EPA/DHA arm)
Study funding: Netherlands Heart Foundation, National Institutes of Health and
Unilever R&D (latter provided unrestricted grant for distribution of trial margarines)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk On the computer by a random number
generator before the start of the trial
Allocation concealment (selection bias) Low risk Author confirmed allocation was concealed
from clinicians/ researchers
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk The 4 types of margarine were “similar in
taste, texture and colour”. A trained test
panel did not perceive a fishy taste or odour.
Randomisation tables were stored safely
under supervision
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Randomisation tables were stored safely
under supervision. There was an indepen-
dent statistician for data analysis. Quote:
“Events were coded by three members of
the end-point adjudication committee who
were unaware of the identity of the patient,
the identity of the treating physician and
the patients assigned study group”
Incomplete outcome data (attrition bias)
All outcomes
Low risk All patients were followed up for events
computerised linkage with municipal reg-
istries. 2531 patients were only followed
up for baseline anthropometric and medi-
cal measurements
Selective reporting (reporting bias) High risk Sudden cardiac death endpoint omitted.
Registered in August 2005, recruitment
was from 2002 to 2006. Outcomes papers
published in 2010
Attention Low risk All participants appear to have had simi-
lar frequency and quantity of attention and
follow-up
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Compliance Low risk Unused margarine tubs were returned;
daily intakes of margarine and n-3 fatty
acids were calculated on the basis of the
amount unused. Adherence was measured
by levels of fatty acids in plasma cholesteryl
esters, margarine and questionnaires. 90.
5% of patients adhered to the protocol and
consumed 20.6 (SD 2.8) g of margarine/d
Other bias Low risk None noted
AlphaOmega - EPA+DHA 2010
Methods RCT, (EPA + DHA vs MUFA), 40 months
Summary risk of bias: low
Participants 60-80 year-olds with previous MI
N: 1192 EPA/DHA intervention, 1236 control (1212 ALA + EPA/DHA intervention
group)
Level of risk for CVD: high
Men: 78.1% intervention, 78.7% control
Mean age in years (SD): 69.1 (5.6) intervention, 68.9 (5.6) control
Age range: 60-80 years
Smokers: 16.8%, intervention, 18% control
Hypertension: unclear
Medications taken by at least 50% of those in the control group: lipid-lowering medi-
cation, antihypertensives, antithrombotics
Medications taken by 20%-49% of those in the control group: not reported
Medications taken by some, but less than 20% of the control group: antiarrythmic drugs,
antidiabetic drugs
Location: the Netherlands
Ethnicty: not reported
Interventions Type: supplementary margarine
Comparison 1: EPA + DHA vs MUFA
Intervention: 20 g of enriched margarine per day incorporating 400 mg EPA-DHA (240
mg EPA and 160 mg DHA). Dose: average achieved 376 mg/d EPA + DHA
Control: 20 g of margarine per day. No additional n-3 PUFAs. Identical margarine (oleic
acid) placebo
Compliance: unused margarine tubs were returned; daily intakes of margarine and n-3
fatty acids were calculated on the basis of the amount unused. Adherence was measured
by levels of fatty acids in plasma cholesteryl esters, margarine and questionnaires. 90.5%
of patients adhered to the protocol
Length of intervention: 40 months
Outcomes Main study outcome: cardiovascular disease events
Dropouts: 95 died, 119 discontinued intervention, 93 died, 93 discontinued control
Available outcomes: deaths, MI, cardiovascular events, ventricular arrhythmia, incident
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cardiovascular disease
Response to contact: yes (data provided)
Notes The study has three intervention arms (ALAmargarine, EPA/DHAmargarine,mixture of
the two interventions). This table represents theEPA/DHA only intervention. Outcome
data is used for the EPA/DHA group where available or for the combined (EPA/DHA
arm, EPA/DHA + ALA arm)
Study funding: Netherlands Heart Foundation, National Institutes of Health and
Unilever R&D (latter provided unrestricted grant for distribution of trial margarines)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk On the computer by a random number
generator before the start of the trial
Allocation concealment (selection bias) Low risk Author confirmed allocation was concealed
from clinicians/ researchers
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk The 4 types of margarine were “similar in
taste, texture and colour”. A trained test
panel did not perceive a fishy taste or odour.
Randomisation tables were stored safely
under supervision
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Randomisation tables were stored safely
under supervision. There was an indepen-
dent statistician for data analysis. Quote:
“Events were coded by three members of
the end-point adjudication committee who
were unaware of the identity of the patient,
the identity of the treating physician and
the patients assigned study group”
Incomplete outcome data (attrition bias)
All outcomes
Low risk All patients were followed up for events
computerised linkage with municipal reg-
istries. 2531 patients were only followed
up for baseline anthropometric and medi-
cal measurements
Selective reporting (reporting bias) High risk Sudden cardiac death endpoint omitted.
Registered from August 2005, recruitment
was from 2002 to 2006. Outcomes papers
published in 2010
Attention Low risk All participants appear to have had simi-
lar frequency and quantity of attention and
follow-up
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Compliance Low risk Unused margarine tubs were returned;
daily intakes of margarine and n-3 fatty
acids were calculated on the basis of the
amount unused. Adherence was measured
by levels of fatty acids in plasma cholesteryl
esters, margarine and questionnaires. 90.
5% of patients adhered to the protocol and
consumed 20.6 (SD 2.8) g of margarine/d
Other bias Low risk None noted
AREDS2 2014
Methods Age-Related Eye Disease Study 2 (AREDS2)
RCT, parallel, 2 × 2 factorial (n-3 EPA + DHA vs nil) also randomised to lutein and
zeaxanthin vs nil), 5 years
Summary risk of bias: low
Participants People aged 50-85 years at high risk of progression to advanced age-related macular
degeneration (AMD)
N: 2147 intervention (1068 DHA/EPA, 1079 DHA/EPA + lutein/zeaxanthin), 2056
control (1012 placebo, 1044 lutein/zeaxanthin)
Level of risk for CVD: low (however ~20% had previous CV event)
Men: intervention 42.1%, control 44.4%
Age in years: intervention median 74.6 (IQR 11.1), control median 74 (IQR 11.1)
Age range: 68-79 years
Smokers: intervention 6.3%, control 7.2%
Hypertension: unclear
Medications taken by at least 50% of those in the control group: multivitamins
Medications taken by 20%-49% of those in the control group: cholesterol lowering
drugs, aspirin
Medications taken by some, but less than 20%of the control group:NSAID, paracetamol
Location: USA
Ethnicty: white 96.5% intervention, 96.6% control; Hispanic: 2.6 intervention, 1.3
control
Interventions Type: supplement (capsule)
Comparison: EPA + DHA vs nil
Intervention 350 mg/d DHA plus 650 mg/d EPA added to the standard AREDS sup-
plement of Vitamin C (500 mg/d), Vitamin E (440 IU/d), beta-carotene (15 mg/d),
zinc oxide (80 mg/d) and cupric oxide (2 mg/d). Dose: +1 g/d EPA + DHA
Control: standard AREDS supplement of Vitamin C (500 mg/d), Vitamin E (400IU/
d), beta-carotene (15 mg/d), zinc oxide (80 mg/d) and cupric oxide (2 mg/d).
Compliance: assessed by pill count - 84% of participants in each group took at least
75% of study medications
Length of intervention: 60 months
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AREDS2 2014 (Continued)
Outcomes Main study outcome: development of advanced AMD
Dropouts: intervention 200 died, 165 discontinued, 80 were lost to follow-up; control
168 died, 140 discontinued, 61 were lost to follow-up
Available outcomes: deaths, cardiovascular death,MI, stroke, angina, heart failure, revas-
cularisation, cognition, eye health, (authors provided data on diabetes diagnosis, depres-
sion diagnosis, breast cancer)
Response to contact: yes (data provided)
Notes Study funding: National Eye Institute/National Institutes of Health, Department of
Health and Human Services
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “random block design was im-
plemented using the AREDS2 Advantage
Electronic Data Capture system by the
AREDS2 Coordinating Center”
Allocation concealment (selection bias) Low risk Each treatment was assigned 5 bottle num-
bers. Bottle numbers were issued via an
electronic randomisation system for each
participant once study eligibility was ver-
ified. The assigned bottle number was
used to distribute the study treatment(s)
. AREDS2 Coordinating centre personnel
involved in creating the randomisation sys-
tem had access to the bottle number/treat-
ment assignments
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Participants, investigators, study coordi-
nators, and all other study personnel are
masked to treatment assignment”. How-
ever, no information was given regarding
the taste, smell, or appearance of the active
or placebo capsules
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The coordinating centre randomly as-
signed the event to a study adjudicator, who
made the final determination of these study
endpoints through review of the medical
records and applying the endpoint crite-
rion defined a priori. All adjudicators were
masked to study assignment
Incomplete outcome data (attrition bias)
All outcomes
Low risk < 20% attrition over 5 years, balanced rea-
sons for dropouts
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Selective reporting (reporting bias) Low risk Outcomes in trials registry entry appear to
all be reported (NCT00345176). Entry re-
ceived June 2006, recruitment September
2006 - October 2012
Attention Low risk Participants, investigators, study coordi-
nators, and all other study personnel are
masked to treatment assignment, so atten-
tion bias not feasible
Compliance Unclear risk Assessed by pill count - 84% of participants
in each group took at least 75% of study
medications
Other bias Low risk None noted
Baldassarre 2006
Methods RCT, (n-3 EPA + DHA vs MUFA), 24 months
Summary risk of bias: moderate or high
Participants 45-70 year olds with combined hyperlipoproteinaemia
N: 32 intervention, 32 control
Level of risk for CVD: moderate
Men: 29% intervention, 29% control
Mean age in years (SD): 53.7 (7.2) intervention, 53.7 (6.9) control
Age range: 45-70 years (inclusion)
Smokers: 28.1% intervention, 28.1% control
Hypertension: none (exclusion criteria)
Medications taken by at least 50% of those in the control group: not reported
Medications taken by 20%-49% of those in the control group: not reported
Medications takenby some, but less than20%of the control group: not reported (patients
on HRT, anti-hypertensive drugs, lipid lowering drugs, or who smoked > 10 cigarettes
were excluded)
Location: Italy
Ethnicty: not reported
Interventions Type: capsules
Comparsion: LCn3 vs MUFA
Intervention: 1 g × 6 soft gelatin capsules/d of fatty acid mixture (19% EPA), 13%
DHA, 19% palmitic acid, 18% oleic acid, 2% LA and 29% other minor components)
providing 1.08 g/d EPA, 0.72 g/d DHA, 0.01 g/d tocopherol acetate, divided to three
doses. Dose: 1.8 g/d EPA + DHA
Control: 1 g × 6 opaque identical soft gelatin capsules/d of olive oil divided in 3 doses
Compliance: assessed by counting returned capsules at each visit and by measuring EPA
and DHA levels at month 24
Length of intervention: 24 months
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Baldassarre 2006 (Continued)
Outcomes Main study outcome: carotid atherosclerosis measures
Dropouts: 2 intervention, 5 control
Available outcomes: deaths (nil), MI (lipids, weight, BP and heart rate reported but not
in a usable format; lipid data were presented at various times without clear numerical
data, suggesting falls in TGs in the intervention but not control arms, and rises in LDL
and HDL cholesterol in intervention but not control arms. For the other outcomes the
text states “a rise in body weight (+ 3%, P < 0.01) was observed at the end of the study
in both groups. Blood pressure and heart rate were unchanged”. Effects on IMT and
platelets also reported but not used)
Response to contact: not yet attempted
Notes Study funding: supported by Institut De Recherche Pierre Fabre, Departement
Recherche Clinique
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk An appropriate software was used to obtain
2 groups balanced for sex, age and smoking
Allocation concealment (selection bias) Unclear risk No further details
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Double-blind and placebo capsules were
opaque and identical looking to interven-
tion. However no information provided on
capsules taste or smell
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No details
Incomplete outcome data (attrition bias)
All outcomes
Low risk All dropouts are accounted for. “One pa-
tient left the study after 3 months because
he moved to another city and was therefore
excluded from statistical analyses. Two pa-
tients were excluded because of major de-
viation from the protocol during the fol-
low-up (anti-hypertensive assumption) and
four because of non-compliance on the
basis of returning capsules (compliance <
70%). The final analysed group included
57 patients (30 on active treatment).”
Selective reporting (reporting bias) Unclear risk No protocol or trial register record
Attention Low risk Both groups had the same contact and
number of visits.
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Compliance Low risk Pill count, we know they excluded 4/64
who returned > 70% of capsules. So 60/
64 had > 70% compliance with significant
increase in serum EPA and DHA in the in-
tervention group
Other bias Low risk None noted
Bates 1989
Methods RCT, parallel, (n-3 EPA + DHA vs MUFA), 24 months
Summary risk of bias: moderate or high
Participants People with multiple sclerosis
N: 155 intervention, 157 control. (analysed, intervention: 145 control: 147)
Level of risk for CVD: low
Men: 34.2% intervention, 30.6% control
Mean age in years (SD): 34.0 (6.6) intervention, 33.7 (6.3) control
Age range: not reported but 16-45 years inclusion criteria
Smokers: not reported
Hypertension: not reported
Medications taken by at least 50% of those in the control group: not reported
Medications taken by 20%-49%: not reported
Medications taken by some, but < 20%: not reported
Location: UK
Ethnicity: not reported
Interventions Type: supplement (fish oil capsule)
Comparison: EPA + DHA vs MUFA
Intervention: 20 × 0.5 g/d capsules MaxEPA fish body oil (10 g/d fish oil providing 1.
71 g/d EPA +1.14 g/d DHA +10 IU/d vitamin E), plus all advised to reduce animal fat
and ensure plentiful omega-6 fats. Dose: +2.85 g/d EPA + DHA
Control: 20 × 0.5 g/d capsules olive oil (10 g/d olive oil), plus all advised to reduce
animal fat and ensure plentiful omega-6 fats. All capsules contained 0.5 IU vit E and
100 ppm dodecyl gallate to minimise peroxide formation
Compliance: serum EPA and DHA rose in intervention group but fell in controls
Duration of intervention: 24 months (5 years mentioned but outcomes not reported)
Outcomes Main study outcome: multiple sclerosis progress
Dropouts: 10 intervention, 10 control
Available outcomes: all-cause mortality, progress of MS, rate of MS relapse
Response to contact: yes (no data provided)
Notes Study funding: Multiple Sclerosis Society of Great Britain and Northern Ireland, but
Marfleet Refining provided fish oil and placebo capsules
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “randomised”
Allocation concealment (selection bias) Unclear risk No further details
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Paper states research was “double blind”
and control capsules “had the same appear-
ance and flavour as the fish oil capsules
and were packed and dispensed in identical
fashion”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated
Incomplete outcome data (attrition bias)
All outcomes
Low risk Low risk at reported time points
Selective reporting (reporting bias) High risk No protocol or trials registration entries
found. Study was intended to run for 5
years, but outcomes only appear to be re-
ported for the first 2 years
Attention Low risk Unlikely as each had capsules
Compliance Low risk Serum EPA and DHA rose in intervention
group but fell in controls
Other bias Low risk Not noted
Berson 2004
Methods RCT, parallel, (n-3 DHA vs n-6 LA), 48 months
Summary risk of bias: low
Participants People with retinitis pigmentosa aged 18-55 years
N: 221 randomised overall, analysed 105 intervention, 103 control
Level of risk for CVD: low
Men: 48% intervention, 54% control
Mean age in years (SD): 37.8 (6.5) intervention, 36.0 (7.2) control
Age range: unclear (18-55 inclusion criterion)
Smokers: not reported
Hypertension: not reported
Medications taken by at least 50% of those in the control group: vitamin A
Medications taken by 20%-49% of those in the control group: multivitamins
Medications taken by some, but less than 20% of the control group: not reported
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Location: USA
Ethnicity: unclear (6% of the study population were minorities)
Interventions Type: supplement (DHA capsules)
Comparison: DHA vs omega 6
Intervention: 6 × 500 mg capsules/d of DHA (1.2 g/d DHA plus 1.8 g vegetable oil)
plus < 0.0006 mg/d tocopherols plus 15,000 IU retinyl palmitate (vitamin A). Dose: +1.
2 g/d DHA
Control: 6 × 500 mg capsules/d of soy and corn oils (half each) with 120 mg/d ALA,
plus < 0.0006 mg/d tocopherols plus 15000 IU retinyl palmitate (vitamin A)
Compliance: 92% of capsules taken by both intervention and control groups (assessed
by monthly calendars), Plasma DHA much higher in intervention than control
Length of intervention: 48 months
Outcomes Main study outcome: retinal degeneration
Dropouts: 5 or 6 intervention, 7 or 8 control
Available outcomes: mortality, cancer diagnoses, lipids, eyesight
Response to contact: yes (no data provided)
Notes Study funding: National Eye Institute and Foundation Fighting Blindness
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated random numbers
Allocation concealment (selection bias) Low risk Random numbers available only to pro-
grammerwhoprovided assignments to data
manager, all staff in contact with patients
were masked to group assignment
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk States that all staff in contact with partic-
ipants were masked to group assignment,
as were participants. However no informa-
tion was provided regarding the taste, smell
and appearance of the active and placebo
capsules
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk All assessments were performed blind to
study allocation. Each ocular examination
was performed without review of previous
records. All serum samples were analysed
without knowledge of treatment group as-
signment
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Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Numbers of dropouts and reasons for
dropouts not stated. 221 participants ran-
domised, data presented on 208 partici-
pants
Selective reporting (reporting bias) Unclear risk No trials registry entry or protocol found.
Attention Low risk Staff in contact with patients were masked,
so unable to bias time, etc
Compliance Low risk 92%of capsules taken by both intervention
and control groups (assessed by monthly
calendars), Plasma DHA much higher in
intervention than control
Other bias Low risk None noted
Brox 2001
Methods RCT, parallel, 3 arms (n-3 EPA + DHA from cod liver vs n-3 EPA + DHA from seal oil
vs nil), 14 months
Summary risk of bias: moderate or high
Participants Subjects with moderate hypercholesterolaemia
N: 40 seal oil (SO), 40 cod liver oil (CLO), 40 control (numbers analysed vary by
outcome)
Level of risk for CVD: moderate (dyslipidaemia)
Men: 53% seal oil, 50% cod liver oil, 48% control
Mean age in years: 53.2 seal oil, 55.0 cod liver oil, 55.8 control
Age range: 43-66 years
Smokers: unclear
Hypertension: unclear
Medications taken by at least 50% of those in the control group: none allowed
Medications taken by 20%-49% of those in the control group: not reported
Medications taken by some, but less than 20% of the control group: not reported
Location: Norway
Ethnicity: not reported
Interventions Type: supplement (oil)
Comparison: EPA + DHA vs nil
Intervention: Intervention: seal oil - 15 mL/d (2.6 g, 1.1 g/d EPA + 1.5/d DHA) (total
n-3 3.9 g/d, total PUFA 4.2 g/d): SO dose: EPA + DHA 2.6 g/d
Cod liver oil - 15 mL/d (3.3 g, 1.5 g /d EPA + 1.8 g/d DHA) (total n-3 4.1 g/d, total
PUFA 4.35 g/d): CLO dose: EPA + DHA 3.3 g/d
Control: nil, no supplement
Compliance: serum omega-3 fatty acids, rose from around 1 mmoL/L to 2.4 (seal oil),
2.1 (cod liver oil) and 1.2 mmoL/L (control)
Length of intervention: 14 months
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Outcomes Main study outcome: serum lipids
Dropouts: 8 seal oil, 2 cod liver oil, 1 control
Available outcomes: total and cardiovascular deaths, MI, combined CV events, lipids,
adverse events
Response to contact: yes (author provided methodological details)
Notes Data of two intervention groups combined for dichotomous outcomes and CLO vs
control data used for continuous outcomes
Study funding: the study was supported by the programme Medical Research in Finn-
mark County, University of Tromsø
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk J Brox stated (personal communication,
January 2017): ”The randomization of the
120 participants was done by first generat-
ing 3 groups (seal oil, cod liver oil, control)
, then giving each participant a number (1-
120), “’putting all the numbers into the
same hat’ and blindly drawing one num-
ber at the time from the hat. The first 40
numbers (1-40) were allocated to the seal
oil group, the next 40 numbers (41-80) to
the cod liver oil group and the rest (81-120)
were allocated to the control group.”
Allocation concealment (selection bias) Low risk J Brox stated (personal communication,
January 2017): “The researcher/clinician
who invited the participants had no knowl-
edge of to which group the participants
would be allocated.”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “controls were aware - not given a
supplement”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk J Brox stated (personal communication,
2003): “All the persons involved in the
drawing & analysing of blood were
unaware of treatment. The technicians
analysing the blood did not have any per-
sonal contact with the participants except
K. Olaussen who did the FA analysis …
she only had access to the sample num-
bers not names and code. The participants
did not know their number (says elsewhere
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Brox 2001 (Continued)
that K Olaussen did not know allocations).
The only outcome assessor was J Brox who
did not have personal contact with partic-
ipants, randomising, collecting results or
analysing process.” “The only assessor was
J Brox who did not have any personal con-
tact with the participants, had nothing to
do with the randomising or analysing pro-
cess, or the collecting of results.”
Incomplete outcome data (attrition bias)
All outcomes
High risk Control group 3 dropouts, seal oil group
10 dropouts, cod liver oil 3 dropouts. So
substantial differences in rates of dropouts
between the groups
Selective reporting (reporting bias) Unclear risk No study protocol or trials register entry
was found
Attention Low risk No suggestion of differential attention
Compliance Low risk Serum omega-3 fatty acids, rose from
around 1mmoL/L to 2.4 (seal oil), 2.1 (cod
liver oil) and 1.2 mmoL/L (control)
Other bias Low risk No further bias noted
Caldwell 2011
Methods RCT, parallel, (n-3 EPA + DHA vs n-6 LA), 12 months
Summary risk of bias: low
Participants Participants with non-cirrhotic NASH (non-alcoholic steatohepatitis)
N: 20 intervention, 21 control (analysed 17 intervention, 17 control)
Level of risk for CVD: moderate
Men: 35.3% intervention, 41.2% control
Mean age in years (SD): 46.4 (12.1) intervention, 47.2 (12) control
Age range: 25-72 years
Smokers: not reported
Hypertension: not reported
Medications taken by at least 50% of those in the control group: not reported
Medications taken by 20%-49% of those in the control group: not reported
Medications taken by some, but less than 20% of the control group: not reported
Location: USA
Ethnicity: intervention, 100% white, control 94.% white, 5.9% other
Interventions Type: supplement (capsule)
Comparison: EPA + DHA vs omega 6
Intervention: 3 × 1 g fish oil capsules/d (Nordic Natural) for a total 2.1 g/d n-3, each
capsule contained 70% of n-3 (1050 mg EPA, 750 mgDHA + 300 mg other n-3). Dose:
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1.8 g/d EPA + DHA
Control: 3 × 1 g identical placebo (soybean) capsules per day containing 8% fish oils
Both groups had dietary counselling on caloric intake and physical activity
Compliance: unclear (measured n-6-n-3 ratio due to its link to hepatic lipid composition)
Length of intervention: 12 months
Outcomes Main study outcome: NASH activity score
Dropouts: 3 intervention, 3 control
Available outcomes: lipids (TG too unbalanced at baseline to use), measures of adiposity
(weight, BMI, visceral fat - all unbalanced at baseline so not used), fasting glucose,
insulin, HOMA-IR, QUICKI (also NASH progression, hepatic fat, ALT, VO2 max,
activity level, markers of cell injury, adiponectin not used)
Response to contact: yes, change data supplied for BMI and body weight, confirmed no
deaths, cardiovascular events, diabetes, depression, breast cancer or IBD diagnoses
Notes Data on; BMI, weight, visceral fat, TG and glucose were not used as they were different
between groups at baseline
Study funding: study was supported by NIH NCCAM Grant 5R21AT2901-2 and 5
M01 RR00847. Study medication and identical appearing placebo was provided at no
charge by Nordic Natural. RBC phospholipid profile was performed by Metametrix (
www.metametrix.com). M30, M65, adiponectin, and IGFBP-1 electro chemilumines-
cence assays were performed by Wellstat Diagnostics (www.wellstatdiagnostics.com).
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants were randomised to n-3 or
placebo using a stratified block 1:1 ran-
domisation scheme. An independent bio-
statistician generated the randomisation list
which was confidentially forwarded to the
Investigational pharmacy
Allocation concealment (selection bias) Low risk As above
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk All staff and subjects were blinded to ther-
apy assignment throughout the study pe-
riod. Both capsules were identical. How-
ever no information provided on capsules
taste or smell
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinded for main outcome
Incomplete outcome data (attrition bias)
All outcomes
Low risk 15% dropouts explained and equal in both
groups
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Selective reporting (reporting bias) Low risk The trial was prospectively registered
Attention Low risk Both groups had the same attention
Compliance Unclear risk No details on compliance measurement
Other bias Low risk None noted
DART 1989
Methods Diet And Reinfarction Trial (DART) - oily fish advice (or capsule) arm
RCT - parallel, 2 × 2 × 2 factorial (n-3 EPA + DHA vs nil or fat advice vs not, oily fish
advice (or capsule) vs not, dietary fibre advice vs not)), 2 years
Summary risk of bias: moderate or high
Participants Men recovering from myocardial infarction
N: 1015 intervention, 1018
Level of risk for CVD: high (post-MI)
Men: 100%
Mean age, SD: 56.7 intervention, 56.4 control (SDs not stated)
Age range: unclear
Smokers: 61.7% intervention, 62.2% control
Hypertension: 22.7% intervention, 24.6% control
Medications taken by at least 50% of those in the control group: none reported
Medications taken by 20%-49%: beta-blockers, other antihypertensives, antianginals
Medications taken by some, but < 20%: anticoagulant, aspirin/antiplatelet, digoxin/
antiarrhythmic
Location: UK
Ethnicity: not stated
Interventions Type: dietary advice (to eat more oily fish)
Comparison: EPA + DHA vs SFA + MUFA (by dietary achievement below)
Intervention: advised to eat at least 2 weekly portions of 200-400 g fatty fish (mackerel,
herring, kipper, pilchard, sardine, salmon, trout). If this was not possible, givenMaxEPA
capsules, 3/d (0.5 g EPA/d). 191/883 participants were takingMaxEPA at 2 years. Advice
was reinforced 3-monthly. Dose: aimed for 0.5 g/d EPA
Control: No such dietary advice or capsules
Compliance: 7 day weighed food diary of a random sub-sample indicated intake of 2.5
g/week EPA intervention, 0.8 g/week EPA control
Dietary achievements
Total fat intake, %E (through study): control 35 (SD 6), intervention 31 (SD 7) (MD
−4.00, 95% CI −4.57 to −3.43); significant reduction
Saturated fat intake, %E (through study): control 15 (SD 3), intervention 11 (SD 3),
(MD −4.00, 95% CI −4.26 to −3.74); significant reduction
PUFA intake (through study), %E: control 7 (SD unclear), intervention 9 (SD unclear)
, (MD 2.00, 95% CI 1.57 to 2.43 assuming SDs of 5) significant increase
PUFA n-3 intake: EPA, control 0.6 (SD 0.7) g/week, intervention 2.4 (SD 1.4) g/week
PUFA n-6 intake: not reported
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MUFA intake (through study), %E: control 13 (SD unclear), intervention 11 (SD
unclear) (MD−2.00, 95%CI−2.43 to−1.57 assuming SDs of 5); significant reduction
CHO intake (through study), %E: control 44 (SD 6),intervention 46 (SD 7) (MD 2.
00, 95% CI 1.43 to 2.57); significant increase
Protein intake (through study), %E: control 17(SD 4), intervention 18 (SD 4) (MD 1.
00, 95% CI 0.65 to 1.35); significant increase
Trans fat intake: not reported
Length of intervention: 24 months
Outcomes Main study outcome: total mortality, reinfarction, CHD death
Dropouts: none for mortality
Available outcomes: total andCV deaths,MI, CHD events, lipids, blood pressure, cancer
deaths
Response to contact: yes (data provided)
Notes Some of each group were also advised on low fat and high PUFA and/or high fibre diets,
all participants who smoked were advised to stop and all with a BMI > 30 kg/m2 were
given weight reduction advice, regardless of randomisation arm. The low fat high PUFA
comparison was included in the omega-6 review
Study funding: by theWelsh Scheme for theDevelopment ofHealth and Social Research,
the Welsh Heart Foundation and the Health Promotion, Research Trust. Seven Seas
Health Care and Duncan Flockhart provided Maxepa capsules
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “randomised” confirmed by author
Allocation concealment (selection bias) Unclear risk Pre-prepared sequentially numbered en-
veloped opened by dietitian (unclear if en-
velopes were opaque)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Blinding of dietary advice (or lack of it) is
not possible
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcome assessors were not aware of study
allocation (Prof Burr stated he did not
know assignments)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Hospital notes and death registers were
flagged to catch all outcome data
Selective reporting (reporting bias) Unclear risk No study protocol or trials register entry
was found
103Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
DART 1989 (Continued)
Attention High risk More attention was paid to those given di-
etary advice
Compliance Unclear risk 7 day weighed food diary of a random sub-
sample indicated intake of 2.5 g/week EPA
intervention, 0.8 g/week EPA control
Other bias Low risk None noted
DART2 2003
Methods Diet and Angina Randomised Trial (DART2)
RCT, 2 × 2, (oily fish or capsulesn-3 EPA + DHA vs nil, also no specific advice, also
fruit, vegetables and oats vs no specific advice), 3-9 years
Summary risk of bias: moderate or high
Participants Men treated for angina
N: 1571 intervention, 1543 control (all analysed for events)
Control level of risk for CVD: high
Men: 100%
Mean age in years (SD): 61.1 (NR) intervention, 61.1 (NR) control
Age range: unclear
Smokers: 25% intervention, 23% control
Hypertension: 49% intervention, 47% control
Medications taken by at least 50% of those in the control group: not reported
Medications taken by 20%-49%: lipid lowering, beta-blockers
Medications taken by some, but less than 20% of the control group: not reported
Location: UK
Ethnicity: not reported
Interventions Type: dietary advice (to eat more oily fish or take fish oil capsules)
Comparison: EPA + DHA vs unclear (not total fat, SFA or alcohol, presumably CHO
and/or protein but not clear)
Intervention: most (1109) advised to eat at least 2 weekly portions of fatty fish OR
take MaxEPA capsules, 3/d (0.5 g EPA/d). But 462 participants were sub-randomised
to receive only fish oil capsules, not dietary fish advice. Dose: aimed for 0.5 g/d EPA
Control: none specific sensible eating advice that did not include either of the interven-
tions
Compliance: postal dietary questionnaire suggested dietary EPA intake increased by 2.
4 g /week intervention, 0.2 g /week control
Dietary achievements
Total fat intake, (change from baseline to 6 months): control −8.6 g/d (SD 20.9),
intervention −5.2 (g/d SD 21.4) (MD 3.4 g/d)
Saturated fat intake, (change from baseline to 6 months): control −3.5 g/d (SD 9.3),
intervention −2.8 g/d (SD 9.4), (MD 0.7 g/d)
PUFA intake (change from baseline to 6 months): control−1.6 g/d (SD 5.4), interven-
tion −0.1 g/d (SD 5.8) (MD 1.5 g/d)
PUFA n-3 intake (change from baseline to 6 months): EPA, control 0.12 g/week (SD 0.
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73), intervention 2.65 g/week (SD 1.35) (MD 2.53 g/week)
PUFA n-6 intake: not reported
MUFA intake: not reported
CHO intake: not reported
Protein intake: not reported
Trans fat intake: not reported
Duration of intervention: 36 to 108 months
Outcomes Main study outcome: total mortality
Dropouts: none for mortality
Available outcomes: total and CV deaths, sudden death, stroke, heart failure, cancer
deaths
Response to contact: yes (data provided)
Notes Some of each group were also advised on high fruit, vegetables and oat diets, and those
who received neither fish nor fruit advice received ’non-specific’ dietary advice. All those
whose BMI > 30 kg/m2 in both groups received weight reduction advice.
Study funding: probably British Heart Foundation, Seven Seas Ltd, Novex Pharma Ltd
and the Fish Foundation (these were acknowledged)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “randomly allocated”
Allocation concealment (selection bias) Unclear risk Pre-prepared sequentially numbered en-
veloped opened by dietitian (unclear if en-
velopes were opaque)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Dietary advice, so not possible for partici-
pants to be blinded to intervention
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcome assessors were not aware of study
allocation (Prof Burr stated he did not
know assignments)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Hospital notes and death registers were
flagged to catch all outcome data
Selective reporting (reporting bias) Unclear risk No study protocol was found, or trials reg-
istry entry
Attention High risk More attention was paid to those given di-
etary advice
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Compliance Unclear risk Postal dietary questionnaire suggested di-
etary EPA intake increased by 2.4 g/week
intervention, 0.2 g/week control
Other bias Low risk None noted
Derosa 2016
Methods RCT, parallel, (n-3 PUFA capsules vs placebo), 18 months
Summary risk of bias: low
Participants White overweight/obese patientswith impaired fasting glucose (IFG) or impaired glucose
tolerance (IGT)
N: 138 intervention, 143 control (analysed 128 intervention, 130 control)
Level of risk for CVD: low
Men: 50.72% intervention, 48.95% control
Mean age in years (SD): 53.4 (11.2) intervention, 54.8 (12.1) control
Age range: unclear
Smokers: not reported
Hypertension: not reported
Medications taken by at least 50% of those in the control group: not reported
Medications taken by 20%-49% of those in the control group: not reported
Medications taken by some, but less than 20% of the control group: not reported
Location: Italy
Ethnicity: white
Interventions Type: capsule (n-3 PUFA)
Comparison: EPA + DHA vs CHO + SFA
Intervention: 3 ×1 g capsule/ day n-3 PUFAs (ethylic esters, each 1-g capsule of n-3
PUFAs contains highly concentrated ethyl esters of omega-3 fatty acids, primarily EPA,
and DHA in the proportion of 0.9-1.5). Dose: unclear (approx 2-3 g/d)
Control: placebo (a capsule containing sucrose, mannitol and mineral salts, magnesium
stearate (a saturated fat) and silicon dioxide, used as anti-caking agents)
Both groups were given diet advice to follow a controlled-energy diet based on AHA
recommendations (50% of calories from carbohydrates, 30% from fat (6% saturated)
, and 20% from proteins, with a maximum cholesterol content of 300 mg/day and 35
g/day of fibre). Individuals were also encouraged to increase their physical activity by
walking briskly for 20 to 30 min, 3 to 5 times per week, or by cycling
Compliance: measured by counting the number of pills returned at the time of specified
clinic visits
Length of intervention: 18 months
Outcomes Main study outcome: insulin resistance
Dropouts: 23 across arms (no details on groups but stated that there were no difference
between groups)
Available outcomes:mortality,CVmortality,CHDevent, stroke, combinedCVDevents,
MI, AF, weight, BMI, lipids, diabetes mellitus
Response to contact: yes (data provided)
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Notes Study funding: “The authors have no relevant affiliations or financial involvement with
any organization or entity with a financial interest in or financial conflict with the
subject matter or materials discussed in the manuscript. This includes employment,
consultancies, honoraria, stock ownership or options, expert testimony, grants or patents
received or pending, or royalties”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was done using a draw-
ing of envelopes containing randomisation
codes prepared by a statistician
Allocation concealment (selection bias) Low risk Author stated that allocation was concealed
from clinicians and researchers, but no
methodology provided
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Both n-3 PUFAs and placebo were sup-
plied as identical, opaque, white capsules
in coded bottles to ensure the blind status
of the study. However no information pro-
vided on capsules taste or smell
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk A copy of the code was provided only to the
person performing the statistical analysis
Incomplete outcome data (attrition bias)
All outcomes
Low risk An intention-to-treat analysis was con-
ducted for patients who received 1 dose of
study medication
Selective reporting (reporting bias) Unclear risk No trial registry or protocol found
Attention Low risk No difference reported
Compliance Unclear risk Measured by counting the number of pills
returned at the time of specified clinic visits
Other bias Low risk None noted
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Methods RCT 4 arms, ( n-3 EPA + DHA (3 different doses) vs MUFA), 12 months
Summary risk of bias: moderate or high
Participants Healthy monks
N: 14 high, 15 medium, 15 low dose intervention, 14 control
Level of risk for CVD: low
Men: 100%
Mean age in years (SD): 56.2 (16.5) (not reported by arm)
Age range: 21-87
Smokers: none
Hypertension: not reported
Medications taken by at least 50% of those in the control group: not reported
Medications taken by 20%-49% of those in the control group: not reported
Medications taken by some, but less than 20% of the control group: not reported (no
medications influencing lipidmetabolism or non-steroidal anti-inflammatory drugswere
allowed)
Location: the Netherlands
Ethnicity: not reported
Interventions Type: capsules
Comparsion: LCn3 vs MUFA
Intervention 9 capsules (9 g vol.) per day, of which 3, 6 or 9 were fish oil (Labaz, Brussels,
Belgium) and any remainder were placebo (providing respectively 1.12; 2.24 or 3.37 g
n-3 FA/day). Dose: 1.12 g/d; 2.24 g/d or 3.37 g/d EPA + DHA)
Control: 9 placebo capsules made up of olive oil (Puget Marseille, France) and Palmoil
(Loders-Kroklaan Wormerveen, the Netherlands) with the same SFA, cholesterol and
vitamin E as the fish oil capsules
Compliance: assessed by counting remaining capsules every 2 months and by measuring
EPA concentration. Excellent compliance reported and shown by the EPA concentration
results
Length of intervention: 12 months
Outcomes Main study outcome: effect on coronary risk factors
Dropouts: none
Available outcomes: deaths (nil), CVD events (nil), lipids, BP, HbA1c, weight (measured
but only text suggests “no significant changes in the anthropometric parameters (weight,
length, waist, hip and thigh circumferences) during the study”), IL-6, TNF-alpha and
several IL-1s (IL-6 reported as below detection range, for the others there was “no
significant difference between the two treatment groups at any point in time”)
Response to contact: yes
Notes Study funding: capsules supplied by Labaz (Brussels Belgium). The placebo capsules
contained olive oil (Puget) and palm oil (Loders-Kroklaan, Wormerveer). Financial sup-
port by Sanofi-Labaz
Data entered for high fish oil versus placebo groups
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Low risk Quote (author correspondence): “The
manufacturer provided envelopes contain-
ing numbers corresponding with boxes of
capsules. For each enrolled subject, random
envelope was opened.”
Allocation concealment (selection bias) Low risk Allocation concealed from all this way
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Although double blind, the fishy taste of
the active treatment was not matched (au-
thor states that the fishy taste was clear in
the intervention capsules)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Authors confirmed outcome assessors were
unaware until afterwards
Incomplete outcome data (attrition bias)
All outcomes
Low risk No dropouts
Selective reporting (reporting bias) Unclear risk No protocol or trial registry record
Attention Low risk No difference between groups
Compliance Low risk Significant difference in EPA concentra-
tion
Other bias Low risk None noted
DIPP 2015
Methods Dietary Intervention for Patients Polypectomized for tumours of the colorectum (DIPP)
RCT, parallel, 2 arms (n-3 EPA + DHA + n-3 ALA vs nil), 24 months
Summary risk of bias: moderate or high
Participants Patients previously polypectomised for colorectal tumours
N: 104 intervention, 101 control
Level of risk for CVD: low
Men: 73.1% intervention, 74.3% control
Mean age in years (SD): 58.3 (9.5) intervention, 59.7 (8.9) control
Age range: 35-75
Smokers: 65.4% intervention, 61.4% control
Hypertension: not reported
Medications taken by at least 50% of those in the control group: supplements
Medications taken by 20%-49% of those in the control group: none
Medications taken by some, but less than 20% of the control group: oral contraceptive
pills
Location: Japan
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Ethnicity: not reported
Interventions Type: advice + supplement (fish oil capsules)
Comparison: EPA + DHA + ALA vs omega-6
Intervention: advice to reduce total fat intake, decrease consumption of n-6 PUFAs,
increase intake of n-3 PUFAs from fish/marine foods, increase intake of n-3 PUFAs from
perilla oil rich in ALA, take 8 capsules of fish oil/day (equivalent to 96 mg/day of EPA
and 360 mg/day of DHA). Dose: 456mg/d EPA + DHA and unknown dose of ALA
Control: advice to decrease intake of fats/oils as a whole
Compliance: measured via semi-quantitative food frequency questionnaire, plasma fatty
acid concentrations, fatty acid compositions in the membranes of red blood cells and
the sigmoid colon. Reported satisfactorily high compliance with protocol in both groups
but no figures provided
Length of intervention: 24 months
Outcomes Main study outcome: number and size of colorectal tumours
Dropouts: 3 intervention, 5 control
Available outcomes: all cause mortality, dietary intake, plasma fatty acids, lipids, side
effects, glucose
Response to contact: yes (methodological details provided)
Notes Study funding: all were either government or charity grants
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomly allocated using random digit
number for allocation of participants
Allocation concealment (selection bias) Low risk Author confirmed “Allocation information
was blinded to clinicians and researchers”
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk From the 2015 paper, “The attending
physicians as well as the participants were
blinded to the assignment information”.
However in the discussion section they say
“complete participant blinding could not
have been achieved because free living par-
ticipants might have exchanged informa-
tion on their dietary intervention, say in the
hospital waiting room”. Author confirmed
blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “physicians, including colono-
scopists, a scientist who conducted blood
and specimen analyses, and pathologists
were blinded”
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Incomplete outcome data (attrition bias)
All outcomes
Low risk All those randomised were accounted for
Selective reporting (reporting bias) High risk The researchers chose not to report data
on the number, size and pathological type
of the colorectal tumours as they said they
would in the trials register. They reported
more outcomes in the paper than initially
stated
UMIN000000461 Registered 3 August
2006, recruitment completed 1 March
2007
Attention Low risk Participants were given equal follow-up
Compliance Unclear risk Reported satisfactorily high compliance
with protocol was noted in both groups but
no figures
Other bias Low risk None noted
DISAF 2003
Methods Dietary Intervention Study for AF (DISAF)
RCT, parallel, 2 arms (n-3 EPA + DHA vs nil), 12 months
Summary risk of bias: moderate or high
Participants People presenting for first treatment of acute/persistent atrial fibrillation or flutter, con-
firmed by ECG
N: intervention 201, control 206
Level of risk for CVD: high (patients with atrial fibrillation)
Men: intervention 64.7%, control 63.6%
Mean age in years (SD): intervention 67.7 (9.4), control 68.7 (9.5)
Age range: unclear
Smokers: intervention 10.9%, control 12.1%
Hypertension: intervention 48.2%, control 40.8%
Medications taken by at least 50% of those in the control group: not reported
Medications taken by 20%-49% of those in the control group: antiarrythmics, an-
tithrombotics
Medications taken by some, but less than 20% of the control group: not reported
Location: UK
Ethnicity: white British
Interventions Type: dietary advice
Comparison: EPA + DHA vs unclear
Intervention: dietary assistants gave advice and support to eat 2 to 3 portions of oily fish
per week (providing up to 10 g LCn3/ week), plus 2 to 3 portions of fruit and vegetables
per day. Dose: 1.4 g/d EPA + DHA
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Control: dietary assistants gave advice and support to eat 2 to 3 portions of fruit and
vegetables per day. No other health/lifestyle given as part of the trial
Compliance: assessed red blood cell fatty acids and found some increases in EPA and
DHA in intervention compared to control (no further intake data)
Length of intervention: 12 months
Outcomes Main study outcome: sinus rhythm after 12 months
Dropouts: unclear
Available outcomes: deaths, AF recurrence
Response to contact: yes (data provided)
Notes Study funding: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was by phone to an inde-
pendent randomisation office, which used
pre-printed random number tables
Allocation concealment (selection bias) Low risk Randomisation was by phone to an inde-
pendent randomisation office, which used
pre-printed random number tables
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Dietary advice was clear, so allocation
known by participants
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Unclear
Incomplete outcome data (attrition bias)
All outcomes
High risk Some discrepancies between papers, rea-
sons unclear
Selective reporting (reporting bias) High risk ISRCTN16448451 registered 23 January
2004, recruitment from 1 July 1998 to 1
July 2002; some secondary outcomes were
not reported
Attention Low risk Intervention (advice to eat more oil-rich
fish, fruit and vegetables) and control (ad-
vice to eatmore fruit and vegetables) groups
appeared to be given equivalent time and
attention
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Compliance Low risk Assessed red blood cell fatty acids and
found some increases in EPA and DHA in
intervention compared to control
Other bias High risk The trial was stopped early
DO IT 2010
Methods Diet and Omega 3 Intervention Trial on Atherosclerosis (DO IT)
Randomisation: RCT, parallel, 2 × 2 factorial, (n-3 DHA + EPA vs n-6 LA also dietary
advice intervention), 36 months
Summary risk of bias: moderate or high
Participants Elderly men with longstanding dyslipidaemia or hypertension (a subset of Oslo Diet
heart study)
N: intervention 282 (140 n-3 capsules + 142 n-3 capsules and dietary advice), control
281 (142 placebo capsules + 139 placebo capsules and dietary advice)
Level of risk for CVD: moderate
Men: intervention 100%, control 100%
Mean age in years (SD): intervention 70.4 (2.9), control 69.7 (3.0) years
Age range: 64-76 years
Smokers: intervention 35%, control 33%
Hypertension: intervention 29%, control 27%
Medications taken by at least 50% of those in the control group: none
Medications taken by 20%-49% of those in the control group: statins and acetylsalicylic
acid
Medications taken by some, but less than 20% of the control group: β-blockers, ACE
inhibitors and nitrates
Location: Norway
Ethnicity: not reported
Interventions Type: supplement/ capsule (also dietary advice as the factorial intervention)
Comparison: EPA + DHA vs omega-6
Intervention: 2 × 2 capsules/d incl 2.4 g/d of omega-3 PUFA (Pikasol, 0.84 g/d EPA
plus 0.48 g/d DHA plus 8.4 mg/d tocopherols). Dose: 1.32 g/d EPA + DHA
Control: 2 × 2 capsules/d inc 4 g/d corn oil (2.24 g/d linoleic, 1.28 g/d oleic acid, 16
mg/d tocopherols)
Compliance: pharmacy records suggested that > 90% of supplements were taken, and
plasma EPA and DHA were raised in intervention compared to control participants
Duration of intervention: 36 months
Outcomes Main study outcome: atherosclerosis progression.
Dropouts: intervention 14 died, 20 others discontinued, control 24 died, 18 others
discontinued
Available outcomes: mortality, cardiovascular deaths, CHD events, CV events, MI,
stroke, diabetes, glucose, lipids, cancer diagnosis, cancer deaths, sudden death, BMI
(waist circumference reported as median, IQR)
Response to contact: yes (data provided)
113Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
DO IT 2010 (Continued)
Notes The other 2 × 2 intervention was dietary counselling to increase both omega-3 and
omega-6 fats as well as fruit and vegetables
Study funding: Norwegian Cardiovascular Council, Norwegian retail company RIMI,
vegetable oil and margarine supplied by the Norwegian food company Mills DA and
placebo capsules by LUBE
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Permuted block randomisation, no clear
mechanism provided
Allocation concealment (selection bias) Unclear risk No details provided
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Capsules of fish oil or placebo taken, but
unclear whether blinded and if so, howwell
or successfully
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Mortality data were supplied from the
Norwegian Cause of Death Registry, and
all clinical events were confirmed by hospi-
tal records and verified by an independent
cardiologist”
Incomplete outcome data (attrition bias)
All outcomes
Low risk No attrition as deaths and events collected
from centralised register
Selective reporting (reporting bias) Unclear risk Trials registry entry submitted after the out-
comes papers were published
Attention Low risk No suggestion of attention bias between
verum and placebo supplement arms
Compliance Low risk Pharmacy records suggested that > 90% of
supplements were taken, and plasma EPA
and DHAwere raised in intervention com-
pared to control participants
Other bias Low risk None noted
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Dodin 2005
Methods RCT, parallel, (n-3 ALA vs n-6 LA), 12 months
Summary risk of bias: moderate or high
Participants Healthy menopausal women
N: 101 intervention, 98 control. (analysed, intervention: 85 control: 94)
Level of risk for CVD: low
Men: 0% intervention, 0% control
Mean age in years (SD): 54.0 (4.0) intervention, 55.4 (4.5) control
Age range: 49-65
Smokers: 8% intervention, 6% control
Hypertension: not reported
Medications taken by at least 50% of those in the control group: not reported
Medications taken by 20%-49% of those in the control group: not reported
Medications taken by some, but less than 20% of the control group: not reported
Location: Canada
Ethnicity: French Canadian
Interventions Type: food supplement (flaxseed)
Comparison: ALA vs unclear (probably includes lipids, CHO and protein, but not clear)
Intervention: 40 g/d flaxseed incorporated into diets (providing 21,071 g total lignans,
180 calories, 16 g lipids (57% ALA), and 11 g total dietary fibre). Dose: 9.1 g/d ALA
Control: 40 g/d wheat germ incorporated into diets (providing 196 g total lignans, 144
calories, 4 g lipids (6.9% ALA), and 6 g total dietary fibre
Compliance: first morning urine collection was performed at randomisation and at
month 12 to measure urinary lignin levels. In addition, study participants recorded their
daily intake of seeds on diary cards and were asked to return unused bread and packages
of seeds at each visit. Good compliance reported
Duration of intervention: 12 months
Outcomes Main study outcome: bone mineral density
Dropouts: 26 intervention, 17 control (but 13/17 had an endpoint evaluation)
Available outcomes: weight, BMI, QoL, blood pressure, lipids, glucose, adverse events,
dietary intake, plasma fatty acids
Response to contact: yes
Notes Auhors replied to tell us that there were no deaths or CV events during the study
Study funding: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The randomisation schedule was prepared
by the clinical unit of the research centre
using computer generated randomisation
in blocks of 4-8
Allocation concealment (selection bias) Unclear risk No details
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Dodin 2005 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants, investigators, staff, and statis-
ticians were blinded to dietary assignments
for the duration of the study
Quote: ”a local baker prepared loaves of
bread. Each week, the loaves of bread
were delivered in sealed, opaque unmarked
wrappers to the Department of Food and
Nutrition Sciences at Laval University. The
seeds were ground up and vacuum-packed
in the same laboratory. The Department of
Food and Nutrition Sciences was responsi-
ble for labelling the bags of bread and pack-
ages of seeds with the subject’s randomiza-
tion number. Bread and packages of seeds
were provided on a 3-month basis. The
foods that both groups received was similar
in appearance and packaging and was kept
frozen until consumption to avoid essential
fatty acid
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Participants, investigators, staff, and statis-
ticians were blinded to dietary assignments
for the duration of the study
Incomplete outcome data (attrition bias)
All outcomes
Low risk Intention-to-treat analysis. Loss to follow-
up 10%, reasons given
Selective reporting (reporting bias) Unclear risk No protocol or clinical trial registry entry
found
Attention Low risk All participants had same number of visits
Compliance Low risk First morning urine collection was per-
formed at randomisation and at month 12
to measure urinary lignin levels. In addi-
tion, study participants recorded their daily
intake of seeds on diary cards and were
asked to return unused bread and packages
of seeds at each visit. Good compliance re-
ported
Other bias Low risk None noted
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Doi 2014
Methods RCT, parallel, (n-3 EPA vs nil), 12 months
Summary risk of bias: moderate or high
Participants Patients having PCI after acute MI
N: 119 intervention, 119 control analysed
Level of risk for CVD: high
Men: 77% intervention, 76% control
Mean age in years (SD): 70 (11) intervention, 71 (12) control
Age range: unclear
Smokers: 28% intervention, 32% control
Hypertension: 71% intervention, 69% control
Medications taken by at least 50% of those in the control group: aspirin, ticlopidine,
beta-blockers, statins (as part of treatment)
Medications taken by 20%-49% of those in the control group: ARB/ACE inhibitors
Medications taken by some, but less than 20% of the control group: none
Location: Japan
Ethnicity: not reported
Interventions Type: supplement (EPA)
Comparison: EPA vs nil
Intervention: purified EPA ethyl esters (> 98%) 1800 mg EPA/day within 24 hours after
PCI plus statins. Dose: 1.8 g/d EPA
Control: statins with no EPA
Compliance: not reported
Length of intervention: 12 months
Outcomes Main study outcome: cardiovascular events
Dropouts: 1 intervention, 2 control
Available outcomes: mortality, stroke, MI, sudden death, CV death, revascularisation
Response to contact: no
Notes Study funding: trial registry state “self-funded”. The authors received honoraria from
Mochida Pharmaceutical Co
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A computer-generated, randomisation
plan, which included stratification by age
and sex
Allocation concealment (selection bias) Unclear risk Carried out by research technician but un-
clear
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open label but blind endpoint
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Doi 2014 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Data onoutcomeswere collected fromclin-
ical charts. Unclear if blinded. Diagnoses
were confirmed by investigator blind to
treatment allocation
Incomplete outcome data (attrition bias)
All outcomes
Low risk Only 3 dropouts, similar rates between the
groups and reasons given
Selective reporting (reporting bias) High risk Data collection completed before trial reg-
istry entry. Only 1% dropouts
Attention Low risk Timing of follow-up similar
Compliance Unclear risk Not reported
Other bias Low risk None observed
EPE-A 2014
Methods EPE-A
RCT, parallel, 3 arms (n-3 EPA, low dose vs high dose vs unclear placebo), 12 months
Summary risk of bias: moderate or high
Participants People with non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease
(NAFLD)
N: 86 intervention-high, 82 int low, 75 control (analysed 64, 55, 55 respectively, ITT
analysis for primary outcomes)
Level of risk for CVD: low (although 35% had type II diabetes)
Men: 33.7% intervention-high, 41.5% intervention-low, 42.7% control
Mean age in years (SD): 47.8 (11.1) intervention-high, 47.8 (12.5) intervention-low,
50.5 (12.5) control
Age range: not reported
Smokers: not reported
Hypertension: not reported
Medications taken by at least 50% of those in the control group: not reported
Medications taken by 20%-49% of those in the control group: not reported
Medications taken by some, but less than 20% of the control group: not reported
Location: USA
Ethnicity: white intervention-low: 94%, intervention-high: 87%, control: 90.7%
African American intervention-low: 3.7%, intervention-high: 2.3%, control: 4.0%
Others intervention-low: 2.4%, intervention-high: 10.5%, control: 5.3%
Interventions Type: supplement (omega 3 capsule)
Comparison 1: high EPA vs low EPA (unclear what replaced EPA)
Comparison 2: EPA vs unclear (placebo contents not reported)
Intervention-high: EPA-E 2.7 g/d, 3 × EPA-E 300 mg capsules. Dose: 2.7 g/d EPA +
DHA
Intervention-low: EPA-E 1.8 g/d, 2 × EPA-E 300 mg capsules + 1 placebo capsule
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EPE-A 2014 (Continued)
Dose: 1.8 g/d EPA + DHA
Control: 3 × placebo capsules. The pills were identical with respect to size, colour and
smell
Compliance: estimated by pill count andmeasuring the ratio of serumEPA to arachidonic
acid. compliance rates for the 3 groups (placebo vs EPA-E 1800 mg/d vs EPA-E 2700
mg/d) were 89.5% (6.8%), 90.3% (5.7%) and 89.5% (5.3%), respectively
Length of intervention: 12 months
Outcomes Main study outcome: histological response in standardised scoring of liver biopsies and
change in ALT level
Dropouts: 22 intervention-high, 27 intervention-low, 20 control
Available outcomes: cardiac events, deaths (none), angina, adverse events (weight, BMI,
lipids, glucose, HbA1c, HOMA, hsCRP all reported as medians so not useable in meta-
analyses)
Response to contact: yes (provided methodological details)
Notes Data combined for the 2 intervention groups for binary outcomes and higher dose data
vs control used for continuous outcomes
Study funding: supported entirely by Mochida Pharmaceuticals
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Block randomisation using an interactive
voice-response system to assign subjects in
a 1:1:1 ratio between the 2 arms for each
site separately. Participants were stratified
by the presence of type 2 diabetes. The total
fraction of such individuals was capped at
40% of the study cohort
Allocation concealment (selection bias) Low risk As above (remote computer-generated ran-
domisation)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind stated, but no further details.
Author confirmed researchers and outcome
assessors were blinded to treatment alloca-
tion and pills were identical with respect to
size, colour and smell
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No details
Incomplete outcome data (attrition bias)
All outcomes
High risk Number and characteristics of participants
lost to follow-up similar across arms, how-
ever < 80%provided outcome data relevant
to this systematic review
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EPE-A 2014 (Continued)
Selective reporting (reporting bias) Low risk Registered June 2010, study started June
2010, completed October 2012. All out-
comes in trials registry entry were also re-
ported in the trials registry. Secondary out-
comes reported were not planned (com-
pared with first version of clinicaltrials.gov
entry)
Attention Low risk All participants had same follow-up visits.
Compliance Low risk Compliance was estimated by pill count
and measuring the ratio of serum EPA to
arachidonic acid. Compliance rates for the
3 groups (placebo vs EPA-E 1800 mg/d vs
EPA-E 2700 mg/d) were 89.5% (6.8%),
90.3% (5.7%) and 89.5% (5.3%) respec-
tively
Other bias Low risk None noted
EPIC-1 2008
Methods EPANOVA in Crohn’s disease, study 1 (EPIC-1)
RCT, parallel, 2-arm (omega 3 vs MCT), 52 weeks
Summary risk of bias: moderate or high
Participants Adults with quiescent Crohn’s disease (CDAI) score < 150
N: 188 intervention, 186 control
Level of risk for CVD: low
Men: 48.1% intervention, 41.1% control
Mean age in years (SD): 40.5 (15.2) intervention, 38.2 (13.1) control
Age range: 18-70 years
Smokers: 30.6% intervention, 34.4% control
Hypertension: unclear
Medications taken by at least 50% of those in the control group: oral 5-ASA therapy,
Systemic corticosteroids - prednisolone, budesonide
Medications taken by 20%-49% of those in the control group: not reported
Medications taken by some, but less than 20% of the control group: antibiotic therapy,
topical rectal therapy, immune-modifying agents, immune modifiers/biologics
Location: Canada, Europe, Israel, USA
Ethnicity: not reported
Interventions Type: supplement (capsule)
Comparison: EPA + DHA vs SFA (medium chain triglycerides of short SFAs)
Intervention: 2 × 2 1 g gelatin capsules omega-3 free fatty acids (Epanova- 2.2 g EPA,
0.8 g DHA). Dose: 3 g/d EPA + DHA
Control: 4 x1 g capsules medium chain triglycerides
Compliance: pill counts, 79.2% adhered intervention, 75.6% adhered control
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EPIC-1 2008 (Continued)
Length of intervention: mean 52 weeks
Outcomes Main study outcome: Crohns relapse-free time
Dropouts: 80 intervention, 91 control
Available outcomes: total deaths, non-fatal arrhythmias, cancer diagnoses, cancer deaths,
adverse events
Response to contact: yes (data provided)
Notes Study funding: Tillotts Pharma, authors had extensive financial disclosures
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation by number generator. Used
a centralised randomisation procedure via
interactive voice recognition system
Allocation concealment (selection bias) Low risk Centralised randomisation (see above)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double blinding stated, identical capsule
(slow-release capsules). Neither investiga-
tor nor participant knew the allocation
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Study states double-blind but does not state
that outcome assessors were blinded or pro-
vide a mechanism for this
Incomplete outcome data (attrition bias)
All outcomes
Low risk Number of dropouts and reasons provided.
171 of 187 in intervention group and 174
of 184 in control group provided data for
primary outcome, (7% dropout), though
80 in the intervention group and 91 in the
control group terminated early
Selective reporting (reporting bias) High risk Trials registration (NCT00613197) first
received in 2008, but study started in 2003
and was published in 2008
Attention Low risk As investigators were blinded attention bias
was not possible
Compliance Unclear risk Pill counts, 79.2% adhered intervention,
75.6% adhered control
Other bias Low risk No further bias noted
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EPIC-2 2008
Methods EPANOVA in Crohn’s Disease, Study 2 (EPIC-2)
RCT, parallel, 2 arms (omega 3 vs MCT), 58 weeks
Summary risk of bias: moderate or high
Participants Adults with a confirmed diagnosis of Crohn’s Disease and a Crohn’s Disease Activity
Index (CDAI) score < 150 who are responding to steroid induction therapy
N: intervention, 189, control 190 (187 intervention, 188 control analysed)
Level of risk for CVD: low (people with quiescent Crohn’s disease)
Men: 48.1% intervention, 41.1% control
Mean age in years (SD): 38.5 (13.8) intervention, 40.0 (13.6) years control
Age range: > 16 years
Smokers: 25.1% intervention, 37.2% control
Hypertension: unclear
Medications taken by at least 50% of those in the control group: systemic corticosteroids
- prednisolone, budesonide (but tapered and discontinued during the study)
Medications taken by 20%-49% of those in the control group: only reported for prior
12 months
Medications taken by some, but less than 20% of the control group: only reported for
prior 12 months
Location: Canada, Europe, Israel, USA
Ethnicity: not reported
Interventions Type: supplement (capsule)
Comparison: EPA + DHA vs SFA (medium chain triglycerides of short SFAs)
Intervention: 2 × 2 1 g gelatin capsules omega-3 free fatty acids (Epanova) providing
total dose ~2.2 g/d EPA, 0.8 g/d DHA. Dose: ~3.0 g/d EPA + DHA
Control: 2 × 2 1 g capsules medium chain triglyceride oil
Compliance: measured by patient interviews and pill counts, 75.4% adhered interven-
tion, 81.4% adhered control
Length of intervention: mean 58 weeks
Outcomes Main study outcome: maintain Crohns symptomatic remission
Dropouts: 114 intervention, 112 control
Available outcomes: mortality, CV events (nil), cancer diagnoses, adverse events
Response to contact: yes (data provided)
Notes Study funding: Tillotts Pharma, authors had extensive financial disclosures
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation by number generator. Used
a centralised randomisation procedure via
interactive voice recognition system
Allocation concealment (selection bias) Low risk Centralised randomisation (see above)
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EPIC-2 2008 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Double blinding stated, identical capsule
(slow-release capsules). Neither investiga-
tor nor participant knew the allocation.
However no information provided on cap-
sules taste or smell
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Study states double-blind but does not state
that outcome assessors were blinded or pro-
vide a mechanism for this
Incomplete outcome data (attrition bias)
All outcomes
High risk Number of dropouts and reasons provided,
however 114 of 189 in intervention group
and112of 190 in control group terminated
early
Selective reporting (reporting bias) High risk NCT00074542. First received 2003, study
start 2002. Published 2008. Some out-
comes, such as quality of life, stated in trials
registry but not in published papers
Attention Low risk As investigators were blinded, attention
bias was not possible
Compliance Unclear risk Measured by patient interviews and pill
counts, 75.4% adhered intervention, 81.
4% adhered control
Other bias Low risk No further bias noted
EPOCH 2014
Methods Older People, Omega-3 and Cognitive Health (EPOCH)
RCT, parallel (n-3 EPA + DHA vs MUFA), 18 months
Summary risk of bias: low
Participants Healthy older adults with no cognitive impairment
N: 195 intervention, 196 control (reported by author)
Level of risk for CVD: low
Men: not reported
Mean age in years (SD): not reported
Age range: not reported, but 65-90 recruited
Smokers: not reported
Hypertension: not reported
Medications taken by at least 50% of those in the control group: not reported
Medications taken by 20%-49% of those in the control group: not reported
Medications taken by some, but less than 20% of the control group: not reported
Location: Australia
Ethnicity: not reported
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EPOCH 2014 (Continued)
Interventions Type: supplement (fish oil capsules)
Comparison: EPA + DHA vs MUFA
Intervention: 4 capsules/d (1.72 g/d DHA and 0.60 g/d EPA). Dose: 2.32 g/d EPA +
DHA
Control: 4 capsules/d (3.960 g/d olive oil and 40 mg/d fish oil)
Compliance: count of all unused supplements returned at three-monthly intervals, plus
self-report calendars, mailed back on a monthly basis. If compliance fell below 85% (re
calendars), they were contacted by a researcher who noted the reasons. Compliance also
assessed by erythrocyte membrane n-3 LC PUFA status
Length of intervention: 18 months
Outcomes Main study outcome: change in cognitive performance
Dropouts: not reported
Available outcomes:mortality (nil),MI, stroke, revascularisation, arrhythmias,CV events
Response to contact: yes (data provided)
Notes Authors reported some events, but don’t appear to be published
Study funding: EPAX donated the Omega-3 concentrate and Blackmores Pty Ltd do-
nated the placebo and packaging of the Omega-3 concentrate. The trial was supported
by the Brailsford Robertson Award 2007-2008 (University of Adelaide and CSIRO Food
and Nutritional Sciences), and is funded by a National Health and Medical Research
Project Grant (#578800)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Age-stratified, permuted-block randomisa-
tion, with mixed block-sizes (2-8, size un-
known to study investigators), 1:1 alloca-
tion. Computer-generated randomisation
schedule
Allocation concealment (selection bias) Low risk An independent researcher prepared allo-
cation to treatment
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk The researchers, project staff, and partici-
pants remained blinded to treatment allo-
cation until the trial was completed and the
database locked. However, no information
provided on capsules appearance, taste or
smell
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk As above
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No data for each group presented, and no
attrition data presented
124Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
EPOCH 2014 (Continued)
Selective reporting (reporting bias) High risk Only cognitive functions reported for
whole population (not by arm). No sec-
ondary outcomes reported (MMSE; per-
ceived health status, depressive symptoms,
positive and negative affect, life satis-
faction, self-reported cognitive function-
ing, and functional capacity; blood pres-
sure; biomarkers of glucose, glycated hae-
moglobin, triglycerides, total cholesterol,
HDL, LDL, homocysteine, CRP, MDA,
and telomere length)
Attention Low risk All had the same contact and attention
Compliance Unclear risk Count of all unused supplements returned
at 3-monthly intervals, plus self-report cal-
endars, mailed back on a monthly basis.
If compliance fell below 85% (re calen-
dars), they were contacted by a researcher
who noted the reasons. Compliance also
assessed by erythrocyte membrane n-3 LC
PUFA status but results not reported
Other bias Low risk None noted
Erdogan 2007
Methods RCT, parallel (n-3 EPA + DHA vs unclear), 12 months
Summary risk of bias: moderate to high
Participants People with successful external cardioversion
N: unclear intervention, unclear control (54 analysed intervention, 54 control)
Level of risk for CVD: high
Men: 70% intervention, 74% control
Mean age in years (SD): 65.0 (mean for whole group, SD not reported)
Age range: not reported
Smokers: not reported
Hypertension: not reported
Medications taken by at least 50% of those in the control group: not reported
Medications taken by 20%-49% of those in the control group: not reported
Medications taken by some, but less than 20% of the control group: not reported
Location: Germany
Ethnicity: not reported
Interventions Type: supplement (probably, not described)
Comparison: high EPA + DHA vs unclear placebo
Intervention: described only as “PUFA” but included in systematic review (Mariani
2013) by Erdogan et al on effects of n-3 PUFA. Dose: unclear
125Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Erdogan 2007 (Continued)
Control: described only as “placebo”
Compliance: not reported
Length of intervention: 12 months
Outcomes Main study outcome: atrial fibrillation relapse
Dropouts: not reported
Available outcomes: recurrent AF (reported in Mariani 2013), mortality (none)
Response to contact: no reply to date
Notes Funding source: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “randomly assigned”
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Described as triple blind, but no further de-
tails provided (only an abstract with some
details in a related trial publication and
some in a systematic review by the same
author)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described, but analysis appears to have
been carried out blind to intervention/con-
trol status
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Number randomised not described
Selective reporting (reporting bias) Unclear risk Unclear, no trial registry entry or protocol
found
Attention Unclear risk Not described
Compliance Unclear risk Not described
Other bias Low risk None noted
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FAAT 2005
Methods Fatty Acid Antiarrhythmia Trial - FAAT
Randomisation: RCT, parallel, 2 arms, (n-3 EPA + DHA vs MUFA), 12 months
Summary risk of bias: moderate or high
Participants People with implanted cardioverter defibrillators (ICDs)
N: intervention 200, control 202
Level of risk for CVD: high (patients with ICDs).
Men: intervention 84.5%, control 81.7%
Mean age in years (SD): intervention 65.7 (11.6), control 65.3 (11.7)
Age range: unclear
Smokers: intervention 15%, control 11.4%
Hypertension: unclear
Medications taken by at least 50% of those in the control group: ACE inhibitors, beta-
blockers
Medications taken by 20% - 49%: diuretics
Medications taken by some, but < 20%: calcium channel blockers, amiodarone, sotalol,
type 1 antiarrhythmics
Location: USA
Ethnicity: intervention 95.5% white, control 96.5% white
Interventions Type: supplement/capsule
Comparison: EPA + DHA vs MUFA
Intervention: 4 ×1 g/d fish oil gelatin capsules, 2.6 g/d EPA + DHA (Pronova Biocare,
quantities of EPA + DHA unclear). Dose: 2.6 g/d EPA + DHA
Control: 4 ×1 g/d olive oil capsules, 4 g/d (in identical gelatin capsules, < 0.06 g/d EPA
and < 0.06 g/d DHA)
All were advised to use olive oil rather than the common plant seed oils for cooking,
dressings, and sauces
Compliance: pill counts and platelet phospholipid data suggested greater omega 3 in-
take in intervention participants. 35% were non-compliers (36.5% intervention, 34.2%
control)
Duration of intervention: 12 months
Outcomes Main study outcome: fatal ventricular arrhythmias
Dropouts: intervention 13 deaths, unclear no. of dropouts, control 12 deaths, dropouts
unclear
Available outcomes: deaths, cardiovascular deaths,CVDevents, deaths fromheart failure,
fatal arrhythmias, MI, angina
Response to contact: yes (data provided)
Notes Study funding: the study was supported in part by a grant from the NHLBI, NIH
(HL62154)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation tables
for each collaborating site, stratified by site
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FAAT 2005 (Continued)
Allocation concealment (selection bias) Low risk Author confirmed allocation was concealed
from investigators
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Study referred to as “double blind” and
gelatin capsules (verum and placebo) were
stated as being of identical appearance but
no discussion of taste or smell. Author con-
firmed that investigators and patients were
blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk VT and VF events were assessed blinded to
allocation
Incomplete outcome data (attrition bias)
All outcomes
High risk Large numbers dropped out so some
deaths, etc. may have been missed, 35%
discontinued early due to non-compliance
but were assessed at study end, data cen-
sored for some participants
Selective reporting (reporting bias) High risk Trials registry data received September
2005, paper published November 2005
Attention Low risk Time and attention appeared similar be-
tween the 2 arms
Compliance High risk Pill counts and platelet phospholipid data
suggested greater omega 3 intake in inter-
vention participants. 35% were non-com-
pliers (36.5% intervention, 34.2% control)
Other bias Low risk None noted
FLAX-PAD 2013
Methods Effects of Dietary Flaxseed on Symptoms of Cardiovascular Disease in Patients With
Peripheral Arterial Disease (FLAX PAD)
RCT, parallel, (n-3 ALA vs mixed fat), 12 months
Summary risk of bias: low
Participants Patients with peripheral artery disease, over 40 years old
N: 58 intervention, 52 control
Level of risk for CVD: high (all had peripheral artery disease, 80% had hyperlipidaemia)
Men: 74.1% intervention, 73.1% control
Mean age in years (SD): 67.4 (8.06) intervention, 65.3 (9.4) control
Age range: unclear
Smokers: 19.2% intervention, 34.6% control
Hypertension: 81% intervention, 69.2% control
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FLAX-PAD 2013 (Continued)
Medications taken by at least 50% of those in the control group: lipid lowering medica-
tion, antihypertensives, antithrombotics
Medications taken by 20%-49% of those in the control group: not reported
Medications taken by some, but less than 20% of the control group: insulin or blood
sugar-lowering drugs
Location: Canada
Ethnicity: unclear
Interventions Type: food supplement (milled flaxseed)
Comparison: ALA vs unclear (mix of wheat, wheat germ and mixed dietary oils)
Intervention: food products (i.e. bagels, muffins, bars, pasta, buns, and milled seeds)
containing 30 g of milled flaxseed daily. Dose: ~6.8 g/d ALA (calculated based on 30 g
milled flaxseed/d)
Control: placebo food products (i.e. bagels, muffins, bars, pasta, buns, and milled seeds)
containing a mixture of wheat, wheat bran, and mixed dietary oils to replace the flaxseed
daily
Compliance: plasma levels of enterolignans and the n-3 fatty acid ALA were used as
markers of dietary compliancy
Length of intervention: 12 months
Outcomes Main study outcome: all-causemortality, cardiovascularmortality, stroke, andmyocardial
infarctions
Dropouts: 15 intervention, 11 control
Available outcomes: blood pressure, lipids, adverse events, plasma ALA
Response to contact: yes (but no data provided)
Notes Different intervention dropout figures reported in two publications (13 or 15)
Study funding: funded by government organisations but foods created and provided by
a company
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomly selected by a computer pro-
gramme
Allocation concealment (selection bias) Low risk Allocation was concealed. The person who
determined if a participant was eligible for
inclusion in the trial was unaware, when
this decision was made, of which group the
subject would be allocated
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Product colour and texture were similar to
disguise the composition of the product.
Participants, personnel administering the
intervention and those assessing the out-
comes were blinded to group assignment
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FLAX-PAD 2013 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk All personnel that collected or analysed
data were blinded to the intervention
Incomplete outcome data (attrition bias)
All outcomes
Low risk All randomised accounted for in main out-
comes
Selective reporting (reporting bias) High risk Prospectively registered October 2008,
study start October 2008, primary out-
come data completed March 2011, end
date December 2017. Cardiovascular mor-
tality and measures of adiposity not re-
ported in a useable way
Attention Low risk Both groups had the same care
Compliance Unclear risk 12 in intervention group and 8 in placebo
group unwilling to comply with diet
Other bias Low risk None noted
FORWARD 2013
Methods Randomized trial to assess efficacy of PUFA for the maintenance of sinus rhythm in
persistent atrial fibrillation (FORWARD)
RCT, parallel, (n-3 EPA + DHA vs MUFA), 12 months
Summary risk of bias: low
Participants Patients with paroxysmal atrial fibrillation
N: 289 intervention, 297 control
Level of risk for CVD: high
Men: 57.8% intervention, 51.9% control
Mean age in years (SD): 66.3 (12) intervention, 65.9 (10.5) control
Age range: > 21
Smokers: 9% intervention, 6.2% control
Hypertension: 92.2% intervention, 90.8% control
Medications taken by at least 50% of those in the control group: aspirin, amiodarone,
’any antithrombotic treatment’, beta-blockers
Medications taken by 20%-49% of those in the control group: anticoagulants
Medications taken by some, but less than 20% of the control group: none reported
Location: Argentina
Ethnicity: not reported
Interventions Type: supplement (capsule)
Comparison: EPA + DHA vs MUFA
Intervention: one capsule/ day containing 1 g of n-3 PUFA (Societá Prodotti Antibiotici
and SigmaTau, Italy) (provided 850 mg to 882 mg EPA/DHA). Dose: 0.85 g/d EPA +
DHA
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Control: identical placebo capsule containing olive oil
Compliance: not reported.
Length of intervention: 12 months
Outcomes Main study outcome: survival free of atrial fibrillation
Dropouts: 20 intervention, 25 control
Available outcomes: mortality, MI, AF, heart failure, stroke, hospitalisation, side effects.
Authors supplied further info on CVD events and methodology
Response to contact: yes
Notes Study funding: through unrestricted grants provided by companies that supplied study
drugs, however “these companies did not have representatives on the Steering Commit-
tee” who terminated the trial after 1 year
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Participants were centrally as-
signed to receive either 1 g of n-3 PUFA or
placebo in a ratio of 1:1” - computer gener-
ated in blocks of 4 and 6 stratified by study
location
Allocation concealment (selection bias) Low risk As above, centrally allocated. Communica-
tion from authors was ambiguous, stated
that the person recruiting was aware of
which arm the individual would be allo-
cated to, but that the “study was double-
blind, placebo-controlled.”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “Each study site will be supplied
with study drug and placebo in identically
appearing packaging”. “Both placebo and
active treatment have the same odour and
produce a comparable degree of fishy after-
taste”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “Patients, investigator staff, persons
performing the assessments, and data an-
alysts will remain blind to the identity of
the treatment from the time of randomisa-
tion until database lock” “The adjudication
committee members are unaware of partic-
ipant allocation and assess all available data
and documentation with reference to pre-
established criteria”
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FORWARD 2013 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
High risk Quote: “the study was cut short by the trial
steering committee due to ’a slower-than-
expected recruitment rate and lower event
rates’. This ’resulted in an underpowered
clinical trial unable to verify its hypothe-
sis’. Therefore the outcome data were not
as complete as they were initially meant to
be”
Selective reporting (reporting bias) Low risk Prospectively registered January 2008,
study start January 2008, completion Au-
gust 2011. All outcomes in trials registry
appear to have been reported
Attention Low risk Both intervention and control given the
same exposure to research personnel. 2013
paper: “Clinical outcomes, adherence, and
adverse events were assessed 2, 4, 8, and 12
months after randomization”
Compliance Unclear risk Not reported
Other bias Low risk None noted
FOSTAR 2016
Methods Fish Oil in knee OSTeoARthritis (FOSTAR)
RCT, parallel, (n-3 EPA + DHA vs low n-3), 24 months
Summary risk of bias: low
Participants Adults aged 40+ years with knee osteoarthritis
N: 101 intervention, 101 control
Level of risk for CVD: low
Men: 41% intervention, 60% control
Mean age in years (SD): 60.8 (10) intervention, 61.1 (10) control
Age range: > 40
Smokers: not reported
Hypertension: not reported
Medications taken by at least 50% of those in the control group: none reported
Medications taken by 20%-49% of those in the control group: not reported at baseline,
but ’during’ includes Vit. D ~ 32%
Medications taken by some, but less than 20% of the control group: not reported at
baseline, but ’during’ includes Glucocorticoid, HRT/anti-resorptive, both ~ 10%
Location: Australia
Ethnicity: not reported
Interventions Type: supplementary food (enriched orange juice)
Comparison: high EPA + DHA vs low EPA + DHA plus ALA (replacement unclear, but
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FOSTAR 2016 (Continued)
low omega 3)
Intervention: 1-3 × a day drink of fruit juice mixed with day total = 15 mL of fish oil
supplement (18% EPA, 12% DHA, 4.5 g/day total omega 3). Dose: 4.5 g/d EPA +
DHA
Control: liquid oral oil 15 mL sunola oil/day (which contains fish oil 2 mL plus 13 mL
canola oil) (total omega-3 fat: ≥ 0.45 g EPA + DHA from 15 mL)
Compliance: assessed by measuring the oil volume in returned bottles, compliance was
> 80% in both groups. Both groups had increases from baseline in plasma EPA and
DHA with the high-dose group having substantially larger increases, consistent with
compliance with study oil
Length of intervention: 24 months
Outcomes Main study outcome: change in pain scale of WOMAC index
Dropouts: 18 intervention, 16 control
Available outcomes: mortality, CVD events, adverse events, analgesic use, bone marrow
density, weight gain and serum fatty acids
Response to contact: yes
Notes Data on quality of life and pain score are presented in a figure and not in a usable format
Study funding: government funding
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated random allocation
sequence
Allocation concealment (selection bias) Low risk A security-protected central automated al-
location procedure was used to allocate par-
ticipants to one of the 2 treatment arms.
This was performed centrally at one phar-
macy and then used to allocate and admin-
ister the oil at each site
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Citrus flavouring was added to both oils
to achieve comparable taste and optimise
masking. Both were provided in identical
dark 500-mL bottles with similar labelling.
At the end of the study, 52%of participants
were unsure which group to which they
had been allocated (50% high dose, 50%
low dose). Of the remaining who thought
they knewwhich group theywere allocated,
only 57% answered correctly, suggesting
that blinding had been well maintained
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Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Participants and staff involved in patient
care and assessment of BMD remained
blinded throughout the study
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Oil intolerance in 1st year differed, others
appear similar, but numbers confused
Selective reporting (reporting bias) High risk Prospectively registered August 2007, re-
cruitment started July 2007, outcomes
published 2016. Variety of outcomes such
as quality of life stated in trials registry but
not published
Attention Low risk Same contact and instruction schedule for
all participants.
Compliance Low risk Assessed by measuring the oil volume in
returned bottles, compliance was > 80%
in both groups. Both groups had increases
from baseline in plasma EPA and DHA
with the high-dose group having substan-
tially larger increases, consistent with com-
pliance with study oil
Other bias Low risk None noted
Franzen 1993
Methods RCT, parallel (n-3 EPA + DHA vs MUFA), 12 months
Summary risk of bias: moderate to high
Participants Adults with documented coronary heart disease
N: 15 intervention, 15 control
Level of risk for CVD: high
Men: unclear
Mean age in years (SD): 52 (9) intervention, 54 (7) control
Age range: not reported
Smokers: 87% intervention, 100% control
Hypertension: not reported
Medications taken by at least 50% of those in the control group: aspirin, beta-blockers
Medications taken by 20%-49% of those in the control group: not reported
Medications taken by some, but less than 20% of the control group: not reported
Lipid lowering medications were not allowed
Location: Germany
Ethnicity: not reported
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Interventions Type: fish oil capsules
Comparison: EPA + DHA vs MUFA
Intervention: 9 × 1 g capsules/day of fish oils (20% EPA, 15% DHA, 3.15 g/day total
omega 3). Dose: 3.15 g/d EPA + DHA
Control: 9 × 1 g capsules/day olive oil (which contains 6.3 g/day MUFA, 1.35 g/day
SFA, 1.35 g/d total omega 6 fat)
Compliance: assessed by pill counts and FA in body tissue analysis
Length of intervention: 12 months
Outcomes Main study outcome: blood lipids and FA in body tissues
Dropouts: 0 intervention, 0 control
Available outcomes: mortality (nil death), CVD events (nil), lipids (only TC used as the
others were different at baseline), adverse events, serum fatty acids
Response to contact: yes
Notes Study funding: unclear
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated list
Allocation concealment (selection bias) Unclear risk No details. They received their initial allo-
cation in a sealed box in person; subsequent
doses arrived in the post
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No further details beyond stating “double
blind”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No details
Incomplete outcome data (attrition bias)
All outcomes
Low risk No attrition
Selective reporting (reporting bias) Unclear risk No trial register or protocol found
Attention Low risk No difference between groups
Compliance Unclear risk Measured but no results
Other bias Low risk None noted
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Methods RCT, parallel, (EPA + DHA vs unclear), 24 months
Summary risk of bias: moderate or high
Participants Adults with Metabolic syndrome
N: unclear, total randomised 101
Level of risk for CVD: low
Men: 47% total, no details by group
Mean age in years (SD): 55 (10) total
Age range: 18-75 years
Smokers: 0% intervention, 0% control
Hypertension: not reported
Medications taken by at least 50% of those in the control group: not reported
Medications taken by 20%-49% of those in the control group: not reported
Medications taken by some, but less than 20% of the control group: not reported
Location: USA
Ethnicity: unclear
Interventions Type: supplement (fish oil capsules)
Comparison: EPA + DHA vs placebo (unclear what)
Intervention: fO3FA capsules 1.8 g of EPA + DHA daily. Dose: 1.8 g/d EPA + DHA
Control: matching placebo supplement
Compliance: not reported
Length of intervention: 12 months
Outcomes Main study outcome: change in carotid IMT
Dropouts: unclear
Available outcomes: lipids, insulin and glucose are stated as secondary outcomes but no
usable data published
Response to contact: no
Notes Results cannot be used as numbers are not reported by study arm
Study funding: unclear, but mentions that Pfizer, NIH and “Northwest Lipids Clinic”
are partners
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No details
Allocation concealment (selection bias) Unclear risk No details
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No data
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Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No data
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No data
Selective reporting (reporting bias) High risk Inadequate detail in reporting as no full
text publication found; Gill 2014 does give
detail on carotid IMT, but not on other
primary or secondary outcomes. The trial
was prospectively registered (registered July
2006, unclear when recruitment started, fi-
nal data collection 2011, first data pub-
lished 2012)
Attention Unclear risk No data
Compliance Unclear risk No data
Other bias Unclear risk No data
GISSI-HF 2008
Methods Gruppo Italiano per la Sperimentazione della Streptochinasi nell’Infarto Miocardico -
Heart Failure (GISSI-HF)
RCT, parallel, 2 arms (n-3 EPA + DHA vs MUFA), 3.9 years
Summary risk of bias: moderate or high
Participants Patients with chronic heart failure
N: 3494 intervention, 3481 control
Level of risk for CVD: high
Men: 77.8% intervention, 78.8% control
Mean age: 67 (11) intervention,67 (11) control
Age range: 18+ years
Smokers: 14.4% intervention, 13.9% control
Hypertension: 54.0% intervention, 55.2% control
Medications taken by at least 50% of those in the control group: ACE inhibitors, beta-
blockers, diuretics
Medications taken by 20%-49% of those in the control group: spironolactone, digitalis,
oral anticoagulants, aspirin, nitrates, statin
Medications taken by some, but less than 20% of the control group: ARBs, other an-
tiplatelets, calcium channel blockers, amiodarone
Location: Italy
Ethnicity: unclear
Interventions Type: supplement (capsule)
Comparison: EPA + DHA vs MUFA
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GISSI-HF 2008 (Continued)
Intervention:1 capsule per day of 1 g n-3 mainly EPA and DHA as ethyl esters in the
average ratio of 1:1.2. Dose: ~0.866 g/d EPA + DHA
Control: 1 g/d matching olive oil placebo capsule
Compliance: unclear
Length of intervention: median 3.9 years
Outcomes Main study outcome: time to death or admission to hospital for cardiovascular reasons
Dropouts: 34 intervention, 46 control (1004 intervention and 1029 control stopped
study treatment)
Available outcomes: mortality, CV mortality, MI, stroke, new heart failure, incident AF,
resumed arrhythmia gatalitis
Response to contact: yes (no data provided)
Notes Study funding: funders included Pfizer, AstraZeneca and others
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomly assigned (with stratification by
site) to treatment groups
Allocation concealment (selection bias) Low risk Randomly assigned (with stratification
by site) to treatment groups by a con-
cealed computerised telephone randomisa-
tion system
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Double blinding stated, but taste not re-
ported as masked and blinding of partici-
pants not checked
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk All events “adjudicated blindly by an ad-
hoc committee on the basis of pre-agreed
definitions and procedures”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Reasons for attrition and exclusion were
stated and addressed. Numbers in each in-
tervention compared to numbers were sim-
ilar
Selective reporting (reporting bias) Unclear risk Published rationale and design (Tavazzi
2004) suggested primary outcomes were
deaths and death or CV hospitalisa-
tion (published). Secondary outcomes not
stated and no trials registry entry found
Attention Low risk Scheduled clinic visits at 1, 3, 6 months
then 6 monthly until the end of the trial
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(for both arms)
Compliance Unclear risk No details
Other bias Low risk No further bias noted
GISSI-P 1999
Methods Gruppo Italiano per la Sperimentazione della Streptochinasi nell’Infarto Miocardico -
Prevention (GISSI-P)
RCT, 2 × 2 (n-3 EPA + DHA vs nil), 42 months
Summary risk of bias: moderate or high
Participants People with recent (≤ 3 months) myocardial infarction
N: 5666 intervention, 5658 control (99.9% follow-up at study end)
Level of risk for CVD: high
Men: 85.7% intervention, 84.9% control
Mean age in years (SD): 59.3 (10.6) intervention, 59.5 (10.5) years control
Age range: < 50 to > 80
Smokers: 42.6% intervention, 42.3% control
Hypertension: 36.2% intervention, 34.9% control
Medications taken by at least 50% of those in the control group: anti-platelet
Medications taken by 20%-49% of those in the control group: ACE inhibitors, beta-
blockers
Medications taken by some, but less than 20% of the control group: lipid lowering
Location: Italy
Ethnicity: not reported
Interventions Type: supplement (capsule)
Comparison: EPA + DHA vs nil
Intervention: gelatin capsules of omega-3-acid ethyl esters 90 (Omacor), 1/d (850-882
mg/d EPA + DHA daily, ratio 1:2)
Dose: ~0.866 g/d EPA + DHA
Control: nil (no placebo)
Compliance: capsule counts, 11.6% had stopped taking Omacor by 12 months, 28.5%
by the end of the study
Duration of intervention: median follow-up 40 months
Outcomes Main study outcome: all cause mortality, CV mortality, stroke, MI
Dropouts: unclear (however, all randomised were included in analyses)
Available outcomes: total, sudden and CV deaths, MI, stroke, angioplasty or CABG,
angina, CHD, cancer diagnosis, cancer death, combined CV events, side effects
Response to contact: no
Notes Numbers are slightly different in different publications (Lancet 1999 paper used as main
source). Half of both groups were on vitamin E supplements (300 mg/d synthetic α-
tocopherol) as this was the other 2 × 2 intervention
Study funding: Bristol Meyers Squibb, Pharmacia Upjohn, Societa Produtti Antibiotici,
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Pfizer
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Telephone/computer network, stratified by
hospital, based on a biased coin algorithm
Allocation concealment (selection bias) Low risk Randomisation by telephone with the co-
ordinating centre
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No placebo intervention (capsule vs nil) so
participants not blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “validation of clinical events ... was assured
by an ad-hoc committee of expert cardiol-
ogists and neurologists blinded to patients
treatment assignment”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Clearly described, good follow-up (< 28%
dropped out over 3.5 years)
Selective reporting (reporting bias) Unclear risk No study protocol or trials registry entry
was found
Attention Low risk Slight as no placebo, otherwise similar
Compliance Unclear risk Capsule counts, 11.6% had stopped taking
Omacor by 12 months, 28.5% by the end
of the study
Other bias Low risk No further bias noted
HARP 1995
Methods Harvard Atherosclerosis Reversibility Project (HARP)
RCT, (n-3 EPA + DHA vs MUFA), 24 months
Summary risk of bias: moderate or high
Participants Patients with coronary heart disease
N: 41 intervention, 39 control (99.9% follow-up at study end)
Level of risk for CVD: high
Men: 93.5% intervention, 92.9 % control
Mean age in years (SD): 62 (7) intervention, 62 (7) years control
Age range: 30-75
Smokers: 0% (exclusion criteria)
140Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
HARP 1995 (Continued)
Hypertension: 48% intervention, 36% control
Medications takenby at least 50%of those in the control group: beta blockers, antiplatelet
agents
Medications taken by 20%-49% of those in the control group: calcium channel blockers,
nitrates
Medications taken by some, but less than 20% of the control group: ACE inhibitors,
oral hypoglycaemic drugs
Location: USA
Ethnicity: not reported
Interventions Type: supplement (capsule)
Comparison: LCn3 vs MUFA
Intervention: 12 fish oil capsules/day (Promega, Parke-Davis) in divided doses, preferably
after meals. Each fish oil capsule contained 500 mg of n-3 polyunsaturated fatty acids
composed of EPA (240mg),DHA (160mg) and other (100mg) (mainlyDPA) providing
total daily dose of 6 g of n-3 fatty acids. Dose: 6 g/d LCn3
Control: olive oil capsules identical in appearance to the fish oil capsules.
Compliance: capsule counts and serum level measurements. Adherence averaged 80%
intervention, and 90% control with significant levels of adipose n-3 fatty acids in the
fish oil group.
Duration of intervention: average 28 months
Outcomes Main study outcome: regression of coronary artery lesions
Dropouts: 10 intervention, 11 control
Available outcomes: all-cause and CV deaths, fatal and non-fatal MI, stroke, angioplasty
or CABG, unstable angina, CHD, cancer diagnosis, combined CV events, side effects
Response to contact: yes
Notes Study funding: National Heart, Lung, and Blood Institute (NHLBI), National Insti-
tutes of Health, Bethesda, Maryland, Warner Lambert-Parke Davis, East Hanover, New
Jersey; and by an Established Investigator Award to Dr Sacks from the American Heart
Association, Dallas, Texas
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “randomization” stratified by clin-
ical management regime and total/HDL
cholesterol ratio
Allocation concealment (selection bias) Unclear risk No further details
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote: “patients and personnel responsible
for lab measurements, cardiac catheteriza-
tion, and analysis of angiography filmswere
blinded to the treatment assignment”. Al-
though capsules were identical in appear-
ance, no information on their taste and
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smell
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “patients and personnel responsible
for lab measurements, cardiac catheteriza-
tion, and analysis of angiography filmswere
blinded to the treatment assignment”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Low attrition rate over 28 months and all
reasons are well documented
Selective reporting (reporting bias) High risk Trial registered retrospectively after publi-
cation
Attention Low risk Nothing in description implies the arms
were treated differently
Compliance Low risk Very clear (P < 0.001) differences between
arms for the 3 main n-3 components in the
fish oil
Other bias Low risk None noted
HERO 2009
Methods Healthy Eating to Reduce Overweight in people with type 2 diabetes (HERO)
RCT, parallel, (n-3 ALA vs low n-3), 12 months
Summary risk of bias: moderate or high
Participants Overweight adults with non-insulin treated diabetes
N: 26 intervention, 24 control (analysed, intervention: 18 control: 17)
Level of risk for CVD: moderate
Male %: not reported
Mean age in years (SD): 54 (8.7), not reported by arm
Age range: 33-70 years
Smokers: not reported
Hypertension: not reported
Medications taken by at least 50% of those in the control group: lipid lowering drugs,
oral hypoglycemics
Medications taken by 20%-49% of those in the control group: not reported
Medications taken by some, but less than 20% of the control group: not reported
Location: Australia
Ethnicity: not reported
Interventions Type: food supplement (walnuts)
Comparison: ALA vs nil
Intervention: 30 g/d snack portions of walnuts (provided 10% MUFA, 10% E PUFA,
and a P/S ratio of 1.0) and advised not to take fish oil supplements. ALA dose not
reported. Dose: ~3 g/d ALA based on 30 g/d intake of walnuts
Control: no supplements
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Both groups were given low-fat isocaloric dietary advice (30% E fat (10% E SFA, 15%
EMUFA; 5% E PUFA, P/S ratio of 0.5), 20% E protein and 50% E CHO) plus advice
to brisk walk 30 min × 3 times/week
Compliance: measured by erythrocyte membrane fatty acid levels which were similar in
both groups
Duration of intervention: 12 months
Outcomes Main study outcome: change in body weight and % body fat
Dropouts: 8 intervention, 5 control
Available outcomes: all cause mortality (nil deaths), weight, visceral adipose tissue, lipids,
glucose, insulin, HbA1c (body fat % and subcutaneous adipose tissue measured but too
different at baseline to use)
Response to contact: not yet attempted
Notes Body fat % was too different between groups at baseline hence data not used
Study funding: California Walnuts Commission
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was conducted using a
computerised random number generator
by a researcher independent of the subject
interface
Allocation concealment (selection bias) Unclear risk No further details
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “Subjects, but not dietitians, were
blinded to the type of overall diet (a
prepackaged 30 g snack portion of walnuts
was given to the walnut group unbeknown
to the controls)”. However, there was no
placebo supplement, so blinding easily bro-
ken
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Paper states “code was concealed from the
researchers collecting data, as well as from
subjects.” However as participants could
not be blinded outcome assessors may not
have been (problem formeasures of adipos-
ity, not for biochemical measures)
Incomplete outcome data (attrition bias)
All outcomes
High risk High dropout rate 35 of 50 analysed (30%
attrition rate)
Selective reporting (reporting bias) Unclear risk Trial was registered postanalysis
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Attention Low risk Both groups appear to have had same level
of attention
Compliance High risk ALA levels almost exactly the same in in-
tervention and control
Other bias Low risk None noted
JELIS 2007
Methods Japan Eicosapentaenoic acid Lipid Intervention Study (JELIS)
RCT, parallel, 2-arm (EPA capsule vs nil), 5 years
Summary risk of bias: moderate or high
Participants People with hypercholesterolaemia
N: intervention, 9326, control 9319 (analysed intervention 9326, control 9319)
Level of risk for CVD: moderate (Patients with hypercholesterolaemia)
Men: 32% intervention, 31% control
Mean age in years (SD): 61 (8) intervention 61 (9) control
Age range: 40-75 years
Smokers: 20% intervention, 18% control
Hypertension: 36% intervention, 35% control
Medications taken by at least 50% of those in the control group: statins
Medications taken by 20%-49% of those in the control group: calcium channel blockers,
other antihypertensives
Medications taken by some, but less than 20% of the control group: beta-blockers,
antiplatelet, hypoglycemics, nitrates
Location: Japan
Ethnicity: Japanese
Interventions Type: supplement (EPA capsule)
Comparison 1: EPA vs nil
Intervention: 3 × 2 × 300 mg capsules/d EPA ethyl ester (total dose of 1.8 g/d EPA),
after meals. Dose: 1.8 g/d EPA
Control: nothing (though all in both groups received “appropriate” dietary advice). All
patients in both groups were on statins
Compliance: monitored by local physicians and measuring plasma fatty acids concentra-
tions. Study drug regimens, 71% adhered EPA intervention, 73% adhered EPA control,
74% adhered statin
Duration of intervention: maximum 5 years, mean 4.7 (1.1) years
Outcomes Main study outcome: major coronary events
Dropouts: 1766 intervention, 1582 control (but all had endpoint evaluation)
Available outcomes: major coronary events: sudden cardiac death, fatal or non-fatal MI,
unstable angina, angioplasty or CABG. Also all-cause mortality, stroke, peripheral artery
disease, cancer, lipids, rise in blood sugar, fasting glucose, HbA1c
Response to contact: no
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Notes Study funding: Mochida Pharmaceutical Company
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Statistical co-ordination centre: “permitted
block randomisation with a block size of 4”
Allocation concealment (selection bias) Low risk Centralised. Statistical coordinating centre
(see above)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not blinded as there was no placebo.
Quote: “[o]pen label blinded end point”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Clinical endpoints ... reported by local
physicians were checked by members of a
regional organizing committee in a blinded
fashion. Then an endpoints adjudication
committee ... confirmed them once a year
without knowledge of the treatment allo-
cation”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Well documented, dropout numbers low
Selective reporting (reporting bias) Unclear risk NCT00231738 registered October 2005,
recruitment November 1996 to November
1999, main results published 2007. Ratio-
nale and design paper published in 2003
(reported baseline characteristics, so before
completed follow-up, but after data collec-
tion began). All reported outcomes appear
to have been published
Attention Low risk Slight, as no placebo provided to control
group, but only capsules to intervention
group. Otherwise 2 groups appeared to be
treated equally
Compliance Unclear risk Monitored by local physicians and mea-
suring plasma fatty acids concentrations.
Study drug regimens,71% adhered EPA
intervention, 73% adhered EPA control,
74% adhered statin
Other bias Low risk No further bias noted
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Methods RCT, parallel, (fish oil vs nil), 12 months
Summary risk of bias: moderate or high
Participants Patients with persistent atrial fibrillation (AF) on warfarin
N: 92 intervention, 90 control (91 and 87 analysed ITT)
Level of risk for CVD: high
Male %: 82.4 intervention, 72.4 control
Mean age in years (SD): 63 (10) intervention, 61(13) control
Age range: 18-85 years (inclusion criteria)
Smokers: 22.2% intervention, 11.5% control
Hypertension: 45.6% intervention, 58.6% control
Medications taken by at least 50% of those in the control group: anti-arrhythmic drugs,
renin-angiotensin system inhibitors
Medications taken by 20%-49% of those in the control group: statins
Medications taken by some, but less than 20% of the control group: not reported
Location: Australia
Ethnicity: not reported
Interventions Type: fish oil capsule
Comparison: EPA + DHA vs nil
Intervention: 6 capsules/day of a fish oil preparation containing a total dose of 1.02 g of
EPA and 0.72 g DHA. Participants in the omega-3 group were asked to continue fish
oils till a maximum of 1 year or till return of persistent AF. Dose: 1.7 g/d EPA + DHA
Control: no supplements. Patients were advised not to take any fish oil supplements
All patients underwent cardioversion following randomisation
Compliance: was monitored on a weekly basis via telephone and during follow-up by
using a pill count plus serum EPA and DHA levels which were significantly increased
Duration of intervention: 1 year (or AF recurrence)
Outcomes Main study outcome: atrial fibrillation recurrence
Dropouts: 4 intervention, 0 control
Available outcomes: all-cause mortality (nil death), AF recurrence, time to AF recurrence,
adverse events
Response to contact: contact not yet established
Notes Study funding: the study was funded in part by the National Heart Foundation of
Australia and the Pfizer Cardiovascular Lipid Research Grant
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Patients were randomised to a control or an
omega-3 group in a 1:1 fashion (no details
of method)
Allocation concealment (selection bias) Unclear risk No further details
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Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open label with no placebo control
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Open label
Incomplete outcome data (attrition bias)
All outcomes
Low risk ITT analysis was conducted
Selective reporting (reporting bias) Unclear risk Trial registered 2005 but data collection
started 2003
Attention Unclear risk Intervention group had capsules, while
control group did not. Potential for greater
contact and checking with intervention
group on this basis, although otherwise
both groups seem to have had the same care
Compliance Low risk EPA and DHA levels were significantly
higher in intervention group
Other bias Low risk None noted
Kumar 2013
Methods RCT, parallel, (fish oil vs nil), 12 months
Summary risk of bias: moderate or high
Participants Patients > 60 years with sinoatrial node disease and dual chamber pacemakers
N: 39 intervention, 39 control randomised (18 intervention vs 39 control at 12 months)
Level of risk for CVD: moderate/high
Male %: 46% intervention, 56% control
Mean age in years (SD): 78 (7) intervention, 77(8) control
Age range: not reported
Smokers: not reported
Hypertension: 72%
Medications taken by at least 50%of those in the control group: statin, renin-angiotensin
system inhibitors
Medications taken by 20%-49% of those in the control group: anti-arrhythmic drugs
Medications taken by some, but less than 20% of the control group: not reported
Location: Australia
Ethnicity: not reported
Interventions Type: omega 3 capsule
Comparison: EPA + DHA vs nil
Intervention: a triglyceride preparation containing a total of 6 g/day of omega-3 polyun-
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saturated fatty acids of which 1.8 g/day were n-3 (1.02 g EPA and 0.72 g DHA). Dose:
1.8 g/d EPA + DHA
Control: no supplements
Compliance: measured by weekly dietary history and pill count. Fatty acid status mea-
sured at randomisation and between 1-3 months post randomisation (blood samples)
Duration of intervention: median 378 days
Outcomes Main study outcome: atrial fibrillation burden
Dropouts: 1 intervention, 0 control
Available outcomes: all cause mortality, CV mortality, AF (frequency and duration but
not recurrence so not used), adverse events
Response to contact: written but no contact yet
Notes Study funding: unclear
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was performed using se-
quentially numbered, opaque, sealed en-
velopes
Allocation concealment (selection bias) Low risk As above
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open label design
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote: “At each visit, stored AT/AF diag-
nostic data were retrieved in an un-blinded
fashion”
Incomplete outcome data (attrition bias)
All outcomes
High risk Only 1 lost, and reason explained. 21 of
the 39 randomised to the intervention were
crossed over to control at 6 months so 12-
month outcomes are reported for 17/18 in-
tervention while baseline characteristics are
reported for the 39 patients
Selective reporting (reporting bias) Low risk Trial prospectively registered and outcomes
stated were reported
Attention Unclear risk As only the intervention group had supple-
ments there was potential for attention dif-
ferences. Other contact appears the same
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Compliance Low risk EPA was 3-fold higher and DHA 1.8 fold
higher compared with controls. EPA and
DHA did not change significantly in con-
trols upon repeat testing
Other bias High risk Odd design - 21 of the 39 randomised to
the intervention were crossed over to con-
trol at 6 months
Lorenz-Meyer 1996
Methods RCT- parallel, 2 arms (omega 3 vs corn oil), 12 months
Summary risk of bias: low
Participants People with Crohn’s disease in remission (but with a recent relapse)
N: 70 intervention, 63 control
Level of risk for CVD: low
Men: 35.7% intervention, 27.0% control
Mean age in years (SD): 29.5 (9.6) intervention, 31.8 (10.9) control
Age range: 17-62 years intervention, 17-65 years control
Smokers: not reported
Hypertension: not reported
Medications taken by at least 50% of those in the control group: methylprednisolone
(all for 1st 8 weeks)
Medications taken by 20%-49%: not reported
Medications taken by some, but < 20%: not reported
Location: Germany
Ethnicity: not reported
Interventions Type: supplement (fish oil)
Comparison: EPA + DHA vs omega 6
Intervention: 2 × 3 1 g gelatin capsules/d of ethylester fish oil concentrate (3.3 g/d EPA
+ 1.8 g/d DHA). Dose: 5.1 g/d EPA + DHA
Control: 2 × 3 1 g gelatin capsules/d of corn oil
Compliance: pill count, 5 non-compliant patients, among compliant patients, 18 were
censored (for not using the medication for 3 continuous weeks)
Duration of intervention: 12 months
Outcomes Main study outcome: Crohn’s disease duration of remission
Dropouts: unclear
Available outcomes: mortality (nil), Crohn’s disease activity and relapses, serum triglyc-
erides
Response to contact: yes (methodological details provided)
Notes There was a third arm of dietary advice (for low CHO diet)
Study funding: not reported
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised within the centres in blocks of
six (block size blinded to the centres)
Allocation concealment (selection bias) Low risk Author reported allocation was concealed
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “Double blind conditions were
intended for the verum-placebo compar-
isons”. Author stated that capsules were
identical in appearance (taste not men-
tioned)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Primary outcome was relapses “classified
in a blind fashion by a primary end-point
committee”
Incomplete outcome data (attrition bias)
All outcomes
High risk Participants were accounted for based on
the main outcome of the study (relapses)
, however 20% omitted from analyses and
numbers confusing
Selective reporting (reporting bias) Unclear risk No trials registry entry or protocol found
Attention Low risk All patients were seen by their physician
in the respective centre after regular time
intervals (1, 2, 3, 6, 9 and 12 months)
Compliance Unclear risk Pill count, 5 non-compliant patients,
among compliant patients, 18 were cen-
sored (for not using the medication for
three continuous weeks). 23 of 133 non-
compliant
Other bias Low risk None noted
MAPT 2017
Methods Multidomain Alzheimer Preventive Trial (MAPT)
4 arms RCT, parallel, (n-3 ± multidomain intervention vs placebo ± multidomain inter-
vention), 36 months
Summary risk of bias: low
Participants Population: people aged at least 70 years without dementia but with memory complaint,
IADL limitation or slow gait speed
N: 840 intervention (arms 1 and 3), 840 control (arms 2 and 4) randomised. Numbers
analysed differ by outcome
Level of risk for CVD: low
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Men: 37.2% intervention, 34.5% control. (combined groups)
Mean age in years (SD): 75.6 (4.7) and 74.4 (4.4) intervention, 75.1 (4.3) and 75 (4.1)
control
Age range: not reported
Smokers: not reported
Hypertension: not reported
Medications taken by at least 50% of those in the control group: not reported
Medications taken by 20%-49% of those in the control group: not reported
Medications taken by some, but less than 20% of the control group: not reported
Location: France and Monaco
Ethnicity: not reported
Interventions Type: supplement (capsule)
Comparison: EPA + DHA vs paraffin oil (non-fat)
Intervention
Arm 1: omega-3 (V0137 CA 800 mg/d DHA; 225 mg/d EPA in soft caps). Dose for
arms 1 and 3: 1.025 g/d EPA + DHA
Arm 3: omega 3 (V0137 CA 800 mg/d DHA; 225 mg/d EPA in soft caps) plus multi-
domain intervention (nutrition, physical exercise, cognitive stimulation, social activities)
Control:
Arm 2: placebo capsules containing flavoured paraffin oil. All capsules were supplied by
Pierre Fabre Médicament (Castres, France)
Arm 4: placebo capsules plus multi-domain intervention (nutrition, physical exercise,
cognitive stimulation, social activities)
Compliance: adherence to study interventions was assessed every 6 months. For sup-
plementation, adherence was assessed by counting the number of capsules returned by
participants (or based on treatment dates if the number of capsules was missing). Fur-
thermore, biological samples were obtained at baseline and after 12 months to assess
concentrations of DHA and EPA in red blood cell membranes
Duration of intervention: 36 months
Outcomes Main study outcome: change in cognitive function )
Dropouts: 200 intervention, 194 control
Available outcomes: mortality, CVD events, haemorrhagic stroke, adverse events, func-
tional capacity, other cognitive functions, safety and tolerability
Response to contact: no
Notes Study funding: Gérontopôle of Toulouse, the French Ministry of Health (PHRC 2008,
2009), the Pierre Fabre Research Institute (manufacturer of the polyunsaturated fatty
acid supplement), Exhonit Therapeutics, and Avid Radiopharmaceuticals
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants were randomly assigned (1:1:
1:1) to the combined intervention (i.e. the
multidomain intervention plus polyunsat-
urated fatty acids), the multidomain inter-
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vention plus placebo, polyunsaturated fatty
acids only, or placebo only. A computer-
generated randomisation procedure (done
byClinInfo, a subcontractor)was usedwith
block sizes of 8 and stratification by centre
Allocation concealment (selection bias) Low risk A clinical research assistant, who was not
involved in the assessment of participants,
used a centralised interactive voice response
system to identify which group to allocate
the participant to, and which lot number
to administer
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk All participants and study staff were
blinded to polyunsaturated fatty acid or
placebo assignment - both sets of capsules
looked and tasted identical. In view of the
nature of the multidomain intervention,
the study was unblinded for this compo-
nent, but the independent neuropsycholo-
gists who were trained to assess cognitive
outcomes were blinded to group assign-
ment
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk All participants and study staff were
blinded to polyunsaturated fatty acid or
placebo assignment-both sets of capsules
looked and tasted identical. In view of the
nature of the multidomain intervention,
the study was unblinded for this compo-
nent, but the independent neuropsycholo-
gists who were trained to assess cognitive
outcomes were blinded to group assign-
ment. Data analysts were not blinded to
group assignment, but two data managers,
one statistician (CC) and two physicians
(SA and BV) did a blinded data review
Incomplete outcome data (attrition bias)
All outcomes
Low risk 1680 participants were enrolled and ran-
domly allocated, the modified intention-
to-treat population (N = 1525), i.e. 155 ex-
cluded (9% over 3 years)
Selective reporting (reporting bias) Low risk Protocol registered Clini-
calTrials.gov (NCT00672685) - outcomes
match report. Because of advances in the
field since our trial was designed in 2007,
we decided tomodify the primary outcome
from one cognitive test to a composite cog-
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nitive score, which is now thought to be a
better endpoint
This protocol amendment was submitted
to the local ethical committee on 2 Febru-
ary 2015 and was subsequently approved
Attention Low risk Both groups assessed at baseline, 6, 12, 24,
36 months. Groups 1 and 2 only differed
by content of capsules
Compliance Unclear risk Adherence to study interventions was as-
sessed every 6 months, by counting the
number of capsules returned (or based on
treatment dates if the number of capsules
was missing). Biological samples were ob-
tained at baseline and after 12 months to
assess concentrations of DHA and EPA in
red blood cell membranes, but outcomes
not reported
Other bias Low risk None noted
MARGARIN 2002
Methods Mediterranean alpha-linolenic enriched Groningen dietary intervention study (MAR-
GARIN)
RCT, factorial 2 × 2 (ALA rich margarine vs LA rich margarine, also nutrition education
vs no education but this is not included), 2 years
Summary risk of bias: low
Participants Hypercholestrolemic adults with 2 or more CVD risk factors
N: total 282 randomised; 114 intervention (51 with nutrition education, 58 without
NE) 157 control (52 with NE, 105 without NE)
Level of risk for CVD: moderate (multiple cardiovascular risk factors, 10-year IHD risk
~20%)
Men: 41.9% intervention, 45.7% control
Mean age in years (SD): 54.4 (9.5) intervention, 53.9 (9.8) control
Age range: 30-70
Smokers: 49.1% intervention, 49.3% control
Hypertension: 52.9% intervention, 45.3% control (on anti-hypertensives)
Medications taken by at least 50% of those in the control group: antihypertensives
Medications taken by 20%-49%: not reported
Medications taken by some, but < 20%: not reported
Location: the Netherlands
Ethnicity: not reported
Interventions Type: supplementary food (ALA enriched margarine)
Intervention: provided with ALA rich margarine (80% fat of which 15% was ALA and
46% LA) to be eaten ad libitum. Dose: average intake 6.3 g/d ALA (was also 1 g/d ALA
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in the control group)
Control: provided with linoleic rich margarine (80% fat of which 0.3% was ALA and
58% LA), identical in taste and packaging. Both margarines contained 0.66 mg vit E/g,
9 micro-g vit A/g and 0.023 micro-g vit D/g
Comparison: ALA vs omega 6
Compliance: serum fatty acids used to assess, ALA rose by 0.47 mol % (SD 0.04) and
0.36 mol% (SD 0.04) intervention arms (with and without NE) and fell by 0.06 mol %
(SD 0.04) and 0.11 mol % (SD 0.03) control arms (with and without NE), significantly
different.
Duration of intervention: 24 months
Outcomes Main study outcome: cardiovascular risk factors and IHD risk
Dropouts: unclear
Available outcomes: total and CV deaths, non-fatal MI, stroke, CABG and angioplasty,
BMI, lipids, BP
Response to contact: yes
Notes Study funding: Prevent fund and Unilever Research
Other intervention (2×2)was educational, teaching amultifactorial dietary intervention.
It was excluded as multifactorial
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated random allocation,
allocated by an independent trial coordina-
tion centre that organised masked distribu-
tion of margarines
Allocation concealment (selection bias) Low risk Allocated by an independent trial coordi-
nation centre which organised masked dis-
tribution of margarines
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind; the 2 margarines are de-
scribed as identical as to taste and packag-
ing (though not reported as checked)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk 2 independent physicians, a cardiologist
and a general practitioner validated and
classified results in a blinded fashion
Incomplete outcome data (attrition bias)
All outcomes
Low risk The number randomised to each arm was
unclear, but one publication clarifies (55
randomised to each arm, 51 intervention
and 52 control analysed)
Selective reporting (reporting bias) Unclear risk No study protocol or trials registry entry
was found.
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Attention High risk There was no difference in attention be-
tween margarine types, but the dietary ad-
vice group spent more time with study staff
than the control group, and some (not quite
randomly allocated) were sent individual
motivational letters (Siero 2000)
Compliance Low risk Serum fatty acids used to assess, ALA rose
by 0.47 mol% (SD 0.04) and 0.36 mol
% (SD 0.04) intervention arms (with and
without NE) and fell by 0.06 mol % (SD
0.04) and 0.11 mol % (SD 0.03) control
arms (with and without NE), Significantly
different
Other bias Low risk No further bias noted
MARINA 2011
Methods Modulation of Atherosclerosis Risk by Increasing dose of n-3 fatty Acids (MARINA)
RCT, parallel, 4 arms (n-3 PUFA 3 different doses or olive oil placebo), 12 months
Summary risk of bias: low
Participants Non-smoking men and women aged 45-70 years
N: intervention. 279 in 3 groups (G1 0.45 g/d n = 94, G2 0.9 g/d n = 93, G3 1.8 g/d
n = 92); control: 88 (analysed G1 0.45 g/d n = 81, G2 0.9 g/d n = 80, G3 1.8 g/d n =
80, control 71)
Level of risk for CVD: low
Men: 38.7% intervention, 38.6% control
Mean age in years (CI): G1: 55 (53, 56), G2: 55 (54, 56), G3: 55 (54, 57) intervention
55 (54,57) control
Age range: 45-70
Smokers: 0% intervention, 0% control
Hypertension: 5.4% intervention, 5% control
Medications taken by at least 50% of those in the control group: none
Medications taken by 20%-49% of those in the control group: none
Medications taken by some, but less than 20% of the control group: statins, antihyper-
tensives, HRT, thyroxine
Location: UK
Ethnicity: G1: white 80.9%, black 4.3%, Asian 6.4%, East Asian 4.3%, other 4.3%
G2: white 78.5%, black 6.5%, Asian 10.8%, East Asian 0%, other 4.3%
G3: white 85.9%, black 1.1%, Asian 2.2%, East Asian 4.3%, other 6.5%
Control: white 77.3%, black 10.2%, Asian 6.8%, East Asian 2.3%, other 3.4%
Interventions Type: supplement (fish oil capsules)
Comparison 1: EPA + DHA vs MUFA
Comparison 2: high EPA + DHA vs low EPA + DHA
Intervention: 3 × 1 g oil gelatin capsule/day consisting of blend of EPA concentrate,
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DHA concentrate, refined olive oil and 0.1% peppermint oil. Providing a daily dose of:
0.45 g, 0.9 g, or 1.8 g per day (all with EPA/DHA ratio of 1.51). Dose: 1.8 g/d EPA +
DHA (G3 used for outcomes)
Control: 3 gelatin capsules/ day containing refined olive oil + 0.1% peppermint oil
Compliance: measured by capsule counting and erythrocyte lipids for proportion of
EPA/DHA @ baseline, 6 months, 12 months. 88.5% of participants consumed > 90%
of capsules provided. EPA and DHA in erythrocyte lipids increased in dose-dependent
manner compared with placebo, indicating long-term compliance with intervention
Length of intervention: 12 months
Outcomes Main study outcome: endothelial function, arterial stiffness
Dropouts: 38 intervention (13,13,12), 17 control
Available outcomes: lipids, dietary intake, CRP, BP (supine and ambulatory - numeric
data not provided, but study states that there were no significant differences between
arms). Weight data not used as baseline is different between groups (FMD, arterials
stiffness, carotid intima media thickness, heart rate variability, heart rate, endothelial
progenitor cells reported but not used)
Contact with authors: yes (many outcomes above provided in end of study report from
authors)
Notes Outcome data usedG3 (highest dose) vs placebo for continuous outcomes and combined
the 3 intervention groups vs placebo for dichotomous outcomes
Study funding: Food Standards Agency
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “the random allocation sequence
was generated with a computer program by
using the process of minimisation to bal-
ance age, sex and ethnicity between treat-
ment groups.”
Allocation concealment (selection bias) Low risk Quote: “We enrolled eligible participants
and the study database program allocated
a serious of capsules to the participant.
The treatments associated with the capsule
codes were concealed from all investigators
and associated clinical staff until the data
analysis was complete. The code breaker
was an employee of MedSciNet who con-
structed the trial database.”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “We enrolled eligible participants
and the study database program allocated
a serious of capsules to the participant.
The treatments associated with the capsule
codes were concealed from all investigators
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and associated clinical staff until the data
analysis was complete. The code breaker
was an employee of MedSciNet who con-
structed the trial database.” “blends of the
test fat with 0.1% peppermint oil to dis-
guise the fish taste of the EPA and DHA”
(peppermint oil in both intervention and
control capsules)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “We enrolled eligible participants
and the study database program allocated
a serious of capsules to the participant.
The treatments associated with the capsule
codes were concealed from all investigators
and associated clinical staff until the data
analysis was complete. The code breaker
was an employee of MedSciNet who con-
structed the trial database.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk 15% withdrawal, reasons for attrition re-
ported
Selective reporting (reporting bias) Low risk Outcomes published match trials register.
Registered September 2008, trial started
June 2008, ended December 2010, main
publication 2011
Attention Low risk No difference between groups
Compliance Low risk Statistically significant difference in ery-
throcyte omega 3 fats at 12 months be-
tween different arms
Other bias Low risk None noted
MENU 2016
Methods Metabolism, Exercise and Nutrition at UCSD (MENU)
RCT, parallel, (walnut rich moderate fat diet vs moderate fat diet), 12 months
Summary risk of bias: moderate or high
Participants Overweight and obese women, of whom half were insulin resistant
N: 82 intervention, 81 control (analysed, intervention: 65 control: 61)
Level of risk for CVD: low
Men: 0% intervention, 0% control
Mean age (SD) years: 51 (NR) intervention, 50 (NR) control
Age range: 22-67 years intervention, 25-72 years control
Smokers: not reported
Hypertension: not reported
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Medications taken by at least 50% of those in the control group: not reported
Medications taken by 20%-49% of those in the control group: not reported
Medications taken by some, but less than 20% of the control group: 10% were on
cholesterol medications
Location: USA
Ethnicity:Hispanic 18% intervention, 14% control; black 9% intervention, 3% control;
Asian American 1% intervention, 4% control; white non-Hispanic 71% intervention,
78% control
Interventions Type: food and advice
Comparison: walnut rich moderate fat diet (ALA) vs moderate fat diet (MUFA)
Intervention: advice to follow walnut-rich higher fat diet (35%E fat with limited SFA,
MUFA encouraged, including 42 g/d walnuts (provided by study), 45%E CHO, 20%E
protein). Participants given print materials on diet and exercise, attended group sessions
weekly for 1st 4 months, biweekly for next 2 months, then monthly to 1 year), provided
web-based tracking for dietary constituents, scale, pedometer, measuring cups and exer-
cise videos. Regular dietetic and group leader support. Clinic visits were at 0, 6 and 12
months. Dose: ~4.2 g/d ALA (calculated based on 42 g/d intake of walnuts)
Control: exactly as intervention for goals, materials and support except higher fat diet
did not include walnuts (35% E fat with limited SFA,MUFA encouraged, 45%E CHO,
20%E protein)
Compliance: walnut consumption reported on form and nuts provided. Red blood cell
ALA significantly higher in intervention at 12 months than control
Duration of intervention: 12 months
Outcomes Main study outcome: body weight
Dropouts: 13 of 82 intervention, 12 of 81 control
Available outcomes: weight, waist circumference, HDL and LDL cholesterol, triglyc-
erides, insulin, glucose, HOMA-IR, HOMA-beta, CRP and IL-6 (estradiol, SHBG,
nutrient gene interactions, physical activity and heart rate also presented)
Response to contact: no reply received to date
Notes Study funding: National Cancer Institute and California Walnut Commission
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation stratified by age and insulin
resistance
Allocation concealment (selection bias) Unclear risk No details
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open study, participants were advised on
their diets extensively
Blinding of outcome assessment (detection
bias)
Unclear risk Blinding not mentioned, so unclear for
their primary outcome, weight
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All outcomes
Incomplete outcome data (attrition bias)
All outcomes
Low risk Paper states ITT analysis but 25 dropouts
(15%) not included in 1 year data, but
dropout reasons clear
Selective reporting (reporting bias) Low risk Pre-registered, all mentioned outcomes re-
ported at 12 months
Attention Low risk Appear very equal
Compliance Low risk Statistically significant difference between
intervention and control arms for ALA in
blood cell membranes at 12 months
Other bias Low risk None noted
Mita 2007
Methods RCT, parallel, (EPA capsules vs nil), 2 years
Summary risk of bias: moderate to high
Participants Japanese type 2 diabetics
N: intervention. 40, control: 41 (analysed 30, 30)
Level of risk for CVD: moderate
Men: 53% intervention, 67% control
Mean age in years (SD): 59 (11.2) intervention 61.2 (8.4) control
Age range: not reported
Smokers: 40% intervention, 43% control
Hypertension: not reported
Medications taken by at least 50% of those in the control group: oral hypoglycemics
Medications taken by 20%-49% of those in the control group: insulin, lipid lowering
drugs, antihypertensives
Medications taken by some, but less than 20% of the control group: antithrombotics
Location: Japan
Ethnicity: 100% Japanese
Interventions Type: supplement (EPA oil capsules)
Comparison: EPA vs nil
Intervention: 1800 mg/d EPA EPADEL capsules (Mochida Pharmaceutical Co Ltd
Japan)- 98% pure ethyl-ester EPA (unclear how many caps). Dose: ~1.8 g/d EPA
Control: no intervention
Compliance: checked during 3 month reviews throughout trial and 5 participants were
excluded for poor compliance but no details on method or results
Length of intervention: mean 2.1 (0.2) years
Outcomes Main study outcome: progression of diabetic macroangiopathy measured by carotid
intima-media thickness and brachial-ankle pulse wave velocity
Dropouts: 10 intervention, 11 control
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Available outcomes: BMI, lipids, BP, HbA1c, cancer diagnosis
Response to contact: not yet attempted
Notes Blood pressure data not used as groups are different at baseline
Study funding: not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Patients randomly divided into 2 groups
matched for age and gender
Allocation concealment (selection bias) Unclear risk No details
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open label
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessors of main study outcomes were
blinded to the treatment
Incomplete outcome data (attrition bias)
All outcomes
Low risk Dropout rate (26%) over 2 years. All drop-
outs explained, however, 5 were excluded
for poor compliance but no clear prede-
fined protocol for exclusion
Selective reporting (reporting bias) Unclear risk No protocol
Attention Low risk All participants had the same contact
Compliance Unclear risk Compliance measured but no clear meth-
ods or reported results
Other bias Low risk None noted
NAT2 2013
Methods Nutritional AMD Treatment-2 (NAT2)
RCT, parallel, (EPA + DHA vs MUFA), 36 months
Summary risk of bias: low
Participants Patients with early age related macular degeneration
N: 150 intervention, 150 control
Level of risk for CVD: high (92.5% intervention and 79.8 controls had past CVD)
Men: 31.3% intervention, 39.5% control
Mean age in years (SD): 73.9 (6.6) intervention, 73.2 (6.8) control
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NAT2 2013 (Continued)
Age range: 55-85
Smokers: 6.7% intervention, 8.5% control
Hypertension: 58% total (not reported by study arm)
Medications taken by at least 50% of those in the control group: lipid-lowering medi-
cation
Medications taken by 20%-49% of those in the control group: agents acting on renin-
angiotensin system, anti-inflammatory and anti-rheumatic products
Medications taken by some, but less than 20% of the control group: insulin or blood
sugar lowering drugs
Location: France
Ethnicity: unclear
Interventions Type: supplement (fish oil capsule)
Comparison: EPA + DHA vs MUFA
Intervention: 3 daily fish oil capsules containing 1110 total n-3 FAs (EPA: 270 mg/day
DHA: 840 mg/day) and vit E: 6 mg/day. Dose: 1.1 g/d EPA + DHA
Control: 3 × 602 mg olive oil capsules a day containing 0.2 g total PUFA and vit E: 0.
09 g/d
Compliance: assessed during visits fromunused capsules and serumPUFA levels. Overall
compliance over the 3 years; 69.4% intervention, 70.5% control
Length of intervention: 36 months
Outcomes Main study outcome: time to occurrence of choroidal new vessels (CNV) in the study
eye from prospective assessment of fluorescein angiography
Dropouts: 29 intervention, 34 control
Available outcomes: all cause mortality, plasma lipids, adverse events, serum FAs
Response to contact: yes (no added data)
Notes TG data not used as presented as median (5th-95th percentile)
Study funding: Laboratoire Chauvin, Bausch & Lomb Inc
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk QL Ranclin software was used to generate
the randomisation list before enrolment.
The patients and the study personnel both
were blinded to the treatment assignment
Allocation concealment (selection bias) Low risk As above
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk The capsules had the same appearance, the
same size, and the same weight (602 mg)
in both DHA and placebo groups. No
masking flavour was added to the capsules,
which were otherwise odourless
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NAT2 2013 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Author confirmed blinding of outcome as-
sessors
Incomplete outcome data (attrition bias)
All outcomes
Low risk Any temporary discontinuation of the
treatment was considered to be a deviation
from the study protocol. Discontinuation
for more than 5 months was considered to
be a major deviation from the study pro-
tocol. Participants who dropped out were
taken in account in the survival analysis and
occurrence of CNV and were counted at
last angiography performed
Selective reporting (reporting bias) Unclear risk ISRCTN98246501. Retrospectively regis-
tered May 2007, recruitment started De-
cember 2003, completed November 2008,
key publication 2013
Attention Low risk Same amount of time spend with both
study arms
Compliance Low risk Assessed during visits fromunused capsules
and serum PUFA levels. Overall compli-
ance over the 3 years; 69.4% intervention,
70.5% control
Other bias Low risk None noted
Nodari 2011 AF
Methods RCT, parallel, (DHA + EPA vs MUFA), 12 months
Summary risk of bias: moderate or high
Participants Patients with persistent atrial fibrillation with at least 1 relapse after cardioversion
N: 102 intervention, 103 control. (analysed, intervention: 94 control: 94)
Level of risk for CVD: high
Men: 70% intervention, 63% control
Mean age in years (SD): 70 (6) intervention, 69 (9) control
Age range: not reported (18-80 inclusion criteria)
Smokers: 10% intervention, 9.1% control
Hypertension: 47% intervention, 40% control
Medications taken by at least 50% of those in the control group: beta-blockers, ACE
inhibitors, anticoagulant therapy, amiodarone
Medications taken by 20%-49% of those in the control group: diuretics, antiplatelet,
statins
Medications taken by some, but less than 20% of the control group: calcium channel
blockers
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Nodari 2011 AF (Continued)
Location: Italy
Ethnicity: not reported
Interventions Type: supplement (omega-3-acid ethyl esters 90: Omacor)
Comparison: EPA + DHA vs MUFA
Intervention: 2 × 1 g/d Omacor (total 1.7 g/d EPA + DHA at a ratio of 0.9 to 1.5).
Dose: 1.7 g/d EPA + DHA
Control: 2 × 1 g/d olive oil (gelatin capsules identical in appearance to Omacor)
Compliance: no details
Duration of intervention: 12 months
Outcomes Main study outcome: probability of maintenance of sinus rhythm
Dropouts: 6 intervention, 5 control
Available outcomes: adverse events, AF recurrence (nil death)
Response to contact: no
Notes Study funding: ’Centro per lo Studio ed il Trattamento dello Scompenso Cardiaco’ of the
University of Brescia, Brescia, Italy. The work of Dr Campia was supported by National
Institutes of Health grant K12 HL083790-01a1
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random assignment followed a computer-
generated randomisation list obtained us-
ing blocks of size 4
Allocation concealment (selection bias) Low risk The randomisation schedule was kept in
the research pharmacy area and was avail-
able only to unblinded pharmacy person-
nel until after the database was locked. At
that time, the unblinded patient treatment
information was made available to the in-
vestigators
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Placebo gelatin capsules identical in ap-
pearance toOmacor.However no informa-
tion provided as to their smell and taste
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No details
Incomplete outcome data (attrition bias)
All outcomes
Low risk All randomised were accounted for. ITT
analysis for main outcomes
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Nodari 2011 AF (Continued)
Selective reporting (reporting bias) Unclear risk NCT01198275. Registered retrospectively
in September 2010, study started January
2006, completed May 2008, main publi-
cation 2011
Attention Low risk No difference between groups
Compliance Unclear risk No details
Other bias Low risk None noted
Nodari 2011 HF
Methods RCT, parallel, (DHA + EPA vs MUFA), 12 months
Summary risk of bias: moderate or high
Participants People with heart failure (non-ischaemic dilated cardiomyopathy)
N: 67 intervention, 66 control. (analysed, intervention: 67 control: 66)
Level of risk for CVD: high
Men: 95.5% intervention, 84.9% control
Mean age in years (SD): 61 (11) intervention, 64 (9) control
Age range: not reported (18-75 inclusion criteria)
Smokers: not reported
Hypertension: not reported
Medications taken by at least 50% of those in the control group: beta-blockers, ACE
inhibitors, furosemide, amiodarone, aldosterone blockers
Medications taken by 20%-49% of those in the control group: not reported
Medications taken by some, but less than 20% of the control group: statins, ARB
Location: Italy
Ethnicity: not reported
Interventions Type: supplement (Omacor)
Comparison: EPA + DHA vs MUFA
Intervention: 2 × 1 g/d Omacor (1.7 g/d EPA + DHA at a ratio of 0.9 to 1.5)
Control: 2 × 1 g/d olive oil (gelatin capsules identical in appearance to Omacor)
Compliance: pill counts - participants were withdrawn if < 80% capsules taken (none
were withdrawn). Fatty acid EPA +DHA 0.83% in intervention group, 0.41% in control
group
Duration of intervention: 12 months
Outcomes Main study outcome: left ventricular function and functional capacity
Dropouts: 0 intervention, 0 control
Available outcomes: mortality (nil death), combined CVD events, AF, BMI, hospitalisa-
tion for cardiovascular reasons, hospitalisation for worsening heart failure, lipids, blood
glucose (but too different at baseline to use), serum cytokine
Response to contact: yes
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Nodari 2011 HF (Continued)
Notes Study funding: Centro per lo Studio ed il Trattamento dello Scompenso Cardiaco, one
author was a consultant for 8 pharmaceutical companies
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “randomised”
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Paper states that placebo and verum were
identical and that the study was double
blind, but blinding of participants not
checked. Author confirmed investigators
not blinded
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Author confirmed assessors not blinded
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Unclear whether all participants were as-
sessed for all outcomes (e.g. hospitalisation)
, but some outcomes report no attrition
Selective reporting (reporting bias) Unclear risk NCT01223703 - study registration Octo-
ber 2010, recruitment November 2007 to
June 2009. Retrospective
Attention Low risk No suggestion of this, and investigators ap-
peared blinded (so could not differ in at-
tention provided by allocation)
Compliance Low risk See characteristics table
Other bias Low risk None noted
Norouzi 2014
Methods RCT, parallel, (MorDHA capsules vs unclear placebo), 14 months
Summary risk of bias: moderate or high
Participants Patients with chronic traumatic spinal cord injury
N: 55 intervention, 55 control. (analysed, intervention: 54 control: 50)
Level of risk for CVD: low
Men: 81.5% intervention, 82% control
Mean age in years (SD): 51.15 (13.43) intervention, 54.12 (11.76) control
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Norouzi 2014 (Continued)
Age range: 15-74 years intervention, 30-74 years control
Smokers: 0% (exclusion criteria)
Hypertension: not reported
Medications taken by at least 50% of those in the control group: not reported
Medications taken by 20%-49% of those in the control group: not reported
Medications taken by some, but less than 20% of the control group: not reported
Location: Iran
Ethnicity: not reported
Interventions Type: supplement (n-3 capsules)
Comparison: EPA + DHA vs placebo (unclear what)
Intervention: 2 MorDHA capsules (providing 870 mg DHA and 130 mg EPA) per day.
Dose: 1 g/d DHA + EPA
Control: 2 placebo capsules per day. Both capsules were similar in colour, shape, and
taste. Both groups received one calcium capsules per day consisting of 1000 mg calcium
and 400 IU vitamin D
Compliance: pill counts - compliance averaged 80% in both groups
Duration of intervention: 14 months
Outcomes Main study outcome: professionals evaluation of neurological function
Dropouts: 1 intervention, 5 control
Available outcomes: functional measures (total and sub-scales), BMI, leptin and
adiponectin concentration
Response to contact: no
Notes Study funding: PhD university funding. Omega 3 capsules were provided by Minami
Nutrition Co (Aartselaar, Belgium) and placebo capsules were supplied by Zahravi Phar-
maceutical Co. (Tabriz, Iran). Calcium capsules were provided by Darou Pakhsh Pharm
Co. (Tehran, Iran)
Data were collected at the beginning of the study and after 14 months
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised using permuted balanced
block randomisation method
Allocation concealment (selection bias) Unclear risk No further detail on allocation
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Stated as double blind but content of
placebo not stated and no report of attempt
to mask n-3 FA taste
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Unclear, few details
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Norouzi 2014 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition was 1 in intervention group, 5
in control group, so minor. “the two most
common reasons for dropouts were experi-
encing GI side effects or difficulty to main-
tain scheduled clinic visits”
Selective reporting (reporting bias) High risk Some of the outcomes stated in the trial
register are not reported. Registered March
2011, study startNovember 2010, comple-
tion April 2012
Attention Low risk No difference between groups
Compliance Unclear risk Pill counts - compliance averaged 80% in
both groups
Other bias Low risk None noted
Norwegian 1968
Methods Norwegian Vegetable Oil Experiment of 1965-6
RCT, parallel, 2 arms (ALA linseed oil vs omega 6 sunflower oil), 1 year
Risk of bias: moderate or high
Participants Men working in Norwegian companies aged 50-59 years
N: 6716 intervention, 6690 control
Level of risk for CVD: low (working men, though a few had had a previous MI or angina)
Men: 100%
Mean age in years (SD): unclear
Age range: 50-59 years
Smokers: unclear (~48% non-smokers)
Hypertension: unclear
Medications taken by at least 50% of those in the control group: not reported
Medications taken by 20%-49% of those in the control group: not reported
Medications taken by some, but less than 20% of the control group: not reported
Location: Norway
Ethnicity: unclear
Interventions Type: supplementary food (oil)
Comparison: ALA vs omega 6
Intervention: linseed oil, 10 mL/d (55% ALA), 5.5 g/d ALA, 1.5 g/d linoleic. Dose: 5.
5 g/d ALA
Control: sunflower oil, 10 mL/d (1.4% ALA), 0.1 g/d ALA, 6.3 g/d linoleic. Vitamin E
was added to both oils
Compliance: 73% were still taking the linseed oil at 1 year, 72% were still taking their
sunflower oil at 1 year (unclear how this was ascertained)
Duration of intervention: 12 months
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Norwegian 1968 (Continued)
Outcomes Main study outcome: morbidity and mortality
Dropouts: survival status was traced for all but 4 includedmen, health status was missing
for about 80 men in total or 0.6%
Available outcomes: total and CV deaths, MI, angina, stroke, peripheral vascular disease,
combined CV events, total cholesterol (subgroup)
Response to contact: no
Notes Study funding: not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Paper states “simple randomisation” with-
out clarification
Allocation concealment (selection bias) Unclear risk Few details provided
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Paper states that the workplace doctors who
administered the trial locally were sent bot-
tles for each participant marked only with
their trial number, and that “appearance
and taste of the products were so similar
that most participants were unable to iden-
tify the type”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Company physicians recorded health sta-
tus, and were also blinded to intervention
(as above)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Detailed description, and those who left
employment during the study were fol-
lowed up for survival and morbidity via the
main health system
Selective reporting (reporting bias) Unclear risk No protocol or trials registration found
Attention Low risk As company physicians administered oils
and assessed outcomes but were blind to
treatment arm there could not be attention
bias
Compliance Unclear risk 73% were still taking the linseed oil at 1
year, 72% were still taking their sunflower
oil at 1 year (unclear how this was ascer-
tained)
Other bias Low risk No further bias noted
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Nutristroke 2009
Methods Nutristroke
RCT, parallel, (diet rich in vitamins and omega 3 plus omega 3 supplement vs diet rich
in vitamins and omega 3), 12 months
Summary risk of bias: moderate or high
Participants People in a rehabilitation unit who had survived a stroke
N: 38 intervention, 34 control. (analysed, intervention: 32 control: 20)
Level of risk for CVD: high
Men: 74% intervention, 56% control
Mean age in years (SD): 61.3 (13.6) n-3, 66.3 (11.4) n-3 + antioxidant intervention,
68.4 (12.6) placebo, 65.1 (12.8) antioxidant - control
Age range: not reported
Smokers: not reported
Hypertension: not reported
Medications taken by at least 50% of those in the control group: not reported
Medications taken by 20%-49% of those in the control group: not reported
Medications taken by some, but less than 20% of the control group: not reported
Location: Italy
Ethnicity: not reported
Interventions Type: supplement (capsule)
Comparison: fish oil vs unclear placebo
Intervention: fish oil gelatin capsules including 250 mg DHA + 250 mg EPA. Dose: 0.
5 g/d EPA + DHA
Control: “identical to supplement but contained no antioxidants or polyunsaturated
fatty acids”
Compliance: appears to have been assessed at meetings or on the phone monthly, but
results unclear
Duration of intervention: 12 months
Outcomes Main study outcome: functional status in stroke survivors
Dropouts: 6 intervention, 14 control
Available outcomes: mortality and cardiovascular mortality, lipids (6 months), albumin
and lymphocyte counts (6 months), Barthel Index (functional status), neurological im-
pairment (not reported by intervention group), mobility, adiposity (no numerical data
presented; quote: “there were no statistically significant differences in body weight, BMI,
arm circumference and triceps skin fold at the different time points”)
Response to contact: not yet attempted
Notes 2 × 2 study that also had an antioxidant supplementary focus (supplementary vitamins
C and E, beta carotene and polyphenols)
Study funding: Italian Ministry of Health, Sigma-Tau Health Science provided omega
3 capsules
Risk of bias
Bias Authors’ judgement Support for judgement
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Nutristroke 2009 (Continued)
Random sequence generation (selection
bias)
Unclear risk Quote: “randomized by means of a specific
list”
Allocation concealment (selection bias) Unclear risk Randomisation methodology not men-
tioned
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote: “the placebo was identical to the
supplement but contained no antioxidants
or polyunsaturated fatty acids; no patient,
research assistant, investigator or any other
medical or nursing staff could distinguish
the placebo from the supplements during
the study”. However, only one placebo dis-
cussed and unclear whether it was a placebo
capsule (for omega 3) or pill (for antioxi-
dants)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “assays were quality
control checked by internal standard and
calibration curve in a random and double
blind way”
Incomplete outcome data (attrition bias)
All outcomes
High risk High rates of dropouts
Selective reporting (reporting bias) Unclear risk No protocol or trials registry entry found
Attention Low risk All assessments and treatments appear
equal across the intervention groups
Compliance Unclear risk Appears to have been assessed at meetings
or on the phone monthly, but results un-
clear
Other bias Low risk None noted
Nye 1990
Methods Randomisation: parallel, 3 groups (omega 3 vs olive oil vs aspirin and dipyridamole), 1
year
Risk of bias: moderate or high
Participants People undergoing PTCA
N: 36 intervention, 37 control (also 35 allocated to arm 3, aspirin and dipyridamole)
Level of risk for CVD: high (people undergoing angioplasty)
Men: 78% intervention, 76% control
Mean age in years (SD): 54 (8) intervention, 55 (8) control years
Age range: unclear
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Nye 1990 (Continued)
Smokers: unclear
Hypertension: unclear
Medications taken by at least 50% of those in the control group: not reported
Medications taken by 20%-49% of those in the control group: not reported
Medications taken by some, but less than 20% of the control group: not reported
Location: New Zealand
Ethnicity: unclear
Interventions Type: supplement (capsules)
Comparison: EPA vs MUFA
Intervention: MaxEPA capsules 12/d (2.2 g EPA). Dose: 2.2 g/d EPA
Control: olive oil capsules, 12/d, identical to MaxEPA. Both capsules included vitamin
E
Compliance: no data
Length of intervention: 12 months
Outcomes Main study outcome: angina, restenosis
Dropouts: none
Available outcomes: angina, interventions, lipids (Nil death)
Response to contact: no
Notes Study funding:Medical ResearchCouncil ofNewZealand andScherer Ltd (who supplied
MaxEPA and the olive oil capsules)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “randomly divided without exclu-
sions into 3 groups”
Allocation concealment (selection bias) Unclear risk Unclear, no further info
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk States that placebo capsules were identical
to the MaxEPA, and “neither the patient
nor the attending cardiologist knew which
capsules were being used” (but no mask-
ing of taste was reported, and participant
guesses as to allocation were not reported)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “neither the patient, nor the attend-
ing cardiologist knew which capsules were
being used” ... “Angioplasty was repeated
electively at one year or before where symp-
toms recurred, and assessedwithout knowl-
edge of the patient’s treatment group.”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Some participants were lost to follow-up
and reasons for this were unclear
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Nye 1990 (Continued)
Selective reporting (reporting bias) Unclear risk No protocol or trials registration found
Attention Low risk No suggestion of attention bias, symp-
tomatic patients were reviewed between
scheduled visits, otherwise all on the same
schedule
Compliance Unclear risk No data
Other bias Low risk No further bias noted
OFAMI 2001
Methods Omacor Following Acute Myocardial Infarction (OFAMI)
RCT, parallel, 2 arms (omega 3 vs corn oil), 2 years
Summary risk of bias: moderate or high
Participants Patients recruited 4-8 days after confirmed MI
N: 150 intervention, 150 control
Level of risk for CVD: high
Men: 77% intervention, 82% control
Mean age in years (SD): 64.4 intervention, 63.6 control (no SD)
Age range: 28-86 years intervention, 29-87 years control
Smokers: 39% intervention, 38% control
Hypertension: 29% intervention, 23% control
Medications taken by at least 50% of those in the control group: b-blockers, aspirin
Medications taken by 20%-49% of those in the control group: statins, ACE inhibitors
Medications taken by some, but less than 20% of the control group: diuretics, warfarin
Location: Norway
Ethnicity: unclear
Interventions Type: supplement (capsules)
Comparison: EPA + DHA vs omega 6
Intervention: 4 gelatin capsules of omega-3-acid ethyl esters 90 (Omacor, Pronova A/
S, Oslo, Norway), each is 1 g containing 850-882 mg EPA and DHA as concentrated
ethylesters Dose ~3.4- 3.5 g/d EPA + DHA
Control: corn oil capsules, 4/d, each contains 1 g of corn oil
Compliance: assessed by questionnaire and capsule count, 82% intervention group had
complete compliance after 6 weeks, 86% of controls
Length of intervention: 24 months
Outcomes Main study outcome: CV events
Dropouts: unclear
Available outcomes: total and CV deaths, MI, unstable angina, interventions, combined
CV events, BMI, lipids, BP (authors provided additional data on glucose, AF, stroke)
Response to contact: yes
Notes Study funding: Pharmacia-Upjohn and Pronova
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OFAMI 2001 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “randomly assigned” - Pharmacia
was responsible for randomisation. Author
response: participants were randomised in
blocks of 4
Allocation concealment (selection bias) Low risk Author confirmed allocation was con-
cealed
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical capsules containing either Oma-
cor or corn oil. Double blinding stated, but
taste not reported as masked and blinding
of participants not checked
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Author stated: all later analyses performed
without the knowledge of outcome
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Number of dropouts was unclear
Selective reporting (reporting bias) Unclear risk Trials registry NCT01422317. Outcomes
reported in trials registry appear to have
been published, but registration was retro-
spective
Attention Low risk All participants appear to have been re-
viewed at the same intervals
Compliance Unclear risk Assessed by questionnaire and capsule
count, 82% intervention group had com-
plete compliance after 6 weeks, 86% of
controls
Other bias Low risk No further bias noted
OMEGA 2009
Methods Effect of Omega 3 fatty acids on reduction of sudden cardiac death after MI (OMEGA)
2 arm, parallel RCT (omega 3 vs olive oil), 12 months
Summary risk of bias: low
Participants People who have had an acute myocardial infarction
N: 1940 intervention,1911 control (analysed for primary endpoints 1919 intervention,
1885 control)
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OMEGA 2009 (Continued)
Level of risk for CVD: high
Men: 75.1% intervention, 73.7% control
Age (median): 64.0 years, intervention, 64.0 years control
Age range: unclear (upper and lower quartiles 54-72)
Smokers: 35.9% intervention, 37.5% control
Hypertension: 66.9% intervention, 66.1% control
Medications taken by at least 50% of those in the control group: statins, ACE inhibitors,
beta-blockers, clopidogrel, aspirin
Medications taken by 20%-49%: diuretics
Medications taken by some, but < 20%: AT1 receptor blockers, vit K antagonist, calcium
channel blockers, digitalis, amiodarone, oral antidiabetics, insulin
Location: Germany
Ethnicity: not reported
Interventions Type: supplement (capsules)
Comparison: EPA + DHA vs MUFA
Intervention: 1 × 1 g/d Pronova BiCare soft gelatin capsule ’zodin’ omega-3 acid ethyl
esters (460 mg/d EPA and 386 mg/d DHA). Dose: 0.85 g/d EPA + DHA
Control: 1 × 1 g/d olive oil capsule identical to intervention
Compliance: 93.1% of intervention group and 93.2% of control participants took >
70% of capsules
Duration of intervention: 12 months
Outcomes Main study outcome: sudden cardiac death, cardiac arrest
Dropouts: Control: 26 (8-lost to follow-up, 2-withdrew before allocation, 16-excluded.
) intervention: 21
Available outcomes: deaths, CV mortality, MACCE, MI, arrhythmias, heart failure,
stroke, revascularisation, lipids, authors supplied information on angina, depression,
cancers, AF
Response to contact: yes
Notes Study funding: Tromsdorff Arzneimittel commissioned the research
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation code generated by alpha
med PHARBIL, done in blocks of 8. Ran-
domisation was stratified by centre
Allocation concealment (selection bias) Low risk Appearance of the drugs or the drug con-
tainers did not allow patients and physi-
cians to deduce the study arm. 4-digit num-
ber on a concealed container
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Capsules for placebo and intervention
looked the same, randomisation code un-
known to investigator (taste and smell not
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OMEGA 2009 (Continued)
mentioned)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Classification of adverse events blinded to
allocation, and there was a blinded end-
point committee for all pre-specified out-
comes
Incomplete outcome data (attrition bias)
All outcomes
Low risk All events were documented by the inves-
tigators and reported to the assigned clin-
ical research organisation and the sponsor.
The data safety monitoring board judged
any imbalances between the study arms
Selective reporting (reporting bias) Low risk NCT00251134 registered in 2005. Study
start date: 2003, Completed: 2008, study
design: 2006, Published paper: 2010. All
trials registry primary and secondary out-
comes reported
Attention Low risk Capsules for both arms
Compliance Low risk 93.1% of intervention group and 93.2%
of control participants took > 70% of cap-
sules. EAIC 0.65 intervention, and control
Other bias Low risk None noted
OPAL 2010
Methods Older People And n-3 Long-chain polyunsaturated fatty acid (OPAL)
2 arm, parallel, RCT, 12 months
Summary risk of bias: low
Participants Healthy cognitively normal adults aged 70-79 years
N: 434 intervention, 433 control (analysed 376 intervention, 372 control)
Level of risk for CVD: low
Men: 53.4% intervention, 56.6% control
Mean age in years (SD): 74.7 (2.5) intervention, 74.6 (2.7) control
Age range: 70-79 years
Smokers: not reported
Hypertension: 54.9% intervention, 56.9% control
Medications taken by at least 50% of those in the control group: not reported
Medications taken by 20%-49%: not reported
Medications taken by some, but < 20%: not reported
Location: England and Wales
Ethnicity: not reported
175Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
OPAL 2010 (Continued)
Interventions Type: supplement (capsules)
Comparison: EPA + DHA vs MUFA
Intervention: 2 × 650mg capsule/dOceanNutrition vanilla flavoured soft gelatin capsule
(total daily dose of 200 mg EPA and 500 mg DHA). Dose: 0.7 g/d EPA + DHA
Control: 2 × 650 mg olive oil capsule identical to intervention
Compliance: count returned capsules.
Capsules not returned:
• Intervention - median: 0.95; IQR: 0.82, 1.00
• Control - median: 0.95; IQR: 0.81, 1.00
Fasting serum fatty acids, mg/L, mean (SD)
• EPA: intervention 49.9, (2.7); control 39.1 (3.1)
• DHA: intervention 95.6 (3.1); control, 70.7 (2.9)
• α-linoleic: intervention 21.5 (0.8); control 22.0 (0.9)
Length of intervention: 24 months
Outcomes Main study outcome: delayed onset of cognitive decline
Dropouts: control: 78 (8 died, 53 withdrew, 17 discontinued intervention but provided
data);
intervention: 67 (9 died, 49 withdrew, 9 discontinued intervention but provided data)
Available outcomes: deaths, MI, arrhythmias, stroke, diabetes, lipids
Response to contact: yes
Notes Study funding: UK Food Standards Agency, NHS R&D provided support costs
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants were “selected in random
blocks”. “Research nurses telephoned a cen-
tral computerized randomization service to
obtain treatment allocation codes”
Allocation concealment (selection bias) Low risk Central allocation via telephone
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical capsules (vanilla-flavoured, dark-
brown coloured). Supplements packaged
into identical pots, each containing 180
capsules, labelled by staff not involved in
the study. All project staff were unaware of
group assignments until after data analysis
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk All project staff were unaware of group as-
signments until after data analysis
Incomplete outcome data (attrition bias)
All outcomes
Low risk Participants who discontinued the supple-
ments invited to an interview at 24months.
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OPAL 2010 (Continued)
Dropouts explained and similar in both
arms (intervention 49withdrew, control 53
withdrew)
Selective reporting (reporting bias) High risk ISRCTN72331636. Trial registered 2004,
before study began. Protocol published
2006. Publication of first results 2010.
Many outcomes, such as depression andBP
were stated in trials registry entry but not
reported
Attention Low risk All participants had the same review sched-
ule, and staff were unaware of assignments
Compliance Low risk Count returned capsules. Capsules not re-
turned (intervention - median: 0.95; IQR:
0.82, 1.00; control - median: 0.95; IQR:
0.81, 1.00). Fasting serum fatty acids, mg/
L, mean (SD): EPA, intervention 49.9 (2.
7); control 39.1 (3.1). DHA, intervention
95.6 (3.1); control 70.7 (2.9). α-linoleic:
intervention 21.5 (0.8); control 22.0 (0.9)
Other bias Low risk No further bias noted
ORIGIN 2012
Methods Outcome Reduction With Initial Glargine Intervention (ORIGIN)
RCT, 2 × 2 factorial, (capsule of n-3 fatty acids or placebo), 72 months
Summary risk of bias: low
Participants People at high risk of CV events with impaired fasting glucose, impaired glucose tolerance
or diabetes
N: 6319 intervention, 6292 control. (analysed, intervention: 6281 control: 6255)
Level of risk for CVD: moderate
Men: 65.4% intervention, 64.7% control
Mean age in years (SD): 63.5 (7.8) intervention, 63.6 (7.9) control
Age range: unclear, eligible if aged ≥ 50 years
Smokers: current smokers 12.1% intervention, 12.6% control
Hypertension: 78.7% intervention, 80.3% control
Medications taken by at least 50% of those in the control group: ACE inhibitor or ARB,
aspirin or other antiplatelet, beta-blocker, statin, glucose-lowering drug
Medications taken by 20%-49%: calcium-channel blocker
Medications taken by some, but less than 20%: thiazide diuretics, anticoagulant
Location: 40 study locations in Europe and the Americas
Ethnicity: unclear
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Interventions Type: supplement capsule (Omacor)
Comparison: EPA + DHA vs MUFA
Intervention: 1 gelatin capsule/d Omacor containing at least 900 mg ethyl esters of n-3
fats (465 mg EPA + 375 mg DHA). Dose: 0.84 g/d EPA + DHA
Control: 1 × 1 g gelatin capsule/d olive oil
Compliance: methods of assessment unclear, but reported that “rates of adherence to the
study-drug regimen were similar in the two groups with 96% of patients continuing to
receive the study drug at 1 year ... and 88% at the end of the study”
Length of intervention: 74 months mean follow-up (median 6.2 years)
Outcomes Main study outcome: composite of the First Occurrence of Cardiovascular (CV) Death,
Nonfatal Myocardial Infarction (MI) or Nonfatal Stroke
Dropouts: 38 intervention, 37 control (some of the remainder did not have final outcome
status, were lost or withdrew consent, but were included in analysis)
Available outcomes: mortality, CV mortality, fatal arrhythmia, MI, stroke, heart failure,
angina, revascularisation, breast cancer, cancer diagnoses and cancer deaths, BP, lipids
(HbA1c given as medians only)
Response to contact: yes but no data provided
Notes The other 2 × 2 assignment was to insulin glargine versus standard care, and is not
discussed here. Results are reported here for the trial duration and not the follow-up post
trial (the ORIGIN and Legacy Effects, ORIGINALE)
Study funding: Sanofi Aventis, Omacor provided by Pronova Biocare
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “randomized by an automated tele-
phone randomization system (using ran-
domly varying block sizes)”
Allocation concealment (selection bias) Low risk As above
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Study described as “double blind” and
placebo described as identical. Blinding of
patients, investigators, local and central tri-
als personnel described. However, no infor-
mation provided as to the capsule’s smell
and taste
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “all primary and secondary out-
comes were adjudicated with the use of pre-
specified definitions by a committee whose
members were unaware of study-group as-
signments”
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ORIGIN 2012 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Almost all participants were included in
outcomes
Selective reporting (reporting bias) Low risk NCT00069784 - registeredOctober 2003,
study started August 2003, final data col-
lection December 2011. Most outcomes
appear to have been reported in various
publications (cardiovascular events only re-
ported by glargine randomisation)
Attention Low risk No suggestion of differences between
groups
Compliance Unclear risk Methods of assessment unclear, but re-
ported that “rates of adherence to the
study-drug regimen were similar in the two
groups with 96% of patients continuing to
receive the study drug at 1 year ... and 88%
at the end of the study”
Other bias Low risk None noted
ORL 2013
Methods Omega-3 fatty acids randomised long-term (ORL)
RCT- parallel, 3 arms (TAK-085 2 g, TAK-085 4 g, and EPA-E 1.8 g), 12 months
Summary risk of bias: moderate or high
Participants Population: Japanese adults with hypertriglyceridaemia
N: 171 intervention (4 g TAK), 165 control (2 g TAK)
Level of risk for CVD: moderate
Men: 70.8% intervention, 71.5% control
Mean age in years (SD): 55.9 (10.12) intervention, 56 (10.95) control
Age range: 20-74
Smokers (current): 27.5% intervention, 31.5% control
Hypertension: 66.7% intervention, 67.3% control
Medications taken by at least 50% of those in the control group: HMG-CoA reductase
inhibitor
Medications taken by 20%-49%: statin
Medications taken by some, but less than 20%: not reported
Location: Japan
Ethnicity: unclear
Interventions Type: supplement (TAK-085 capsules)
Comparison: EPA + DHA higher vs lower dose
Intervention: 1 × 2/d capsule each containing 2 g of TAK-085 (1 g of fatty acid in TAK-
085 capsules contains approximately 465 mg of EPA-E plus 375 mg of DHA-E). Total
dose of 1.86 g/d EPA + 1.5 g/d DHA. Dose: ~3.4 g/d EPA + DHA) (difference of +1.7
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ORL 2013 (Continued)
g/d from control arm)
Control: 1 capsule/d containing 2 g of TAK-085 (1 g of fatty acid in TAK-085 capsules
contains approximately 465 mg of EPA-E plus 375 mg of DHA-E). Total dose of 0.93
g/d EPA + 0.75 g/d DHA. Dose: 1.7 g/d EPA + DHA
Compliance: monitored every 4 weeks, mean rate of compliance reported as > 96% in
each group
Length of intervention: 12 months
Outcomes Main study outcome: safety outcomes and adverse events
Dropouts: group 1: 8, group 2: 14, group 3 (not analysed): 21
Available outcomes: adverse events (including CVD events, cancers), CRP, waist circum-
ference, weight, blood pressure (nil death), lipids provided as % change from baseline,
but no baseline data available, so not used in meta-analyses
Response to contact: no
Notes A third arm of EPA-E 1.8 g supplementation is not used here. Outcome data used TAK-
4 vs TAK-2
Study funding: Takeda Pharmaceutical Company
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was stratified according to
statin use and performed by an indepen-
dent registration centre
Allocation concealment (selection bias) Low risk As above
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open label
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Open label
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants were accounted for and
analysed for main outcomes
Selective reporting (reporting bias) Low risk Trials registry entry May 2011, study start
date November 2009, completion Novem-
ber 2011, so partially retrospective. How-
ever, entry appears to reflect reported out-
comes
Attention Low risk Capsules, appears similar
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Compliance Low risk Monitored every 4 weeks, mean rate of
compliance reported as > 96% in each
group
Other bias Low risk None noted
Proudman 2015
Methods RCT, parallel, (EPA + DHA fish oil vs omega 6 sunola oil), 12 months
Summary risk of bias: low
Participants Patients with rheumatoid arthritis < 12 months’ duration, DMARD-naive
N: 87 intervention, 53 control. (analysed, intervention: 75 control: 47)
Level of risk for CVD: low
Men: 29% intervention, 25% control
Mean age in years (SD): 56.1 (15.9) intervention, 55.5 (14.1) control
Age range: unclear
Smokers: 65.1% intervention, 54.7% control (includes current and previous smokers)
Hypertension: not reported
Medications taken by at least 50% of those in the control group: triple DMARD therapy
(SSZ 0.5 g/d, HCQ 200 mg twice/day and MTX 10 mg once per week)
Medications taken by 20%-49% of those in the control group: NSAIDS
Medications taken by some, but less than 20% of the control group: oral or parenteral
steroids
Location: Australia
Ethnicity: not reported
Interventions Type: supplement (fish oil)
Comparison: high EPA + DHA vs omega 6 (low EPA + DHA with sunola oil)
Intervention: 10 mL/d fish oil concentrate (BLT Incromega TG3525) providing 5.5 g/
day (3.2 EPA + 2.3 DHA). Dose: 5.5 g/d EPA + DHA
Control: 10 mL/d sunola oil:capelin oil (2:1) providing 0.21 g EPA + 0.19 g DHA/d as
TAG (0.40 g/day EPA + DHA)
Compliance: consumption checked at each visit. 100% compliance would be consump-
tion of 3650 mL oil at 12 months. The fish oil group was less compliant than the control
group with median intakes of 2482 mL and 3248 mL, respectively (P = 0.015, Mann-
Whitney U test). This provided an average daily intake of EPA + DHA of 3.7 g and 0.
36 g in the fish oil and control groups, respectively
Duration of intervention: 12 months
Outcomes Main study outcome: disease-modifying anti-rheumatic drugs (DMARD) failure and
remission
Dropouts: 11 intervention, 6 control
Available outcomes: mortality (nil death), adverse events including CVD, DAS score,
diabetes, authors supplied methodology data plus BMI change
Response to contact: yes
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Proudman 2015 (Continued)
Notes DAS scores are reported as median and IQR in Proudman 2012 abstract
Study funding: National Health Medical Research Council of Australia and Royal Ade-
laide Hospital Research Committee. Melrose Health provided support for ongoing stud-
ies. The oil was made by the Royal Adelaide Hospital Pharmacy
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “The randomisation schedule was
prepared using an online random num-
ber generator and involved randomly per-
muted blocks of size six.”
Allocation concealment (selection bias) Low risk Quote: “Randomisation was performed by
the RAH pharmacy, which also prepared
andprovided the study oils in 500mL iden-
tical dark brown bottles labelled with con-
secutive study numbers”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “Both participants and investiga-
tors/assessors were blinded to the group al-
location. Although the control oil was paler
in colour than the fish oil, this was not evi-
dent in the brownbottles. The ’fishy’ odour
of each oil was similar.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Both participants and investigators/asses-
sors were blinded to the group alloca-
tion. Quote: “Investigators and subjects re-
mained blinded for all withdrawals.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk The flow of all study participants shown in
FIGURE 2
Selective reporting (reporting bias) Unclear risk Outcomes reported in trial regis-
ter matched with the outcomes reported in
publications. However, the study was ret-
rospectively registered - registered in 2013,
recruitment began in 2001
Attention Low risk No difference between groups
Compliance High risk Consumption checked at each visit. 100%
compliance would be consumption of
3650 mL oil at 12 months. The fish oil
group was less compliant than the control
group with median intakes of 2482 mL
(68%) and 3248 mL (89%), respectively
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Proudman 2015 (Continued)
(P = 0.015, Mann-Whitney U test). This
provided an average daily intake of EPA +
DHA of 3.7 g and 0.36 g in the fish oil and
control groups, respectively
Other bias Low risk None noted
Puri 2005
Methods RCT, parallel (ethyl-EPA vs paraffin), 2 arm, 12 months
Summary risk of bias: low
Participants People with Huntington’s Disease
N: 67 intervention, 68 control (analysed, intervention: 39 control: 44)
Level of risk for CVD: low
Men: 57% intervention, 44% control
Mean age in years (SD): 50 (9.3) intervention, 49 (9.0) control
Age range: not reported
Smokers: not reported
Hypertension: not reported
Medications taken by at least 50% of those in the control group: not reported
Medications taken by 20%-49% of those in the control group: antidepressants
Medications taken by some, but < 20%: neuroleptics
Location: UK, USA, Canada, Australia
Ethnicity: intervention: 94% white, 4% black, 1% Asian; control: 97%, 3%, 0%, re-
spectively
Interventions Type: supplement (ethyl-EPA)
Comparison: EPA vs paraffin (non-fat)
Intervention: 2 × 2 × 500 mg capsules/d, total dose of 2 g/day ethyl-EPA (code name
LAX-101, purity 95%). Dose: 1.9 g/d EPA
Control: 2 × 2 × 500 mg capsules/d liquid paraffin
Compliance: 38 were excluded for protocol violations, 4 intervention and 16 control
were non-compliant with capsules
Duration of intervention: 12 months
Outcomes Main study outcome: functional status in Huntington’s Disease
Dropouts: 7 intervention, 7 control
Available outcomes: measures of functional capacity, CV events, cancers (nil deaths)
Response to contact: yes (no additional data provided)
Notes Study funding: Amarin Neuroscience Ltd. (formerly known as Laxdale Ltd.), provided
organisation, funding and salaries
Risk of bias
Bias Authors’ judgement Support for judgement
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Puri 2005 (Continued)
Random sequence generation (selection
bias)
Low risk Quote: “After screening and acceptance...
patients were assigned to treatment by re-
ceiving a numbered pack supplied by a clin-
ical trials packaging organization ... inde-
pendent of all other aspects of the trial.
Randomizationwas stratified in a block size
of four, with the appropriate number of
blocks allocated to each center. PCI Clin-
ical Services held the randomization code
until the database had been closed and all
patients had been assigned”
Allocation concealment (selection bias) Low risk As above
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “[p]lacebo and ethyl-EPA capsules
were of identical appearance” (though taste
and smell not reported)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Randomisation described as “double-
blind”, “neither the patients nor the partic-
ipating medical staff had access to this code
during the course of the study”
Incomplete outcome data (attrition bias)
All outcomes
High risk Clearly reported and complete, however >
20% attrition
Selective reporting (reporting bias) Unclear risk No protocol or trials registry entry identi-
fied
Attention Low risk Unlikely
Compliance Unclear risk 38 were excluded for protocol violations,
4 intervention and 16 control were non-
compliant with capsules
Other bias Low risk None noted
Raitt 2005
Methods RCT, parallel, (fish oil or olive oil), 24 months
Summary risk of bias: moderate or high
Participants Peoplewith implantable cardioverter defibrillators and recent sustained ventricular tachy-
cardia or ventricular fibrillation (VT/VF)
N: 100 intervention, 100 control
Level of risk for CVD: high
Men: 86% intervention, 86% control
Mean age in years (SD): 63 (13) intervention, 62 (13) control
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Age range: not reported but 18-75 inclusion criteria
Smokers: not reported
Hypertension: 46% intervention, 55% control
Medications taken by at least 50% of those in the control group: diuretic, beta blockers,
ACE inhibitors
Medications taken by 20%-49% of those in the control group: digoxin, statins
Medications taken by some, but less than 20% of the control group: calcium channel
blocker
Location: USA
Ethnicity: 94% white in intervention group, 97% in control group
Interventions Type: supplement (fish oil capsules vs olive oil capsules)
Comparison: EPA + DHA vs MUFA
Intervention: 1.8 g/d fish oil capsules (Hoffman LaRoche, including ethyl esters of EPA
and DHA, 0.76 g/d EPA, 0.54 g/d DHA). Dose: 1.3 g/d EPA + DHA
Control: 1.8 g/d olive oil capsules (Hoffman LaRoche, 73% oleic acid)
Compliance: while control group plasma and platelet DHA and EPA did not change,
there were increases of 2%-8.3% in the intervention group
Duration of intervention: 24 months (median 718 days)
Outcomes Main study outcome: time to first episode of VT/VF
Dropouts: 17 intervention, 26 control
Available outcomes: deaths, CV death, MI, angina, revascularisation, arrhythmias, sud-
den cardiac death, cancer
Response to contact: yes but no data provided
Notes Study funding: NIH and Hoffman LaRoche
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “computer generated block ran-
domisation scheme”
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Participant blinding unclear
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk ICD traces were viewed by researchers
blinded to allocation, “double blind
placebo-controlled”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Almost all participants were included in
outcome assessment, well described
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Selective reporting (reporting bias) High risk NCT registered in February 2000, study
carried out from February 1999 to January
2004. Most outcomes stated in registry en-
try reported, but quality of life missing
Attention Low risk Capsules were the only different interven-
tions between arms, little opportunity for
attention bias
Compliance Low risk While control group plasma and platelet
DHA and EPA did not change, there were
increases of 2%-8.3% in the intervention
group
Other bias Low risk None noted
Ramirez-Ramirez 2013
Methods RCT, parallel, (fish oil vs sunflower oil), 12 months
Summary risk of bias: moderate or high
Participants People with relapsing remitting multiple sclerosis
N: 25 intervention, 25 control. (analysed, intervention: 20 control: 19)
Level of risk for CVD: low
Men: 83% intervention, 82% control (but these appear unlikely)
Mean age (SD) years: 35.1 (7.6) intervention, 34.9 (7.8) control
Age range: not reported but 18-55 years were inclusion criteria
Smokers: not reported
Hypertension: not reported
Medications taken by at least 50% of those in the control group: 100% treated with
interferon beta1b for at least 1 year before the trial began
Medications taken by 20%-49% of those in the control group: not reported
Medications taken by some, but less than 20% of the control group: not reported
Location: Mexico
Ethnicity: not reported
Interventions Type: supplement
Comparison: DHA + EPA vs sunflower oil
Intervention: 4 g/d omega Rx capsules (Dr Sears zone diet, with excipient of glycerin,
water, tocopherol, sunflower oil, titanium dioxide, includes 0.8 g/d EPA plus 1.6 g/d
DHA). Dose: 2.4 g/d EPA + DHA
Control: excipient only (Perfect Source Natural Products, glycerin, water, tocopherol,
sunflower oil, titanium dioxide)
Compliance: consumption diary plus pills returned at each visit, adherence calculated
(correct formula?? pills consumed × 100/pills returned), optimal adherence was consid-
ered to be > 80%, 1 intervention and 3 control were excluded due to compliance < 80%.
Blood DHA and EPA were significantly different at 12 months
Duration of intervention: 12 months
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Outcomes Main study outcome: TNF-alpha
Dropouts: 5 of 25 intervention, 6 of 25 control
Available outcomes: TNF-alpha, IL-6, IL-1 beta, nitric oxide catabolites, MS relapse,
disability EDSS, liver and renal function tests, haemoglobin, leucocytes, platelets, ox-
idative outcomes (glucose and lipids data collected but not reported, for BMI and BP
paper reports “no difference through study”)
Response to contact: not yet attempted
Notes Study funding: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation se-
quence (blocks of 4)
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “capsules were identical in appear-
ance, packaging and labelling”, “physicians
and patients were blind to the interven-
tion”, and there was a rosemary flavour to
mask
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “an independent physician evalu-
ated the EDSS score and collected samples
at each clinic visit”
Incomplete outcome data (attrition bias)
All outcomes
High risk Loss of 11/50 over 1 year, 22% loss
Selective reporting (reporting bias) High risk Paper reports analysis of glucose and lipids
but these are not reported
Attention Low risk Appeared similar, reviewed every 3 months
Compliance Low risk Blood DHA and EPA were significantly
different at 12 months
Other bias Low risk None noted
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Reed 2014
Methods RCT, parallel, 3 arms (fish oil or borage oil), 18 months
Summary risk of bias: low
Participants Adults with rheumatoid arthritis
N: 53 intervention, 52 control (28 intervention, 24 control analysed)
Level of risk for CVD: low
Men: 13.2% intervention, 23.1% control
Mean age in years (SD): 57.3 (12.3) intervention, 60.3 (9.2) control
Age range: not reported but 18-85 inclusion criteria
Smokers: not reported
Hypertension: not reported
Medications taken by at least 50% of those in the control group: methotrexate,
DMARDs, and TNF blockers
Medications taken by 20%-49% of those in the control group: corticosteroids and TNF
blockers
Medications taken by some, but less than 20% of the control group: not reported
Location: USA
Ethnicity: black/African-American: intervention (fish oil): 7.8% control (borage oil): 7.
8%
Interventions Type: supplement (fish oil vs borage oil)
Comparison: EPA + DHA vs Omega 6
Intervention: 7 fish oil (2.1 gm EPA:1.4 gm DHA) capsules and 6 sunflower seed oil
capsules daily = 13 capsules divided doses. Dose: 3.5 g/d EPA + DHA
Control: 6 borage seed oil (1.8 g GLA) capsules plus 7 sunflower seed oil capsules daily
Compliance: assessed by capsule counts and patient report. Patient report, indicates that
45% of patients reported ever missing a dose (borage: 42%, fish 48%). Median total
capsules missed (excluding those with 0) were 182 (borage: 164, fish 169)
Duration of intervention: 18 months
Outcomes Main study outcome: RA modified disease activity score
Dropouts: 25 intervention, 28 control
Available outcomes: mortality (nil death), CVD events (nil), DAS score, CDAI score.
Authors suggested that LDL and total cholesterol were reduced in the intervention group
at 18 months, and HDL was increased in both intervention and control at 18 months,
while diastolic BP was reduced in the intervention group at 18 months, but no numbers
provided. CRP and ESR data were provided combined for the intervention and control
arms in the author response, so not useable
Response to contact: yes, authors supplied details of methodology but no usable outcome
data
Notes A third arm (45 participants) were given a combination of both oils but not discussed
here
Study funding: National Institutes of Health Grant RO1-AT000309 from the National
Center for Complementary and Alternative Medicine
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Low risk Author stated “stratified random block,
stratified by site using random blocks of 3
& 6”
Allocation concealment (selection bias) Low risk Nomethodology provided in the paper, but
the author suggested concealment
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind, all capsules were identical in
appearance and colour, they were shipped
in opaque plastic bottles to the University
ofMassachusetts University Hospital phar-
macy, from where they were distributed to
participating centres.However no informa-
tion provided as to their smell and taste
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Author confirmed outcome assessors were
blinded.
Incomplete outcome data (attrition bias)
All outcomes
High risk Authors mention intention-to-treat analy-
sis but shows completers analysis. Num-
bers of participants are not provided for
all outcomes measured. Provide results for
the overall group (69 participants table 3a)
while the flow diagram states there are 74
completers. 51% dropped out
Selective reporting (reporting bias) Low risk Study prospectively registered in 2003, esti-
mated study completion November 2008,
published in 2014. Both outcomes re-
ported in registry are reported in the pub-
lication
Attention Low risk All patients were evaluated at 3-month in-
tervals, by the same examiner
Compliance Unclear risk Assessed by capsule counts and patient re-
port. Patient report, indicates that 45% of
patients reported ever missing a dose (bor-
age: 42%, fish 48%). Median total capsules
missed (excluding those with 0) were 182
(borage: 164, fish 169)
Other bias Low risk None noted
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Methods RCT, parallel, (n-3 vs olive oil), 60 months
Summary risk of bias: moderate or high
Participants Patients with multiple cardiovascular risk factors
N: 6244 intervention, 6269 control (analysed, intervention: 6239 control: 6266)
Level of risk for CVD: high
Men: 62.3% intervention, 60.6% control
Mean age in years (SD): 63.9 (9.3) intervention, 64.0 (9.6) control
Age range: not reported
Smokers: 22.1% intervention, 21.4% control.
Hypertension: 84.6% intervention, 84.5% control
Medications taken by at least 50% of those in the control group: not reported
Medications taken by 20%-49% of those in the control group: ACE inhibitor; ARB;
diuretic agent; calcium-channel blocker; beta-blocker; oral hypoglycaemic drug; statin;
antiplatelet agent
Medications taken by some, but less than 20% of the control group: insulin
Location: Italy
Ethnicity: not reported
Interventions Type: supplement (n-3 capsules)
Comparison: EPA + DHA vs MUFA
Intervention: 1 g/d n-3 capsules polyunsaturated fatty acid ethyl esters (EPA and DHA
content 850-882 mg with an average ratio of 1.0 to 1.2). Dose: ~0.87 g/d EPA + DHA
Control: 1 g/d olive oil capsules
Compliance: measured by self-report during follow-up visits but no results reported
Duration of intervention: 60 months
Outcomes Main study outcome: composite of time to death from cardiovascular causes or hospital
admission for cardiovascular causes
Dropouts: intervention: 5 withdrew consent before baseline, 43 lost to follow-up, 1115
stopped treatment. 6239 analysed
Control: 3 (withdrew consent before baseline), 39 lost to follow-up, 1218 stopped treat-
ment. 6266 analysed
Available outcomes: mortality, CV mortality, CV events, coronary related events and
mortality, MI, AF, heart failure, side effects, stroke, cancer diagnosis, cancer death. Au-
thors provided data on diabetes diagnosis, glucose and HbA1c
Response to contact: yes
Notes All continuous outcomes change data are reported as least squares mean hence not used
Study funding, quote: “The steering committee had the full and sole responsibility for
planning and coordinating the study, analyzing and interpreting the data, and preparing
the manuscript and submitting it for publication. Società Prodotti Antibiotici, Pfizer,
and Sigma Tau funded the trial but had no role in the study design, planning, conduct,
or analysis or in the interpretation or reporting of the results”
Risk of bias
Bias Authors’ judgement Support for judgement
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Risk & Prevention 2013 (Continued)
Random sequence generation (selection
bias)
Low risk Quote: “Treatment was centrally assigned
bymeans of telephone on the basis of a con-
cealed, computer-generated randomization
list, stratified according to general practi-
tioner.”
Allocation concealment (selection bias) Low risk As above
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote: “Patients, general practitioners, co-
ordination and statistical staff, and out-
come assessors were unaware of the study
assignments until the final analyses were
completed.” However, there was no men-
tion of placebo appearance or other meth-
ods of blinding, so unclear
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “Patients, general practitioners, co-
ordination and statistical staff, and out-
come assessors were unaware of the study
assignments until the final analyses were
completed.”
Quote: “All events included in the primary
efficacy end point were documented with
the use of a narrative summary and sup-
porting documentation and were adjudi-
cated on the basis of prespecified criteria by
an ad hoc committee consisting of a cardi-
ologist, an internist, and a neurologist who
were unaware of the study assignments”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “Analyses were performed in the
intention-to-treat population, except for a
prespecified per protocol analysis of the pri-
mary end point in patients with no ma-
jor protocol violations who did not per-
manently stop treatment.” Figures differ
in Visentin 2008: (p. i73)“At the end of
March 2006, 12 521 patients have been
Randomized”; “After 1-year of follow-up,
2.5% of the patients withdrawn from the
trial and 5% of the patients discontinued
treatment. The reasons for drug discontin-
uation were 1.7% for side effects (mainly
gastrointestinal) and 3.3% others (clinical
or patient’s refusal)… After 1-year of fol-
low-up, 1.0% had CV death and 3.4%
hospitalisation for CV events (primary end
point)”
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Risk & Prevention 2013 (Continued)
Selective reporting (reporting bias) High risk Primary endpoint was amended part way
through study. Differences in groupings of
cardiovascular events in tables 2; S4 and S5.
For hospital admissions notes each patient
could have more than one cardiovascular
cause
Attention Unclear risk Does not state attention differs or is the
same between groups- regularly see GP for
follow-up and blinding not clear
Compliance Unclear risk No results
Other bias Low risk None noted
Rossing 1996
Methods RCT, parallel, (fish oil vs olive oil), 12 months
Summary risk of bias: moderate or high
Participants Adults with insulin-dependant diabetes mellitus, diabetic nephropathy and normal BP
N: 18 intervention, 18 control (analysed, 17 intervention, 15 control)
Level of risk for CVD: moderate
Men: 64% intervention, 67% control
Mean age (SD) years: 32 (7) intervention, 34 (10) control
Age range: 18-55 years
Smokers: 50% intervention, 47% control
Hypertension: not reported
Medications taken by at least 50% of those in the control group: insulin
Medications taken by 20%-49% of those in the control group: not reported
Medications taken by some, but less than 20% of the control group: not reported
Location: Denmark
Ethnicity: not reported
Interventions Type: supplement
Comparison: EPA + DHA vs MUFA
Intervention: cod-liver oil emulsion (Pharma-Vinci A/S Denmark). EPA 2 g, DHA 2.6
g, total PUFA 4.6 g/day. Dose: 4.6 g/d EPA + DHA
Control: olive oil emulsion (Pharma-Vinci A/S Denmark)
Compliance: assessed through omega 3 incorporation in platelets, and the paper reports
significantly higher omega 3 levels in platelets at 12 months
Duration of intervention: 12 months
Outcomes Main study outcome: diabetic nephropathy
Dropouts: 1 intervention, 3 control (though 3 further intervention participants are not
included in all data)
Available outcomes: mortality (nil), breast cancer, total and LDL cholesterol, sBP (TGs
reported as medians so not used, albuminurea, fractional albumin clearance, transcap-
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Rossing 1996 (Continued)
illary escape rate of albumin, prothrombin fragment reported as geometric means or
medians, HbA1c, HDL and diastolic BP too different at baseline to include, GFR, PAI1,
TPA, fibrinogen, etc. not relevant)
Response to contact: yes
Notes Study funding: the Danish Heart Association. Eskisol Fish oil and placebo oil emulsions
were provided by Pharma-Vinci A/S, Frederiksvaerk, Denmark
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Patients were randomised using concealed
randomisation to receive either fish oil or
olive oil in blocks of 4 according to their
glomerular filtration rate.”
Allocation concealment (selection bias) Unclear risk No further details
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Active and placebo (olive oil) were given
as emulsions with orange flavour. At the
end patients were allowed to guess about
treatment and ~50% were right”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No details
Incomplete outcome data (attrition bias)
All outcomes
Low risk Dropouts similar between groups although
relatively high for small sample size. 3 drop-
outs from fish oil and 1 from control due to
side effects. Intention-to-treat analysis ap-
pears to have been given for albuminuria
only
Selective reporting (reporting bias) Unclear risk No trials registry entry or protocol found
Attention Low risk Time and attention appear to be the same.
All patients were given dietary advice
Compliance Low risk Reports significantly higher omega 3 levels
in platelets at 12 months for the interven-
tion group
Other bias Low risk None noted
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Sandhu 2016
Methods RCT, parallel 5 arms (combined groups 4 and 5 omega-3-acid ethyl esters (Lovaza) n-3
± raloxifene vs control groups 1 and 3 ± raloxifene), 24 months
Summary risk of bias: moderate or high
Participants Healthy postmenopausal women (50% normal weight, 30% overweight, 20% obese)
with high breast density detected on their routine screening mammograms
N: 54 + 53 intervention, 53 + 53 control
Level of risk for CVD: low
Men: 0% intervention, 0% control
Mean age in years (SD): 56.56 (6.9) + 57.85 (5.1) intervention, 57.11 (5.9) + 57.68 (5.
1) control
Age range: not reported
Smokers: 0% intervention, 0% control
Hypertension: not reported
Medications taken by at least 50% of those in the control group: not reported
Medications taken by 20%-49% of those in the control group: not reported
Medications taken by some, but less than 20% of the control group: not reported
Location: USA
Ethnicity: not reported
Interventions Type: supplement (n-3 capsules)
Comparison: EPA + DHA vs nil
Intervention: group 4, Lovaza 4 g per day. Lovaza is the FDA-approved n-3 FA formu-
lation containing 465 mg of EPA + 375 mg of DHA per gram, total dose; 1860 mg/d
EPA, 1500 mg/d DHA. Group 5 as group 4 plus 30 mg raloxifene/d. Dose: 3.36 g/d
EPA + DHA
Control: group 1, no treatment; group 3, 30 mg raloxifene/d
Compliance: measured by pill count, recorded at follow-up visits and further verified by
serum fatty acids monitoring. Compliance was 94% (SE 2%) at 6 months and 97% (SE
2%) at 12 months. Only 2 participants had a compliance < 85% (84% and 81%)
Duration of intervention: 24 months
Outcomes Main study outcome: change in breast density
Dropouts: 5 intervention, 6 control
Available outcomes: cardiovascular events, breast cancer, lipids, dietary intake, plasma
FAs, adverse events (including one incidence of hyperglycaemia)
Response to contact: yes
Notes The study had 5 arms: group 1, no treatment, control; group 2, raloxifene 60 mg orally
daily; group 3, raloxifene 30 mg orally daily; group 4, Lovaza 4 g orally daily; and group
5, Lovaza 4 g/d plus raloxifene 30 mg orally daily. Data here is combined for groups 4
and 5 vs 1 and 3 for binary outcomes and group 1 vs 4 used for continuous outcomes
Study funding: GlaxoSmith Kline and Eli Lilly provided Lovaza and raloxifene, respec-
tively. Funded by Susan G Komen for the Cure, KG081632 (A Manni) and pilot funds
from the Penn State Hershey Cancer Institute (K El-Bayoumy)
Risk of bias
Bias Authors’ judgement Support for judgement
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Sandhu 2016 (Continued)
Random sequence generation (selection
bias)
Low risk Sandhu 2016 pg 276: “each study partic-
ipant was randomly assigned with equal
probability to one of the following five
groups. A block randomization schemewas
used to ensure balance treatment allocation
during the course of enrolment.”
Allocation concealment (selection bias) Unclear risk No description of concealment of alloca-
tion
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open label
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Open label
Incomplete outcome data (attrition bias)
All outcomes
Low risk < 20% lost over 2 years, detailed reasons
provided, no suggestion these are unbal-
anced
Selective reporting (reporting bias) High risk Biomarkers of oxidative stress (Urinary 8-
(isoprostane) F-2α and 8OHdG, Lympho-
cyte 8-OHdG, DNA etheno adducts), Uri-
nary 2-OHE1, 4-OHE1, and 16α-OHE1,
Serum level of C-reactive protein and IL-6,
Serum level of IGF-I and IGFBP-3, com-
plete blood count mentioned in trial reg-
istry but not reported in Sandhu 2016.
(More outcomes reported than in registry -
diet, physical activity levels, adverse events)
Attention Low risk Participants assessed at baseline, 1-year and
2-year follow-up
Compliance Unclear risk Measured by pill count, recorded at follow-
up visits and further verified by serum fatty
acids monitoring. Compliance was 94%
(SE 2%) at 6 months and 97% (SE 2%)
at 12 months. Only 2 participants had a
compliance < 85% (84% and 81%)
Other bias Low risk None noted
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SCIMO 1999
Methods Study on prevention of Coronary atherosclerosis with Marine Omega 3 fatty acids
(SCIMO)
RCT, parallel (omega 3 vs average European fats), 2 years
Summary risk of bias: low
Participants People with angiographically proven coronary artery disease
N: 112 intervention, 111 control (analysed 82 intervention, 80 control)
Level of risk for CVD: high
Men: 82% intervention, 78.6% control
Mean age in years (SD): 57.8 (9.7) intervention, 58.9 (8.1) control
Age range: unclear (18-75 inclusion criteria)
Smokers: 16.2% intervention, 22.3% control
Hypertension: 53.1% intervention, 45.5% control (history of high blood pressure)
Medications taken by at least 50% of those in the control group: platelet inhibitors, beta-
blockers
Medications taken by 20%-49% of those in the control group: long-term nitrate therapy,
lipid-lowering agents, ACE inhibitors, diuretics, calcium antagonists, other antihyper-
tensive agents and digitalis
Medications taken by some, but less than 20% of the control group: nitrates only on
demand
Location: Germany
Ethnicity: not reported
Interventions Type: supplement (capsule)
Comparison: EPA + DHA vs SFA + MUFA (average European fat composition)
Intervention: concentrated fish oil capsules, 6x 1 g capsules/d for first 3 months, 3 × 1
g/d for rest of study (4 g/d EPA +DHA + DPA + ALA for first 3 months, then 2 g/d).
Dose: ~2 g/d LCn3
Control: capsules containing fat which replicated the fat composition of the average
European diet, 6/d for first 3 months, 3/d for rest of study, opaque soft gelatin capsules
identical to fish capsules in identical screw-top containers
Compliance: capsule count, overall 2284 (SD 313) capsules taken of 2460 prescribed
for each person, erythrocyte phospholipids rose from 4.6% to 11.8% at 24 months in
intervention, and didn’t alter from baseline in controls
Length of intervention: 24 months
Outcomes Main study outcome: changes in stenosis on angiography
Dropouts: unclear
Available outcomes: mortality, MI, CV events, revascularisation, angina, stroke, cancer
diagnosis, weight, lipids, BP, side effects
Response to contact: yes
Notes Asked participants to guess treatment allocation, of those in intervention 63/90 were
unsure, 5/90 guessed placebo and 22/90 guessed fish oil; of those in control 66/85 were
unsure, 9/85 guessed placebo and 10/85 guessed fish oil
Study funding: Pronova provided capsules and funds for study monitoring but it was
stated that the funders played no part in analysis or publication
Risk of bias
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SCIMO 1999 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Stratified, and for the resulting 9 strata “a
random sequence of study group assign-
ments was computer generated by the trial
monitor”
Allocation concealment (selection bias) Low risk Sealed, sequential numbered envelopes
used (opaque not stated, but provided only
a random number which linked to a spe-
cific container of capsules)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Placebo and fish oil capsules “looked iden-
tical and were made of soft opaque gelatin
and each contained 1 g of a fatty acid mix-
ture”. Thesewere provided in identical con-
tainers with identical labels with a ran-
domisation number. Patients were told that
capsules differed in composition but not in
taste
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinding is described and is very strong for
angiographic outcomes, but there is no de-
scription of how cardiovascular events were
assessed or recorded. However outcomes
assessors were probably the same assessors
and so blinded
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Unclear for how many participants clinical
events were assessed (though described in
detail for angiographic outcomes), so trial
flow unclear
Selective reporting (reporting bias) Unclear risk No study trials register entry or protocol
was found
Attention Low risk As study personnel were unaware of assign-
ments bias in attention was not possible
Compliance Low risk Capsule count, overall 2284 (SD 313) cap-
sules taken of 2460 prescribed for each per-
son, erythrocyte phospholipids rose from4.
6% to 11.8% at 24 months in intervention
and didn’t alter from baseline in controls
Other bias Low risk No further bias noted
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Shinto 2014
Methods RCT, parallel (fish oil capsule vs soybean oil capsule), 12 months
Summary risk of bias: moderate to high
Participants Patients aged 55 or more with probable Alzheimer dementia diagnosis
N: 13 intervention, 13 control
Level of risk for CVD: low
Men: 61% intervention 46% control
Mean age in years (SD): 75.9 (8.1) intervention, 75.2 (10.8) control
Age range: 55+ (inclusion criteria)
Smokers: not reported
Hypertension: not reported
Medications taken by at least 50% of those in the control group: anti-cholinesterases or
memantine
Medications taken by 20%-49% of those in the control group: not reported
Medications taken by some, but less than 20% of the control group: not reported
Lipid-lowering medications and many other drugs were not allowed
Location: USA
Ethnicity: 100% white
Interventions Type: fish oil capsules
Comparison: EPA + DHA vs n-6
Intervention: 3 × 1 g capsules/day of fish oils (975 mg EPA, 675 mg DHA per day).
Dose: 1.65 g/d EPA + DHA
Control: 3 × 1 g capsules/day soybean oil (which contains 5% fish oil)
Both groups had a placebo lipoic acid tablet and lemon-flavoured capsules
Compliance: assessed by pill counts and FA in red blood cell membranes. Results showed
increased EPA + DHA levels in the intervention group
Length of intervention: 12 months
Outcomes Main study outcome: F2-isoprostane levels (oxidative stress measure)
Dropouts: 2 intervention, 2 control
Available outcomes: mortality, CVD events, adverse events, serum fatty acids, measures
of cognition (ADAS Cog and MMSE), ADL, IADL (also F2 isoprostane)
Response to contact: not attempted
Notes Study funding: National Institutes of Health/National Institute of Aging (NIH/NIA)
and NIH General Clinical Research
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants were randomised by a com-
puter-generated scheme that was stratified
by smoking status
Allocation concealment (selection bias) Unclear risk No details
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Shinto 2014 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Capsules matched for taste and flavour.
Blinding assessed at the end and majority
of staff and participants were unaware of
treatment
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk As above
Incomplete outcome data (attrition bias)
All outcomes
Low risk 15% dropouts explained and included
Selective reporting (reporting bias) Low risk NCT00090402 first received: 25 August
2004, study start date April 2004. More
secondary outcomes reported than in-
cluded in the trial register entry
Attention Low risk Both arms seem to have had the same con-
tact
Compliance Low risk Compliance measured and FAs levels re-
ported. Results showed increased EPA +
DHA levels in the intervention group
Other bias Low risk None noted
SHOT 1996
Methods SHunt Occlusion Trial (SHOT)
RCT, parallel (omega 3 vs nil), 4 arms, 1 year
Summary risk of bias: moderate or high
Participants People admitted for coronary bypass grafting
N: 317 intervention, 293 control
Level of risk for CVD: high
Men: 86% intervention, 88% control
Mean age in years (SD): 59.9 (8.7) intervention, 59.4 (8.8) control
Age range: unclear
Smokers: 19% intervention, 20% control
Hypertension: 20% intervention, 25% control
Medications taken by at least 50% of those in the control group: not reported
Medications taken by 20%-49% of those in the control group: antihypertensives
Medications taken by some, but less than 20% of the control group: not reported
Location: Norway
Ethnicity: not reported
Interventions Type: supplement (capsule)
Comparison: EPA + DHA vs nil
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SHOT 1996 (Continued)
Intervention: 4 fish-oil concentrate soft gelatin capsules/d (Omacor; Pronova AS, Oslo,
Norway) containing 51% EPA and 32% DHA ethyl esters and 3.7 mg
vitamin E as an antioxidant. Dose: 3.3 g/d EPA + DHA
Control: no treatment
Compliance: capsule count, 88% taken, serum EPA + DHA rose in the intervention
group (176 to 257 mg/L at 9 months) and fell in the control group (170 to 169 mg/L
at 9 months)
Length of intervention: 12 months
Outcomes Main study outcome: CABG graft patency
Dropouts: 15 intervention, 14 control
Available outcomes: deaths, CV deaths, MI, stroke, repeat CABG, combined CV events,
lipids, side effects
Response to contact: yes
Notes The study had 4 arms; aspirin; warfarin; fish oil + aspirin; and warfarin + fish oil. The
first 2 groups are combined as the control and the last two combined as intervention
Dietary assessment suggested total diet plus supplement intakes as follows: 2.7 g/d EPA
+ DHA at baseline, 5.5 g/d at 9 months intervention, 2.5 g/d at baseline, 2.2 g/d at 9
months control group
Study funding: in part by Pronova and Nycomed Pharma
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random numbers were provided in con-
secutively sealed envelopes generated cen-
trally
Allocation concealment (selection bias) Unclear risk Envelopes not reported as opaque
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open trial, no blinding apart from out-
come assessors so participants and study
personnel were aware of assignments.How-
ever, author suggested in personal commu-
nication that participants were not aware
of their assignments
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcome assessors (radiologists) reported
as blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Reasons for attrition and exclusions stated,
numbers clear, dropouts < 20% per year
Selective reporting (reporting bias) Unclear risk No study protocol or trials register entry
was found
200Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
SHOT 1996 (Continued)
Attention Low risk Appeared equivalent between arms
Compliance Low risk Capsule count, 88% taken, serum EPA +
DHA rose in the intervention group (176
to 257 mg/L at 9 months) and fell in
the control group (170 to 169 mg/L at 9
months)
Other bias Low risk No further bias noted
Sianni 2013
Methods RCT, parallel, (fish oil vs placebo), 12 months
Summary risk of bias: moderate or high
Participants Patients with hypertension and paroxysmal or persistent atrial fibrillation (AF)
N: 268 intervention, 60 control
Level of risk for CVD: moderate
Men: not reported
Mean age (SD) years: 62 (6), not reported by arm
Age range: not reported
Smokers: not reported
Hypertension: 100%
Medications taken by at least 50% of those in the control group: not reported
Medications taken by 20%-49% of those in the control group: not reported
Medications taken by some, but less than 20% of the control group: not reported
Location: Greece
Ethnicity: not reported
Interventions Type: supplement
Comparison: fish oil vs unclear placebo
Intervention: omega-3 fatty acids with no further details. Dose: 4 g/d omega
Control: placebo, no further details
Compliance: no details
Duration of intervention: 12 months
Outcomes Main study outcome: AF recurrence and BP
Dropouts: no details
Available outcomes: new AF episodes, BP (not in a usable format)
Response to contact: no
Notes Study funding: unclear
The study’s only publication was a conference abstract.
Risk of bias
Bias Authors’ judgement Support for judgement
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Sianni 2013 (Continued)
Random sequence generation (selection
bias)
Unclear risk No details, probably randomised but un-
clear
Allocation concealment (selection bias) Unclear risk No details
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No details
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No details
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No details
Selective reporting (reporting bias) Unclear risk No protocol or trial register record found
Attention Unclear risk No details
Compliance Unclear risk No details
Other bias Unclear risk No details
SMART 2013
Methods SMART trial (from the Smart Foods Centre)
RCT, 3-arm parallel, (Fish + S: hypocaloric diet plus fish plus fish oil capsules vs Fish:
hypocaloric diet plus fish plus olive oil capsules vs control: hypocaloric diet plus olive oil
capsules), 12 months
Summary risk of bias: moderate or high
Participants Overweight adults
N: fish + S intervention 41, fish 43, control 42. (analysed, fish + S intervention 21, fish
25, control 18)
Level of risk for CVD: low
Men: 27% fish + S intervention, 23% fish intervention, 28% control
Mean age (SD) years: unclear by arm, overall 45.1 (8.4)
Age range: not reported but 18-60 years eligible
Smokers: not reported but 5.9% overall
Hypertension: not reported
Medications taken by at least 50% of those in the control group: not reported
Medications taken by 20%-49% of those in the control group: not reported
Medications taken by some, but less than 20% of the control group: not reported
Location: Australia
Ethnicity: not reported
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Interventions Type: supplement and food
Comparison: EPA + DHA vs MUFA (Fish plus fish oil supplements vs Fish plus olive
oil supplements vs olive oil supplements)
Intervention, Fish + S: hypocaloric diet aiming at 30% E from fat, 25% E from protein,
45% E from CHO, plus 180 g fish/week plus capsules including 420 mg/d EPA + 210
mg/d DHA (Blackmores Promega Heart). Dose: 0.63 g/d EPA + DHA
Intervention, fish: hypocaloric diet aiming at 30% E from fat, 25% E from protein, 45%
E from CHO, plus 180 g fish/week plus capsules including 1 g olive oil/d
Control: hypocaloric diet aiming at 30% E from fat, 25% E from protein, 45% E from
CHO, plus capsules including 1 g olive oil/d
Compliance: assessed through diet histories (fish) and erythrocyte fatty acid supplements
(capsules), but results not reported
Duration of intervention: 12 months
Outcomes Main study outcome: total % body fat
Dropouts: fish + supplement intervention 20, fish intervention 18, control 24
Available outcomes: weight, BMI, lipids, BP, fasting glucose, fasting insulin, % body fat
(leptin also reported), no deaths or cardiovascular events occurred (authors report)
Response to contact: authors provided data on CVD events (none) and mean/SD data
for TGs and fasting insulin
Notes To assess effects of omega 3 fats the best comparison in this study is fish + S vs fish, so
numerical data reflect this comparison
Study funding: Australian National Health andMedical Research Council, fish and olive
oil capsules were provided free by Blackmores Australia
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “A researcher independent of the
subject interface undertook the randomisa-
tion of participants into diet groups (strat-
ified by sex and block randomised...)”
Allocation concealment (selection bias) Low risk Quote: “Randomisation was performed
centrally, off-site and the holder of the al-
location schedule provided the codes to a
single researcher who was independent to
the subject interface. The placebo and ac-
tive ingredient capsules were coded off-site
. The codes were kept from the researchers
collecting dietary data and delivering treat-
ment. Allocation concealment was main-
tained as the persons responsible for screen-
ing eligible participants for inclusion in
the trial was unaware to which supplement
group the subject would be allocated. Dif-
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SMART 2013 (Continued)
ferent dietitians collected the dietary data
and provided dietary advice”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk As above, but impossible to blind partici-
pants to the fish advice
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk As above
Incomplete outcome data (attrition bias)
All outcomes
Low risk Very high levels of attrition, though inten-
tion-to-treat analyses carried out
Selective reporting (reporting bias) High risk We were unable to find data on 24 hour
energy expenditure, oxidation or heart rate
whichwere stated as primary and secondary
outcomes in the trials registry
Attention Unclear risk While dietary education was for 1 hour
then 6 further half hour follow-ups plus
written materials and monthly newslet-
ters plus dietary interviews it is not clear
whether this was in all arms or only some
of them
Compliance High risk Quote: “Of the 12 months completers,
57% were judged to be compliant, 39% (n
= 7) for the control group who reported
< 180 g fish/week, 48% (n = 12) for the
Fish groupwho reported≥180 g fish/week,
and 85% (n = 17) for the Fish + S group
who reported ≥180 g fish/week or ≥90%
supplements”. However, erythrocyte (EPA
+ DHA)/total fatty acids × 100 was sig-
nificantly different for the fish oil supple-
mented group compared to the two others
- but it was onlymeasured in around half of
the participants as the others dropped out,
so presumably were non-compliant
Other bias Low risk None noted
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Methods Study on Omega-3 Fatty Acids and Ventricular Arrhythmia (SOFA)
2 arm, parallel RCT (n-3 EPA + DHA vs MUFA), 12 months
Summary risk of bias: low
Participants People with previous ventricular arrhythmias and implantable cardioverter defibrillators
N: 273 intervention, 273 control (273 intervention, 273 control analysed)
Level of risk for CVD: high
Men: 84% intervention, 85 % control
Mean age in years (SD): 60.5 (12.8) intervention, 62.4 (11.4) control
Age range: unclear (18 years and older)
Smokers: 16% intervention, 8% control
Hypertension: 53% intervention, 49% control
Medications taken by at least 50% of those in the control group: beta-blockers
Medications taken by 20%-49% of those in the control group: lipid lowering, antiarry-
thmic medications (combined)
Medications taken by some, but less than 20% of the control group: amiodarone, sotalol
Location: 8 countries in Europe
Ethnicity: not reported
Interventions Type: supplement (capsule)
Comparison: EPA + DHA vs MUFA + omega 6
Intervention: 2 g/d (4 capsules) purified fish oil. 961 mg n-3 PUFAS (464 mg EPA + 335
mg DHA and 162 mg other n-3 PUFAs) daily. 3000 ppm vitamin E (Loders Croklann,
Wormeveer). Dose: 0.8 g/d EPA + DHA
Control: 2 g/d high-oleic acid sunflower oil. 3000 ppm vitamin E (Loders Croklann,
Wormeveer)
Compliance: daily diary, checked by research nurses every 4 months. Judging by capsule
count, 207 patients in the fish oil group and 218 in the placebo took more than 80%
of their capsules. N-3 fatty acid composition in serum cholesterol levels was measured
at baseline and the end of the trial. The EPA concentration in serum cholesterol esters
increased in the expected range. No data provided
Length of intervention: 12 months
Outcomes Main study outcome: spontaneous ventricular tachyarrhythmias and all-cause mortality
Dropouts: 33 intervention (23 partial follow-up), 33 control (14 partial follow-up)
Available outcomes: deaths, MI, new angina, new heart failure, no fatal arrhythmias,
cancer, cardiovascular events, side effects
Response to contact: yes but no data provided
Notes Study funding: Wageningen Centre for Food Sciences (alliance of major Dutch food
industries and others)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Patients using beta-blockerswere separately
randomised in blocks of 2. A computer ran-
domisation programme randomly took the
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first treatment of a block. The second pa-
tient in a block of 2 always received the op-
posite treatment
Allocation concealment (selection bias) Low risk Treatments (blinded medication numbers)
were centrally assigned by a telephone allo-
cation service
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double blinding. Bottles containing cap-
sules labelled with medication numbers
that are unidentifiable for patients as well
as investigators. Fish oil and placebo cap-
sules have identical appearance. Difference
can’t be tasted if swallowed with water (as
suggested)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “blinded endpoint adjudication
committee”
Incomplete outcome data (attrition bias)
All outcomes
Low risk ITT analysis. Did a partial follow-up on
somepatientswhodroppedout due tonon-
compliance
Selective reporting (reporting bias) Low risk NCT00110838, trial registered in May
2005, end of trial January 2005, trial results
published in 2006. However, rationale and
design paper (stating outcomes) published
in 2003. Outcomes in the 2006 paper ap-
pear to be the same as in Rationale paper
Attention Low risk Unlikely as intervention blinded to inves-
tigators and only intervention was capsules
Compliance Unclear risk Daily diary, checked by research nurses ev-
ery 4 months. Judging by capsule count,
207 patients in the fish oil group and 218
in the placebo took more than 80% of
their capsules. N-3 fatty acid composition
in serum cholesterol levels was measured at
baseline and the end of the trial. The EPA
concentration in serum cholesterol esters
increased in the expected range. No data
provided
Other bias Low risk No further bias noted
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Sofi 2010
Methods 2-arm, parallel RCT (enriched olive oil vs olive oil), 12 months
Summary risk of bias: moderate or high
Participants Non-alcoholic fatty liver disease patients
N: 6 intervention, 5 control
Level of risk for CVD: low
Men: 66.7% intervention, 100% control
Median age: 55 intervention, 54 control
Age range: 30-41 intervention, 42-70 control
Smokers: not reported
Hypertension: not reported
Medications taken by at least 50% of those in the control group: not reported
Medications taken by 20%-49% of those in the control group: not reported
Medications taken by some, but less than 20% of the control group: not reported
Location: Italy
Ethnicity: not reported
Interventions Type: supplement (oil)
Comparison: EPA + DHA vs MUFA
Intervention: 6.5 mL/d olive oil enriched with n-3 (t-Omega 3, tFarma srl, Italy) con-
taining 0.47 g EPA, 0.24 g DHA plus dietary recommendations. Dose: 0.83 g/d EPA +
DHA
Control: 6.5 mL/d olive oil plus dietary recommendations
Compliance: was verified by counting the empty boxes on return but no data reported
Length of intervention: 12 months
Outcomes Main study outcome: fatty liver status
Dropouts: unclear
Available outcomes: lipids, glucose, insulin, HOMA, (BMI not in usable format, also
LFTs, oxidative markers, adiponectin, fatty liver and steatosis outcomes)
Response to contact: not yet attempted
Notes Study funding: oil supplied by tFarma and funding not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “The patients were randomized
into two groups”
Allocation concealment (selection bias) Unclear risk No details
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No details
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Sofi 2010 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No details
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Numbers analysed for liver health are for
those randomised. Numbers analysed for
other outcomes not stated. No mention of
dropouts
Selective reporting (reporting bias) Unclear risk No protocol or trial registration
Attention Low risk Both groups received same contact
Compliance Unclear risk Measured but no results reported
Other bias Low risk None noted
SU.FOL.OM3 2010
Methods Supplementation en Folates et Omega 3 (SU.FOL.OM3)
RCT, 2 × 2 factorial (LCn3 omega 3 vs placebo, also B vitamin comparison), 4 years
Summary risk of bias: low
Participants People with a history of MI, unstable angina or ischemic stroke
N: control: 1248, intervention: 1253
Level of risk for CVD: high
Men: 80.85% intervention, 78.25% control
Mean age in years (SD): 61.1 (8.8) intervention, 60.8 (8.7) control
Age range: 53-68 years intervention, 54-68 years control
Smokers: 11.1% intervention, 10.4% control
Hypertension: not reported
Medications taken by at least 50% of those in the control group: beta-blockers, aspirin
or antiplatelets, lipid lowering, ACE inhibitors
Medications taken by 20%-49%: not reported
Medications taken by some, but < 20%: calcium channel blocker, angiotensin II receptor
blockers
Location: France
Ethnicity: not reported
Interventions Type: supplement (capsule)
Comparison: EPA + DHA vs non fat placebo
Intervention: 2 gelatin capsules Pierre Fabre omega 3 (400 mg/d EPA and 200 mg/d
DHA)
Control: 2 gelatin capsules/d placebo (liquid paraffin with fish flavour)
Compliance: tested by questionnaire, response rate was on average 96%. Out of this,
86% complied
Duration of intervention: 4 years
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SU.FOL.OM3 2010 (Continued)
Outcomes Main study outcome: composite of myocardial infarction, cerebral vascular ischemic
accident or cardiovascular deaths
Dropouts: control: 145 (66 withdrew, 11 lost to follow-up, 68 deaths), intervention:
134 (61 withdrew, 7 lost to follow-up, 66 deaths)
Available outcomes: deaths, cardiovascular death, non fatal MI, stroke, CV events, coro-
nary events, cancer events, Geriatric Depression Scale score, authors provided additional
information on outcomes and methodology
Response to contact: yes (data provided)
Notes The other factorial intervention was B-vitamins (560 µg methyl-terahydrofolate, 3 mg
B-6, 20 µg B12) vs placebo
Study funding: French Ministry of Research, Ministry of Health, Sodexo, Candia,
Unilever, Danone, Roche, Merck
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Used computerized block ran-
domisation with stratification by sex, age,
prior CVD, and city of residence”. “Per-
muted block randomisation (with a block
size randomly selected as 8) was used”
Allocation concealment (selection bias) Low risk Allocation of participants was programmed
by the statistical coordinating centre, who
sent participants sufficient treatment cap-
sules for 1 year in an appropriately labelled
package
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “All subjects and investigators
were blinded to treatment allocation”, and
placebo capsules looked and tasted “identi-
cal to the active supplementation”. Fish oil
flavour was used in placebos
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcome investigators were blinded to al-
location
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attritions and exclusions were well de-
scribed. Only 10% loss over 4 years, well
balanced
Selective reporting (reporting bias) Low risk ISRCTN41926726 registered 2005, 2003
publication on background and rationale,
recruitment started April 2003, 2008 pro-
tocol, recruitment ended June 2009, 2010
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SU.FOL.OM3 2010 (Continued)
results published. Outcomes in registry en-
try appear to have been published
Attention Low risk Not likely as capsules used
Compliance Low risk Quote: “Allocation to omega 3 fatty acids
increased plasma concentrations of omega
3 fatty acids by 37% compared with
placebo” (appears statistically significantly
different, though not explicitly stated) …
“The overall response rate for return of
completed questionnaires was 99%, 96%,
94%, and 95%at 6, 12, and 24months and
at the end of the trial, respectively. About
86% of those who returned a questionnaire
reported that they were compliant with the
study treatment and compliance was simi-
lar in all four groups”
Other bias Low risk No further bias noted
Tande 2016
Methods 2 arm, parallel RCT (calanus (marine) oil vs olive oil), 12 months
Summary risk of bias: moderate to high
Participants Healthy male and female volunteers with BMI 25-35 kg/m2
N: 64 intervention, 63 control (50 intervention, 50 control analysed)
Level of risk for CVD: low
Men: 42% intervention, 43 % control
Mean age in years (SD): 50.7 (7.7) intervention, 49 (9.4) control
Age range: unclear (18 years and older)
Smokers: not reported
Hypertension: not reported
Medications taken by at least 50% of those in the control group: not reported
Medications taken by 20%-49% of those in the control group: not reported
Medications taken by some, but less than 20% of the control group: not reported
Location: Norway
Ethnicity: not reported
Interventions Type: supplement (capsule)
Comparison: EPA + DHA vs MUFA
Intervention: 2 × 500 mg Calanus oil capsules twice daily to provide a daily dose of 2 g.
Supplements were provided by Ayanda AS (Norway) as blister packs of 60 capsules each.
The Calanus oil contained approximately 85% wax ester with a sum of neutral lipids >
90%. Dose: 2 g/d EPA + DHA
Control: identical capsules of olive oil. Compositional analysis indicated that the fatty
acid content of the olive oil was primarily oleic acid (76.9%), palmitic acid (10.2%),
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Tande 2016 (Continued)
and linoleic acid (7.7%)
Compliance: assessed through the return of unused capsules. Compliance rate reported
for both intervention and placebo groups was good (86-88%)
Length of intervention: 12 months
Outcomes Main study outcome: safety of Calanus oil consumption
Dropouts: 14 intervention, 13 control
Available outcomes: BMI, waist-hip ratio, BP, pulse, HbA1c, ESR, CRP, lipids, glucose
tolerance, insulin, clinical chemistry parameters, adverse events (no CVD events, deaths
or other major health outcomes occurred according to author reply)
Response to contact: author replied with methodological and event information
Notes Study funding: Calanus AS
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Randomization of the study sub-
jects into the intervention group or the
placebo group was performed by the Uni-
versity Hospital of North Norway clinical
research unit and was stratified by gender.”
Author reply stated that “[r]andomization
was performed by competent people at the
drugstore affiliated to the University Hos-
pital, with no interconnection, formally or
materially with the research department
from where the study was managed. Ran-
domization was performed prior to recruit-
ing subjects.”
Allocation concealment (selection bias) Unclear risk As above, unclear.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants in the placebo group received
identical capsules at similar daily doses as
the intervention group. However, no infor-
mation provided as to their smell and taste.
Also unclear if investigators were blinded.
Author reply stated “Each study subject
was given a randomization number, which
carried the name of the person, date of
birth and treatment information (interven-
tion or control). The randomization num-
ber was the only information made avail-
able to the study personnel, and the code
was managed by personnel outside the re-
search department. This code was broken
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after the completion of all analysis with all
primary data processed.” Blinding of par-
ticipants only possible for fish plus supple-
mentation vs fish plus placebo
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk As above
Incomplete outcome data (attrition bias)
All outcomes
Low risk All dropouts (~20%) are explained
Selective reporting (reporting bias) Unclear risk No trials registry entry or protocol found
Attention Low risk Appear to be similar in both groups
Compliance Unclear risk Quote: “levels of DHA and EPA in the
blood were generally higher in the Calanus
oil group over baseline values relative to the
placebo controls” but no data provided
Other bias Low risk None noted
THIS DIET 2008
Methods The Heart Institute of Spokane Diet Study (THIS-DIET)
RCT- parallel, 24 months
Summary risk of bias: moderate or high
Participants Recent survivors of first myocardial infarction (within < 6 weeks)
N: 51 intervention, 50 control
Level of CVD risk: high
Men: 80% intervention, 68% control
Mean age in years (SD): 58 (10) intervention, 58 (9) control
Age range: unclear
Smokers: 25% intervention, 30% control
Hypertension: 43% intervention, 50% control (uncontrolled or secondary hypertension
excluded)
Medications taken by at least 50% of those in the control group: aspirin, statins, beta-
blockers, and ACE inhibitors or angiotensin receptor blockers
Medications taken by 20%-49%: not reported
Medications taken by some, but < 20%: not reported
Location: USA
Ethnicity: intervention 98% white; control 94% white
Interventions Type: dietary advice (to follow a Mediterranean style diet high in n-3)
Comparison: EPA + DHA vs MUFA (biggest dietary change)
Intervention: Mediterranean style diet high in n-3. Dietary counselling group sessions;
two in first month then at months 3, 6, 12 and 24. Sessions focused on behaviour
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modification and practical aspects of assigned diet including recipes, shopping and dining
out. Aim to increase omega 3 fat intake to > 0.75% kcal. Dose: ~1.5 g/d omega 3 fat, or
0.31% E by intake assessment
Control: dietary advice (to follow the American Heart Association Step II diet). Same
number of group sessions as intervention
The 2 diets were low in saturated fat (< 7% kcal) and cholesterol (< 200 mg/day); the
Mediterranean-style diet was distinguished by greater omega-3 fat intake (> 0.75% kcal)
Compliance: participants were required to attend six sessions and only invited but not
required to attend extra sessions. 3-day food diaries were reviewed with dietitians. Com-
pliance results not stated
Dietary achievements:
Total fat intake, % E (at 24 months): control 29.7 (SD 9.3), intervention 29.1 (SD 8.6)
Saturated fat intake, % E (at 24 months): control 8.0 (SD 2.9), intervention 7.9 (SD 3.
2)
PUFA intake, % E (at 24 months): control 5.7 (SD 3.1), intervention 5.7 (SD 2.4)
PUFA n-3 intake, % E: control 0.46 (SD 0.38), intervention 0.67 (SD 0.35) g/week
PUFA n-6 intake: not reported
MUFA intake, % E (at 24 months): control 10.3 (SD 5.1), intervention 9.7 (SD 3.6)
CHO intake, % E (at 24 months): control 54 (SD 11), intervention 54 (SD 10)
Protein intake, % E (at 24 months): control 17 (SD 2), intervention 18 (SD 3)
Trans fat intake: not reported
Length of intervention: 24 months
Outcomes Main study outcome: a composite of endpoints including all-cause and cardiac death,
MI, hospital admissions for heart failure, unstable angina, or stroke
Dropouts: none for primary outcomes
Available outcomes: total and CVD deaths (nil deaths), CV events, stroke, MI, diagnosis
of diabetes mellitus, BMI and weight (different at baseline hence not used), waist circum,
lipids, blood pressure, albuminuria, CRP, creatinine and dietary intake (authors supplied
further data on newly diagnosed DM, glucose and insulin data, cancers, depression,
atrial fibrillation)
Response to contact: yes further data supplied as above
Notes The study compared the 2 intervention groups to a non-randomised usual care control
group (not reported here)
Study funding: no funding details is provided but some reported conflict of interests for
an author
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Sealed envelopes concealing the allocation
sequence were prepared by a research co-
ordinator. Assignment was stratified by di-
abetes mellitus status using 10-envelope
blocks. Envelopes were selected in the pre-
pared order from a locked drawer by a study
dietitian to assign interventions
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THIS DIET 2008 (Continued)
Allocation concealment (selection bias) Unclear risk As above but opacity of envelopes is not
stated.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Neither the intervention team nor partic-
ipants could be blinded to dietary assign-
ment
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The PI was blinded for the purpose of ad-
judicating clinical end points and adverse
events by the removal of identifiers from
records used for review
Incomplete outcome data (attrition bias)
All outcomes
Low risk Primary outcomes data provided for all ran-
domised
Selective reporting (reporting bias) High risk NCT00269425. Trial was registered in
2005, data collection started in October
2000, January 2008 (final data collection
date for primary outcome measure), pub-
lication 2008. A number of the outcomes
from the registration were not reported e.
g. cardiovascular revascularisation, periph-
eral revascularisation or amputation, dou-
bling of serum creatinine, dialysis, or kid-
ney transplant, new hypertension. Also nu-
merous secondary measures were reported
that were not in the original registration
Attention Low risk Both arms had the same contact and atten-
tion
Compliance Unclear risk No details
Other bias Low risk None noted
WAHA 2016
Methods The Walnut and Healthy Aging Study (WAHA)
2-arm, parallel RCT (usual diet plus walnuts vs usual diet), 2 years
Summary risk of bias: moderate to high
Participants Middle-aged healthy adults
N: 362 intervention, 346 control (only preliminary data on 312 participants from one
of the two centres is available)
Level of risk for CVD: low
Men: 32.6% intervention, 31.5% control
Mean age in years (SD): 69.4 (3.8) intervention, 68.9 (3.5) control
Age range: 63-79 (inclusion criteria)
Smokers: 4.4% intervention, 1.2% control
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Hypertension: 52.8% intervention, 52.9% control
Medications taken by at least 50% of those in the control group: not reported
Medications taken by 20%-49% of those in the control group: not reported
Medications taken by some, but less than 20% of the control group: not reported
Location: Spain and USA
Ethnicity: not reported
Interventions Type: supplement (food)
Comparison: ALA vs unclear
Intervention: 15% of daily energy intake as walnuts. The estimated amount of walnuts
ranged from about 30-60 g/day (1-2 ounces). Sachets for daily consumption containing
30 g, 45 g, or 60 g of raw, pieced walnuts were provided as 8-week allotments to be
eaten daily, preferably as the raw product, either as a snack or by incorporating them
into shakes, yogurts, cereals, or salads. To improve participants’ compliance, 1-kg extra
walnut allowances were provided every 2 months to take into account family needs.
Dose: ~5 g/d ALA
Control: usual diet without walnut
Compliance: assessed by dietitians through FFQs, recount of empty packages, and
changes in FAs concentrations. 95% consumed at least 30 g/d. The proportion of α-
linolenic acid in red blood cells increased in the walnut group by 0.16% (95% CI 0.14
to 0.18) and in the control group by 0.02% (95% CI −0.01 to 0.04; P < 0.001). No
data on dietary intake provided.
Length of intervention: 2 years (only 1 year results have partly been published)
Outcomes Main study outcome: change in cognitive decline (results not yet published)
Dropouts: 36 intervention, 21 control (after 1 year)
Available outcomes: lipids (for TG andHDLonly data states “no between diet differences
were observed”), weight (waist circumference was provided but without variance, abstract
stated that “there were no significant changes in body fat and waist-to-hip ratio over time
and between the two groups”). Authors provided data on mortality, CVD events, cancer
deaths and diagnoses, IBD diagnosis (no CVD deaths). Cognitive, ophthalmological,
inflammatory markers, glycaemic status and other outcomes are not yet available
Response to contact: authors provided additional outcome and methodology data
Notes Study funding: Calfornia Walnut Commission
The 2-year results as well the full 1-year results are yet to be published. Outcome data
reported are for only for participants from one centre (USA)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “randomized to either the control
or walnut group using a computerized ran-
dom number table with stratification by
center, sex, and age range. Couples enter-
ing the study were treated as one number
and were randomized into the same group”
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Allocation concealment (selection bias) Low risk Author reply states, “Baseline subject data
was collected before randomization. Ran-
domization was done by the clinician,
pressing the key on the computer. Since
this was a dual center (Barcelona and Loma
Linda) trial, a single computer software ran-
domized participants for both the centers.
”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Single blind. “An unavoidable limitation of
the study is not being able to blind partic-
ipants to the intervention since it consists
of a whole food” Rajaram 2017
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Author reply states “Study personnel not in
contact with the subjects were blind to the
treatment assignment. So (lab technicians,
ophthalmology technician, neuro cognitive
testers) were not aware of the treatment as-
signment. Of course clinicians who were
visited by subjects every two months, knew
the treatment assignment”. This suggests
that allocation was known by physicians,
so high risk for event data
Incomplete outcome data (attrition bias)
All outcomes
Low risk 38/362 dropouts in intervention group =
10.5%. 34/346 dropouts in control group
= 9.8%. Similar dropout in groups over 2
years
Selective reporting (reporting bias) Unclear risk Although prospectively registered, no full
results paper published - results from con-
ference abstracts only report some sec-
ondary outcomes
Attention Unclear risk Not enough details
Compliance Low risk ALA levels were significantly higher in the
intervention group
Other bias Low risk None noted
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Weinstock-Guttman 2005
Methods RCT, parallel, (low fat diet (15% fat) with n-3 fish oils vs AHA Step I diet (fat ≤ 30%)
with olive oil supplements), 12 months
Summary risk of bias: moderate or high
Participants Population: adults with multiple sclerosis
N: 15 intervention, 16 control (analysed, intervention: 13, control: 14)
Level of risk for CVD: low
Men: 15.4% intervention, 14.3% control
Mean age in years (SD): 39.9 (10.0) intervention, 45.1 (7.7) control
Age range: not reported
Smokers: not reported
Hypertension: not reported
Medications taken by at least 50% of those in the control group: all patients received
400 units of vitamin E, one multivitamin tablet (not containing any PUFA) and at least
500 mg calcium per day
Medications taken by 20%-49% of those in the control group: not reported
Medications taken by some, but less than 20% of the control group: not reported
Location: USA
Ethnicity: not reported
Interventions Type: dietary advice plus supplement
Comparison: EPA + DHA vs MUFA (low fat diet (15% fat) with n-3 fish oils vs AHA
Step I diet (fat ≤ 30%) with olive oil supplements)
Intervention: 1.98 g/d EPA, 1.32 g/d DHA supplements (EPAX 5500 EE, Tishcon
Corp) + low fat diet (< 15% total calories). Dose: 3.3 g/d EPA + DHA
Control: one 1 g olive oil placebo capsules 6 times daily, moderate fat diet (< 30% total
calories) (American Heart Association Step 1 diet)
Compliance: assessed by individual food records; intervention 69.2% control 66.7%
compliance; also at 12 months there was a significant difference between the fatty acid
status of the intervention and control groups in terms of EPA (P = 0.027), as described
in table 3 of the main paper
Duration of intervention: 12 months
Outcomes Main study outcome: physical component scale (PCS)
Dropouts: 3 intervention, 7 control
Available outcomes: Mental Health Inventory, Modified Fatigue Impact Scale, weight
change, HDL and LDL cholesterol, adverse events (MS relapse, TNF-alpha, ICAM-1,
VCAM-1 and other inflammatory markers, SF-36 not used)
Response to contact: no
Notes Study funding: National Multiple Sclerosis Society (PP0620T), Mellen Center Founda-
tion and ”The Jog for the Jake” grant
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk States “randomly assigned”, no further de-
tails
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Weinstock-Guttman 2005 (Continued)
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “Patients knew the percentage of
dietary fat but did not know the assignment
of capsules oil supplementation.”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
High risk Discrepancy in numbers of participants
discontinued and numbers analysed. Per
protocol analysis
Selective reporting (reporting bias) Unclear risk No protocol or trials register entry found
Attention Low risk Treated equally
Compliance Low risk Assessed by individual food records; inter-
vention 69.2% control 66.7% compliance.
At 12 months there was a significant differ-
ence between the EPA status of the inter-
vention and control groups (P = 0.027)
Other bias Low risk None noted
WELCOME 2015
Methods Wessex Evaluation of Fatty Liver and Cardiovascular Markers in NAFLD with Omacor
Therapy (WELCOME)
RCT, parallel, (Omacor or placebo), 15-18 months
Summary risk of bias: low
Participants Patients with NAFLD
N: 51 intervention, 52 control (analysed, 47 intervention, 48 control)
Level of risk for CVD: moderate
Men: 49% intervention, 67% control
Mean age in years (SD): 48.6 (11.1) intervention, 54 (9.6) control
Age range: not reported (18-75 years inclusion criteria)
Smokers: 14.3% intervention, 11.8% control
Hypertension: not reported
Medications taken by at least 50% of those in the control group: lipid lowering drugs
Medications taken by 20%-49% of those in the control group: antihypertensives, met-
formin (data not provided by group)
Medications taken by some, but less than 20% of the control group: none reported
Location: UK
Ethnicity: not reported
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Interventions Type: supplement (Omacor capsules)
Comparison: DHA + EPA vs MUFA
Intervention: 4 gOMACOR per day (providing 1.84 g EPA, 1.52 g DHA as ethyl esters)
]. Dose: 3.36 g/d EPA + DHA
Control: 4 g olive oil capsules/ day (providing; ALA1%, oleic acid 67%, palmitic acid
15%, stearic acid 2%, n-6 fat: 15%)
Compliance: was assessed by recording the returned unused capsules and quantification
of erthrocyte EPA + DHA enrichment (a prespecified threshold of 2% for DHA &
threshold of 0.7% for EPA enrichment)
Duration of intervention: 15-18 months
Outcomes Main study outcome: changes in mean liver fat %, changes in 2 liver fibrosis scores,
change in serum biomarkers
Dropouts: 4 intervention, 4 control
Available outcomes: weight, BMI, lipids, blood pressure, glucose, insulin sensitivity, body
fat measures, liver enzymes, HbA1c, serum n-3 FAs, authors provided details of diabetes
diagnoses, % body fat, BP and carotid intima media thickness
Response to contact: yes
Notes Study funding:National Institute forHealthResearch (NIHR) SouthamptonBiomedical
Research Unit grant and by a Diabetes UK allied health research training fellowship
awarded to KGM (Diabetes UK. BDA 09/ 0003937). CDB, PCC and ES are supported
in part by the NIHR Southampton Biomedical Research Centre. Omacor and placebo
were provided by Pronova Biopharma through Abbott Laboratories, Southampton, UK
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants were block randomised by an
independent clinical trials pharmacist to
treatment with identical capsules bymouth
of either n-3 fatty acid ethyl esters (4 g/d
Omacor; Pronova, Sandefjord, Norway) or
placebo (4 g/d olive oil) for a minimum of
15 months and a maximum of 18 months
(McCormick-2015, p2)
Patients were randomised according to
standardised procedures (computerised
block randomisation) by a research phar-
macist at University Hospital Southamp-
ton NHS Foundation Trust. Simple ran-
domisation in blocks of 4, either to trial
medication or placebo was used. (Scorletti-
2014, p 2)
Allocation concealment (selection bias) Low risk Participants were block randomised by an
independent clinical trials pharmacist to
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treatment with identical capsules bymouth
of either n-3 fatty acid ethyl esters (4 g/d
Omacor; Pronova, Sandefjord, Norway) or
placebo (4 g/d olive oil) for a minimum of
15 months and a maximum of 18 months
(McCormick-2015, p2). Only the clinical
trials pharmacist was unblinded, and ran-
domisation group allocation was concealed
from all study members throughout the
trial. (McCormick-2015, p 2)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Paper states that only the clinical trials
pharmacist was unblinded, and randomi-
sation group allocation was concealed from
all study members throughout the trial.
However, the trial register record states
“single blind (investigator)”. Although the
capsules were identical, no information
provided as to their smell and taste
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk As above
Incomplete outcome data (attrition bias)
All outcomes
Low risk The ITT analysis included all patients ran-
domised who had complete data (base-
line and end-of-study measurements), re-
gardless of whether they were later found
to be ineligible, a protocol violator, given
the wrong treatment allocation, or never
treated) (Scorletti 2014, p 4)
Selective reporting (reporting bias) Unclear risk Prospectively registered September 2008,
study start September 2009, end February
2017. Outcome data for cardiac function
not yet published, though other cardiovas-
cular measures reported - take as ongoing
as recent end date
Attention Low risk Both groups had the same attention
Compliance Low risk Assessed by recording the returned un-
used capsules and quantification of erthro-
cyte EPA + DHA enrichment (a prespeci-
fied threshold of 2% for DHA and thresh-
old of 0.7% for EPA enrichment). Quote:
“Enrichment was highly variable in the
DHA+EPA group and 5 and 6 participants
in the DHA+EPA group did not reach the
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WELCOME 2015 (Continued)
prespecified threshold for EPA and DHA
enrichment, respectively. In the placebo
group, we expected no enrichment between
baseline and end of study in all partici-
pants in this group, but 3 and 4 partic-
ipants reached the thresholds set for the
DHA+EPA group, for EPA and DHA, re-
spectively. One participant in the placebo
group admitted to taking cod liver oil dur-
ing the study and another markedly in-
creased consumptionof fish.” 10of 95non-
compliant
Other bias Low risk None noted
Zhang 2017
Methods RCT, parallel, (n-3 DHA vs n-6 LA), 12 months
Summary risk of bias: moderate to high
Participants Otherwise healthy elderly people with mild cognitive impairment
N: 120 intervention, 120 control (analysed, intervention: 110 control: 109)
Level of risk for CVD: low
Men: 35.8% intervention, 34.2% control
Mean age in years (SD): 74.5 (2.65) intervention, 74.6 (3.31) control
Age range: eligibility criteria were age 65-85 years at trial start
Smokers: 59.17% intervention, 61.67% control
Hypertension: 9.17% intervention, 7.50% control
Medications taken by at least 50% of those in the control group: not reported
Medications taken by 20%-49% of those in the control group: not reported
Medications taken by some, but less than 20% of the control group: not reported
Location: China
Ethnicity: assumed Chinese
Interventions Type: supplement (capsule)
Comparison: DHA vs corn oil (n-6)
Intervention: 1 capsule twice a day, with meals, including 2 g algal DHA (45-55% DHA
by weight). Martek Biosciences, Columbia, MD. Dose: ~1 g/d DHA
Control: corn oil, orange-flavoured and orange colour to protect the study blind
Compliance: participants were asked to return any remaining tablets. Compliance was
defined as a ratio (actually taken/should have taken). Achieved 97% for intervention,
95% for control. Serum levels of DHA also measured, DHA at 6 months barely higher
in intervention than in controls
Duration of intervention: 12 months
Outcomes Main study outcome: cognitive function and hippocampal volume
Dropouts: 10 intervention, 11 control
Available outcomes: mortality, cognitive outcomes and cerebral volume measurements
Response to contact: no reply to date
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Zhang 2017 (Continued)
Notes Study funding: Chinese Nutrition Society (CNS)Nutrition Research Foundation- DSM
Research Fund
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated, also statistics analyst
ignorant to this study used randomnumber
table
Allocation concealment (selection bias) Unclear risk Insufficient information
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Placebo capsules … identical in appear-
ance. All capsules were orange-flavoured
and orange colour to protect the study
blind . Packaged into identical pots, each
containing 180 capsules, and labelled by
staff who were not involved in the study.
A blinding key linked each participant to
his or her assigned treatment. This key was
kept by an investigator not involved in any
data collection or analyses, in a secure elec-
tronic file. The code was revealed at the
completion of the trial following analyses
of the main study aims
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk All project staff were unaware of group as-
signments until the completion of the trial
and after data analysis
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk They did not describe how they imputed
missingdata (lost contactwith patients, but
called this an ITT analysis). Overall well
matched and not high attrition
Selective reporting (reporting bias) Low risk Registered trial prospectively. Outcomes
match protocol
Attention Low risk “Adherencewas encouraged andmonitored
throughout the trial by telephone assess-
ment at 15 time points, and by blood assay
at baseline” 6 months and 12 months. This
and assessments were described as same for
both arms
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Zhang 2017 (Continued)
Compliance Unclear risk Quote: “participants were requested to re-
turn any remaining tablets in order to
measure compliance, together with the re-
plenishment of capsules for the following
month.” Compliance … defined “as a ra-
tio = actually taken/should have taken”.
“Adherencewas encouraged andmonitored
throughout the trial by telephone assess-
ment at 15 time points, and by blood assay
at baseline” 6 months and 12 months
On compliance tree, leads to “No, because
no P values were supplied” therefore risk of
compliance bias unclear
Other bias Unclear risk Although the register says single blind, the
publication very clearly describes a double-
blind RCT
Özaydin 2011
Methods RCT, parallel, (n-3 fish oil + amiodarone vs amiodarone), 12 months
Summary risk of bias: moderate or high
Participants Patients with persistent atrial fibrillation (AF) referred to cardioversion
N: 23 intervention, 24 control
Level of risk for CVD: high
Men: 47.8% intervention, 37.5% control
Mean age in years (SD): 62 (12) intervention, 61 (11) control
Age range: 37-81
Smokers: not reported
Hypertension: 56.5% intervention, 50% control
Medications taken by at least 50% of those in the control group: all patients received
amiodarone (an antiarrhythmic medication)
Medications taken by 20%-49% of those in the control group: beta-blockers, statins,
ACE inhibitors and ARBs
Medications taken by some, but less than 20% of the control group: calcium antagonists
Location: Turkey
Ethnicity: not reported
Interventions Type: supplement (capsule)
Comparison: LCn3 vs nil
Intervention: 2 g/d n-3 PUFA (Marincap, Kocak, Turkey). 4 × 500mg capsules providing
EPA 18% (360 mg/d); DHA 12% (240 mg/d). Dose: 0.6 g/d EPA + DHA
Control: no placebo. Amiodarone was given to both groups.
Compliance: no details
Duration of intervention: 12 months or AF recurrence
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Özaydin 2011 (Continued)
Outcomes Main study outcome: AF recurrence(endpoint)
Dropouts: no details
Available outcomes: all cause mortality (nil death), stroke, TIA, AF recurrence (hyper-
thyroidism diagnosis, hospitalisation)
Response to contact: not yet attempted
Notes Study funding: unclear
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No details
Allocation concealment (selection bias) Unclear risk Quote: “randomised”; no further details
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No placebo
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No details
Incomplete outcome data (attrition bias)
All outcomes
Low risk All were accounted for
Selective reporting (reporting bias) Unclear risk No trial registry entry or protocol found
Attention Low risk Both groups seem to have the same care
Compliance Unclear risk No information
Other bias Low risk None noted
ACE: angiotensin-converting enzyme; ADAS: Alzheimer’s Disease Assessment Scale; ADL: activities of daily living; AF: atrial fibrilla-
tion; AHA: American Heart Association; BMI: body mass index; ALT: alanine transaminase; ARB: angiotensin-receptor blocker;
BMD: bone mineral density; BMI: body mass index; BP: blood pressure; CABG: coronary artery bypass grafting; CDAI: Clinical
Disease Activity Index; CHD: coronary heart disease; CHO: carbohydrate; CV: cardiovascular;CRP: C-reactive protein; CVD:
cardiovascular disease; DAS: Disease Activity Score; DBP: diastolic blood pressure; DHA: docosahexaenoic acid; DM: diabetes
mellitus; DMARD: disease-modifying antirheumatic drugs; DPA: docosapentaenoic acid; E: dietary energy; ECG: electrocardio-
gram; EDSS: Expanded Disability Status Scale; EPA: eicosapentaenoic acid; ESR: erythrocyte sedimentation rate; FA: fatty acid;
FFQ: food frequency questionnaire; FH: family history; FMD: flow-mediated dilation;GFR: glomular filtration rate;GLA: gamma
linolenic acid; HbA1c: glycated haemoglobin; HCQ: hydroxychloroquine; HDL: high-density lipoprotein; H/O: personal history
of; HOMA-IR: homeostatic model assessment of insulin resistance; HRT: hormone replacement therapy;HT: hypertension; IBD:
inflammatory bowel disease; IADL: instrumental activities of daily living; ICAM-1: intercellular adhesion molecule 1; IL: inter-
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leukin;IMT: immune-mediated thrombocytopenia; IQR: interquartile range; LCn3: long-chain omega-3 fatty acids; LDL: low-
density lipoprotein;MD: mean difference;MDA: malondialdehyde;MI: myocardial infarction;MMSE: Mini-Mental State Exam-
ination; MS: multiple sclerosis; MUFA: mono-unsaturated fatty acids; MXT: methotrexate;n-3: omega-3; NASH: non-alcoholic
steatohepatitis; NSAID: non-steroidal anti-inflammatory drug; PAI1: plasminogen activator inhibitor-1; PI: principal investigator;
PUFA: poly-unsaturated fatty acids; PTCA: percutaneous transluminal coronary angioplasty; P/S: poly-unsaturated/saturated fat
ratio; QoL: quality of life; QUICKI: quantitative insulin sensitivity check index; RA: rheumatoid arthritis; RCT: randomised
controlled trial; SBP: systolic blood pressure; SD: standard deviation;SE: standard error; RCT: randomised controlled trial; SFA:
saturated fatty acids; SSZ: sulfasalazine; TAG: triacylglycerol;TG: serum triglycerides;TIA: transient ischaemic attack;TNF: tumour
necrosis factor; VCAM-1: vascular cell adhesion molecule 1;WHO: World Health Organization.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Alekseeva 2000 Study not randomised
Baleztena 2015 No relevant outcomes measured
Belch 1988 No relevant outcomes measured
Belluzzi 1996 Authors confirmed no relevant outcomes measured
Berthoux 1992 Participants not adult humans, or participants unwell at baseline
Borchgrevink 1966 Mean duration of intervention 10 months (range 3 to 16 months)
Busnach 1998 Participants not adult humans, or participants unwell at baseline
CANN 2015 Intervention is multifactorial (FA/flavanoid blend)
Cappelli 1997 Participants not adult humans, or participants unwell at baseline
CARES 2015 Multisupplement intervention
Cheng 1990a No appropriate control group
Cheng 1990b No appropriate control group
Clark 1993 No relevant outcomes measured
Clark 1994 Participants not adult humans, or participants unwell at baseline
Clark 2001 Participants not adult humans, or participants unwell at baseline
Clausen 1989 Multifactorial intervention (cannot separate effects of omega-3 fats from those of other dietary, be-
havioural or drug interventions)
Diskin 1990 No omega-3 supplementation or dietary advice
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(Continued)
Donadio 1994 Participants not adult humans, or participants unwell at baseline
Doyle 2001 Multifactorial intervention (cannot separate effects of omega-3 fats from those of other dietary, be-
havioural or drug interventions)
Dry 1991 No relevant outcomes measured
Ezaki 1999 Study not randomised
Feher 2005 Intervention is multifactorial (omega 3 given with coenzyme Q and other compounds vs placebo)
FISH 2012 No clinical outcomes collected (confirmed by corresponding author, 30 November 2016)
Fonolla 2009 Intervention wasmilk enrichedwith EPA andDHA but also other vitamins andminerals -multifactorial
dietary intervention
Fonolla-Joya 2016 Intervention wasmilk enrichedwith EPA andDHA but also other vitamins andminerals -multifactorial
dietary intervention
Franzen 1989 Study not randomised
Galarraga 2008 9-month intervention period
Gapparova 2000 Study not randomised
Gazso 1992 No omega-3 supplementation or dietary advice
Geusens 1994 No relevant outcomes measured
Gogos 1998 Participants not adult humans, or participants unwell at baseline
Greatrex 2000 Study not randomised
Griffin 1999 Study not randomised
Hamazaki 1984 Participants not adult humans, or participants unwell at baseline
Hansen 1996 Multi-factorial intervention (cannot separate effects of omega-3 fats from those of other dietary, be-
havioural or drug interventions)
Harris 1991 No appropriate control group
Hashimoto 2012 No relevant outcomes measured
Hashimoto 2016 No relevant outcomes measured
Hawthorne 1992 Authors confirmed no relevant outcomes measured
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HEARTS 2015 Intervention included intensive behavioural changes including exercise and nutrition counselling geared
towards weight loss
Hogg 1995 Participants not adult humans, or participants unwell at baseline
HOPE epilepsy 2012 Trial recruitment was suspended due to lack of funding
Huang 1996 No relevant outcomes measured
Huang 2008 Intervention was 9 months and no relevant outcomes
ISRCTN38354847 The proposed one-year study was never conducted
Junker 1990 Follow-up not at least a year
Kachorovskii 1977 No omega-3 supplementation or dietary advice
Kanorskii 2007 LCn3 compared to sotalol (group 1), sotalol & perindopril (group 2), sotalol, perindopril & rosuvastatin
(group 3), so no useful control group
Karlsson 1998 Multifactorial intervention (cannot separate effects of omega-3 fats from those of other dietary, be-
havioural or drug interventions)
Kaul 1992 Intervention duration 6 months
Khan 2003 Intervention was 8 months
Konya 2000 Study not randomised
Kremer 1995 < 1 year duration
Kruger 1998 No relevant outcomes measured
Kurabayashi 2000 < 1 year duration
Lau 1993 Authors confirmed no relevant outcomes
Leaf 1995 Study not randomised
Lee 2010 Authors confirmed no relevant outcomes measured
Leng 1998 Multifactorial intervention (cannot separate effects of omega-3 fats from those of other dietary, be-
havioural or drug interventions)
LipiDiDiet 2016 Multifactorial dietary intervention that included omega 3 fats but many other nutrition components
Loeschke 1996 No relevant outcomes measured
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LUTEGA 2013 Multisupplement intervention
Lyon Diet Heart 1994 Multifactorial intervention (cannot separate effects of omega-3 fats from those of other dietary inter-
ventions)
Maachi 1995 Participants not adult humans, or participants unwell at baseline
Macsai 2008 No relevant outcomes measured
Mansel 1990 Not an omega-3 intervention
Mantzaris 1996 No relevant outcomes measured
Mate-Jimenez 1991 Authors confirmed no relevant outcomes
Matsuyama 2005 Publication retracted (fraudulent)
Middleton 2002 Unbalanced intervention as the intervention arm contains additional GLA
MoodFOOD 2016 Multisupplement intervention
NAYAB 2017 No planned relevant outcomes. Follow-up < 12 months
NCT01235533 48 weeks intervention planned in trials register entry
NU-AGE 2014 Multifactorial dietary intervention
NutriMEMO 2014 Mutlisupplement intervention
OFAMS 2012 No relevant outcomes measured
Okuda 1996 No appropriate control group
OLIVE 1998 Study was not funded and did not achieve full recruitment (info provided by co-author)
Oslo DIET HEART 1970 Multifactorial intervention (cannot separate effects of omega-3 fats from those of other dietary, be-
havioural or drug interventions)
Pogozheva 1997 Study not randomised
Pogozheva 2000 Study not randomised
Puri 2008 Authors confirmed no relevant outcomes
Quazi 1994 Study not randomised, < 1 year intervention
Sacks 1994 < 1 year intervention
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Saynor 1988 Study not randomised
Saynor 1992 No appropriate control group
Selvais 1995 Intervention was < 1 year
Shimizu 1995 Authors confirmed no relevant outcomes
Singh 1992 Expressions of concern issued by the BMJ and The Lancet regarding research by this first author (BMJ
2005; Horton 2005)
Singh 1997a Expressions of concern issued by theBMJ and The Lancet regarding research by this first author (BMJ
2005; Horton 2005)
Singh 1997b Expressions of concern issued by the BMJ and The Lancet regarding research by this first author (BMJ
2005; Horton 2005)
Singh 2002 Expressions of concern issued by the BMJ and The Lancet regarding research by this first author (BMJ
2005; Horton 2005)
Tariq 1989 Participants not adult humans, or participants unwell at baseline and intervention is < 1 year
Terano 1999 Authors confirmed no relevant outcomes during trial
Tomer 2001 No relevant outcomes. Measured lipids but unclear baseline and endpoint is probably 4 weeks
Torjesen 1997 Multifactorial intervention (cannot separate effects of omega-3 fats from those of other dietary, be-
havioural or drug interventions)
VSDR 2015 The supplement (Nutrof Omega) contained DHA, Vit C, E, B1, B2, B3, B6, B9, B12, Zn, Mn, Se,
Cu, lutein and zeaxanthin (multifactorial dietary intervention)
Wheaton 2010 Participants were not a minimum of 18 years old
Yasui 2001 No appropriate control group
Zinger 1987 Study not randomised
DHA: docosahexaenoic acid; EPA: eicosapentaenoic acid; FA: fatty acid; GLA: gamma linolenic acid.
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Characteristics of ongoing studies [ordered by study ID]
AC Omega3 2014
Trial name or title Aboriginal Cardiovascular Omega-3 randomised controlled trial (AC Omega3)
Methods RCT
Participants Indigenous Australian adults with stable coronary artery disease
Interventions Each for 12 months:
Arm 1: omega-3 (1800 mg/d AlaskOmega: 3 capsules/d: 400 mg EPA and 200 mg DHA)
Arm 2: placebo mixed oil capsules (1000 mg/d: 3 capsules/d containing palm oil, gelatin, glycerol, sunflower
oil, rapeseed oil, mixed tocopherols, and a “small amount” of fish oil (for taste to aid blinding)
Outcomes Primary: serum non-HDL-C
Secondary: triglycerides, total cholesterol, LDLcholesterol,HDLcholesterol, lipid functionality by cholesterol
efflux and CETP, heart rate variability, platelet function and thrombosis markers, inflammation markers,
cumulative combined rate of major adverse cardiac events (including death, non-fatal MI, unstable angina,
non-fatal stroke, revascularisation and cardiac related hospital admissions)
Starting date Registered on trials registry: 10 July 2014
Study start date: 1 October 2014
Estimated study completion date: unclear
Contact information Alex Brown (PI), Wardliparingga Aboriginal Unit, Adelaide, Australia, alex.brown@sahmri.com
Notes ACTRN12614000732684
Alex Brown contacted in 2016: confirmed study is actively recruiting
AFORRD 2010
Trial name or title Atorvastatin in Factorial with Omega-3 fatty acid Risk Reduction in Diabetes (AFORRD)
Methods RCT
Participants Patients with type 2 diabetes with no known CVD and not taking lipid-lowering therapy, adults (> 18 years)
N: intervention 397, control 403 (analysed intervention 371, control 361)
Interventions Each for 12 months:
Arm 1: atorvastatin (Lipitor 20 mg/d) and olive oil placebo (2 g/d)
Arm 2: omega-3 (Omacor 2 g/d: 46% EPA, 38% DHA) and placebo tablets for atorvastatin
Arm 3: atorvastatin (Lipitor 20 mg/d) and Omega-3 (Omacor 2 g/d: 46% EPA, 38% DHA)
Arm 4: placebo tablets for atorvastatin and olive oil placebo (2 g/d)
Outcomes Primary: lipid profiles
Secondary: phytosterol changes, HbA1c, estimated CVD risk using the UK Prospective Diabetes Study risk
engine
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AFORRD 2010 (Continued)
Starting date Registered on trials registry: 4 April 2004
Study start date: 1 November 2004
Estimated study completion date: 31 July 2006
Contact information Rury Holman, Oxford Centre for Diabetes
Notes ISRCTN76737502
Rury Holman contacted in 2016: confirmed results are not yet published, but planned
ASCEND 2012
Trial name or title A Study of Cardiovascular Events iN Diabetes (ASCEND)
Methods RCT
Participants Patients with diabetes, without vascular disease
Interventions Each for 7 years:
Arm 1: omega-3 (1 g/d: 0.41 g EPA, 0.34 g DHA) and placebo tablets for aspirin
Arm 2: aspirin (100 mg/d) and olive oil placebo capsule
Arm 3: omega-3 (1 g/d) and aspirin (100 mg/d)
Arm 4: olive oil placebo and placebo tablets for aspirin
Outcomes Primary: cardiovascular events
Secondary: mortality, hospitalisations, cancer
Starting date Registered on trials registry: 24 August 2005
Study start date: March 2005
Estimated study completion date: September 2017
Contact information Jane Armitage (PI), University of Oxford Clinical Trial Service Unit
Notes NCT00135226
Trial website: ascend.medsci.ox.ac.uk; rum.ctsu.ox.ac.uk/ascend
Bartold 2010
Trial name or title Clinical efficacy of fish oil as adjunct therapy for patients with chronic periodontitis
Methods RCT
Participants Patients (25-80 years, non-smokers) with newly diagnosed severe but non-aggressive periodontitis
Interventions Each for 13 months:
Arm 1: fish oil rich in EPA (6 × 500 mg capsules/d: 277 mg EPA; 27 mg DHA) and standard periodontal
treatment (scaling and debridement)
Arm 2: fish oil rich in DHA (6 × 500 mg capsules/d: 66 mg EPA; 258 mg DHA) and standard periodontal
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Bartold 2010 (Continued)
treatment
Arm 3: soya oil placebo (6 × 500 mg capsules/d) and standard periodontal treatment
Outcomes Primary: probing pocket depth, clinical attachment level (CAL)
Secondary: inflammatory biomarkers in gingival crevicular fluid, erythrocyte omega-3, C-reactive protein
Starting date Registered on trials registry: 23 July 2010
Study start date: July 2010
Estimated study completion date: unclear
Contact information Mark Bartold, University of Adelaide, mark.bartold@adelaide.edu.au
Notes ACTRN12610000594022
PhD, Boram Park, available giving 4 month outcome data for pilot study N = 33 participants
Mark Bartold written to in 2016. Confirmed preparing full publications for submission
Beyond Aging Project 2015
Trial name or title Beyond Ageing Project phase 2: a selective prevention trial using novel pharmacotherapies in an older age
cohort at risk for depression
Methods RCT
Participants Older adults (60+ years) at risk of depression (K-10 score ranging from 16-29) who initially participated in
the first Beyond Ageing Project
Interventions Each for 12 months:
Arm 1: omega-3 (4 capsules, total 2 g/d: 1200 mg EPA and 800 mg DHA) and placebo microcrystalline
cellulose (1 capsule)
Arm 2: paraffin oil placebo (4 capsules) and sertraline hydrochloride (1 capsule, 50 mg)
Arm 3: paraffin oil placebo (4 capsules) and placebo microcrystalline cellulose (1 capsule)
Outcomes Primary: depressive symptoms (PHQ-9, patient health questionnaire 9)
Secondary: cognitive decline, MMSE, brain metabolism, hippocampal volume, anxiety (assessed using GAD-
7), disability (WHODAS-II), sleeping problems (PSQI, Pittsburgh Sleep Quality Index), exercise (Active
Australian Survey)
Starting date Registered on trials registry: 12 January 2010
Study start date: June 2011
Estimated study completion date: main results expected in 2017
Contact information Ian Hickie (PI), Brain and Mind Centre, University of Sydney, ian.hickie@sydney.adu.au
Notes ACTRN12610000032055
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Chandrakala 2010
Trial name or title Long-term effects of a reduced fat diet intervention in pre-diabetes
Methods RCT
Participants Participants with pre-diabetes, impaired fasting glucose (IFG) or impaired glucose tolerance (IGT), 201
participants discussed in one abstract, 134 in a later abstract
Interventions Each for 3 years:
Arm 1: reduced fat diet (fat content at or below 20% total energy, ratio of PUFA/SFA 0.8 to 1.0)
Arm 2: normal/control diet
Outcomes Incidence of diabetes, BMI, lipids, insulin, plasma glucose, HbA1c, blood pressure, nutritional intake
Starting date Registered on trials registry: no registration found
Study start date: not stated
Estimated study completion date: not stated
Contact information Chandrakala Galla, chandrakala.galla@gmail.com; Arpana Gaddam, dr.arpanag@gmail.com
Notes Authors written to in 2016: Dr Gaddam confirmed work submitted as a PhD but not published in full.
Requested copy of PhD thesis, but no reply to date
Funding: DiabetOmics India
ChiCTR-TRC-12002014
Trial name or title Influence of different sources of n-3 fatty acid on plasma lipid in moderately hypercholesterolaemic subjects
Methods RCT
Participants Adults (40-65 years) with mild to moderate hypercholesterolaemia
Interventions Arm 1: EPA/DHA 1.8 g/d
Arm 2: EPA/DHA 3.6 g/d
Arm 3: ALA 4 g/d
Arm 4: placebo
Outcomes Fatty acids, lipids, cytokines (IL-6, IL-1a)
Starting date Registered on trials registry: 13 March 2012
Study start date: unclear
Estimated study completion date: unclear
Contact information Su Yixiang, Sun-Yat Sen University, China, suyx@mail.sysu.edu.cn; Zhou Quan, Guangzhou Medical Uni-
versity, joan zq@126.com
Notes ChiCTR-TRC−12002014
Su Yixiang and Zhou Quan contacted in 2016: no response
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DO HEALTH
Trial name or title Vitamin D3- omega3- home exercise- healthy ageing and longevity trial (DO-HEALTH)
Methods RCT
Participants Community dwelling adults 70 years and older, 50% of seniors enrolled based on a fall in the year before
enrolment
Interventions Each for 3 years:
Arm 1: omega-3 (1 g/d, ratio EPA:DHA = 1:2) and vitamin D3 (2000 IU/d) capsules and strength home
exercise (3 × 30 min/week)
Arm 2: omega-3 (1 g/d, ratio EPA:DHA = 1:2) and vitamin D3 (2000 IU/d) capsules and flexibility home
exercise (3 × 30 min/week)
Arm 3: omega-3 (1 g/d, ratio EPA:DHA = 1:2) and placebo capsules and strength home exercise (3 × 30 min/
week)
Arm 4: omega-3 (1 g/d, ratio EPA:DHA = 1:2) and placebo capsules and flexibility home exercise (3 × 30
min/week)
Arm 5: placebo and vitamin D3 (2000 IU/d) capsules and strength home exercise (3 × 30 min/week)
Arm 6: placebo and vitamin D3 (2000 IU/d) capsules and flexibility home exercise (3 × 30 min/week)
Arm 7: placebo and placebo capsules and strength home exercise (3 × 30 min/week)
Arm 8: placebo and placebo capsules and flexibility home exercise (3 × 30 min/week)
Outcomes Primary: non-vertebral fractures, functional decline, blood pressure, cognitive decline, rate of any infection
Secondary: other fractures, falls, pain in knee osteoarthritis, musculoskeletal changes, gastro-intestinal symp-
toms, mental and oral health, quality of life, life-expectancy, cardiovascular events, cancer, glucose measures,
cost-benefit. All endpoints supported by a DO-HEALTH biomarker study
Starting date Registered on trials registry: 6 December 2012
Study start date: December 2012
Estimated study completion date: November 2017
Contact information Heike Bischoff-Ferrari (PI), Centre on Aging and Mobility, University of Zurich
Notes NCT01745263
EudraCT: 2012−001249-41
www.do-health.eu
DREAM 2014
Trial name or title DRy Eye Assessment and Management study (DREAM)
Methods RCT
Participants Adults with dry eye
Interventions Each for 2 years
Arm 1: omega-3 supplements (2000 mg EPA + 1000 mgDHA/d as 5 gel caps)
Arm 2: olive oil supplements (5 gel caps)
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DREAM 2014 (Continued)
Outcomes Primary: OSDI score (ocular surface disease index)
Secondary: other eye health measures, SF-36, healthcare utilisation costs, cost-effectiveness
Starting date Registered on Trials Registry 28 April 2014
Study start date: November 2014
Estimated study completion date: July 2017
Contact information Penny Asbell, Mount Sinai Icahn School of Medicine (Study Chair), Maureen Maguire, University of Penn-
sylvania (PI)
Notes NCT02128763
ENRGISE 2016
Trial name or title ENabling Reduction of low-Grade Inflammation in SEniors (ENRGISE)
Methods RCT
Participants People aged 70+ years with self-reported walking or stair-climbing difficulty
Interventions Each for 1 year
Arm 1: omega-3 fish oil (1.4 g/d for 6 months, possibly increasing to 2.8 g/d)
Arm 2: losartan 25 mg/d
Arm 3: placebo corn oil (for omega-3) plus placebo cellulose (for losartan)
Arm 4: omega-3 plus losartan
Arm 5: placebo corn oil (for omega-3)
Arm 6: placebo cellulose (for losartan)
Outcomes Primary: IL-6, 400 meter walk test
Secondary: short physical performance battery, frailty, hand grip strength, knee dynamometry, SF-36
Starting date Registered on Trials Registry 3 February 2016
Study start date: February 2016
Estimated study completion date: March 2018
Contact information Jane Lu janelu@ufl.edu
Michael Stancil mstancil@ufl.edu
Notes NCT02676466
InTrePad 2013
Trial name or title Intervention of testosterone and fish oil for the prevention of Alzheimer’s Disease: InTrePad
Methods RCT
Participants PiB-PET (Pittsburgh compound B) positive men aged 60 years and over with subjective memory complaints
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InTrePad 2013 (Continued)
Interventions Each for 56 weeks:
Arm 1: DHA capsules (1720 mg/d) and testosterone undecanoate (intramuscular injection 1000 mg/4 mL
every 8 weeks)
Arm 2: placebo DHA and testosterone undecanoate (intramuscular injection 1000 mg/4 mL every 8 weeks)
Arm 3: placebo DHA and placebo testosterone
Outcomes Primary: PiB score
Secondary: neuropsychological, mood and daily functioning questionnaires, beta amyloid levels, fluo-
rodeoxyglucose to assess brain glucose metabolism, inflammatory and oxidative biomarkers, hippocampal
volume, quality of life, safety and tolerability of treatment
Starting date Registered on trials registry: 14 January 2013
Study start date: 28 February 2013
Estimated study completion date: not stated
Contact information Ralph Martins (PI), Sir James McCusker Alzheimer’s Disease Research Unit, Hollywood Medical Centre,
Nedlands, Australia, r.martins@ecu.edu.au
Notes ACTRN12613000034730
Ralph Martins written to in 2016- no response
MAPT PLUS
Trial name or title Long-term effects of interventional strategies to prevent cognitive decline in elderly (MAPT PLUS)
Methods RCT - extension of MAPT trial
Participants Participants of MAPT trial
Interventions Follow-up 2 year extension of patients in MAPT, after completion of MAPT interventions
Outcomes Primary: cognitive and functional status (Grober and Buschke test)
Secondary: markers of cerebral atrophy, cost-effectiveness
Starting date Registered on trials registry: 30 December 2011
Study start date: December 2011
Estimated study completion date: November 2016
Contact information Bruno Vellas (PI), University Hospital, Toulouse, vellas.b@chu-toulouse.fr
Notes NCT01513252
Bruno Vellas written to in 2016- no response
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NCT00010868
Trial name or title Omega 3 fatty acids in bipolar disorder prophylaxis
Methods RCT
Participants People aged 18 to 65 with bipolar disorder
Interventions Each for 12 months:
Arm 1: omega-3
Arm 2: placebo
Outcomes Prophylactic efficacy
Starting date Trial Registration entry: 2 February 2001
Trial start date: July 2000
Estimated study completion: July 2004
Contact information Andrew Stoll, Mclean Hospital
Notes NCT00010868
The PI, Andrew Stoll, appears to have been struck off the medical register in Massachusetts in 2011 (Com-
monwealth of Massachusetts Board of Registration in Medicine, Adjudicatory Case number 2011−026) so
it has not been possible to contact him and no publication of results has been found
NCT00309439
Trial name or title Studies of serum PSA (prostate specific antigen) to help resolve the current implication of alpha-linolenic acid
and prostate cancer
Methods RCT
Participants Adults 18-77 years
Interventions Arm 1: ALA rich diet
Arm 2: control (not detailed)
Outcomes Prostate specific antigen, atrial fibrillation
Starting date Registered on trials registry: 29 March 2006
Study start date: unclear
Estimated study completion date: unclear
Contact information David Jenkins, University of Toronnto, nutritionproject@smh.toronto.on.ca
Notes NCT00309439
David Jenkins written to in 2016: confirmed not published in full and data incomplete
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NCT00410020
Trial name or title Arrhythmia prevention with an alpha-linolenic enriched diet
Methods RCT, parallel, 2 arm, 12 months
Participants 98 people with successful atrial fibrillation electrical cardioversion
Interventions Canola margarine and oil, rich in ALA, versus a conventional diet (control), for 1 year
Outcomes Length of time to first recurrence of AF
Starting date June 1999, expected finish date June 2003, registered December 2006 so appears to have been carried out
Contact information Principal Investigator: Jean-Paul Broustet, MD, PhD, Universitary Hospital Haut-Lévêque Bordeaux France
Notes NCT00410020, registered December 2006, no publication found
NCT01784042
Trial name or title Dietary energy restriction and omega-3 fatty acids on mammary tissue
Methods RCT
Participants Overweight women (30-55 years) with increased breast cancer risk
Interventions For 1 year:
Arm 1: lovaza (omega-3-acid ethyl esters)
Arm 2: lovaza and dietary energy restriction
Arm 3: placebo
Arm 4: placebo and dietary energy restriction
Outcomes Ki67 expression at 1 year
Starting date Registered on trials registry: 31 January 2013
Study start date: March 2013
Estimated study completion date: March 2018
Contact information Andrea Manni, Hershey Medical Centre, amanni@hmc.psu.edu (PI) or Cynthia DuBrock, cdubrock@hmc.
psu.edu
Notes NCT01784042. Trials register states “Withdrawn (no funding)”
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NCT02211560
Trial name or title Investigating a phosphatidylserine based dietary approach for the management of mild cognitive impairment
Methods RCT
Participants People with mild cognitive impairment (MCI) aged 65-85 years
Interventions Each for 24 months:
Arm 1: phosphatidylserine omega-3 (DHA enriched)
Arm 2: placebo cellulose capsules
Outcomes Primary: selective reminding test (SRT)
Secondary: mini mental state examination (MMSE), neurological battery test (NBT), dementia (DSM-4
criteria), mini sleep questionnaire (MSQ), Hamilton Anxiety rating scale (HAM-A), safety and adverse events
Starting date Registered on trials registry: 6 August 2014
Study start date: September 2014
Estimated study completion date: September 2019
Contact information Nadia Niemerzyanski, nadiaN@enzymotec.com; Yael Richter, yaelr@enzymotec.com
Notes NCT02211560
NCT02295059
Trial name or title Omega 3 fatty acids and ERPR(-)HER2(±) breast cancer prevention
Methods RCT
Participants Women at risk for recurrent breast cancer- with prior diagnosis of stage 0 to III breast cancer and completion
of surgery, chemotherapy or trastuzumab or radiation therapy
Interventions Each for 12 months:
Arm 1: omega-3 high dose capsules (5 g/d EPA + DHA)
Arm 2: omega-3 low dose capsules (0.9 g/d EPA + DHA)
Outcomes Primary: breast adipose tissue metabolites
Secondary: cytomorphology or cell proliferation of mammary epithelial cells, DNA promoter methylation
and pro-inflammatory gene expression in mammary epithelial and adipose tissue
Starting date Registered on trials registry: 14 October 2014
Study start date: August 2014
Estimated study completion date: January 2019
Contact information Anitra Sumbry, anitra.sumbry@osumc.edu; Lisa Yee (PI), Ohio State University
Notes NCT02295059
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NCT02719327
Trial name or title Impact of icosapent ethyl on Alzheimer’s disease (AD) biomarkers in preclinical adults
Methods RCT
Participants Cognitively healthy adults aged 50 to 70 years whose parents had AD
Interventions Each for 18 months:
Arm 1: Icosapent ethyl EPA (Vascepa) 4 g/d gel cap
Arm 2: matching gel cap placebo
Outcomes Primary: cerebral blood flow by MRI (magnetic resonance imaging)
Secondary: CSF biomarkers of AD, cognitive performance (preclinical Alzheimer’s cognitive composite,
PACC)
Starting date Registered on trials registry: 21 March 2016
Study start date: December 2016
Estimated study completion date: November 2021
Contact information Cynthia Carlsson, cynthia.carlsson@va.gov; Elena Beckman, elena.beckman@va.gov
Notes NCT02719327
OMEMI 2014
Trial name or title OMega-3 fatty acids in Elderly patients with Myocardial Infarction study (OMEMI)
Methods RCT
Participants Elderly patients (70-82 years) with acute MI
Interventions Each for 24 months:
Arm 1: omega-3 capsules, 3/d (Pikasol, total of 1.8 g/d EPA + DHA) and standard therapy
Arm 2: corn oil placebo, 3/d and standard therapy
Outcomes Primary: composite of total mortality, first non-fatal recurring AMI, stroke and revascularisation
Secondary: new onset atrial fibrillation, adipose tissue, serum fatty acids, makers of endothelial function,
inflammation, coagulation and fibrinolytic activity, genes associated with atherothrombosis
Starting date Registered on trials registry: 16 April 2013
Study start date: November 2012
Estimated study completion date: November 2019
Contact information Svein Solheim, Center for Clinical Heart Research, Oslo University Hospital, arnljot.tveit@vestreviken.no
Notes NCT01841944
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REDUCE-IT 2011
Trial name or title Reduction of cardiovascular events with EPA-intervention trial (REDUCE-IT)
Methods RCT
Participants Patients (45 years or over) with hypertriglyceridaemia, with cardiovascular disease or at high risk for cardio-
vascular disease, and on statin
Interventions Each for 4-6 years:
Arm 1: EPA ethyl ester (AMR101 4 g/d)
Arm 2: placebo
Outcomes Primary: composite of cardiovascular death, MI, stroke, coronary revascularisation and hospitalisation for
unstable angina
Secondary: incidence of additional cardiovascular events, lipid and lipoprotein levels
Starting date Registered on trials registry: 13 December 2011
Study start date: November 2011
Estimated study completion date: December 2017
Contact information Deepak Bhatt (PI), Brigham and Women’s Hospital
Notes NCT01492361
seAFOOD 2013
Trial name or title The seAFOod (systematic evaluation of Aspirin and Fish Oil) Polyp Prevention Trial
Methods RCT
Participants NHS Bowel Cancer Screening Programme patients (55-73 years) identified as “high risk” (5 or more small
adenomas; or 3 or more adenomas with at least one being 10mm or more in diameter) after their 1st screening
colonoscopy
Interventions Each for 12 months:
Arm 1: EPA (ALFA capsules: 2 × 500 mg twice daily = 2 g/d) and aspirin placebo (1/d)
Arm 2: EPA placebo (capric and capryllic acid triglycerides: 2/d) and aspirin (1/d = 300 mg/d)
Arm 3: EPA (ALFA capsules: 2 × 500 mg twice daily = 2 g/d) and aspirin (1/d = 300 mg/d)
Arm 4: EPA placebo (cparic and capryllic acid triglycerides: 2/d) and aspirin placebo (1/d)
Outcomes Primary: number of patients with one or more adenomas at 12 months
Secondary: adverse events, number of “advanced” adenomas per patients, number of “high risk” patients re-
classified as “intermediate risk”, number patients with one or more advanced adenomas, adenoma region in
the colorectum, total number of adenomas per patient, number of patients with colorectal cancer, levels of
bioactive lipid mediators e.g. omega-3
Starting date Trial Registration entry: 6 May 2011
Trial start date: 30 May 2011
Estimated study completion: 31 July 2017
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seAFOOD 2013 (Continued)
Contact information Mark Hull, Leeds Institute of Molecular Medicine, m.a.hull@leeds.ac.uk
Notes ISRCTN05926847
EudraCT 2010−020943−10
www.seafood-trial.co.uk
Shinto 2015
Trial name or title N-3 PUFA for vascular cognitive aging
Methods RCT
Participants Older adults (80 years and older) at high risk for cognitive decline and dementia of Alzheimer’s type
Interventions Each for 3 years:
Arm 1: omega-3 fish oil (1.65 g/d EPA + DHA)
Arm 2: soybean oil placebo (1.65 g/d)
Outcomes Primary: total cerebral white matter volume
Secondary: biomarkers of endothelial health, total brain atrophy, medial temporal lobe atrophy, ventricular
expansion, trail making test part B, digit symbol WAIS-R, cerebral blood flow, fractional anisotropy within
frontal gyri
Starting date Registered on trials registry: 24 September 2013
Study start date: May 2014
Estimated study completion date: March 2019
Contact information Alena Borgatti, borgatti@ohsu.edu; James Dursch, dursch@ohsu.edu; Gene Bowman and Lynne Shinto (PIs)
, Oregon Health and Science University
Notes NCT01953705
STRENGTH 2015
Trial name or title A long-term outcomes study to assess statin residual risk reduction with EpaNova in high cardiovascular risk
patients with hypertriglyceridemia (STRENGTH)
Methods RCT
Participants Adult patients with hypertriglyceridaemia and low HDL and high risk for CVD
Interventions Each for 3-5 years:
Arm 1: omega-3 carboxylic acid capsule (Epanova, not less than 800 mg/g) and statin (once daily)
Arm 2: corn oil placebo capsule and statin (once daily)
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STRENGTH 2015 (Continued)
Outcomes Primary: time to first occurrence of any component of the composite MACE (cardiovascular death, nonfatal
MI, nonfatal stroke, emergent/elective coronary revascularisation, hospitalisation for unstable angina)
Secondary: composite measure of cardiovascular events that include the first occurrence of cardiovascular
death, nonfatalMI andnon-fatal stroke; compositemeasure of coronary events that include the first occurrence
of cardiac death; first occurrence of individual components of MACE; time to cardiovascular death. Other
measures include: all cause mortality, new atrial fibrillation, thrombotic events, heart failure events
Starting date Trial Registration entry: 2 April 2014
Trial start date: October 2014
Estimated study completion: November 2019
Contact information AstraZeneca Clinical Study Information Centre, information.center@astrazeneca.com. PIs Steven Nissen
(Cleveland Clinic), Michael Lincoff (Cleveland Clinic) Stephen Nicholls (Adelaide Clinical Research)
Notes NCT02104817
EudraCT: 2014−001069−28
SUPERIORSVG 2010
Trial name or title Improving the results of heart bypass surgery using new approaches to surgery and medication (SUPERI-
ORSVG)
Methods RCT
Participants Adults having coronary artery bypass graft (CABG) using saphenous vein graft (SVG)
Interventions Each for 12 months:
Arm 1: fish oil supplements (2 × 1 g/d Ocean Nutrition capsules: 55% fish oils EPA:DHA 33%:22%) and
SVG conventionally harvested
Arm 2: placebo and SVG conventionally harvested
Arm 3: fish oil supplements (2 × 1 g/d Ocean Nutrition capsules: 55% fish oils EPA:DHA 33%:22%) and
SVG no-touch harvest
Arm 4: placebo and SVG no-touch harvest
Outcomes Primary: proportion of grafts occluded
Secondary: significant stenosis, adverse SVG harvesting events, composite outcome of all-cause mortality,
non-fatal MI and repeat revascularisation
Starting date Registered on trials registry: 12 January 2010
Study start date: July 2011
Estimated study completion date: December 2016
Contact information Stephen Fremes, Sunnybrook Health Sciences Centre (PI)
Notes NCT01047449
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UMIN000012825
Trial name or title Effect of PUFA on vascular healing process in hypercholesterolemic patients with ACS
Methods RCT
Participants Hypercholesterolemic patients (20-80 years) with acute coronary syndrome who have received successful
OCT-guided PCI (optical coherence tomography-guided percutaneous coronary intervention)
Interventions Each for 12 months:
Arm 1: intensive lipid lowering therapy with both statin and EPA + DHA
Arm 2: intensive lipid lowering therapy with both statin and EPA
Arm 3: standard lipid lowering therapy with statins
Outcomes Primary: changes in OCT parameter
Secondary: lipids, serum plasma profile, inflammatory parameters, adverse cardiovascular events
Starting date Registered on trials registry: 1 February 2014
Study start date: 1 February 2014
Estimated study completion date: 30 June 2019
Contact information Shiro Uemura (PI), Nara Medical University, Japan, suemura@naramed-u.ac.jp
Notes UMIN000012825
VITAL 2018
Trial name or title VITamin D and omegA-3 triaL (VITAL)
Methods RCT
Participants Multi-ethnic population of > 25,000 apparently healthy adults (men 50 years plus, women 55 years plus)
without cancer or CVD at baseline
Interventions Each for mean 5 years:
Arm 1: omega-3 (Omacor fish oil, EPA + DHA 1 g/d: 465 mg EPA; 375 mg DHA) and placebo
Arm 2: placebo and vitamin D3 (1/d, 2,000IU)
Arm 3: omega-3 (Omacor fish oil, EPA + DHA 1 g/d: 465 mg EPA; 375 mg DHA) and vitamin D3 (1/d,
2000 IU)
Arm 4: placebo and placebo
Outcomes Primary: reduction in risk for total cancer and CVD events (a composite of MI, stroke, and cardiovascular
mortality)
Secondary: lowered risk for expanded composite cardiovascular endpoint (MI, stroke, cardiovascular mor-
tality, coronary revascularisation), the individual components of the primary endpoint, site specific cancers,
mortality, diabetes, hypertension, cognitive decline, autoimmune conditions, infections, chronic respiratory
disease, depression, bone health, fractures, chronic knee pain, body composition, physical disability, falls,
plasma biomarker measures
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VITAL 2018 (Continued)
Starting date Registered on trials registry: 13 January 2010
Study start date: July 2010
Estimated study completion date: December 2017
Contact information JoAnn Manson or Julie Buring (PIs), Brigham and Women’s Hospital, Boston and Harvard School of Public
Health, Boston, vitalstudy@rics.bwh.harvard.edu
Notes NCT01169259
www.vitalstudy.org
ACS: acute coronary syndrome; AD: Alzheimer’s disease; AF: atrial fibrillation; BMI: body mass index; BMI: body mass index; CABG:
coronary artery bypass graft; CETP: cholesteryl ester transfer protein; CHD: coronary heart disease; CVD: cardiovascular disease;
DHA: docosahexaenoic acid; EPA: eicosapentaenoic acid; GAD-7: generalised anxiety disorder 7; HbA1c: glycated haemoglobin;
HDL: high-density lipoprotein; IFG: impaired fasting glucose; IGT: impaired glucose tolerance; IL: interleukin; LDL: low-density
lipoprotein; MACE: major adverse coronary event; MI: myocardial infarction; MRI: magentic resonance imaging; OCT: optical
coherence tomography; OSDI: ocular surface disease index; PCI: percutaneous coronary intervention; PHQ-9: patient health
questionnaire 9; PI: principal investigator; PSA: prostate specific antigen; PSQI: Pittsburgh Sleep Quality Index; PUFA: poly-
unsaturated fatty acids; RCT: randomised controlled trial; RCT: randomised controlled trial; SFA: saturated fatty acids; SVG:
saphenous vein graft.
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D A T A A N D A N A L Y S E S
Comparison 1. High vs low LCn3 omega-3 fats (primary outcomes)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 All-cause mortality (overall) -
LCn3
39 92653 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.93, 1.03]
2 All-cause mortality - LCn3
- sensitivity analysis (SA)
fixed-effect
39 90244 Risk Ratio (M-H, Fixed, 95% CI) 0.97 [0.93, 1.01]
3 All-cause mortality - LCn3 - SA
by summary risk of bias
39 92653 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.93, 1.03]
3.1 Low risk of bias 15 33146 Risk Ratio (M-H, Random, 95% CI) 1.01 [0.94, 1.08]
3.2 Moderate/high risk of bias 24 59507 Risk Ratio (M-H, Random, 95% CI) 0.94 [0.86, 1.03]
4 All-cause mortality - LCn3 - SA
by compliance and study size
38 Risk Ratio (M-H, Random, 95% CI) Subtotals only
4.1 SA - low risk of
compliance bias
18 15654 Risk Ratio (M-H, Random, 95% CI) 0.99 [0.86, 1.14]
4.2 SA - 100+ randomised 35 92397 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.93, 1.03]
5 All-cause mortality - LCn3 -
subgroup by dose
39 92653 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.93, 1.03]
5.1 LCn3 ≤150 mg/d 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
5.2 LCn3 > 150 ≤ 250 mg/d 1 407 Risk Ratio (M-H, Random, 95% CI) 0.77 [0.27, 2.18]
5.3 LCn3 > 250 ≤400 mg/d 1 2033 Risk Ratio (M-H, Random, 95% CI) 0.72 [0.56, 0.92]
5.4 LCn3 > 400 ≤ 2400 mg/d 28 87445 Risk Ratio (M-H, Random, 95% CI) 0.99 [0.93, 1.05]
5.5 LCn3 > 2.4 ≤ 4.4 g/d 7 2486 Risk Ratio (M-H, Random, 95% CI) 1.06 [0.67, 1.70]
5.6 LCn3 > 4.4 g/d 2 282 Risk Ratio (M-H, Random, 95% CI) 0.33 [0.03, 3.08]
6 All-cause mortality - LCn3 -
subgroup by replacement
39 Risk Ratio (M-H, Random, 95% CI) Subtotals only
6.1 LCn3 replacing SFA 5 3279 Risk Ratio (M-H, Random, 95% CI) 0.72 [0.56, 0.92]
6.2 LCn3 replacing MUFA 15 46176 Risk Ratio (M-H, Random, 95% CI) 0.96 [0.90, 1.02]
6.3 LCn3 replacing N-6 9 2806 Risk Ratio (M-H, Random, 95% CI) 0.74 [0.51, 1.09]
6.4 LCn3 replacing CHO 1 281 Risk Ratio (M-H, Random, 95% CI) 0.52 [0.05, 5.65]
6.5 LCn3 replacing nil/low n-
3 placebo
10 39601 Risk Ratio (M-H, Random, 95% CI) 0.99 [0.86, 1.14]
6.6 LCn3 replacement unclear 3 3593 Risk Ratio (M-H, Random, 95% CI) 0.91 [0.46, 1.79]
7 All-cause mortality - LCn3 -
subgroup by intervention type
39 92653 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.93, 1.03]
7.1 Dietary advice 3 5554 Risk Ratio (M-H, Random, 95% CI) 0.90 [0.60, 1.35]
7.2 Supplemental foods 2 5039 Risk Ratio (M-H, Random, 95% CI) 1.02 [0.84, 1.24]
7.3 Supplements (capsule) 33 81855 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.92, 1.01]
7.4 Any combination 1 205 Risk Ratio (M-H, Random, 95% CI) 0.65 [0.11, 3.79]
8 All-cause mortality - LCn3 -
subgroup by duration
39 92653 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.93, 1.03]
8.1 Medium duration 1 to < 2
years in study
18 9737 Risk Ratio (M-H, Random, 95% CI) 1.03 [0.82, 1.30]
8.2 Medium-long duration: 2
to < 4 years in study
14 29234 Risk Ratio (M-H, Random, 95% CI) 0.91 [0.86, 0.96]
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8.3 Long duration: ≥ 4 years
in study
7 53682 Risk Ratio (M-H, Random, 95% CI) 1.03 [0.98, 1.09]
9 All-cause mortality - LCn3
- subgroup by primary or
secondary prevention
39 92653 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.93, 1.03]
9.1 Primary CVD prevention 17 41202 Risk Ratio (M-H, Random, 95% CI) 1.01 [0.94, 1.08]
9.2 Secondary CVD
prevention
22 51451 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.88, 1.04]
10 All-cause mortality - LCn3 -
subgroup by statin use
39 90244 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.92, 1.03]
10.1 LCn3 - ≥50% of control
group on statins
8 40500 Risk Ratio (M-H, Random, 95% CI) 1.02 [0.93, 1.11]
10.2 LCn3 - < 50% of control
group on statins
26 46604 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.88, 1.03]
10.3 LCn3 - use of statins
unclear
5 3140 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.58, 1.63]
11 Cardiovascular mortality
(overall) - LCn3
25 67772 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.87, 1.03]
12 CVD mortality - LCn3 - SA
fixed-effect
25 67772 Risk Ratio (M-H, Fixed, 95% CI) 0.94 [0.89, 1.00]
13 CVD mortality - LCn3 - SA by
summary risk of bias
25 67772 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.87, 1.03]
13.1 Low risk of bias 9 29133 Risk Ratio (M-H, Random, 95% CI) 0.99 [0.90, 1.09]
13.2 Moderate/high risk of
bias
16 38639 Risk Ratio (M-H, Random, 95% CI) 0.92 [0.80, 1.05]
14 CVD mortality - LCn3 - SA by
compliance and study size
24 Risk Ratio (M-H, Random, 95% CI) Subtotals only
14.1 SA - low risk of
compliance bias
12 13244 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.82, 1.23]
14.2 SA - 100+ randomised 21 67516 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.87, 1.04]
15 CVD mortality - LCn3 -
subgroup by dose
26 67873 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.87, 1.03]
15.1 LCn3 ≤ 150 mg/d 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
15.2 LCn3 > 150 ≤ 250 mg/d 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
15.3 LCn3 > 250 ≤ 400 mg/d 1 2033 Risk Ratio (M-H, Random, 95% CI) 0.70 [0.53, 0.91]
15.4 LCn3 > 400 ≤ 2400 mg/
d
19 64126 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.89, 1.06]
15.5 LCn3 > 2.4 ≤ 4.4 g/d 4 1432 Risk Ratio (M-H, Random, 95% CI) 1.01 [0.58, 1.77]
15.6 LCn3 > 4.4 g/d 2 282 Risk Ratio (M-H, Random, 95% CI) 0.33 [0.03, 3.08]
16 CVD mortality - LCn3 -
subgroup by replacement
26 Risk Ratio (M-H, Random, 95% CI) Subtotals only
16.1 N-3 replacing SFA 3 2537 Risk Ratio (M-H, Random, 95% CI) 0.69 [0.53, 0.90]
16.2 N-3 replacing MUFA 12 44242 Risk Ratio (M-H, Random, 95% CI) 0.94 [0.86, 1.04]
16.3 N-3 replacing N-6 4 1435 Risk Ratio (M-H, Random, 95% CI) 0.69 [0.41, 1.19]
16.4 N-3 replacing
carbohydrates/sugars
1 281 Risk Ratio (M-H, Random, 95% CI) 0.69 [0.12, 4.07]
16.5 N-3 replacing nil/low n-
3 placebo
8 19275 Risk Ratio (M-H, Random, 95% CI) 0.84 [0.73, 0.96]
16.6 Replacement unclear 2 3186 Risk Ratio (M-H, Random, 95% CI) 0.54 [0.05, 5.77]
17 CVD mortality - LCn3 -
subgroup by intervention type
25 67772 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.87, 1.03]
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17.1 Dietary advice 2 5147 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.52, 1.71]
17.2 Supplemental foods 2 5039 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.72, 1.32]
17.3 Supplements (capsule) 21 57586 Risk Ratio (M-H, Random, 95% CI) 0.94 [0.88, 0.99]
17.4 Any combination 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
18 CVD mortality - LCn3 -
subgroup by duration
25 67772 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.87, 1.03]
18.1 Medium duration 1 to <
2 years in study
10 6177 Risk Ratio (M-H, Random, 95% CI) 0.88 [0.57, 1.36]
18.2 Medium-long duration:
2 to < 4 years in study
10 26736 Risk Ratio (M-H, Random, 95% CI) 0.89 [0.82, 0.95]
18.3 Long duration: ≥ 4 years
in study
5 34859 Risk Ratio (M-H, Random, 95% CI) 1.05 [0.93, 1.18]
19 CVD mortality - LCn3 -
subgroup by primary or
secondary prevention
25 67772 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.87, 1.03]
19.1 Primary prevention 7 17931 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.88, 1.09]
19.2 Secondary prevention 18 49841 Risk Ratio (M-H, Random, 95% CI) 0.94 [0.83, 1.06]
20 CVD mortality - LCn3 -
subgroup by statin uses
25 67772 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.87, 1.03]
20.1 LCn3 -≥ 50% of control
group on statins
6 23994 Risk Ratio (M-H, Random, 95% CI) 0.99 [0.90, 1.10]
20.2 LCn3 - < 50% of control
group on statins
17 43425 Risk Ratio (M-H, Random, 95% CI) 0.92 [0.82, 1.04]
20.3 LCn3- Use of statins
unclear
2 353 Risk Ratio (M-H, Random, 95% CI) 0.36 [0.06, 2.30]
21 Cardiovascular events (overall)
- LCn3
38 90378 Risk Ratio (M-H, Random, 95% CI) 0.99 [0.94, 1.04]
22 CVD events - LCn3 - SA
fixed-effect
38 90378 Risk Ratio (M-H, Fixed, 95% CI) 0.98 [0.95, 1.00]
23 CVD events - LCn3 - SA by
summary risk of bias
38 90378 Risk Ratio (M-H, Random, 95% CI) 0.99 [0.94, 1.04]
23.1 Low risk of bias 14 31649 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.96, 1.05]
23.2 Moderate/high risk of
bias
24 58729 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.87, 1.03]
24 CVD events - LCn3 - SA by
compliance and study size
37 Risk Ratio (M-H, Random, 95% CI) Subtotals only
24.1 SA - low risk of
compliance bias
16 13649 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.84, 1.14]
24.2 SA - 100+ randomised 33 90058 Risk Ratio (M-H, Random, 95% CI) 0.99 [0.94, 1.04]
25 CVD events - LCn3 - subgroup
by dose
38 90453 Risk Ratio (M-H, Random, 95% CI) 0.99 [0.94, 1.04]
25.1 LCn3 ≤ 150 mg/d 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
25.2 LCn3 > 150 ≤ 250 mg/d 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
25.3 LCn3 > 250 ≤ 400 mg/d 1 2033 Risk Ratio (M-H, Random, 95% CI) 0.96 [0.88, 1.05]
25.4 LCn3 > 400 ≤ 2400 mg/
d
28 85818 Risk Ratio (M-H, Random, 95% CI) 0.99 [0.93, 1.05]
25.5 LCn3 > 2.4 ≤ 4.4 g/d 7 2180 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.75, 1.28]
25.6 LCn3 > 4.4 g/d 3 422 Risk Ratio (M-H, Random, 95% CI) 1.09 [0.65, 1.81]
26 CVD events - LCn3 - subgroup
by replacement
38 Risk Ratio (M-H, Random, 95% CI) Subtotals only
26.1 N-3 replacing SFA 4 2888 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.87, 1.04]
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26.2 N-3 replacing MUFA 16 45065 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.94, 1.02]
26.3 N-3 replacing n-6 6 1891 Risk Ratio (M-H, Random, 95% CI) 1.10 [0.90, 1.35]
26.4 N-3 replacing
carbohydrates/sugars
1 258 Risk Ratio (M-H, Random, 95% CI) 0.68 [0.12, 3.98]
26.5 N-3 replacing nil/low n-
3 placebo
12 39907 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.85, 1.07]
26.6 Replacement unclear 3 3429 Risk Ratio (M-H, Random, 95% CI) 0.58 [0.16, 2.07]
27 CVD events - LCn3 - subgroup
by intervention type
38 90378 Risk Ratio (M-H, Random, 95% CI) 0.99 [0.94, 1.04]
27.1 Dietary advice 3 5248 Risk Ratio (M-H, Random, 95% CI) 1.13 [0.86, 1.49]
27.2 Supplemental foods 2 5039 Risk Ratio (M-H, Random, 95% CI) 1.02 [0.89, 1.17]
27.3 Supplements (capsule) 33 80091 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.91, 1.02]
27.4 Any combination 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
28 CVD events - LCn3 - subgroup
by duration
38 90378 Risk Ratio (M-H, Random, 95% CI) 0.99 [0.94, 1.04]
28.1 Medium duration 1 to <
2 years in study
18 8107 Risk Ratio (M-H, Random, 95% CI) 0.89 [0.68, 1.16]
28.2 Medium-long duration:
2 to < 4 years in study
14 28767 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.93, 1.01]
28.3 Long duration: ≥ 4 years
in study
6 53504 Risk Ratio (M-H, Random, 95% CI) 0.99 [0.91, 1.08]
29 CVD events - LCn3 - subgroup
by primary or secondary
prevention
38 90378 Risk Ratio (M-H, Random, 95% CI) 0.99 [0.94, 1.04]
29.1 Primary prevention of
CVD
16 39751 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.89, 1.05]
29.2 Secondary prevention 22 50627 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.93, 1.07]
30 CVD events - LCn3 - subgroup
by statin use
38 90378 Risk Ratio (M-H, Random, 95% CI) 0.99 [0.94, 1.04]
30.1 LCn3 -≥ 50% of control
group on statins
8 42389 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.89, 1.08]
30.2 LCn3 - < 50% of control
group on statins
24 45160 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.91, 1.04]
30.3 LCn3 - use of statins
unclear
6 2829 Risk Ratio (M-H, Random, 95% CI) 0.93 [0.53, 1.63]
31 Coronary heart disease
mortality (overall) - LCn3
21 73491 Risk Ratio (M-H, Random, 95% CI) 0.93 [0.79, 1.09]
32 CHD mortality - LCn3 - SA
fixed-effect
21 73491 Risk Ratio (M-H, Fixed, 95% CI) 0.94 [0.85, 1.03]
33 CHD mortality - LCn3 - SA
by summary risk of bias
21 73491 Risk Ratio (M-H, Random, 95% CI) 0.93 [0.79, 1.09]
33.1 Low risk of bias 7 16372 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.72, 1.37]
33.2 Moderate/high risk of
bias
14 57119 Risk Ratio (M-H, Random, 95% CI) 0.91 [0.75, 1.10]
34 CHD mortality - LCn3 - SA
by compliance and study size
21 Risk Ratio (M-H, Random, 95% CI) Subtotals only
34.1 SA - low risk of
compliance bias
9 12938 Risk Ratio (M-H, Random, 95% CI) 1.05 [0.83, 1.32]
34.2 SA - 100+ randomised 20 73411 Risk Ratio (M-H, Random, 95% CI) 0.93 [0.79, 1.09]
35 CHD mortality - LCn3 - SA
omitting cardiac death
16 65325 Risk Ratio (M-H, Random, 95% CI) 0.83 [0.74, 0.94]
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35.1 Low risk of bias 5 12022 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.69, 1.30]
35.2 Moderate/high risk of
bias
11 53303 Risk Ratio (M-H, Random, 95% CI) 0.82 [0.72, 0.94]
36 CHD mortality - LCn3 -
subgroup by dose
21 73491 Risk Ratio (M-H, Random, 95% CI) 0.93 [0.79, 1.09]
36.1 LCn3 ≤ 150 mg/d 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
36.2 LCn3 > 150 ≤ 250 mg/d 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
36.3 LCn3 > 250 ≤ 400 mg/d 2 5147 Risk Ratio (M-H, Random, 95% CI) 0.93 [0.50, 1.74]
36.4 LCn3 > 400 ≤ 2400 mg/
d
15 67442 Risk Ratio (M-H, Random, 95% CI) 0.92 [0.80, 1.07]
36.5 LCn3 > 2.4 ≤ 4.4 g/d 3 822 Risk Ratio (M-H, Random, 95% CI) 0.93 [0.49, 1.78]
36.6 LCn3 > 4.4 g/d 1 80 Risk Ratio (M-H, Random, 95% CI) 0.32 [0.01, 7.57]
37 CHD mortality - LCn3 -
subgroup by replacement
21 Risk Ratio (M-H, Random, 95% CI) Subtotals only
37.1 N-3 replacing SFA 3 2514 Risk Ratio (M-H, Random, 95% CI) 0.67 [0.51, 0.88]
37.2 N-3 replacing MUFA 10 31605 Risk Ratio (M-H, Random, 95% CI) 0.89 [0.72, 1.10]
37.3 N-3 replacing n-6 3 1409 Risk Ratio (M-H, Random, 95% CI) 0.64 [0.33, 1.24]
37.4 N-3 replacing
carbohydrates/sugars
1 258 Risk Ratio (M-H, Random, 95% CI) 0.34 [0.01, 8.23]
37.5 N-3 replacing nil/low n-
3 placebo
7 37651 Risk Ratio (M-H, Random, 95% CI) 0.83 [0.70, 0.97]
37.6 Replacement unclear 1 3114 Risk Ratio (M-H, Random, 95% CI) 1.27 [1.03, 1.57]
38 CHD mortality - LCn3 -
subgroup by intervention type
21 73491 Risk Ratio (M-H, Random, 95% CI) 0.93 [0.79, 1.09]
38.1 Dietary advice 2 5147 Risk Ratio (M-H, Random, 95% CI) 0.93 [0.50, 1.74]
38.2 Supplemental foods 1 4837 Risk Ratio (M-H, Random, 95% CI) 0.96 [0.69, 1.33]
38.3 Supplements (capsule) 18 63507 Risk Ratio (M-H, Random, 95% CI) 0.90 [0.79, 1.02]
38.4 Any combination 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
39 CHD mortality - LCn3 -
subgroup by duration
21 73491 Risk Ratio (M-H, Random, 95% CI) 0.93 [0.79, 1.09]
39.1 Medium duration 1 to <
2 years in study
7 5978 Risk Ratio (M-H, Random, 95% CI) 0.96 [0.62, 1.50]
39.2 Medium-long duration:
2 to < 4 years in study
9 26545 Risk Ratio (M-H, Random, 95% CI) 0.79 [0.69, 0.90]
39.3 Long duration: ≥ 4 years
in study
5 40968 Risk Ratio (M-H, Random, 95% CI) 1.18 [1.00, 1.39]
40 CHD mortality - LCn3 -
subgroup by primary or
secondary prevention
21 73491 Risk Ratio (M-H, Random, 95% CI) 0.93 [0.79, 1.09]
40.1 Primary prevention of
CVD
5 23789 Risk Ratio (M-H, Random, 95% CI) 0.86 [0.46, 1.61]
40.2 Secondary prevention of
CVD
16 49702 Risk Ratio (M-H, Random, 95% CI) 0.93 [0.79, 1.11]
41 CHD mortality - LCn3 -
subgroup by statin use
21 73491 Risk Ratio (M-H, Random, 95% CI) 0.93 [0.79, 1.09]
41.1 LCn3 -≥ 50% of control
group on statins
5 30025 Risk Ratio (M-H, Random, 95% CI) 1.05 [0.84, 1.30]
41.2 LCn3 - < 50% of control
group on statins
15 43208 Risk Ratio (M-H, Random, 95% CI) 0.89 [0.72, 1.10]
41.3 LCn3 - use of statins
unclear
1 258 Risk Ratio (M-H, Random, 95% CI) 0.34 [0.01, 8.23]
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42 CHD mortality - LCn3 -
subgroup by CAD history
21 73491 Risk Ratio (M-H, Random, 95% CI) 0.93 [0.80, 1.09]
42.1 Previous CAD 11 29074 Risk Ratio (M-H, Random, 95% CI) 0.96 [0.77, 1.20]
42.2 No previous CAD 10 44417 Risk Ratio (M-H, Random, 95% CI) 0.93 [0.74, 1.16]
43 Coronary heart disease events
(overall) - LCn3
28 84301 Risk Ratio (M-H, Random, 95% CI) 0.93 [0.88, 0.97]
44 CHD events - LCn3 - SA
fixed-effect
28 84301 Risk Ratio (M-H, Fixed, 95% CI) 0.93 [0.88, 0.97]
45 CHD events - LCn3 - SA by
summary risk of bias
28 84301 Risk Ratio (M-H, Random, 95% CI) 0.93 [0.88, 0.97]
45.1 Low risk of bias 12 30227 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.90, 1.05]
45.2 Moderate/high risk of
bias
16 54074 Risk Ratio (M-H, Random, 95% CI) 0.89 [0.84, 0.95]
46 CHD events - LCn3 - SA by
compliance and study size
27 Risk Ratio (M-H, Random, 95% CI) Subtotals only
46.1 SA - low risk of
compliance bias
12 13447 Risk Ratio (M-H, Random, 95% CI) 0.94 [0.86, 1.02]
46.2 SA - 100+ randomised 25 84084 Risk Ratio (M-H, Random, 95% CI) 0.93 [0.88, 0.98]
47 CHD events - LCn3 - subgroup
by dose
28 84376 Risk Ratio (M-H, Random, 95% CI) 0.93 [0.89, 0.98]
47.1 LCn3 ≤ 150 mg/d 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
47.2 LCn3 > 150 ≤ 250 mg/d 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
47.3 LCn3 > 250 ≤ 400 mg/d 1 2033 Risk Ratio (M-H, Random, 95% CI) 0.92 [0.82, 1.04]
47.4 LCn3 > 400 ≤ 2400 mg/
d
21 80730 Risk Ratio (M-H, Random, 95% CI) 0.93 [0.88, 0.98]
47.5 LCn3 > 2.4 ≤ 4.4 g/d 4 1191 Risk Ratio (M-H, Random, 95% CI) 0.90 [0.53, 1.53]
47.6 LCn3 > 4.4 g/d 3 422 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.54, 1.85]
48 CHD events - LCn3 - subgroup
by replacement
28 Risk Ratio (M-H, Random, 95% CI) Subtotals only
48.1 N-3 replacing SFA 3 2514 Risk Ratio (M-H, Random, 95% CI) 0.53 [0.16, 1.75]
48.2 N-3 replacing MUFA 15 44954 Risk Ratio (M-H, Random, 95% CI) 0.96 [0.90, 1.01]
48.3 N-3 replacing n-6 4 1549 Risk Ratio (M-H, Random, 95% CI) 1.10 [0.88, 1.39]
48.4 N-3 replacing
carbohydrates/sugars
1 258 Risk Ratio (M-H, Random, 95% CI) 0.11 [0.01, 2.07]
48.5 N-3 replacing nil/low n-
3 placebo
8 37843 Risk Ratio (M-H, Random, 95% CI) 0.85 [0.78, 0.94]
48.6 Replacement unclear 1 243 Risk Ratio (M-H, Random, 95% CI) 0.89 [0.08, 9.70]
49 CHD events - LCn3 - subgroup
by intervention type
28 84301 Risk Ratio (M-H, Random, 95% CI) 0.93 [0.89, 0.98]
49.1 Dietary advice 2 2134 Risk Ratio (M-H, Random, 95% CI) 1.01 [0.67, 1.52]
49.2 Supplemental foods 2 5039 Risk Ratio (M-H, Random, 95% CI) 0.94 [0.75, 1.18]
49.3 Supplements (capsule) 24 77128 Risk Ratio (M-H, Random, 95% CI) 0.93 [0.88, 0.98]
49.4 Any combination 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
50 CHD events - LCn3 - subgroup
by duration
28 84301 Risk Ratio (M-H, Random, 95% CI) 0.93 [0.89, 0.98]
50.1 Medium duration 1 to <
2 years in study
11 7009 Risk Ratio (M-H, Random, 95% CI) 0.94 [0.86, 1.03]
50.2 Medium-long duration:
2 to < 4 years in study
12 26902 Risk Ratio (M-H, Random, 95% CI) 0.91 [0.84, 0.98]
50.3 Long duration: ≥ 4 years
in study
5 50390 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.83, 1.07]
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51 CHD events - LCn3 - subgroup
by primary or secondary
prevention
28 84301 Risk Ratio (M-H, Random, 95% CI) 0.93 [0.89, 0.98]
51.1 Primary prevention of
CVD
11 37365 Risk Ratio (M-H, Random, 95% CI) 0.94 [0.81, 1.10]
51.2 Secondary prevention of
CVD
17 46936 Risk Ratio (M-H, Random, 95% CI) 0.93 [0.88, 0.98]
52 CHD events - LCn3 - subgroup
by statin use
28 84301 Risk Ratio (M-H, Random, 95% CI) 0.93 [0.89, 0.98]
52.1 LCn3 -≥ 50% of control
group on statins
8 42735 Risk Ratio (M-H, Random, 95% CI) 0.94 [0.85, 1.05]
52.2 LCn3 - < 50% of control
group on statins
17 40674 Risk Ratio (M-H, Random, 95% CI) 0.92 [0.86, 0.98]
52.3 LCn3 - use of statins
unclear
3 892 Risk Ratio (M-H, Random, 95% CI) 0.65 [0.11, 3.83]
53 CHD events - LCn3 subgroup
by CAD history
28 84301 Risk Ratio (M-H, Random, 95% CI) 0.93 [0.88, 0.97]
53.1 Previous CAD 12 26124 Risk Ratio (M-H, Random, 95% CI) 0.92 [0.87, 0.98]
53.2 No previous CAD 16 58177 Risk Ratio (M-H, Random, 95% CI) 0.94 [0.86, 1.01]
54 Stroke (overall) - LCn3 28 89358 Risk Ratio (M-H, Random, 95% CI) 1.06 [0.96, 1.16]
55 Stroke - LCn3 - SA fixed-effect 28 89358 Risk Ratio (M-H, Fixed, 95% CI) 1.06 [0.97, 1.16]
56 Stroke - LCn3 - SA by summary
risk of bias
28 89358 Risk Ratio (M-H, Random, 95% CI) 1.06 [0.96, 1.16]
56.1 Low risk of bias 12 32039 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.86, 1.12]
56.2 Moderate/high risk of
bias
16 57319 Risk Ratio (M-H, Random, 95% CI) 1.13 [1.00, 1.29]
57 Stroke - LCn3 - SA by
compliance and study size
27 Risk Ratio (M-H, Random, 95% CI) Subtotals only
57.1 SA - low risk of
compliance bias
12 14451 Risk Ratio (M-H, Random, 95% CI) 1.19 [0.86, 1.65]
57.2 SA - 100+ randomised 26 89231 Risk Ratio (M-H, Random, 95% CI) 1.07 [0.97, 1.18]
58 Stroke - LCn3 - subgroup by
stroke type
13 Risk Ratio (M-H, Random, 95% CI) Subtotals only
58.1 Ischaemic stroke - LCn3 8 35040 Risk Ratio (M-H, Random, 95% CI) 1.09 [0.89, 1.33]
58.2 Haemorrhagic stroke -
LCn3
8 36645 Risk Ratio (M-H, Random, 95% CI) 1.20 [0.85, 1.69]
58.3 Transient ischaemic
attack (TIA)
5 5032 Risk Ratio (M-H, Random, 95% CI) 0.74 [0.39, 1.39]
59 Stroke - LCn3 - subgroup by
dose
28 Risk Ratio (M-H, Random, 95% CI) Subtotals only
59.1 LCn3 ≤ 150 mg/d 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
59.2 LCn3 > 150 ≤ 250 mg/d 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
59.3 LCn3 > 250 ≤ 400 mg/d 1 2033 Risk Ratio (M-H, Random, 95% CI) 0.45 [0.14, 1.44]
59.4 LCn3 > 400 ≤ 2400 mg/
d
24 86335 Risk Ratio (M-H, Random, 95% CI) 1.06 [0.97, 1.16]
59.5 LCn3 > 2.4 ≤ 4.4 g/d 1 610 Risk Ratio (M-H, Random, 95% CI) 0.69 [0.16, 3.07]
59.6 LCn3 > 4.4 g/d 2 380 Risk Ratio (M-H, Random, 95% CI) 6.58 [0.78, 55.16]
60 Stroke - LCn3 - subgroup by
replacement
28 Risk Ratio (M-H, Random, 95% CI) Subtotals only
60.1 N-3 replacing SFA 3 2514 Risk Ratio (M-H, Random, 95% CI) 0.53 [0.19, 1.50]
60.2 N-3 replacing MUFA 14 45252 Risk Ratio (M-H, Random, 95% CI) 1.11 [0.94, 1.31]
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60.3 N-3 replacing n-6 3 1179 Risk Ratio (M-H, Random, 95% CI) 2.08 [0.18, 24.31]
60.4 N-3 replacing
carbohydrates/sugars
1 258 Risk Ratio (M-H, Random, 95% CI) 0.34 [0.01, 8.23]
60.5 N-3 replacing nil/low n-
3 placebo
9 39555 Risk Ratio (M-H, Random, 95% CI) 1.07 [0.92, 1.24]
60.6 Replacement unclear 1 3114 Risk Ratio (M-H, Random, 95% CI) 1.12 [0.55, 2.29]
61 Stroke - LCn3 - subgroup by
intervention type
28 89358 Risk Ratio (M-H, Random, 95% CI) 1.06 [0.96, 1.16]
61.1 Dietary advice 3 5248 Risk Ratio (M-H, Random, 95% CI) 0.93 [0.42, 2.05]
61.2 Supplemental foods 1 4837 Risk Ratio (M-H, Random, 95% CI) 1.11 [0.47, 2.62]
61.3 Supplements (capsule) 24 79273 Risk Ratio (M-H, Random, 95% CI) 1.07 [0.97, 1.18]
61.4 Any combination 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
62 Stroke - LCn3 - subgroup by
duration
28 89358 Risk Ratio (M-H, Random, 95% CI) 1.06 [0.96, 1.16]
62.1 Medium duration 1 to <
2 years in study
11 7467 Risk Ratio (M-H, Random, 95% CI) 1.35 [0.86, 2.12]
62.2 Medium-long duration:
2 to < 4 years in study
11 28387 Risk Ratio (M-H, Random, 95% CI) 1.15 [0.93, 1.41]
62.3 Long duration: ≥ 4 years
in study
6 53504 Risk Ratio (M-H, Random, 95% CI) 1.01 [0.91, 1.13]
63 Stroke - LCn3 - subgroup
by primary or secondary
prevention
28 89358 Risk Ratio (M-H, Random, 95% CI) 1.06 [0.96, 1.16]
63.1 Primary prevention of
CVD
9 39332 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.86, 1.09]
63.2 Secondary prevention of
CVD
19 50026 Risk Ratio (M-H, Random, 95% CI) 1.21 [1.05, 1.40]
64 Stroke - LCn3 - subgroup by
statin use
28 89358 Risk Ratio (M-H, Random, 95% CI) 1.06 [0.96, 1.16]
64.1 LCn3 -≥ 50% of control
group on statins
8 42962 Risk Ratio (M-H, Random, 95% CI) 1.03 [0.86, 1.23]
64.2 LCn3 - < 50% of control
group on statins
17 44999 Risk Ratio (M-H, Random, 95% CI) 1.18 [1.02, 1.37]
64.3 LCn3 - use of statins
unclear
3 1397 Risk Ratio (M-H, Random, 95% CI) 0.94 [0.38, 2.34]
65 Arrythmia (overall) - LCn3 27 53796 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.90, 1.05]
66 Arrhythmia- LCn3 - SA
fixed-effect
27 53796 Risk Ratio (M-H, Fixed, 95% CI) 1.01 [0.96, 1.07]
67 Arrhythmia- LCn3 - SA by
summary risk of bias
27 53796 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.90, 1.05]
67.1 Low risk of bias 10 25801 Risk Ratio (M-H, Random, 95% CI) 1.10 [0.98, 1.23]
67.2 Moderate/high risk of
bias
17 27995 Risk Ratio (M-H, Random, 95% CI) 0.93 [0.84, 1.02]
68 Arrhythmia- LCn3 - SA by
compliance and study size
26 Risk Ratio (M-H, Random, 95% CI) Subtotals only
68.1 SA - low risk of
compliance bias
10 12914 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.86, 1.09]
68.2 SA - 100+ randomised 26 53749 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.89, 1.05]
69 Arrhythmia - LCn3 - subgroup
by new or recurrent
27 Risk Ratio (M-H, Random, 95% CI) Subtotals only
69.1 New arrhythmia 16 50175 Risk Ratio (M-H, Random, 95% CI) 1.07 [0.99, 1.16]
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69.2 Recurrent arrhythmia 12 4425 Risk Ratio (M-H, Random, 95% CI) 0.93 [0.84, 1.03]
70 Arrhythmia - LCn3 - subgroup
by fatality
17 Risk Ratio (M-H, Random, 95% CI) Subtotals only
70.1 Fatal arrhythmias - LCn3 2 12938 Risk Ratio (M-H, Random, 95% CI) 1.11 [0.95, 1.31]
70.2 Non-fatal arrhythmias -
LCn3
8 2079 Risk Ratio (M-H, Random, 95% CI) 0.74 [0.57, 0.96]
70.3 Fatal and non-fatal
arrhythmias combined - LCn3
10 36007 Risk Ratio (M-H, Random, 95% CI) 1.06 [0.97, 1.17]
71 Arrhythmia - LCn3 - subgroup
by dose
27 53796 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.89, 1.04]
71.1 LCn3 ≤ 150 mg/d 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
71.2 LCn3 > 150 ≤ 250 mg/d 1 407 Risk Ratio (M-H, Random, 95% CI) 1.01 [0.90, 1.12]
71.3 LCn3 > 250 ≤ 400 mg/d 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
71.4 LCn3 > 400 ≤ 2400 mg/
d
19 51535 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.88, 1.08]
71.5 LCn3 > 2.4 ≤ 4.4 g/d 3 1076 Risk Ratio (M-H, Random, 95% CI) 0.72 [0.55, 0.94]
71.6 LCn3 > 4.4 g/d 2 342 Risk Ratio (M-H, Random, 95% CI) 1.10 [0.32, 3.83]
71.7 Unclear LCn3 dose 2 436 Risk Ratio (M-H, Random, 95% CI) 0.99 [0.76, 1.28]
72 Arrhythmia - LCn3 - subgroup
by replacement
27 Risk Ratio (M-H, Random, 95% CI) Subtotals only
72.1 N-3 replacing SFA 2 632 Risk Ratio (M-H, Random, 95% CI) 0.74 [0.10, 5.67]
72.2 N-3 replacing MUFA 12 42246 Risk Ratio (M-H, Random, 95% CI) 0.99 [0.88, 1.11]
72.3 N-3 replacing n-6 4 1302 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.86, 1.16]
72.4 N-3 replacing
carbohydrates/sugars
1 258 Risk Ratio (M-H, Random, 95% CI) 0.34 [0.04, 3.21]
72.5 N-3 replacing nil/low n-
3 placebo
6 8983 Risk Ratio (M-H, Random, 95% CI) 0.80 [0.69, 0.91]
72.6 Replacement unclear 4 1179 Risk Ratio (M-H, Random, 95% CI) 0.99 [0.91, 1.08]
73 Arrhythmia - LCn3 - subgroup
by intervention type
27 53796 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.90, 1.05]
73.1 Dietary advice 2 508 Risk Ratio (M-H, Random, 95% CI) 0.87 [0.44, 1.72]
73.2 Supplemental foods 2 5039 Risk Ratio (M-H, Random, 95% CI) 0.92 [0.67, 1.26]
73.3 Supplements (capsule) 23 48249 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.88, 1.06]
73.4 Any combination 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
74 Arrhythmia - LCn3 - subgroup
by duration
27 53796 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.89, 1.04]
74.1 Medium duration 1 to <
2 years in study
17 8553 Risk Ratio (M-H, Random, 95% CI) 0.93 [0.84, 1.04]
74.2 Medium-long duration:
2 to < 4 years in study
7 17701 Risk Ratio (M-H, Random, 95% CI) 0.96 [0.84, 1.10]
74.3 Long duration: ≥ 4 years
in study
3 27542 Risk Ratio (M-H, Random, 95% CI) 1.13 [0.99, 1.29]
75 Arrhythmia - LCn3 - subgroup
by primary or secondary
prevention3
27 Risk Ratio (M-H, Random, 95% CI) Subtotals only
75.1 Primary prevention 8 14565 Risk Ratio (M-H, Random, 95% CI) 1.11 [0.97, 1.28]
75.2 Secondary prevention 19 39231 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.86, 1.03]
76 Arrhythmia - LCn3 - subgroup
by statin use
27 Risk Ratio (M-H, Random, 95% CI) Subtotals only
76.1 LCn3 -≥ 50% of control
group on statins
5 23779 Risk Ratio (M-H, Random, 95% CI) 1.07 [0.95, 1.22]
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76.2 LCn3 - < 50% of control
group on statins
18 28932 Risk Ratio (M-H, Random, 95% CI) 0.94 [0.85, 1.04]
76.3 LCn3 - use of statins
unclear
4 1085 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.80, 1.18]
Comparison 2. High vs low LCn3 omega-3 fats (secondary outcomes)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 MACCEs - LCn3 5 34730 Risk Ratio (M-H, Random, 95% CI) 1.03 [0.97, 1.09]
2 Myocardial infarction (overall) -
LCn3
23 72159 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.88, 1.03]
3 Total MI - sensitivity analysis
(SA) by summary risk of bias
23 72159 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.88, 1.03]
3.1 Low summary risk of bias 11 30025 Risk Ratio (M-H, Random, 95% CI) 1.03 [0.92, 1.15]
3.2 Moderate to high risk of
bias
12 42134 Risk Ratio (M-H, Random, 95% CI) 0.88 [0.79, 0.99]
4 Total MI - LCn3 - SA by
compliance and study size
23 Risk Ratio (M-H, Random, 95% CI) Subtotals only
4.1 SA - low risk of
compliance bias
10 13002 Risk Ratio (M-H, Random, 95% CI) 0.94 [0.79, 1.13]
4.2 SA - 100+ randomised 21 72015 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.88, 1.03]
5 Total MI - LCn3 - subgroup by
fatality
23 Risk Ratio (M-H, Random, 95% CI) Subtotals only
5.1 Fatal MI 15 60471 Risk Ratio (M-H, Random, 95% CI) 0.76 [0.53, 1.10]
5.2 Non-fatal MI 21 70407 Risk Ratio (M-H, Random, 95% CI) 0.96 [0.87, 1.06]
6 Sudden cardiac death (overall) -
LCn3
14 65004 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.80, 1.18]
7 Angina - LCn3 11 39907 Risk Ratio (M-H, Random, 95% CI) 0.99 [0.91, 1.06]
8 Heart failure - LCn3 15 49644 Risk Ratio (M-H, Random, 95% CI) 0.93 [0.85, 1.03]
8.1 Low summary risk of bias 6 24176 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.89, 1.06]
8.2 Moderate to high risk of
bias
9 25468 Risk Ratio (M-H, Random, 95% CI) 0.78 [0.57, 1.08]
9 Revascularisation - LCn3 15 Risk Ratio (M-H, Random, 95% CI) Subtotals only
9.1 CABG - LCn3 5 1535 Risk Ratio (M-H, Random, 95% CI) 0.56 [0.15, 2.14]
9.2 Angioplasty - LCn3 4 3195 Risk Ratio (M-H, Random, 95% CI) 0.96 [0.74, 1.24]
9.3 Any revascularisation -
LCn3
12 66095 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.94, 1.03]
10 Peripheral arterial disease -
LCn3
6 49035 Risk Ratio (M-H, Random, 95% CI) 0.93 [0.74, 1.18]
11 PAD - LCn3 - SA by summary
risk of bias
6 Risk Ratio (M-H, Random, 95% CI) Subtotals only
11.1 Low summary risk of
bias
2 12738 Risk Ratio (M-H, Random, 95% CI) 1.10 [0.75, 1.62]
11.2 Moderate to high
summary risk of bias
4 36297 Risk Ratio (M-H, Random, 95% CI) 0.85 [0.64, 1.14]
12 PAD - LCn3 - SA compliance
and study size
6 Risk Ratio (M-H, Random, 95% CI) Subtotals only
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12.1 SA compliance 1 202 Risk Ratio (M-H, Random, 95% CI) 1.0 [0.06, 15.77]
12.2 SA study size 100+ 6 49035 Risk Ratio (M-H, Random, 95% CI) 0.93 [0.74, 1.18]
13 Acute coronary syndrome -
LCn3
2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
13.1 LCn3 2 2703 Risk Ratio (M-H, Random, 95% CI) 1.19 [0.71, 2.00]
14 Body weight, kg - LCn3 12 15812 Mean Difference (IV, Random, 95% CI) -0.01 [-0.84, 0.82]
15 Weight, kg - LCn3 - SA by
summary risk of bias
12 15812 Mean Difference (IV, Random, 95% CI) -0.01 [-0.84, 0.82]
15.1 Low risk of bias 7 15458 Mean Difference (IV, Random, 95% CI) -0.01 [-0.91, 0.90]
15.2 Moderate/high risk of
bias
5 354 Mean Difference (IV, Random, 95% CI) -0.28 [-3.12, 2.55]
16 Weight, kg - LCn3 - SA by
compliance and study size
10 Mean Difference (IV, Random, 95% CI) Subtotals only
16.1 SA - low risk of
compliance bias
7 828 Mean Difference (IV, Random, 95% CI) 0.58 [-0.52, 1.69]
16.2 SA - 100+ randomised 7 15545 Mean Difference (IV, Random, 95% CI) 0.07 [-0.84, 0.97]
17 Weight, kg - LCn3 - subgroup
by dose
12 Mean Difference (IV, Random, 95% CI) Subtotals only
17.1 LCn3 ≤ 150 mg/d 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
17.2 LCn3 > 150 ≤ 250 mg/d 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
17.3 LCn3 > 250 ≤ 400 mg/d 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
17.4 LCn3 > 400 ≤ 2400 mg/
d
8 15420 Mean Difference (IV, Random, 95% CI) -0.29 [-1.16, 0.58]
17.5 LCn3 > 2.4 ≤ 4.4 g/d 3 241 Mean Difference (IV, Random, 95% CI) 0.07 [-6.38, 6.51]
17.6 LCn3 > 4.4 g/d 2 261 Mean Difference (IV, Random, 95% CI) 1.51 [0.28, 2.75]
18 Weight, kg - LCn3 - subgroup
by replacement
12 Mean Difference (IV, Random, 95% CI) Subtotals only
18.1 N-3 replacing SFA 2 433 Mean Difference (IV, Random, 95% CI) -2.51 [-4.30, -0.72]
18.2 N-3 replacing MUFA 7 15088 Mean Difference (IV, Random, 95% CI) 0.23 [-0.28, 0.75]
18.3 N-3 replacing n-6 1 41 Mean Difference (IV, Random, 95% CI) -1.3 [-3.83, 1.23]
18.4 N-3 replacing carbs/
sugars
1 258 Mean Difference (IV, Random, 95% CI) -2.70 [-4.75, -0.65]
18.5 N-3 replacing nil/low n-
3 placebo
1 202 Mean Difference (IV, Random, 95% CI) 1.5 [0.25, 2.75]
18.6 Replacement unclear 2 223 Mean Difference (IV, Random, 95% CI) 0.60 [-4.93, 6.13]
19 Weight, kg - LCn3 - subgroup
by intervention type
12 15812 Mean Difference (IV, Random, 95% CI) -0.01 [-0.84, 0.82]
19.1 Dietary advice 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19.2 Supplemental foods 1 202 Mean Difference (IV, Random, 95% CI) 1.5 [0.25, 2.75]
19.3 Supplement (capsule) 9 15538 Mean Difference (IV, Random, 95% CI) -0.23 [-1.08, 0.63]
19.4 Any combination 2 72 Mean Difference (IV, Random, 95% CI) -0.43 [-6.47, 5.61]
20 Weight, kg - LCn3 - subgroup
by duration
12 Mean Difference (IV, Random, 95% CI) Subtotals only
20.1 Medium duration 1 to <
2 years in study
8 840 Mean Difference (IV, Random, 95% CI) -0.54 [-2.21, 1.12]
20.2 Medium-long duration:
2 to < 4 years in study
3 436 Mean Difference (IV, Random, 95% CI) 0.67 [-1.58, 2.91]
20.3 Long duration ≥ 4 years
in study
1 14536 Mean Difference (IV, Random, 95% CI) 0.10 [-0.48, 0.68]
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21 Weight, kg - LCn3 - subgroup
by primary or secondary
prevention
12 Mean Difference (IV, Random, 95% CI) Subtotals only
21.1 Primary CVD prevention 10 15578 Mean Difference (IV, Random, 95% CI) 0.05 [-0.83, 0.92]
21.2 Secondary CVD
prevention
2 234 Mean Difference (IV, Random, 95% CI) -1.13 [-4.43, 2.16]
22 Weight, kg - LCn3 - subgroup
by statin use
12 Mean Difference (IV, Random, 95% CI) Subtotals only
22.1 LCn3 -≥ 50% of control
group on statins
2 14631 Mean Difference (IV, Random, 95% CI) 0.64 [-1.88, 3.17]
22.2 LCn3 - < 50% of control
group on statins
5 614 Mean Difference (IV, Random, 95% CI) 0.47 [-0.66, 1.60]
22.3 LCn3 - use of statins
unclear
5 567 Mean Difference (IV, Random, 95% CI) -1.51 [-3.30, 0.27]
23 Body mass index, kg/m² -
LCn3
14 15234 Mean Difference (IV, Random, 95% CI) 0.04 [-0.16, 0.24]
24 BMI, kg/m²- LCn3 - SA by
summary risk of bias
14 15234 Mean Difference (IV, Random, 95% CI) 0.04 [-0.16, 0.24]
24.1 Low risk of bias 5 14190 Mean Difference (IV, Random, 95% CI) -0.01 [-0.36, 0.33]
24.2 Moderate/high risk of
bias
9 1044 Mean Difference (IV, Random, 95% CI) 0.04 [-0.13, 0.20]
25 BMI, kg/m²- LCn3 - SA by
compliance and study size
10 Mean Difference (IV, Random, 95% CI) Subtotals only
25.1 SA - low risk of
compliance bias
5 1848 Mean Difference (IV, Random, 95% CI) 0.09 [-0.21, 0.38]
25.2 SA - 100+ randomised 9 14982 Mean Difference (IV, Random, 95% CI) 0.01 [-0.12, 0.14]
26 BMI, kg/m² - LCn3 - subgroup
by dose
14 Mean Difference (IV, Random, 95% CI) Subtotals only
26.1 LCn3 > 150 ≤ 250 mg/d 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
26.2 LCn3 ≤ 150 mg/d 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
26.3 LCn3 > 250 ≤ 400 mg/d 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
26.4 LCn3 > 400 ≤ 2400 mg/
d
11 14789 Mean Difference (IV, Random, 95% CI) 0.01 [-0.11, 0.13]
26.5 LCn3 > 2.4 ≤ 4.4 g/d 3 445 Mean Difference (IV, Random, 95% CI) 1.42 [-0.51, 3.35]
26.6 LCn3 > 4.4 g/d 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
27 BMI, kg/m² - LCn3 - subgroup
by replacement
14 Mean Difference (IV, Random, 95% CI) Subtotals only
27.1 N-3 replacing SFA 1 258 Mean Difference (IV, Random, 95% CI) -0.60 [-1.14, -0.06]
27.2 N-3 replacing MUFA 7 14180 Mean Difference (IV, Random, 95% CI) 0.08 [-0.12, 0.28]
27.3 N-3 replacing n-6 3 513 Mean Difference (IV, Random, 95% CI) 0.18 [-0.46, 0.81]
27.4 N-3 replacing carbs/
sugars
1 258 Mean Difference (IV, Random, 95% CI) -0.60 [-1.14, -0.06]
27.5 N-3 replacing nil/low n-
3 placebo
1 60 Mean Difference (IV, Random, 95% CI) 1.0 [-1.18, 3.18]
27.6 Replacement unclear 2 223 Mean Difference (IV, Random, 95% CI) 0.58 [-1.17, 2.33]
28 BMI, kg/m² - LCn3 - subgroup
by intervention type
14 15234 Mean Difference (IV, Random, 95% CI) 0.04 [-0.16, 0.24]
28.1 Dietary advice 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
28.2 Supplemental foods 1 1260 Mean Difference (IV, Random, 95% CI) 0.1 [-0.10, 0.30]
28.3 Supplement (capsule) 12 13929 Mean Difference (IV, Random, 95% CI) 0.01 [-0.25, 0.27]
28.4 Any combination 1 45 Mean Difference (IV, Random, 95% CI) 1.60 [-0.43, 3.63]
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29 BMI, kg/m² - LCn3 - subgroup
by duration
14 Mean Difference (IV, Random, 95% CI) Subtotals only
29.1 Medium duration 1 to <
2 years in study
9 906 Mean Difference (IV, Random, 95% CI) 0.24 [-0.40, 0.88]
29.2 Medium-long duration:
2 to < 4 years in study
4 1792 Mean Difference (IV, Random, 95% CI) 0.12 [-0.07, 0.31]
29.3 Long duration ≥ 4 years
in study
1 12536 Mean Difference (IV, Random, 95% CI) 0.0 [-0.20, 0.20]
30 BMI, kg/m² - LCn3 - subgroup
by primary or secondary
prevention
14 Mean Difference (IV, Random, 95% CI) Subtotals only
30.1 Primary CVD prevention 11 13610 Mean Difference (IV, Random, 95% CI) 0.15 [-0.36, 0.66]
30.2 Secondary CVD
prevention
3 1624 Mean Difference (IV, Random, 95% CI) 0.05 [-0.08, 0.18]
31 BMI, kg/m² - LCn3 - subgroup
by statin use
14 Mean Difference (IV, Random, 95% CI) Subtotals only
31.1 LCn3 -≥ 50% of control
group on statins
3 13891 Mean Difference (IV, Random, 95% CI) 0.13 [-0.22, 0.48]
31.2 LCn3 - < 50% of control
group on statins
4 665 Mean Difference (IV, Random, 95% CI) 0.02 [-0.15, 0.19]
31.3 LCn3 - use of statins
unclear
7 678 Mean Difference (IV, Random, 95% CI) 0.06 [-0.86, 0.97]
32 Other measures of adiposity -
LCn3
6 Mean Difference (IV, Random, 95% CI) Subtotals only
32.1 Percentage body fat 2 127 Mean Difference (IV, Random, 95% CI) 0.85 [-6.87, 8.57]
32.2 Percentage visceral fat 1 95 Mean Difference (IV, Random, 95% CI) -1.80 [-15.03, 11.
43]
32.3 Waist circumference, cm 3 676 Mean Difference (IV, Random, 95% CI) 0.66 [-0.09, 1.42]
32.4 Waist-hip ratio 1 100 Mean Difference (IV, Random, 95% CI) 0.0 [-0.01, 0.01]
32.5 Abdominal
circumference, cm
1 256 Mean Difference (IV, Random, 95% CI) -0.70 [-8.78, 7.38]
32.6 Hip circumference, cm 1 258 Mean Difference (IV, Random, 95% CI) -2.40 [-9.80, 5.00]
33 Total cholesterol, serum,
mmoL/L - LCn3
28 37281 Mean Difference (IV, Random, 95% CI) -0.01 [-0.05, 0.04]
34 TC, mmoL/L - LCn3 - SA by
summary risk of bias
28 37281 Mean Difference (IV, Random, 95% CI) -0.01 [-0.05, 0.03]
34.1 Low risk of bias 9 14930 Mean Difference (IV, Random, 95% CI) 0.01 [-0.05, 0.06]
34.2 Moderate/high risk of
bias
19 22351 Mean Difference (IV, Random, 95% CI) -0.03 [-0.09, 0.03]
35 TC, mmoL/L - LCn3 - SA by
compliance and study size
20 Mean Difference (IV, Random, 95% CI) Subtotals only
35.1 SA - low risk of
compliance bias
14 3341 Mean Difference (IV, Random, 95% CI) 0.02 [-0.05, 0.09]
35.2 SA - 100+ randomised 15 36622 Mean Difference (IV, Random, 95% CI) 0.00 [-0.05, 0.06]
36 TC, mmoL/L - LCn3 -
subgroup by dose
28 Mean Difference (IV, Random, 95% CI) Subtotals only
36.1 LCn3 ≤ 150 mg/d 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
36.2 LCn3 > 150 ≤ 250 mg/d 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
36.3 LCn3 > 250 ≤ 400 mg/d 1 1715 Mean Difference (IV, Random, 95% CI) 0.10 [-0.01, 0.21]
36.4 LCn3 > 400 ≤ 2400 mg/
d
18 34262 Mean Difference (IV, Random, 95% CI) -0.03 [-0.06, 0.00]
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36.5 LCn3 > 2.4 ≤ 4.4 g/d 7 1216 Mean Difference (IV, Random, 95% CI) -0.14 [-0.28, -0.01]
36.6 LCn3 > 4.4 g/d 2 88 Mean Difference (IV, Random, 95% CI) 0.08 [-0.28, 0.45]
37 TC, mmoL/L - LCn3 -
subgroup by replacement
28 Mean Difference (IV, Random, 95% CI) Subtotals only
37.1 N-3 replacing SFA 3 2148 Mean Difference (IV, Random, 95% CI) 0.10 [-0.01, 0.20]
37.2 N-3 replacing MUFA 15 16504 Mean Difference (IV, Random, 95% CI) 0.01 [-0.04, 0.06]
37.3 N-3 replacing n-6 5 895 Mean Difference (IV, Random, 95% CI) 0.02 [-0.22, 0.26]
37.4 N-3 replacing carbs/
sugars
1 258 Mean Difference (IV, Random, 95% CI) -0.20 [-1.03, 0.63]
37.5 N-3 replacing nil/low n-
3 placebo
5 19431 Mean Difference (IV, Random, 95% CI) -0.05 [-0.07, -0.03]
37.6 Replacement unclear 2 193 Mean Difference (IV, Random, 95% CI) -0.15 [-0.47, 0.17]
38 TC, mmoL/L - LCn3 -
subgroup by intervention type
28 Mean Difference (IV, Random, 95% CI) Subtotals only
38.1 Dietary advice 1 1715 Mean Difference (IV, Random, 95% CI) 0.10 [-0.01, 0.21]
38.2 Supplemental foods 1 1210 Mean Difference (IV, Random, 95% CI) 0.02 [-0.09, 0.13]
38.3 Supplement (capsule) 24 34145 Mean Difference (IV, Random, 95% CI) -0.05 [-0.07, -0.03]
38.4 Any combination 2 211 Mean Difference (IV, Random, 95% CI) 0.13 [-0.10, 0.37]
39 TC, mmoL/L - LCn3 -
subgroup by duration
28 Mean Difference (IV, Random, 95% CI) Subtotals only
39.1 Medium duration 1 to <
2 years in study
15 1661 Mean Difference (IV, Random, 95% CI) -0.06 [-0.16, 0.04]
39.2 Medium-long duration:
2 to < 4 years in study
10 4231 Mean Difference (IV, Random, 95% CI) 0.02 [-0.05, 0.10]
39.3 Long duration ≥ 4 years
in study
3 31389 Mean Difference (IV, Random, 95% CI) 0.00 [-0.09, 0.09]
40 TC, mmoL/L - LCn3 -
subgroup by primary or
secondary prevention
28 Mean Difference (IV, Random, 95% CI) Subtotals only
40.1 Primary prevention 17 32796 Mean Difference (IV, Random, 95% CI) -0.04 [-0.07, -0.02]
40.2 Secondary prevention 11 4485 Mean Difference (IV, Random, 95% CI) -0.01 [-0.09, 0.08]
41 TC, mmoL/L - LCn3 -
subgroup by statin use
28 Mean Difference (IV, Random, 95% CI) Subtotals only
41.1 LCn3 -≥ 50% of control
group on statins
6 32823 Mean Difference (IV, Random, 95% CI) -0.05 [-0.07, -0.02]
41.2 LCn3 - < 50% of control
group on statins
15 3871 Mean Difference (IV, Random, 95% CI) 0.01 [-0.08, 0.10]
41.3 LCn3 - use of statins
unclear
7 587 Mean Difference (IV, Random, 95% CI) -0.03 [-0.27, 0.22]
42 Triglycerides, fasting, serum,
mmoL/L - LCn3
25 35579 Mean Difference (IV, Random, 95% CI) -0.24 [-0.31, -0.16]
43 TG, fasting, mmoL/L - LCn3 -
SA by summary risk of bias
25 35579 Mean Difference (IV, Random, 95% CI) -0.23 [-0.30, -0.16]
43.1 Low risk of bias 8 14654 Mean Difference (IV, Random, 95% CI) -0.17 [-0.25, -0.09]
43.2 Moderate/high risk of
bias
17 20925 Mean Difference (IV, Random, 95% CI) -0.25 [-0.35, -0.15]
44 TG, fasting, mmoL/L - LCn3
- SA by compliance and study
size
19 Mean Difference (IV, Random, 95% CI) Subtotals only
44.1 SA - low risk of
compliance bias
12 3306 Mean Difference (IV, Random, 95% CI) -0.26 [-0.36, -0.16]
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44.2 SA - 100+ randomised 18 35197 Mean Difference (IV, Random, 95% CI) -0.24 [-0.32, -0.16]
45 TG, fasting, mmoL/L - LCn3 -
subgroup by dose
25 Mean Difference (IV, Random, 95% CI) Subtotals only
45.1 LCn3 ≤ 150 mg/d 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
45.2 LCn3 > 150 ≤ 250 mg/d 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
45.3 LCn3 > 250 ≤ 400 mg/d 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
45.4 LCn3 > 400 ≤ 2400 mg/
d
18 34388 Mean Difference (IV, Random, 95% CI) -0.18 [-0.25, -0.11]
45.5 LCn3 > 2.4 ≤ 4.4 g/d 5 1107 Mean Difference (IV, Random, 95% CI) -0.36 [-0.53, -0.20]
45.6 LCn3 > 4.4 g/d 2 84 Mean Difference (IV, Random, 95% CI) -0.41 [-0.68, -0.14]
46 TG, fasting, mmoL/L - LCn3 -
subgroup by replacement
25 Mean Difference (IV, Random, 95% CI) Subtotals only
46.1 N-3 replacing SFA 2 429 Mean Difference (IV, Random, 95% CI) -0.27 [-0.59, 0.04]
46.2 N-3 replacing MUFA 13 14634 Mean Difference (IV, Random, 95% CI) -0.18 [-0.25, -0.10]
46.3 N-3 replacing n-6 5 876 Mean Difference (IV, Random, 95% CI) -0.27 [-0.45, -0.08]
46.4 N-3 replacing carbs/
sugars
1 258 Mean Difference (IV, Random, 95% CI) -0.5 [-1.49, 0.49]
46.5 N-3 replacing nil/low n-
3 placebo
4 19357 Mean Difference (IV, Random, 95% CI) -0.18 [-0.51, 0.14]
46.6 Replacement unclear 2 454 Mean Difference (IV, Random, 95% CI) -0.38 [-0.57, -0.19]
47 TG, fasting, mmoL/L - LCn3 -
subgroup by intervention type
25 Mean Difference (IV, Random, 95% CI) Subtotals only
47.1 Dietary advice 1 71 Mean Difference (IV, Random, 95% CI) 0.02 [-0.36, 0.40]
47.2 Supplemental foods 1 1210 Mean Difference (IV, Random, 95% CI) -0.03 [-0.15, 0.09]
47.3 Supplement (capsule) 22 34137 Mean Difference (IV, Random, 95% CI) -0.19 [-0.38, -0.00]
47.4 Any combination 1 161 Mean Difference (IV, Random, 95% CI) 0.01 [-0.28, 0.30]
48 TG, fasting, mmoL/L - LCn3 -
subgroup by duration
25 Mean Difference (IV, Random, 95% CI) Subtotals only
48.1 Medium duration 1 to <
2 years in study
13 1880 Mean Difference (IV, Random, 95% CI) -0.27 [-0.36, -0.19]
48.2 Medium-long duration:
2 to < 4 years in study
9 2310 Mean Difference (IV, Random, 95% CI) -0.16 [-0.31, -0.02]
48.3 Long duration ≥ 4 years
in study
3 31389 Mean Difference (IV, Random, 95% CI) -0.20 [-0.32, -0.07]
49 TG, fasting, mmoL/L - LCn3
- subgroup by primary or
secondary prevention
25 Mean Difference (IV, Random, 95% CI) Subtotals only
49.1 Primary prevention 17 33114 Mean Difference (IV, Random, 95% CI) -0.20 [-0.26, -0.14]
49.2 Secondary prevention 8 2465 Mean Difference (IV, Random, 95% CI) -0.27 [-0.44, -0.10]
50 TG, fasting, mmoL/L - LCn3 -
subgroup by statin use
25 Mean Difference (IV, Random, 95% CI) Subtotals only
50.1 LCn3 -≥ 50% of control
group on statins
5 32557 Mean Difference (IV, Random, 95% CI) -0.11 [-0.21, -0.01]
50.2 LCn3 - < 50% of control
group on statins
14 2414 Mean Difference (IV, Random, 95% CI) -0.27 [-0.36, -0.18]
50.3 LCn3 - use of statins
unclear
6 608 Mean Difference (IV, Random, 95% CI) -0.23 [-0.38, -0.08]
51 High-density lipoprotein,
serum, mmoL/L - LCn3
27 37237 Mean Difference (IV, Random, 95% CI) 0.02 [0.00, 0.04]
52 HDL, mmoL/L - LCn3 - SA
by summary risk of bias
27 37237 Mean Difference (IV, Random, 95% CI) 0.03 [0.01, 0.05]
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52.1 Low risk of bias 8 14892 Mean Difference (IV, Random, 95% CI) 0.03 [-0.01, 0.07]
52.2 Moderate/high risk of
bias
19 22345 Mean Difference (IV, Random, 95% CI) 0.03 [0.00, 0.06]
53 HDL, mmoL/L - LCn3 - SA
by compliance and study size
20 Mean Difference (IV, Random, 95% CI) Subtotals only
53.1 SA - low risk of
compliance bias
13 3202 Mean Difference (IV, Random, 95% CI) 0.05 [0.01, 0.10]
53.2 SA - 100+ randomised 15 36573 Mean Difference (IV, Random, 95% CI) 0.03 [0.00, 0.05]
54 HDL, mmoL/L - LCn3 -
subgroup by dose
27 Mean Difference (IV, Random, 95% CI) Subtotals only
54.1 LCn3 ≤ 150 mg/d 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
54.2 LCn3 > 150 ≤ 250 mg/d 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
54.3 LCn3 > 250 ≤ 400 mg/d 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
54.4 LCn3 > 400 ≤ 2400 mg/
d
19 35972 Mean Difference (IV, Random, 95% CI) 0.02 [-0.00, 0.04]
54.5 LCn3 > 2.4 ≤ 4.4 g/d 7 1206 Mean Difference (IV, Random, 95% CI) 0.06 [0.00, 0.12]
54.6 LCn3 > 4.4 g/d 1 59 Mean Difference (IV, Random, 95% CI) 0.0 [-0.16, 0.16]
55 HDL, mmoL/L - LCn3 -
subgroup by replacement
27 Mean Difference (IV, Random, 95% CI) Subtotals only
55.1 N-3 replacing SFA 3 2143 Mean Difference (IV, Random, 95% CI) -0.02 [-0.10, 0.07]
55.2 N-3 replacing MUFA 15 16505 Mean Difference (IV, Random, 95% CI) 0.02 [-0.01, 0.06]
55.3 N-3 replacing n-6 4 850 Mean Difference (IV, Random, 95% CI) 0.04 [-0.01, 0.09]
55.4 N-3 replacing carbs/
sugars
1 258 Mean Difference (IV, Random, 95% CI) 0.10 [-0.17, 0.37]
55.5 N-3 replacing nil/low n-
3 placebo
5 19431 Mean Difference (IV, Random, 95% CI) 0.04 [-0.03, 0.11]
55.6 Replacement unclear 2 193 Mean Difference (IV, Random, 95% CI) 0.05 [-0.10, 0.20]
56 HDL, mmoL/L - LCn3 -
subgroup by intervention type
27 Mean Difference (IV, Random, 95% CI) Subtotals only
56.1 Dietary advice 2 1785 Mean Difference (IV, Random, 95% CI) 0.01 [-0.02, 0.04]
56.2 Supplemental foods 1 1210 Mean Difference (IV, Random, 95% CI) 0.03 [0.00, 0.06]
56.3 Supplement (capsule) 21 34008 Mean Difference (IV, Random, 95% CI) 0.03 [0.00, 0.06]
56.4 Any combination 3 234 Mean Difference (IV, Random, 95% CI) 0.10 [-0.10, 0.31]
57 HDL, mmoL/L - LCn3 -
subgroup by duration
27 Mean Difference (IV, Random, 95% CI) Subtotals only
57.1 Medium duration 1 to <
2 years in study
13 1562 Mean Difference (IV, Random, 95% CI) 0.08 [0.01, 0.14]
57.2 Medium-long duration:
2 to < 4 years in study
11 4286 Mean Difference (IV, Random, 95% CI) 0.02 [-0.01, 0.04]
57.3 Long duration ≥ 4 years
in study
3 31389 Mean Difference (IV, Random, 95% CI) 0.00 [-0.01, 0.01]
58 HDL, mmoL/L - LCn3
- subgroup by primary or
secondary prevention
26 Mean Difference (IV, Random, 95% CI) Subtotals only
58.1 Primary prevention 17 32856 Mean Difference (IV, Random, 95% CI) 0.03 [-0.00, 0.05]
58.2 Secondary prevention 9 4307 Mean Difference (IV, Random, 95% CI) 0.03 [-0.01, 0.07]
59 HDL, mmoL/L - LCn3 -
subgroup by statin use
27 Mean Difference (IV, Random, 95% CI) Subtotals only
59.1 LCn3 -≥ 50% of control
group on statins
7 32894 Mean Difference (IV, Random, 95% CI) 0.01 [-0.01, 0.03]
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59.2 LCn3 - < 50% of control
group on statins
13 3690 Mean Difference (IV, Random, 95% CI) 0.04 [-0.00, 0.08]
59.3 LCn3 - use of statins
unclear
7 653 Mean Difference (IV, Random, 95% CI) 0.07 [-0.07, 0.21]
60 Low-density lipoprotein,
serum, mmoL/L - LCn3
23 35035 Mean Difference (IV, Random, 95% CI) 0.01 [-0.01, 0.03]
61 LDL, mmoL/L - LCn3 - SA by
summary risk of bias
23 35035 Mean Difference (IV, Random, 95% CI) 0.01 [-0.01, 0.03]
61.1 Low risk of bias 9 14840 Mean Difference (IV, Random, 95% CI) 0.02 [-0.03, 0.07]
61.2 Moderate/high risk of
bias
14 20195 Mean Difference (IV, Random, 95% CI) 0.00 [-0.02, 0.03]
62 LDL, mmoL/L - LCn3 - SA by
compliance and study size
17 37718 Mean Difference (IV, Random, 95% CI) 0.02 [-0.01, 0.05]
62.1 SA - low risk of
compliance bias
13 3165 Mean Difference (IV, Random, 95% CI) 0.05 [-0.02, 0.11]
62.2 SA - 100+ randomised 14 34553 Mean Difference (IV, Random, 95% CI) 0.01 [-0.02, 0.04]
63 LDL, mmoL/L - LCn3 -
subgroup by dose
23 Mean Difference (IV, Random, 95% CI) Subtotals only
63.1 LCn3 ≤ 150 mg/d 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
63.2 LCn3 > 150 ≤ 250 mg/d 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
63.3 LCn3 > 250 ≤ 400 mg/d 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
63.4 LCn3 > 400 ≤ 2400 mg/
d
16 34054 Mean Difference (IV, Random, 95% CI) 0.01 [-0.01, 0.02]
63.5 LCn3 > 2.4 ≤ 4.4 g/d 5 893 Mean Difference (IV, Random, 95% CI) 0.01 [-0.14, 0.15]
63.6 LCn3 > 4.4 g/d 2 88 Mean Difference (IV, Random, 95% CI) 0.22 [-0.09, 0.54]
64 LDL, mmoL/L - LCn3 -
subgroup by replacement
23 Mean Difference (IV, Random, 95% CI) Subtotals only
64.1 N-3 replacing SFA 2 429 Mean Difference (IV, Random, 95% CI) 0.17 [-0.14, 0.47]
64.2 N-3 replacing MUFA 14 14710 Mean Difference (IV, Random, 95% CI) 0.01 [-0.03, 0.05]
64.3 N-3 replacing n-6 2 242 Mean Difference (IV, Random, 95% CI) 0.14 [-0.26, 0.55]
64.4 N-3 replacing carbs/
sugars
1 258 Mean Difference (IV, Random, 95% CI) 0.20 [-0.51, 0.91]
64.5 N-3 replacing nil/low n-
3 placebo
3 19297 Mean Difference (IV, Random, 95% CI) 0.00 [-0.02, 0.02]
64.6 Replacement unclear 3 528 Mean Difference (IV, Random, 95% CI) 0.10 [-0.03, 0.23]
65 LDL, mmoL/L - LCn3 -
subgroup by intervention type
23 Mean Difference (IV, Random, 95% CI) Subtotals only
65.1 Dietary advice 1 71 Mean Difference (IV, Random, 95% CI) 0.08 [-0.22, 0.38]
65.2 Supplemental foods 1 1124 Mean Difference (IV, Random, 95% CI) -0.02 [-0.10, 0.06]
65.3 Supplement (capsule) 19 33768 Mean Difference (IV, Random, 95% CI) 0.01 [-0.01, 0.03]
65.4 Any combination 2 72 Mean Difference (IV, Random, 95% CI) 0.08 [-0.44, 0.61]
66 LDL, mmoL/L - LCn3 -
subgroup by duration
23 Mean Difference (IV, Random, 95% CI) Subtotals only
66.1 Medium duration 1 to <
2 years in study
14 1862 Mean Difference (IV, Random, 95% CI) 0.06 [-0.03, 0.14]
66.2 Medium-long duration:
2 to < 4 years in study
6 1784 Mean Difference (IV, Random, 95% CI) -0.01 [-0.08, 0.06]
66.3 Long duration ≥ 4 years
in study
3 31389 Mean Difference (IV, Random, 95% CI) 0.03 [-0.04, 0.10]
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67 LDL, mmoL/L - LCn3 -
subgroup by primary or
secondary prevention
23 Mean Difference (IV, Random, 95% CI) Subtotals only
67.1 Primary prevention 16 32717 Mean Difference (IV, Random, 95% CI) 0.01 [-0.01, 0.03]
67.2 Secondary prevention 7 2318 Mean Difference (IV, Random, 95% CI) 0.01 [-0.05, 0.08]
68 LDL, mmoL/L - LCn3 -
subgroup by statin use
23 Mean Difference (IV, Random, 95% CI) Subtotals only
68.1 LCn3 -≥ 50% of control
group on statins
7 32808 Mean Difference (IV, Random, 95% CI) 0.00 [-0.02, 0.02]
68.2 LCn3 - < 50% of control
group on statins
9 1564 Mean Difference (IV, Random, 95% CI) 0.12 [0.03, 0.21]
68.3 LCn3 - use of statins
unclear
7 663 Mean Difference (IV, Random, 95% CI) -0.01 [-0.17, 0.14]
Comparison 3. High vs low LCn3 omega-3 fats (tertiary outcomes)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Blood pressure, mmHg - LCn3 15 Mean Difference (IV, Random, 95% CI) Subtotals only
1.1 Systolic BP - LCn3 15 34413 Mean Difference (IV, Random, 95% CI) 0.02 [-0.32, 0.35]
1.2 Diastolic BP - LCn3 14 35386 Mean Difference (IV, Random, 95% CI) -0.02 [-0.22, 0.17]
2 Serious adverse events - LCn3 14 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 Any serious adverse events 1 402 Risk Ratio (M-H, Random, 95% CI) 1.05 [0.78, 1.41]
2.2 Bleeding 8 45562 Risk Ratio (M-H, Random, 95% CI) 1.06 [0.73, 1.52]
2.3 GI hospitalisation 1 200 Risk Ratio (M-H, Random, 95% CI) 1.75 [0.53, 5.79]
2.4 Pulmonary embolus or
DVT - LCn3
4 3011 Risk Ratio (M-H, Random, 95% CI) 1.25 [0.41, 3.78]
2.5 Progression to advanced
AMD (age-related macular
degeneration)
1 4203 Risk Ratio (M-H, Random, 95% CI) 0.96 [0.90, 1.02]
3 Side effects - LCn3 33 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 Dropouts due to side
effects
23 16755 Risk Ratio (M-H, Random, 95% CI) 1.16 [0.99, 1.36]
3.2 Abdominal pain or
discomfort
7 14650 Risk Ratio (M-H, Random, 95% CI) 1.10 [0.84, 1.45]
3.3 Diarrhoea 10 2428 Risk Ratio (M-H, Random, 95% CI) 1.15 [0.92, 1.43]
3.4 Nausea 5 1234 Risk Ratio (M-H, Random, 95% CI) 1.73 [1.23, 2.44]
3.5 Any gastrointestinal side
effect - LCn3 fats
29 65185 Risk Ratio (M-H, Random, 95% CI) 1.12 [0.94, 1.34]
3.6 Skin problems (itching,
rashes)
8 36186 Risk Ratio (M-H, Random, 95% CI) 1.04 [0.47, 2.30]
3.7 Headache or worsening
migraine
3 991 Risk Ratio (M-H, Random, 95% CI) 0.80 [0.48, 1.35]
3.8 Reflux 1 202 Risk Ratio (M-H, Random, 95% CI) 1.42 [0.71, 2.81]
3.9 Pain (joint, lumbar,
muscle pain)
1 18645 Risk Ratio (M-H, Random, 95% CI) 0.80 [0.64, 0.99]
3.10 All side effects combined 13 38904 Risk Ratio (M-H, Random, 95% CI) 1.01 [0.95, 1.08]
4 Dropouts - LCn3 30 31321 Risk Ratio (M-H, Random, 95% CI) 1.02 [0.95, 1.09]
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Comparison 4. High vs low ALA omega-3 fat (primary outcomes)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 All-cause mortality (overall) -
ALA
5 19327 Risk Ratio (M-H, Random, 95% CI) 1.01 [0.84, 1.20]
2 All-cause mortality - ALA
- sensitivity analysis (SA)
fixed-effect
5 16923 Risk Ratio (M-H, Fixed, 95% CI) 1.06 [0.84, 1.34]
3 All-cause mortality - ALA - SA
by summary risk of bias
5 19327 Risk Ratio (M-H, Random, 95% CI) 1.01 [0.84, 1.20]
3.1 Low risk of bias 3 5213 Risk Ratio (M-H, Random, 95% CI) 1.02 [0.72, 1.45]
3.2 Moderate/high risk of bias 2 14114 Risk Ratio (M-H, Random, 95% CI) 1.09 [0.71, 1.67]
4 All-cause mortality - ALA - SA
by compliance and study size
5 Risk Ratio (M-H, Random, 95% CI) Subtotals only
4.1 SA - low risk of
compliance bias
3 5811 Risk Ratio (M-H, Random, 95% CI) 1.05 [0.68, 1.63]
4.2 SA - 100+ randomised 5 19327 Risk Ratio (M-H, Random, 95% CI) 1.01 [0.84, 1.20]
5 All-cause mortality - ALA -
subgroup by dose
5 19327 Risk Ratio (M-H, Random, 95% CI) 1.01 [0.84, 1.20]
5.1 ALA low < 5 g/d 1 4837 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.80, 1.19]
5.2 ALA high ≥ 5 g/d 4 14490 Risk Ratio (M-H, Random, 95% CI) 1.16 [0.77, 1.75]
6 All-cause mortality - ALA -
subgroup by replacement
5 Risk Ratio (M-H, Random, 95% CI) Subtotals only
6.1 ALA replacing SFA 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
6.2 ALA replacing MUFA 1 4837 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.80, 1.19]
6.3 ALA replacing n-6 2 13672 Risk Ratio (M-H, Random, 95% CI) 1.37 [0.48, 3.86]
6.4 ALA replacing CHO 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
6.5 ALA replacing nil/low n-3
placebo
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
6.6 ALA replacement unclear 2 818 Risk Ratio (M-H, Random, 95% CI) 2.78 [0.29, 26.49]
7 All cause mortality - ALA -
subgroup by intervention type
5 19327 Risk Ratio (M-H, Random, 95% CI) 1.01 [0.84, 1.20]
7.1 Dietary advice 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
7.2 Supplemental foods 4 5921 Risk Ratio (M-H, Random, 95% CI) 0.99 [0.82, 1.21]
7.3 Supplements (capsule) 1 13406 Risk Ratio (M-H, Random, 95% CI) 1.07 [0.70, 1.64]
7.4 Any combination 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
8 All-cause mortality - ALA -
subgroup by duration
5 19327 Risk Ratio (M-H, Random, 95% CI) 1.01 [0.84, 1.20]
8.1 Medium duration 1 to < 2
years in study
2 13516 Risk Ratio (M-H, Random, 95% CI) 1.09 [0.71, 1.67]
8.2 Medium-long duration: 2
to < 4 years in study
3 5811 Risk Ratio (M-H, Random, 95% CI) 1.05 [0.68, 1.63]
8.3 Long duration: ≥ 4 years
in study
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
9 All-cause mortality - ALA
- subgroup by primary or
secondary prevention
5 19327 Risk Ratio (M-H, Random, 95% CI) 1.01 [0.84, 1.20]
9.1 Primary CVD prevention 3 14380 Risk Ratio (M-H, Random, 95% CI) 1.14 [0.75, 1.74]
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9.2 Secondary CVD
prevention
2 4947 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.81, 1.19]
10 All-cause mortality - ALA -
subgroup by statin use
5 16923 Risk Ratio (M-H, Random, 95% CI) 1.05 [0.84, 1.33]
10.1 ALA - ≥ 50% of control
group on statins
2 2543 Risk Ratio (M-H, Random, 95% CI) 1.02 [0.77, 1.34]
10.2 ALA - < 50% of control
group on statins
3 14380 Risk Ratio (M-H, Random, 95% CI) 1.14 [0.75, 1.74]
11 Cardiovascular mortality
(overall) - ALA
4 18619 Risk Ratio (M-H, Random, 95% CI) 0.96 [0.74, 1.25]
12 CVD mortality - ALA - SA
fixed-effect
4 18619 Risk Ratio (M-H, Fixed, 95% CI) 0.96 [0.74, 1.25]
13 CVD mortality - ALA - SA by
summary risk of bias
4 18619 Risk Ratio (M-H, Random, 95% CI) 0.96 [0.74, 1.25]
13.1 Low risk of bias 3 5213 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.70, 1.28]
13.2 Moderate/high risk of
bias
1 13406 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.58, 1.70]
14 CVD mortality - ALA - SA by
compliance and study size
4 23722 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.78, 1.16]
14.1 SA - low risk of
compliance bias
2 5103 Risk Ratio (M-H, Random, 95% CI) 0.94 [0.70, 1.27]
14.2 SA - 100+ randomised 4 18619 Risk Ratio (M-H, Random, 95% CI) 0.96 [0.74, 1.25]
15 CVD mortality - ALA -
subgroup by dose
4 18619 Risk Ratio (M-H, Random, 95% CI) 0.96 [0.74, 1.25]
15.1 ALA low < 5 g/d 1 4837 Risk Ratio (M-H, Random, 95% CI) 0.94 [0.69, 1.27]
15.2 ALA high ≥ 5 g/d 3 13782 Risk Ratio (M-H, Random, 95% CI) 1.04 [0.62, 1.73]
16 CVD mortality - ALA -
subgroup by replacement
4 Risk Ratio (M-H, Random, 95% CI) Subtotals only
16.1 N-3 replacing SFA 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
16.2 N-3 replacing MUFA 1 4837 Risk Ratio (M-H, Random, 95% CI) 0.94 [0.69, 1.27]
16.3 N-3 replacing n-6 2 13672 Risk Ratio (M-H, Random, 95% CI) 1.01 [0.60, 1.70]
16.4 N-3 replacing
carbohydrates/sugars
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
16.5 N-3 replacing nil/low n-
3 placebo
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
16.6 Replacement unclear 1 110 Risk Ratio (M-H, Random, 95% CI) 2.69 [0.11, 64.74]
17 CVD mortality - ALA -
subgroup by intervention type
4 18619 Risk Ratio (M-H, Random, 95% CI) 0.96 [0.74, 1.25]
17.1 Dietary advice 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
17.2 Supplemental foods 3 5213 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.70, 1.28]
17.3 Supplements (capsule) 1 13406 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.58, 1.70]
17.4 Any combination 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
18 CVD mortality - ALA -
subgroup by duration
4 18619 Risk Ratio (M-H, Random, 95% CI) 0.96 [0.74, 1.25]
18.1 Medium duration 1 to <
2 years in study
2 13516 Risk Ratio (M-H, Random, 95% CI) 1.02 [0.61, 1.73]
18.2 Medium-long duration:
2 to < 4 years in study
2 5103 Risk Ratio (M-H, Random, 95% CI) 0.94 [0.70, 1.27]
18.3 Long duration: ≥ 4 years
in study
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
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19 CVD mortality - ALA -
subgroup by primary or
secondary prevention
4 18619 Risk Ratio (M-H, Random, 95% CI) 0.96 [0.74, 1.25]
19.1 Primary prevention 1 13406 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.58, 1.70]
19.2 Secondary prevention 3 5213 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.70, 1.28]
20 CVD mortality - ALA -
subgroup by statin uses
4 18619 Risk Ratio (M-H, Random, 95% CI) 0.96 [0.74, 1.25]
20.1 ALA - ≥ 50% of control
group on statins
2 4947 Risk Ratio (M-H, Random, 95% CI) 0.94 [0.70, 1.28]
20.2 ALA - < 50% of control
group on statins
2 13672 Risk Ratio (M-H, Random, 95% CI) 1.01 [0.60, 1.70]
21 Cardiovascular events (overall)
- ALA
5 19327 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.83, 1.07]
22 CVD events - ALA - SA
fixed-effect
5 19327 Risk Ratio (M-H, Fixed, 95% CI) 0.95 [0.84, 1.07]
23 CVD events - ALA - SA by
summary risk of bias
5 19327 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.83, 1.07]
23.1 Low risk of bias 3 5213 Risk Ratio (M-H, Random, 95% CI) 0.91 [0.79, 1.04]
23.2 Moderate/high risk of
bias
2 14114 Risk Ratio (M-H, Random, 95% CI) 1.12 [0.84, 1.48]
24 CVD events - ALA - SA by
compliance and study size
5 Risk Ratio (M-H, Random, 95% CI) Subtotals only
24.1 SA - low risk of
compliance bias
3 5811 Risk Ratio (M-H, Random, 95% CI) 0.90 [0.79, 1.04]
24.2 SA - 100+ randomised 5 19327 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.83, 1.07]
25 CVD events - ALA - subgroup
by dose
5 19327 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.83, 1.07]
25.1 ALA low < 5 g/d 1 4837 Risk Ratio (M-H, Random, 95% CI) 0.91 [0.79, 1.05]
25.2 ALA high ≥ 5 g/d 4 14490 Risk Ratio (M-H, Random, 95% CI) 1.07 [0.82, 1.40]
26 CVD events - ALA - subgroup
by replacement
5 Risk Ratio (M-H, Random, 95% CI) Subtotals only
26.1 N-3 replacing SFA 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
26.2 N-3 replacing MUFA 1 4837 Risk Ratio (M-H, Random, 95% CI) 0.91 [0.79, 1.05]
26.3 N-3 replacing n-6 2 13672 Risk Ratio (M-H, Random, 95% CI) 0.76 [0.24, 2.41]
26.4 N-3 replacing
carbohydrates/sugars
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
26.5 N-3 replacing nil/low n-
3 placebo
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
26.6 Replacement unclear 2 818 Risk Ratio (M-H, Random, 95% CI) 0.93 [0.36, 2.43]
27 CVD events - ALA - subgroup
by intervention type
6 19526 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.83, 1.07]
27.1 Dietary advice 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
27.2 Supplemental foods 5 6120 Risk Ratio (M-H, Random, 95% CI) 0.91 [0.79, 1.04]
27.3 Supplements (capsule) 1 13406 Risk Ratio (M-H, Random, 95% CI) 1.13 [0.85, 1.51]
27.4 Any combination 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
28 CVD events - ALA - subgroup
by duration
5 19327 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.83, 1.07]
28.1 Medium duration 1 to <
2 years in study
2 13516 Risk Ratio (M-H, Random, 95% CI) 1.13 [0.86, 1.50]
28.2 Medium-long duration:
2 to < 4 years in study
3 5811 Risk Ratio (M-H, Random, 95% CI) 0.90 [0.79, 1.04]
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28.3 Long duration: ≥ 4 years
in study
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
29 CVD events - ALA - subgroup
by primary or secondary
prevention
5 19327 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.83, 1.07]
29.1 Primary prevention 3 14380 Risk Ratio (M-H, Random, 95% CI) 0.87 [0.46, 1.67]
29.2 Secondary prevention 2 4947 Risk Ratio (M-H, Random, 95% CI) 0.92 [0.80, 1.05]
30 CVD events - ALA - subgroup
by statin use
5 19327 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.83, 1.07]
30.1 ALA - ≥ 50% of control
group on statins
2 4947 Risk Ratio (M-H, Random, 95% CI) 0.92 [0.80, 1.05]
30.2 ALA - < 50% of control
group on statins
3 14380 Risk Ratio (M-H, Random, 95% CI) 0.87 [0.46, 1.67]
31 Coronary heart disease
mortality (overall) - ALA
3 18353 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.72, 1.26]
32 CHD mortality - ALA - SA
fixed-effect
3 18353 Risk Ratio (M-H, Fixed, 95% CI) 0.95 [0.72, 1.26]
33 CHD mortality - ALA - SA by
summary risk of bias
3 18353 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.72, 1.26]
33.1 Low risk of bias 2 4947 Risk Ratio (M-H, Random, 95% CI) 0.93 [0.67, 1.30]
33.2 Moderate/high risk of
bias
1 13406 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.58, 1.70]
34 CHD mortality - ALA - SA by
compliance and study size
3 Risk Ratio (M-H, Random, 95% CI) Subtotals only
34.1 SA - low risk of
compliance bias
1 4837 Risk Ratio (M-H, Random, 95% CI) 0.92 [0.66, 1.28]
34.2 SA - 100+ randomised 3 18353 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.72, 1.26]
35 CHD mortality - ALA -
subgroup by dose
3 18353 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.72, 1.26]
35.1 ALA low < 5 g/d 1 4837 Risk Ratio (M-H, Random, 95% CI) 0.92 [0.66, 1.28]
35.2 ALA high ≥ 5 g/d 2 13516 Risk Ratio (M-H, Random, 95% CI) 1.02 [0.61, 1.73]
36 CHD mortality - ALA -
subgroup by replacement
3 Risk Ratio (M-H, Random, 95% CI) Subtotals only
36.1 N-3 replacing SFA 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
36.2 Coronary heart
mortality- ALA
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
36.3 N-3 replacing MUFA 1 4837 Risk Ratio (M-H, Random, 95% CI) 0.92 [0.66, 1.28]
36.4 N-3 replacing n-6 1 13406 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.58, 1.70]
36.5 N-3 replacing
carbohydrates/sugars
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
36.6 N-3 replacing nil/low n-
3 placebo
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
36.7 Replacement unclear 1 110 Risk Ratio (M-H, Random, 95% CI) 2.69 [0.11, 64.74]
37 CHD mortality - ALA -
subgroup by intervention type
3 18353 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.72, 1.26]
37.1 Dietary advice 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
37.2 Supplemental foods 2 4947 Risk Ratio (M-H, Random, 95% CI) 0.93 [0.67, 1.30]
37.3 Supplements (capsule) 1 13406 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.58, 1.70]
37.4 Any combination 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
38 CHD mortality - ALA -
subgroup by duration
3 18353 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.72, 1.26]
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38.1 Medium duration 1 to <
2 years in study
2 13516 Risk Ratio (M-H, Random, 95% CI) 1.02 [0.61, 1.73]
38.2 Medium-long duration:
2 to < 4 years in study
1 4837 Risk Ratio (M-H, Random, 95% CI) 0.92 [0.66, 1.28]
38.3 Long duration: ≥ 4 years
in study
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
39 CHD mortality - ALA -
subgroup by primary or
secondary prevention
3 18353 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.72, 1.26]
39.1 Primary prevention of
CVD
1 13406 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.58, 1.70]
39.2 Secondary prevention of
CVD
2 4947 Risk Ratio (M-H, Random, 95% CI) 0.93 [0.67, 1.30]
40 CHD mortality - ALA -
subgroup by statin use
3 18353 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.72, 1.26]
40.1 ALA - ≥ 50% of control
group on statins
2 4947 Risk Ratio (M-H, Random, 95% CI) 0.93 [0.67, 1.30]
40.2 ALA - < 50% of control
group on statins
1 13406 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.58, 1.70]
41 CHD mortality - ALA -
subgroup by CAD history
3 18353 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.72, 1.26]
41.1 Previous CAD 1 4837 Risk Ratio (M-H, Random, 95% CI) 0.92 [0.66, 1.28]
41.2 No previous CAD 2 13516 Risk Ratio (M-H, Random, 95% CI) 1.02 [0.61, 1.73]
42 Coronary heart disease events
(overall) - ALA
4 19061 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.82, 1.22]
43 CHD events - ALA - SA
fixed-effect
4 19061 Risk Ratio (M-H, Fixed, 95% CI) 1.00 [0.82, 1.21]
44 CHD events - ALA - SA by
summary risk of bias
4 19061 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.82, 1.22]
44.1 Low risk of bias 2 4947 Risk Ratio (M-H, Random, 95% CI) 0.91 [0.71, 1.15]
44.2 Moderate/high risk of
bias
2 14114 Risk Ratio (M-H, Random, 95% CI) 1.20 [0.86, 1.67]
45 CHD events - ALA - SA by
compliance and study size
4 Risk Ratio (M-H, Random, 95% CI) Subtotals only
45.1 SA - low risk of
compliance bias
2 5545 Risk Ratio (M-H, Random, 95% CI) 0.92 [0.73, 1.17]
45.2 SA - 100+ randomised 4 19061 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.82, 1.22]
46 CHD events - ALA - subgroup
by dose
4 19061 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.82, 1.22]
46.1 ALA low < 5 g/d 1 4837 Risk Ratio (M-H, Random, 95% CI) 0.92 [0.72, 1.17]
46.2 ALA high ≥ 5 g/d 3 14224 Risk Ratio (M-H, Random, 95% CI) 1.16 [0.84, 1.61]
47 CHD events - ALA - subgroup
by replacement
4 Risk Ratio (M-H, Random, 95% CI) Subtotals only
47.1 N-3 replacing SFA 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
47.2 N-3 replacing MUFA 1 4837 Risk Ratio (M-H, Random, 95% CI) 0.92 [0.72, 1.17]
47.3 N-3 replacing n-6 1 13406 Risk Ratio (M-H, Random, 95% CI) 1.19 [0.85, 1.65]
47.4 N-3 replacing
carbohydrates/sugars
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
47.5 N-3 replacing nil/low n-
3 placebo
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
47.6 Replacement unclear 2 818 Risk Ratio (M-H, Random, 95% CI) 0.69 [0.08, 5.81]
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48 CHD events - ALA - subgroup
by intervention type
4 19061 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.82, 1.22]
48.1 Dietary advice 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
48.2 Supplemental foods 3 5655 Risk Ratio (M-H, Random, 95% CI) 0.91 [0.72, 1.16]
48.3 Supplements (capsule) 1 13406 Risk Ratio (M-H, Random, 95% CI) 1.19 [0.85, 1.65]
48.4 Any combination 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
49 CHD events - ALA - subgroup
by duration
4 19061 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.82, 1.22]
49.1 Medium duration 1 to <
2 years in study
2 13516 Risk Ratio (M-H, Random, 95% CI) 0.94 [0.34, 2.58]
49.2 Medium-long duration:
2 to < 4 years in study
2 5545 Risk Ratio (M-H, Random, 95% CI) 0.92 [0.73, 1.17]
49.3 Long duration: ≥ 4 years
in study
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
50 CHD events - ALA - subgroup
by primary or secondary
prevention
4 19061 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.82, 1.22]
50.1 Primary prevention 2 14114 Risk Ratio (M-H, Random, 95% CI) 1.20 [0.86, 1.67]
50.2 Secondary prevention 2 4947 Risk Ratio (M-H, Random, 95% CI) 0.91 [0.71, 1.15]
51 CHD events - ALA - subgroup
by statin use
4 19061 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.82, 1.22]
51.1 ALA - ≥ 50% of control
group on statins
2 4947 Risk Ratio (M-H, Random, 95% CI) 0.91 [0.71, 1.15]
51.2 ALA - < 50% of control
group on statins
2 14114 Risk Ratio (M-H, Random, 95% CI) 1.20 [0.86, 1.67]
52 CHD events - ALA - subgroup
by CAD history
4 19061 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.82, 1.22]
52.1 Previous CAD 1 4837 Risk Ratio (M-H, Random, 95% CI) 0.92 [0.72, 1.17]
52.2 No previous CAD 3 14224 Risk Ratio (M-H, Random, 95% CI) 1.16 [0.84, 1.61]
53 Stroke (overall) - ALA 5 19327 Risk Ratio (M-H, Random, 95% CI) 1.15 [0.66, 2.01]
54 Stroke - ALA - SA fixed-effect 5 19327 Risk Ratio (M-H, Fixed, 95% CI) 1.23 [0.71, 2.13]
55 Stroke - ALA - SA by summary
risk of bias
5 19327 Risk Ratio (M-H, Random, 95% CI) 1.15 [0.66, 2.01]
55.1 Low risk of bias 3 5213 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.45, 2.09]
55.2 Moderate/high risk of
bias
2 14114 Risk Ratio (M-H, Random, 95% CI) 1.39 [0.62, 3.13]
56 Stroke - ALA - SA by
compliance and study size
5 25138 Risk Ratio (M-H, Random, 95% CI) 1.04 [0.66, 1.64]
56.1 SA - low risk of
compliance bias
3 5811 Risk Ratio (M-H, Random, 95% CI) 0.85 [0.39, 1.87]
56.2 SA - 100+ randomised 5 19327 Risk Ratio (M-H, Random, 95% CI) 1.15 [0.66, 2.01]
57 Stroke - ALA - subgroup by
dose
5 Risk Ratio (M-H, Random, 95% CI) Subtotals only
57.1 ALA low < 5 g/d 1 4837 Risk Ratio (M-H, Random, 95% CI) 0.92 [0.39, 2.15]
57.2 ALA high ≥ 5 g/d 4 14490 Risk Ratio (M-H, Random, 95% CI) 1.36 [0.65, 2.85]
58 Stroke - ALA - subgroup by
replacement
5 Risk Ratio (M-H, Random, 95% CI) Subtotals only
58.1 N-3 replacing SFA 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
58.2 N-3 replacing MUFA 1 4837 Risk Ratio (M-H, Random, 95% CI) 0.92 [0.39, 2.15]
58.3 N-3 replacing n-6 2 13672 Risk Ratio (M-H, Random, 95% CI) 1.26 [0.53, 3.01]
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58.4 N-3 replacing
carbohydrates/sugars
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
58.5 N-3 replacing nil/low n-
3 placebo
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
58.6 Replacement unclear 2 818 Risk Ratio (M-H, Random, 95% CI) 1.79 [0.31, 10.17]
59 Stroke - ALA - subgroup by
intervention type
5 19327 Risk Ratio (M-H, Random, 95% CI) 1.15 [0.66, 2.01]
59.1 Dietary advice 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
59.2 Supplemental foods 4 5921 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.46, 2.03]
59.3 Supplements (capsule) 1 13406 Risk Ratio (M-H, Random, 95% CI) 1.44 [0.62, 3.36]
59.4 Any combination 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
60 Stroke - ALA - subgroup by
duration
5 19327 Risk Ratio (M-H, Random, 95% CI) 1.15 [0.66, 2.01]
60.1 Medium duration 1 to <
2 years in study
2 13516 Risk Ratio (M-H, Random, 95% CI) 1.56 [0.70, 3.44]
60.2 Medium-long duration:
2 to < 4 years in study
3 5811 Risk Ratio (M-H, Random, 95% CI) 0.85 [0.39, 1.87]
60.3 Long duration: ≥ 4 years
in study
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
61 Stroke - ALA - subgroup
by primary or secondary
prevention
5 19327 Risk Ratio (M-H, Random, 95% CI) 1.15 [0.66, 2.01]
61.1 Primary prevention 3 14380 Risk Ratio (M-H, Random, 95% CI) 1.25 [0.57, 2.74]
61.2 Secondary prevention 2 4947 Risk Ratio (M-H, Random, 95% CI) 1.05 [0.47, 2.34]
62 Stroke - ALA - subgroup by
statin use
5 19327 Risk Ratio (M-H, Random, 95% CI) 1.25 [0.71, 2.18]
62.1 ALA - ≥ 50% of control
group on statins
2 4947 Risk Ratio (M-H, Random, 95% CI) 1.25 [0.56, 2.77]
62.2 ALA - < 50% of control
group on statins
3 14380 Risk Ratio (M-H, Random, 95% CI) 1.25 [0.57, 2.74]
63 Stroke - ALA - subgroup by
stroke type
3 13782 Risk Ratio (M-H, Random, 95% CI) 1.40 [0.65, 3.01]
63.1 Ischaemic stroke - ALA 3 13782 Risk Ratio (M-H, Random, 95% CI) 1.40 [0.65, 3.01]
63.2 Haemorrhagic stroke -
ALA
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
64 Arrythmia (overall) - ALA 1 4837 Risk Ratio (M-H, Random, 95% CI) 0.79 [0.57, 1.10]
64.1 ALA - new arrhythmias 1 4837 Risk Ratio (M-H, Random, 95% CI) 0.79 [0.57, 1.10]
64.2 ALA - recurrent
arrhythmias
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
65 Arrhythmia - ALA - SA by
summary risk of bias
1 4837 Risk Ratio (M-H, Random, 95% CI) 0.79 [0.57, 1.10]
65.1 Low risk of bias 1 4837 Risk Ratio (M-H, Random, 95% CI) 0.79 [0.57, 1.10]
65.2 Moderate/high risk of
bias
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
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Comparison 5. High vs low ALA omega-3 fat (secondary outcomes)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 MACCEs - ALA 1 110 Risk Ratio (M-H, Random, 95% CI) 1.12 [0.32, 3.95]
2 Myocardial infarction (overall) -
ALA
3 18353 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.76, 1.32]
3 Total MI - ALA - subgroup by
fatality
3 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 Fatal MI 2 4947 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.62, 1.46]
3.2 Non-fatal MI 3 5213 Risk Ratio (M-H, Random, 95% CI) 0.52 [0.15, 1.77]
4 Angina - ALA 2 13516 Risk Ratio (M-H, Random, 95% CI) 1.41 [0.75, 2.64]
5 Revascularisation - ALA 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
5.1 CABG - ALA 1 266 Risk Ratio (M-H, Random, 95% CI) 0.29 [0.01, 5.93]
5.2 Angioplasty - ALA 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
5.3 Any revascularisation -
ALA
1 266 Risk Ratio (M-H, Random, 95% CI) 0.72 [0.07, 7.84]
6 Peripheral arterial disease - ALA 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
7 Body weight, kg - ALA 4 664 Mean Difference (IV, Random, 95% CI) -1.49 [-4.17, 1.18]
8 Weight, kg - ALA - sensitivity
analysis (SA) fixed-effect
4 664 Mean Difference (IV, Fixed, 95% CI) 0.17 [-0.61, 0.96]
9 Weight, kg - ALA - SA by
summary risk of bias
4 Mean Difference (IV, Random, 95% CI) Subtotals only
9.1 Low risk of bias 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
9.2 Moderate/high risk of bias 4 664 Mean Difference (IV, Random, 95% CI) -1.49 [-4.17, 1.18]
10 Weight, kg - ALA - SA by
compliance and study size
3 Mean Difference (IV, Random, 95% CI) Subtotals only
10.1 SA - low risk of
compliance bias
3 629 Mean Difference (IV, Random, 95% CI) -1.59 [-4.47, 1.30]
10.2 SA - 100+ randomised 3 629 Mean Difference (IV, Random, 95% CI) -1.59 [-4.47, 1.30]
11 Weight, kg - ALA - subgroup
by dose
4 Mean Difference (IV, Random, 95% CI) Subtotals only
11.1 ALA low < 5 g/d 3 485 Mean Difference (IV, Random, 95% CI) -0.71 [-3.31, 1.90]
11.2 ALA high > 5 g/d 1 179 Mean Difference (IV, Random, 95% CI) -4.20 [-7.61, -0.79]
12 Weight, kg - ALA - subgroup
by intervention type
4 Mean Difference (IV, Random, 95% CI) Subtotals only
12.1 Dietary advice 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
12.2 Supplemental foods 3 526 Mean Difference (IV, Random, 95% CI) -1.23 [-5.27, 2.80]
12.3 Supplement (capsule) 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
12.4 Any combination 1 138 Mean Difference (IV, Random, 95% CI) -1.98 [-5.89, 1.92]
13 Weight, kg - ALA - subgroup
by replacement
4 Mean Difference (IV, Random, 95% CI) Subtotals only
13.1 ALA replacing SFA 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
13.2 ALA replacing MUFA 1 138 Mean Difference (IV, Random, 95% CI) -1.98 [-5.89, 1.92]
13.3 ALA replacing n-6 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
13.4 ALA replacing carbs/
sugars
0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
13.5 ALA replacing nil/low n-
3 placebo
1 35 Mean Difference (IV, Random, 95% CI) -0.30 [-10.57, 9.97]
13.6 Replacement unclear 2 491 Mean Difference (IV, Random, 95% CI) -1.43 [-6.26, 3.39]
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14 Weight, kg - ALA - subgroup
by duration
4 Mean Difference (IV, Random, 95% CI) Subtotals only
14.1 Medium duration 1 to <
2 years in study
4 664 Mean Difference (IV, Random, 95% CI) -1.49 [-4.17, 1.18]
14.2 Medium-long duration:
2 to < 4 years in study
0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14.3 Long duration ≥ 4 years
in study
0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15 Weight, kg - ALA - subgroup
by statin use
4 Mean Difference (IV, Random, 95% CI) Subtotals only
15.1 ALA - ≥ 50% of control
group on statins
1 35 Mean Difference (IV, Random, 95% CI) -0.30 [-10.57, 9.97]
15.2 ALA - < 50% of control
group on statins
1 138 Mean Difference (IV, Random, 95% CI) -1.98 [-5.89, 1.92]
15.3 ALA - use of statins
unclear
2 491 Mean Difference (IV, Random, 95% CI) -1.43 [-6.26, 3.39]
16 Weight, kg - ALA - subgroup
by primary or secondary
prevention
4 Mean Difference (IV, Random, 95% CI) Subtotals only
16.1 Low CVD risk 3 629 Mean Difference (IV, Random, 95% CI) -1.59 [-4.47, 1.30]
16.2 Moderate CVD risk 1 35 Mean Difference (IV, Random, 95% CI) -0.30 [-10.57, 9.97]
16.3 High CVD risk 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
17 Body mass index, kg/m² - ALA 3 1581 Mean Difference (IV, Random, 95% CI) -0.42 [-1.53, 0.69]
18 BMI, kg/m² - ALA - SA
fixed-effect
3 1581 Mean Difference (IV, Fixed, 95% CI) 0.12 [-0.06, 0.30]
19 BMI, kg/m² - ALA - SA by
summary risk of bias
3 Mean Difference (IV, Random, 95% CI) Subtotals only
19.1 Low risk of bias 2 1402 Mean Difference (IV, Random, 95% CI) 0.15 [-0.04, 0.33]
19.2 Moderate/high risk of
bias
1 179 Mean Difference (IV, Random, 95% CI) -1.5 [-2.86, -0.14]
20 BMI, kg/m² - ALA - SA by
compliance and study size
3 Mean Difference (IV, Random, 95% CI) Subtotals only
20.1 SA - low risk of
compliance bias
3 1581 Mean Difference (IV, Random, 95% CI) -0.42 [-1.53, 0.69]
20.2 SA - 100+ randomised 3 1581 Mean Difference (IV, Random, 95% CI) -0.42 [-1.53, 0.69]
21 BMI, kg/m² - ALA - subgroup
by dose
3 Mean Difference (IV, Random, 95% CI) Subtotals only
21.1 ALA low < 5 g/d 1 1260 Mean Difference (IV, Random, 95% CI) 0.15 [-0.03, 0.33]
21.2 ALA high > 5 g/d 2 321 Mean Difference (IV, Random, 95% CI) -1.12 [-2.24, 0.01]
22 BMI, kg/m² - ALA - subgroup
by intervention type
3 Mean Difference (IV, Random, 95% CI) Subtotals only
22.1 Dietary advice 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
22.2 Supplemental foods 3 1581 Mean Difference (IV, Random, 95% CI) -0.42 [-1.53, 0.69]
22.3 Supplement (capsule) 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
22.4 Any combination 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
23 BMI, kg/m² - ALA - subgroup
by replacement
3 1581 Mean Difference (IV, Random, 95% CI) -0.42 [-1.53, 0.69]
23.1 ALA replacing SFA 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
23.2 ALA replacing MUFA 1 1260 Mean Difference (IV, Random, 95% CI) 0.15 [-0.03, 0.33]
23.3 ALA replacing n-6 1 142 Mean Difference (IV, Random, 95% CI) -0.3 [-2.29, 1.69]
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23.4 ALA replacing carbs/
sugars
0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
23.5 ALA replacing nil/low n-
3 placebo
0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
23.6 Replacement unclear 1 179 Mean Difference (IV, Random, 95% CI) -1.5 [-2.86, -0.14]
24 BMI, kg/m² - ALA - subgroup
by duration
3 Mean Difference (IV, Random, 95% CI) Subtotals only
24.1 Medium duration 1 to <
2 years in study
1 179 Mean Difference (IV, Random, 95% CI) -1.5 [-2.86, -0.14]
24.2 Medium-long duration:
2 to < 4 years in study
2 1402 Mean Difference (IV, Random, 95% CI) 0.15 [-0.04, 0.33]
24.3 Long duration ≥ 4 years
in study
0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
25 BMI, kg/m² - ALA - subgroup
by statin use
3 Mean Difference (IV, Random, 95% CI) Subtotals only
25.1 ALA - ≥ 50% of control
group on statins
1 1260 Mean Difference (IV, Random, 95% CI) 0.15 [-0.03, 0.33]
25.2 ALA - < 50% of control
group on statins
1 142 Mean Difference (IV, Random, 95% CI) -0.3 [-2.29, 1.69]
25.3 ALA - use of statins
unclear
1 179 Mean Difference (IV, Random, 95% CI) -1.5 [-2.86, -0.14]
26 BMI, kg/m² - ALA - subgroup
by primary or secondary
preventionA
3 Mean Difference (IV, Random, 95% CI) Subtotals only
26.1 Primary prevention of
CVD
2 321 Mean Difference (IV, Random, 95% CI) -1.12 [-2.24, 0.01]
26.2 Secondary prevention of
CVD
1 1260 Mean Difference (IV, Random, 95% CI) 0.15 [-0.03, 0.33]
27 Other measures of adiposity -
ALA
4 Mean Difference (IV, Fixed, 95% CI) Subtotals only
27.1 Visceral adipose tissue,
cm²
1 35 Mean Difference (IV, Fixed, 95% CI) 27.0 [-21.28, 75.28]
27.2 Subcutaneous adipose
tissue, cm²
1 35 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
27.3 Waist circumference, cm 3 629 Mean Difference (IV, Fixed, 95% CI) -1.59 [-3.10, -0.07]
28 Total cholesterol, serum,
mmoL/L - ALA
6 2164 Mean Difference (IV, Random, 95% CI) -0.09 [-0.23, 0.05]
29 TC, mmoL/L - ALA - SA
fixed-effect
6 2164 Mean Difference (IV, Fixed, 95% CI) -0.10 [-0.17, -0.03]
30 TC, mmoL/L - ALA - SA by
summary risk of bias
6 Mean Difference (IV, Random, 95% CI) Subtotals only
30.1 Low risk of bias 3 1436 Mean Difference (IV, Random, 95% CI) 0.00 [-0.13, 0.14]
30.2 Moderate/high risk of
bias
3 728 Mean Difference (IV, Random, 95% CI) -0.19 [-0.36, -0.01]
31 TC, mmoL/L - ALA - SA by
compliance and study size
4 Mean Difference (IV, Random, 95% CI) Subtotals only
31.1 SA - low risk of
compliance bias
4 2045 Mean Difference (IV, Random, 95% CI) -0.10 [-0.25, 0.05]
31.2 SA - 100+ randomised 4 2045 Mean Difference (IV, Random, 95% CI) -0.10 [-0.25, 0.05]
32 TC, mmoL/L - ALA - subgroup
by dose
6 Mean Difference (IV, Random, 95% CI) Subtotals only
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32.1 ALA low < 5 g/d 3 1759 Mean Difference (IV, Random, 95% CI) -0.07 [-0.24, 0.09]
32.2 ALA high > 5 g/d 3 405 Mean Difference (IV, Random, 95% CI) -0.13 [-0.47, 0.21]
33 TC, mmoL/L - ALA - subgroup
by intervention type
6 Mean Difference (IV, Random, 95% CI) Subtotals only
33.1 Dietary advice 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
33.2 Supplemental foods 6 2164 Mean Difference (IV, Random, 95% CI) -0.09 [-0.23, 0.05]
33.3 Supplement (capsule) 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
33.4 Any combination 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
34 TC, mmoL/L - ALA - subgroup
by replacement
6 Mean Difference (IV, Random, 95% CI) Subtotals only
34.1 ALA replacing SFA 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
34.2 ALA replacing MUFA 1 1210 Mean Difference (IV, Random, 95% CI) -0.02 [-0.13, 0.09]
34.3 ALA replacing n-6 1 142 Mean Difference (IV, Random, 95% CI) 0.14 [-0.10, 0.38]
34.4 ALA replacing carbs/
sugars
0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
34.5 ALA replacing nil/low n-
3 placebo
1 35 Mean Difference (IV, Random, 95% CI) 0.30 [-0.30, 0.90]
34.6 Replacement unclear 3 777 Mean Difference (IV, Random, 95% CI) -0.21 [-0.31, -0.11]
35 TC, mmoL/L - ALA - subgroup
by duration
6 Mean Difference (IV, Random, 95% CI) Subtotals only
35.1 Medium duration 1 to <
2 years in study
4 812 Mean Difference (IV, Random, 95% CI) -0.20 [-0.33, -0.07]
35.2 Medium-long duration:
2 to < 4 years in study
2 1352 Mean Difference (IV, Random, 95% CI) 0.02 [-0.12, 0.16]
35.3 Long duration ≥ 4 years
in study
0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
36 TC, mmoL/L - ALA - subgroup
by statin use
6 Mean Difference (IV, Random, 95% CI) Subtotals only
36.1 ALA - ≥ 50% of control
group on statins
3 1329 Mean Difference (IV, Random, 95% CI) -0.02 [-0.15, 0.11]
36.2 ALA - < 50% of control
group on statins
1 142 Mean Difference (IV, Random, 95% CI) 0.14 [-0.10, 0.38]
36.3 ALA - use of statins
unclear
2 693 Mean Difference (IV, Random, 95% CI) -0.21 [-0.30, -0.11]
37 TC, mmoL/L - ALA - subgroup
by primary or secondary
preventionA
6 Mean Difference (IV, Random, 95% CI) Subtotals only
37.1 Primary prevention of
CVD
4 870 Mean Difference (IV, Random, 95% CI) -0.09 [-0.30, 0.12]
37.2 Secondary prevention of
CVD
2 1294 Mean Difference (IV, Random, 95% CI) -0.03 [-0.14, 0.08]
38 Triglycerides, fasting, serum,
mmoL/L - ALA
6 1776 Mean Difference (IV, Random, 95% CI) -0.03 [-0.11, 0.05]
39 TG, fasting, mmoL/L - ALA -
SA fixed-effect
6 1776 Mean Difference (IV, Fixed, 95% CI) -0.03 [-0.11, 0.05]
40 TG, fasting, mmoL/L- ALA -
SA by summary risk of bias
6 Mean Difference (IV, Random, 95% CI) Subtotals only
40.1 Low risk of bias 3 1436 Mean Difference (IV, Random, 95% CI) 0.03 [-0.13, 0.19]
40.2 Moderate/high risk of
bias
3 340 Mean Difference (IV, Random, 95% CI) -0.05 [-0.18, 0.09]
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41 TG, fasting, mmoL/L- ALA -
SA by compliance and study
size
4 Mean Difference (IV, Random, 95% CI) Subtotals only
41.1 SA - low risk of
compliance bias
4 1657 Mean Difference (IV, Random, 95% CI) -0.05 [-0.13, 0.04]
41.2 SA - 100+ randomised 4 1657 Mean Difference (IV, Random, 95% CI) -0.05 [-0.13, 0.04]
42 TG, fasting, mmoL/L - ALA -
subgroup by dose
6 Mean Difference (IV, Random, 95% CI) Subtotals only
42.1 ALA low < 5 g/d 3 1371 Mean Difference (IV, Random, 95% CI) -0.07 [-0.16, 0.03]
42.2 ALA high > 5 g/d 3 405 Mean Difference (IV, Random, 95% CI) 0.05 [-0.09, 0.19]
43 TG, fasting, mmoL/L- ALA -
subgroup by intervention type
6 Mean Difference (IV, Random, 95% CI) Subtotals only
43.1 Dietary advice 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
43.2 Supplemental foods 5 1650 Mean Difference (IV, Random, 95% CI) -0.01 [-0.10, 0.07]
43.3 Supplement (capsule) 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
43.4 Any combination 1 126 Mean Difference (IV, Random, 95% CI) -0.12 [-0.33, 0.09]
44 TG, fasting, mmoL/L-AL -
subgroup by replacementA
6 Mean Difference (IV, Random, 95% CI) Subtotals only
44.1 ALA replacing SFA 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
44.2 ALA replacing MUFA 2 1336 Mean Difference (IV, Random, 95% CI) -0.07 [-0.17, 0.02]
44.3 ALA replacing n-6 1 142 Mean Difference (IV, Random, 95% CI) 0.13 [-0.16, 0.42]
44.4 ALA replacing carbs/
sugars
0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
44.5 ALA replacing nil/low n-
3 placebo
1 35 Mean Difference (IV, Random, 95% CI) 0.30 [-0.39, 0.99]
44.6 Replacement unclear 2 263 Mean Difference (IV, Random, 95% CI) 0.04 [-0.15, 0.23]
45 TG, fasting, mmoL/L- ALA -
subgroup by duration
6 Mean Difference (IV, Random, 95% CI) Subtotals only
45.1 Medium duration 1 to <
2 years in study
4 424 Mean Difference (IV, Random, 95% CI) -0.01 [-0.15, 0.12]
45.2 Medium-long duration:
2 to < 4 years in study
2 1352 Mean Difference (IV, Random, 95% CI) -0.01 [-0.17, 0.15]
45.3 Long duration ≥ 4 years
in study
0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
46 TG, fasting, mmoL/L - ALA -
subgroup by statin use
6 Mean Difference (IV, Random, 95% CI) Subtotals only
46.1 ALA - ≥ 50% of control
group on statins
3 1329 Mean Difference (IV, Random, 95% CI) 0.03 [-0.17, 0.23]
46.2 ALA - < 50% of control
group on statins
2 268 Mean Difference (IV, Random, 95% CI) -0.02 [-0.26, 0.23]
46.3 ALA - use of statins
unclear
1 179 Mean Difference (IV, Random, 95% CI) -0.02 [-0.20, 0.16]
47 TG, fasting, mmoL/L- ALA
- subgroup by primary or
secondary prevention
6 Mean Difference (IV, Random, 95% CI) Subtotals only
47.1 Primary prevention 4 482 Mean Difference (IV, Random, 95% CI) -0.02 [-0.14, 0.11]
47.2 Secondary prevention 2 1294 Mean Difference (IV, Random, 95% CI) 0.02 [-0.22, 0.25]
48 High-density lipoprotein,
serum, mmoL/L - ALA
6 1776 Mean Difference (IV, Random, 95% CI) -0.02 [-0.08, 0.03]
49 HDL, mmoL/L - ALA - SA
fixed-effect
6 1776 Mean Difference (IV, Fixed, 95% CI) -0.02 [-0.05, 0.00]
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50 HDL, mmoL/L - ALA - SA by
summary risk of bias
6 Mean Difference (IV, Random, 95% CI) Subtotals only
50.1 Low risk of bias 3 1436 Mean Difference (IV, Random, 95% CI) -0.03 [-0.06, 0.00]
50.2 Moderate/high risk of
bias
3 340 Mean Difference (IV, Random, 95% CI) 0.04 [-0.14, 0.22]
51 HDL, mmoL/L - ALA - SA by
compliance and study size
4 Mean Difference (IV, Random, 95% CI) Subtotals only
51.1 SA - low risk of
compliance bias
4 1657 Mean Difference (IV, Random, 95% CI) -0.02 [-0.08, 0.04]
51.2 SA - 100+ randomised 4 1657 Mean Difference (IV, Random, 95% CI) -0.02 [-0.08, 0.04]
52 HDL, mmoL/L - ALA -
subgroup by dose
6 Mean Difference (IV, Random, 95% CI) Subtotals only
52.1 ALA low < 5 g/d 3 1371 Mean Difference (IV, Random, 95% CI) 0.06 [-0.08, 0.19]
52.2 ALA high > 5 g/d 3 405 Mean Difference (IV, Random, 95% CI) -0.07 [-0.12, -0.01]
53 HDL, mmoL/L - ALA -
subgroup by intervention type
6 Mean Difference (IV, Random, 95% CI) Subtotals only
53.1 Dietary advice 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
53.2 Supplemental foods 5 1650 Mean Difference (IV, Random, 95% CI) -0.03 [-0.06, -0.00]
53.3 Supplement (capsule) 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
53.4 Any combination 1 126 Mean Difference (IV, Random, 95% CI) 0.15 [0.01, 0.29]
54 HDL, mmoL/L - ALA -
subgroup by replacement
6 Mean Difference (IV, Random, 95% CI) Subtotals only
54.1 ALA replacing SFA 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
54.2 ALA replacing MUFA 2 1336 Mean Difference (IV, Random, 95% CI) 0.05 [-0.11, 0.22]
54.3 ALA replacing n-6 1 142 Mean Difference (IV, Random, 95% CI) -0.04 [-0.11, 0.03]
54.4 ALA replacing carbs/
sugars
0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
54.5 ALA replacing nil/low n-
3 placebo
1 35 Mean Difference (IV, Random, 95% CI) 0.10 [-0.17, 0.37]
54.6 Replacement unclear 2 263 Mean Difference (IV, Random, 95% CI) -0.09 [-0.17, -0.02]
55 HDL, mmoL/L - ALA -
subgroup by duration
6 Mean Difference (IV, Random, 95% CI) Subtotals only
55.1 Medium duration 1 to <
2 years in study
4 424 Mean Difference (IV, Random, 95% CI) -0.00 [-0.13, 0.13]
55.2 Medium-long duration:
2 to < 4 years in study
2 1352 Mean Difference (IV, Random, 95% CI) -0.02 [-0.05, 0.00]
55.3 Long duration ≥ 4 years
in study
0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
56 HDL, mmoL/L - ALA -
subgroup by statin use
6 Mean Difference (IV, Random, 95% CI) Subtotals only
56.1 ALA - ≥ 50% of control
group on statins
3 1329 Mean Difference (IV, Random, 95% CI) -0.03 [-0.09, 0.03]
56.2 ALA - < 50% of control
group on statins
2 268 Mean Difference (IV, Random, 95% CI) 0.05 [-0.14, 0.23]
56.3 ALA - use of statins
unclear
1 179 Mean Difference (IV, Random, 95% CI) -0.09 [-0.20, 0.02]
57 HDL, mmoL/L - ALA -
subgroup by primary or
secondary prevention
7 Mean Difference (IV, Random, 95% CI) Subtotals only
57.1 Low CVD risk 2 305 Mean Difference (IV, Random, 95% CI) 0.03 [-0.21, 0.26]
57.2 Moderate CVD risk 2 177 Mean Difference (IV, Random, 95% CI) -0.03 [-0.10, 0.04]
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57.3 High CVD risk 3 1368 Mean Difference (IV, Random, 95% CI) -0.03 [-0.08, 0.03]
58 Low-density lipoprotein,
serum, mmoL/L - ALA
7 2201 Mean Difference (IV, Random, 95% CI) -0.05 [-0.15, 0.04]
59 LDL, mmoL/L - ALA - SA
fixed-effect
7 2201 Mean Difference (IV, Fixed, 95% CI) -0.05 [-0.11, 0.00]
60 LDL, mmoL/L - ALA - SA by
summary risk of bias
7 Mean Difference (IV, Random, 95% CI) Subtotals only
60.1 Low risk of bias 3 1350 Mean Difference (IV, Random, 95% CI) 0.02 [-0.05, 0.10]
60.2 Moderate/high risk of
bias
4 851 Mean Difference (IV, Random, 95% CI) -0.14 [-0.22, -0.06]
61 LDL, mmoL/L - ALA - SA by
compliance and study size
5 Mean Difference (IV, Random, 95% CI) Subtotals only
61.1 SA - low risk of
compliance bias
5 2085 Mean Difference (IV, Random, 95% CI) -0.05 [-0.16, 0.06]
61.2 SA - 100+ randomised 5 2085 Mean Difference (IV, Random, 95% CI) -0.05 [-0.16, 0.06]
62 LDL, mmoL/L - ALA -
subgroup by dose
7 Mean Difference (IV, Random, 95% CI) Subtotals only
62.1 ALA low < 5 g/d 4 1796 Mean Difference (IV, Random, 95% CI) -0.06 [-0.17, 0.05]
62.2 ALA high > 5 g/d 3 405 Mean Difference (IV, Random, 95% CI) -0.04 [-0.28, 0.19]
63 LDL, mmoL/L - ALA -
subgroup by intervention type
7 Mean Difference (IV, Random, 95% CI) Subtotals only
63.1 Dietary advice 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
63.2 Supplemental foods 6 2075 Mean Difference (IV, Random, 95% CI) -0.06 [-0.17, 0.05]
63.3 Supplement (capsule) 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
63.4 Any combination 1 126 Mean Difference (IV, Random, 95% CI) 0.0 [-0.25, 0.25]
64 LDL, mmoL/L - ALA -
subgroup by replacement
7 Mean Difference (IV, Random, 95% CI) Subtotals only
64.1 ALA replacing SFA 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
64.2 ALA replacing MUFA 2 1250 Mean Difference (IV, Random, 95% CI) 0.01 [-0.07, 0.09]
64.3 ALA replacing n-6 1 142 Mean Difference (IV, Random, 95% CI) 0.14 [-0.08, 0.36]
64.4 ALA replacing carbs/
sugars
0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
64.5 ALA replacing nil/low n-
3 placebo
1 32 Mean Difference (IV, Random, 95% CI) -0.10 [-0.59, 0.39]
64.6 Replacement unclear 3 777 Mean Difference (IV, Random, 95% CI) -0.16 [-0.24, -0.07]
65 LDL, mmoL/L - ALA -
subgroup by duration
7 Mean Difference (IV, Random, 95% CI) Subtotals only
65.1 Medium duration 1 to <
2 years in study
5 935 Mean Difference (IV, Random, 95% CI) -0.14 [-0.22, -0.06]
65.2 Medium-long duration:
2 to < 4 years in study
2 1266 Mean Difference (IV, Random, 95% CI) 0.03 [-0.06, 0.13]
65.3 Long duration ≥ 4 years
in study
0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
66 LDL, mmoL/L - ALA -
subgroup by statin use
7 Mean Difference (IV, Random, 95% CI) Subtotals only
66.1 ALA - ≥ 50% of control
group on statins
3 1240 Mean Difference (IV, Random, 95% CI) 0.00 [-0.08, 0.08]
66.2 ALA - < 50% of control
group on statins
2 268 Mean Difference (IV, Random, 95% CI) 0.08 [-0.09, 0.24]
66.3 ALA - use of statins
unclear
2 693 Mean Difference (IV, Random, 95% CI) -0.16 [-0.25, -0.07]
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67 LDL, mmoL/L - ALA -
subgroup by primary or
secondary prevention
7 Mean Difference (IV, Random, 95% CI) Subtotals only
67.1 Primary prevention of
CVD
5 993 Mean Difference (IV, Random, 95% CI) -0.08 [-0.20, 0.05]
67.2 Secondary prevention of
CVD
2 1208 Mean Difference (IV, Random, 95% CI) 0.01 [-0.08, 0.09]
Comparison 6. High vs low ALA omega-3 fats (tertiary outcomes)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Blood pressure, mmHg - ALA 4 Mean Difference (IV, Random, 95% CI) Subtotals only
1.1 Systolic BP - ALA 4 1671 Mean Difference (IV, Random, 95% CI) -0.87 [-4.48, 2.75]
1.2 Diastolic BP - ALA 4 1671 Mean Difference (IV, Random, 95% CI) -1.42 [-4.40, 1.57]
2 Serious adverse events - ALA 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 Any serious adverse events 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
2.2 Bleeding 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
2.3 GI hospitalisation 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
2.4 Pulmonary embolus or
DVT
1 708 Risk Ratio (M-H, Random, 95% CI) 0.32 [0.01, 7.80]
2.5 Thrombophleibitis 1 13406 Risk Ratio (M-H, Random, 95% CI) 1.59 [0.72, 3.51]
2.6 Urolithiasis 1 13406 Risk Ratio (M-H, Random, 95% CI) 0.80 [0.47, 1.36]
3 Side effects - ALA 5 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 Dropouts due to side
effects
5 3480 Risk Ratio (M-H, Random, 95% CI) 2.10 [0.66, 6.71]
3.2 Abdominal pain or
discomfort
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
3.3 Diarrhoea 1 708 Risk Ratio (M-H, Random, 95% CI) 3.82 [0.82, 17.88]
3.4 Nausea 1 110 Risk Ratio (M-H, Random, 95% CI) 6.29 [0.33, 118.93]
3.5 Any gastrointestinal side
effect - ALA
4 3450 Risk Ratio (M-H, Random, 95% CI) 2.06 [0.62, 6.80]
3.6 Pain (joint, lumbar,
muscle pain)
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
3.7 All side effects combined 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
4 Dropouts - ALA 6 3663 Risk Ratio (M-H, Random, 95% CI) 1.08 [0.92, 1.25]
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Analysis 1.1. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 1 All-cause
mortality (overall) - LCn3.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)
Outcome: 1 All-cause mortality (overall) - LCn3
Study or subgroup
Favours
higher
omega 3 Lower omega 3 fats Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
ADCS 2010 11/238 4/164 0.2 % 1.89 [ 0.61, 5.85 ]
AFFORD 2013 0/153 1/163 0.0 % 0.35 [ 0.01, 8.65 ]
AlphaOmega - EPA+DHA 2010 (1) 186/2404 184/2433 6.0 % 1.02 [ 0.84, 1.24 ]
AREDS2 2014 200/2147 168/2056 6.0 % 1.14 [ 0.94, 1.39 ]
Bates 1989 1/155 0/157 0.0 % 3.04 [ 0.12, 74.02 ]
Berson 2004 0/105 1/103 0.0 % 0.33 [ 0.01, 7.94 ]
Brox 2001 0/80 1/40 0.0 % 0.17 [ 0.01, 4.05 ]
DART 1989 94/1015 131/1018 4.0 % 0.72 [ 0.56, 0.92 ]
DART2 2003 283/1571 242/1543 8.4 % 1.15 [ 0.98, 1.34 ]
Derosa 2016 1/138 2/143 0.1 % 0.52 [ 0.05, 5.65 ]
DIPP 2015 2/104 3/101 0.1 % 0.65 [ 0.11, 3.79 ]
DISAF 2003 6/201 8/206 0.3 % 0.77 [ 0.27, 2.18 ]
DO IT 2010 14/282 24/281 0.7 % 0.58 [ 0.31, 1.10 ]
Doi 2014 2/119 9/119 0.1 % 0.22 [ 0.05, 1.01 ]
EPIC-1 2008 1/183 0/180 0.0 % 2.95 [ 0.12, 71.97 ]
EPIC-2 2008 0/189 1/190 0.0 % 0.34 [ 0.01, 8.17 ]
FAAT 2005 13/200 12/202 0.5 % 1.09 [ 0.51, 2.34 ]
FORWARD 2013 4/289 5/297 0.2 % 0.82 [ 0.22, 3.03 ]
FOSTAR 2016 0/101 1/101 0.0 % 0.33 [ 0.01, 8.09 ]
GISSI-HF 2008 955/3494 1014/3481 18.8 % 0.94 [ 0.87, 1.01 ]
GISSI-P 1999 472/5666 545/5658 12.2 % 0.86 [ 0.77, 0.97 ]
HARP 1995 0/41 1/39 0.0 % 0.32 [ 0.01, 7.57 ]
JELIS 2007 286/9326 265/9319 7.8 % 1.08 [ 0.91, 1.27 ]
0.05 0.2 1 5 20
Favours higher omega 3 Favours lower omega 3
(Continued . . . )
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(. . . Continued)
Study or subgroup
Favours
higher
omega 3 Lower omega 3 fats Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Kumar 2013 1/39 1/39 0.0 % 1.00 [ 0.06, 15.43 ]
MAPT 2017 18/840 16/840 0.6 % 1.13 [ 0.58, 2.19 ]
NAT2 2013 3/150 6/150 0.2 % 0.50 [ 0.13, 1.96 ]
Nutristroke 2009 0/38 4/34 0.0 % 0.10 [ 0.01, 1.79 ]
OFAMI 2001 11/150 11/150 0.4 % 1.00 [ 0.45, 2.24 ]
OMEGA 2009 88/1919 70/1885 2.7 % 1.23 [ 0.91, 1.68 ]
OPAL 2010 9/434 8/433 0.3 % 1.12 [ 0.44, 2.88 ]
ORIGIN 2012 951/6281 964/6225 17.5 % 0.98 [ 0.90, 1.06 ]
Raitt 2005 4/100 10/100 0.2 % 0.40 [ 0.13, 1.23 ]
Risk % Prevention 2013 348/6239 337/6266 9.3 % 1.04 [ 0.90, 1.20 ]
SCIMO 1999 1/112 2/111 0.1 % 0.50 [ 0.05, 5.39 ]
Shinto 2014 1/13 1/13 0.0 % 1.00 [ 0.07, 14.34 ]
SHOT 1996 8/317 6/293 0.3 % 1.23 [ 0.43, 3.51 ]
SOFA 2006 8/273 14/273 0.4 % 0.57 [ 0.24, 1.34 ]
SU.FOL.OM3 2010 66/1253 68/1248 2.4 % 0.97 [ 0.70, 1.34 ]
Zhang 2017 0/120 1/120 0.0 % 0.33 [ 0.01, 8.10 ]
Total (95% CI) 46479 46174 100.0 % 0.98 [ 0.93, 1.03 ]
Total events: 4048 (Favours higher omega 3), 4141 (Lower omega 3 fats)
Heterogeneity: Tau2 = 0.00; Chi2 = 43.01, df = 38 (P = 0.27); I2 =12%
Test for overall effect: Z = 0.87 (P = 0.39)
Test for subgroup differences: Not applicable
0.05 0.2 1 5 20
Favours higher omega 3 Favours lower omega 3
(1) AlphaOmega - comparing EPA+DHA ALA with no EPA+DHA ALA
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Analysis 1.2. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 2 All-cause
mortality - LCn3 - sensitivity analysis (SA) fixed-effect.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)
Outcome: 2 All-cause mortality - LCn3 - sensitivity analysis (SA) fixed-effect
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
ADCS 2010 11/238 4/164 0.1 % 1.89 [ 0.61, 5.85 ]
AFFORD 2013 0/153 1/163 0.0 % 0.35 [ 0.01, 8.65 ]
AlphaOmega - EPA+DHA 2010 (1) 95/1192 93/1236 2.3 % 1.06 [ 0.80, 1.39 ]
AREDS2 2014 200/2147 168/2056 4.2 % 1.14 [ 0.94, 1.39 ]
Bates 1989 1/155 0/157 0.0 % 3.04 [ 0.12, 74.02 ]
Berson 2004 0/105 1/103 0.0 % 0.33 [ 0.01, 7.94 ]
Brox 2001 0/80 1/40 0.0 % 0.17 [ 0.01, 4.05 ]
DART 1989 94/1015 131/1018 3.2 % 0.72 [ 0.56, 0.92 ]
DART2 2003 283/1571 242/1543 6.0 % 1.15 [ 0.98, 1.34 ]
Derosa 2016 1/138 2/143 0.0 % 0.52 [ 0.05, 5.65 ]
DIPP 2015 2/104 3/101 0.1 % 0.65 [ 0.11, 3.79 ]
DISAF 2003 6/201 8/206 0.2 % 0.77 [ 0.27, 2.18 ]
DO IT 2010 14/282 24/281 0.6 % 0.58 [ 0.31, 1.10 ]
Doi 2014 2/119 9/119 0.2 % 0.22 [ 0.05, 1.01 ]
EPIC-1 2008 1/183 0/180 0.0 % 2.95 [ 0.12, 71.97 ]
EPIC-2 2008 0/189 1/190 0.0 % 0.34 [ 0.01, 8.17 ]
FAAT 2005 13/200 12/202 0.3 % 1.09 [ 0.51, 2.34 ]
FORWARD 2013 4/289 5/297 0.1 % 0.82 [ 0.22, 3.03 ]
FOSTAR 2016 0/101 1/101 0.0 % 0.33 [ 0.01, 8.09 ]
GISSI-HF 2008 955/3494 1014/3481 25.0 % 0.94 [ 0.87, 1.01 ]
GISSI-P 1999 472/5666 545/5658 13.4 % 0.86 [ 0.77, 0.97 ]
HARP 1995 0/41 1/39 0.0 % 0.32 [ 0.01, 7.57 ]
JELIS 2007 286/9326 265/9319 6.5 % 1.08 [ 0.91, 1.27 ]
Kumar 2013 1/39 1/39 0.0 % 1.00 [ 0.06, 15.43 ]
MAPT 2017 18/840 16/840 0.4 % 1.13 [ 0.58, 2.19 ]
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Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
NAT2 2013 3/150 6/150 0.1 % 0.50 [ 0.13, 1.96 ]
Nutristroke 2009 0/38 4/34 0.1 % 0.10 [ 0.01, 1.79 ]
OFAMI 2001 11/150 11/150 0.3 % 1.00 [ 0.45, 2.24 ]
OMEGA 2009 88/1919 70/1885 1.7 % 1.23 [ 0.91, 1.68 ]
OPAL 2010 9/434 8/433 0.2 % 1.12 [ 0.44, 2.88 ]
ORIGIN 2012 951/6281 964/6225 23.9 % 0.98 [ 0.90, 1.06 ]
Raitt 2005 4/100 10/100 0.2 % 0.40 [ 0.13, 1.23 ]
Risk % Prevention 2013 348/6239 337/6266 8.3 % 1.04 [ 0.90, 1.20 ]
SCIMO 1999 1/112 2/111 0.0 % 0.50 [ 0.05, 5.39 ]
Shinto 2014 1/13 1/13 0.0 % 1.00 [ 0.07, 14.34 ]
SHOT 1996 8/317 6/293 0.2 % 1.23 [ 0.43, 3.51 ]
SOFA 2006 8/273 14/273 0.3 % 0.57 [ 0.24, 1.34 ]
SU.FOL.OM3 2010 58/1253 59/1248 1.5 % 0.98 [ 0.69, 1.39 ]
Zhang 2017 0/120 1/120 0.0 % 0.33 [ 0.01, 8.10 ]
Total (95% CI) 45267 44977 100.0 % 0.97 [ 0.93, 1.01 ]
Total events: 3949 (Higher omega 3), 4041 (Lower omega 3)
Heterogeneity: Chi2 = 43.12, df = 38 (P = 0.26); I2 =12%
Test for overall effect: Z = 1.43 (P = 0.15)
Test for subgroup differences: Not applicable
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Analysis 1.3. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 3 All-cause
mortality - LCn3 - SA by summary risk of bias.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)
Outcome: 3 All-cause mortality - LCn3 - SA by summary risk of bias
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Low risk of bias
ADCS 2010 11/238 4/164 0.2 % 1.89 [ 0.61, 5.85 ]
AlphaOmega - EPA+DHA 2010 (1) 186/2404 184/2433 6.0 % 1.02 [ 0.84, 1.24 ]
AREDS2 2014 200/2147 168/2056 6.0 % 1.14 [ 0.94, 1.39 ]
Berson 2004 0/105 1/103 0.0 % 0.33 [ 0.01, 7.94 ]
Derosa 2016 1/138 2/143 0.1 % 0.52 [ 0.05, 5.65 ]
FORWARD 2013 4/289 5/297 0.2 % 0.82 [ 0.22, 3.03 ]
FOSTAR 2016 0/101 1/101 0.0 % 0.33 [ 0.01, 8.09 ]
MAPT 2017 18/840 16/840 0.6 % 1.13 [ 0.58, 2.19 ]
NAT2 2013 3/150 6/150 0.2 % 0.50 [ 0.13, 1.96 ]
OMEGA 2009 88/1919 70/1885 2.7 % 1.23 [ 0.91, 1.68 ]
OPAL 2010 9/434 8/433 0.3 % 1.12 [ 0.44, 2.88 ]
ORIGIN 2012 951/6281 964/6225 17.5 % 0.98 [ 0.90, 1.06 ]
SCIMO 1999 1/112 2/111 0.1 % 0.50 [ 0.05, 5.39 ]
SOFA 2006 8/273 14/273 0.4 % 0.57 [ 0.24, 1.34 ]
SU.FOL.OM3 2010 66/1253 68/1248 2.4 % 0.97 [ 0.70, 1.34 ]
Subtotal (95% CI) 16684 16462 36.6 % 1.01 [ 0.94, 1.08 ]
Total events: 1546 (Higher omega 3), 1513 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 9.55, df = 14 (P = 0.79); I2 =0.0%
Test for overall effect: Z = 0.23 (P = 0.81)
2 Moderate/high risk of bias
AFFORD 2013 0/153 1/163 0.0 % 0.35 [ 0.01, 8.65 ]
Bates 1989 1/155 0/157 0.0 % 3.04 [ 0.12, 74.02 ]
Brox 2001 0/80 1/40 0.0 % 0.17 [ 0.01, 4.05 ]
DART 1989 94/1015 131/1018 4.0 % 0.72 [ 0.56, 0.92 ]
DART2 2003 283/1571 242/1543 8.4 % 1.15 [ 0.98, 1.34 ]
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Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
DIPP 2015 2/104 3/101 0.1 % 0.65 [ 0.11, 3.79 ]
DISAF 2003 6/201 8/206 0.3 % 0.77 [ 0.27, 2.18 ]
DO IT 2010 14/282 24/281 0.7 % 0.58 [ 0.31, 1.10 ]
Doi 2014 2/119 9/119 0.1 % 0.22 [ 0.05, 1.01 ]
EPIC-1 2008 1/183 0/180 0.0 % 2.95 [ 0.12, 71.97 ]
EPIC-2 2008 0/189 1/190 0.0 % 0.34 [ 0.01, 8.17 ]
FAAT 2005 13/200 12/202 0.5 % 1.09 [ 0.51, 2.34 ]
GISSI-HF 2008 955/3494 1014/3481 18.8 % 0.94 [ 0.87, 1.01 ]
GISSI-P 1999 472/5666 545/5658 12.2 % 0.86 [ 0.77, 0.97 ]
HARP 1995 0/41 1/39 0.0 % 0.32 [ 0.01, 7.57 ]
JELIS 2007 286/9326 265/9319 7.8 % 1.08 [ 0.91, 1.27 ]
Kumar 2013 1/39 1/39 0.0 % 1.00 [ 0.06, 15.43 ]
Nutristroke 2009 0/38 4/34 0.0 % 0.10 [ 0.01, 1.79 ]
OFAMI 2001 11/150 11/150 0.4 % 1.00 [ 0.45, 2.24 ]
Raitt 2005 4/100 10/100 0.2 % 0.40 [ 0.13, 1.23 ]
Risk % Prevention 2013 348/6239 337/6266 9.3 % 1.04 [ 0.90, 1.20 ]
Shinto 2014 1/13 1/13 0.0 % 1.00 [ 0.07, 14.34 ]
SHOT 1996 8/317 6/293 0.3 % 1.23 [ 0.43, 3.51 ]
Zhang 2017 0/120 1/120 0.0 % 0.33 [ 0.01, 8.10 ]
Subtotal (95% CI) 29795 29712 63.4 % 0.94 [ 0.86, 1.03 ]
Total events: 2502 (Higher omega 3), 2628 (Lower omega 3)
Heterogeneity: Tau2 = 0.01; Chi2 = 31.55, df = 23 (P = 0.11); I2 =27%
Test for overall effect: Z = 1.29 (P = 0.20)
Total (95% CI) 46479 46174 100.0 % 0.98 [ 0.93, 1.03 ]
Total events: 4048 (Higher omega 3), 4141 (Lower omega 3)
Heterogeneity: Tau2 = 0.00; Chi2 = 43.01, df = 38 (P = 0.27); I2 =12%
Test for overall effect: Z = 0.87 (P = 0.39)
Test for subgroup differences: Chi2 = 1.36, df = 1 (P = 0.24), I2 =27%
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Analysis 1.4. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 4 All-cause
mortality - LCn3 - SA by compliance and study size.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)
Outcome: 4 All-cause mortality - LCn3 - SA by compliance and study size
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 SA - low risk of compliance bias
AFFORD 2013 0/153 1/163 0.2 % 0.35 [ 0.01, 8.65 ]
AlphaOmega - EPA+DHA 2010 (1) 186/2404 184/2433 48.6 % 1.02 [ 0.84, 1.24 ]
Bates 1989 1/155 0/157 0.2 % 3.04 [ 0.12, 74.02 ]
Berson 2004 0/105 1/103 0.2 % 0.33 [ 0.01, 7.94 ]
Brox 2001 0/80 1/40 0.2 % 0.17 [ 0.01, 4.05 ]
DISAF 2003 6/201 8/206 1.7 % 0.77 [ 0.27, 2.18 ]
DO IT 2010 14/282 24/281 4.6 % 0.58 [ 0.31, 1.10 ]
FOSTAR 2016 0/101 1/101 0.2 % 0.33 [ 0.01, 8.09 ]
HARP 1995 0/41 1/39 0.2 % 0.32 [ 0.01, 7.57 ]
Kumar 2013 1/39 1/39 0.2 % 1.00 [ 0.06, 15.43 ]
NAT2 2013 3/150 6/150 1.0 % 0.50 [ 0.13, 1.96 ]
OMEGA 2009 88/1919 70/1885 19.7 % 1.23 [ 0.91, 1.68 ]
OPAL 2010 9/434 8/433 2.1 % 1.12 [ 0.44, 2.88 ]
Raitt 2005 4/100 10/100 1.5 % 0.40 [ 0.13, 1.23 ]
SCIMO 1999 1/112 2/111 0.3 % 0.50 [ 0.05, 5.39 ]
Shinto 2014 1/13 1/13 0.3 % 1.00 [ 0.07, 14.34 ]
SHOT 1996 8/317 6/293 1.7 % 1.23 [ 0.43, 3.51 ]
SU.FOL.OM3 2010 66/1253 68/1248 17.2 % 0.97 [ 0.70, 1.34 ]
Subtotal (95% CI) 7859 7795 100.0 % 0.99 [ 0.86, 1.14 ]
Total events: 388 (Higher omega 3), 393 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 12.50, df = 17 (P = 0.77); I2 =0.0%
Test for overall effect: Z = 0.12 (P = 0.90)
2 SA - 100+ randomised
ADCS 2010 11/238 4/164 0.2 % 1.89 [ 0.61, 5.85 ]
AFFORD 2013 0/153 1/163 0.0 % 0.35 [ 0.01, 8.65 ]
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Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
AlphaOmega - EPA+DHA 2010 (2) 186/2404 184/2433 6.2 % 1.02 [ 0.84, 1.24 ]
AREDS2 2014 200/2147 168/2056 6.2 % 1.14 [ 0.94, 1.39 ]
Bates 1989 1/155 0/157 0.0 % 3.04 [ 0.12, 74.02 ]
Berson 2004 0/105 1/103 0.0 % 0.33 [ 0.01, 7.94 ]
Brox 2001 0/80 1/40 0.0 % 0.17 [ 0.01, 4.05 ]
DART 1989 94/1015 131/1018 4.2 % 0.72 [ 0.56, 0.92 ]
DART2 2003 283/1571 242/1543 8.6 % 1.15 [ 0.98, 1.34 ]
Derosa 2016 1/138 2/143 0.1 % 0.52 [ 0.05, 5.65 ]
DIPP 2015 2/104 3/101 0.1 % 0.65 [ 0.11, 3.79 ]
DISAF 2003 6/201 8/206 0.3 % 0.77 [ 0.27, 2.18 ]
DO IT 2010 14/282 24/281 0.7 % 0.58 [ 0.31, 1.10 ]
Doi 2014 2/119 9/119 0.1 % 0.22 [ 0.05, 1.01 ]
EPIC-1 2008 1/183 0/180 0.0 % 2.95 [ 0.12, 71.97 ]
EPIC-2 2008 0/189 1/190 0.0 % 0.34 [ 0.01, 8.17 ]
FAAT 2005 13/200 12/202 0.5 % 1.09 [ 0.51, 2.34 ]
FORWARD 2013 4/289 5/297 0.2 % 0.82 [ 0.22, 3.03 ]
FOSTAR 2016 0/101 1/101 0.0 % 0.33 [ 0.01, 8.09 ]
GISSI-HF 2008 955/3494 1014/3481 17.9 % 0.94 [ 0.87, 1.01 ]
GISSI-P 1999 472/5666 545/5658 12.1 % 0.86 [ 0.77, 0.97 ]
JELIS 2007 286/9326 265/9319 8.0 % 1.08 [ 0.91, 1.27 ]
MAPT 2017 18/840 16/840 0.7 % 1.13 [ 0.58, 2.19 ]
NAT2 2013 3/150 6/150 0.2 % 0.50 [ 0.13, 1.96 ]
OFAMI 2001 11/150 11/150 0.5 % 1.00 [ 0.45, 2.24 ]
OMEGA 2009 88/1919 70/1885 2.9 % 1.23 [ 0.91, 1.68 ]
OPAL 2010 9/434 8/433 0.3 % 1.12 [ 0.44, 2.88 ]
ORIGIN 2012 951/6281 964/6225 16.7 % 0.98 [ 0.90, 1.06 ]
Raitt 2005 4/100 10/100 0.2 % 0.40 [ 0.13, 1.23 ]
Risk % Prevention 2013 348/6239 337/6266 9.4 % 1.04 [ 0.90, 1.20 ]
SCIMO 1999 1/112 2/111 0.1 % 0.50 [ 0.05, 5.39 ]
SHOT 1996 8/317 6/293 0.3 % 1.23 [ 0.43, 3.51 ]
SOFA 2006 8/273 14/273 0.4 % 0.57 [ 0.24, 1.34 ]
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Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
SU.FOL.OM3 2010 66/1253 68/1248 2.6 % 0.97 [ 0.70, 1.34 ]
Zhang 2017 0/120 1/120 0.0 % 0.33 [ 0.01, 8.10 ]
Subtotal (95% CI) 46348 46049 100.0 % 0.98 [ 0.93, 1.03 ]
Total events: 4046 (Higher omega 3), 4134 (Lower omega 3)
Heterogeneity: Tau2 = 0.00; Chi2 = 40.14, df = 34 (P = 0.22); I2 =15%
Test for overall effect: Z = 0.78 (P = 0.44)
Test for subgroup differences: Chi2 = 0.03, df = 1 (P = 0.86), I2 =0.0%
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Analysis 1.5. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 5 All-cause
mortality - LCn3 - subgroup by dose.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)
Outcome: 5 All-cause mortality - LCn3 - subgroup by dose
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 LCn3≤150 mg/d
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 3), 0 (Lower omega 3)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 LCn3 > 150≤ 250 mg/d
DISAF 2003 6/201 8/206 0.3 % 0.77 [ 0.27, 2.18 ]
Subtotal (95% CI) 201 206 0.3 % 0.77 [ 0.27, 2.18 ]
Total events: 6 (Higher omega 3), 8 (Lower omega 3)
Heterogeneity: not applicable
Test for overall effect: Z = 0.50 (P = 0.62)
3 LCn3 > 250≤400 mg/d
DART 1989 94/1015 131/1018 4.0 % 0.72 [ 0.56, 0.92 ]
Subtotal (95% CI) 1015 1018 4.0 % 0.72 [ 0.56, 0.92 ]
Total events: 94 (Higher omega 3), 131 (Lower omega 3)
Heterogeneity: not applicable
Test for overall effect: Z = 2.58 (P = 0.010)
4 LCn3 > 400≤ 2400 mg/d
ADCS 2010 11/238 4/164 0.2 % 1.89 [ 0.61, 5.85 ]
AFFORD 2013 0/153 1/163 0.0 % 0.35 [ 0.01, 8.65 ]
AlphaOmega - EPA+DHA 2010 (1) 186/2404 184/2433 6.0 % 1.02 [ 0.84, 1.24 ]
AREDS2 2014 200/2147 168/2056 6.0 % 1.14 [ 0.94, 1.39 ]
Berson 2004 0/105 1/103 0.0 % 0.33 [ 0.01, 7.94 ]
DART2 2003 283/1571 242/1543 8.4 % 1.15 [ 0.98, 1.34 ]
Derosa 2016 1/138 2/143 0.1 % 0.52 [ 0.05, 5.65 ]
DIPP 2015 2/104 3/101 0.1 % 0.65 [ 0.11, 3.79 ]
DO IT 2010 14/282 24/281 0.7 % 0.58 [ 0.31, 1.10 ]
Doi 2014 2/119 9/119 0.1 % 0.22 [ 0.05, 1.01 ]
FORWARD 2013 4/289 5/297 0.2 % 0.82 [ 0.22, 3.03 ]
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Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
GISSI-HF 2008 955/3494 1014/3481 18.9 % 0.94 [ 0.87, 1.01 ]
GISSI-P 1999 472/5666 545/5658 12.3 % 0.86 [ 0.77, 0.97 ]
JELIS 2007 286/9326 265/9319 7.8 % 1.08 [ 0.91, 1.27 ]
Kumar 2013 1/39 1/39 0.0 % 1.00 [ 0.06, 15.43 ]
MAPT 2017 18/840 16/840 0.6 % 1.13 [ 0.58, 2.19 ]
NAT2 2013 3/150 6/150 0.2 % 0.50 [ 0.13, 1.96 ]
Nutristroke 2009 0/38 4/34 0.0 % 0.10 [ 0.01, 1.79 ]
OMEGA 2009 88/1919 70/1885 2.8 % 1.23 [ 0.91, 1.68 ]
OPAL 2010 9/434 8/433 0.3 % 1.12 [ 0.44, 2.88 ]
ORIGIN 2012 951/6281 964/6225 17.5 % 0.98 [ 0.90, 1.06 ]
Raitt 2005 4/100 10/100 0.2 % 0.40 [ 0.13, 1.23 ]
Risk % Prevention 2013 348/6239 337/6266 9.3 % 1.04 [ 0.90, 1.20 ]
SCIMO 1999 1/112 2/111 0.1 % 0.50 [ 0.05, 5.39 ]
Shinto 2014 1/13 1/13 0.0 % 1.00 [ 0.07, 14.34 ]
SOFA 2006 8/273 14/273 0.4 % 0.57 [ 0.24, 1.34 ]
SU.FOL.OM3 2010 58/1253 59/1248 2.1 % 0.98 [ 0.69, 1.39 ]
Zhang 2017 0/120 1/120 0.0 % 0.33 [ 0.01, 8.10 ]
Subtotal (95% CI) 43847 43598 94.4 % 0.99 [ 0.93, 1.05 ]
Total events: 3906 (Higher omega 3), 3960 (Lower omega 3)
Heterogeneity: Tau2 = 0.00; Chi2 = 33.41, df = 27 (P = 0.18); I2 =19%
Test for overall effect: Z = 0.29 (P = 0.77)
5 LCn3 > 2.4≤ 4.4 g/d
Bates 1989 1/155 0/157 0.0 % 3.04 [ 0.12, 74.02 ]
Brox 2001 0/80 1/40 0.0 % 0.17 [ 0.01, 4.05 ]
EPIC-1 2008 1/183 0/180 0.0 % 2.95 [ 0.12, 71.97 ]
EPIC-2 2008 0/189 1/190 0.0 % 0.34 [ 0.01, 8.17 ]
FAAT 2005 13/200 12/202 0.5 % 1.09 [ 0.51, 2.34 ]
OFAMI 2001 11/150 11/150 0.4 % 1.00 [ 0.45, 2.24 ]
SHOT 1996 8/317 6/293 0.3 % 1.23 [ 0.43, 3.51 ]
Subtotal (95% CI) 1274 1212 1.3 % 1.06 [ 0.67, 1.70 ]
Total events: 34 (Higher omega 3), 31 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.70, df = 6 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 0.25 (P = 0.80)
6 LCn3 > 4.4 g/d
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Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
FOSTAR 2016 0/101 1/101 0.0 % 0.33 [ 0.01, 8.09 ]
HARP 1995 0/41 1/39 0.0 % 0.32 [ 0.01, 7.57 ]
Subtotal (95% CI) 142 140 0.1 % 0.33 [ 0.03, 3.08 ]
Total events: 0 (Higher omega 3), 2 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 0.98 (P = 0.33)
Total (95% CI) 46479 46174 100.0 % 0.98 [ 0.93, 1.03 ]
Total events: 4040 (Higher omega 3), 4132 (Lower omega 3)
Heterogeneity: Tau2 = 0.00; Chi2 = 43.01, df = 38 (P = 0.27); I2 =12%
Test for overall effect: Z = 0.85 (P = 0.39)
Test for subgroup differences: Chi2 = 7.21, df = 4 (P = 0.13), I2 =45%
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Analysis 1.6. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 6 All-cause
mortality - LCn3 - subgroup by replacement.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)
Outcome: 6 All-cause mortality - LCn3 - subgroup by replacement
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 LCn3 replacing SFA
DART 1989 94/1015 131/1018 96.7 % 0.72 [ 0.56, 0.92 ]
Derosa 2016 1/138 2/143 1.1 % 0.52 [ 0.05, 5.65 ]
EPIC-1 2008 1/183 0/180 0.6 % 2.95 [ 0.12, 71.97 ]
EPIC-2 2008 0/189 1/190 0.6 % 0.34 [ 0.01, 8.17 ]
SCIMO 1999 1/112 2/111 1.1 % 0.50 [ 0.05, 5.39 ]
Subtotal (95% CI) 1637 1642 100.0 % 0.72 [ 0.56, 0.92 ]
Total events: 97 (Higher omega 3), 136 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.14, df = 4 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 2.65 (P = 0.0081)
2 LCn3 replacing MUFA
AlphaOmega - EPA+DHA 2010 (1) 186/2404 184/2433 8.9 % 1.02 [ 0.84, 1.24 ]
Bates 1989 1/155 0/157 0.0 % 3.04 [ 0.12, 74.02 ]
DART 1989 94/1015 131/1018 5.8 % 0.72 [ 0.56, 0.92 ]
FAAT 2005 13/200 12/202 0.7 % 1.09 [ 0.51, 2.34 ]
FORWARD 2013 4/289 5/297 0.2 % 0.82 [ 0.22, 3.03 ]
GISSI-HF 2008 955/3494 1014/3481 33.7 % 0.94 [ 0.87, 1.01 ]
HARP 1995 0/41 1/39 0.0 % 0.32 [ 0.01, 7.57 ]
NAT2 2013 3/150 6/150 0.2 % 0.50 [ 0.13, 1.96 ]
OMEGA 2009 88/1919 70/1885 4.0 % 1.23 [ 0.91, 1.68 ]
OPAL 2010 9/434 8/433 0.4 % 1.12 [ 0.44, 2.88 ]
ORIGIN 2012 951/6281 964/6225 30.6 % 0.98 [ 0.90, 1.06 ]
Raitt 2005 4/100 10/100 0.3 % 0.40 [ 0.13, 1.23 ]
Risk % Prevention 2013 348/6239 337/6266 14.5 % 1.04 [ 0.90, 1.20 ]
SCIMO 1999 1/112 2/111 0.1 % 0.50 [ 0.05, 5.39 ]
SOFA 2006 8/273 14/273 0.5 % 0.57 [ 0.24, 1.34 ]
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Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Subtotal (95% CI) 23106 23070 100.0 % 0.96 [ 0.90, 1.02 ]
Total events: 2665 (Higher omega 3), 2758 (Lower omega 3)
Heterogeneity: Tau2 = 0.00; Chi2 = 15.86, df = 14 (P = 0.32); I2 =12%
Test for overall effect: Z = 1.21 (P = 0.23)
3 LCn3 replacing N-6
ADCS 2010 11/238 4/164 11.4 % 1.89 [ 0.61, 5.85 ]
AFFORD 2013 0/153 1/163 1.4 % 0.35 [ 0.01, 8.65 ]
Berson 2004 0/105 1/103 1.4 % 0.33 [ 0.01, 7.94 ]
DIPP 2015 2/104 3/101 4.6 % 0.65 [ 0.11, 3.79 ]
DO IT 2010 14/282 24/281 35.5 % 0.58 [ 0.31, 1.10 ]
OFAMI 2001 11/150 11/150 22.3 % 1.00 [ 0.45, 2.24 ]
Shinto 2014 1/13 1/13 2.0 % 1.00 [ 0.07, 14.34 ]
SOFA 2006 8/273 14/273 19.9 % 0.57 [ 0.24, 1.34 ]
Zhang 2017 0/120 1/120 1.4 % 0.33 [ 0.01, 8.10 ]
Subtotal (95% CI) 1438 1368 100.0 % 0.74 [ 0.51, 1.09 ]
Total events: 47 (Higher omega 3), 60 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 4.88, df = 8 (P = 0.77); I2 =0.0%
Test for overall effect: Z = 1.53 (P = 0.13)
4 LCn3 replacing CHO
Derosa 2016 1/138 2/143 100.0 % 0.52 [ 0.05, 5.65 ]
Subtotal (95% CI) 138 143 100.0 % 0.52 [ 0.05, 5.65 ]
Total events: 1 (Higher omega 3), 2 (Lower omega 3)
Heterogeneity: not applicable
Test for overall effect: Z = 0.54 (P = 0.59)
5 LCn3 replacing nil/low n-3 placebo
AREDS2 2014 200/2147 168/2056 22.6 % 1.14 [ 0.94, 1.39 ]
Brox 2001 0/80 1/40 0.2 % 0.17 [ 0.01, 4.05 ]
Doi 2014 2/119 9/119 0.8 % 0.22 [ 0.05, 1.01 ]
FOSTAR 2016 0/101 1/101 0.2 % 0.33 [ 0.01, 8.09 ]
GISSI-P 1999 472/5666 545/5658 32.0 % 0.86 [ 0.77, 0.97 ]
JELIS 2007 286/9326 265/9319 26.1 % 1.08 [ 0.91, 1.27 ]
Kumar 2013 1/39 1/39 0.3 % 1.00 [ 0.06, 15.43 ]
MAPT 2017 18/840 16/840 3.9 % 1.13 [ 0.58, 2.19 ]
SHOT 1996 8/317 6/293 1.7 % 1.23 [ 0.43, 3.51 ]
SU.FOL.OM3 2010 66/1253 68/1248 12.3 % 0.97 [ 0.70, 1.34 ]
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Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Subtotal (95% CI) 19888 19713 100.0 % 0.99 [ 0.86, 1.14 ]
Total events: 1053 (Higher omega 3), 1080 (Lower omega 3)
Heterogeneity: Tau2 = 0.01; Chi2 = 13.49, df = 9 (P = 0.14); I2 =33%
Test for overall effect: Z = 0.15 (P = 0.88)
6 LCn3 replacement unclear
DART2 2003 283/1571 242/1543 68.5 % 1.15 [ 0.98, 1.34 ]
DISAF 2003 6/201 8/206 26.4 % 0.77 [ 0.27, 2.18 ]
Nutristroke 2009 0/38 4/34 5.1 % 0.10 [ 0.01, 1.79 ]
Subtotal (95% CI) 1810 1783 100.0 % 0.91 [ 0.46, 1.79 ]
Total events: 289 (Higher omega 3), 254 (Lower omega 3)
Heterogeneity: Tau2 = 0.17; Chi2 = 3.31, df = 2 (P = 0.19); I2 =40%
Test for overall effect: Z = 0.27 (P = 0.79)
Test for subgroup differences: Chi2 = 7.35, df = 5 (P = 0.20), I2 =32%
0.1 0.2 0.5 1 2 5 10
Favours higher omega 3 Favours lower omega 3
(1) AlphaOmega - comparing EPA+DHA ALA with no EPA+DHA ALA
293Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.7. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 7 All-cause
mortality - LCn3 - subgroup by intervention type.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)
Outcome: 7 All-cause mortality - LCn3 - subgroup by intervention type
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Dietary advice
DART 1989 94/1015 131/1018 4.0 % 0.72 [ 0.56, 0.92 ]
DART2 2003 283/1571 242/1543 8.4 % 1.15 [ 0.98, 1.34 ]
DISAF 2003 6/201 8/206 0.3 % 0.77 [ 0.27, 2.18 ]
Subtotal (95% CI) 2787 2767 12.6 % 0.90 [ 0.60, 1.35 ]
Total events: 383 (Higher omega 3), 381 (Lower omega 3)
Heterogeneity: Tau2 = 0.08; Chi2 = 9.90, df = 2 (P = 0.01); I2 =80%
Test for overall effect: Z = 0.51 (P = 0.61)
2 Supplemental foods
AlphaOmega - EPA+DHA 2010 (1) 186/2404 184/2433 6.0 % 1.02 [ 0.84, 1.24 ]
FOSTAR 2016 0/101 1/101 0.0 % 0.33 [ 0.01, 8.09 ]
Subtotal (95% CI) 2505 2534 6.0 % 1.02 [ 0.84, 1.24 ]
Total events: 186 (Higher omega 3), 185 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.47, df = 1 (P = 0.49); I2 =0.0%
Test for overall effect: Z = 0.19 (P = 0.85)
3 Supplements (capsule)
ADCS 2010 11/238 4/164 0.2 % 1.89 [ 0.61, 5.85 ]
AFFORD 2013 0/153 1/163 0.0 % 0.35 [ 0.01, 8.65 ]
AREDS2 2014 200/2147 168/2056 6.0 % 1.14 [ 0.94, 1.39 ]
Bates 1989 1/155 0/157 0.0 % 3.04 [ 0.12, 74.02 ]
Berson 2004 0/105 1/103 0.0 % 0.33 [ 0.01, 7.94 ]
Brox 2001 0/80 1/40 0.0 % 0.17 [ 0.01, 4.05 ]
Derosa 2016 1/138 2/143 0.1 % 0.52 [ 0.05, 5.65 ]
DO IT 2010 14/282 24/281 0.7 % 0.58 [ 0.31, 1.10 ]
Doi 2014 2/119 9/119 0.1 % 0.22 [ 0.05, 1.01 ]
EPIC-1 2008 1/183 0/180 0.0 % 2.95 [ 0.12, 71.97 ]
EPIC-2 2008 0/189 1/190 0.0 % 0.34 [ 0.01, 8.17 ]
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Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
FAAT 2005 13/200 12/202 0.5 % 1.09 [ 0.51, 2.34 ]
FORWARD 2013 4/289 5/297 0.2 % 0.82 [ 0.22, 3.03 ]
GISSI-HF 2008 955/3494 1014/3481 18.8 % 0.94 [ 0.87, 1.01 ]
GISSI-P 1999 472/5666 545/5658 12.2 % 0.86 [ 0.77, 0.97 ]
HARP 1995 0/41 1/39 0.0 % 0.32 [ 0.01, 7.57 ]
JELIS 2007 286/9326 265/9319 7.8 % 1.08 [ 0.91, 1.27 ]
Kumar 2013 1/39 1/39 0.0 % 1.00 [ 0.06, 15.43 ]
MAPT 2017 18/840 16/840 0.6 % 1.13 [ 0.58, 2.19 ]
NAT2 2013 3/150 6/150 0.2 % 0.50 [ 0.13, 1.96 ]
Nutristroke 2009 0/38 4/34 0.0 % 0.10 [ 0.01, 1.79 ]
OFAMI 2001 11/150 11/150 0.4 % 1.00 [ 0.45, 2.24 ]
OMEGA 2009 88/1919 70/1885 2.7 % 1.23 [ 0.91, 1.68 ]
OPAL 2010 9/434 8/433 0.3 % 1.12 [ 0.44, 2.88 ]
ORIGIN 2012 951/6281 964/6225 17.5 % 0.98 [ 0.90, 1.06 ]
Raitt 2005 4/100 10/100 0.2 % 0.40 [ 0.13, 1.23 ]
Risk % Prevention 2013 348/6239 337/6266 9.3 % 1.04 [ 0.90, 1.20 ]
SCIMO 1999 1/112 2/111 0.1 % 0.50 [ 0.05, 5.39 ]
Shinto 2014 1/13 1/13 0.0 % 1.00 [ 0.07, 14.34 ]
SHOT 1996 8/317 6/293 0.3 % 1.23 [ 0.43, 3.51 ]
SOFA 2006 8/273 14/273 0.4 % 0.57 [ 0.24, 1.34 ]
SU.FOL.OM3 2010 66/1253 68/1248 2.4 % 0.97 [ 0.70, 1.34 ]
Zhang 2017 0/120 1/120 0.0 % 0.33 [ 0.01, 8.10 ]
Subtotal (95% CI) 41083 40772 81.3 % 0.97 [ 0.92, 1.01 ]
Total events: 3477 (Higher omega 3), 3572 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 31.92, df = 32 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 1.60 (P = 0.11)
4 Any combination
DIPP 2015 2/104 3/101 0.1 % 0.65 [ 0.11, 3.79 ]
Subtotal (95% CI) 104 101 0.1 % 0.65 [ 0.11, 3.79 ]
Total events: 2 (Higher omega 3), 3 (Lower omega 3)
Heterogeneity: not applicable
Test for overall effect: Z = 0.48 (P = 0.63)
Total (95% CI) 46479 46174 100.0 % 0.98 [ 0.93, 1.03 ]
Total events: 4048 (Higher omega 3), 4141 (Lower omega 3)
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Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Heterogeneity: Tau2 = 0.00; Chi2 = 43.01, df = 38 (P = 0.27); I2 =12%
Test for overall effect: Z = 0.87 (P = 0.39)
Test for subgroup differences: Chi2 = 0.59, df = 3 (P = 0.90), I2 =0.0%
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Analysis 1.8. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 8 All-cause
mortality - LCn3 - subgroup by duration.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)
Outcome: 8 All-cause mortality - LCn3 - subgroup by duration
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Medium duration 1 to < 2 years in study
ADCS 2010 11/238 4/164 0.2 % 1.89 [ 0.61, 5.85 ]
AFFORD 2013 0/153 1/163 0.0 % 0.35 [ 0.01, 8.65 ]
Brox 2001 0/80 1/40 0.0 % 0.17 [ 0.01, 4.05 ]
Derosa 2016 1/138 2/143 0.1 % 0.52 [ 0.05, 5.65 ]
DISAF 2003 6/201 8/206 0.3 % 0.77 [ 0.27, 2.18 ]
Doi 2014 2/119 9/119 0.1 % 0.22 [ 0.05, 1.01 ]
EPIC-1 2008 1/183 0/180 0.0 % 2.95 [ 0.12, 71.97 ]
EPIC-2 2008 0/189 1/190 0.0 % 0.34 [ 0.01, 8.17 ]
FAAT 2005 13/200 12/202 0.5 % 1.09 [ 0.51, 2.34 ]
FORWARD 2013 4/289 5/297 0.2 % 0.82 [ 0.22, 3.03 ]
Kumar 2013 1/39 1/39 0.0 % 1.00 [ 0.06, 15.43 ]
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Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Nutristroke 2009 0/38 4/34 0.0 % 0.10 [ 0.01, 1.79 ]
OMEGA 2009 88/1919 70/1885 2.8 % 1.23 [ 0.91, 1.68 ]
OPAL 2010 9/434 8/433 0.3 % 1.12 [ 0.44, 2.88 ]
Shinto 2014 1/13 1/13 0.0 % 1.00 [ 0.07, 14.34 ]
SHOT 1996 8/317 6/293 0.3 % 1.23 [ 0.43, 3.51 ]
SOFA 2006 8/273 14/273 0.4 % 0.57 [ 0.24, 1.34 ]
Zhang 2017 0/120 1/120 0.0 % 0.33 [ 0.01, 8.10 ]
Subtotal (95% CI) 4943 4794 5.3 % 1.03 [ 0.82, 1.30 ]
Total events: 153 (Higher omega 3), 148 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 14.81, df = 17 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 0.29 (P = 0.77)
2 Medium-long duration: 2 to < 4 years in study
AlphaOmega - EPA+DHA 2010 (1) 186/2404 184/2433 6.0 % 1.02 [ 0.84, 1.24 ]
Bates 1989 1/155 0/157 0.0 % 3.04 [ 0.12, 74.02 ]
DART 1989 94/1015 131/1018 4.0 % 0.72 [ 0.56, 0.92 ]
DIPP 2015 2/104 3/101 0.1 % 0.65 [ 0.11, 3.79 ]
DO IT 2010 14/282 24/281 0.7 % 0.58 [ 0.31, 1.10 ]
FOSTAR 2016 0/101 1/101 0.0 % 0.33 [ 0.01, 8.09 ]
GISSI-HF 2008 955/3494 1014/3481 18.9 % 0.94 [ 0.87, 1.01 ]
GISSI-P 1999 472/5666 545/5658 12.3 % 0.86 [ 0.77, 0.97 ]
HARP 1995 0/41 1/39 0.0 % 0.32 [ 0.01, 7.57 ]
MAPT 2017 18/840 16/840 0.6 % 1.13 [ 0.58, 2.19 ]
NAT2 2013 3/150 6/150 0.2 % 0.50 [ 0.13, 1.96 ]
OFAMI 2001 11/150 11/150 0.4 % 1.00 [ 0.45, 2.24 ]
Raitt 2005 4/100 10/100 0.2 % 0.40 [ 0.13, 1.23 ]
SCIMO 1999 1/112 2/111 0.1 % 0.50 [ 0.05, 5.39 ]
Subtotal (95% CI) 14614 14620 43.5 % 0.91 [ 0.86, 0.96 ]
Total events: 1761 (Higher omega 3), 1948 (Lower omega 3)
Heterogeneity: Tau2 = 0.00; Chi2 = 13.01, df = 13 (P = 0.45); I2 =0%
Test for overall effect: Z = 3.28 (P = 0.0011)
3 Long duration:≥ 4 years in study
AREDS2 2014 200/2147 168/2056 6.0 % 1.14 [ 0.94, 1.39 ]
Berson 2004 0/105 1/103 0.0 % 0.33 [ 0.01, 7.94 ]
DART2 2003 283/1571 242/1543 8.4 % 1.15 [ 0.98, 1.34 ]
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Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
JELIS 2007 286/9326 265/9319 7.8 % 1.08 [ 0.91, 1.27 ]
ORIGIN 2012 951/6281 964/6225 17.5 % 0.98 [ 0.90, 1.06 ]
Risk % Prevention 2013 348/6239 337/6266 9.3 % 1.04 [ 0.90, 1.20 ]
SU.FOL.OM3 2010 58/1253 59/1248 2.1 % 0.98 [ 0.69, 1.39 ]
Subtotal (95% CI) 26922 26760 51.2 % 1.03 [ 0.98, 1.09 ]
Total events: 2126 (Higher omega 3), 2036 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 5.30, df = 6 (P = 0.51); I2 =0.0%
Test for overall effect: Z = 1.12 (P = 0.26)
Total (95% CI) 46479 46174 100.0 % 0.98 [ 0.93, 1.03 ]
Total events: 4040 (Higher omega 3), 4132 (Lower omega 3)
Heterogeneity: Tau2 = 0.00; Chi2 = 43.01, df = 38 (P = 0.27); I2 =12%
Test for overall effect: Z = 0.85 (P = 0.39)
Test for subgroup differences: Chi2 = 10.01, df = 2 (P = 0.01), I2 =80%
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Analysis 1.9. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 9 All-cause
mortality - LCn3 - subgroup by primary or secondary prevention.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)
Outcome: 9 All-cause mortality - LCn3 - subgroup by primary or secondary prevention
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Primary CVD prevention
ADCS 2010 11/238 4/164 0.2 % 1.89 [ 0.61, 5.85 ]
AREDS2 2014 200/2147 168/2056 6.0 % 1.14 [ 0.94, 1.39 ]
Bates 1989 1/155 0/157 0.0 % 3.04 [ 0.12, 74.02 ]
Berson 2004 0/105 1/103 0.0 % 0.33 [ 0.01, 7.94 ]
Brox 2001 0/80 1/40 0.0 % 0.17 [ 0.01, 4.05 ]
Derosa 2016 1/138 2/143 0.1 % 0.52 [ 0.05, 5.65 ]
DIPP 2015 2/104 3/101 0.1 % 0.65 [ 0.11, 3.79 ]
DO IT 2010 14/282 24/281 0.7 % 0.58 [ 0.31, 1.10 ]
EPIC-1 2008 1/183 0/180 0.0 % 2.95 [ 0.12, 71.97 ]
EPIC-2 2008 0/189 1/190 0.0 % 0.34 [ 0.01, 8.17 ]
FOSTAR 2016 0/101 1/101 0.0 % 0.33 [ 0.01, 8.09 ]
JELIS 2007 286/9326 265/9319 7.8 % 1.08 [ 0.91, 1.27 ]
MAPT 2017 18/840 16/840 0.6 % 1.13 [ 0.58, 2.19 ]
OPAL 2010 9/434 8/433 0.3 % 1.12 [ 0.44, 2.88 ]
ORIGIN 2012 951/6281 964/6225 17.5 % 0.98 [ 0.90, 1.06 ]
Shinto 2014 1/13 1/13 0.0 % 1.00 [ 0.07, 14.34 ]
Zhang 2017 0/120 1/120 0.0 % 0.33 [ 0.01, 8.10 ]
Subtotal (95% CI) 20736 20466 33.6 % 1.01 [ 0.94, 1.08 ]
Total events: 1495 (Higher omega 3), 1460 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 11.42, df = 16 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 0.24 (P = 0.81)
2 Secondary CVD prevention
AFFORD 2013 0/153 1/163 0.0 % 0.35 [ 0.01, 8.65 ]
AlphaOmega - EPA+DHA 2010 (1) 186/2404 184/2433 6.0 % 1.02 [ 0.84, 1.24 ]
DART 1989 94/1015 131/1018 4.0 % 0.72 [ 0.56, 0.92 ]
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Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
DART2 2003 283/1571 242/1543 8.4 % 1.15 [ 0.98, 1.34 ]
DISAF 2003 6/201 8/206 0.3 % 0.77 [ 0.27, 2.18 ]
Doi 2014 2/119 9/119 0.1 % 0.22 [ 0.05, 1.01 ]
FAAT 2005 13/200 12/202 0.5 % 1.09 [ 0.51, 2.34 ]
FORWARD 2013 4/289 5/297 0.2 % 0.82 [ 0.22, 3.03 ]
GISSI-HF 2008 955/3494 1014/3481 18.9 % 0.94 [ 0.87, 1.01 ]
GISSI-P 1999 472/5666 545/5658 12.3 % 0.86 [ 0.77, 0.97 ]
HARP 1995 0/41 1/39 0.0 % 0.32 [ 0.01, 7.57 ]
Kumar 2013 1/39 1/39 0.0 % 1.00 [ 0.06, 15.43 ]
NAT2 2013 3/150 6/150 0.2 % 0.50 [ 0.13, 1.96 ]
Nutristroke 2009 0/38 4/34 0.0 % 0.10 [ 0.01, 1.79 ]
OFAMI 2001 11/150 11/150 0.4 % 1.00 [ 0.45, 2.24 ]
OMEGA 2009 88/1919 70/1885 2.8 % 1.23 [ 0.91, 1.68 ]
Raitt 2005 4/100 10/100 0.2 % 0.40 [ 0.13, 1.23 ]
Risk % Prevention 2013 348/6239 337/6266 9.3 % 1.04 [ 0.90, 1.20 ]
SCIMO 1999 1/112 2/111 0.1 % 0.50 [ 0.05, 5.39 ]
SHOT 1996 8/317 6/293 0.3 % 1.23 [ 0.43, 3.51 ]
SOFA 2006 8/273 14/273 0.4 % 0.57 [ 0.24, 1.34 ]
SU.FOL.OM3 2010 58/1253 59/1248 2.1 % 0.98 [ 0.69, 1.39 ]
Subtotal (95% CI) 25743 25708 66.4 % 0.95 [ 0.88, 1.04 ]
Total events: 2545 (Higher omega 3), 2672 (Lower omega 3)
Heterogeneity: Tau2 = 0.01; Chi2 = 29.78, df = 21 (P = 0.10); I2 =29%
Test for overall effect: Z = 1.11 (P = 0.27)
Total (95% CI) 46479 46174 100.0 % 0.98 [ 0.93, 1.03 ]
Total events: 4040 (Higher omega 3), 4132 (Lower omega 3)
Heterogeneity: Tau2 = 0.00; Chi2 = 43.01, df = 38 (P = 0.27); I2 =12%
Test for overall effect: Z = 0.85 (P = 0.39)
Test for subgroup differences: Chi2 = 1.03, df = 1 (P = 0.31), I2 =3%
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Analysis 1.10. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 10 All-cause
mortality - LCn3 - subgroup by statin use.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)
Outcome: 10 All-cause mortality - LCn3 - subgroup by statin use
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 LCn3 -≥50% of control group on statins
AlphaOmega - EPA+DHA 2010 (1) 95/1192 93/1236 3.5 % 1.06 [ 0.80, 1.39 ]
Doi 2014 2/119 9/119 0.1 % 0.22 [ 0.05, 1.01 ]
JELIS 2007 286/9326 265/9319 8.1 % 1.08 [ 0.91, 1.27 ]
Kumar 2013 1/39 1/39 0.0 % 1.00 [ 0.06, 15.43 ]
NAT2 2013 3/150 6/150 0.2 % 0.50 [ 0.13, 1.96 ]
OMEGA 2009 88/1919 70/1885 2.9 % 1.23 [ 0.91, 1.68 ]
ORIGIN 2012 951/6281 964/6225 17.8 % 0.98 [ 0.90, 1.06 ]
SU.FOL.OM3 2010 58/1253 59/1248 2.2 % 0.98 [ 0.69, 1.39 ]
Subtotal (95% CI) 20279 20221 34.8 % 1.02 [ 0.93, 1.11 ]
Total events: 1484 (Higher omega 3), 1467 (Lower omega 3)
Heterogeneity: Tau2 = 0.00; Chi2 = 7.85, df = 7 (P = 0.35); I2 =11%
Test for overall effect: Z = 0.38 (P = 0.70)
2 LCn3 - < 50% of control group on statins
ADCS 2010 11/238 4/164 0.2 % 1.89 [ 0.61, 5.85 ]
AFFORD 2013 0/153 1/163 0.0 % 0.35 [ 0.01, 8.65 ]
AREDS2 2014 200/2147 168/2056 6.2 % 1.14 [ 0.94, 1.39 ]
Bates 1989 1/155 0/157 0.0 % 3.04 [ 0.12, 74.02 ]
Berson 2004 0/105 1/103 0.0 % 0.33 [ 0.01, 7.94 ]
Brox 2001 0/80 1/40 0.0 % 0.17 [ 0.01, 4.05 ]
DART 1989 94/1015 131/1018 4.1 % 0.72 [ 0.56, 0.92 ]
DART2 2003 283/1571 242/1543 8.7 % 1.15 [ 0.98, 1.34 ]
DIPP 2015 2/104 3/101 0.1 % 0.65 [ 0.11, 3.79 ]
DISAF 2003 6/201 8/206 0.3 % 0.77 [ 0.27, 2.18 ]
DO IT 2010 14/282 24/281 0.7 % 0.58 [ 0.31, 1.10 ]
EPIC-1 2008 1/183 0/180 0.0 % 2.95 [ 0.12, 71.97 ]
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(. . . Continued)
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
EPIC-2 2008 0/189 1/190 0.0 % 0.34 [ 0.01, 8.17 ]
FAAT 2005 13/200 12/202 0.5 % 1.09 [ 0.51, 2.34 ]
FORWARD 2013 4/289 5/297 0.2 % 0.82 [ 0.22, 3.03 ]
FOSTAR 2016 0/101 1/101 0.0 % 0.33 [ 0.01, 8.09 ]
GISSI-HF 2008 955/3494 1014/3481 19.2 % 0.94 [ 0.87, 1.01 ]
GISSI-P 1999 472/5666 545/5658 12.6 % 0.86 [ 0.77, 0.97 ]
HARP 1995 0/41 1/39 0.0 % 0.32 [ 0.01, 7.57 ]
OFAMI 2001 11/150 11/150 0.5 % 1.00 [ 0.45, 2.24 ]
Raitt 2005 4/100 10/100 0.2 % 0.40 [ 0.13, 1.23 ]
Risk % Prevention 2013 348/6239 337/6266 9.6 % 1.04 [ 0.90, 1.20 ]
SCIMO 1999 1/112 2/111 0.1 % 0.50 [ 0.05, 5.39 ]
Shinto 2014 1/13 1/13 0.0 % 1.00 [ 0.07, 14.34 ]
SHOT 1996 8/317 6/293 0.3 % 1.23 [ 0.43, 3.51 ]
SOFA 2006 8/273 14/273 0.4 % 0.57 [ 0.24, 1.34 ]
Subtotal (95% CI) 23418 23186 64.1 % 0.95 [ 0.88, 1.03 ]
Total events: 2437 (Higher omega 3), 2543 (Lower omega 3)
Heterogeneity: Tau2 = 0.00; Chi2 = 30.26, df = 25 (P = 0.21); I2 =17%
Test for overall effect: Z = 1.19 (P = 0.23)
3 LCn3 - use of statins unclear
Derosa 2016 1/138 2/143 0.1 % 0.52 [ 0.05, 5.65 ]
MAPT 2017 18/840 16/840 0.7 % 1.13 [ 0.58, 2.19 ]
Nutristroke 2009 0/38 4/34 0.0 % 0.10 [ 0.01, 1.79 ]
OPAL 2010 9/434 8/433 0.3 % 1.12 [ 0.44, 2.88 ]
Zhang 2017 0/120 1/120 0.0 % 0.33 [ 0.01, 8.10 ]
Subtotal (95% CI) 1570 1570 1.1 % 0.97 [ 0.58, 1.63 ]
Total events: 28 (Higher omega 3), 31 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.45, df = 4 (P = 0.49); I2 =0.0%
Test for overall effect: Z = 0.11 (P = 0.92)
Total (95% CI) 45267 44977 100.0 % 0.98 [ 0.92, 1.03 ]
Total events: 3949 (Higher omega 3), 4041 (Lower omega 3)
Heterogeneity: Tau2 = 0.00; Chi2 = 43.12, df = 38 (P = 0.26); I2 =12%
Test for overall effect: Z = 0.83 (P = 0.41)
Test for subgroup differences: Chi2 = 1.16, df = 2 (P = 0.56), I2 =0.0%
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Analysis 1.11. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 11
Cardiovascular mortality (overall) - LCn3.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)
Outcome: 11 Cardiovascular mortality (overall) - LCn3
Study or subgroup
Favours
higher
omega 3 Lower omega 3 fats Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
AlphaOmega - EPA+DHA 2010 80/2404 82/2433 6.3 % 0.99 [ 0.73, 1.34 ]
AREDS2 2014 14/2147 13/2056 1.3 % 1.03 [ 0.49, 2.19 ]
Brox 2001 0/80 1/40 0.1 % 0.17 [ 0.01, 4.05 ]
DART 1989 84/1015 121/1018 7.7 % 0.70 [ 0.53, 0.91 ]
DART2 2003 (1) 180/1571 139/1543 10.4 % 1.27 [ 1.03, 1.57 ]
Derosa 2016 2/138 3/143 0.2 % 0.69 [ 0.12, 4.07 ]
DO IT 2010 7/282 11/281 0.8 % 0.63 [ 0.25, 1.61 ]
Doi 2014 1/119 5/119 0.2 % 0.20 [ 0.02, 1.69 ]
FAAT 2005 (2) 9/200 9/202 0.9 % 1.01 [ 0.41, 2.49 ]
FOSTAR 2016 0/101 1/101 0.1 % 0.33 [ 0.01, 8.09 ]
GISSI-HF 2008 712/3494 765/3481 20.1 % 0.93 [ 0.85, 1.02 ]
GISSI-P 1999 291/5665 348/5658 14.5 % 0.84 [ 0.72, 0.97 ]
HARP 1995 0/41 1/39 0.1 % 0.32 [ 0.01, 7.57 ]
Kumar 2013 1/39 1/39 0.1 % 1.00 [ 0.06, 15.43 ]
Nutristroke 2009 0/38 4/34 0.1 % 0.10 [ 0.01, 1.79 ]
OFAMI 2001 (3) 8/150 8/150 0.8 % 1.00 [ 0.39, 2.59 ]
OMEGA 2009 (4) 67/1919 51/1885 4.8 % 1.29 [ 0.90, 1.85 ]
ORIGIN 2012 574/6281 581/6255 18.3 % 0.98 [ 0.88, 1.10 ]
Raitt 2005 2/100 5/100 0.3 % 0.40 [ 0.08, 2.01 ]
Risk % Prevention 2013 142/6239 137/6266 9.1 % 1.04 [ 0.83, 1.31 ]
SCIMO 1999 0/112 1/111 0.1 % 0.33 [ 0.01, 8.02 ]
Shinto 2014 1/13 0/13 0.1 % 3.00 [ 0.13, 67.51 ]
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Study or subgroup
Favours
higher
omega 3 Lower omega 3 fats Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
SHOT 1996 7/317 5/293 0.6 % 1.29 [ 0.42, 4.03 ]
SOFA 2006 (5) 6/273 13/273 0.8 % 0.46 [ 0.18, 1.20 ]
SU.FOL.OM3 2010 23/1253 28/1248 2.3 % 0.82 [ 0.47, 1.41 ]
Total (95% CI) 33991 33781 100.0 % 0.95 [ 0.87, 1.03 ]
Total events: 2211 (Favours higher omega 3), 2333 (Lower omega 3 fats)
Heterogeneity: Tau2 = 0.01; Chi2 = 31.76, df = 24 (P = 0.13); I2 =24%
Test for overall effect: Z = 1.26 (P = 0.21)
Test for subgroup differences: Not applicable
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Analysis 1.12. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 12 CVD
mortality - LCn3 - SA fixed-effect.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)
Outcome: 12 CVD mortality - LCn3 - SA fixed-effect
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
AlphaOmega - EPA+DHA 2010 80/2404 82/2433 3.5 % 0.99 [ 0.73, 1.34 ]
AREDS2 2014 14/2147 13/2056 0.6 % 1.03 [ 0.49, 2.19 ]
Brox 2001 0/80 1/40 0.1 % 0.17 [ 0.01, 4.05 ]
DART 1989 84/1015 121/1018 5.2 % 0.70 [ 0.53, 0.91 ]
DART2 2003 180/1571 139/1543 6.0 % 1.27 [ 1.03, 1.57 ]
Derosa 2016 2/138 3/143 0.1 % 0.69 [ 0.12, 4.07 ]
DO IT 2010 7/282 11/281 0.5 % 0.63 [ 0.25, 1.61 ]
Doi 2014 1/119 5/119 0.2 % 0.20 [ 0.02, 1.69 ]
FAAT 2005 9/200 9/202 0.4 % 1.01 [ 0.41, 2.49 ]
FOSTAR 2016 0/101 1/101 0.1 % 0.33 [ 0.01, 8.09 ]
GISSI-HF 2008 712/3494 765/3481 32.7 % 0.93 [ 0.85, 1.02 ]
GISSI-P 1999 291/5665 348/5658 14.9 % 0.84 [ 0.72, 0.97 ]
HARP 1995 0/41 1/39 0.1 % 0.32 [ 0.01, 7.57 ]
Kumar 2013 1/39 1/39 0.0 % 1.00 [ 0.06, 15.43 ]
Nutristroke 2009 0/38 4/34 0.2 % 0.10 [ 0.01, 1.79 ]
OFAMI 2001 8/150 8/150 0.3 % 1.00 [ 0.39, 2.59 ]
OMEGA 2009 67/1919 51/1885 2.2 % 1.29 [ 0.90, 1.85 ]
ORIGIN 2012 574/6281 581/6255 24.9 % 0.98 [ 0.88, 1.10 ]
Raitt 2005 2/100 5/100 0.2 % 0.40 [ 0.08, 2.01 ]
Risk % Prevention 2013 142/6239 137/6266 5.8 % 1.04 [ 0.83, 1.31 ]
SCIMO 1999 0/112 1/111 0.1 % 0.33 [ 0.01, 8.02 ]
Shinto 2014 1/13 0/13 0.0 % 3.00 [ 0.13, 67.51 ]
SHOT 1996 7/317 5/293 0.2 % 1.29 [ 0.42, 4.03 ]
SOFA 2006 6/273 13/273 0.6 % 0.46 [ 0.18, 1.20 ]
SU.FOL.OM3 2010 23/1253 28/1248 1.2 % 0.82 [ 0.47, 1.41 ]
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Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Total (95% CI) 33991 33781 100.0 % 0.94 [ 0.89, 1.00 ]
Total events: 2211 (Higher omega 3), 2333 (Lower omega 3)
Heterogeneity: Chi2 = 31.76, df = 24 (P = 0.13); I2 =24%
Test for overall effect: Z = 2.07 (P = 0.038)
Test for subgroup differences: Not applicable
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Analysis 1.13. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 13 CVD
mortality - LCn3 - SA by summary risk of bias.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)
Outcome: 13 CVD mortality - LCn3 - SA by summary risk of bias
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Low risk of bias
AlphaOmega - EPA+DHA 2010 80/2404 82/2433 6.3 % 0.99 [ 0.73, 1.34 ]
AREDS2 2014 14/2147 13/2056 1.3 % 1.03 [ 0.49, 2.19 ]
Derosa 2016 2/138 3/143 0.2 % 0.69 [ 0.12, 4.07 ]
FOSTAR 2016 0/101 1/101 0.1 % 0.33 [ 0.01, 8.09 ]
OMEGA 2009 67/1919 51/1885 4.8 % 1.29 [ 0.90, 1.85 ]
ORIGIN 2012 574/6281 581/6255 18.3 % 0.98 [ 0.88, 1.10 ]
SCIMO 1999 0/112 1/111 0.1 % 0.33 [ 0.01, 8.02 ]
SOFA 2006 6/273 13/273 0.8 % 0.46 [ 0.18, 1.20 ]
SU.FOL.OM3 2010 23/1253 28/1248 2.3 % 0.82 [ 0.47, 1.41 ]
Subtotal (95% CI) 14628 14505 34.2 % 0.99 [ 0.90, 1.09 ]
Total events: 766 (Higher omega 3), 773 (Lower omega 3)
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Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Heterogeneity: Tau2 = 0.0; Chi2 = 6.11, df = 8 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 0.25 (P = 0.81)
2 Moderate/high risk of bias
Brox 2001 0/80 1/40 0.1 % 0.17 [ 0.01, 4.05 ]
DART 1989 84/1015 121/1018 7.7 % 0.70 [ 0.53, 0.91 ]
DART2 2003 180/1571 139/1543 10.4 % 1.27 [ 1.03, 1.57 ]
DO IT 2010 7/282 11/281 0.8 % 0.63 [ 0.25, 1.61 ]
Doi 2014 1/119 5/119 0.2 % 0.20 [ 0.02, 1.69 ]
FAAT 2005 9/200 9/202 0.9 % 1.01 [ 0.41, 2.49 ]
GISSI-HF 2008 712/3494 765/3481 20.1 % 0.93 [ 0.85, 1.02 ]
GISSI-P 1999 291/5665 348/5658 14.5 % 0.84 [ 0.72, 0.97 ]
HARP 1995 0/41 1/39 0.1 % 0.32 [ 0.01, 7.57 ]
Kumar 2013 1/39 1/39 0.1 % 1.00 [ 0.06, 15.43 ]
Nutristroke 2009 0/38 4/34 0.1 % 0.10 [ 0.01, 1.79 ]
OFAMI 2001 8/150 8/150 0.8 % 1.00 [ 0.39, 2.59 ]
Raitt 2005 2/100 5/100 0.3 % 0.40 [ 0.08, 2.01 ]
Risk % Prevention 2013 142/6239 137/6266 9.1 % 1.04 [ 0.83, 1.31 ]
Shinto 2014 1/13 0/13 0.1 % 3.00 [ 0.13, 67.51 ]
SHOT 1996 7/317 5/293 0.6 % 1.29 [ 0.42, 4.03 ]
Subtotal (95% CI) 19363 19276 65.8 % 0.92 [ 0.80, 1.05 ]
Total events: 1445 (Higher omega 3), 1560 (Lower omega 3)
Heterogeneity: Tau2 = 0.02; Chi2 = 24.46, df = 15 (P = 0.06); I2 =39%
Test for overall effect: Z = 1.23 (P = 0.22)
Total (95% CI) 33991 33781 100.0 % 0.95 [ 0.87, 1.03 ]
Total events: 2211 (Higher omega 3), 2333 (Lower omega 3)
Heterogeneity: Tau2 = 0.01; Chi2 = 31.76, df = 24 (P = 0.13); I2 =24%
Test for overall effect: Z = 1.26 (P = 0.21)
Test for subgroup differences: Chi2 = 0.73, df = 1 (P = 0.39), I2 =0.0%
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Analysis 1.14. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 14 CVD
mortality - LCn3 - SA by compliance and study size.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)
Outcome: 14 CVD mortality - LCn3 - SA by compliance and study size
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 SA - low risk of compliance bias
AlphaOmega - EPA+DHA 2010 80/2404 82/2433 43.7 % 0.99 [ 0.73, 1.34 ]
Brox 2001 0/80 1/40 0.4 % 0.17 [ 0.01, 4.05 ]
DO IT 2010 7/282 11/281 4.6 % 0.63 [ 0.25, 1.61 ]
FOSTAR 2016 0/101 1/101 0.4 % 0.33 [ 0.01, 8.09 ]
HARP 1995 0/41 1/39 0.4 % 0.32 [ 0.01, 7.57 ]
Kumar 2013 1/39 1/39 0.5 % 1.00 [ 0.06, 15.43 ]
OMEGA 2009 67/1919 51/1885 31.1 % 1.29 [ 0.90, 1.85 ]
Raitt 2005 2/100 5/100 1.5 % 0.40 [ 0.08, 2.01 ]
SCIMO 1999 0/112 1/111 0.4 % 0.33 [ 0.01, 8.02 ]
Shinto 2014 1/13 0/13 0.4 % 3.00 [ 0.13, 67.51 ]
SHOT 1996 7/317 5/293 3.1 % 1.29 [ 0.42, 4.03 ]
SU.FOL.OM3 2010 23/1253 28/1248 13.4 % 0.82 [ 0.47, 1.41 ]
Subtotal (95% CI) 6661 6583 100.0 % 1.00 [ 0.82, 1.23 ]
Total events: 188 (Higher omega 3), 187 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 7.92, df = 11 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 0.04 (P = 0.97)
2 SA - 100+ randomised
AlphaOmega - EPA+DHA 2010 80/2404 82/2433 6.5 % 0.99 [ 0.73, 1.34 ]
AREDS2 2014 14/2147 13/2056 1.3 % 1.03 [ 0.49, 2.19 ]
Brox 2001 0/80 1/40 0.1 % 0.17 [ 0.01, 4.05 ]
DART 1989 84/1015 121/1018 7.8 % 0.70 [ 0.53, 0.91 ]
DART2 2003 180/1571 139/1543 10.5 % 1.27 [ 1.03, 1.57 ]
Derosa 2016 2/138 3/143 0.3 % 0.69 [ 0.12, 4.07 ]
DO IT 2010 7/282 11/281 0.9 % 0.63 [ 0.25, 1.61 ]
Doi 2014 1/119 5/119 0.2 % 0.20 [ 0.02, 1.69 ]
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Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
FAAT 2005 9/200 9/202 0.9 % 1.01 [ 0.41, 2.49 ]
FOSTAR 2016 0/101 1/101 0.1 % 0.33 [ 0.01, 8.09 ]
GISSI-HF 2008 712/3494 765/3481 19.7 % 0.93 [ 0.85, 1.02 ]
GISSI-P 1999 291/5665 348/5658 14.5 % 0.84 [ 0.72, 0.97 ]
OFAMI 2001 8/150 8/150 0.9 % 1.00 [ 0.39, 2.59 ]
OMEGA 2009 67/1919 51/1885 5.0 % 1.29 [ 0.90, 1.85 ]
ORIGIN 2012 574/6281 581/6255 18.0 % 0.98 [ 0.88, 1.10 ]
Raitt 2005 2/100 5/100 0.3 % 0.40 [ 0.08, 2.01 ]
Risk % Prevention 2013 142/6239 137/6266 9.3 % 1.04 [ 0.83, 1.31 ]
SCIMO 1999 0/112 1/111 0.1 % 0.33 [ 0.01, 8.02 ]
SHOT 1996 7/317 5/293 0.6 % 1.29 [ 0.42, 4.03 ]
SOFA 2006 6/273 13/273 0.9 % 0.46 [ 0.18, 1.20 ]
SU.FOL.OM3 2010 23/1253 28/1248 2.4 % 0.82 [ 0.47, 1.41 ]
Subtotal (95% CI) 33860 33656 100.0 % 0.95 [ 0.87, 1.04 ]
Total events: 2209 (Higher omega 3), 2327 (Lower omega 3)
Heterogeneity: Tau2 = 0.01; Chi2 = 28.44, df = 20 (P = 0.10); I2 =30%
Test for overall effect: Z = 1.19 (P = 0.23)
Test for subgroup differences: Chi2 = 0.27, df = 1 (P = 0.60), I2 =0.0%
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Analysis 1.15. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 15 CVD
mortality - LCn3 - subgroup by dose.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)
Outcome: 15 CVD mortality - LCn3 - subgroup by dose
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 LCn3≤ 150 mg/d
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 3), 0 (Lower omega 3)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 LCn3 > 150≤ 250 mg/d
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 3), 0 (Lower omega 3)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 LCn3 > 250≤ 400 mg/d
DART 1989 84/1015 121/1018 7.7 % 0.70 [ 0.53, 0.91 ]
Subtotal (95% CI) 1015 1018 7.7 % 0.70 [ 0.53, 0.91 ]
Total events: 84 (Higher omega 3), 121 (Lower omega 3)
Heterogeneity: not applicable
Test for overall effect: Z = 2.68 (P = 0.0073)
4 LCn3 > 400≤ 2400 mg/d
AlphaOmega - EPA+DHA 2010 80/2404 82/2433 6.3 % 0.99 [ 0.73, 1.34 ]
AREDS2 2014 14/2147 13/2056 1.3 % 1.03 [ 0.49, 2.19 ]
DART2 2003 180/1571 139/1543 10.4 % 1.27 [ 1.03, 1.57 ]
Derosa 2016 2/138 3/143 0.2 % 0.69 [ 0.12, 4.07 ]
DO IT 2010 7/282 11/281 0.8 % 0.63 [ 0.25, 1.61 ]
Doi 2014 1/119 5/119 0.2 % 0.20 [ 0.02, 1.69 ]
GISSI-HF 2008 712/3494 765/3481 20.1 % 0.93 [ 0.85, 1.02 ]
GISSI-P 1999 291/5665 348/5658 14.5 % 0.84 [ 0.72, 0.97 ]
Kumar 2013 1/39 1/39 0.1 % 1.00 [ 0.06, 15.43 ]
Nutristroke 2009 0/38 4/34 0.1 % 0.10 [ 0.01, 1.79 ]
OMEGA 2009 67/1919 51/1885 4.8 % 1.29 [ 0.90, 1.85 ]
ORIGIN 2012 574/6281 581/6255 18.3 % 0.98 [ 0.88, 1.10 ]
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(. . . Continued)
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Raitt 2005 2/100 5/100 0.3 % 0.40 [ 0.08, 2.01 ]
Risk % Prevention 2013 142/6239 137/6266 9.1 % 1.04 [ 0.83, 1.31 ]
SCIMO 1999 0/112 1/111 0.1 % 0.33 [ 0.01, 8.02 ]
Shinto 2014 1/13 0/13 0.1 % 3.00 [ 0.13, 67.51 ]
SOFA 2006 6/273 13/273 0.8 % 0.46 [ 0.18, 1.20 ]
SU.FOL.OM3 2010 23/1253 28/1248 2.3 % 0.82 [ 0.47, 1.41 ]
THIS DIET 2008 0/51 0/50 Not estimable
Subtotal (95% CI) 32138 31988 89.8 % 0.97 [ 0.89, 1.06 ]
Total events: 2103 (Higher omega 3), 2187 (Lower omega 3)
Heterogeneity: Tau2 = 0.01; Chi2 = 24.07, df = 17 (P = 0.12); I2 =29%
Test for overall effect: Z = 0.64 (P = 0.52)
5 LCn3 > 2.4≤ 4.4 g/d
Brox 2001 0/80 1/40 0.1 % 0.17 [ 0.01, 4.05 ]
FAAT 2005 9/200 9/202 0.9 % 1.01 [ 0.41, 2.49 ]
OFAMI 2001 8/150 8/150 0.8 % 1.00 [ 0.39, 2.59 ]
SHOT 1996 7/317 5/293 0.6 % 1.29 [ 0.42, 4.03 ]
Subtotal (95% CI) 747 685 2.4 % 1.01 [ 0.58, 1.77 ]
Total events: 24 (Higher omega 3), 23 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.40, df = 3 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 0.04 (P = 0.97)
6 LCn3 > 4.4 g/d
FOSTAR 2016 0/101 1/101 0.1 % 0.33 [ 0.01, 8.09 ]
HARP 1995 0/41 1/39 0.1 % 0.32 [ 0.01, 7.57 ]
Subtotal (95% CI) 142 140 0.2 % 0.33 [ 0.03, 3.08 ]
Total events: 0 (Higher omega 3), 2 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 0.98 (P = 0.33)
Total (95% CI) 34042 33831 100.0 % 0.95 [ 0.87, 1.03 ]
Total events: 2211 (Higher omega 3), 2333 (Lower omega 3)
Heterogeneity: Tau2 = 0.01; Chi2 = 31.76, df = 24 (P = 0.13); I2 =24%
Test for overall effect: Z = 1.26 (P = 0.21)
Test for subgroup differences: Chi2 = 6.32, df = 3 (P = 0.10), I2 =53%
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Analysis 1.16. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 16 CVD
mortality - LCn3 - subgroup by replacement.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)
Outcome: 16 CVD mortality - LCn3 - subgroup by replacement
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 N-3 replacing SFA
DART 1989 84/1015 121/1018 97.2 % 0.70 [ 0.53, 0.91 ]
Derosa 2016 2/138 3/143 2.2 % 0.69 [ 0.12, 4.07 ]
SCIMO 1999 0/112 1/111 0.7 % 0.33 [ 0.01, 8.02 ]
Subtotal (95% CI) 1265 1272 100.0 % 0.69 [ 0.53, 0.90 ]
Total events: 86 (Higher omega 3), 125 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.21, df = 2 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 2.76 (P = 0.0058)
2 N-3 replacing MUFA
AlphaOmega - EPA+DHA 2010 80/2404 82/2433 8.3 % 0.99 [ 0.73, 1.34 ]
DART 1989 84/1015 121/1018 10.3 % 0.70 [ 0.53, 0.91 ]
FAAT 2005 9/200 9/202 1.1 % 1.01 [ 0.41, 2.49 ]
GISSI-HF 2008 712/3494 765/3481 31.9 % 0.93 [ 0.85, 1.02 ]
HARP 1995 0/41 1/39 0.1 % 0.32 [ 0.01, 7.57 ]
OMEGA 2009 67/1919 51/1885 6.2 % 1.29 [ 0.90, 1.85 ]
ORIGIN 2012 574/6281 581/6255 28.2 % 0.98 [ 0.88, 1.10 ]
Raitt 2005 2/100 5/100 0.4 % 0.40 [ 0.08, 2.01 ]
Risk % Prevention 2013 142/6239 137/6266 12.5 % 1.04 [ 0.83, 1.31 ]
SCIMO 1999 0/112 1/111 0.1 % 0.33 [ 0.01, 8.02 ]
SOFA 2006 6/273 13/273 1.0 % 0.46 [ 0.18, 1.20 ]
THIS DIET 2008 0/51 0/50 Not estimable
Subtotal (95% CI) 22129 22113 100.0 % 0.94 [ 0.86, 1.04 ]
Total events: 1676 (Higher omega 3), 1766 (Lower omega 3)
Heterogeneity: Tau2 = 0.01; Chi2 = 13.61, df = 10 (P = 0.19); I2 =27%
Test for overall effect: Z = 1.20 (P = 0.23)
3 N-3 replacing N-6
DO IT 2010 7/282 11/281 33.3 % 0.63 [ 0.25, 1.61 ]
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(. . . Continued)
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
OFAMI 2001 8/150 8/150 31.9 % 1.00 [ 0.39, 2.59 ]
Shinto 2014 1/13 0/13 3.0 % 3.00 [ 0.13, 67.51 ]
SOFA 2006 6/273 13/273 31.9 % 0.46 [ 0.18, 1.20 ]
Subtotal (95% CI) 718 717 100.0 % 0.69 [ 0.41, 1.19 ]
Total events: 22 (Higher omega 3), 32 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.15, df = 3 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 1.33 (P = 0.18)
4 N-3 replacing carbohydrates/sugars
Derosa 2016 2/138 3/143 100.0 % 0.69 [ 0.12, 4.07 ]
Subtotal (95% CI) 138 143 100.0 % 0.69 [ 0.12, 4.07 ]
Total events: 2 (Higher omega 3), 3 (Lower omega 3)
Heterogeneity: not applicable
Test for overall effect: Z = 0.41 (P = 0.68)
5 N-3 replacing nil/low n-3 placebo
AREDS2 2014 14/2147 13/2056 3.5 % 1.03 [ 0.49, 2.19 ]
Brox 2001 0/80 1/40 0.2 % 0.17 [ 0.01, 4.05 ]
Doi 2014 1/119 5/119 0.4 % 0.20 [ 0.02, 1.69 ]
FOSTAR 2016 0/101 1/101 0.2 % 0.33 [ 0.01, 8.09 ]
GISSI-P 1999 291/5665 348/5658 87.1 % 0.84 [ 0.72, 0.97 ]
Kumar 2013 1/39 1/39 0.3 % 1.00 [ 0.06, 15.43 ]
SHOT 1996 7/317 5/293 1.5 % 1.29 [ 0.42, 4.03 ]
SU.FOL.OM3 2010 23/1253 28/1248 6.7 % 0.82 [ 0.47, 1.41 ]
Subtotal (95% CI) 9721 9554 100.0 % 0.84 [ 0.73, 0.96 ]
Total events: 337 (Higher omega 3), 402 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.91, df = 7 (P = 0.79); I2 =0.0%
Test for overall effect: Z = 2.47 (P = 0.013)
6 Replacement unclear
DART2 2003 180/1571 139/1543 66.5 % 1.27 [ 1.03, 1.57 ]
Nutristroke 2009 0/38 4/34 33.5 % 0.10 [ 0.01, 1.79 ]
Subtotal (95% CI) 1609 1577 100.0 % 0.54 [ 0.05, 5.77 ]
Total events: 180 (Higher omega 3), 143 (Lower omega 3)
Heterogeneity: Tau2 = 2.18; Chi2 = 3.00, df = 1 (P = 0.08); I2 =67%
Test for overall effect: Z = 0.51 (P = 0.61)
Test for subgroup differences: Chi2 = 6.66, df = 5 (P = 0.25), I2 =25%
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Analysis 1.17. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 17 CVD
mortality - LCn3 - subgroup by intervention type.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)
Outcome: 17 CVD mortality - LCn3 - subgroup by intervention type
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Dietary advice
DART 1989 84/1015 121/1018 7.7 % 0.70 [ 0.53, 0.91 ]
DART2 2003 180/1571 139/1543 10.4 % 1.27 [ 1.03, 1.57 ]
Subtotal (95% CI) 2586 2561 18.0 % 0.95 [ 0.52, 1.71 ]
Total events: 264 (Higher omega 3), 260 (Lower omega 3)
Heterogeneity: Tau2 = 0.17; Chi2 = 12.24, df = 1 (P = 0.00047); I2 =92%
Test for overall effect: Z = 0.18 (P = 0.85)
2 Supplemental foods
AlphaOmega - EPA+DHA 2010 80/2404 82/2433 6.3 % 0.99 [ 0.73, 1.34 ]
FOSTAR 2016 0/101 1/101 0.1 % 0.33 [ 0.01, 8.09 ]
Subtotal (95% CI) 2505 2534 6.4 % 0.98 [ 0.72, 1.32 ]
Total events: 80 (Higher omega 3), 83 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.44, df = 1 (P = 0.51); I2 =0.0%
Test for overall effect: Z = 0.15 (P = 0.88)
3 Supplements (capsule)
AREDS2 2014 14/2147 13/2056 1.3 % 1.03 [ 0.49, 2.19 ]
Brox 2001 0/80 1/40 0.1 % 0.17 [ 0.01, 4.05 ]
Derosa 2016 2/138 3/143 0.2 % 0.69 [ 0.12, 4.07 ]
DO IT 2010 7/282 11/281 0.8 % 0.63 [ 0.25, 1.61 ]
Doi 2014 1/119 5/119 0.2 % 0.20 [ 0.02, 1.69 ]
FAAT 2005 9/200 9/202 0.9 % 1.01 [ 0.41, 2.49 ]
GISSI-HF 2008 712/3494 765/3481 20.1 % 0.93 [ 0.85, 1.02 ]
GISSI-P 1999 291/5665 348/5658 14.5 % 0.84 [ 0.72, 0.97 ]
HARP 1995 0/41 1/39 0.1 % 0.32 [ 0.01, 7.57 ]
Kumar 2013 1/39 1/39 0.1 % 1.00 [ 0.06, 15.43 ]
Nutristroke 2009 0/38 4/34 0.1 % 0.10 [ 0.01, 1.79 ]
OFAMI 2001 8/150 8/150 0.8 % 1.00 [ 0.39, 2.59 ]
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Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
OMEGA 2009 67/1919 51/1885 4.8 % 1.29 [ 0.90, 1.85 ]
ORIGIN 2012 574/6281 581/6255 18.3 % 0.98 [ 0.88, 1.10 ]
Raitt 2005 2/100 5/100 0.3 % 0.40 [ 0.08, 2.01 ]
Risk % Prevention 2013 142/6239 137/6266 9.1 % 1.04 [ 0.83, 1.31 ]
SCIMO 1999 0/112 1/111 0.1 % 0.33 [ 0.01, 8.02 ]
Shinto 2014 1/13 0/13 0.1 % 3.00 [ 0.13, 67.51 ]
SHOT 1996 7/317 5/293 0.6 % 1.29 [ 0.42, 4.03 ]
SOFA 2006 6/273 13/273 0.8 % 0.46 [ 0.18, 1.20 ]
SU.FOL.OM3 2010 23/1253 28/1248 2.3 % 0.82 [ 0.47, 1.41 ]
Subtotal (95% CI) 28900 28686 75.6 % 0.94 [ 0.88, 0.99 ]
Total events: 1867 (Higher omega 3), 1990 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 18.36, df = 20 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 2.18 (P = 0.029)
4 Any combination
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 3), 0 (Lower omega 3)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 33991 33781 100.0 % 0.95 [ 0.87, 1.03 ]
Total events: 2211 (Higher omega 3), 2333 (Lower omega 3)
Heterogeneity: Tau2 = 0.01; Chi2 = 31.76, df = 24 (P = 0.13); I2 =24%
Test for overall effect: Z = 1.26 (P = 0.21)
Test for subgroup differences: Chi2 = 0.08, df = 2 (P = 0.96), I2 =0.0%
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Analysis 1.18. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 18 CVD
mortality - LCn3 - subgroup by duration.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)
Outcome: 18 CVD mortality - LCn3 - subgroup by duration
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Medium duration 1 to < 2 years in study
Brox 2001 0/80 1/40 0.1 % 0.17 [ 0.01, 4.05 ]
Derosa 2016 2/138 3/143 0.2 % 0.69 [ 0.12, 4.07 ]
Doi 2014 1/119 5/119 0.2 % 0.20 [ 0.02, 1.69 ]
FAAT 2005 9/200 9/202 0.9 % 1.01 [ 0.41, 2.49 ]
Kumar 2013 1/39 1/39 0.1 % 1.00 [ 0.06, 15.43 ]
Nutristroke 2009 0/38 4/34 0.1 % 0.10 [ 0.01, 1.79 ]
OMEGA 2009 67/1919 51/1885 4.8 % 1.29 [ 0.90, 1.85 ]
Shinto 2014 1/13 0/13 0.1 % 3.00 [ 0.13, 67.51 ]
SHOT 1996 7/317 5/293 0.6 % 1.29 [ 0.42, 4.03 ]
SOFA 2006 6/273 13/273 0.8 % 0.46 [ 0.18, 1.20 ]
Subtotal (95% CI) 3136 3041 7.9 % 0.88 [ 0.57, 1.36 ]
Total events: 94 (Higher omega 3), 92 (Lower omega 3)
Heterogeneity: Tau2 = 0.09; Chi2 = 11.17, df = 9 (P = 0.26); I2 =19%
Test for overall effect: Z = 0.57 (P = 0.57)
2 Medium-long duration: 2 to < 4 years in study
AlphaOmega - EPA+DHA 2010 80/2404 82/2433 6.3 % 0.99 [ 0.73, 1.34 ]
DART 1989 84/1015 121/1018 7.7 % 0.70 [ 0.53, 0.91 ]
DO IT 2010 7/282 11/281 0.8 % 0.63 [ 0.25, 1.61 ]
FOSTAR 2016 0/101 1/101 0.1 % 0.33 [ 0.01, 8.09 ]
GISSI-HF 2008 712/3494 765/3481 20.1 % 0.93 [ 0.85, 1.02 ]
GISSI-P 1999 291/5665 348/5658 14.5 % 0.84 [ 0.72, 0.97 ]
HARP 1995 0/41 1/39 0.1 % 0.32 [ 0.01, 7.57 ]
OFAMI 2001 8/150 8/150 0.8 % 1.00 [ 0.39, 2.59 ]
Raitt 2005 2/100 5/100 0.3 % 0.40 [ 0.08, 2.01 ]
SCIMO 1999 0/112 1/111 0.1 % 0.33 [ 0.01, 8.02 ]
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Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Subtotal (95% CI) 13364 13372 50.8 % 0.89 [ 0.82, 0.95 ]
Total events: 1184 (Higher omega 3), 1343 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 7.88, df = 9 (P = 0.55); I2 =0.0%
Test for overall effect: Z = 3.32 (P = 0.00089)
3 Long duration:≥ 4 years in study
AREDS2 2014 14/2147 13/2056 1.3 % 1.03 [ 0.49, 2.19 ]
DART2 2003 180/1571 139/1543 10.4 % 1.27 [ 1.03, 1.57 ]
ORIGIN 2012 574/6281 581/6255 18.3 % 0.98 [ 0.88, 1.10 ]
Risk % Prevention 2013 142/6239 137/6266 9.1 % 1.04 [ 0.83, 1.31 ]
SU.FOL.OM3 2010 23/1253 28/1248 2.3 % 0.82 [ 0.47, 1.41 ]
Subtotal (95% CI) 17491 17368 41.4 % 1.05 [ 0.93, 1.18 ]
Total events: 933 (Higher omega 3), 898 (Lower omega 3)
Heterogeneity: Tau2 = 0.00; Chi2 = 5.24, df = 4 (P = 0.26); I2 =24%
Test for overall effect: Z = 0.79 (P = 0.43)
Total (95% CI) 33991 33781 100.0 % 0.95 [ 0.87, 1.03 ]
Total events: 2211 (Higher omega 3), 2333 (Lower omega 3)
Heterogeneity: Tau2 = 0.01; Chi2 = 31.76, df = 24 (P = 0.13); I2 =24%
Test for overall effect: Z = 1.26 (P = 0.21)
Test for subgroup differences: Chi2 = 5.68, df = 2 (P = 0.06), I2 =65%
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Analysis 1.19. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 19 CVD
mortality - LCn3 - subgroup by primary or secondary prevention.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)
Outcome: 19 CVD mortality - LCn3 - subgroup by primary or secondary prevention
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Primary prevention
AREDS2 2014 14/2147 13/2056 1.3 % 1.03 [ 0.49, 2.19 ]
Brox 2001 0/80 1/40 0.1 % 0.17 [ 0.01, 4.05 ]
Derosa 2016 2/138 3/143 0.2 % 0.69 [ 0.12, 4.07 ]
DO IT 2010 7/282 11/281 0.8 % 0.63 [ 0.25, 1.61 ]
FOSTAR 2016 0/101 1/101 0.1 % 0.33 [ 0.01, 8.09 ]
ORIGIN 2012 574/6281 581/6255 18.3 % 0.98 [ 0.88, 1.10 ]
Shinto 2014 1/13 0/13 0.1 % 3.00 [ 0.13, 67.51 ]
Subtotal (95% CI) 9042 8889 20.9 % 0.98 [ 0.88, 1.09 ]
Total events: 598 (Higher omega 3), 610 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.11, df = 6 (P = 0.79); I2 =0.0%
Test for overall effect: Z = 0.44 (P = 0.66)
2 Secondary prevention
AlphaOmega - EPA+DHA 2010 80/2404 82/2433 6.3 % 0.99 [ 0.73, 1.34 ]
DART 1989 84/1015 121/1018 7.7 % 0.70 [ 0.53, 0.91 ]
DART2 2003 180/1571 139/1543 10.4 % 1.27 [ 1.03, 1.57 ]
Doi 2014 1/119 5/119 0.2 % 0.20 [ 0.02, 1.69 ]
FAAT 2005 9/200 9/202 0.9 % 1.01 [ 0.41, 2.49 ]
GISSI-HF 2008 712/3494 765/3481 20.1 % 0.93 [ 0.85, 1.02 ]
GISSI-P 1999 291/5665 348/5658 14.5 % 0.84 [ 0.72, 0.97 ]
HARP 1995 0/41 1/39 0.1 % 0.32 [ 0.01, 7.57 ]
Kumar 2013 1/39 1/39 0.1 % 1.00 [ 0.06, 15.43 ]
Nutristroke 2009 0/38 4/34 0.1 % 0.10 [ 0.01, 1.79 ]
OFAMI 2001 8/150 8/150 0.8 % 1.00 [ 0.39, 2.59 ]
OMEGA 2009 67/1919 51/1885 4.8 % 1.29 [ 0.90, 1.85 ]
Raitt 2005 2/100 5/100 0.3 % 0.40 [ 0.08, 2.01 ]
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(. . . Continued)
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Risk % Prevention 2013 142/6239 137/6266 9.1 % 1.04 [ 0.83, 1.31 ]
SCIMO 1999 0/112 1/111 0.1 % 0.33 [ 0.01, 8.02 ]
SHOT 1996 7/317 5/293 0.6 % 1.29 [ 0.42, 4.03 ]
SOFA 2006 6/273 13/273 0.8 % 0.46 [ 0.18, 1.20 ]
SU.FOL.OM3 2010 23/1253 28/1248 2.3 % 0.82 [ 0.47, 1.41 ]
Subtotal (95% CI) 24949 24892 79.1 % 0.94 [ 0.83, 1.06 ]
Total events: 1613 (Higher omega 3), 1723 (Lower omega 3)
Heterogeneity: Tau2 = 0.02; Chi2 = 28.20, df = 17 (P = 0.04); I2 =40%
Test for overall effect: Z = 1.02 (P = 0.31)
Total (95% CI) 33991 33781 100.0 % 0.95 [ 0.87, 1.03 ]
Total events: 2211 (Higher omega 3), 2333 (Lower omega 3)
Heterogeneity: Tau2 = 0.01; Chi2 = 31.76, df = 24 (P = 0.13); I2 =24%
Test for overall effect: Z = 1.26 (P = 0.21)
Test for subgroup differences: Chi2 = 0.21, df = 1 (P = 0.64), I2 =0.0%
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Analysis 1.20. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 20 CVD
mortality - LCn3 - subgroup by statin uses.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)
Outcome: 20 CVD mortality - LCn3 - subgroup by statin uses
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 LCn3 -≥ 50% of control group on statins
AlphaOmega - EPA+DHA 2010 80/2404 82/2433 6.3 % 0.99 [ 0.73, 1.34 ]
Doi 2014 1/119 5/119 0.2 % 0.20 [ 0.02, 1.69 ]
Kumar 2013 1/39 1/39 0.1 % 1.00 [ 0.06, 15.43 ]
OMEGA 2009 67/1919 51/1885 4.8 % 1.29 [ 0.90, 1.85 ]
ORIGIN 2012 574/6281 581/6255 18.3 % 0.98 [ 0.88, 1.10 ]
SU.FOL.OM3 2010 23/1253 28/1248 2.3 % 0.82 [ 0.47, 1.41 ]
Subtotal (95% CI) 12015 11979 32.0 % 0.99 [ 0.90, 1.10 ]
Total events: 746 (Higher omega 3), 748 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 4.73, df = 5 (P = 0.45); I2 =0.0%
Test for overall effect: Z = 0.10 (P = 0.92)
2 LCn3 - < 50% of control group on statins
AREDS2 2014 14/2147 13/2056 1.3 % 1.03 [ 0.49, 2.19 ]
Brox 2001 0/80 1/40 0.1 % 0.17 [ 0.01, 4.05 ]
DART 1989 84/1015 121/1018 7.7 % 0.70 [ 0.53, 0.91 ]
DART2 2003 180/1571 139/1543 10.4 % 1.27 [ 1.03, 1.57 ]
DO IT 2010 7/282 11/281 0.8 % 0.63 [ 0.25, 1.61 ]
FAAT 2005 9/200 9/202 0.9 % 1.01 [ 0.41, 2.49 ]
FOSTAR 2016 0/101 1/101 0.1 % 0.33 [ 0.01, 8.09 ]
GISSI-HF 2008 712/3494 765/3481 20.1 % 0.93 [ 0.85, 1.02 ]
GISSI-P 1999 291/5665 348/5658 14.5 % 0.84 [ 0.72, 0.97 ]
HARP 1995 0/41 1/39 0.1 % 0.32 [ 0.01, 7.57 ]
OFAMI 2001 8/150 8/150 0.8 % 1.00 [ 0.39, 2.59 ]
Raitt 2005 2/100 5/100 0.3 % 0.40 [ 0.08, 2.01 ]
Risk % Prevention 2013 142/6239 137/6266 9.1 % 1.04 [ 0.83, 1.31 ]
SCIMO 1999 0/112 1/111 0.1 % 0.33 [ 0.01, 8.02 ]
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Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Shinto 2014 1/13 0/13 0.1 % 3.00 [ 0.13, 67.51 ]
SHOT 1996 7/317 5/293 0.6 % 1.29 [ 0.42, 4.03 ]
SOFA 2006 6/273 13/273 0.8 % 0.46 [ 0.18, 1.20 ]
Subtotal (95% CI) 21800 21625 67.7 % 0.92 [ 0.82, 1.04 ]
Total events: 1463 (Higher omega 3), 1578 (Lower omega 3)
Heterogeneity: Tau2 = 0.01; Chi2 = 23.10, df = 16 (P = 0.11); I2 =31%
Test for overall effect: Z = 1.36 (P = 0.17)
3 LCn3- Use of statins unclear
Derosa 2016 2/138 3/143 0.2 % 0.69 [ 0.12, 4.07 ]
Nutristroke 2009 0/38 4/34 0.1 % 0.10 [ 0.01, 1.79 ]
Subtotal (95% CI) 176 177 0.3 % 0.36 [ 0.06, 2.30 ]
Total events: 2 (Higher omega 3), 7 (Lower omega 3)
Heterogeneity: Tau2 = 0.50; Chi2 = 1.34, df = 1 (P = 0.25); I2 =25%
Test for overall effect: Z = 1.08 (P = 0.28)
Total (95% CI) 33991 33781 100.0 % 0.95 [ 0.87, 1.03 ]
Total events: 2211 (Higher omega 3), 2333 (Lower omega 3)
Heterogeneity: Tau2 = 0.01; Chi2 = 31.76, df = 24 (P = 0.13); I2 =24%
Test for overall effect: Z = 1.26 (P = 0.21)
Test for subgroup differences: Chi2 = 2.06, df = 2 (P = 0.36), I2 =3%
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Analysis 1.21. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 21
Cardiovascular events (overall) - LCn3.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)
Outcome: 21 Cardiovascular events (overall) - LCn3
Study or subgroup
Favours
higher
omega 3 Lower omega 3 fats Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
AFFORD 2013 20/153 11/163 0.5 % 1.94 [ 0.96, 3.91 ]
AlphaOmega - EPA+DHA 2010 (1) 336/2404 335/2433 6.7 % 1.02 [ 0.88, 1.17 ]
AREDS2 2014 183/2147 187/2056 4.6 % 0.94 [ 0.77, 1.14 ]
Baldassarre 2006 1/32 0/32 0.0 % 3.00 [ 0.13, 71.00 ]
Brox 2001 0/80 1/40 0.0 % 0.17 [ 0.01, 4.05 ]
DART 1989 467/1015 487/1018 9.5 % 0.96 [ 0.88, 1.05 ]
DART2 2003 206/1571 155/1543 4.5 % 1.31 [ 1.07, 1.59 ]
Derosa 2016 2/128 3/130 0.1 % 0.68 [ 0.12, 3.98 ]
DO IT 2010 32/282 36/281 1.2 % 0.89 [ 0.57, 1.38 ]
Doi 2014 11/119 24/119 0.6 % 0.46 [ 0.24, 0.89 ]
EPE-A 2014 (2) 5/168 6/75 0.2 % 0.37 [ 0.12, 1.18 ]
EPIC-1 2008 1/188 0/186 0.0 % 2.97 [ 0.12, 72.40 ]
EPOCH 2014 8/195 5/196 0.2 % 1.61 [ 0.54, 4.83 ]
FAAT 2005 31/200 39/202 1.3 % 0.80 [ 0.52, 1.23 ]
FORWARD 2013 4/289 4/297 0.1 % 1.03 [ 0.26, 4.07 ]
FOSTAR 2016 18/101 16/101 0.7 % 1.13 [ 0.61, 2.08 ]
GISSI-HF 2008 1635/3494 1687/3481 12.2 % 0.97 [ 0.92, 1.01 ]
GISSI-P 1999 547/5666 608/5658 8.4 % 0.90 [ 0.81, 1.00 ]
HARP 1995 7/41 7/39 0.3 % 0.95 [ 0.37, 2.46 ]
JELIS 2007 (3) 262/9326 324/9319 5.8 % 0.81 [ 0.69, 0.95 ]
Kumar 2013 (4) 1/39 1/39 0.0 % 1.00 [ 0.06, 15.43 ]
MAPT 2017 192/820 164/832 4.9 % 1.19 [ 0.99, 1.43 ]
Nodari 2011 HF 10/67 26/66 0.6 % 0.38 [ 0.20, 0.72 ]
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(. . . Continued)
Study or subgroup
Favours
higher
omega 3 Lower omega 3 fats Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Nutristroke 2009 (5) 0/38 4/34 0.0 % 0.10 [ 0.01, 1.79 ]
OFAMI 2001 42/150 36/150 1.6 % 1.17 [ 0.80, 1.71 ]
OMEGA 2009 182/1752 149/1701 4.2 % 1.19 [ 0.97, 1.46 ]
ORIGIN 2012 2055/6281 2087/6255 12.1 % 0.98 [ 0.93, 1.03 ]
Proudman 2015 1/87 0/53 0.0 % 1.84 [ 0.08, 44.38 ]
Puri 2005 1/60 0/61 0.0 % 3.05 [ 0.13, 73.40 ]
Raitt 2005 (6) 2/100 5/100 0.1 % 0.40 [ 0.08, 2.01 ]
Risk % Prevention 2013 620/6239 630/6266 8.7 % 0.99 [ 0.89, 1.10 ]
Sandhu 2016 2/107 1/106 0.0 % 1.98 [ 0.18, 21.52 ]
SCIMO 1999 17/112 26/111 0.8 % 0.65 [ 0.37, 1.13 ]
Shinto 2014 (7) 1/13 0/13 0.0 % 3.00 [ 0.13, 67.51 ]
SHOT 1996 15/317 12/293 0.5 % 1.16 [ 0.55, 2.43 ]
SOFA 2006 (8) 65/273 62/273 2.3 % 1.05 [ 0.77, 1.42 ]
SU.FOL.OM3 2010 303/1253 290/1248 6.7 % 1.04 [ 0.90, 1.20 ]
THIS DIET 2008 14/51 10/50 0.5 % 1.37 [ 0.67, 2.80 ]
Total (95% CI) 45358 45020 100.0 % 0.99 [ 0.94, 1.04 ]
Total events: 7299 (Favours higher omega 3), 7438 (Lower omega 3 fats)
Heterogeneity: Tau2 = 0.00; Chi2 = 58.47, df = 37 (P = 0.01); I2 =37%
Test for overall effect: Z = 0.54 (P = 0.59)
Test for subgroup differences: Not applicable
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(2) Higher EPA vs lower EPA
(3) CHD events
(4) CVD death data used
(5) CV death used
(6) Cardiac death data
(7) CV mortality data
(8) Cardiac adverse event
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Analysis 1.22. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 22 CVD events
- LCn3 - SA fixed-effect.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)
Outcome: 22 CVD events - LCn3 - SA fixed-effect
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
AFFORD 2013 20/153 11/163 0.1 % 1.94 [ 0.96, 3.91 ]
AlphaOmega - EPA+DHA 2010 (1) 336/2404 335/2433 4.5 % 1.02 [ 0.88, 1.17 ]
AREDS2 2014 183/2147 187/2056 2.6 % 0.94 [ 0.77, 1.14 ]
Baldassarre 2006 1/32 0/32 0.0 % 3.00 [ 0.13, 71.00 ]
Brox 2001 0/80 1/40 0.0 % 0.17 [ 0.01, 4.05 ]
DART 1989 467/1015 487/1018 6.5 % 0.96 [ 0.88, 1.05 ]
DART2 2003 206/1571 155/1543 2.1 % 1.31 [ 1.07, 1.59 ]
Derosa 2016 2/128 3/130 0.0 % 0.68 [ 0.12, 3.98 ]
DO IT 2010 32/282 36/281 0.5 % 0.89 [ 0.57, 1.38 ]
Doi 2014 11/119 24/119 0.3 % 0.46 [ 0.24, 0.89 ]
EPE-A 2014 5/168 6/75 0.1 % 0.37 [ 0.12, 1.18 ]
EPIC-1 2008 1/188 0/186 0.0 % 2.97 [ 0.12, 72.40 ]
EPOCH 2014 8/195 5/196 0.1 % 1.61 [ 0.54, 4.83 ]
FAAT 2005 31/200 39/202 0.5 % 0.80 [ 0.52, 1.23 ]
FORWARD 2013 4/289 4/297 0.1 % 1.03 [ 0.26, 4.07 ]
FOSTAR 2016 18/101 16/101 0.2 % 1.13 [ 0.61, 2.08 ]
GISSI-HF 2008 1635/3494 1687/3481 22.7 % 0.97 [ 0.92, 1.01 ]
GISSI-P 1999 547/5666 608/5658 8.2 % 0.90 [ 0.81, 1.00 ]
HARP 1995 7/41 7/39 0.1 % 0.95 [ 0.37, 2.46 ]
JELIS 2007 (2) 262/9326 324/9319 4.3 % 0.81 [ 0.69, 0.95 ]
Kumar 2013 (3) 1/39 1/39 0.0 % 1.00 [ 0.06, 15.43 ]
MAPT 2017 192/820 164/832 2.2 % 1.19 [ 0.99, 1.43 ]
Nodari 2011 HF 10/67 26/66 0.4 % 0.38 [ 0.20, 0.72 ]
Nutristroke 2009 (4) 0/38 4/34 0.1 % 0.10 [ 0.01, 1.79 ]
OFAMI 2001 42/150 36/150 0.5 % 1.17 [ 0.80, 1.71 ]
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Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
OMEGA 2009 182/1752 149/1701 2.0 % 1.19 [ 0.97, 1.46 ]
ORIGIN 2012 2055/6281 2087/6255 28.0 % 0.98 [ 0.93, 1.03 ]
Proudman 2015 1/87 0/53 0.0 % 1.84 [ 0.08, 44.38 ]
Puri 2005 1/60 0/61 0.0 % 3.05 [ 0.13, 73.40 ]
Raitt 2005 (5) 2/100 5/100 0.1 % 0.40 [ 0.08, 2.01 ]
Risk % Prevention 2013 620/6239 630/6266 8.4 % 0.99 [ 0.89, 1.10 ]
Sandhu 2016 2/107 1/106 0.0 % 1.98 [ 0.18, 21.52 ]
SCIMO 1999 17/112 26/111 0.4 % 0.65 [ 0.37, 1.13 ]
Shinto 2014 (6) 1/13 0/13 0.0 % 3.00 [ 0.13, 67.51 ]
SHOT 1996 15/317 12/293 0.2 % 1.16 [ 0.55, 2.43 ]
SOFA 2006 (7) 65/273 62/273 0.8 % 1.05 [ 0.77, 1.42 ]
SU.FOL.OM3 2010 303/1253 290/1248 3.9 % 1.04 [ 0.90, 1.20 ]
THIS DIET 2008 14/51 10/50 0.1 % 1.37 [ 0.67, 2.80 ]
Total (95% CI) 45358 45020 100.0 % 0.98 [ 0.95, 1.00 ]
Total events: 7299 (Higher omega 3), 7438 (Lower omega 3)
Heterogeneity: Chi2 = 58.47, df = 37 (P = 0.01); I2 =37%
Test for overall effect: Z = 1.63 (P = 0.10)
Test for subgroup differences: Not applicable
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(1) AlphaOmega - comparing EPA+DHA ALA with no EPA+DHA ALA
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(6) CV mortality data
(7) Cardiac adverse event
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Analysis 1.23. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 23 CVD events
- LCn3 - SA by summary risk of bias.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)
Outcome: 23 CVD events - LCn3 - SA by summary risk of bias
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Low risk of bias
AlphaOmega - EPA+DHA 2010 (1) 336/2404 335/2433 6.7 % 1.02 [ 0.88, 1.17 ]
AREDS2 2014 183/2147 187/2056 4.6 % 0.94 [ 0.77, 1.14 ]
Derosa 2016 2/128 3/130 0.1 % 0.68 [ 0.12, 3.98 ]
EPOCH 2014 8/195 5/196 0.2 % 1.61 [ 0.54, 4.83 ]
FORWARD 2013 4/289 4/297 0.1 % 1.03 [ 0.26, 4.07 ]
FOSTAR 2016 18/101 16/101 0.7 % 1.13 [ 0.61, 2.08 ]
MAPT 2017 192/820 164/832 4.9 % 1.19 [ 0.99, 1.43 ]
OMEGA 2009 182/1752 149/1701 4.2 % 1.19 [ 0.97, 1.46 ]
ORIGIN 2012 2055/6281 2087/6255 12.1 % 0.98 [ 0.93, 1.03 ]
Proudman 2015 1/87 0/53 0.0 % 1.84 [ 0.08, 44.38 ]
Puri 2005 1/60 0/61 0.0 % 3.05 [ 0.13, 73.40 ]
SCIMO 1999 17/112 26/111 0.8 % 0.65 [ 0.37, 1.13 ]
SOFA 2006 (2) 65/273 62/273 2.3 % 1.05 [ 0.77, 1.42 ]
SU.FOL.OM3 2010 303/1253 290/1248 6.7 % 1.04 [ 0.90, 1.20 ]
Subtotal (95% CI) 15902 15747 43.5 % 1.00 [ 0.96, 1.05 ]
Total events: 3367 (Higher omega 3), 3328 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 11.46, df = 13 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 0.17 (P = 0.87)
2 Moderate/high risk of bias
AFFORD 2013 20/153 11/163 0.5 % 1.94 [ 0.96, 3.91 ]
Baldassarre 2006 1/32 0/32 0.0 % 3.00 [ 0.13, 71.00 ]
Brox 2001 0/80 1/40 0.0 % 0.17 [ 0.01, 4.05 ]
DART 1989 467/1015 487/1018 9.5 % 0.96 [ 0.88, 1.05 ]
DART2 2003 206/1571 155/1543 4.5 % 1.31 [ 1.07, 1.59 ]
DO IT 2010 32/282 36/281 1.2 % 0.89 [ 0.57, 1.38 ]
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(. . . Continued)
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Doi 2014 11/119 24/119 0.6 % 0.46 [ 0.24, 0.89 ]
EPE-A 2014 5/168 6/75 0.2 % 0.37 [ 0.12, 1.18 ]
EPIC-1 2008 1/188 0/186 0.0 % 2.97 [ 0.12, 72.40 ]
FAAT 2005 31/200 39/202 1.3 % 0.80 [ 0.52, 1.23 ]
GISSI-HF 2008 1635/3494 1687/3481 12.2 % 0.97 [ 0.92, 1.01 ]
GISSI-P 1999 547/5666 608/5658 8.4 % 0.90 [ 0.81, 1.00 ]
HARP 1995 7/41 7/39 0.3 % 0.95 [ 0.37, 2.46 ]
JELIS 2007 (3) 262/9326 324/9319 5.8 % 0.81 [ 0.69, 0.95 ]
Kumar 2013 (4) 1/39 1/39 0.0 % 1.00 [ 0.06, 15.43 ]
Nodari 2011 HF 10/67 26/66 0.6 % 0.38 [ 0.20, 0.72 ]
Nutristroke 2009 (5) 0/38 4/34 0.0 % 0.10 [ 0.01, 1.79 ]
OFAMI 2001 42/150 36/150 1.6 % 1.17 [ 0.80, 1.71 ]
Raitt 2005 (6) 2/100 5/100 0.1 % 0.40 [ 0.08, 2.01 ]
Risk % Prevention 2013 620/6239 630/6266 8.7 % 0.99 [ 0.89, 1.10 ]
Sandhu 2016 2/107 1/106 0.0 % 1.98 [ 0.18, 21.52 ]
Shinto 2014 (7) 1/13 0/13 0.0 % 3.00 [ 0.13, 67.51 ]
SHOT 1996 15/317 12/293 0.5 % 1.16 [ 0.55, 2.43 ]
THIS DIET 2008 14/51 10/50 0.5 % 1.37 [ 0.67, 2.80 ]
Subtotal (95% CI) 29456 29273 56.5 % 0.95 [ 0.87, 1.03 ]
Total events: 3932 (Higher omega 3), 4110 (Lower omega 3)
Heterogeneity: Tau2 = 0.01; Chi2 = 44.28, df = 23 (P = 0.005); I2 =48%
Test for overall effect: Z = 1.21 (P = 0.22)
Total (95% CI) 45358 45020 100.0 % 0.99 [ 0.94, 1.04 ]
Total events: 7299 (Higher omega 3), 7438 (Lower omega 3)
Heterogeneity: Tau2 = 0.00; Chi2 = 58.47, df = 37 (P = 0.01); I2 =37%
Test for overall effect: Z = 0.54 (P = 0.59)
Test for subgroup differences: Chi2 = 1.36, df = 1 (P = 0.24), I2 =26%
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(1) AlphaOmega - comparing EPA+DHA ALA with no EPA+DHA ALA
(2) Cardiac adverse event
(3) CHD events
(4) CVD death data used
(5) CV death used
(6) Cardiac death data
(7) CV mortality data
Analysis 1.24. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 24 CVD events
- LCn3 - SA by compliance and study size.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)
Outcome: 24 CVD events - LCn3 - SA by compliance and study size
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 SA - low risk of compliance bias
AFFORD 2013 20/153 11/163 4.0 % 1.94 [ 0.96, 3.91 ]
AlphaOmega - EPA+DHA 2010 (1) 336/2404 335/2433 22.2 % 1.02 [ 0.88, 1.17 ]
Baldassarre 2006 1/32 0/32 0.2 % 3.00 [ 0.13, 71.00 ]
Brox 2001 0/80 1/40 0.2 % 0.17 [ 0.01, 4.05 ]
DO IT 2010 32/282 36/281 8.2 % 0.89 [ 0.57, 1.38 ]
EPE-A 2014 5/168 6/75 1.6 % 0.37 [ 0.12, 1.18 ]
FOSTAR 2016 18/101 16/101 5.0 % 1.13 [ 0.61, 2.08 ]
HARP 1995 7/41 7/39 2.4 % 0.95 [ 0.37, 2.46 ]
Kumar 2013 (2) 1/39 1/39 0.3 % 1.00 [ 0.06, 15.43 ]
Nodari 2011 HF 10/67 26/66 4.6 % 0.38 [ 0.20, 0.72 ]
OMEGA 2009 182/1752 149/1701 18.2 % 1.19 [ 0.97, 1.46 ]
Raitt 2005 (3) 2/100 5/100 0.9 % 0.40 [ 0.08, 2.01 ]
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(. . . Continued)
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
SCIMO 1999 17/112 26/111 6.0 % 0.65 [ 0.37, 1.13 ]
Shinto 2014 (4) 1/13 0/13 0.2 % 3.00 [ 0.13, 67.51 ]
SHOT 1996 15/317 12/293 3.7 % 1.16 [ 0.55, 2.43 ]
SU.FOL.OM3 2010 303/1253 290/1248 22.2 % 1.04 [ 0.90, 1.20 ]
Subtotal (95% CI) 6914 6735 100.0 % 0.98 [ 0.84, 1.14 ]
Total events: 950 (Higher omega 3), 921 (Lower omega 3)
Heterogeneity: Tau2 = 0.02; Chi2 = 23.95, df = 15 (P = 0.07); I2 =37%
Test for overall effect: Z = 0.31 (P = 0.76)
2 SA - 100+ randomised
AFFORD 2013 20/153 11/163 0.5 % 1.94 [ 0.96, 3.91 ]
AlphaOmega - EPA+DHA 2010 (5) 336/2404 335/2433 6.8 % 1.02 [ 0.88, 1.17 ]
AREDS2 2014 183/2147 187/2056 4.7 % 0.94 [ 0.77, 1.14 ]
Brox 2001 0/80 1/40 0.0 % 0.17 [ 0.01, 4.05 ]
DART 1989 467/1015 487/1018 9.4 % 0.96 [ 0.88, 1.05 ]
DART2 2003 206/1571 155/1543 4.6 % 1.31 [ 1.07, 1.59 ]
Derosa 2016 2/128 3/130 0.1 % 0.68 [ 0.12, 3.98 ]
DO IT 2010 32/282 36/281 1.2 % 0.89 [ 0.57, 1.38 ]
Doi 2014 11/119 24/119 0.6 % 0.46 [ 0.24, 0.89 ]
EPE-A 2014 5/168 6/75 0.2 % 0.37 [ 0.12, 1.18 ]
EPIC-1 2008 1/188 0/186 0.0 % 2.97 [ 0.12, 72.40 ]
EPOCH 2014 8/195 5/196 0.2 % 1.61 [ 0.54, 4.83 ]
FAAT 2005 31/200 39/202 1.3 % 0.80 [ 0.52, 1.23 ]
FORWARD 2013 4/289 4/297 0.1 % 1.03 [ 0.26, 4.07 ]
FOSTAR 2016 18/101 16/101 0.7 % 1.13 [ 0.61, 2.08 ]
GISSI-HF 2008 1635/3494 1687/3481 11.9 % 0.97 [ 0.92, 1.01 ]
GISSI-P 1999 547/5666 608/5658 8.4 % 0.90 [ 0.81, 1.00 ]
JELIS 2007 (6) 262/9326 324/9319 5.9 % 0.81 [ 0.69, 0.95 ]
MAPT 2017 192/820 164/832 5.0 % 1.19 [ 0.99, 1.43 ]
Nodari 2011 HF 10/67 26/66 0.6 % 0.38 [ 0.20, 0.72 ]
OFAMI 2001 42/150 36/150 1.6 % 1.17 [ 0.80, 1.71 ]
OMEGA 2009 182/1752 149/1701 4.3 % 1.19 [ 0.97, 1.46 ]
ORIGIN 2012 2055/6281 2087/6255 11.9 % 0.98 [ 0.93, 1.03 ]
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Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Proudman 2015 1/87 0/53 0.0 % 1.84 [ 0.08, 44.38 ]
Puri 2005 1/60 0/61 0.0 % 3.05 [ 0.13, 73.40 ]
Raitt 2005 (7) 2/100 5/100 0.1 % 0.40 [ 0.08, 2.01 ]
Risk % Prevention 2013 620/6239 630/6266 8.6 % 0.99 [ 0.89, 1.10 ]
Sandhu 2016 2/107 1/106 0.0 % 1.98 [ 0.18, 21.52 ]
SCIMO 1999 17/112 26/111 0.8 % 0.65 [ 0.37, 1.13 ]
SHOT 1996 15/317 12/293 0.5 % 1.16 [ 0.55, 2.43 ]
SOFA 2006 (8) 65/273 62/273 2.4 % 1.05 [ 0.77, 1.42 ]
SU.FOL.OM3 2010 303/1253 290/1248 6.8 % 1.04 [ 0.90, 1.20 ]
THIS DIET 2008 14/51 10/50 0.5 % 1.37 [ 0.67, 2.80 ]
Subtotal (95% CI) 45195 44863 100.0 % 0.99 [ 0.94, 1.04 ]
Total events: 7289 (Higher omega 3), 7426 (Lower omega 3)
Heterogeneity: Tau2 = 0.01; Chi2 = 55.08, df = 32 (P = 0.01); I2 =42%
Test for overall effect: Z = 0.52 (P = 0.60)
Test for subgroup differences: Chi2 = 0.02, df = 1 (P = 0.90), I2 =0.0%
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(8) Cardiac adverse event
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Analysis 1.25. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 25 CVD events
- LCn3 - subgroup by dose.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)
Outcome: 25 CVD events - LCn3 - subgroup by dose
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 LCn3≤ 150 mg/d
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 3), 0 (Lower omega 3)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 LCn3 > 150≤ 250 mg/d
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 3), 0 (Lower omega 3)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 LCn3 > 250≤ 400 mg/d
DART 1989 467/1015 487/1018 9.5 % 0.96 [ 0.88, 1.05 ]
Subtotal (95% CI) 1015 1018 9.5 % 0.96 [ 0.88, 1.05 ]
Total events: 467 (Higher omega 3), 487 (Lower omega 3)
Heterogeneity: not applicable
Test for overall effect: Z = 0.83 (P = 0.41)
4 LCn3 > 400≤ 2400 mg/d
AFFORD 2013 20/153 11/163 0.5 % 1.94 [ 0.96, 3.91 ]
AlphaOmega - EPA+DHA 2010 (1) 336/2404 335/2433 6.7 % 1.02 [ 0.88, 1.17 ]
AREDS2 2014 183/2147 187/2056 4.6 % 0.94 [ 0.77, 1.14 ]
Baldassarre 2006 1/32 0/32 0.0 % 3.00 [ 0.13, 71.00 ]
DART2 2003 206/1571 155/1543 4.5 % 1.31 [ 1.07, 1.59 ]
Derosa 2016 2/128 3/130 0.1 % 0.68 [ 0.12, 3.98 ]
DO IT 2010 32/282 36/281 1.2 % 0.89 [ 0.57, 1.38 ]
Doi 2014 11/119 24/119 0.6 % 0.46 [ 0.24, 0.89 ]
EPE-A 2014 3/82 6/75 0.1 % 0.46 [ 0.12, 1.76 ]
EPOCH 2014 8/195 5/196 0.2 % 1.61 [ 0.54, 4.83 ]
FORWARD 2013 4/289 4/297 0.1 % 1.03 [ 0.26, 4.07 ]
GISSI-HF 2008 1635/3494 1687/3481 12.2 % 0.97 [ 0.92, 1.01 ]
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(. . . Continued)
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
GISSI-P 1999 547/5666 608/5658 8.4 % 0.90 [ 0.81, 1.00 ]
JELIS 2007 (2) 262/9326 324/9319 5.8 % 0.81 [ 0.69, 0.95 ]
Kumar 2013 (3) 1/39 1/39 0.0 % 1.00 [ 0.06, 15.43 ]
MAPT 2017 192/820 164/832 4.9 % 1.19 [ 0.99, 1.43 ]
Nodari 2011 HF 10/67 26/66 0.6 % 0.38 [ 0.20, 0.72 ]
Nutristroke 2009 (4) 0/38 4/34 0.0 % 0.10 [ 0.01, 1.79 ]
OMEGA 2009 182/1752 149/1701 4.2 % 1.19 [ 0.97, 1.46 ]
ORIGIN 2012 2055/6281 2087/6255 12.2 % 0.98 [ 0.93, 1.03 ]
Puri 2005 1/60 0/61 0.0 % 3.05 [ 0.13, 73.40 ]
Raitt 2005 (5) 2/100 5/100 0.1 % 0.40 [ 0.08, 2.01 ]
Risk % Prevention 2013 620/6239 630/6266 8.7 % 0.99 [ 0.89, 1.10 ]
SCIMO 1999 17/112 26/111 0.8 % 0.65 [ 0.37, 1.13 ]
Shinto 2014 (6) 1/13 0/13 0.0 % 3.00 [ 0.13, 67.51 ]
SOFA 2006 (7) 65/273 62/273 2.3 % 1.05 [ 0.77, 1.42 ]
SU.FOL.OM3 2010 303/1253 290/1248 6.7 % 1.04 [ 0.90, 1.20 ]
THIS DIET 2008 14/51 10/50 0.5 % 1.37 [ 0.67, 2.80 ]
Subtotal (95% CI) 42986 42832 86.1 % 0.99 [ 0.93, 1.05 ]
Total events: 6713 (Higher omega 3), 6839 (Lower omega 3)
Heterogeneity: Tau2 = 0.01; Chi2 = 52.73, df = 27 (P = 0.002); I2 =49%
Test for overall effect: Z = 0.40 (P = 0.69)
5 LCn3 > 2.4≤ 4.4 g/d
Brox 2001 0/80 1/40 0.0 % 0.17 [ 0.01, 4.05 ]
EPE-A 2014 2/86 6/75 0.1 % 0.29 [ 0.06, 1.40 ]
EPIC-1 2008 1/188 0/186 0.0 % 2.97 [ 0.12, 72.40 ]
FAAT 2005 31/200 39/202 1.3 % 0.80 [ 0.52, 1.23 ]
OFAMI 2001 42/150 36/150 1.6 % 1.17 [ 0.80, 1.71 ]
Sandhu 2016 2/107 1/106 0.0 % 1.98 [ 0.18, 21.52 ]
SHOT 1996 15/317 12/293 0.5 % 1.16 [ 0.55, 2.43 ]
Subtotal (95% CI) 1128 1052 3.5 % 0.98 [ 0.75, 1.28 ]
Total events: 93 (Higher omega 3), 95 (Lower omega 3)
Heterogeneity: Tau2 = 0.00; Chi2 = 6.11, df = 6 (P = 0.41); I2 =2%
Test for overall effect: Z = 0.18 (P = 0.86)
6 LCn3 > 4.4 g/d
FOSTAR 2016 18/101 16/101 0.7 % 1.13 [ 0.61, 2.08 ]
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(. . . Continued)
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
HARP 1995 7/41 7/39 0.3 % 0.95 [ 0.37, 2.46 ]
Proudman 2015 1/87 0/53 0.0 % 1.84 [ 0.08, 44.38 ]
Subtotal (95% CI) 229 193 1.0 % 1.09 [ 0.65, 1.81 ]
Total events: 26 (Higher omega 3), 23 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.19, df = 2 (P = 0.91); I2 =0.0%
Test for overall effect: Z = 0.32 (P = 0.75)
Total (95% CI) 45358 45095 100.0 % 0.99 [ 0.94, 1.04 ]
Total events: 7299 (Higher omega 3), 7444 (Lower omega 3)
Heterogeneity: Tau2 = 0.00; Chi2 = 59.29, df = 38 (P = 0.02); I2 =36%
Test for overall effect: Z = 0.57 (P = 0.57)
Test for subgroup differences: Chi2 = 0.38, df = 3 (P = 0.94), I2 =0.0%
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Favours higher omega 3 Favours lower omega 3
(1) AlphaOmega - comparing EPA+DHA ALA with no EPA+DHA ALA
(2) CHD events
(3) CVD death data used
(4) CV death used
(5) Cardiac death data
(6) CV mortality data
(7) Cardiac adverse event
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Analysis 1.26. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 26 CVD events
- LCn3 - subgroup by replacement.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)
Outcome: 26 CVD events - LCn3 - subgroup by replacement
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 N-3 replacing SFA
DART 1989 467/1015 487/1018 96.9 % 0.96 [ 0.88, 1.05 ]
Derosa 2016 2/128 3/130 0.3 % 0.68 [ 0.12, 3.98 ]
EPIC-1 2008 1/188 0/186 0.1 % 2.97 [ 0.12, 72.40 ]
SCIMO 1999 17/112 26/111 2.7 % 0.65 [ 0.37, 1.13 ]
Subtotal (95% CI) 1443 1445 100.0 % 0.95 [ 0.87, 1.04 ]
Total events: 487 (Higher omega 3), 516 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.55, df = 3 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 1.07 (P = 0.28)
2 N-3 replacing MUFA
AlphaOmega - EPA+DHA 2010 (1) 336/2404 335/2433 8.1 % 1.02 [ 0.88, 1.17 ]
Baldassarre 2006 1/32 0/32 0.0 % 3.00 [ 0.13, 71.00 ]
DART 1989 467/1015 487/1018 14.9 % 0.96 [ 0.88, 1.05 ]
EPOCH 2014 8/195 5/196 0.2 % 1.61 [ 0.54, 4.83 ]
FAAT 2005 31/200 39/202 1.1 % 0.80 [ 0.52, 1.23 ]
FORWARD 2013 4/289 4/297 0.1 % 1.03 [ 0.26, 4.07 ]
GISSI-HF 2008 1635/3494 1687/3481 27.6 % 0.97 [ 0.92, 1.01 ]
HARP 1995 7/41 7/39 0.2 % 0.95 [ 0.37, 2.46 ]
Nodari 2011 HF 10/67 26/66 0.5 % 0.38 [ 0.20, 0.72 ]
OMEGA 2009 182/1752 149/1701 4.2 % 1.19 [ 0.97, 1.46 ]
ORIGIN 2012 2055/6281 2087/6255 27.4 % 0.98 [ 0.93, 1.03 ]
Raitt 2005 (2) 2/100 5/100 0.1 % 0.40 [ 0.08, 2.01 ]
Risk % Prevention 2013 620/6239 630/6266 12.6 % 0.99 [ 0.89, 1.10 ]
SCIMO 1999 17/112 26/111 0.6 % 0.65 [ 0.37, 1.13 ]
SOFA 2006 (3) 65/273 62/273 2.0 % 1.05 [ 0.77, 1.42 ]
THIS DIET 2008 14/51 10/50 0.4 % 1.37 [ 0.67, 2.80 ]
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(. . . Continued)
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Subtotal (95% CI) 22545 22520 100.0 % 0.98 [ 0.94, 1.02 ]
Total events: 5454 (Higher omega 3), 5559 (Lower omega 3)
Heterogeneity: Tau2 = 0.00; Chi2 = 18.85, df = 15 (P = 0.22); I2 =20%
Test for overall effect: Z = 0.93 (P = 0.35)
3 N-3 replacing n-6
AFFORD 2013 20/153 11/163 8.2 % 1.94 [ 0.96, 3.91 ]
DO IT 2010 32/282 36/281 20.2 % 0.89 [ 0.57, 1.38 ]
OFAMI 2001 42/150 36/150 27.4 % 1.17 [ 0.80, 1.71 ]
Proudman 2015 1/87 0/53 0.4 % 1.84 [ 0.08, 44.38 ]
Shinto 2014 (4) 1/13 0/13 0.4 % 3.00 [ 0.13, 67.51 ]
SOFA 2006 (5) 65/273 62/273 43.4 % 1.05 [ 0.77, 1.42 ]
Subtotal (95% CI) 958 933 100.0 % 1.10 [ 0.90, 1.35 ]
Total events: 161 (Higher omega 3), 145 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 4.09, df = 5 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 0.97 (P = 0.33)
4 N-3 replacing carbohydrates/sugars
Derosa 2016 2/128 3/130 100.0 % 0.68 [ 0.12, 3.98 ]
Subtotal (95% CI) 128 130 100.0 % 0.68 [ 0.12, 3.98 ]
Total events: 2 (Higher omega 3), 3 (Lower omega 3)
Heterogeneity: not applicable
Test for overall effect: Z = 0.43 (P = 0.67)
5 N-3 replacing nil/low n-3 placebo
AREDS2 2014 183/2147 187/2056 15.4 % 0.94 [ 0.77, 1.14 ]
Brox 2001 0/80 1/40 0.1 % 0.17 [ 0.01, 4.05 ]
Doi 2014 11/119 24/119 2.6 % 0.46 [ 0.24, 0.89 ]
FOSTAR 2016 18/101 16/101 3.1 % 1.13 [ 0.61, 2.08 ]
GISSI-P 1999 547/5666 608/5658 22.3 % 0.90 [ 0.81, 1.00 ]
JELIS 2007 (6) 262/9326 324/9319 18.0 % 0.81 [ 0.69, 0.95 ]
Kumar 2013 (7) 1/39 1/39 0.2 % 1.00 [ 0.06, 15.43 ]
MAPT 2017 192/820 164/832 16.1 % 1.19 [ 0.99, 1.43 ]
Puri 2005 1/60 0/61 0.1 % 3.05 [ 0.13, 73.40 ]
Sandhu 2016 2/107 1/106 0.2 % 1.98 [ 0.18, 21.52 ]
SHOT 1996 15/317 12/293 2.2 % 1.16 [ 0.55, 2.43 ]
SU.FOL.OM3 2010 303/1253 290/1248 19.6 % 1.04 [ 0.90, 1.20 ]
Subtotal (95% CI) 20035 19872 100.0 % 0.95 [ 0.85, 1.07 ]
Total events: 1535 (Higher omega 3), 1628 (Lower omega 3)
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(. . . Continued)
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Heterogeneity: Tau2 = 0.01; Chi2 = 19.40, df = 11 (P = 0.05); I2 =43%
Test for overall effect: Z = 0.86 (P = 0.39)
6 Replacement unclear
DART2 2003 206/1571 155/1543 50.2 % 1.31 [ 1.07, 1.59 ]
EPE-A 2014 5/168 6/75 35.8 % 0.37 [ 0.12, 1.18 ]
Nutristroke 2009 (8) 0/38 4/34 14.1 % 0.10 [ 0.01, 1.79 ]
Subtotal (95% CI) 1777 1652 100.0 % 0.58 [ 0.16, 2.07 ]
Total events: 211 (Higher omega 3), 165 (Lower omega 3)
Heterogeneity: Tau2 = 0.83; Chi2 = 7.39, df = 2 (P = 0.02); I2 =73%
Test for overall effect: Z = 0.84 (P = 0.40)
Test for subgroup differences: Chi2 = 2.77, df = 5 (P = 0.74), I2 =0.0%
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(3) Cardiac adverse event
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(5) Cardiac adverse event
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Analysis 1.27. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 27 CVD events
- LCn3 - subgroup by intervention type.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)
Outcome: 27 CVD events - LCn3 - subgroup by intervention type
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Dietary advice
DART 1989 467/1015 487/1018 9.5 % 0.96 [ 0.88, 1.05 ]
DART2 2003 206/1571 155/1543 4.5 % 1.31 [ 1.07, 1.59 ]
THIS DIET 2008 14/51 10/50 0.5 % 1.37 [ 0.67, 2.80 ]
Subtotal (95% CI) 2637 2611 14.5 % 1.13 [ 0.86, 1.49 ]
Total events: 687 (Higher omega 3), 652 (Lower omega 3)
Heterogeneity: Tau2 = 0.04; Chi2 = 8.74, df = 2 (P = 0.01); I2 =77%
Test for overall effect: Z = 0.90 (P = 0.37)
2 Supplemental foods
AlphaOmega - EPA+DHA 2010 (1) 336/2404 335/2433 6.7 % 1.02 [ 0.88, 1.17 ]
FOSTAR 2016 18/101 16/101 0.7 % 1.13 [ 0.61, 2.08 ]
Subtotal (95% CI) 2505 2534 7.4 % 1.02 [ 0.89, 1.17 ]
Total events: 354 (Higher omega 3), 351 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.10, df = 1 (P = 0.75); I2 =0.0%
Test for overall effect: Z = 0.29 (P = 0.77)
3 Supplements (capsule)
AFFORD 2013 20/153 11/163 0.5 % 1.94 [ 0.96, 3.91 ]
AREDS2 2014 183/2147 187/2056 4.6 % 0.94 [ 0.77, 1.14 ]
Baldassarre 2006 1/32 0/32 0.0 % 3.00 [ 0.13, 71.00 ]
Brox 2001 0/80 1/40 0.0 % 0.17 [ 0.01, 4.05 ]
Derosa 2016 2/128 3/130 0.1 % 0.68 [ 0.12, 3.98 ]
DO IT 2010 32/282 36/281 1.2 % 0.89 [ 0.57, 1.38 ]
Doi 2014 11/119 24/119 0.6 % 0.46 [ 0.24, 0.89 ]
EPE-A 2014 5/168 6/75 0.2 % 0.37 [ 0.12, 1.18 ]
EPIC-1 2008 1/188 0/186 0.0 % 2.97 [ 0.12, 72.40 ]
EPOCH 2014 8/195 5/196 0.2 % 1.61 [ 0.54, 4.83 ]
FAAT 2005 31/200 39/202 1.3 % 0.80 [ 0.52, 1.23 ]
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Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
FORWARD 2013 4/289 4/297 0.1 % 1.03 [ 0.26, 4.07 ]
GISSI-HF 2008 1635/3494 1687/3481 12.2 % 0.97 [ 0.92, 1.01 ]
GISSI-P 1999 547/5666 608/5658 8.4 % 0.90 [ 0.81, 1.00 ]
HARP 1995 7/41 7/39 0.3 % 0.95 [ 0.37, 2.46 ]
JELIS 2007 (2) 262/9326 324/9319 5.8 % 0.81 [ 0.69, 0.95 ]
Kumar 2013 (3) 1/39 1/39 0.0 % 1.00 [ 0.06, 15.43 ]
MAPT 2017 192/820 164/832 4.9 % 1.19 [ 0.99, 1.43 ]
Nodari 2011 HF 10/67 26/66 0.6 % 0.38 [ 0.20, 0.72 ]
Nutristroke 2009 (4) 0/38 4/34 0.0 % 0.10 [ 0.01, 1.79 ]
OFAMI 2001 42/150 36/150 1.6 % 1.17 [ 0.80, 1.71 ]
OMEGA 2009 182/1752 149/1701 4.2 % 1.19 [ 0.97, 1.46 ]
ORIGIN 2012 2055/6281 2087/6255 12.1 % 0.98 [ 0.93, 1.03 ]
Proudman 2015 1/87 0/53 0.0 % 1.84 [ 0.08, 44.38 ]
Puri 2005 1/60 0/61 0.0 % 3.05 [ 0.13, 73.40 ]
Raitt 2005 (5) 2/100 5/100 0.1 % 0.40 [ 0.08, 2.01 ]
Risk % Prevention 2013 620/6239 630/6266 8.7 % 0.99 [ 0.89, 1.10 ]
Sandhu 2016 2/107 1/106 0.0 % 1.98 [ 0.18, 21.52 ]
SCIMO 1999 17/112 26/111 0.8 % 0.65 [ 0.37, 1.13 ]
Shinto 2014 (6) 1/13 0/13 0.0 % 3.00 [ 0.13, 67.51 ]
SHOT 1996 15/317 12/293 0.5 % 1.16 [ 0.55, 2.43 ]
SOFA 2006 (7) 65/273 62/273 2.3 % 1.05 [ 0.77, 1.42 ]
SU.FOL.OM3 2010 303/1253 290/1248 6.7 % 1.04 [ 0.90, 1.20 ]
Subtotal (95% CI) 40216 39875 78.2 % 0.97 [ 0.91, 1.02 ]
Total events: 6258 (Higher omega 3), 6435 (Lower omega 3)
Heterogeneity: Tau2 = 0.00; Chi2 = 48.44, df = 32 (P = 0.03); I2 =34%
Test for overall effect: Z = 1.14 (P = 0.26)
4 Any combination
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 3), 0 (Lower omega 3)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 45358 45020 100.0 % 0.99 [ 0.94, 1.04 ]
Total events: 7299 (Higher omega 3), 7438 (Lower omega 3)
Heterogeneity: Tau2 = 0.00; Chi2 = 58.47, df = 37 (P = 0.01); I2 =37%
Test for overall effect: Z = 0.54 (P = 0.59)
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Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Test for subgroup differences: Chi2 = 1.61, df = 2 (P = 0.45), I2 =0.0%
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Analysis 1.28. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 28 CVD events
- LCn3 - subgroup by duration.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)
Outcome: 28 CVD events - LCn3 - subgroup by duration
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Medium duration 1 to < 2 years in study
AFFORD 2013 20/153 11/163 0.5 % 1.94 [ 0.96, 3.91 ]
Brox 2001 0/80 1/40 0.0 % 0.17 [ 0.01, 4.05 ]
Derosa 2016 2/128 3/130 0.1 % 0.68 [ 0.12, 3.98 ]
Doi 2014 11/119 24/119 0.6 % 0.46 [ 0.24, 0.89 ]
EPE-A 2014 5/168 6/75 0.2 % 0.37 [ 0.12, 1.18 ]
EPIC-1 2008 1/188 0/186 0.0 % 2.97 [ 0.12, 72.40 ]
EPOCH 2014 8/195 5/196 0.2 % 1.61 [ 0.54, 4.83 ]
FAAT 2005 31/200 39/202 1.3 % 0.80 [ 0.52, 1.23 ]
FORWARD 2013 4/289 4/297 0.1 % 1.03 [ 0.26, 4.07 ]
Kumar 2013 (1) 1/39 1/39 0.0 % 1.00 [ 0.06, 15.43 ]
Nodari 2011 HF 10/67 26/66 0.6 % 0.38 [ 0.20, 0.72 ]
Nutristroke 2009 (2) 0/38 4/34 0.0 % 0.10 [ 0.01, 1.79 ]
OMEGA 2009 182/1752 149/1701 4.2 % 1.19 [ 0.97, 1.46 ]
Proudman 2015 1/87 0/53 0.0 % 1.84 [ 0.08, 44.38 ]
Puri 2005 1/60 0/61 0.0 % 3.05 [ 0.13, 73.40 ]
Shinto 2014 (3) 1/13 0/13 0.0 % 3.00 [ 0.13, 67.51 ]
SHOT 1996 15/317 12/293 0.5 % 1.16 [ 0.55, 2.43 ]
SOFA 2006 (4) 65/273 62/273 2.3 % 1.05 [ 0.77, 1.42 ]
Subtotal (95% CI) 4166 3941 10.8 % 0.89 [ 0.68, 1.16 ]
Total events: 358 (Higher omega 3), 347 (Lower omega 3)
Heterogeneity: Tau2 = 0.09; Chi2 = 30.14, df = 17 (P = 0.03); I2 =44%
Test for overall effect: Z = 0.84 (P = 0.40)
2 Medium-long duration: 2 to < 4 years in study
AlphaOmega - EPA+DHA 2010 (5) 336/2404 335/2433 6.7 % 1.02 [ 0.88, 1.17 ]
Baldassarre 2006 1/32 0/32 0.0 % 3.00 [ 0.13, 71.00 ]
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Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
DART 1989 467/1015 487/1018 9.5 % 0.96 [ 0.88, 1.05 ]
DO IT 2010 32/282 36/281 1.2 % 0.89 [ 0.57, 1.38 ]
FOSTAR 2016 18/101 16/101 0.7 % 1.13 [ 0.61, 2.08 ]
GISSI-HF 2008 1635/3494 1687/3481 12.2 % 0.97 [ 0.92, 1.01 ]
GISSI-P 1999 547/5666 608/5658 8.4 % 0.90 [ 0.81, 1.00 ]
HARP 1995 7/41 7/39 0.3 % 0.95 [ 0.37, 2.46 ]
MAPT 2017 192/820 164/832 4.9 % 1.19 [ 0.99, 1.43 ]
OFAMI 2001 42/150 36/150 1.6 % 1.17 [ 0.80, 1.71 ]
Raitt 2005 (6) 2/100 5/100 0.1 % 0.40 [ 0.08, 2.01 ]
Sandhu 2016 2/107 1/106 0.0 % 1.98 [ 0.18, 21.52 ]
SCIMO 1999 17/112 26/111 0.8 % 0.65 [ 0.37, 1.13 ]
THIS DIET 2008 14/51 10/50 0.5 % 1.37 [ 0.67, 2.80 ]
Subtotal (95% CI) 14375 14392 46.8 % 0.97 [ 0.93, 1.01 ]
Total events: 3312 (Higher omega 3), 3418 (Lower omega 3)
Heterogeneity: Tau2 = 0.00; Chi2 = 13.20, df = 13 (P = 0.43); I2 =2%
Test for overall effect: Z = 1.52 (P = 0.13)
3 Long duration:≥ 4 years in study
AREDS2 2014 183/2147 187/2056 4.6 % 0.94 [ 0.77, 1.14 ]
DART2 2003 206/1571 155/1543 4.5 % 1.31 [ 1.07, 1.59 ]
JELIS 2007 (7) 262/9326 324/9319 5.8 % 0.81 [ 0.69, 0.95 ]
ORIGIN 2012 2055/6281 2087/6255 12.1 % 0.98 [ 0.93, 1.03 ]
Risk % Prevention 2013 620/6239 630/6266 8.7 % 0.99 [ 0.89, 1.10 ]
SU.FOL.OM3 2010 303/1253 290/1248 6.7 % 1.04 [ 0.90, 1.20 ]
Subtotal (95% CI) 26817 26687 42.4 % 0.99 [ 0.91, 1.08 ]
Total events: 3629 (Higher omega 3), 3673 (Lower omega 3)
Heterogeneity: Tau2 = 0.01; Chi2 = 14.65, df = 5 (P = 0.01); I2 =66%
Test for overall effect: Z = 0.19 (P = 0.85)
Total (95% CI) 45358 45020 100.0 % 0.99 [ 0.94, 1.04 ]
Total events: 7299 (Higher omega 3), 7438 (Lower omega 3)
Heterogeneity: Tau2 = 0.00; Chi2 = 58.47, df = 37 (P = 0.01); I2 =37%
Test for overall effect: Z = 0.54 (P = 0.59)
Test for subgroup differences: Chi2 = 0.61, df = 2 (P = 0.74), I2 =0.0%
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(1) CVD death data used
(2) CV death used
(3) CV mortality data
(4) Cardiac adverse event
(5) AlphaOmega - comparing EPA+DHA ALA with no EPA+DHA ALA
(6) Cardiac death data
(7) CHD events
Analysis 1.29. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 29 CVD events
- LCn3 - subgroup by primary or secondary prevention.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)
Outcome: 29 CVD events - LCn3 - subgroup by primary or secondary prevention
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Primary prevention of CVD
AREDS2 2014 183/2147 187/2056 4.6 % 0.94 [ 0.77, 1.14 ]
Baldassarre 2006 1/32 0/32 0.0 % 3.00 [ 0.13, 71.00 ]
Brox 2001 0/80 1/40 0.0 % 0.17 [ 0.01, 4.05 ]
Derosa 2016 2/128 3/130 0.1 % 0.68 [ 0.12, 3.98 ]
DO IT 2010 32/282 36/281 1.2 % 0.89 [ 0.57, 1.38 ]
EPE-A 2014 (1) 5/168 6/75 0.2 % 0.37 [ 0.12, 1.18 ]
EPIC-1 2008 1/188 0/186 0.0 % 2.97 [ 0.12, 72.40 ]
EPOCH 2014 8/195 5/196 0.2 % 1.61 [ 0.54, 4.83 ]
FOSTAR 2016 18/101 16/101 0.7 % 1.13 [ 0.61, 2.08 ]
JELIS 2007 (2) 262/9326 324/9319 5.8 % 0.81 [ 0.69, 0.95 ]
MAPT 2017 192/820 164/832 4.9 % 1.19 [ 0.99, 1.43 ]
ORIGIN 2012 2055/6281 2087/6255 12.1 % 0.98 [ 0.93, 1.03 ]
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(. . . Continued)
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Proudman 2015 1/87 0/53 0.0 % 1.84 [ 0.08, 44.38 ]
Puri 2005 1/60 0/61 0.0 % 3.05 [ 0.13, 73.40 ]
Sandhu 2016 2/107 1/106 0.0 % 1.98 [ 0.18, 21.52 ]
Shinto 2014 (3) 1/13 0/13 0.0 % 3.00 [ 0.13, 67.51 ]
Subtotal (95% CI) 20015 19736 30.0 % 0.97 [ 0.89, 1.05 ]
Total events: 2764 (Higher omega 3), 2830 (Lower omega 3)
Heterogeneity: Tau2 = 0.00; Chi2 = 17.54, df = 15 (P = 0.29); I2 =14%
Test for overall effect: Z = 0.76 (P = 0.45)
2 Secondary prevention
AFFORD 2013 20/153 11/163 0.5 % 1.94 [ 0.96, 3.91 ]
AlphaOmega - EPA+DHA 2010 (4) 336/2404 335/2433 6.7 % 1.02 [ 0.88, 1.17 ]
DART 1989 467/1015 487/1018 9.5 % 0.96 [ 0.88, 1.05 ]
DART2 2003 206/1571 155/1543 4.5 % 1.31 [ 1.07, 1.59 ]
Doi 2014 11/119 24/119 0.6 % 0.46 [ 0.24, 0.89 ]
FAAT 2005 31/200 39/202 1.3 % 0.80 [ 0.52, 1.23 ]
FORWARD 2013 4/289 4/297 0.1 % 1.03 [ 0.26, 4.07 ]
GISSI-HF 2008 1635/3494 1687/3481 12.2 % 0.97 [ 0.92, 1.01 ]
GISSI-P 1999 547/5666 608/5658 8.4 % 0.90 [ 0.81, 1.00 ]
HARP 1995 7/41 7/39 0.3 % 0.95 [ 0.37, 2.46 ]
Kumar 2013 (5) 1/39 1/39 0.0 % 1.00 [ 0.06, 15.43 ]
Nodari 2011 HF 10/67 26/66 0.6 % 0.38 [ 0.20, 0.72 ]
Nutristroke 2009 (6) 0/38 4/34 0.0 % 0.10 [ 0.01, 1.79 ]
OFAMI 2001 42/150 36/150 1.6 % 1.17 [ 0.80, 1.71 ]
OMEGA 2009 182/1752 149/1701 4.2 % 1.19 [ 0.97, 1.46 ]
Raitt 2005 (7) 2/100 5/100 0.1 % 0.40 [ 0.08, 2.01 ]
Risk % Prevention 2013 620/6239 630/6266 8.7 % 0.99 [ 0.89, 1.10 ]
SCIMO 1999 17/112 26/111 0.8 % 0.65 [ 0.37, 1.13 ]
SHOT 1996 15/317 12/293 0.5 % 1.16 [ 0.55, 2.43 ]
SOFA 2006 (8) 65/273 62/273 2.3 % 1.05 [ 0.77, 1.42 ]
SU.FOL.OM3 2010 303/1253 290/1248 6.7 % 1.04 [ 0.90, 1.20 ]
THIS DIET 2008 14/51 10/50 0.5 % 1.37 [ 0.67, 2.80 ]
Subtotal (95% CI) 25343 25284 70.0 % 1.00 [ 0.93, 1.07 ]
Total events: 4535 (Higher omega 3), 4608 (Lower omega 3)
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(. . . Continued)
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Heterogeneity: Tau2 = 0.01; Chi2 = 40.98, df = 21 (P = 0.01); I2 =49%
Test for overall effect: Z = 0.14 (P = 0.89)
Total (95% CI) 45358 45020 100.0 % 0.99 [ 0.94, 1.04 ]
Total events: 7299 (Higher omega 3), 7438 (Lower omega 3)
Heterogeneity: Tau2 = 0.00; Chi2 = 58.47, df = 37 (P = 0.01); I2 =37%
Test for overall effect: Z = 0.54 (P = 0.59)
Test for subgroup differences: Chi2 = 0.25, df = 1 (P = 0.61), I2 =0.0%
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Analysis 1.30. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 30 CVD events
- LCn3 - subgroup by statin use.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)
Outcome: 30 CVD events - LCn3 - subgroup by statin use
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 LCn3 -≥ 50% of control group on statins
AlphaOmega - EPA+DHA 2010 (1) 336/2404 335/2433 6.7 % 1.02 [ 0.88, 1.17 ]
Doi 2014 11/119 24/119 0.6 % 0.46 [ 0.24, 0.89 ]
JELIS 2007 (2) 262/9326 324/9319 5.8 % 0.81 [ 0.69, 0.95 ]
Kumar 2013 (3) 1/39 1/39 0.0 % 1.00 [ 0.06, 15.43 ]
OMEGA 2009 182/1752 149/1701 4.2 % 1.19 [ 0.97, 1.46 ]
ORIGIN 2012 2055/6281 2087/6255 12.1 % 0.98 [ 0.93, 1.03 ]
SU.FOL.OM3 2010 303/1253 290/1248 6.7 % 1.04 [ 0.90, 1.20 ]
THIS DIET 2008 14/51 10/50 0.5 % 1.37 [ 0.67, 2.80 ]
Subtotal (95% CI) 21225 21164 36.7 % 0.98 [ 0.89, 1.08 ]
Total events: 3164 (Higher omega 3), 3220 (Lower omega 3)
Heterogeneity: Tau2 = 0.01; Chi2 = 15.66, df = 7 (P = 0.03); I2 =55%
Test for overall effect: Z = 0.38 (P = 0.70)
2 LCn3 - < 50% of control group on statins
AFFORD 2013 20/153 11/163 0.5 % 1.94 [ 0.96, 3.91 ]
AREDS2 2014 183/2147 187/2056 4.6 % 0.94 [ 0.77, 1.14 ]
Baldassarre 2006 1/32 0/32 0.0 % 3.00 [ 0.13, 71.00 ]
Brox 2001 0/80 1/40 0.0 % 0.17 [ 0.01, 4.05 ]
DART 1989 467/1015 487/1018 9.5 % 0.96 [ 0.88, 1.05 ]
DART2 2003 206/1571 155/1543 4.5 % 1.31 [ 1.07, 1.59 ]
DO IT 2010 32/282 36/281 1.2 % 0.89 [ 0.57, 1.38 ]
EPIC-1 2008 1/188 0/186 0.0 % 2.97 [ 0.12, 72.40 ]
FAAT 2005 31/200 39/202 1.3 % 0.80 [ 0.52, 1.23 ]
FORWARD 2013 4/289 4/297 0.1 % 1.03 [ 0.26, 4.07 ]
FOSTAR 2016 18/101 16/101 0.7 % 1.13 [ 0.61, 2.08 ]
GISSI-HF 2008 1635/3494 1687/3481 12.2 % 0.97 [ 0.92, 1.01 ]
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(. . . Continued)
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
GISSI-P 1999 547/5666 608/5658 8.4 % 0.90 [ 0.81, 1.00 ]
HARP 1995 7/41 7/39 0.3 % 0.95 [ 0.37, 2.46 ]
Nodari 2011 HF 10/67 26/66 0.6 % 0.38 [ 0.20, 0.72 ]
OFAMI 2001 42/150 36/150 1.6 % 1.17 [ 0.80, 1.71 ]
Proudman 2015 1/87 0/53 0.0 % 1.84 [ 0.08, 44.38 ]
Puri 2005 1/60 0/61 0.0 % 3.05 [ 0.13, 73.40 ]
Raitt 2005 (4) 2/100 5/100 0.1 % 0.40 [ 0.08, 2.01 ]
Risk % Prevention 2013 620/6239 630/6266 8.7 % 0.99 [ 0.89, 1.10 ]
SCIMO 1999 17/112 26/111 0.8 % 0.65 [ 0.37, 1.13 ]
Shinto 2014 (5) 1/13 0/13 0.0 % 3.00 [ 0.13, 67.51 ]
SHOT 1996 15/317 12/293 0.5 % 1.16 [ 0.55, 2.43 ]
SOFA 2006 (6) 65/273 62/273 2.3 % 1.05 [ 0.77, 1.42 ]
Subtotal (95% CI) 22677 22483 57.8 % 0.98 [ 0.91, 1.04 ]
Total events: 3926 (Higher omega 3), 4035 (Lower omega 3)
Heterogeneity: Tau2 = 0.00; Chi2 = 31.84, df = 23 (P = 0.10); I2 =28%
Test for overall effect: Z = 0.77 (P = 0.44)
3 LCn3 - use of statins unclear
Derosa 2016 2/128 3/130 0.1 % 0.68 [ 0.12, 3.98 ]
EPE-A 2014 5/168 6/75 0.2 % 0.37 [ 0.12, 1.18 ]
EPOCH 2014 8/195 5/196 0.2 % 1.61 [ 0.54, 4.83 ]
MAPT 2017 192/820 164/832 4.9 % 1.19 [ 0.99, 1.43 ]
Nutristroke 2009 (7) 0/38 4/34 0.0 % 0.10 [ 0.01, 1.79 ]
Sandhu 2016 2/107 1/106 0.0 % 1.98 [ 0.18, 21.52 ]
Subtotal (95% CI) 1456 1373 5.5 % 0.93 [ 0.53, 1.63 ]
Total events: 209 (Higher omega 3), 183 (Lower omega 3)
Heterogeneity: Tau2 = 0.15; Chi2 = 7.48, df = 5 (P = 0.19); I2 =33%
Test for overall effect: Z = 0.25 (P = 0.80)
Total (95% CI) 45358 45020 100.0 % 0.99 [ 0.94, 1.04 ]
Total events: 7299 (Higher omega 3), 7438 (Lower omega 3)
Heterogeneity: Tau2 = 0.00; Chi2 = 58.47, df = 37 (P = 0.01); I2 =37%
Test for overall effect: Z = 0.54 (P = 0.59)
Test for subgroup differences: Chi2 = 0.04, df = 2 (P = 0.98), I2 =0.0%
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(1) AlphaOmega - comparing EPA+DHA ALA with no EPA+DHA ALA
(2) CHD events
(3) CVD death data used
(4) Cardiac death data
(5) CV mortality data
(6) Cardiac adverse event
(7) CV death used
Analysis 1.31. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 31 Coronary
heart disease mortality (overall) - LCn3.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)
Outcome: 31 Coronary heart disease mortality (overall) - LCn3
Study or subgroup
Favours
higher
omega 3 Lower omega 3 fats Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
AlphaOmega - EPA+DHA 2010 67/2404 71/2433 10.8 % 0.96 [ 0.69, 1.33 ]
AREDS2 2014 (1) 3/2147 0/2056 0.3 % 6.70 [ 0.35, 129.70 ]
Brox 2001 (2) 0/80 1/40 0.2 % 0.17 [ 0.01, 4.05 ]
DART 1989 78/1015 116/1018 12.6 % 0.67 [ 0.51, 0.89 ]
DART2 2003 (3) 180/1571 139/1543 14.9 % 1.27 [ 1.03, 1.57 ]
Derosa 2016 (4) 0/128 1/130 0.2 % 0.34 [ 0.01, 8.23 ]
DO IT 2010 (5) 0/282 2/281 0.3 % 0.20 [ 0.01, 4.13 ]
Doi 2014 (6) 0/119 2/119 0.3 % 0.20 [ 0.01, 4.12 ]
FAAT 2005 (7) 9/200 9/202 2.7 % 1.01 [ 0.41, 2.49 ]
GISSI-HF 2008 (8) 20/3494 25/3481 5.3 % 0.80 [ 0.44, 1.43 ]
GISSI-P 1999 214/5666 265/5668 16.2 % 0.81 [ 0.68, 0.96 ]
HARP 1995 0/41 1/39 0.2 % 0.32 [ 0.01, 7.57 ]
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(. . . Continued)
Study or subgroup
Favours
higher
omega 3 Lower omega 3 fats Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
JELIS 2007 29/9326 31/9319 6.6 % 0.93 [ 0.56, 1.55 ]
OFAMI 2001 (9) 8/150 8/150 2.4 % 1.00 [ 0.39, 2.59 ]
OMEGA 2009 (10) 67/1919 51/1885 9.9 % 1.29 [ 0.90, 1.85 ]
Raitt 2005 2/100 5/100 0.9 % 0.40 [ 0.08, 2.01 ]
Risk % Prevention 2013 82/6239 76/6266 11.4 % 1.08 [ 0.79, 1.48 ]
SCIMO 1999 (11) 0/112 1/111 0.2 % 0.33 [ 0.01, 8.02 ]
SHOT 1996 (12) 7/317 4/293 1.6 % 1.62 [ 0.48, 5.47 ]
SOFA 2006 (13) 6/273 13/273 2.4 % 0.46 [ 0.18, 1.20 ]
SU.FOL.OM3 2010 (14) 1/1253 2/1248 0.4 % 0.50 [ 0.05, 5.49 ]
Total (95% CI) 36836 36655 100.0 % 0.93 [ 0.79, 1.09 ]
Total events: 773 (Favours higher omega 3), 823 (Lower omega 3 fats)
Heterogeneity: Tau2 = 0.03; Chi2 = 30.96, df = 20 (P = 0.06); I2 =35%
Test for overall effect: Z = 0.91 (P = 0.36)
Test for subgroup differences: Not applicable
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Analysis 1.32. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 32 CHD
mortality - LCn3 - SA fixed-effect.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)
Outcome: 32 CHD mortality - LCn3 - SA fixed-effect
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
AlphaOmega - EPA+DHA 2010 67/2404 71/2433 8.5 % 0.96 [ 0.69, 1.33 ]
AREDS2 2014 (1) 3/2147 0/2056 0.1 % 6.70 [ 0.35, 129.70 ]
Brox 2001 (2) 0/80 1/40 0.2 % 0.17 [ 0.01, 4.05 ]
DART 1989 78/1015 116/1018 14.0 % 0.67 [ 0.51, 0.89 ]
DART2 2003 (3) 180/1571 139/1543 16.9 % 1.27 [ 1.03, 1.57 ]
Derosa 2016 (4) 0/128 1/130 0.2 % 0.34 [ 0.01, 8.23 ]
DO IT 2010 (5) 0/282 2/281 0.3 % 0.20 [ 0.01, 4.13 ]
Doi 2014 (6) 0/119 2/119 0.3 % 0.20 [ 0.01, 4.12 ]
FAAT 2005 (7) 9/200 9/202 1.1 % 1.01 [ 0.41, 2.49 ]
GISSI-HF 2008 (8) 20/3494 25/3481 3.0 % 0.80 [ 0.44, 1.43 ]
GISSI-P 1999 214/5666 265/5668 32.0 % 0.81 [ 0.68, 0.96 ]
HARP 1995 0/41 1/39 0.2 % 0.32 [ 0.01, 7.57 ]
JELIS 2007 29/9326 31/9319 3.7 % 0.93 [ 0.56, 1.55 ]
OFAMI 2001 (9) 8/150 8/150 1.0 % 1.00 [ 0.39, 2.59 ]
OMEGA 2009 (10) 67/1919 51/1885 6.2 % 1.29 [ 0.90, 1.85 ]
Raitt 2005 2/100 5/100 0.6 % 0.40 [ 0.08, 2.01 ]
Risk % Prevention 2013 82/6239 76/6266 9.2 % 1.08 [ 0.79, 1.48 ]
SCIMO 1999 (11) 0/112 1/111 0.2 % 0.33 [ 0.01, 8.02 ]
SHOT 1996 (12) 7/317 4/293 0.5 % 1.62 [ 0.48, 5.47 ]
SOFA 2006 (13) 6/273 13/273 1.6 % 0.46 [ 0.18, 1.20 ]
SU.FOL.OM3 2010 (14) 1/1253 2/1248 0.2 % 0.50 [ 0.05, 5.49 ]
Total (95% CI) 36836 36655 100.0 % 0.94 [ 0.85, 1.03 ]
Total events: 773 (Higher omega 3), 823 (Lower omega 3)
Heterogeneity: Chi2 = 30.96, df = 20 (P = 0.06); I2 =35%
Test for overall effect: Z = 1.38 (P = 0.17)
Test for subgroup differences: Not applicable
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Analysis 1.33. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 33 CHD
mortality - LCn3 - SA by summary risk of bias.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)
Outcome: 33 CHD mortality - LCn3 - SA by summary risk of bias
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Low risk of bias
AlphaOmega - EPA+DHA 2010 67/2404 71/2433 10.8 % 0.96 [ 0.69, 1.33 ]
AREDS2 2014 (1) 3/2147 0/2056 0.3 % 6.70 [ 0.35, 129.70 ]
Derosa 2016 (2) 0/128 1/130 0.2 % 0.34 [ 0.01, 8.23 ]
OMEGA 2009 (3) 67/1919 51/1885 9.9 % 1.29 [ 0.90, 1.85 ]
SCIMO 1999 (4) 0/112 1/111 0.2 % 0.33 [ 0.01, 8.02 ]
SOFA 2006 (5) 6/273 13/273 2.4 % 0.46 [ 0.18, 1.20 ]
SU.FOL.OM3 2010 (6) 1/1253 2/1248 0.4 % 0.50 [ 0.05, 5.49 ]
Subtotal (95% CI) 8236 8136 24.3 % 1.00 [ 0.72, 1.37 ]
Total events: 144 (Higher omega 3), 139 (Lower omega 3)
Heterogeneity: Tau2 = 0.03; Chi2 = 7.29, df = 6 (P = 0.29); I2 =18%
Test for overall effect: Z = 0.03 (P = 0.98)
2 Moderate/high risk of bias
Brox 2001 (7) 0/80 1/40 0.2 % 0.17 [ 0.01, 4.05 ]
DART 1989 78/1015 116/1018 12.6 % 0.67 [ 0.51, 0.89 ]
DART2 2003 (8) 180/1571 139/1543 14.9 % 1.27 [ 1.03, 1.57 ]
DO IT 2010 (9) 0/282 2/281 0.3 % 0.20 [ 0.01, 4.13 ]
Doi 2014 (10) 0/119 2/119 0.3 % 0.20 [ 0.01, 4.12 ]
FAAT 2005 (11) 9/200 9/202 2.7 % 1.01 [ 0.41, 2.49 ]
GISSI-HF 2008 (12) 20/3494 25/3481 5.3 % 0.80 [ 0.44, 1.43 ]
GISSI-P 1999 214/5666 265/5668 16.2 % 0.81 [ 0.68, 0.96 ]
HARP 1995 0/41 1/39 0.2 % 0.32 [ 0.01, 7.57 ]
JELIS 2007 29/9326 31/9319 6.6 % 0.93 [ 0.56, 1.55 ]
OFAMI 2001 (13) 8/150 8/150 2.4 % 1.00 [ 0.39, 2.59 ]
Raitt 2005 2/100 5/100 0.9 % 0.40 [ 0.08, 2.01 ]
Risk % Prevention 2013 82/6239 76/6266 11.4 % 1.08 [ 0.79, 1.48 ]
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(. . . Continued)
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
SHOT 1996 (14) 7/317 4/293 1.6 % 1.62 [ 0.48, 5.47 ]
Subtotal (95% CI) 28600 28519 75.7 % 0.91 [ 0.75, 1.10 ]
Total events: 629 (Higher omega 3), 684 (Lower omega 3)
Heterogeneity: Tau2 = 0.04; Chi2 = 22.90, df = 13 (P = 0.04); I2 =43%
Test for overall effect: Z = 1.00 (P = 0.32)
Total (95% CI) 36836 36655 100.0 % 0.93 [ 0.79, 1.09 ]
Total events: 773 (Higher omega 3), 823 (Lower omega 3)
Heterogeneity: Tau2 = 0.03; Chi2 = 30.96, df = 20 (P = 0.06); I2 =35%
Test for overall effect: Z = 0.91 (P = 0.36)
Test for subgroup differences: Chi2 = 0.24, df = 1 (P = 0.62), I2 =0.0%
0.1 0.2 0.5 1 2 5 10
Favours higher omega 3 Favours lower omega 3
(1) Fatal MI
(2) Fatal MI
(3) Cardiac death
(4) Fatal MI
(5) Cardiac death
(6) Fatal MI
(7) Fatal MI
(8) Cardiac deaths
(9) Fatal MI
(10) Fatal MI/ sudden death
(11) Cardiac deaths
(12) Fatal MI
(13) Cardiac deaths
(14) Fatal MI
352Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.34. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 34 CHD
mortality - LCn3 - SA by compliance and study size.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)
Outcome: 34 CHD mortality - LCn3 - SA by compliance and study size
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 SA - low risk of compliance bias
AlphaOmega - EPA+DHA 2010 67/2404 71/2433 49.5 % 0.96 [ 0.69, 1.33 ]
Brox 2001 (1) 0/80 1/40 0.5 % 0.17 [ 0.01, 4.05 ]
DO IT 2010 (2) 0/282 2/281 0.6 % 0.20 [ 0.01, 4.13 ]
HARP 1995 0/41 1/39 0.5 % 0.32 [ 0.01, 7.57 ]
OMEGA 2009 (3) 67/1919 51/1885 41.7 % 1.29 [ 0.90, 1.85 ]
Raitt 2005 2/100 5/100 2.1 % 0.40 [ 0.08, 2.01 ]
SCIMO 1999 (4) 0/112 1/111 0.5 % 0.33 [ 0.01, 8.02 ]
SHOT 1996 (5) 7/317 4/293 3.6 % 1.62 [ 0.48, 5.47 ]
SU.FOL.OM3 2010 (6) 1/1253 2/1248 0.9 % 0.50 [ 0.05, 5.49 ]
Subtotal (95% CI) 6508 6430 100.0 % 1.05 [ 0.83, 1.32 ]
Total events: 144 (Higher omega 3), 138 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 7.30, df = 8 (P = 0.50); I2 =0.0%
Test for overall effect: Z = 0.38 (P = 0.70)
2 SA - 100+ randomised
AlphaOmega - EPA+DHA 2010 67/2404 71/2433 10.8 % 0.96 [ 0.69, 1.33 ]
AREDS2 2014 (7) 3/2147 0/2056 0.3 % 6.70 [ 0.35, 129.70 ]
Brox 2001 (8) 0/80 1/40 0.3 % 0.17 [ 0.01, 4.05 ]
DART 1989 78/1015 116/1018 12.6 % 0.67 [ 0.51, 0.89 ]
DART2 2003 (9) 180/1571 139/1543 14.8 % 1.27 [ 1.03, 1.57 ]
Derosa 2016 (10) 0/128 1/130 0.2 % 0.34 [ 0.01, 8.23 ]
DO IT 2010 (11) 0/282 2/281 0.3 % 0.20 [ 0.01, 4.13 ]
Doi 2014 (12) 0/119 2/119 0.3 % 0.20 [ 0.01, 4.12 ]
FAAT 2005 (13) 9/200 9/202 2.7 % 1.01 [ 0.41, 2.49 ]
GISSI-HF 2008 (14) 20/3494 25/3481 5.4 % 0.80 [ 0.44, 1.43 ]
GISSI-P 1999 214/5666 265/5668 16.0 % 0.81 [ 0.68, 0.96 ]
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(. . . Continued)
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
JELIS 2007 29/9326 31/9319 6.7 % 0.93 [ 0.56, 1.55 ]
OFAMI 2001 (15) 8/150 8/150 2.5 % 1.00 [ 0.39, 2.59 ]
OMEGA 2009 (16) 67/1919 51/1885 10.0 % 1.29 [ 0.90, 1.85 ]
Raitt 2005 2/100 5/100 0.9 % 0.40 [ 0.08, 2.01 ]
Risk % Prevention 2013 82/6239 76/6266 11.4 % 1.08 [ 0.79, 1.48 ]
SCIMO 1999 (17) 0/112 1/111 0.2 % 0.33 [ 0.01, 8.02 ]
SHOT 1996 (18) 7/317 4/293 1.6 % 1.62 [ 0.48, 5.47 ]
SOFA 2006 (19) 6/273 13/273 2.5 % 0.46 [ 0.18, 1.20 ]
SU.FOL.OM3 2010 (20) 1/1253 2/1248 0.4 % 0.50 [ 0.05, 5.49 ]
Subtotal (95% CI) 36795 36616 100.0 % 0.93 [ 0.79, 1.09 ]
Total events: 773 (Higher omega 3), 822 (Lower omega 3)
Heterogeneity: Tau2 = 0.03; Chi2 = 30.51, df = 19 (P = 0.05); I2 =38%
Test for overall effect: Z = 0.88 (P = 0.38)
Test for subgroup differences: Chi2 = 0.66, df = 1 (P = 0.42), I2 =0.0%
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Analysis 1.35. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 35 CHD
mortality - LCn3 - SA omitting cardiac death.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)
Outcome: 35 CHD mortality - LCn3 - SA omitting cardiac death
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Low risk of bias
AlphaOmega - EPA+DHA 2010 67/2404 71/2433 12.5 % 0.96 [ 0.69, 1.33 ]
AREDS2 2014 (1) 3/2147 0/2056 0.2 % 6.70 [ 0.35, 129.70 ]
Derosa 2016 (2) 0/128 1/130 0.1 % 0.34 [ 0.01, 8.23 ]
SCIMO 1999 (3) 0/112 1/111 0.1 % 0.33 [ 0.01, 8.02 ]
SU.FOL.OM3 2010 (4) 1/1253 2/1248 0.2 % 0.50 [ 0.05, 5.49 ]
Subtotal (95% CI) 6044 5978 13.1 % 0.95 [ 0.69, 1.30 ]
Total events: 71 (Higher omega 3), 75 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.78, df = 4 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 0.34 (P = 0.73)
2 Moderate/high risk of bias
Brox 2001 (5) 0/80 1/40 0.1 % 0.17 [ 0.01, 4.05 ]
DART 1989 78/1015 116/1018 18.1 % 0.67 [ 0.51, 0.89 ]
DO IT 2010 (6) 0/282 2/281 0.1 % 0.20 [ 0.01, 4.13 ]
Doi 2014 (7) 0/119 2/119 0.1 % 0.20 [ 0.01, 4.12 ]
GISSI-HF 2008 (8) 20/3494 25/3481 3.9 % 0.80 [ 0.44, 1.43 ]
GISSI-P 1999 214/5666 265/5668 43.5 % 0.81 [ 0.68, 0.96 ]
HARP 1995 0/41 1/39 0.1 % 0.32 [ 0.01, 7.57 ]
JELIS 2007 29/9326 31/9319 5.3 % 0.93 [ 0.56, 1.55 ]
Raitt 2005 2/100 5/100 0.5 % 0.40 [ 0.08, 2.01 ]
Risk % Prevention 2013 82/6239 76/6266 14.1 % 1.08 [ 0.79, 1.48 ]
SHOT 1996 (9) 7/317 4/293 0.9 % 1.62 [ 0.48, 5.47 ]
Subtotal (95% CI) 26679 26624 86.9 % 0.82 [ 0.72, 0.94 ]
Total events: 432 (Higher omega 3), 528 (Lower omega 3)
Heterogeneity: Tau2 = 0.00; Chi2 = 10.28, df = 10 (P = 0.42); I2 =3%
Test for overall effect: Z = 2.94 (P = 0.0032)
Total (95% CI) 32723 32602 100.0 % 0.83 [ 0.74, 0.94 ]
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(. . . Continued)
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Total events: 503 (Higher omega 3), 603 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 13.73, df = 15 (P = 0.55); I2 =0.0%
Test for overall effect: Z = 3.06 (P = 0.0022)
Test for subgroup differences: Chi2 = 0.65, df = 1 (P = 0.42), I2 =0.0%
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357Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.36. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 36 CHD
mortality - LCn3 - subgroup by dose.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)
Outcome: 36 CHD mortality - LCn3 - subgroup by dose
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 LCn3≤ 150 mg/d
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 3), 0 (Lower omega 3)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 LCn3 > 150≤ 250 mg/d
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 3), 0 (Lower omega 3)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 LCn3 > 250≤ 400 mg/d
DART 1989 78/1015 116/1018 12.6 % 0.67 [ 0.51, 0.89 ]
DART2 2003 (1) 180/1571 139/1543 14.9 % 1.27 [ 1.03, 1.57 ]
Subtotal (95% CI) 2586 2561 27.6 % 0.93 [ 0.50, 1.74 ]
Total events: 258 (Higher omega 3), 255 (Lower omega 3)
Heterogeneity: Tau2 = 0.19; Chi2 = 13.01, df = 1 (P = 0.00031); I2 =92%
Test for overall effect: Z = 0.22 (P = 0.82)
4 LCn3 > 400≤ 2400 mg/d
AlphaOmega - EPA+DHA 2010 67/2404 71/2433 10.8 % 0.96 [ 0.69, 1.33 ]
AREDS2 2014 (2) 3/2147 0/2056 0.3 % 6.70 [ 0.35, 129.70 ]
Derosa 2016 (3) 0/128 1/130 0.2 % 0.34 [ 0.01, 8.23 ]
DO IT 2010 (4) 0/282 2/281 0.3 % 0.20 [ 0.01, 4.13 ]
Doi 2014 (5) 0/119 2/119 0.3 % 0.20 [ 0.01, 4.12 ]
GISSI-HF 2008 (6) 20/3494 25/3481 5.3 % 0.80 [ 0.44, 1.43 ]
GISSI-P 1999 214/5666 265/5668 16.2 % 0.81 [ 0.68, 0.96 ]
JELIS 2007 29/9326 31/9319 6.6 % 0.93 [ 0.56, 1.55 ]
OMEGA 2009 (7) 67/1919 51/1885 9.9 % 1.29 [ 0.90, 1.85 ]
Raitt 2005 2/100 5/100 0.9 % 0.40 [ 0.08, 2.01 ]
Risk % Prevention 2013 82/6239 76/6266 11.4 % 1.08 [ 0.79, 1.48 ]
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Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
SCIMO 1999 (8) 0/112 1/111 0.2 % 0.33 [ 0.01, 8.02 ]
SHOT 1996 (9) 7/317 4/293 1.6 % 1.62 [ 0.48, 5.47 ]
SOFA 2006 (10) 6/273 13/273 2.4 % 0.46 [ 0.18, 1.20 ]
SU.FOL.OM3 2010 (11) 1/1253 2/1248 0.4 % 0.50 [ 0.05, 5.49 ]
Subtotal (95% CI) 33779 33663 66.9 % 0.92 [ 0.80, 1.07 ]
Total events: 498 (Higher omega 3), 549 (Lower omega 3)
Heterogeneity: Tau2 = 0.01; Chi2 = 15.37, df = 14 (P = 0.35); I2 =9%
Test for overall effect: Z = 1.10 (P = 0.27)
5 LCn3 > 2.4≤ 4.4 g/d
Brox 2001 (12) 0/80 1/40 0.2 % 0.17 [ 0.01, 4.05 ]
FAAT 2005 (13) 9/200 9/202 2.7 % 1.01 [ 0.41, 2.49 ]
OFAMI 2001 (14) 8/150 8/150 2.4 % 1.00 [ 0.39, 2.59 ]
Subtotal (95% CI) 430 392 5.3 % 0.93 [ 0.49, 1.78 ]
Total events: 17 (Higher omega 3), 18 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.17, df = 2 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 0.21 (P = 0.84)
6 LCn3 > 4.4 g/d
HARP 1995 0/41 1/39 0.2 % 0.32 [ 0.01, 7.57 ]
Subtotal (95% CI) 41 39 0.2 % 0.32 [ 0.01, 7.57 ]
Total events: 0 (Higher omega 3), 1 (Lower omega 3)
Heterogeneity: not applicable
Test for overall effect: Z = 0.71 (P = 0.48)
Total (95% CI) 36836 36655 100.0 % 0.93 [ 0.79, 1.09 ]
Total events: 773 (Higher omega 3), 823 (Lower omega 3)
Heterogeneity: Tau2 = 0.03; Chi2 = 30.96, df = 20 (P = 0.06); I2 =35%
Test for overall effect: Z = 0.91 (P = 0.36)
Test for subgroup differences: Chi2 = 0.44, df = 3 (P = 0.93), I2 =0.0%
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Analysis 1.37. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 37 CHD
mortality - LCn3 - subgroup by replacement.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)
Outcome: 37 CHD mortality - LCn3 - subgroup by replacement
Study or subgroup High omega 3 Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 N-3 replacing SFA
DART 1989 78/1015 116/1018 98.6 % 0.67 [ 0.51, 0.89 ]
Derosa 2016 (1) 0/128 1/130 0.7 % 0.34 [ 0.01, 8.23 ]
SCIMO 1999 (2) 0/112 1/111 0.7 % 0.33 [ 0.01, 8.02 ]
Subtotal (95% CI) 1255 1259 100.0 % 0.67 [ 0.51, 0.88 ]
Total events: 78 (High omega 3), 118 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.37, df = 2 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 2.92 (P = 0.0035)
2 N-3 replacing MUFA
AlphaOmega - EPA+DHA 2010 67/2404 71/2433 19.1 % 0.96 [ 0.69, 1.33 ]
DART 1989 78/1015 116/1018 22.3 % 0.67 [ 0.51, 0.89 ]
FAAT 2005 (3) 9/200 9/202 4.7 % 1.01 [ 0.41, 2.49 ]
GISSI-HF 2008 (4) 20/3494 25/3481 9.4 % 0.80 [ 0.44, 1.43 ]
HARP 1995 0/41 1/39 0.4 % 0.32 [ 0.01, 7.57 ]
OMEGA 2009 (5) 67/1919 51/1885 17.5 % 1.29 [ 0.90, 1.85 ]
Raitt 2005 2/100 5/100 1.6 % 0.40 [ 0.08, 2.01 ]
Risk % Prevention 2013 82/6239 76/6266 20.1 % 1.08 [ 0.79, 1.48 ]
SCIMO 1999 (6) 0/112 1/111 0.4 % 0.33 [ 0.01, 8.02 ]
SOFA 2006 (7) 6/273 13/273 4.3 % 0.46 [ 0.18, 1.20 ]
Subtotal (95% CI) 15797 15808 100.0 % 0.89 [ 0.72, 1.10 ]
Total events: 331 (High omega 3), 368 (Control)
Heterogeneity: Tau2 = 0.03; Chi2 = 13.53, df = 9 (P = 0.14); I2 =33%
Test for overall effect: Z = 1.07 (P = 0.29)
3 N-3 replacing n-6
DO IT 2010 (8) 0/282 2/281 4.7 % 0.20 [ 0.01, 4.13 ]
OFAMI 2001 (9) 8/150 8/150 47.6 % 1.00 [ 0.39, 2.59 ]
SOFA 2006 (10) 6/273 13/273 47.7 % 0.46 [ 0.18, 1.20 ]
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(. . . Continued)
Study or subgroup High omega 3 Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Subtotal (95% CI) 705 704 100.0 % 0.64 [ 0.33, 1.24 ]
Total events: 14 (High omega 3), 23 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.88, df = 2 (P = 0.39); I2 =0.0%
Test for overall effect: Z = 1.32 (P = 0.19)
4 N-3 replacing carbohydrates/sugars
Derosa 2016 (11) 0/128 1/130 100.0 % 0.34 [ 0.01, 8.23 ]
Subtotal (95% CI) 128 130 100.0 % 0.34 [ 0.01, 8.23 ]
Total events: 0 (High omega 3), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.67 (P = 0.51)
5 N-3 replacing nil/low n-3 placebo
AREDS2 2014 (12) 3/2147 0/2056 0.3 % 6.70 [ 0.35, 129.70 ]
Brox 2001 (13) 0/80 1/40 0.3 % 0.17 [ 0.01, 4.05 ]
Doi 2014 (14) 0/119 2/119 0.3 % 0.20 [ 0.01, 4.12 ]
GISSI-P 1999 214/5666 265/5668 86.4 % 0.81 [ 0.68, 0.96 ]
JELIS 2007 29/9326 31/9319 10.5 % 0.93 [ 0.56, 1.55 ]
SHOT 1996 (15) 7/317 4/293 1.8 % 1.62 [ 0.48, 5.47 ]
SU.FOL.OM3 2010 (16) 1/1253 2/1248 0.5 % 0.50 [ 0.05, 5.49 ]
Subtotal (95% CI) 18908 18743 100.0 % 0.83 [ 0.70, 0.97 ]
Total events: 254 (High omega 3), 305 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 5.35, df = 6 (P = 0.50); I2 =0.0%
Test for overall effect: Z = 2.27 (P = 0.023)
6 Replacement unclear
DART2 2003 (17) 180/1571 139/1543 100.0 % 1.27 [ 1.03, 1.57 ]
Subtotal (95% CI) 1571 1543 100.0 % 1.27 [ 1.03, 1.57 ]
Total events: 180 (High omega 3), 139 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.25 (P = 0.025)
Test for subgroup differences: Chi2 = 17.48, df = 5 (P = 0.00), I2 =71%
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Analysis 1.38. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 38 CHD
mortality - LCn3 - subgroup by intervention type.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)
Outcome: 38 CHD mortality - LCn3 - subgroup by intervention type
Study or subgroup High omega 3 Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Dietary advice
DART 1989 78/1015 116/1018 12.6 % 0.67 [ 0.51, 0.89 ]
DART2 2003 (1) 180/1571 139/1543 14.9 % 1.27 [ 1.03, 1.57 ]
Subtotal (95% CI) 2586 2561 27.6 % 0.93 [ 0.50, 1.74 ]
Total events: 258 (High omega 3), 255 (Control)
Heterogeneity: Tau2 = 0.19; Chi2 = 13.01, df = 1 (P = 0.00031); I2 =92%
Test for overall effect: Z = 0.22 (P = 0.82)
2 Supplemental foods
AlphaOmega - EPA+DHA 2010 67/2404 71/2433 10.8 % 0.96 [ 0.69, 1.33 ]
Subtotal (95% CI) 2404 2433 10.8 % 0.96 [ 0.69, 1.33 ]
Total events: 67 (High omega 3), 71 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.27 (P = 0.78)
3 Supplements (capsule)
AREDS2 2014 (2) 3/2147 0/2056 0.3 % 6.70 [ 0.35, 129.70 ]
Brox 2001 (3) 0/80 1/40 0.2 % 0.17 [ 0.01, 4.05 ]
Derosa 2016 (4) 0/128 1/130 0.2 % 0.34 [ 0.01, 8.23 ]
DO IT 2010 (5) 0/282 2/281 0.3 % 0.20 [ 0.01, 4.13 ]
Doi 2014 (6) 0/119 2/119 0.3 % 0.20 [ 0.01, 4.12 ]
FAAT 2005 (7) 9/200 9/202 2.7 % 1.01 [ 0.41, 2.49 ]
GISSI-HF 2008 (8) 20/3494 25/3481 5.3 % 0.80 [ 0.44, 1.43 ]
GISSI-P 1999 214/5666 265/5668 16.2 % 0.81 [ 0.68, 0.96 ]
HARP 1995 0/41 1/39 0.2 % 0.32 [ 0.01, 7.57 ]
JELIS 2007 29/9326 31/9319 6.6 % 0.93 [ 0.56, 1.55 ]
OFAMI 2001 (9) 8/150 8/150 2.4 % 1.00 [ 0.39, 2.59 ]
OMEGA 2009 (10) 67/1919 51/1885 9.9 % 1.29 [ 0.90, 1.85 ]
Raitt 2005 2/100 5/100 0.9 % 0.40 [ 0.08, 2.01 ]
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(. . . Continued)
Study or subgroup High omega 3 Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Risk % Prevention 2013 82/6239 76/6266 11.4 % 1.08 [ 0.79, 1.48 ]
SCIMO 1999 (11) 0/112 1/111 0.2 % 0.33 [ 0.01, 8.02 ]
SHOT 1996 (12) 7/317 4/293 1.6 % 1.62 [ 0.48, 5.47 ]
SOFA 2006 (13) 6/273 13/273 2.4 % 0.46 [ 0.18, 1.20 ]
SU.FOL.OM3 2010 (14) 1/1253 2/1248 0.4 % 0.50 [ 0.05, 5.49 ]
Subtotal (95% CI) 31846 31661 61.6 % 0.90 [ 0.79, 1.02 ]
Total events: 448 (High omega 3), 497 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 16.86, df = 17 (P = 0.46); I2 =0.0%
Test for overall effect: Z = 1.64 (P = 0.10)
4 Any combination
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (High omega 3), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 36836 36655 100.0 % 0.93 [ 0.79, 1.09 ]
Total events: 773 (High omega 3), 823 (Control)
Heterogeneity: Tau2 = 0.03; Chi2 = 30.96, df = 20 (P = 0.06); I2 =35%
Test for overall effect: Z = 0.91 (P = 0.36)
Test for subgroup differences: Chi2 = 0.12, df = 2 (P = 0.94), I2 =0.0%
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365Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease (Review)
Copyright © 2018 The Cochrane Collaboration. Published by J
Analysis 1.39. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 39 CHD
mortality - LCn3 - subgroup by duration.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)
Outcome: 39 CHD mortality - LCn3 - subgroup by duration
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Medium duration 1 to < 2 years in study
Brox 2001 (1) 0/80 1/40 0.2 % 0.17 [ 0.01, 4.05 ]
Derosa 2016 (2) 0/128 1/130 0.2 % 0.34 [ 0.01, 8.23 ]
Doi 2014 (3) 0/119 2/119 0.3 % 0.20 [ 0.01, 4.12 ]
FAAT 2005 (4) 9/200 9/202 2.7 % 1.01 [ 0.41, 2.49 ]
OMEGA 2009 (5) 67/1919 51/1885 9.9 % 1.29 [ 0.90, 1.85 ]
SHOT 1996 (6) 7/317 4/293 1.6 % 1.62 [ 0.48, 5.47 ]
SOFA 2006 (7) 6/273 13/273 2.4 % 0.46 [ 0.18, 1.20 ]
Subtotal (95% CI) 3036 2942 17.3 % 0.96 [ 0.62, 1.50 ]
Total events: 89 (Higher omega 3), 81 (Lower omega 3)
Heterogeneity: Tau2 = 0.07; Chi2 = 7.47, df = 6 (P = 0.28); I2 =20%
Test for overall effect: Z = 0.16 (P = 0.87)
2 Medium-long duration: 2 to < 4 years in study
AlphaOmega - EPA+DHA 2010 67/2404 71/2433 10.8 % 0.96 [ 0.69, 1.33 ]
DART 1989 78/1015 116/1018 12.6 % 0.67 [ 0.51, 0.89 ]
DO IT 2010 (8) 0/282 2/281 0.3 % 0.20 [ 0.01, 4.13 ]
GISSI-HF 2008 (9) 20/3494 25/3481 5.3 % 0.80 [ 0.44, 1.43 ]
GISSI-P 1999 214/5666 265/5668 16.2 % 0.81 [ 0.68, 0.96 ]
HARP 1995 0/41 1/39 0.2 % 0.32 [ 0.01, 7.57 ]
OFAMI 2001 (10) 8/150 8/150 2.4 % 1.00 [ 0.39, 2.59 ]
Raitt 2005 2/100 5/100 0.9 % 0.40 [ 0.08, 2.01 ]
SCIMO 1999 (11) 0/112 1/111 0.2 % 0.33 [ 0.01, 8.02 ]
Subtotal (95% CI) 13264 13281 49.1 % 0.79 [ 0.69, 0.90 ]
Total events: 389 (Higher omega 3), 494 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 4.94, df = 8 (P = 0.76); I2 =0.0%
Test for overall effect: Z = 3.55 (P = 0.00039)
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Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
3 Long duration:≥ 4 years in study
AREDS2 2014 (12) 3/2147 0/2056 0.3 % 6.70 [ 0.35, 129.70 ]
DART2 2003 (13) 180/1571 139/1543 14.9 % 1.27 [ 1.03, 1.57 ]
JELIS 2007 29/9326 31/9319 6.6 % 0.93 [ 0.56, 1.55 ]
Risk % Prevention 2013 82/6239 76/6266 11.4 % 1.08 [ 0.79, 1.48 ]
SU.FOL.OM3 2010 (14) 1/1253 2/1248 0.4 % 0.50 [ 0.05, 5.49 ]
Subtotal (95% CI) 20536 20432 33.6 % 1.18 [ 1.00, 1.39 ]
Total events: 295 (Higher omega 3), 248 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.41, df = 4 (P = 0.49); I2 =0.0%
Test for overall effect: Z = 1.97 (P = 0.049)
Total (95% CI) 36836 36655 100.0 % 0.93 [ 0.79, 1.09 ]
Total events: 773 (Higher omega 3), 823 (Lower omega 3)
Heterogeneity: Tau2 = 0.03; Chi2 = 30.96, df = 20 (P = 0.06); I2 =35%
Test for overall effect: Z = 0.91 (P = 0.36)
Test for subgroup differences: Chi2 = 14.06, df = 2 (P = 0.00), I2 =86%
0.1 0.2 0.5 1 2 5 10
Favours higher omega 3 Favours lower omega 3
(1) Fatal MI
(2) Fatal MI
(3) Fatal MI/ sudden death
(4) Cardiac deaths
(5) Cardiac death
(6) Fatal MI
(7) Cardiac death
(8) Fatal MI
(9) Fatal MI
(10) Cardiac deaths
(11) Fatal MI
(12) Fatal MI
(13) Cardiac deaths
(14) Fatal MI
367Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.40. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 40 CHD
mortality - LCn3 - subgroup by primary or secondary prevention.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)
Outcome: 40 CHD mortality - LCn3 - subgroup by primary or secondary prevention
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Primary prevention of CVD
AREDS2 2014 (1) 3/2147 0/2056 0.3 % 6.70 [ 0.35, 129.70 ]
Brox 2001 (2) 0/80 1/40 0.2 % 0.17 [ 0.01, 4.05 ]
Derosa 2016 (3) 0/128 1/130 0.2 % 0.34 [ 0.01, 8.23 ]
DO IT 2010 (4) 0/282 2/281 0.3 % 0.20 [ 0.01, 4.13 ]
JELIS 2007 29/9326 31/9319 6.6 % 0.93 [ 0.56, 1.55 ]
Subtotal (95% CI) 11963 11826 7.6 % 0.86 [ 0.46, 1.61 ]
Total events: 32 (Higher omega 3), 35 (Lower omega 3)
Heterogeneity: Tau2 = 0.05; Chi2 = 4.16, df = 4 (P = 0.38); I2 =4%
Test for overall effect: Z = 0.47 (P = 0.64)
2 Secondary prevention of CVD
AlphaOmega - EPA+DHA 2010 67/2404 71/2433 10.8 % 0.96 [ 0.69, 1.33 ]
DART 1989 78/1015 116/1018 12.6 % 0.67 [ 0.51, 0.89 ]
DART2 2003 (5) 180/1571 139/1543 14.9 % 1.27 [ 1.03, 1.57 ]
Doi 2014 (6) 0/119 2/119 0.3 % 0.20 [ 0.01, 4.12 ]
FAAT 2005 (7) 9/200 9/202 2.7 % 1.01 [ 0.41, 2.49 ]
GISSI-HF 2008 (8) 20/3494 25/3481 5.3 % 0.80 [ 0.44, 1.43 ]
GISSI-P 1999 214/5666 265/5668 16.2 % 0.81 [ 0.68, 0.96 ]
HARP 1995 0/41 1/39 0.2 % 0.32 [ 0.01, 7.57 ]
OFAMI 2001 (9) 8/150 8/150 2.4 % 1.00 [ 0.39, 2.59 ]
OMEGA 2009 (10) 67/1919 51/1885 9.9 % 1.29 [ 0.90, 1.85 ]
Raitt 2005 2/100 5/100 0.9 % 0.40 [ 0.08, 2.01 ]
Risk % Prevention 2013 82/6239 76/6266 11.4 % 1.08 [ 0.79, 1.48 ]
SCIMO 1999 (11) 0/112 1/111 0.2 % 0.33 [ 0.01, 8.02 ]
SHOT 1996 (12) 7/317 4/293 1.6 % 1.62 [ 0.48, 5.47 ]
SOFA 2006 (13) 6/273 13/273 2.4 % 0.46 [ 0.18, 1.20 ]
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Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
SU.FOL.OM3 2010 (14) 1/1253 2/1248 0.4 % 0.50 [ 0.05, 5.49 ]
Subtotal (95% CI) 24873 24829 92.4 % 0.93 [ 0.79, 1.11 ]
Total events: 741 (Higher omega 3), 788 (Lower omega 3)
Heterogeneity: Tau2 = 0.04; Chi2 = 26.75, df = 15 (P = 0.03); I2 =44%
Test for overall effect: Z = 0.81 (P = 0.42)
Total (95% CI) 36836 36655 100.0 % 0.93 [ 0.79, 1.09 ]
Total events: 773 (Higher omega 3), 823 (Lower omega 3)
Heterogeneity: Tau2 = 0.03; Chi2 = 30.96, df = 20 (P = 0.06); I2 =35%
Test for overall effect: Z = 0.91 (P = 0.36)
Test for subgroup differences: Chi2 = 0.06, df = 1 (P = 0.81), I2 =0.0%
0.01 0.1 1 10 100
Favours higher omega 3 Favours lower omega 3
(1) Fatal MI
(2) Fatal MI
(3) Fatal MI
(4) Fatal MI
(5) Cardiac deaths
(6) Fatal MI/ sudden death
(7) Cardiac deaths
(8) Fatal MI
(9) Cardiac deaths
(10) Cardiac death
(11) Fatal MI
(12) Fatal MI
(13) Cardiac death
(14) Fatal MI
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Analysis 1.41. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 41 CHD
mortality - LCn3 - subgroup by statin use.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)
Outcome: 41 CHD mortality - LCn3 - subgroup by statin use
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 LCn3 -≥ 50% of control group on statins
AlphaOmega - EPA+DHA 2010 67/2404 71/2433 10.8 % 0.96 [ 0.69, 1.33 ]
Doi 2014 (1) 0/119 2/119 0.3 % 0.20 [ 0.01, 4.12 ]
JELIS 2007 29/9326 31/9319 6.6 % 0.93 [ 0.56, 1.55 ]
OMEGA 2009 (2) 67/1919 51/1885 9.9 % 1.29 [ 0.90, 1.85 ]
SU.FOL.OM3 2010 (3) 1/1253 2/1248 0.4 % 0.50 [ 0.05, 5.49 ]
Subtotal (95% CI) 15021 15004 28.0 % 1.05 [ 0.84, 1.30 ]
Total events: 164 (Higher omega 3), 157 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.32, df = 4 (P = 0.51); I2 =0.0%
Test for overall effect: Z = 0.42 (P = 0.67)
2 LCn3 - < 50% of control group on statins
AREDS2 2014 (4) 3/2147 0/2056 0.3 % 6.70 [ 0.35, 129.70 ]
Brox 2001 (5) 0/80 1/40 0.2 % 0.17 [ 0.01, 4.05 ]
DART 1989 78/1015 116/1018 12.6 % 0.67 [ 0.51, 0.89 ]
DART2 2003 (6) 180/1571 139/1543 14.9 % 1.27 [ 1.03, 1.57 ]
DO IT 2010 (7) 0/282 2/281 0.3 % 0.20 [ 0.01, 4.13 ]
FAAT 2005 (8) 9/200 9/202 2.7 % 1.01 [ 0.41, 2.49 ]
GISSI-HF 2008 (9) 20/3494 25/3481 5.3 % 0.80 [ 0.44, 1.43 ]
GISSI-P 1999 214/5666 265/5668 16.2 % 0.81 [ 0.68, 0.96 ]
HARP 1995 0/41 1/39 0.2 % 0.32 [ 0.01, 7.57 ]
OFAMI 2001 (10) 8/150 8/150 2.4 % 1.00 [ 0.39, 2.59 ]
Raitt 2005 2/100 5/100 0.9 % 0.40 [ 0.08, 2.01 ]
Risk % Prevention 2013 82/6239 76/6266 11.4 % 1.08 [ 0.79, 1.48 ]
SCIMO 1999 (11) 0/112 1/111 0.2 % 0.33 [ 0.01, 8.02 ]
SHOT 1996 (12) 7/317 4/293 1.6 % 1.62 [ 0.48, 5.47 ]
SOFA 2006 (13) 6/273 13/273 2.4 % 0.46 [ 0.18, 1.20 ]
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Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Subtotal (95% CI) 21687 21521 71.8 % 0.89 [ 0.72, 1.10 ]
Total events: 609 (Higher omega 3), 665 (Lower omega 3)
Heterogeneity: Tau2 = 0.05; Chi2 = 26.04, df = 14 (P = 0.03); I2 =46%
Test for overall effect: Z = 1.11 (P = 0.27)
3 LCn3 - use of statins unclear
Derosa 2016 (14) 0/128 1/130 0.2 % 0.34 [ 0.01, 8.23 ]
Subtotal (95% CI) 128 130 0.2 % 0.34 [ 0.01, 8.23 ]
Total events: 0 (Higher omega 3), 1 (Lower omega 3)
Heterogeneity: not applicable
Test for overall effect: Z = 0.67 (P = 0.51)
Total (95% CI) 36836 36655 100.0 % 0.93 [ 0.79, 1.09 ]
Total events: 773 (Higher omega 3), 823 (Lower omega 3)
Heterogeneity: Tau2 = 0.03; Chi2 = 30.96, df = 20 (P = 0.06); I2 =35%
Test for overall effect: Z = 0.91 (P = 0.36)
Test for subgroup differences: Chi2 = 1.57, df = 2 (P = 0.46), I2 =0.0%
0.1 0.2 0.5 1 2 5 10
Favours higher omega 3 Favours lower omega 3
(1) Fatal MI/ sudden death
(2) Cardiac death
(3) Fatal MI
(4) Fatal MI
(5) Fatal MI
(6) Cardiac deaths
(7) Fatal MI
(8) Cardiac deaths
(9) Fatal MI
(10) Cardiac deaths
(11) Fatal MI
(12) Fatal MI
(13) Cardiac death
(14) Fatal MI
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Analysis 1.42. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 42 CHD
mortality - LCn3 - subgroup by CAD history.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)
Outcome: 42 CHD mortality - LCn3 - subgroup by CAD history
Study or subgroup High omega 3 Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Previous CAD
AlphaOmega - EPA+DHA 2010 67/2404 71/2433 10.8 % 0.96 [ 0.69, 1.33 ]
DART 1989 78/1015 116/1018 12.7 % 0.67 [ 0.51, 0.89 ]
DART2 2003 (1) 180/1571 139/1543 15.0 % 1.27 [ 1.03, 1.57 ]
Doi 2014 (2) 0/119 0/119 Not estimable
GISSI-P 1999 214/5666 265/5668 16.2 % 0.81 [ 0.68, 0.96 ]
HARP 1995 0/41 1/39 0.2 % 0.32 [ 0.01, 7.57 ]
OFAMI 2001 (3) 8/150 8/150 2.4 % 1.00 [ 0.39, 2.59 ]
OMEGA 2009 (4) 67/1919 51/1885 9.9 % 1.29 [ 0.90, 1.85 ]
SCIMO 1999 (5) 0/112 1/111 0.2 % 0.33 [ 0.01, 8.02 ]
SHOT 1996 (6) 7/317 4/293 1.6 % 1.62 [ 0.48, 5.47 ]
SU.FOL.OM3 2010 (7) 1/1253 2/1248 0.4 % 0.50 [ 0.05, 5.49 ]
Subtotal (95% CI) 14567 14507 69.6 % 0.96 [ 0.77, 1.20 ]
Total events: 622 (High omega 3), 658 (Control)
Heterogeneity: Tau2 = 0.05; Chi2 = 21.39, df = 9 (P = 0.01); I2 =58%
Test for overall effect: Z = 0.36 (P = 0.72)
2 No previous CAD
AREDS2 2014 (8) 3/2147 0/2056 0.3 % 6.70 [ 0.35, 129.70 ]
Brox 2001 (9) 0/80 1/40 0.2 % 0.17 [ 0.01, 4.05 ]
Derosa 2016 (10) 0/128 1/130 0.2 % 0.34 [ 0.01, 8.23 ]
DO IT 2010 (11) 0/282 2/281 0.3 % 0.20 [ 0.01, 4.13 ]
FAAT 2005 (12) 9/200 9/202 2.7 % 1.01 [ 0.41, 2.49 ]
GISSI-HF 2008 (13) 20/3494 25/3481 5.4 % 0.80 [ 0.44, 1.43 ]
JELIS 2007 29/9326 31/9319 6.6 % 0.93 [ 0.56, 1.55 ]
Raitt 2005 2/100 5/100 0.9 % 0.40 [ 0.08, 2.01 ]
Risk % Prevention 2013 82/6239 76/6266 11.4 % 1.08 [ 0.79, 1.48 ]
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Study or subgroup High omega 3 Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
SOFA 2006 (14) 6/273 13/273 2.4 % 0.46 [ 0.18, 1.20 ]
Subtotal (95% CI) 22269 22148 30.4 % 0.93 [ 0.74, 1.16 ]
Total events: 151 (High omega 3), 163 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 8.55, df = 9 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 0.66 (P = 0.51)
Total (95% CI) 36836 36655 100.0 % 0.93 [ 0.80, 1.09 ]
Total events: 773 (High omega 3), 821 (Control)
Heterogeneity: Tau2 = 0.03; Chi2 = 29.96, df = 19 (P = 0.05); I2 =37%
Test for overall effect: Z = 0.86 (P = 0.39)
Test for subgroup differences: Chi2 = 0.05, df = 1 (P = 0.82), I2 =0.0%
0.01 0.1 1 10 100
Favours high LCn3 Favours low LCn3
(1) Cardiac deaths
(2) Fatal MI
(3) Cardiac deaths
(4) Cardiac death
(5) Fatal MI
(6) Fatal MI
(7) Fatal MI
(8) Fatal MI
(9) Fatal MI
(10) Fatal MI
(11) Fatal MI
(12) Cardiac deaths
(13) Fatal MI
(14) Cardiac death
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Analysis 1.43. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 43 Coronary
heart disease events (overall) - LCn3.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)
Outcome: 43 Coronary heart disease events (overall) - LCn3
Study or subgroup
Favours
higher
omega 3 Lower omega 3 fats Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
AlphaOmega - EPA+DHA 2010 122/2404 132/2433 4.1 % 0.94 [ 0.74, 1.19 ]
AREDS2 2014 (1) 28/2147 30/2056 0.9 % 0.89 [ 0.54, 1.49 ]
Baldassarre 2006 (2) 1/32 0/32 0.0 % 3.00 [ 0.13, 71.00 ]
Brox 2001 (3) 0/80 1/40 0.0 % 0.17 [ 0.01, 4.05 ]
DART 1989 337/1015 366/1018 16.5 % 0.92 [ 0.82, 1.04 ]
Derosa 2016 0/128 4/130 0.0 % 0.11 [ 0.01, 2.07 ]
DO IT 2010 (4) 11/282 9/281 0.3 % 1.22 [ 0.51, 2.89 ]
Doi 2014 (5) 1/119 0/119 0.0 % 3.00 [ 0.12, 72.91 ]
EPE-A 2014 (6) 2/168 1/75 0.0 % 0.89 [ 0.08, 9.70 ]
EPOCH 2014 (7) 1/195 0/196 0.0 % 3.02 [ 0.12, 73.57 ]
FORWARD 2013 (8) 1/289 1/297 0.0 % 1.03 [ 0.06, 16.35 ]
FOSTAR 2016 (9) 10/101 10/101 0.3 % 1.00 [ 0.44, 2.30 ]
GISSI-HF 2008 (10) 107/3494 129/3481 3.7 % 0.83 [ 0.64, 1.06 ]
GISSI-P 1999 424/5666 485/5658 15.1 % 0.87 [ 0.77, 0.99 ]
HARP 1995 7/41 7/39 0.3 % 0.95 [ 0.37, 2.46 ]
JELIS 2007 262/9326 324/9319 9.2 % 0.81 [ 0.69, 0.95 ]
Nye 1990 (11) 5/36 11/37 0.3 % 0.47 [ 0.18, 1.21 ]
OFAMI 2001 (12) 42/150 36/150 1.6 % 1.17 [ 0.80, 1.71 ]
OMEGA 2009 547/1919 568/1885 24.2 % 0.95 [ 0.86, 1.04 ]
ORIGIN 2012 (13) 344/6281 316/6255 10.7 % 1.08 [ 0.93, 1.26 ]
Proudman 2015 (14) 1/87 0/53 0.0 % 1.84 [ 0.08, 44.38 ]
Raitt 2005 (15) 1/100 3/100 0.0 % 0.33 [ 0.04, 3.15 ]
Risk % Prevention 2013 310/6239 324/6266 10.3 % 0.96 [ 0.83, 1.12 ]
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Study or subgroup
Favours
higher
omega 3 Lower omega 3 fats Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
SCIMO 1999 (16) 1/112 4/111 0.0 % 0.25 [ 0.03, 2.18 ]
SHOT 1996 (17) 7/317 12/293 0.3 % 0.54 [ 0.22, 1.35 ]
SOFA 2006 (18) 1/273 3/273 0.0 % 0.33 [ 0.03, 3.18 ]
SU.FOL.OM3 2010 51/1253 53/1248 1.7 % 0.96 [ 0.66, 1.40 ]
THIS DIET 2008 10/51 6/50 0.3 % 1.63 [ 0.64, 4.16 ]
Total (95% CI) 42305 41996 100.0 % 0.93 [ 0.88, 0.97 ]
Total events: 2634 (Favours higher omega 3), 2835 (Lower omega 3 fats)
Heterogeneity: Tau2 = 0.0; Chi2 = 23.63, df = 27 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 3.02 (P = 0.0025)
Test for subgroup differences: Not applicable
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Favours higher omega 3 Favours lower omega 3
(1) Total MI
(2) Total MI
(3) Total MI
(4) Total MI
(5) Total MI
(6) Angina
(7) Total MI
(8) Total MI
(9) Acute coronary syndrome
(10) Total MI
(11) Angina
(12) Fatal or non fatal cardiac event
(13) Total MI
(14) Total MI
(15) Total MI
(16) Total MI
(17) Total MI
(18) Total MI
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Analysis 1.44. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 44 CHD events
- LCn3 - SA fixed-effect.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)
Outcome: 44 CHD events - LCn3 - SA fixed-effect
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
AlphaOmega - EPA+DHA 2010 122/2404 132/2433 4.5 % 0.94 [ 0.74, 1.19 ]
AREDS2 2014 (1) 28/2147 30/2056 1.1 % 0.89 [ 0.54, 1.49 ]
Baldassarre 2006 (2) 1/32 0/32 0.0 % 3.00 [ 0.13, 71.00 ]
Brox 2001 (3) 0/80 1/40 0.1 % 0.17 [ 0.01, 4.05 ]
DART 1989 337/1015 366/1018 12.6 % 0.92 [ 0.82, 1.04 ]
Derosa 2016 0/128 4/130 0.2 % 0.11 [ 0.01, 2.07 ]
DO IT 2010 (4) 11/282 9/281 0.3 % 1.22 [ 0.51, 2.89 ]
Doi 2014 (5) 1/119 0/119 0.0 % 3.00 [ 0.12, 72.91 ]
EPE-A 2014 (6) 2/168 1/75 0.0 % 0.89 [ 0.08, 9.70 ]
EPOCH 2014 (7) 1/195 0/196 0.0 % 3.02 [ 0.12, 73.57 ]
FORWARD 2013 (8) 1/289 1/297 0.0 % 1.03 [ 0.06, 16.35 ]
FOSTAR 2016 (9) 10/101 10/101 0.3 % 1.00 [ 0.44, 2.30 ]
GISSI-HF 2008 (10) 107/3494 129/3481 4.5 % 0.83 [ 0.64, 1.06 ]
GISSI-P 1999 424/5666 485/5658 16.7 % 0.87 [ 0.77, 0.99 ]
HARP 1995 7/41 7/39 0.2 % 0.95 [ 0.37, 2.46 ]
JELIS 2007 262/9326 324/9319 11.2 % 0.81 [ 0.69, 0.95 ]
Nye 1990 (11) 5/36 11/37 0.4 % 0.47 [ 0.18, 1.21 ]
OFAMI 2001 (12) 42/150 36/150 1.2 % 1.17 [ 0.80, 1.71 ]
OMEGA 2009 547/1919 568/1885 19.7 % 0.95 [ 0.86, 1.04 ]
ORIGIN 2012 (13) 344/6281 316/6255 10.9 % 1.08 [ 0.93, 1.26 ]
Proudman 2015 (14) 1/87 0/53 0.0 % 1.84 [ 0.08, 44.38 ]
Raitt 2005 (15) 1/100 3/100 0.1 % 0.33 [ 0.04, 3.15 ]
Risk % Prevention 2013 310/6239 324/6266 11.1 % 0.96 [ 0.83, 1.12 ]
SCIMO 1999 (16) 1/112 4/111 0.1 % 0.25 [ 0.03, 2.18 ]
SHOT 1996 (17) 7/317 12/293 0.4 % 0.54 [ 0.22, 1.35 ]
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Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
SOFA 2006 65/273 62/273 2.1 % 1.05 [ 0.77, 1.42 ]
SU.FOL.OM3 2010 51/1253 53/1248 1.8 % 0.96 [ 0.66, 1.40 ]
THIS DIET 2008 10/51 6/50 0.2 % 1.63 [ 0.64, 4.16 ]
Total (95% CI) 42305 41996 100.0 % 0.93 [ 0.88, 0.97 ]
Total events: 2698 (Higher omega 3), 2894 (Lower omega 3)
Heterogeneity: Chi2 = 23.44, df = 27 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 3.03 (P = 0.0025)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
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(1) Total MI
(2) Total MI
(3) Total MI
(4) Total MI
(5) Total MI
(6) Angina
(7) Total MI
(8) Total MI
(9) Acute coronary syndrome
(10) Total MI
(11) Angina
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Analysis 1.45. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 45 CHD events
- LCn3 - SA by summary risk of bias.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)
Outcome: 45 CHD events - LCn3 - SA by summary risk of bias
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Low risk of bias
AlphaOmega - EPA+DHA 2010 122/2404 132/2433 4.1 % 0.94 [ 0.74, 1.19 ]
AREDS2 2014 (1) 28/2147 30/2056 0.9 % 0.89 [ 0.54, 1.49 ]
Derosa 2016 0/128 4/130 0.0 % 0.11 [ 0.01, 2.07 ]
EPOCH 2014 (2) 1/195 0/196 0.0 % 3.02 [ 0.12, 73.57 ]
FORWARD 2013 (3) 1/289 1/297 0.0 % 1.03 [ 0.06, 16.35 ]
FOSTAR 2016 (4) 10/101 10/101 0.3 % 1.00 [ 0.44, 2.30 ]
OMEGA 2009 547/1919 568/1885 24.2 % 0.95 [ 0.86, 1.04 ]
ORIGIN 2012 (5) 344/6281 316/6255 10.7 % 1.08 [ 0.93, 1.26 ]
Proudman 2015 (6) 1/87 0/53 0.0 % 1.84 [ 0.08, 44.38 ]
SCIMO 1999 (7) 1/112 4/111 0.0 % 0.25 [ 0.03, 2.18 ]
SOFA 2006 (8) 1/273 3/273 0.0 % 0.33 [ 0.03, 3.18 ]
SU.FOL.OM3 2010 51/1253 53/1248 1.7 % 0.96 [ 0.66, 1.40 ]
Subtotal (95% CI) 15189 15038 42.1 % 0.97 [ 0.90, 1.05 ]
Total events: 1107 (Higher omega 3), 1121 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 7.69, df = 11 (P = 0.74); I2 =0.0%
Test for overall effect: Z = 0.67 (P = 0.51)
2 Moderate/high risk of bias
Baldassarre 2006 (9) 1/32 0/32 0.0 % 3.00 [ 0.13, 71.00 ]
Brox 2001 (10) 0/80 1/40 0.0 % 0.17 [ 0.01, 4.05 ]
DART 1989 337/1015 366/1018 16.5 % 0.92 [ 0.82, 1.04 ]
DO IT 2010 (11) 11/282 9/281 0.3 % 1.22 [ 0.51, 2.89 ]
Doi 2014 (12) 1/119 0/119 0.0 % 3.00 [ 0.12, 72.91 ]
EPE-A 2014 (13) 2/168 1/75 0.0 % 0.89 [ 0.08, 9.70 ]
GISSI-HF 2008 (14) 107/3494 129/3481 3.7 % 0.83 [ 0.64, 1.06 ]
GISSI-P 1999 424/5666 485/5658 15.1 % 0.87 [ 0.77, 0.99 ]
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(. . . Continued)
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
HARP 1995 7/41 7/39 0.3 % 0.95 [ 0.37, 2.46 ]
JELIS 2007 262/9326 324/9319 9.2 % 0.81 [ 0.69, 0.95 ]
Nye 1990 (15) 5/36 11/37 0.3 % 0.47 [ 0.18, 1.21 ]
OFAMI 2001 (16) 42/150 36/150 1.6 % 1.17 [ 0.80, 1.71 ]
Raitt 2005 (17) 1/100 3/100 0.0 % 0.33 [ 0.04, 3.15 ]
Risk % Prevention 2013 310/6239 324/6266 10.3 % 0.96 [ 0.83, 1.12 ]
SHOT 1996 (18) 7/317 12/293 0.3 % 0.54 [ 0.22, 1.35 ]
THIS DIET 2008 10/51 6/50 0.3 % 1.63 [ 0.64, 4.16 ]
Subtotal (95% CI) 27116 26958 57.9 % 0.89 [ 0.84, 0.95 ]
Total events: 1527 (Higher omega 3), 1714 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 13.04, df = 15 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 3.41 (P = 0.00066)
Total (95% CI) 42305 41996 100.0 % 0.93 [ 0.88, 0.97 ]
Total events: 2634 (Higher omega 3), 2835 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 23.63, df = 27 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 3.02 (P = 0.0025)
Test for subgroup differences: Chi2 = 2.91, df = 1 (P = 0.09), I2 =66%
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Analysis 1.46. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 46 CHD events
- LCn3 - SA by compliance and study size.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)
Outcome: 46 CHD events - LCn3 - SA by compliance and study size
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 SA - low risk of compliance bias
AlphaOmega - EPA+DHA 2010 122/2404 132/2433 13.1 % 0.94 [ 0.74, 1.19 ]
Baldassarre 2006 (1) 1/32 0/32 0.1 % 3.00 [ 0.13, 71.00 ]
Brox 2001 (2) 0/80 1/40 0.1 % 0.17 [ 0.01, 4.05 ]
DO IT 2010 (3) 11/282 9/281 1.0 % 1.22 [ 0.51, 2.89 ]
EPE-A 2014 (4) 2/168 1/75 0.1 % 0.89 [ 0.08, 9.70 ]
FOSTAR 2016 (5) 10/101 10/101 1.1 % 1.00 [ 0.44, 2.30 ]
HARP 1995 7/41 7/39 0.8 % 0.95 [ 0.37, 2.46 ]
OMEGA 2009 547/1919 568/1885 77.2 % 0.95 [ 0.86, 1.04 ]
Raitt 2005 (6) 1/100 3/100 0.1 % 0.33 [ 0.04, 3.15 ]
SCIMO 1999 (7) 1/112 4/111 0.2 % 0.25 [ 0.03, 2.18 ]
SHOT 1996 (8) 7/317 12/293 0.9 % 0.54 [ 0.22, 1.35 ]
SU.FOL.OM3 2010 51/1253 53/1248 5.3 % 0.96 [ 0.66, 1.40 ]
Subtotal (95% CI) 6809 6638 100.0 % 0.94 [ 0.86, 1.02 ]
Total events: 760 (Higher omega 3), 800 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 5.71, df = 11 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 1.41 (P = 0.16)
2 SA - 100+ randomised
AlphaOmega - EPA+DHA 2010 122/2404 132/2433 4.1 % 0.94 [ 0.74, 1.19 ]
AREDS2 2014 (9) 28/2147 30/2056 0.9 % 0.89 [ 0.54, 1.49 ]
Brox 2001 (10) 0/80 1/40 0.0 % 0.17 [ 0.01, 4.05 ]
DART 1989 337/1015 366/1018 16.6 % 0.92 [ 0.82, 1.04 ]
Derosa 2016 0/128 4/130 0.0 % 0.11 [ 0.01, 2.07 ]
DO IT 2010 (11) 11/282 9/281 0.3 % 1.22 [ 0.51, 2.89 ]
Doi 2014 (12) 1/119 0/119 0.0 % 3.00 [ 0.12, 72.91 ]
EPE-A 2014 (13) 2/168 1/75 0.0 % 0.89 [ 0.08, 9.70 ]
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(. . . Continued)
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
EPOCH 2014 (14) 1/195 0/196 0.0 % 3.02 [ 0.12, 73.57 ]
FORWARD 2013 (15) 1/289 1/297 0.0 % 1.03 [ 0.06, 16.35 ]
FOSTAR 2016 (16) 10/101 10/101 0.3 % 1.00 [ 0.44, 2.30 ]
GISSI-HF 2008 (17) 107/3494 129/3481 3.7 % 0.83 [ 0.64, 1.06 ]
GISSI-P 1999 424/5666 485/5658 15.2 % 0.87 [ 0.77, 0.99 ]
JELIS 2007 262/9326 324/9319 9.2 % 0.81 [ 0.69, 0.95 ]
OFAMI 2001 (18) 42/150 36/150 1.6 % 1.17 [ 0.80, 1.71 ]
OMEGA 2009 547/1919 568/1885 24.4 % 0.95 [ 0.86, 1.04 ]
ORIGIN 2012 (19) 344/6281 316/6255 10.7 % 1.08 [ 0.93, 1.26 ]
Proudman 2015 (20) 1/87 0/53 0.0 % 1.84 [ 0.08, 44.38 ]
Raitt 2005 (21) 1/100 3/100 0.0 % 0.33 [ 0.04, 3.15 ]
Risk % Prevention 2013 310/6239 324/6266 10.3 % 0.96 [ 0.83, 1.12 ]
SCIMO 1999 (22) 1/112 4/111 0.1 % 0.25 [ 0.03, 2.18 ]
SHOT 1996 (23) 7/317 12/293 0.3 % 0.54 [ 0.22, 1.35 ]
SOFA 2006 (24) 1/273 3/273 0.0 % 0.33 [ 0.03, 3.18 ]
SU.FOL.OM3 2010 51/1253 53/1248 1.7 % 0.96 [ 0.66, 1.40 ]
THIS DIET 2008 10/51 6/50 0.3 % 1.63 [ 0.64, 4.16 ]
Subtotal (95% CI) 42196 41888 100.0 % 0.93 [ 0.88, 0.98 ]
Total events: 2621 (Higher omega 3), 2817 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 21.10, df = 24 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 2.96 (P = 0.0031)
Test for subgroup differences: Chi2 = 0.05, df = 1 (P = 0.83), I2 =0.0%
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Analysis 1.47. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 47 CHD events
- LCn3 - subgroup by dose.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)
Outcome: 47 CHD events - LCn3 - subgroup by dose
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 LCn3≤ 150 mg/d
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 3), 0 (Lower omega 3)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 LCn3 > 150≤ 250 mg/d
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 3), 0 (Lower omega 3)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 LCn3 > 250≤ 400 mg/d
DART 1989 337/1015 366/1018 16.1 % 0.92 [ 0.82, 1.04 ]
Subtotal (95% CI) 1015 1018 16.1 % 0.92 [ 0.82, 1.04 ]
Total events: 337 (Higher omega 3), 366 (Lower omega 3)
Heterogeneity: not applicable
Test for overall effect: Z = 1.30 (P = 0.19)
4 LCn3 > 400≤ 2400 mg/d
AlphaOmega - EPA+DHA 2010 122/2404 132/2433 4.0 % 0.94 [ 0.74, 1.19 ]
AREDS2 2014 (1) 28/2147 30/2056 0.9 % 0.89 [ 0.54, 1.49 ]
Baldassarre 2006 (2) 1/32 0/32 0.0 % 3.00 [ 0.13, 71.00 ]
Derosa 2016 0/128 4/130 0.0 % 0.11 [ 0.01, 2.07 ]
DO IT 2010 (3) 11/282 9/281 0.3 % 1.22 [ 0.51, 2.89 ]
Doi 2014 (4) 1/119 0/119 0.0 % 3.00 [ 0.12, 72.91 ]
EPE-A 2014 (5) 1/82 0/75 0.0 % 2.75 [ 0.11, 66.42 ]
EPOCH 2014 (6) 1/195 0/196 0.0 % 3.02 [ 0.12, 73.57 ]
FORWARD 2013 (7) 1/289 1/297 0.0 % 1.03 [ 0.06, 16.35 ]
GISSI-HF 2008 (8) 107/3494 129/3481 3.6 % 0.83 [ 0.64, 1.06 ]
GISSI-P 1999 424/5666 485/5658 14.7 % 0.87 [ 0.77, 0.99 ]
JELIS 2007 262/9326 324/9319 9.0 % 0.81 [ 0.69, 0.95 ]
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(. . . Continued)
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Nye 1990 (9) 5/36 11/37 0.3 % 0.47 [ 0.18, 1.21 ]
OMEGA 2009 547/1919 568/1885 23.6 % 0.95 [ 0.86, 1.04 ]
ORIGIN 2012 (10) 344/6281 316/6255 10.4 % 1.08 [ 0.93, 1.26 ]
Raitt 2005 (11) 1/100 3/100 0.0 % 0.33 [ 0.04, 3.15 ]
Risk % Prevention 2013 310/6239 324/6266 10.0 % 0.96 [ 0.83, 1.12 ]
SCIMO 1999 (12) 1/112 4/111 0.0 % 0.25 [ 0.03, 2.18 ]
SOFA 2006 65/273 62/273 2.5 % 1.05 [ 0.77, 1.42 ]
SU.FOL.OM3 2010 51/1253 53/1248 1.6 % 0.96 [ 0.66, 1.40 ]
THIS DIET 2008 10/51 6/50 0.3 % 1.63 [ 0.64, 4.16 ]
Subtotal (95% CI) 40428 40302 81.4 % 0.93 [ 0.88, 0.98 ]
Total events: 2293 (Higher omega 3), 2461 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 19.85, df = 20 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 2.66 (P = 0.0079)
5 LCn3 > 2.4≤ 4.4 g/d
Brox 2001 (13) 0/80 1/40 0.0 % 0.17 [ 0.01, 4.05 ]
EPE-A 2014 (14) 1/86 1/75 0.0 % 0.87 [ 0.06, 13.70 ]
OFAMI 2001 (15) 42/150 36/150 1.6 % 1.17 [ 0.80, 1.71 ]
SHOT 1996 (16) 7/317 12/293 0.3 % 0.54 [ 0.22, 1.35 ]
Subtotal (95% CI) 633 558 1.9 % 0.90 [ 0.53, 1.53 ]
Total events: 50 (Higher omega 3), 50 (Lower omega 3)
Heterogeneity: Tau2 = 0.07; Chi2 = 3.63, df = 3 (P = 0.30); I2 =17%
Test for overall effect: Z = 0.38 (P = 0.70)
6 LCn3 > 4.4 g/d
FOSTAR 2016 (17) 10/101 10/101 0.3 % 1.00 [ 0.44, 2.30 ]
HARP 1995 7/41 7/39 0.3 % 0.95 [ 0.37, 2.46 ]
Proudman 2015 (18) 1/87 0/53 0.0 % 1.84 [ 0.08, 44.38 ]
Subtotal (95% CI) 229 193 0.6 % 1.00 [ 0.54, 1.85 ]
Total events: 18 (Higher omega 3), 17 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.15, df = 2 (P = 0.93); I2 =0.0%
Test for overall effect: Z = 0.01 (P = 1.0)
Total (95% CI) 42305 42071 100.0 % 0.93 [ 0.89, 0.98 ]
Total events: 2698 (Higher omega 3), 2894 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 23.88, df = 28 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 2.91 (P = 0.0036)
Test for subgroup differences: Chi2 = 0.08, df = 3 (P = 0.99), I2 =0.0%
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Analysis 1.48. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 48 CHD events
- LCn3 - subgroup by replacement.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)
Outcome: 48 CHD events - LCn3 - subgroup by replacement
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 N-3 replacing SFA
DART 1989 337/1015 366/1018 65.7 % 0.92 [ 0.82, 1.04 ]
Derosa 2016 0/128 4/130 13.5 % 0.11 [ 0.01, 2.07 ]
SCIMO 1999 (1) 1/112 4/111 20.8 % 0.25 [ 0.03, 2.18 ]
Subtotal (95% CI) 1255 1259 100.0 % 0.53 [ 0.16, 1.75 ]
Total events: 338 (Higher omega 3), 374 (Lower omega 3)
Heterogeneity: Tau2 = 0.57; Chi2 = 3.43, df = 2 (P = 0.18); I2 =42%
Test for overall effect: Z = 1.04 (P = 0.30)
2 N-3 replacing MUFA
AlphaOmega - EPA+DHA 2010 122/2404 132/2433 5.6 % 0.94 [ 0.74, 1.19 ]
Baldassarre 2006 (2) 1/32 0/32 0.0 % 3.00 [ 0.13, 71.00 ]
DART 1989 337/1015 366/1018 22.6 % 0.92 [ 0.82, 1.04 ]
EPOCH 2014 (3) 1/195 0/196 0.0 % 3.02 [ 0.12, 73.57 ]
FORWARD 2013 (4) 1/289 1/297 0.0 % 1.03 [ 0.06, 16.35 ]
GISSI-HF 2008 (5) 107/3494 129/3481 5.1 % 0.83 [ 0.64, 1.06 ]
HARP 1995 7/41 7/39 0.4 % 0.95 [ 0.37, 2.46 ]
Nye 1990 (6) 5/36 11/37 0.4 % 0.47 [ 0.18, 1.21 ]
OMEGA 2009 547/1919 568/1885 33.2 % 0.95 [ 0.86, 1.04 ]
ORIGIN 2012 (7) 344/6281 316/6255 14.6 % 1.08 [ 0.93, 1.26 ]
Raitt 2005 (8) 1/100 3/100 0.1 % 0.33 [ 0.04, 3.15 ]
Risk % Prevention 2013 310/6239 324/6266 14.1 % 0.96 [ 0.83, 1.12 ]
SCIMO 1999 (9) 1/112 4/111 0.1 % 0.25 [ 0.03, 2.18 ]
SOFA 2006 65/273 62/273 3.5 % 1.05 [ 0.77, 1.42 ]
THIS DIET 2008 10/51 6/50 0.4 % 1.63 [ 0.64, 4.16 ]
Subtotal (95% CI) 22481 22473 100.0 % 0.96 [ 0.90, 1.01 ]
Total events: 1859 (Higher omega 3), 1929 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 11.56, df = 14 (P = 0.64); I2 =0.0%
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(. . . Continued)
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Test for overall effect: Z = 1.52 (P = 0.13)
3 N-3 replacing n-6
DO IT 2010 (10) 11/282 9/281 7.0 % 1.22 [ 0.51, 2.89 ]
OFAMI 2001 (11) 42/150 36/150 35.8 % 1.17 [ 0.80, 1.71 ]
Proudman 2015 (12) 1/87 0/53 0.5 % 1.84 [ 0.08, 44.38 ]
SOFA 2006 65/273 62/273 56.6 % 1.05 [ 0.77, 1.42 ]
Subtotal (95% CI) 792 757 100.0 % 1.10 [ 0.88, 1.39 ]
Total events: 119 (Higher omega 3), 107 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.34, df = 3 (P = 0.95); I2 =0.0%
Test for overall effect: Z = 0.85 (P = 0.40)
4 N-3 replacing carbohydrates/sugars
Derosa 2016 0/128 4/130 100.0 % 0.11 [ 0.01, 2.07 ]
Subtotal (95% CI) 128 130 100.0 % 0.11 [ 0.01, 2.07 ]
Total events: 0 (Higher omega 3), 4 (Lower omega 3)
Heterogeneity: not applicable
Test for overall effect: Z = 1.47 (P = 0.14)
5 N-3 replacing nil/low n-3 placebo
AREDS2 2014 (13) 28/2147 30/2056 3.3 % 0.89 [ 0.54, 1.49 ]
Brox 2001 (14) 0/80 1/40 0.1 % 0.17 [ 0.01, 4.05 ]
Doi 2014 (15) 1/119 0/119 0.1 % 3.00 [ 0.12, 72.91 ]
FOSTAR 2016 (16) 10/101 10/101 1.2 % 1.00 [ 0.44, 2.30 ]
GISSI-P 1999 424/5666 485/5658 54.9 % 0.87 [ 0.77, 0.99 ]
JELIS 2007 262/9326 324/9319 33.4 % 0.81 [ 0.69, 0.95 ]
SHOT 1996 (17) 7/317 12/293 1.0 % 0.54 [ 0.22, 1.35 ]
SU.FOL.OM3 2010 51/1253 53/1248 6.1 % 0.96 [ 0.66, 1.40 ]
Subtotal (95% CI) 19009 18834 100.0 % 0.85 [ 0.78, 0.94 ]
Total events: 783 (Higher omega 3), 915 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.67, df = 7 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 3.36 (P = 0.00078)
6 Replacement unclear
EPE-A 2014 (18) 2/168 1/75 100.0 % 0.89 [ 0.08, 9.70 ]
Subtotal (95% CI) 168 75 100.0 % 0.89 [ 0.08, 9.70 ]
Total events: 2 (Higher omega 3), 1 (Lower omega 3)
Heterogeneity: not applicable
Test for overall effect: Z = 0.09 (P = 0.93)
Test for subgroup differences: Chi2 = 9.30, df = 5 (P = 0.10), I2 =46%
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Analysis 1.49. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 49 CHD events
- LCn3 - subgroup by intervention type.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)
Outcome: 49 CHD events - LCn3 - subgroup by intervention type
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Dietary advice
DART 1989 337/1015 366/1018 16.1 % 0.92 [ 0.82, 1.04 ]
THIS DIET 2008 10/51 6/50 0.3 % 1.63 [ 0.64, 4.16 ]
Subtotal (95% CI) 1066 1068 16.3 % 1.01 [ 0.67, 1.52 ]
Total events: 347 (Higher omega 3), 372 (Lower omega 3)
Heterogeneity: Tau2 = 0.05; Chi2 = 1.41, df = 1 (P = 0.23); I2 =29%
Test for overall effect: Z = 0.05 (P = 0.96)
2 Supplemental foods
AlphaOmega - EPA+DHA 2010 122/2404 132/2433 4.0 % 0.94 [ 0.74, 1.19 ]
FOSTAR 2016 (1) 10/101 10/101 0.3 % 1.00 [ 0.44, 2.30 ]
Subtotal (95% CI) 2505 2534 4.3 % 0.94 [ 0.75, 1.18 ]
Total events: 132 (Higher omega 3), 142 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.02, df = 1 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 0.52 (P = 0.60)
3 Supplements (capsule)
AREDS2 2014 (2) 28/2147 30/2056 0.9 % 0.89 [ 0.54, 1.49 ]
Baldassarre 2006 (3) 1/32 0/32 0.0 % 3.00 [ 0.13, 71.00 ]
Brox 2001 (4) 0/80 1/40 0.0 % 0.17 [ 0.01, 4.05 ]
Derosa 2016 0/128 4/130 0.0 % 0.11 [ 0.01, 2.07 ]
DO IT 2010 (5) 11/282 9/281 0.3 % 1.22 [ 0.51, 2.89 ]
Doi 2014 (6) 1/119 0/119 0.0 % 3.00 [ 0.12, 72.91 ]
EPE-A 2014 (7) 2/168 1/75 0.0 % 0.89 [ 0.08, 9.70 ]
EPOCH 2014 (8) 1/195 0/196 0.0 % 3.02 [ 0.12, 73.57 ]
FORWARD 2013 (9) 1/289 1/297 0.0 % 1.03 [ 0.06, 16.35 ]
GISSI-HF 2008 (10) 107/3494 129/3481 3.6 % 0.83 [ 0.64, 1.06 ]
GISSI-P 1999 424/5666 485/5658 14.7 % 0.87 [ 0.77, 0.99 ]
HARP 1995 7/41 7/39 0.3 % 0.95 [ 0.37, 2.46 ]
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(. . . Continued)
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
JELIS 2007 262/9326 324/9319 9.0 % 0.81 [ 0.69, 0.95 ]
Nye 1990 (11) 5/36 11/37 0.3 % 0.47 [ 0.18, 1.21 ]
OFAMI 2001 (12) 42/150 36/150 1.6 % 1.17 [ 0.80, 1.71 ]
OMEGA 2009 547/1919 568/1885 23.6 % 0.95 [ 0.86, 1.04 ]
ORIGIN 2012 (13) 344/6281 316/6255 10.4 % 1.08 [ 0.93, 1.26 ]
Proudman 2015 (14) 1/87 0/53 0.0 % 1.84 [ 0.08, 44.38 ]
Raitt 2005 (15) 1/100 3/100 0.0 % 0.33 [ 0.04, 3.15 ]
Risk % Prevention 2013 310/6239 324/6266 10.0 % 0.96 [ 0.83, 1.12 ]
SCIMO 1999 (16) 1/112 4/111 0.0 % 0.25 [ 0.03, 2.18 ]
SHOT 1996 (17) 7/317 12/293 0.3 % 0.54 [ 0.22, 1.35 ]
SOFA 2006 65/273 62/273 2.5 % 1.05 [ 0.77, 1.42 ]
SU.FOL.OM3 2010 51/1253 53/1248 1.6 % 0.96 [ 0.66, 1.40 ]
Subtotal (95% CI) 38734 38394 79.3 % 0.93 [ 0.88, 0.98 ]
Total events: 2219 (Higher omega 3), 2380 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 22.01, df = 23 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 2.63 (P = 0.0086)
4 Any combination
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 3), 0 (Lower omega 3)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 42305 41996 100.0 % 0.93 [ 0.89, 0.98 ]
Total events: 2698 (Higher omega 3), 2894 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 23.44, df = 27 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 2.92 (P = 0.0035)
Test for subgroup differences: Chi2 = 0.16, df = 2 (P = 0.92), I2 =0.0%
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Analysis 1.50. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 50 CHD events
- LCn3 - subgroup by duration.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)
Outcome: 50 CHD events - LCn3 - subgroup by duration
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Medium duration 1 to < 2 years in study
Brox 2001 (1) 0/80 1/40 0.0 % 0.17 [ 0.01, 4.05 ]
Derosa 2016 0/128 4/130 0.0 % 0.11 [ 0.01, 2.07 ]
Doi 2014 (2) 1/119 0/119 0.0 % 3.00 [ 0.12, 72.91 ]
EPE-A 2014 (3) 2/168 1/75 0.0 % 0.89 [ 0.08, 9.70 ]
EPOCH 2014 (4) 1/195 0/196 0.0 % 3.02 [ 0.12, 73.57 ]
FORWARD 2013 (5) 1/289 1/297 0.0 % 1.03 [ 0.06, 16.35 ]
Nye 1990 (6) 5/36 11/37 0.3 % 0.47 [ 0.18, 1.21 ]
OMEGA 2009 547/1919 568/1885 23.6 % 0.95 [ 0.86, 1.04 ]
Proudman 2015 (7) 1/87 0/53 0.0 % 1.84 [ 0.08, 44.38 ]
SHOT 1996 (8) 7/317 12/293 0.3 % 0.54 [ 0.22, 1.35 ]
SOFA 2006 65/273 62/273 2.5 % 1.05 [ 0.77, 1.42 ]
Subtotal (95% CI) 3611 3398 26.8 % 0.94 [ 0.86, 1.03 ]
Total events: 630 (Higher omega 3), 660 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 8.36, df = 10 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 1.26 (P = 0.21)
2 Medium-long duration: 2 to < 4 years in study
AlphaOmega - EPA+DHA 2010 122/2404 132/2433 4.0 % 0.94 [ 0.74, 1.19 ]
Baldassarre 2006 (9) 1/32 0/32 0.0 % 3.00 [ 0.13, 71.00 ]
DART 1989 337/1015 366/1018 16.1 % 0.92 [ 0.82, 1.04 ]
DO IT 2010 (10) 11/282 9/281 0.3 % 1.22 [ 0.51, 2.89 ]
FOSTAR 2016 (11) 10/101 10/101 0.3 % 1.00 [ 0.44, 2.30 ]
GISSI-HF 2008 (12) 107/3494 129/3481 3.6 % 0.83 [ 0.64, 1.06 ]
GISSI-P 1999 424/5666 485/5658 14.7 % 0.87 [ 0.77, 0.99 ]
HARP 1995 7/41 7/39 0.3 % 0.95 [ 0.37, 2.46 ]
OFAMI 2001 (13) 42/150 36/150 1.6 % 1.17 [ 0.80, 1.71 ]
0.1 0.2 0.5 1 2 5 10
Favours higher omega 3 Favours lower omega 3
(Continued . . . )
393Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(. . . Continued)
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Raitt 2005 (14) 1/100 3/100 0.0 % 0.33 [ 0.04, 3.15 ]
SCIMO 1999 (15) 1/112 4/111 0.0 % 0.25 [ 0.03, 2.18 ]
THIS DIET 2008 10/51 6/50 0.3 % 1.63 [ 0.64, 4.16 ]
Subtotal (95% CI) 13448 13454 41.3 % 0.91 [ 0.84, 0.98 ]
Total events: 1073 (Higher omega 3), 1187 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 7.42, df = 11 (P = 0.76); I2 =0.0%
Test for overall effect: Z = 2.49 (P = 0.013)
3 Long duration:≥ 4 years in study
AREDS2 2014 (16) 28/2147 30/2056 0.9 % 0.89 [ 0.54, 1.49 ]
JELIS 2007 262/9326 324/9319 9.0 % 0.81 [ 0.69, 0.95 ]
ORIGIN 2012 (17) 344/6281 316/6255 10.4 % 1.08 [ 0.93, 1.26 ]
Risk % Prevention 2013 310/6239 324/6266 10.0 % 0.96 [ 0.83, 1.12 ]
SU.FOL.OM3 2010 51/1253 53/1248 1.6 % 0.96 [ 0.66, 1.40 ]
Subtotal (95% CI) 25246 25144 31.9 % 0.95 [ 0.83, 1.07 ]
Total events: 995 (Higher omega 3), 1047 (Lower omega 3)
Heterogeneity: Tau2 = 0.01; Chi2 = 7.03, df = 4 (P = 0.13); I2 =43%
Test for overall effect: Z = 0.88 (P = 0.38)
Total (95% CI) 42305 41996 100.0 % 0.93 [ 0.89, 0.98 ]
Total events: 2698 (Higher omega 3), 2894 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 23.44, df = 27 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 2.92 (P = 0.0035)
Test for subgroup differences: Chi2 = 0.46, df = 2 (P = 0.79), I2 =0.0%
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Analysis 1.51. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 51 CHD events
- LCn3 - subgroup by primary or secondary prevention.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)
Outcome: 51 CHD events - LCn3 - subgroup by primary or secondary prevention
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Primary prevention of CVD
AREDS2 2014 (1) 28/2147 30/2056 0.9 % 0.89 [ 0.54, 1.49 ]
Baldassarre 2006 (2) 1/32 0/32 0.0 % 3.00 [ 0.13, 71.00 ]
Brox 2001 (3) 0/80 1/40 0.0 % 0.17 [ 0.01, 4.05 ]
Derosa 2016 0/128 4/130 0.0 % 0.11 [ 0.01, 2.07 ]
DO IT 2010 (4) 11/282 9/281 0.3 % 1.22 [ 0.51, 2.89 ]
EPE-A 2014 (5) 2/168 1/75 0.0 % 0.89 [ 0.08, 9.70 ]
EPOCH 2014 (6) 1/195 0/196 0.0 % 3.02 [ 0.12, 73.57 ]
FOSTAR 2016 (7) 10/101 10/101 0.3 % 1.00 [ 0.44, 2.30 ]
JELIS 2007 262/9326 324/9319 9.0 % 0.81 [ 0.69, 0.95 ]
ORIGIN 2012 (8) 344/6281 316/6255 10.4 % 1.08 [ 0.93, 1.26 ]
Proudman 2015 (9) 1/87 0/53 0.0 % 1.84 [ 0.08, 44.38 ]
Subtotal (95% CI) 18827 18538 21.1 % 0.94 [ 0.81, 1.10 ]
Total events: 660 (Higher omega 3), 695 (Lower omega 3)
Heterogeneity: Tau2 = 0.01; Chi2 = 11.71, df = 10 (P = 0.31); I2 =15%
Test for overall effect: Z = 0.75 (P = 0.45)
2 Secondary prevention of CVD
AlphaOmega - EPA+DHA 2010 122/2404 132/2433 4.0 % 0.94 [ 0.74, 1.19 ]
DART 1989 337/1015 366/1018 16.1 % 0.92 [ 0.82, 1.04 ]
Doi 2014 (10) 1/119 0/119 0.0 % 3.00 [ 0.12, 72.91 ]
FORWARD 2013 (11) 1/289 1/297 0.0 % 1.03 [ 0.06, 16.35 ]
GISSI-HF 2008 (12) 107/3494 129/3481 3.6 % 0.83 [ 0.64, 1.06 ]
GISSI-P 1999 424/5666 485/5658 14.7 % 0.87 [ 0.77, 0.99 ]
HARP 1995 7/41 7/39 0.3 % 0.95 [ 0.37, 2.46 ]
Nye 1990 (13) 5/36 11/37 0.3 % 0.47 [ 0.18, 1.21 ]
OFAMI 2001 (14) 42/150 36/150 1.6 % 1.17 [ 0.80, 1.71 ]
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(. . . Continued)
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
OMEGA 2009 547/1919 568/1885 23.6 % 0.95 [ 0.86, 1.04 ]
Raitt 2005 (15) 1/100 3/100 0.0 % 0.33 [ 0.04, 3.15 ]
Risk % Prevention 2013 310/6239 324/6266 10.0 % 0.96 [ 0.83, 1.12 ]
SCIMO 1999 (16) 1/112 4/111 0.0 % 0.25 [ 0.03, 2.18 ]
SHOT 1996 (17) 7/317 12/293 0.3 % 0.54 [ 0.22, 1.35 ]
SOFA 2006 65/273 62/273 2.5 % 1.05 [ 0.77, 1.42 ]
SU.FOL.OM3 2010 51/1253 53/1248 1.6 % 0.96 [ 0.66, 1.40 ]
THIS DIET 2008 10/51 6/50 0.3 % 1.63 [ 0.64, 4.16 ]
Subtotal (95% CI) 23478 23458 78.9 % 0.93 [ 0.88, 0.98 ]
Total events: 2038 (Higher omega 3), 2199 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 11.61, df = 16 (P = 0.77); I2 =0.0%
Test for overall effect: Z = 2.76 (P = 0.0058)
Total (95% CI) 42305 41996 100.0 % 0.93 [ 0.89, 0.98 ]
Total events: 2698 (Higher omega 3), 2894 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 23.44, df = 27 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 2.92 (P = 0.0035)
Test for subgroup differences: Chi2 = 0.04, df = 1 (P = 0.84), I2 =0.0%
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Analysis 1.52. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 52 CHD events
- LCn3 - subgroup by statin use.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)
Outcome: 52 CHD events - LCn3 - subgroup by statin use
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 LCn3 -≥ 50% of control group on statins
AlphaOmega - EPA+DHA 2010 122/2404 132/2433 4.0 % 0.94 [ 0.74, 1.19 ]
Doi 2014 (1) 1/119 0/119 0.0 % 3.00 [ 0.12, 72.91 ]
JELIS 2007 262/9326 324/9319 9.0 % 0.81 [ 0.69, 0.95 ]
Nye 1990 (2) 5/36 11/37 0.3 % 0.47 [ 0.18, 1.21 ]
OMEGA 2009 547/1919 568/1885 23.6 % 0.95 [ 0.86, 1.04 ]
ORIGIN 2012 (3) 344/6281 316/6255 10.4 % 1.08 [ 0.93, 1.26 ]
SU.FOL.OM3 2010 51/1253 53/1248 1.6 % 0.96 [ 0.66, 1.40 ]
THIS DIET 2008 10/51 6/50 0.3 % 1.63 [ 0.64, 4.16 ]
Subtotal (95% CI) 21389 21346 49.2 % 0.94 [ 0.85, 1.05 ]
Total events: 1342 (Higher omega 3), 1410 (Lower omega 3)
Heterogeneity: Tau2 = 0.01; Chi2 = 10.88, df = 7 (P = 0.14); I2 =36%
Test for overall effect: Z = 1.08 (P = 0.28)
2 LCn3 - < 50% of control group on statins
AREDS2 2014 (4) 28/2147 30/2056 0.9 % 0.89 [ 0.54, 1.49 ]
Baldassarre 2006 (5) 1/32 0/32 0.0 % 3.00 [ 0.13, 71.00 ]
Brox 2001 (6) 0/80 1/40 0.0 % 0.17 [ 0.01, 4.05 ]
DART 1989 337/1015 366/1018 16.1 % 0.92 [ 0.82, 1.04 ]
DO IT 2010 (7) 11/282 9/281 0.3 % 1.22 [ 0.51, 2.89 ]
FORWARD 2013 (8) 1/289 1/297 0.0 % 1.03 [ 0.06, 16.35 ]
FOSTAR 2016 (9) 10/101 10/101 0.3 % 1.00 [ 0.44, 2.30 ]
GISSI-HF 2008 (10) 107/3494 129/3481 3.6 % 0.83 [ 0.64, 1.06 ]
GISSI-P 1999 424/5666 485/5658 14.7 % 0.87 [ 0.77, 0.99 ]
HARP 1995 7/41 7/39 0.3 % 0.95 [ 0.37, 2.46 ]
OFAMI 2001 (11) 42/150 36/150 1.6 % 1.17 [ 0.80, 1.71 ]
Proudman 2015 (12) 1/87 0/53 0.0 % 1.84 [ 0.08, 44.38 ]
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(. . . Continued)
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Raitt 2005 (13) 1/100 3/100 0.0 % 0.33 [ 0.04, 3.15 ]
Risk % Prevention 2013 310/6239 324/6266 10.0 % 0.96 [ 0.83, 1.12 ]
SCIMO 1999 (14) 1/112 4/111 0.0 % 0.25 [ 0.03, 2.18 ]
SHOT 1996 (15) 7/317 12/293 0.3 % 0.54 [ 0.22, 1.35 ]
SOFA 2006 65/273 62/273 2.5 % 1.05 [ 0.77, 1.42 ]
Subtotal (95% CI) 20425 20249 50.7 % 0.92 [ 0.86, 0.98 ]
Total events: 1353 (Higher omega 3), 1479 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 9.65, df = 16 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 2.50 (P = 0.013)
3 LCn3 - use of statins unclear
Derosa 2016 0/128 4/130 0.0 % 0.11 [ 0.01, 2.07 ]
EPE-A 2014 (16) 2/168 1/75 0.0 % 0.89 [ 0.08, 9.70 ]
EPOCH 2014 (17) 1/195 0/196 0.0 % 3.02 [ 0.12, 73.57 ]
Subtotal (95% CI) 491 401 0.1 % 0.65 [ 0.11, 3.83 ]
Total events: 3 (Higher omega 3), 5 (Lower omega 3)
Heterogeneity: Tau2 = 0.44; Chi2 = 2.43, df = 2 (P = 0.30); I2 =18%
Test for overall effect: Z = 0.48 (P = 0.63)
Total (95% CI) 42305 41996 100.0 % 0.93 [ 0.89, 0.98 ]
Total events: 2698 (Higher omega 3), 2894 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 23.44, df = 27 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 2.92 (P = 0.0035)
Test for subgroup differences: Chi2 = 0.32, df = 2 (P = 0.85), I2 =0.0%
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Analysis 1.53. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 53 CHD events
- LCn3 subgroup by CAD history.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)
Outcome: 53 CHD events - LCn3 subgroup by CAD history
Study or subgroup High omega 3 Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Previous CAD
AlphaOmega - EPA+DHA 2010 122/2404 132/2433 4.1 % 0.94 [ 0.74, 1.19 ]
DART 1989 337/1015 366/1018 16.5 % 0.92 [ 0.82, 1.04 ]
Doi 2014 (1) 1/119 0/119 0.0 % 3.00 [ 0.12, 72.91 ]
GISSI-P 1999 424/5666 485/5658 15.1 % 0.87 [ 0.77, 0.99 ]
HARP 1995 7/41 7/39 0.3 % 0.95 [ 0.37, 2.46 ]
Nye 1990 (2) 5/36 11/37 0.3 % 0.47 [ 0.18, 1.21 ]
OFAMI 2001 (3) 42/150 36/150 1.6 % 1.17 [ 0.80, 1.71 ]
OMEGA 2009 547/1919 568/1885 24.2 % 0.95 [ 0.86, 1.04 ]
SCIMO 1999 (4) 1/112 4/111 0.0 % 0.25 [ 0.03, 2.18 ]
SHOT 1996 (5) 7/317 12/293 0.3 % 0.54 [ 0.22, 1.35 ]
SU.FOL.OM3 2010 51/1253 53/1248 1.7 % 0.96 [ 0.66, 1.40 ]
THIS DIET 2008 10/51 6/50 0.3 % 1.63 [ 0.64, 4.16 ]
Subtotal (95% CI) 13083 13041 64.3 % 0.92 [ 0.87, 0.98 ]
Total events: 1554 (High omega 3), 1680 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 9.15, df = 11 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 2.57 (P = 0.010)
2 No previous CAD
AREDS2 2014 (6) 28/2147 30/2056 0.9 % 0.89 [ 0.54, 1.49 ]
Baldassarre 2006 (7) 1/32 0/32 0.0 % 3.00 [ 0.13, 71.00 ]
Brox 2001 (8) 0/80 1/40 0.0 % 0.17 [ 0.01, 4.05 ]
Derosa 2016 0/128 4/130 0.0 % 0.11 [ 0.01, 2.07 ]
DO IT 2010 (9) 11/282 9/281 0.3 % 1.22 [ 0.51, 2.89 ]
EPE-A 2014 (10) 2/168 1/75 0.0 % 0.89 [ 0.08, 9.70 ]
EPOCH 2014 (11) 1/195 0/196 0.0 % 3.02 [ 0.12, 73.57 ]
FORWARD 2013 (12) 1/289 1/297 0.0 % 1.03 [ 0.06, 16.35 ]
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(. . . Continued)
Study or subgroup High omega 3 Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
FOSTAR 2016 (13) 10/101 10/101 0.3 % 1.00 [ 0.44, 2.30 ]
GISSI-HF 2008 (14) 107/3494 129/3481 3.7 % 0.83 [ 0.64, 1.06 ]
JELIS 2007 262/9326 324/9319 9.2 % 0.81 [ 0.69, 0.95 ]
ORIGIN 2012 (15) 344/6281 316/6255 10.7 % 1.08 [ 0.93, 1.26 ]
Proudman 2015 (16) 1/87 0/53 0.0 % 1.84 [ 0.08, 44.38 ]
Raitt 2005 (17) 1/100 3/100 0.0 % 0.33 [ 0.04, 3.15 ]
Risk % Prevention 2013 310/6239 324/6266 10.3 % 0.96 [ 0.83, 1.12 ]
SOFA 2006 (18) 1/273 3/273 0.0 % 0.33 [ 0.03, 3.18 ]
Subtotal (95% CI) 29222 28955 35.7 % 0.94 [ 0.86, 1.01 ]
Total events: 1080 (High omega 3), 1155 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 14.43, df = 15 (P = 0.49); I2 =0.0%
Test for overall effect: Z = 1.62 (P = 0.11)
Total (95% CI) 42305 41996 100.0 % 0.93 [ 0.88, 0.97 ]
Total events: 2634 (High omega 3), 2835 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 23.63, df = 27 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 3.02 (P = 0.0025)
Test for subgroup differences: Chi2 = 0.06, df = 1 (P = 0.81), I2 =0.0%
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Analysis 1.54. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 54 Stroke
(overall) - LCn3.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)
Outcome: 54 Stroke (overall) - LCn3
Study or subgroup
Favours
higher
omega 3 Lower omega 3 fats Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
AFFORD 2013 1/153 0/163 0.1 % 3.19 [ 0.13, 77.83 ]
AlphaOmega - EPA+DHA 2010 11/2404 10/2433 1.1 % 1.11 [ 0.47, 2.62 ]
AREDS2 2014 48/2147 41/2056 4.9 % 1.12 [ 0.74, 1.69 ]
DART 1989 4/1015 9/1018 0.6 % 0.45 [ 0.14, 1.44 ]
DART2 2003 16/1571 14/1543 1.6 % 1.12 [ 0.55, 2.29 ]
Derosa 2016 0/128 1/130 0.1 % 0.34 [ 0.01, 8.23 ]
DO IT 2010 0/282 2/281 0.1 % 0.20 [ 0.01, 4.13 ]
Doi 2014 0/119 4/119 0.1 % 0.11 [ 0.01, 2.04 ]
EPOCH 2014 2/195 0/196 0.1 % 5.03 [ 0.24, 104.01 ]
FORWARD 2013 3/289 3/297 0.3 % 1.03 [ 0.21, 5.05 ]
GISSI-HF 2008 122/3494 103/3481 12.4 % 1.18 [ 0.91, 1.53 ]
GISSI-P 1999 92/5665 77/5658 9.2 % 1.19 [ 0.88, 1.61 ]
HARP 1995 1/41 0/39 0.1 % 2.86 [ 0.12, 68.10 ]
JELIS 2007 166/9326 162/9319 18.0 % 1.02 [ 0.83, 1.27 ]
MAPT 2017 1/820 4/832 0.2 % 0.25 [ 0.03, 2.26 ]
NAT2 2013 0/150 1/150 0.1 % 0.33 [ 0.01, 8.12 ]
Nodari 2011 HF 0/67 1/66 0.1 % 0.33 [ 0.01, 7.92 ]
OFAMI 2001 6/150 0/150 0.1 % 13.00 [ 0.74, 228.73 ]
OMEGA 2009 27/1919 13/1885 1.9 % 2.04 [ 1.06, 3.94 ]
OPAL 2010 7/376 8/372 0.8 % 0.87 [ 0.32, 2.36 ]
ORIGIN 2012 314/6281 336/6255 36.8 % 0.93 [ 0.80, 1.08 ]
ORL 2013 2/171 0/165 0.1 % 4.83 [ 0.23, 99.76 ]
Risk % Prevention 2013 80/6239 60/6266 7.5 % 1.34 [ 0.96, 1.87 ]
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(. . . Continued)
Study or subgroup
Favours
higher
omega 3 Lower omega 3 fats Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
SCIMO 1999 1/112 0/111 0.1 % 2.97 [ 0.12, 72.21 ]
SHOT 1996 3/317 4/293 0.4 % 0.69 [ 0.16, 3.07 ]
SU.FOL.OM3 2010 29/1253 28/1248 3.1 % 1.03 [ 0.62, 1.72 ]
THIS DIET 2008 3/51 1/50 0.2 % 2.94 [ 0.32, 27.33 ]
O¨zaydin 2011 1/23 0/24 0.1 % 3.13 [ 0.13, 73.01 ]
Total (95% CI) 44758 44600 100.0 % 1.06 [ 0.96, 1.16 ]
Total events: 940 (Favours higher omega 3), 882 (Lower omega 3 fats)
Heterogeneity: Tau2 = 0.0; Chi2 = 26.66, df = 27 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 1.17 (P = 0.24)
Test for subgroup differences: Not applicable
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Analysis 1.55. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 55 Stroke -
LCn3 - SA fixed-effect.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)
Outcome: 55 Stroke - LCn3 - SA fixed-effect
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
AFFORD 2013 1/153 0/163 0.1 % 3.19 [ 0.13, 77.83 ]
AlphaOmega - EPA+DHA 2010 11/2404 10/2433 1.1 % 1.11 [ 0.47, 2.62 ]
AREDS2 2014 48/2147 41/2056 4.7 % 1.12 [ 0.74, 1.69 ]
DART 1989 4/1015 9/1018 1.0 % 0.45 [ 0.14, 1.44 ]
DART2 2003 16/1571 14/1543 1.6 % 1.12 [ 0.55, 2.29 ]
Derosa 2016 0/128 1/130 0.2 % 0.34 [ 0.01, 8.23 ]
DO IT 2010 0/282 2/281 0.3 % 0.20 [ 0.01, 4.13 ]
Doi 2014 0/119 4/119 0.5 % 0.11 [ 0.01, 2.04 ]
EPOCH 2014 2/195 0/196 0.1 % 5.03 [ 0.24, 104.01 ]
FORWARD 2013 3/289 3/297 0.3 % 1.03 [ 0.21, 5.05 ]
GISSI-HF 2008 122/3494 103/3481 11.6 % 1.18 [ 0.91, 1.53 ]
GISSI-P 1999 92/5665 77/5658 8.7 % 1.19 [ 0.88, 1.61 ]
HARP 1995 1/41 0/39 0.1 % 2.86 [ 0.12, 68.10 ]
JELIS 2007 166/9326 162/9319 18.2 % 1.02 [ 0.83, 1.27 ]
MAPT 2017 1/820 4/832 0.4 % 0.25 [ 0.03, 2.26 ]
NAT2 2013 0/150 1/150 0.2 % 0.33 [ 0.01, 8.12 ]
Nodari 2011 HF 0/67 1/66 0.2 % 0.33 [ 0.01, 7.92 ]
OFAMI 2001 6/150 0/150 0.1 % 13.00 [ 0.74, 228.73 ]
OMEGA 2009 27/1919 13/1885 1.5 % 2.04 [ 1.06, 3.94 ]
OPAL 2010 7/376 8/372 0.9 % 0.87 [ 0.32, 2.36 ]
ORIGIN 2012 314/6281 336/6255 37.8 % 0.93 [ 0.80, 1.08 ]
ORL 2013 2/171 0/165 0.1 % 4.83 [ 0.23, 99.76 ]
Risk % Prevention 2013 80/6239 60/6266 6.7 % 1.34 [ 0.96, 1.87 ]
SCIMO 1999 1/112 0/111 0.1 % 2.97 [ 0.12, 72.21 ]
SHOT 1996 3/317 4/293 0.5 % 0.69 [ 0.16, 3.07 ]
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Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
SU.FOL.OM3 2010 29/1253 28/1248 3.2 % 1.03 [ 0.62, 1.72 ]
THIS DIET 2008 3/51 1/50 0.1 % 2.94 [ 0.32, 27.33 ]
O¨zaydin 2011 1/23 0/24 0.1 % 3.13 [ 0.13, 73.01 ]
Total (95% CI) 44758 44600 100.0 % 1.06 [ 0.97, 1.16 ]
Total events: 940 (Higher omega 3), 882 (Lower omega 3)
Heterogeneity: Chi2 = 26.66, df = 27 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 1.27 (P = 0.20)
Test for subgroup differences: Not applicable
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Analysis 1.56. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 56 Stroke -
LCn3 - SA by summary risk of bias.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)
Outcome: 56 Stroke - LCn3 - SA by summary risk of bias
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Low risk of bias
AlphaOmega - EPA+DHA 2010 11/2404 10/2433 1.1 % 1.11 [ 0.47, 2.62 ]
AREDS2 2014 48/2147 41/2056 4.9 % 1.12 [ 0.74, 1.69 ]
Derosa 2016 0/128 1/130 0.1 % 0.34 [ 0.01, 8.23 ]
EPOCH 2014 2/195 0/196 0.1 % 5.03 [ 0.24, 104.01 ]
FORWARD 2013 3/289 3/297 0.3 % 1.03 [ 0.21, 5.05 ]
MAPT 2017 1/820 4/832 0.2 % 0.25 [ 0.03, 2.26 ]
NAT2 2013 0/150 1/150 0.1 % 0.33 [ 0.01, 8.12 ]
OMEGA 2009 27/1919 13/1885 1.9 % 2.04 [ 1.06, 3.94 ]
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(. . . Continued)
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
OPAL 2010 7/376 8/372 0.8 % 0.87 [ 0.32, 2.36 ]
ORIGIN 2012 314/6281 336/6255 36.8 % 0.93 [ 0.80, 1.08 ]
SCIMO 1999 1/112 0/111 0.1 % 2.97 [ 0.12, 72.21 ]
SU.FOL.OM3 2010 29/1253 28/1248 3.1 % 1.03 [ 0.62, 1.72 ]
Subtotal (95% CI) 16074 15965 49.5 % 0.98 [ 0.86, 1.12 ]
Total events: 443 (Higher omega 3), 445 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 9.72, df = 11 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 0.25 (P = 0.81)
2 Moderate/high risk of bias
AFFORD 2013 1/153 0/163 0.1 % 3.19 [ 0.13, 77.83 ]
DART 1989 4/1015 9/1018 0.6 % 0.45 [ 0.14, 1.44 ]
DART2 2003 16/1571 14/1543 1.6 % 1.12 [ 0.55, 2.29 ]
DO IT 2010 0/282 2/281 0.1 % 0.20 [ 0.01, 4.13 ]
Doi 2014 0/119 4/119 0.1 % 0.11 [ 0.01, 2.04 ]
GISSI-HF 2008 122/3494 103/3481 12.4 % 1.18 [ 0.91, 1.53 ]
GISSI-P 1999 92/5665 77/5658 9.2 % 1.19 [ 0.88, 1.61 ]
HARP 1995 1/41 0/39 0.1 % 2.86 [ 0.12, 68.10 ]
JELIS 2007 166/9326 162/9319 18.0 % 1.02 [ 0.83, 1.27 ]
Nodari 2011 HF 0/67 1/66 0.1 % 0.33 [ 0.01, 7.92 ]
OFAMI 2001 6/150 0/150 0.1 % 13.00 [ 0.74, 228.73 ]
ORL 2013 2/171 0/165 0.1 % 4.83 [ 0.23, 99.76 ]
Risk % Prevention 2013 80/6239 60/6266 7.5 % 1.34 [ 0.96, 1.87 ]
SHOT 1996 3/317 4/293 0.4 % 0.69 [ 0.16, 3.07 ]
THIS DIET 2008 3/51 1/50 0.2 % 2.94 [ 0.32, 27.33 ]
O¨zaydin 2011 1/23 0/24 0.1 % 3.13 [ 0.13, 73.01 ]
Subtotal (95% CI) 28684 28635 50.5 % 1.13 [ 1.00, 1.29 ]
Total events: 497 (Higher omega 3), 437 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 14.66, df = 15 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 1.90 (P = 0.058)
Total (95% CI) 44758 44600 100.0 % 1.06 [ 0.96, 1.16 ]
Total events: 940 (Higher omega 3), 882 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 26.66, df = 27 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 1.17 (P = 0.24)
Test for subgroup differences: Chi2 = 2.28, df = 1 (P = 0.13), I2 =56%
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Analysis 1.57. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 57 Stroke -
LCn3 - SA by compliance and study size.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)
Outcome: 57 Stroke - LCn3 - SA by compliance and study size
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 SA - low risk of compliance bias
AFFORD 2013 1/153 0/163 1.0 % 3.19 [ 0.13, 77.83 ]
AlphaOmega - EPA+DHA 2010 11/2404 10/2433 14.2 % 1.11 [ 0.47, 2.62 ]
DO IT 2010 0/282 2/281 1.1 % 0.20 [ 0.01, 4.13 ]
HARP 1995 1/41 0/39 1.0 % 2.86 [ 0.12, 68.10 ]
NAT2 2013 0/150 1/150 1.0 % 0.33 [ 0.01, 8.12 ]
Nodari 2011 HF 0/67 1/66 1.0 % 0.33 [ 0.01, 7.92 ]
OMEGA 2009 27/1919 13/1885 24.0 % 2.04 [ 1.06, 3.94 ]
OPAL 2010 7/376 8/372 10.3 % 0.87 [ 0.32, 2.36 ]
ORL 2013 2/171 0/165 1.1 % 4.83 [ 0.23, 99.76 ]
SCIMO 1999 1/112 0/111 1.0 % 2.97 [ 0.12, 72.21 ]
SHOT 1996 3/317 4/293 4.7 % 0.69 [ 0.16, 3.07 ]
SU.FOL.OM3 2010 29/1253 28/1248 39.4 % 1.03 [ 0.62, 1.72 ]
Subtotal (95% CI) 7245 7206 100.0 % 1.19 [ 0.86, 1.65 ]
Total events: 82 (Higher omega 3), 67 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 8.16, df = 11 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 1.08 (P = 0.28)
2 SA - 100+ randomised
AFFORD 2013 1/153 0/163 0.1 % 3.19 [ 0.13, 77.83 ]
AlphaOmega - EPA+DHA 2010 11/2404 10/2433 1.3 % 1.11 [ 0.47, 2.62 ]
AREDS2 2014 48/2147 41/2056 5.5 % 1.12 [ 0.74, 1.69 ]
DART 1989 4/1015 9/1018 0.7 % 0.45 [ 0.14, 1.44 ]
DART2 2003 16/1571 14/1543 1.9 % 1.12 [ 0.55, 2.29 ]
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(. . . Continued)
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Derosa 2016 0/128 1/130 0.1 % 0.34 [ 0.01, 8.23 ]
DO IT 2010 0/282 2/281 0.1 % 0.20 [ 0.01, 4.13 ]
Doi 2014 0/119 4/119 0.1 % 0.11 [ 0.01, 2.04 ]
EPOCH 2014 2/195 0/196 0.1 % 5.03 [ 0.24, 104.01 ]
FORWARD 2013 3/289 3/297 0.4 % 1.03 [ 0.21, 5.05 ]
GISSI-HF 2008 122/3494 103/3481 13.2 % 1.18 [ 0.91, 1.53 ]
GISSI-P 1999 92/5665 77/5658 10.0 % 1.19 [ 0.88, 1.61 ]
JELIS 2007 166/9326 162/9319 18.1 % 1.02 [ 0.83, 1.27 ]
MAPT 2017 1/820 4/832 0.2 % 0.25 [ 0.03, 2.26 ]
NAT2 2013 0/150 1/150 0.1 % 0.33 [ 0.01, 8.12 ]
Nodari 2011 HF 0/67 1/66 0.1 % 0.33 [ 0.01, 7.92 ]
OFAMI 2001 6/150 0/150 0.1 % 13.00 [ 0.74, 228.73 ]
OMEGA 2009 27/1919 13/1885 2.2 % 2.04 [ 1.06, 3.94 ]
OPAL 2010 7/376 8/372 1.0 % 0.87 [ 0.32, 2.36 ]
ORIGIN 2012 314/6281 336/6255 31.9 % 0.93 [ 0.80, 1.08 ]
ORL 2013 2/171 0/165 0.1 % 4.83 [ 0.23, 99.76 ]
Risk % Prevention 2013 80/6239 60/6266 8.3 % 1.34 [ 0.96, 1.87 ]
SCIMO 1999 1/112 0/111 0.1 % 2.97 [ 0.12, 72.21 ]
SHOT 1996 3/317 4/293 0.4 % 0.69 [ 0.16, 3.07 ]
SU.FOL.OM3 2010 29/1253 28/1248 3.6 % 1.03 [ 0.62, 1.72 ]
THIS DIET 2008 3/51 1/50 0.2 % 2.94 [ 0.32, 27.33 ]
Subtotal (95% CI) 44694 44537 100.0 % 1.07 [ 0.97, 1.18 ]
Total events: 938 (Higher omega 3), 882 (Lower omega 3)
Heterogeneity: Tau2 = 0.00; Chi2 = 25.83, df = 25 (P = 0.42); I2 =3%
Test for overall effect: Z = 1.26 (P = 0.21)
Test for subgroup differences: Chi2 = 0.43, df = 1 (P = 0.51), I2 =0.0%
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Analysis 1.58. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 58 Stroke -
LCn3 - subgroup by stroke type.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)
Outcome: 58 Stroke - LCn3 - subgroup by stroke type
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Ischaemic stroke - LCn3
AREDS2 2014 40/2147 31/2056 15.5 % 1.24 [ 0.78, 1.97 ]
DART 1989 2/1015 6/1018 1.6 % 0.33 [ 0.07, 1.65 ]
GISSI-HF 2008 97/3494 79/3481 31.2 % 1.22 [ 0.91, 1.64 ]
JELIS 2007 115/9326 123/9319 37.7 % 0.93 [ 0.73, 1.20 ]
OFAMI 2001 6/150 0/150 0.5 % 13.00 [ 0.74, 228.73 ]
ORL 2013 1/171 0/165 0.4 % 2.90 [ 0.12, 70.57 ]
SU.FOL.OM3 2010 29/1253 26/1248 12.7 % 1.11 [ 0.66, 1.88 ]
O¨zaydin 2011 1/23 0/24 0.4 % 3.13 [ 0.13, 73.01 ]
Subtotal (95% CI) 17579 17461 100.0 % 1.09 [ 0.89, 1.33 ]
Total events: 291 (Higher omega 3), 265 (Lower omega 3)
Heterogeneity: Tau2 = 0.01; Chi2 = 8.07, df = 7 (P = 0.33); I2 =13%
Test for overall effect: Z = 0.86 (P = 0.39)
2 Haemorrhagic stroke - LCn3
AREDS2 2014 3/2147 1/2056 2.3 % 2.87 [ 0.30, 27.60 ]
DART 1989 2/1015 3/1018 3.8 % 0.67 [ 0.11, 3.99 ]
GISSI-HF 2008 13/3494 10/3481 17.7 % 1.30 [ 0.57, 2.95 ]
JELIS 2007 49/9326 39/9319 68.0 % 1.26 [ 0.83, 1.91 ]
MAPT 2017 1/820 2/832 2.1 % 0.51 [ 0.05, 5.58 ]
NAT2 2013 0/150 1/150 1.2 % 0.33 [ 0.01, 8.12 ]
ORL 2013 1/171 0/165 1.2 % 2.90 [ 0.12, 70.57 ]
SU.FOL.OM3 2010 2/1253 3/1248 3.7 % 0.66 [ 0.11, 3.97 ]
Subtotal (95% CI) 18376 18269 100.0 % 1.20 [ 0.85, 1.69 ]
Total events: 71 (Higher omega 3), 59 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.89, df = 7 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 1.02 (P = 0.31)
3 Transient ischaemic attack (TIA)
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(. . . Continued)
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
AFFORD 2013 0/153 2/163 4.3 % 0.21 [ 0.01, 4.40 ]
AREDS2 2014 15/2147 17/2056 82.8 % 0.84 [ 0.42, 1.69 ]
EPE-A 2014 2/168 0/75 4.3 % 2.25 [ 0.11, 46.27 ]
SCIMO 1999 0/112 3/111 4.5 % 0.14 [ 0.01, 2.71 ]
O¨zaydin 2011 0/23 1/24 4.0 % 0.35 [ 0.01, 8.11 ]
Subtotal (95% CI) 2603 2429 100.0 % 0.74 [ 0.39, 1.39 ]
Total events: 17 (Higher omega 3), 23 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.77, df = 4 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 0.94 (P = 0.35)
Test for subgroup differences: Chi2 = 1.74, df = 2 (P = 0.42), I2 =0.0%
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Analysis 1.59. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 59 Stroke -
LCn3 - subgroup by dose.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)
Outcome: 59 Stroke - LCn3 - subgroup by dose
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 LCn3≤ 150 mg/d
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 3), 0 (Lower omega 3)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 LCn3 > 150≤ 250 mg/d
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 3), 0 (Lower omega 3)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 LCn3 > 250≤ 400 mg/d
DART 1989 4/1015 9/1018 100.0 % 0.45 [ 0.14, 1.44 ]
Subtotal (95% CI) 1015 1018 100.0 % 0.45 [ 0.14, 1.44 ]
Total events: 4 (Higher omega 3), 9 (Lower omega 3)
Heterogeneity: not applicable
Test for overall effect: Z = 1.35 (P = 0.18)
4 LCn3 > 400≤ 2400 mg/d
AFFORD 2013 1/153 0/163 0.1 % 3.19 [ 0.13, 77.83 ]
AlphaOmega - EPA+DHA 2010 11/2404 10/2433 1.1 % 1.11 [ 0.47, 2.62 ]
AREDS2 2014 48/2147 41/2056 4.9 % 1.12 [ 0.74, 1.69 ]
DART2 2003 16/1571 14/1543 1.6 % 1.12 [ 0.55, 2.29 ]
Derosa 2016 0/128 1/130 0.1 % 0.34 [ 0.01, 8.23 ]
DO IT 2010 0/282 2/281 0.1 % 0.20 [ 0.01, 4.13 ]
Doi 2014 0/119 4/119 0.1 % 0.11 [ 0.01, 2.04 ]
EPOCH 2014 2/195 0/196 0.1 % 5.03 [ 0.24, 104.01 ]
FORWARD 2013 3/289 3/297 0.3 % 1.03 [ 0.21, 5.05 ]
GISSI-HF 2008 122/3494 103/3481 12.6 % 1.18 [ 0.91, 1.53 ]
GISSI-P 1999 92/5665 77/5658 9.3 % 1.19 [ 0.88, 1.61 ]
JELIS 2007 166/9326 162/9319 18.2 % 1.02 [ 0.83, 1.27 ]
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(. . . Continued)
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
MAPT 2017 1/820 4/832 0.2 % 0.25 [ 0.03, 2.26 ]
NAT2 2013 0/150 1/150 0.1 % 0.33 [ 0.01, 8.12 ]
Nodari 2011 HF 0/67 1/66 0.1 % 0.33 [ 0.01, 7.92 ]
OMEGA 2009 27/1919 13/1885 1.9 % 2.04 [ 1.06, 3.94 ]
OPAL 2010 7/376 8/372 0.8 % 0.87 [ 0.32, 2.36 ]
ORIGIN 2012 314/6281 336/6255 37.3 % 0.93 [ 0.80, 1.08 ]
ORL 2013 2/171 0/165 0.1 % 4.83 [ 0.23, 99.76 ]
Risk % Prevention 2013 80/6239 60/6266 7.5 % 1.34 [ 0.96, 1.87 ]
SCIMO 1999 1/112 0/111 0.1 % 2.97 [ 0.12, 72.21 ]
SU.FOL.OM3 2010 29/1253 28/1248 3.2 % 1.03 [ 0.62, 1.72 ]
THIS DIET 2008 3/51 1/50 0.2 % 2.94 [ 0.32, 27.33 ]
O¨zaydin 2011 1/23 0/24 0.1 % 3.13 [ 0.13, 73.01 ]
Subtotal (95% CI) 43235 43100 100.0 % 1.06 [ 0.97, 1.16 ]
Total events: 926 (Higher omega 3), 869 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 20.95, df = 23 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 1.24 (P = 0.21)
5 LCn3 > 2.4≤ 4.4 g/d
SHOT 1996 3/317 4/293 100.0 % 0.69 [ 0.16, 3.07 ]
Subtotal (95% CI) 317 293 100.0 % 0.69 [ 0.16, 3.07 ]
Total events: 3 (Higher omega 3), 4 (Lower omega 3)
Heterogeneity: not applicable
Test for overall effect: Z = 0.48 (P = 0.63)
6 LCn3 > 4.4 g/d
HARP 1995 1/41 0/39 45.0 % 2.86 [ 0.12, 68.10 ]
OFAMI 2001 6/150 0/150 55.0 % 13.00 [ 0.74, 228.73 ]
Subtotal (95% CI) 191 189 100.0 % 6.58 [ 0.78, 55.16 ]
Total events: 7 (Higher omega 3), 0 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.51, df = 1 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 1.74 (P = 0.083)
Test for subgroup differences: Chi2 = 5.22, df = 3 (P = 0.16), I2 =43%
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Analysis 1.60. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 60 Stroke -
LCn3 - subgroup by replacement.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)
Outcome: 60 Stroke - LCn3 - subgroup by replacement
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 N-3 replacing SFA
DART 1989 4/1015 9/1018 78.7 % 0.45 [ 0.14, 1.44 ]
Derosa 2016 0/128 1/130 10.7 % 0.34 [ 0.01, 8.23 ]
SCIMO 1999 1/112 0/111 10.7 % 2.97 [ 0.12, 72.21 ]
Subtotal (95% CI) 1255 1259 100.0 % 0.53 [ 0.19, 1.50 ]
Total events: 5 (Higher omega 3), 10 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.29, df = 2 (P = 0.53); I2 =0.0%
Test for overall effect: Z = 1.19 (P = 0.23)
2 N-3 replacing MUFA
AlphaOmega - EPA+DHA 2010 11/2404 10/2433 3.6 % 1.11 [ 0.47, 2.62 ]
DART 1989 4/1015 9/1018 2.0 % 0.45 [ 0.14, 1.44 ]
EPOCH 2014 2/195 0/196 0.3 % 5.03 [ 0.24, 104.01 ]
FORWARD 2013 3/289 3/297 1.1 % 1.03 [ 0.21, 5.05 ]
GISSI-HF 2008 122/3494 103/3481 24.7 % 1.18 [ 0.91, 1.53 ]
HARP 1995 1/41 0/39 0.3 % 2.86 [ 0.12, 68.10 ]
NAT2 2013 0/150 1/150 0.3 % 0.33 [ 0.01, 8.12 ]
Nodari 2011 HF 0/67 1/66 0.3 % 0.33 [ 0.01, 7.92 ]
OMEGA 2009 27/1919 13/1885 5.8 % 2.04 [ 1.06, 3.94 ]
OPAL 2010 7/376 8/372 2.7 % 0.87 [ 0.32, 2.36 ]
ORIGIN 2012 314/6281 336/6255 40.4 % 0.93 [ 0.80, 1.08 ]
Risk % Prevention 2013 80/6239 60/6266 17.8 % 1.34 [ 0.96, 1.87 ]
SCIMO 1999 1/112 0/111 0.3 % 2.97 [ 0.12, 72.21 ]
THIS DIET 2008 3/51 1/50 0.6 % 2.94 [ 0.32, 27.33 ]
Subtotal (95% CI) 22633 22619 100.0 % 1.11 [ 0.94, 1.31 ]
Total events: 575 (Higher omega 3), 545 (Lower omega 3)
Heterogeneity: Tau2 = 0.01; Chi2 = 15.09, df = 13 (P = 0.30); I2 =14%
Test for overall effect: Z = 1.18 (P = 0.24)
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(. . . Continued)
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
3 N-3 replacing n-6
AFFORD 2013 1/153 0/163 31.5 % 3.19 [ 0.13, 77.83 ]
DO IT 2010 0/282 2/281 33.3 % 0.20 [ 0.01, 4.13 ]
OFAMI 2001 6/150 0/150 35.2 % 13.00 [ 0.74, 228.73 ]
Subtotal (95% CI) 585 594 100.0 % 2.08 [ 0.18, 24.31 ]
Total events: 7 (Higher omega 3), 2 (Lower omega 3)
Heterogeneity: Tau2 = 2.34; Chi2 = 3.96, df = 2 (P = 0.14); I2 =49%
Test for overall effect: Z = 0.58 (P = 0.56)
4 N-3 replacing carbohydrates/sugars
Derosa 2016 0/128 1/130 100.0 % 0.34 [ 0.01, 8.23 ]
Subtotal (95% CI) 128 130 100.0 % 0.34 [ 0.01, 8.23 ]
Total events: 0 (Higher omega 3), 1 (Lower omega 3)
Heterogeneity: not applicable
Test for overall effect: Z = 0.67 (P = 0.51)
5 N-3 replacing nil/low n-3 placebo
AREDS2 2014 48/2147 41/2056 13.5 % 1.12 [ 0.74, 1.69 ]
Doi 2014 0/119 4/119 0.3 % 0.11 [ 0.01, 2.04 ]
GISSI-P 1999 92/5665 77/5658 25.5 % 1.19 [ 0.88, 1.61 ]
JELIS 2007 166/9326 162/9319 50.0 % 1.02 [ 0.83, 1.27 ]
MAPT 2017 1/820 4/832 0.5 % 0.25 [ 0.03, 2.26 ]
ORL 2013 2/171 0/165 0.3 % 4.83 [ 0.23, 99.76 ]
SHOT 1996 3/317 4/293 1.0 % 0.69 [ 0.16, 3.07 ]
SU.FOL.OM3 2010 29/1253 28/1248 8.7 % 1.03 [ 0.62, 1.72 ]
O¨zaydin 2011 1/23 0/24 0.2 % 3.13 [ 0.13, 73.01 ]
Subtotal (95% CI) 19841 19714 100.0 % 1.07 [ 0.92, 1.24 ]
Total events: 342 (Higher omega 3), 320 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 6.45, df = 8 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 0.84 (P = 0.40)
6 Replacement unclear
DART2 2003 16/1571 14/1543 100.0 % 1.12 [ 0.55, 2.29 ]
Subtotal (95% CI) 1571 1543 100.0 % 1.12 [ 0.55, 2.29 ]
Total events: 16 (Higher omega 3), 14 (Lower omega 3)
Heterogeneity: not applicable
Test for overall effect: Z = 0.32 (P = 0.75)
Test for subgroup differences: Chi2 = 2.68, df = 5 (P = 0.75), I2 =0.0%
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Analysis 1.61. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 61 Stroke -
LCn3 - subgroup by intervention type.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)
Outcome: 61 Stroke - LCn3 - subgroup by intervention type
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Dietary advice
DART 1989 4/1015 9/1018 0.6 % 0.45 [ 0.14, 1.44 ]
DART2 2003 16/1571 14/1543 1.6 % 1.12 [ 0.55, 2.29 ]
THIS DIET 2008 3/51 1/50 0.2 % 2.94 [ 0.32, 27.33 ]
Subtotal (95% CI) 2637 2611 2.4 % 0.93 [ 0.42, 2.05 ]
Total events: 23 (Higher omega 3), 24 (Lower omega 3)
Heterogeneity: Tau2 = 0.15; Chi2 = 2.79, df = 2 (P = 0.25); I2 =28%
Test for overall effect: Z = 0.17 (P = 0.86)
2 Supplemental foods
AlphaOmega - EPA+DHA 2010 11/2404 10/2433 1.1 % 1.11 [ 0.47, 2.62 ]
Subtotal (95% CI) 2404 2433 1.1 % 1.11 [ 0.47, 2.62 ]
Total events: 11 (Higher omega 3), 10 (Lower omega 3)
Heterogeneity: not applicable
Test for overall effect: Z = 0.25 (P = 0.81)
3 Supplements (capsule)
AFFORD 2013 1/153 0/163 0.1 % 3.19 [ 0.13, 77.83 ]
AREDS2 2014 48/2147 41/2056 4.9 % 1.12 [ 0.74, 1.69 ]
Derosa 2016 0/128 1/130 0.1 % 0.34 [ 0.01, 8.23 ]
DO IT 2010 0/282 2/281 0.1 % 0.20 [ 0.01, 4.13 ]
Doi 2014 0/119 4/119 0.1 % 0.11 [ 0.01, 2.04 ]
EPOCH 2014 2/195 0/196 0.1 % 5.03 [ 0.24, 104.01 ]
FORWARD 2013 3/289 3/297 0.3 % 1.03 [ 0.21, 5.05 ]
GISSI-HF 2008 122/3494 103/3481 12.4 % 1.18 [ 0.91, 1.53 ]
GISSI-P 1999 92/5665 77/5658 9.2 % 1.19 [ 0.88, 1.61 ]
HARP 1995 1/41 0/39 0.1 % 2.86 [ 0.12, 68.10 ]
JELIS 2007 166/9326 162/9319 18.0 % 1.02 [ 0.83, 1.27 ]
MAPT 2017 1/820 4/832 0.2 % 0.25 [ 0.03, 2.26 ]
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Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
NAT2 2013 0/150 1/150 0.1 % 0.33 [ 0.01, 8.12 ]
Nodari 2011 HF 0/67 1/66 0.1 % 0.33 [ 0.01, 7.92 ]
OFAMI 2001 6/150 0/150 0.1 % 13.00 [ 0.74, 228.73 ]
OMEGA 2009 27/1919 13/1885 1.9 % 2.04 [ 1.06, 3.94 ]
OPAL 2010 7/376 8/372 0.8 % 0.87 [ 0.32, 2.36 ]
ORIGIN 2012 314/6281 336/6255 36.8 % 0.93 [ 0.80, 1.08 ]
ORL 2013 2/171 0/165 0.1 % 4.83 [ 0.23, 99.76 ]
Risk % Prevention 2013 80/6239 60/6266 7.5 % 1.34 [ 0.96, 1.87 ]
SCIMO 1999 1/112 0/111 0.1 % 2.97 [ 0.12, 72.21 ]
SHOT 1996 3/317 4/293 0.4 % 0.69 [ 0.16, 3.07 ]
SU.FOL.OM3 2010 29/1253 28/1248 3.1 % 1.03 [ 0.62, 1.72 ]
O¨zaydin 2011 1/23 0/24 0.1 % 3.13 [ 0.13, 73.01 ]
Subtotal (95% CI) 39717 39556 96.5 % 1.07 [ 0.97, 1.18 ]
Total events: 906 (Higher omega 3), 848 (Lower omega 3)
Heterogeneity: Tau2 = 0.00; Chi2 = 23.74, df = 23 (P = 0.42); I2 =3%
Test for overall effect: Z = 1.32 (P = 0.19)
4 Any combination
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 3), 0 (Lower omega 3)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 44758 44600 100.0 % 1.06 [ 0.96, 1.16 ]
Total events: 940 (Higher omega 3), 882 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 26.66, df = 27 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 1.17 (P = 0.24)
Test for subgroup differences: Chi2 = 0.12, df = 2 (P = 0.94), I2 =0.0%
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Analysis 1.62. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 62 Stroke -
LCn3 - subgroup by duration.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)
Outcome: 62 Stroke - LCn3 - subgroup by duration
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Medium duration 1 to < 2 years in study
AFFORD 2013 1/153 0/163 0.1 % 3.19 [ 0.13, 77.83 ]
Derosa 2016 0/128 1/130 0.1 % 0.34 [ 0.01, 8.23 ]
Doi 2014 0/119 4/119 0.1 % 0.11 [ 0.01, 2.04 ]
EPOCH 2014 2/195 0/196 0.1 % 5.03 [ 0.24, 104.01 ]
FORWARD 2013 3/289 3/297 0.3 % 1.03 [ 0.21, 5.05 ]
Nodari 2011 HF 0/67 1/66 0.1 % 0.33 [ 0.01, 7.92 ]
OMEGA 2009 27/1919 13/1885 1.9 % 2.04 [ 1.06, 3.94 ]
OPAL 2010 7/376 8/372 0.8 % 0.87 [ 0.32, 2.36 ]
ORL 2013 2/171 0/165 0.1 % 4.83 [ 0.23, 99.76 ]
SHOT 1996 3/317 4/293 0.4 % 0.69 [ 0.16, 3.07 ]
O¨zaydin 2011 1/23 0/24 0.1 % 3.13 [ 0.13, 73.01 ]
Subtotal (95% CI) 3757 3710 4.0 % 1.35 [ 0.86, 2.12 ]
Total events: 46 (Higher omega 3), 34 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 9.43, df = 10 (P = 0.49); I2 =0.0%
Test for overall effect: Z = 1.28 (P = 0.20)
2 Medium-long duration: 2 to < 4 years in study
AlphaOmega - EPA+DHA 2010 11/2404 10/2433 1.1 % 1.11 [ 0.47, 2.62 ]
DART 1989 4/1015 9/1018 0.6 % 0.45 [ 0.14, 1.44 ]
DO IT 2010 0/282 2/281 0.1 % 0.20 [ 0.01, 4.13 ]
GISSI-HF 2008 122/3494 103/3481 12.4 % 1.18 [ 0.91, 1.53 ]
GISSI-P 1999 92/5665 77/5658 9.2 % 1.19 [ 0.88, 1.61 ]
HARP 1995 1/41 0/39 0.1 % 2.86 [ 0.12, 68.10 ]
MAPT 2017 1/820 4/832 0.2 % 0.25 [ 0.03, 2.26 ]
NAT2 2013 0/150 1/150 0.1 % 0.33 [ 0.01, 8.12 ]
OFAMI 2001 6/150 0/150 0.1 % 13.00 [ 0.74, 228.73 ]
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(. . . Continued)
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
SCIMO 1999 1/112 0/111 0.1 % 2.97 [ 0.12, 72.21 ]
THIS DIET 2008 3/51 1/50 0.2 % 2.94 [ 0.32, 27.33 ]
Subtotal (95% CI) 14184 14203 24.1 % 1.15 [ 0.93, 1.41 ]
Total events: 241 (Higher omega 3), 207 (Lower omega 3)
Heterogeneity: Tau2 = 0.01; Chi2 = 10.38, df = 10 (P = 0.41); I2 =4%
Test for overall effect: Z = 1.29 (P = 0.20)
3 Long duration:≥ 4 years in study
AREDS2 2014 48/2147 41/2056 4.9 % 1.12 [ 0.74, 1.69 ]
DART2 2003 16/1571 14/1543 1.6 % 1.12 [ 0.55, 2.29 ]
JELIS 2007 166/9326 162/9319 18.0 % 1.02 [ 0.83, 1.27 ]
ORIGIN 2012 314/6281 336/6255 36.8 % 0.93 [ 0.80, 1.08 ]
Risk % Prevention 2013 80/6239 60/6266 7.5 % 1.34 [ 0.96, 1.87 ]
SU.FOL.OM3 2010 29/1253 28/1248 3.1 % 1.03 [ 0.62, 1.72 ]
Subtotal (95% CI) 26817 26687 71.9 % 1.01 [ 0.91, 1.13 ]
Total events: 653 (Higher omega 3), 641 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 4.26, df = 5 (P = 0.51); I2 =0.0%
Test for overall effect: Z = 0.20 (P = 0.84)
Total (95% CI) 44758 44600 100.0 % 1.06 [ 0.96, 1.16 ]
Total events: 940 (Higher omega 3), 882 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 26.66, df = 27 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 1.17 (P = 0.24)
Test for subgroup differences: Chi2 = 2.32, df = 2 (P = 0.31), I2 =14%
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Analysis 1.63. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 63 Stroke -
LCn3 - subgroup by primary or secondary prevention.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)
Outcome: 63 Stroke - LCn3 - subgroup by primary or secondary prevention
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Primary prevention of CVD
AREDS2 2014 48/2147 41/2056 4.9 % 1.12 [ 0.74, 1.69 ]
Derosa 2016 0/128 1/130 0.1 % 0.34 [ 0.01, 8.23 ]
DO IT 2010 0/282 2/281 0.1 % 0.20 [ 0.01, 4.13 ]
EPOCH 2014 2/195 0/196 0.1 % 5.03 [ 0.24, 104.01 ]
JELIS 2007 166/9326 162/9319 18.0 % 1.02 [ 0.83, 1.27 ]
MAPT 2017 1/820 4/832 0.2 % 0.25 [ 0.03, 2.26 ]
OPAL 2010 7/376 8/372 0.8 % 0.87 [ 0.32, 2.36 ]
ORIGIN 2012 314/6281 336/6255 36.8 % 0.93 [ 0.80, 1.08 ]
ORL 2013 2/171 0/165 0.1 % 4.83 [ 0.23, 99.76 ]
Subtotal (95% CI) 19726 19606 61.0 % 0.97 [ 0.86, 1.09 ]
Total events: 540 (Higher omega 3), 554 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 6.18, df = 8 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 0.54 (P = 0.59)
2 Secondary prevention of CVD
AFFORD 2013 1/153 0/163 0.1 % 3.19 [ 0.13, 77.83 ]
AlphaOmega - EPA+DHA 2010 11/2404 10/2433 1.1 % 1.11 [ 0.47, 2.62 ]
DART 1989 4/1015 9/1018 0.6 % 0.45 [ 0.14, 1.44 ]
DART2 2003 16/1571 14/1543 1.6 % 1.12 [ 0.55, 2.29 ]
Doi 2014 0/119 4/119 0.1 % 0.11 [ 0.01, 2.04 ]
FORWARD 2013 3/289 3/297 0.3 % 1.03 [ 0.21, 5.05 ]
GISSI-HF 2008 122/3494 103/3481 12.4 % 1.18 [ 0.91, 1.53 ]
GISSI-P 1999 92/5665 77/5658 9.2 % 1.19 [ 0.88, 1.61 ]
HARP 1995 1/41 0/39 0.1 % 2.86 [ 0.12, 68.10 ]
NAT2 2013 0/150 1/150 0.1 % 0.33 [ 0.01, 8.12 ]
Nodari 2011 HF 0/67 1/66 0.1 % 0.33 [ 0.01, 7.92 ]
0.1 0.2 0.5 1 2 5 10
Favours higher omega 3 Favours lower omega 3
(Continued . . . )
422Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(. . . Continued)
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
OFAMI 2001 6/150 0/150 0.1 % 13.00 [ 0.74, 228.73 ]
OMEGA 2009 27/1919 13/1885 1.9 % 2.04 [ 1.06, 3.94 ]
Risk % Prevention 2013 80/6239 60/6266 7.5 % 1.34 [ 0.96, 1.87 ]
SCIMO 1999 1/112 0/111 0.1 % 2.97 [ 0.12, 72.21 ]
SHOT 1996 3/317 4/293 0.4 % 0.69 [ 0.16, 3.07 ]
SU.FOL.OM3 2010 29/1253 28/1248 3.1 % 1.03 [ 0.62, 1.72 ]
THIS DIET 2008 3/51 1/50 0.2 % 2.94 [ 0.32, 27.33 ]
O¨zaydin 2011 1/23 0/24 0.1 % 3.13 [ 0.13, 73.01 ]
Subtotal (95% CI) 25032 24994 39.0 % 1.21 [ 1.05, 1.40 ]
Total events: 400 (Higher omega 3), 328 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 15.02, df = 18 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 2.56 (P = 0.010)
Total (95% CI) 44758 44600 100.0 % 1.06 [ 0.96, 1.16 ]
Total events: 940 (Higher omega 3), 882 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 26.66, df = 27 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 1.17 (P = 0.24)
Test for subgroup differences: Chi2 = 5.47, df = 1 (P = 0.02), I2 =82%
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Analysis 1.64. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 64 Stroke -
LCn3 - subgroup by statin use.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)
Outcome: 64 Stroke - LCn3 - subgroup by statin use
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 LCn3 -≥ 50% of control group on statins
AlphaOmega - EPA+DHA 2010 11/2404 10/2433 1.1 % 1.11 [ 0.47, 2.62 ]
Doi 2014 0/119 4/119 0.1 % 0.11 [ 0.01, 2.04 ]
JELIS 2007 166/9326 162/9319 18.0 % 1.02 [ 0.83, 1.27 ]
NAT2 2013 0/150 1/150 0.1 % 0.33 [ 0.01, 8.12 ]
OMEGA 2009 27/1919 13/1885 1.9 % 2.04 [ 1.06, 3.94 ]
ORIGIN 2012 314/6281 336/6255 36.8 % 0.93 [ 0.80, 1.08 ]
SU.FOL.OM3 2010 29/1253 28/1248 3.1 % 1.03 [ 0.62, 1.72 ]
THIS DIET 2008 3/51 1/50 0.2 % 2.94 [ 0.32, 27.33 ]
Subtotal (95% CI) 21503 21459 61.3 % 1.03 [ 0.86, 1.23 ]
Total events: 550 (Higher omega 3), 555 (Lower omega 3)
Heterogeneity: Tau2 = 0.01; Chi2 = 9.01, df = 7 (P = 0.25); I2 =22%
Test for overall effect: Z = 0.28 (P = 0.78)
2 LCn3 - < 50% of control group on statins
AFFORD 2013 1/153 0/163 0.1 % 3.19 [ 0.13, 77.83 ]
AREDS2 2014 48/2147 41/2056 4.9 % 1.12 [ 0.74, 1.69 ]
DART 1989 4/1015 9/1018 0.6 % 0.45 [ 0.14, 1.44 ]
DART2 2003 16/1571 14/1543 1.6 % 1.12 [ 0.55, 2.29 ]
DO IT 2010 0/282 2/281 0.1 % 0.20 [ 0.01, 4.13 ]
FORWARD 2013 3/289 3/297 0.3 % 1.03 [ 0.21, 5.05 ]
GISSI-HF 2008 122/3494 103/3481 12.4 % 1.18 [ 0.91, 1.53 ]
GISSI-P 1999 92/5665 77/5658 9.2 % 1.19 [ 0.88, 1.61 ]
HARP 1995 1/41 0/39 0.1 % 2.86 [ 0.12, 68.10 ]
MAPT 2017 1/820 4/832 0.2 % 0.25 [ 0.03, 2.26 ]
Nodari 2011 HF 0/67 1/66 0.1 % 0.33 [ 0.01, 7.92 ]
OFAMI 2001 6/150 0/150 0.1 % 13.00 [ 0.74, 228.73 ]
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(. . . Continued)
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
ORL 2013 2/171 0/165 0.1 % 4.83 [ 0.23, 99.76 ]
Risk % Prevention 2013 80/6239 60/6266 7.5 % 1.34 [ 0.96, 1.87 ]
SCIMO 1999 1/112 0/111 0.1 % 2.97 [ 0.12, 72.21 ]
SHOT 1996 3/317 4/293 0.4 % 0.69 [ 0.16, 3.07 ]
O¨zaydin 2011 1/23 0/24 0.1 % 3.13 [ 0.13, 73.01 ]
Subtotal (95% CI) 22556 22443 37.7 % 1.18 [ 1.02, 1.37 ]
Total events: 381 (Higher omega 3), 318 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 12.52, df = 16 (P = 0.71); I2 =0.0%
Test for overall effect: Z = 2.20 (P = 0.028)
3 LCn3 - use of statins unclear
Derosa 2016 0/128 1/130 0.1 % 0.34 [ 0.01, 8.23 ]
EPOCH 2014 2/195 0/196 0.1 % 5.03 [ 0.24, 104.01 ]
OPAL 2010 7/376 8/372 0.8 % 0.87 [ 0.32, 2.36 ]
Subtotal (95% CI) 699 698 1.0 % 0.94 [ 0.38, 2.34 ]
Total events: 9 (Higher omega 3), 9 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.61, df = 2 (P = 0.45); I2 =0.0%
Test for overall effect: Z = 0.13 (P = 0.90)
Total (95% CI) 44758 44600 100.0 % 1.06 [ 0.96, 1.16 ]
Total events: 940 (Higher omega 3), 882 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 26.66, df = 27 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 1.17 (P = 0.24)
Test for subgroup differences: Chi2 = 1.55, df = 2 (P = 0.46), I2 =0.0%
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Analysis 1.65. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 65 Arrythmia
(overall) - LCn3.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)
Outcome: 65 Arrythmia (overall) - LCn3
Study or subgroup
Favours
higher
omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
AFFORD 2013 98/153 103/163 7.5 % 1.01 [ 0.86, 1.20 ]
AlphaOmega - EPA+DHA 2010 67/2404 74/2433 3.8 % 0.92 [ 0.66, 1.27 ]
Derosa 2016 1/128 3/130 0.1 % 0.34 [ 0.04, 3.21 ]
DISAF 2003 154/201 157/206 9.4 % 1.01 [ 0.90, 1.12 ]
EPIC-1 2008 1/188 0/186 0.1 % 2.97 [ 0.12, 72.40 ]
EPOCH 2014 2/195 1/196 0.1 % 2.01 [ 0.18, 21.99 ]
Erdogan 2007 41/54 46/54 6.9 % 0.89 [ 0.74, 1.07 ]
FAAT 2005 60/200 79/202 4.8 % 0.77 [ 0.58, 1.01 ]
FORWARD 2013 68/289 56/297 4.0 % 1.25 [ 0.91, 1.71 ]
FOSTAR 2016 4/101 4/101 0.3 % 1.00 [ 0.26, 3.89 ]
GISSI-HF 2008 76/278 98/284 5.3 % 0.79 [ 0.62, 1.02 ]
GISSI-HF 2008 444/2921 408/2914 8.9 % 1.09 [ 0.96, 1.23 ]
GISSI-P 1999 40/2836 46/2828 2.6 % 0.87 [ 0.57, 1.32 ]
Kumar 2012 61/91 78/87 7.7 % 0.75 [ 0.64, 0.88 ]
Nodari 2011 AF 37/100 56/99 4.1 % 0.65 [ 0.48, 0.89 ]
Nodari 2011 HF 1/67 4/66 0.1 % 0.25 [ 0.03, 2.15 ]
OFAMI 2001 8/150 15/150 0.8 % 0.53 [ 0.23, 1.22 ]
OMEGA 2009 99/1919 84/1885 4.5 % 1.16 [ 0.87, 1.54 ]
ORIGIN 2012 288/6281 259/6255 7.6 % 1.11 [ 0.94, 1.30 ]
ORL 2013 0/171 1/165 0.1 % 0.32 [ 0.01, 7.84 ]
Proudman 2015 1/87 0/53 0.1 % 1.84 [ 0.08, 44.38 ]
Raitt 2005 (1) 65/100 59/100 6.0 % 1.10 [ 0.89, 1.37 ]
Risk % Prevention 2013 113/6239 92/6266 4.8 % 1.23 [ 0.94, 1.62 ]
0.5 0.7 1 1.5 2
Favours higher omega 3 Favours lower omega 3
(Continued . . . )
426Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
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Study or subgroup
Favours
higher
omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Sianni 2013 147/268 29/60 4.5 % 1.13 [ 0.85, 1.51 ]
SOFA 2006 36/273 34/273 2.5 % 1.06 [ 0.68, 1.64 ]
SU.FOL.OM3 2010 33/1253 32/1248 2.1 % 1.03 [ 0.64, 1.66 ]
THIS DIET 2008 2/51 5/50 0.2 % 0.39 [ 0.08, 1.93 ]
O¨zaydin 2011 9/23 9/24 1.0 % 1.04 [ 0.51, 2.16 ]
Total (95% CI) 27021 26775 100.0 % 0.97 [ 0.90, 1.05 ]
Total events: 1956 (Favours higher omega 3), 1832 (Lower omega 3)
Heterogeneity: Tau2 = 0.01; Chi2 = 47.34, df = 27 (P = 0.01); I2 =43%
Test for overall effect: Z = 0.83 (P = 0.41)
Test for subgroup differences: Not applicable
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Analysis 1.66. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 66 Arrhythmia-
LCn3 - SA fixed-effect.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)
Outcome: 66 Arrhythmia- LCn3 - SA fixed-effect
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
AFFORD 2013 98/153 103/163 5.4 % 1.01 [ 0.86, 1.20 ]
AlphaOmega - EPA+DHA 2010 67/2404 74/2433 4.0 % 0.92 [ 0.66, 1.27 ]
Derosa 2016 1/128 3/130 0.2 % 0.34 [ 0.04, 3.21 ]
DISAF 2003 154/201 157/206 8.4 % 1.01 [ 0.90, 1.12 ]
EPIC-1 2008 1/188 0/186 0.0 % 2.97 [ 0.12, 72.40 ]
EPOCH 2014 2/195 1/196 0.1 % 2.01 [ 0.18, 21.99 ]
Erdogan 2007 41/54 46/54 2.5 % 0.89 [ 0.74, 1.07 ]
FAAT 2005 57/200 78/202 4.2 % 0.74 [ 0.56, 0.98 ]
FORWARD 2013 68/289 56/297 3.0 % 1.25 [ 0.91, 1.71 ]
FOSTAR 2016 4/101 4/101 0.2 % 1.00 [ 0.26, 3.89 ]
GISSI-HF 2008 76/278 98/284 5.2 % 0.79 [ 0.62, 1.02 ]
GISSI-HF 2008 444/2921 408/2914 22.1 % 1.09 [ 0.96, 1.23 ]
GISSI-P 1999 40/2836 46/2828 2.5 % 0.87 [ 0.57, 1.32 ]
Kumar 2012 61/91 78/87 4.3 % 0.75 [ 0.64, 0.88 ]
Nodari 2011 AF 37/100 56/99 3.0 % 0.65 [ 0.48, 0.89 ]
Nodari 2011 HF 1/67 4/66 0.2 % 0.25 [ 0.03, 2.15 ]
OFAMI 2001 8/150 15/150 0.8 % 0.53 [ 0.23, 1.22 ]
OMEGA 2009 99/1919 84/1885 4.6 % 1.16 [ 0.87, 1.54 ]
ORIGIN 2012 288/6281 259/6255 14.1 % 1.11 [ 0.94, 1.30 ]
ORL 2013 0/171 1/165 0.1 % 0.32 [ 0.01, 7.84 ]
Proudman 2015 1/87 0/53 0.0 % 1.84 [ 0.08, 44.38 ]
Raitt 2005 (1) 65/100 59/100 3.2 % 1.10 [ 0.89, 1.37 ]
Risk % Prevention 2013 113/6239 92/6266 5.0 % 1.23 [ 0.94, 1.62 ]
Sianni 2013 147/268 29/60 2.6 % 1.13 [ 0.85, 1.51 ]
SOFA 2006 36/273 34/273 1.8 % 1.06 [ 0.68, 1.64 ]
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Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
SU.FOL.OM3 2010 33/1253 32/1248 1.7 % 1.03 [ 0.64, 1.66 ]
THIS DIET 2008 2/51 5/50 0.3 % 0.39 [ 0.08, 1.93 ]
O¨zaydin 2011 9/23 9/24 0.5 % 1.04 [ 0.51, 2.16 ]
Total (95% CI) 27021 26775 100.0 % 1.01 [ 0.96, 1.07 ]
Total events: 1953 (Higher omega 3), 1831 (Lower omega 3)
Heterogeneity: Chi2 = 48.15, df = 27 (P = 0.01); I2 =44%
Test for overall effect: Z = 0.35 (P = 0.73)
Test for subgroup differences: Not applicable
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Analysis 1.67. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 67 Arrhythmia-
LCn3 - SA by summary risk of bias.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)
Outcome: 67 Arrhythmia- LCn3 - SA by summary risk of bias
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Low risk of bias
AlphaOmega - EPA+DHA 2010 67/2404 74/2433 3.8 % 0.92 [ 0.66, 1.27 ]
Derosa 2016 1/128 3/130 0.1 % 0.34 [ 0.04, 3.21 ]
EPOCH 2014 2/195 1/196 0.1 % 2.01 [ 0.18, 21.99 ]
FORWARD 2013 68/289 56/297 4.0 % 1.25 [ 0.91, 1.71 ]
FOSTAR 2016 4/101 4/101 0.3 % 1.00 [ 0.26, 3.89 ]
OMEGA 2009 99/1919 84/1885 4.5 % 1.16 [ 0.87, 1.54 ]
ORIGIN 2012 288/6281 259/6255 7.6 % 1.11 [ 0.94, 1.30 ]
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Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Proudman 2015 1/87 0/53 0.1 % 1.84 [ 0.08, 44.38 ]
SOFA 2006 36/273 34/273 2.5 % 1.06 [ 0.68, 1.64 ]
SU.FOL.OM3 2010 33/1253 32/1248 2.1 % 1.03 [ 0.64, 1.66 ]
Subtotal (95% CI) 12930 12871 25.1 % 1.10 [ 0.98, 1.23 ]
Total events: 599 (Higher omega 3), 547 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.49, df = 9 (P = 0.94); I2 =0.0%
Test for overall effect: Z = 1.63 (P = 0.10)
2 Moderate/high risk of bias
AFFORD 2013 98/153 103/163 7.5 % 1.01 [ 0.86, 1.20 ]
DISAF 2003 154/201 157/206 9.4 % 1.01 [ 0.90, 1.12 ]
EPIC-1 2008 1/188 0/186 0.1 % 2.97 [ 0.12, 72.40 ]
Erdogan 2007 41/54 46/54 6.9 % 0.89 [ 0.74, 1.07 ]
FAAT 2005 60/200 79/202 4.8 % 0.77 [ 0.58, 1.01 ]
GISSI-HF 2008 76/278 98/284 5.3 % 0.79 [ 0.62, 1.02 ]
GISSI-HF 2008 444/2921 408/2914 8.9 % 1.09 [ 0.96, 1.23 ]
GISSI-P 1999 40/2836 46/2828 2.6 % 0.87 [ 0.57, 1.32 ]
Kumar 2012 61/91 78/87 7.7 % 0.75 [ 0.64, 0.88 ]
Nodari 2011 AF 37/100 56/99 4.1 % 0.65 [ 0.48, 0.89 ]
Nodari 2011 HF 1/67 4/66 0.1 % 0.25 [ 0.03, 2.15 ]
OFAMI 2001 8/150 15/150 0.8 % 0.53 [ 0.23, 1.22 ]
ORL 2013 0/171 1/165 0.1 % 0.32 [ 0.01, 7.84 ]
Raitt 2005 (1) 65/100 59/100 6.0 % 1.10 [ 0.89, 1.37 ]
Risk % Prevention 2013 113/6239 92/6266 4.8 % 1.23 [ 0.94, 1.62 ]
Sianni 2013 147/268 29/60 4.5 % 1.13 [ 0.85, 1.51 ]
THIS DIET 2008 2/51 5/50 0.2 % 0.39 [ 0.08, 1.93 ]
O¨zaydin 2011 9/23 9/24 1.0 % 1.04 [ 0.51, 2.16 ]
Subtotal (95% CI) 14091 13904 74.9 % 0.93 [ 0.84, 1.02 ]
Total events: 1357 (Higher omega 3), 1285 (Lower omega 3)
Heterogeneity: Tau2 = 0.02; Chi2 = 38.14, df = 17 (P = 0.002); I2 =55%
Test for overall effect: Z = 1.54 (P = 0.12)
Total (95% CI) 27021 26775 100.0 % 0.97 [ 0.90, 1.05 ]
Total events: 1956 (Higher omega 3), 1832 (Lower omega 3)
Heterogeneity: Tau2 = 0.01; Chi2 = 47.34, df = 27 (P = 0.01); I2 =43%
Test for overall effect: Z = 0.83 (P = 0.41)
Test for subgroup differences: Chi2 = 4.99, df = 1 (P = 0.03), I2 =80%
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(1) ICD therapy for VT/VF
Analysis 1.68. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 68 Arrhythmia-
LCn3 - SA by compliance and study size.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)
Outcome: 68 Arrhythmia- LCn3 - SA by compliance and study size
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 SA - low risk of compliance bias
AFFORD 2013 98/153 103/163 18.2 % 1.01 [ 0.86, 1.20 ]
AlphaOmega - EPA+DHA 2010 67/2404 74/2433 8.8 % 0.92 [ 0.66, 1.27 ]
DISAF 2003 154/201 157/206 23.4 % 1.01 [ 0.90, 1.12 ]
FOSTAR 2016 4/101 4/101 0.7 % 1.00 [ 0.26, 3.89 ]
Kumar 2012 61/91 78/87 18.7 % 0.75 [ 0.64, 0.88 ]
Nodari 2011 HF 1/67 4/66 0.3 % 0.25 [ 0.03, 2.15 ]
OMEGA 2009 99/1919 84/1885 10.6 % 1.16 [ 0.87, 1.54 ]
ORL 2013 0/171 1/165 0.1 % 0.32 [ 0.01, 7.84 ]
Raitt 2005 (1) 65/100 59/100 14.4 % 1.10 [ 0.89, 1.37 ]
SU.FOL.OM3 2010 33/1253 32/1248 4.8 % 1.03 [ 0.64, 1.66 ]
Subtotal (95% CI) 6460 6454 100.0 % 0.97 [ 0.86, 1.09 ]
Total events: 582 (Higher omega 3), 596 (Lower omega 3)
Heterogeneity: Tau2 = 0.01; Chi2 = 16.13, df = 9 (P = 0.06); I2 =44%
Test for overall effect: Z = 0.56 (P = 0.57)
2 SA - 100+ randomised
AFFORD 2013 98/153 103/163 7.5 % 1.01 [ 0.86, 1.20 ]
AlphaOmega - EPA+DHA 2010 67/2404 74/2433 3.9 % 0.92 [ 0.66, 1.27 ]
Derosa 2016 1/128 3/130 0.1 % 0.34 [ 0.04, 3.21 ]
DISAF 2003 154/201 157/206 9.4 % 1.01 [ 0.90, 1.12 ]
EPIC-1 2008 1/188 0/186 0.1 % 2.97 [ 0.12, 72.40 ]
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Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
EPOCH 2014 2/195 1/196 0.1 % 2.01 [ 0.18, 21.99 ]
Erdogan 2007 41/54 46/54 7.0 % 0.89 [ 0.74, 1.07 ]
FAAT 2005 60/200 79/202 4.8 % 0.77 [ 0.58, 1.01 ]
FORWARD 2013 68/289 56/297 4.1 % 1.25 [ 0.91, 1.71 ]
FOSTAR 2016 4/101 4/101 0.3 % 1.00 [ 0.26, 3.89 ]
GISSI-HF 2008 76/278 98/284 5.3 % 0.79 [ 0.62, 1.02 ]
GISSI-HF 2008 444/2921 408/2914 8.9 % 1.09 [ 0.96, 1.23 ]
GISSI-P 1999 40/2836 46/2828 2.7 % 0.87 [ 0.57, 1.32 ]
Kumar 2012 61/91 78/87 7.7 % 0.75 [ 0.64, 0.88 ]
Nodari 2011 AF 37/100 56/99 4.2 % 0.65 [ 0.48, 0.89 ]
Nodari 2011 HF 1/67 4/66 0.1 % 0.25 [ 0.03, 2.15 ]
OFAMI 2001 8/150 15/150 0.8 % 0.53 [ 0.23, 1.22 ]
OMEGA 2009 99/1919 84/1885 4.6 % 1.16 [ 0.87, 1.54 ]
ORIGIN 2012 288/6281 259/6255 7.6 % 1.11 [ 0.94, 1.30 ]
ORL 2013 0/171 1/165 0.1 % 0.32 [ 0.01, 7.84 ]
Proudman 2015 1/87 0/53 0.1 % 1.84 [ 0.08, 44.38 ]
Raitt 2005 (2) 65/100 59/100 6.1 % 1.10 [ 0.89, 1.37 ]
Risk % Prevention 2013 113/6239 92/6266 4.8 % 1.23 [ 0.94, 1.62 ]
Sianni 2013 147/268 29/60 4.6 % 1.13 [ 0.85, 1.51 ]
SOFA 2006 36/273 34/273 2.5 % 1.06 [ 0.68, 1.64 ]
SU.FOL.OM3 2010 33/1253 32/1248 2.2 % 1.03 [ 0.64, 1.66 ]
THIS DIET 2008 2/51 5/50 0.2 % 0.39 [ 0.08, 1.93 ]
Subtotal (95% CI) 26998 26751 100.0 % 0.97 [ 0.89, 1.05 ]
Total events: 1947 (Higher omega 3), 1823 (Lower omega 3)
Heterogeneity: Tau2 = 0.01; Chi2 = 47.32, df = 26 (P = 0.01); I2 =45%
Test for overall effect: Z = 0.84 (P = 0.40)
Test for subgroup differences: Chi2 = 0.00, df = 1 (P = 0.99), I2 =0.0%
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Analysis 1.69. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 69 Arrhythmia
- LCn3 - subgroup by new or recurrent.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)
Outcome: 69 Arrhythmia - LCn3 - subgroup by new or recurrent
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 New arrhythmia
AlphaOmega - EPA+DHA 2010 67/2404 74/2433 6.3 % 0.92 [ 0.66, 1.27 ]
Derosa 2016 1/128 3/130 0.1 % 0.34 [ 0.04, 3.21 ]
Derosa 2016 1/128 3/130 0.1 % 0.34 [ 0.04, 3.21 ]
EPIC-1 2008 1/188 0/186 0.1 % 2.97 [ 0.12, 72.40 ]
EPOCH 2014 2/195 1/196 0.1 % 2.01 [ 0.18, 21.99 ]
FOSTAR 2016 4/101 4/101 0.4 % 1.00 [ 0.26, 3.89 ]
GISSI-HF 2008 444/2921 408/2914 43.0 % 1.09 [ 0.96, 1.23 ]
GISSI-P 1999 40/2836 46/2828 3.8 % 0.87 [ 0.57, 1.32 ]
Nodari 2011 HF 1/67 4/66 0.1 % 0.25 [ 0.03, 2.15 ]
OFAMI 2001 8/150 15/150 1.0 % 0.53 [ 0.23, 1.22 ]
OMEGA 2009 99/1919 84/1885 8.2 % 1.16 [ 0.87, 1.54 ]
ORIGIN 2012 288/6281 259/6255 24.6 % 1.11 [ 0.94, 1.30 ]
ORL 2013 0/171 1/165 0.1 % 0.32 [ 0.01, 7.84 ]
Proudman 2015 1/87 0/53 0.1 % 1.84 [ 0.08, 44.38 ]
Risk % Prevention 2013 113/6239 92/6266 8.9 % 1.23 [ 0.94, 1.62 ]
SU.FOL.OM3 2010 33/1253 32/1248 2.9 % 1.03 [ 0.64, 1.66 ]
THIS DIET 2008 2/51 5/50 0.3 % 0.39 [ 0.08, 1.93 ]
Subtotal (95% CI) 25119 25056 100.0 % 1.07 [ 0.99, 1.16 ]
Total events: 1105 (Higher omega 3), 1031 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 12.77, df = 16 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 1.66 (P = 0.097)
2 Recurrent arrhythmia
AFFORD 2013 98/153 103/163 11.1 % 1.01 [ 0.86, 1.20 ]
DISAF 2003 154/201 157/206 13.4 % 1.01 [ 0.90, 1.12 ]
Erdogan 2007 41/54 46/54 10.3 % 0.89 [ 0.74, 1.07 ]
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Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
FAAT 2005 57/200 78/202 7.2 % 0.74 [ 0.56, 0.98 ]
FORWARD 2013 68/289 56/297 6.3 % 1.25 [ 0.91, 1.71 ]
GISSI-HF 2008 76/278 98/284 8.1 % 0.79 [ 0.62, 1.02 ]
Kumar 2012 61/91 78/87 11.3 % 0.75 [ 0.64, 0.88 ]
Nodari 2011 AF 37/100 56/99 6.4 % 0.65 [ 0.48, 0.89 ]
Raitt 2005 (1) 65/100 59/100 9.1 % 1.10 [ 0.89, 1.37 ]
Sianni 2013 147/268 29/60 7.1 % 1.13 [ 0.85, 1.51 ]
SOFA 2006 36/273 34/273 4.0 % 1.06 [ 0.68, 1.64 ]
SOFA 2006 36/273 34/273 4.0 % 1.06 [ 0.68, 1.64 ]
O¨zaydin 2011 9/23 9/24 1.7 % 1.04 [ 0.51, 2.16 ]
Subtotal (95% CI) 2303 2122 100.0 % 0.93 [ 0.84, 1.03 ]
Total events: 885 (Higher omega 3), 837 (Lower omega 3)
Heterogeneity: Tau2 = 0.02; Chi2 = 27.83, df = 12 (P = 0.01); I2 =57%
Test for overall effect: Z = 1.41 (P = 0.16)
Test for subgroup differences: Chi2 = 4.58, df = 1 (P = 0.03), I2 =78%
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Analysis 1.70. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 70 Arrhythmia
- LCn3 - subgroup by fatality.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)
Outcome: 70 Arrhythmia - LCn3 - subgroup by fatality
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Fatal arrhythmias - LCn3
FAAT 2005 3/200 1/202 0.5 % 3.03 [ 0.32, 28.88 ]
ORIGIN 2012 288/6281 259/6255 99.5 % 1.11 [ 0.94, 1.30 ]
Subtotal (95% CI) 6481 6457 100.0 % 1.11 [ 0.95, 1.31 ]
Total events: 291 (Higher omega 3), 260 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.76, df = 1 (P = 0.38); I2 =0.0%
Test for overall effect: Z = 1.28 (P = 0.20)
2 Non-fatal arrhythmias - LCn3
EPIC-1 2008 1/188 0/186 0.7 % 2.97 [ 0.12, 72.40 ]
EPOCH 2014 2/195 1/196 1.2 % 2.01 [ 0.18, 21.99 ]
FAAT 2005 57/200 78/202 88.7 % 0.74 [ 0.56, 0.98 ]
FOSTAR 2016 4/101 4/101 3.8 % 1.00 [ 0.26, 3.89 ]
Nodari 2011 HF 1/67 4/66 1.5 % 0.25 [ 0.03, 2.15 ]
ORL 2013 0/171 1/165 0.7 % 0.32 [ 0.01, 7.84 ]
Proudman 2015 1/87 0/53 0.7 % 1.84 [ 0.08, 44.38 ]
THIS DIET 2008 2/51 5/50 2.7 % 0.39 [ 0.08, 1.93 ]
Subtotal (95% CI) 1060 1019 100.0 % 0.74 [ 0.57, 0.96 ]
Total events: 68 (Higher omega 3), 93 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.77, df = 7 (P = 0.81); I2 =0.0%
Test for overall effect: Z = 2.26 (P = 0.024)
3 Fatal and non-fatal arrhythmias combined - LCn3
AlphaOmega - EPA+DHA 2010 67/2404 74/2433 8.4 % 0.92 [ 0.66, 1.27 ]
Derosa 2016 1/128 3/130 0.2 % 0.34 [ 0.04, 3.21 ]
FOSTAR 2016 4/101 4/101 0.5 % 1.00 [ 0.26, 3.89 ]
GISSI-HF 2008 444/2921 408/2914 57.5 % 1.09 [ 0.96, 1.23 ]
GISSI-P 1999 40/2836 46/2828 5.0 % 0.87 [ 0.57, 1.32 ]
OFAMI 2001 8/150 15/150 1.3 % 0.53 [ 0.23, 1.22 ]
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Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
OMEGA 2009 99/1919 84/1885 11.0 % 1.16 [ 0.87, 1.54 ]
Risk % Prevention 2013 113/6239 92/6266 11.9 % 1.23 [ 0.94, 1.62 ]
SU.FOL.OM3 2010 33/1253 32/1248 3.9 % 1.03 [ 0.64, 1.66 ]
THIS DIET 2008 2/51 5/50 0.3 % 0.39 [ 0.08, 1.93 ]
Subtotal (95% CI) 18002 18005 100.0 % 1.06 [ 0.97, 1.17 ]
Total events: 811 (Higher omega 3), 763 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 8.50, df = 9 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 1.28 (P = 0.20)
Test for subgroup differences: Chi2 = 7.37, df = 2 (P = 0.03), I2 =73%
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Analysis 1.71. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 71 Arrhythmia
- LCn3 - subgroup by dose.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)
Outcome: 71 Arrhythmia - LCn3 - subgroup by dose
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 LCn3≤ 150 mg/d
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 3), 0 (Lower omega 3)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 LCn3 > 150≤ 250 mg/d
DISAF 2003 154/201 157/206 9.3 % 1.01 [ 0.90, 1.12 ]
Subtotal (95% CI) 201 206 9.3 % 1.01 [ 0.90, 1.12 ]
Total events: 154 (Higher omega 3), 157 (Lower omega 3)
Heterogeneity: not applicable
Test for overall effect: Z = 0.10 (P = 0.92)
3 LCn3 > 250≤ 400 mg/d
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 3), 0 (Lower omega 3)
Heterogeneity: not applicable
Test for overall effect: not applicable
4 LCn3 > 400≤ 2400 mg/d
AFFORD 2013 98/153 103/163 7.5 % 1.01 [ 0.86, 1.20 ]
AlphaOmega - EPA+DHA 2010 67/2404 74/2433 3.8 % 0.92 [ 0.66, 1.27 ]
Derosa 2016 1/128 3/130 0.1 % 0.34 [ 0.04, 3.21 ]
EPOCH 2014 2/195 1/196 0.1 % 2.01 [ 0.18, 21.99 ]
FORWARD 2013 68/289 56/297 4.0 % 1.25 [ 0.91, 1.71 ]
GISSI-HF 2008 444/2921 408/2914 8.8 % 1.09 [ 0.96, 1.23 ]
GISSI-HF 2008 76/278 98/284 5.3 % 0.79 [ 0.62, 1.02 ]
GISSI-P 1999 40/2836 46/2828 2.7 % 0.87 [ 0.57, 1.32 ]
Kumar 2012 61/91 78/87 7.7 % 0.75 [ 0.64, 0.88 ]
Nodari 2011 AF 37/100 56/99 4.1 % 0.65 [ 0.48, 0.89 ]
Nodari 2011 HF 1/67 4/66 0.1 % 0.25 [ 0.03, 2.15 ]
OMEGA 2009 99/1919 84/1885 4.6 % 1.16 [ 0.87, 1.54 ]
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Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
ORIGIN 2012 288/6281 259/6255 7.6 % 1.11 [ 0.94, 1.30 ]
ORL 2013 0/171 1/165 0.1 % 0.32 [ 0.01, 7.84 ]
Raitt 2005 (1) 65/100 59/100 6.1 % 1.10 [ 0.89, 1.37 ]
Risk % Prevention 2013 113/6239 92/6266 4.8 % 1.23 [ 0.94, 1.62 ]
SOFA 2006 36/273 34/273 2.5 % 1.06 [ 0.68, 1.64 ]
SU.FOL.OM3 2010 33/1253 32/1248 2.2 % 1.03 [ 0.64, 1.66 ]
THIS DIET 2008 2/51 5/50 0.2 % 0.39 [ 0.08, 1.93 ]
O¨zaydin 2011 9/23 9/24 1.1 % 1.04 [ 0.51, 2.16 ]
Subtotal (95% CI) 25772 25763 73.3 % 0.98 [ 0.88, 1.08 ]
Total events: 1540 (Higher omega 3), 1502 (Lower omega 3)
Heterogeneity: Tau2 = 0.02; Chi2 = 39.22, df = 19 (P = 0.004); I2 =52%
Test for overall effect: Z = 0.42 (P = 0.67)
5 LCn3 > 2.4≤ 4.4 g/d
EPIC-1 2008 1/188 0/186 0.1 % 2.97 [ 0.12, 72.40 ]
FAAT 2005 57/200 78/202 4.6 % 0.74 [ 0.56, 0.98 ]
OFAMI 2001 8/150 15/150 0.8 % 0.53 [ 0.23, 1.22 ]
Subtotal (95% CI) 538 538 5.5 % 0.72 [ 0.55, 0.94 ]
Total events: 66 (Higher omega 3), 93 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.29, df = 2 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 2.43 (P = 0.015)
6 LCn3 > 4.4 g/d
FOSTAR 2016 4/101 4/101 0.3 % 1.00 [ 0.26, 3.89 ]
Proudman 2015 1/87 0/53 0.1 % 1.84 [ 0.08, 44.38 ]
Subtotal (95% CI) 188 154 0.4 % 1.10 [ 0.32, 3.83 ]
Total events: 5 (Higher omega 3), 4 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.12, df = 1 (P = 0.73); I2 =0.0%
Test for overall effect: Z = 0.15 (P = 0.88)
7 Unclear LCn3 dose
Erdogan 2007 41/54 46/54 6.9 % 0.89 [ 0.74, 1.07 ]
Sianni 2013 147/268 29/60 4.6 % 1.13 [ 0.85, 1.51 ]
Subtotal (95% CI) 322 114 11.5 % 0.99 [ 0.76, 1.28 ]
Total events: 188 (Higher omega 3), 75 (Lower omega 3)
Heterogeneity: Tau2 = 0.02; Chi2 = 2.45, df = 1 (P = 0.12); I2 =59%
Test for overall effect: Z = 0.10 (P = 0.92)
Total (95% CI) 27021 26775 100.0 % 0.97 [ 0.89, 1.04 ]
Total events: 1953 (Higher omega 3), 1831 (Lower omega 3)
Heterogeneity: Tau2 = 0.01; Chi2 = 48.15, df = 27 (P = 0.01); I2 =44%
Test for overall effect: Z = 0.86 (P = 0.39)
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Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Test for subgroup differences: Chi2 = 5.35, df = 4 (P = 0.25), I2 =25%
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(1) ICD therapy for VT/VF
Analysis 1.72. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 72 Arrhythmia
- LCn3 - subgroup by replacement.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)
Outcome: 72 Arrhythmia - LCn3 - subgroup by replacement
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 N-3 replacing SFA
Derosa 2016 1/128 3/130 64.2 % 0.34 [ 0.04, 3.21 ]
EPIC-1 2008 1/188 0/186 35.8 % 2.97 [ 0.12, 72.40 ]
Subtotal (95% CI) 316 316 100.0 % 0.74 [ 0.10, 5.67 ]
Total events: 2 (Higher omega 3), 3 (Lower omega 3)
Heterogeneity: Tau2 = 0.37; Chi2 = 1.19, df = 1 (P = 0.28); I2 =16%
Test for overall effect: Z = 0.29 (P = 0.77)
2 N-3 replacing MUFA
AlphaOmega - EPA+DHA 2010 67/2404 74/2433 7.3 % 0.92 [ 0.66, 1.27 ]
FAAT 2005 57/200 78/202 8.5 % 0.74 [ 0.56, 0.98 ]
FORWARD 2013 68/289 56/297 7.5 % 1.25 [ 0.91, 1.71 ]
GISSI-HF 2008 76/278 98/284 9.4 % 0.79 [ 0.62, 1.02 ]
GISSI-HF 2008 (1) 444/2921 408/2914 13.8 % 1.09 [ 0.96, 1.23 ]
Nodari 2011 AF 37/100 56/99 7.7 % 0.65 [ 0.48, 0.89 ]
Nodari 2011 HF 1/67 4/66 0.3 % 0.25 [ 0.03, 2.15 ]
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Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
OMEGA 2009 99/1919 84/1885 8.4 % 1.16 [ 0.87, 1.54 ]
ORIGIN 2012 288/6281 259/6255 12.4 % 1.11 [ 0.94, 1.30 ]
Raitt 2005 (2) 65/100 59/100 10.5 % 1.10 [ 0.89, 1.37 ]
Risk % Prevention 2013 113/6239 92/6266 8.7 % 1.23 [ 0.94, 1.62 ]
SOFA 2006 36/273 34/273 5.0 % 1.06 [ 0.68, 1.64 ]
THIS DIET 2008 2/51 5/50 0.5 % 0.39 [ 0.08, 1.93 ]
Subtotal (95% CI) 21122 21124 100.0 % 0.99 [ 0.88, 1.11 ]
Total events: 1353 (Higher omega 3), 1307 (Lower omega 3)
Heterogeneity: Tau2 = 0.02; Chi2 = 27.26, df = 12 (P = 0.01); I2 =56%
Test for overall effect: Z = 0.19 (P = 0.85)
3 N-3 replacing n-6
AFFORD 2013 98/153 103/163 84.1 % 1.01 [ 0.86, 1.20 ]
OFAMI 2001 8/150 15/150 3.4 % 0.53 [ 0.23, 1.22 ]
Proudman 2015 1/87 0/53 0.2 % 1.84 [ 0.08, 44.38 ]
SOFA 2006 36/273 34/273 12.2 % 1.06 [ 0.68, 1.64 ]
Subtotal (95% CI) 663 639 100.0 % 1.00 [ 0.86, 1.16 ]
Total events: 143 (Higher omega 3), 152 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.51, df = 3 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 0.02 (P = 0.98)
4 N-3 replacing carbohydrates/sugars
Derosa 2016 1/128 3/130 100.0 % 0.34 [ 0.04, 3.21 ]
Subtotal (95% CI) 128 130 100.0 % 0.34 [ 0.04, 3.21 ]
Total events: 1 (Higher omega 3), 3 (Lower omega 3)
Heterogeneity: not applicable
Test for overall effect: Z = 0.94 (P = 0.35)
5 N-3 replacing nil/low n-3 placebo
EPOCH 2014 2/195 1/196 0.3 % 2.01 [ 0.18, 21.99 ]
FOSTAR 2016 4/101 4/101 1.1 % 1.00 [ 0.26, 3.89 ]
GISSI-P 1999 40/2836 46/2828 11.0 % 0.87 [ 0.57, 1.32 ]
Kumar 2012 61/91 78/87 75.4 % 0.75 [ 0.64, 0.88 ]
SU.FOL.OM3 2010 33/1253 32/1248 8.5 % 1.03 [ 0.64, 1.66 ]
O¨zaydin 2011 9/23 9/24 3.7 % 1.04 [ 0.51, 2.16 ]
Subtotal (95% CI) 4499 4484 100.0 % 0.80 [ 0.69, 0.91 ]
Total events: 149 (Higher omega 3), 170 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 4.25, df = 5 (P = 0.51); I2 =0.0%
Test for overall effect: Z = 3.21 (P = 0.0013)
6 Replacement unclear
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Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
DISAF 2003 154/201 157/206 67.6 % 1.01 [ 0.90, 1.12 ]
Erdogan 2007 41/54 46/54 22.5 % 0.89 [ 0.74, 1.07 ]
ORL 2013 0/171 1/165 0.1 % 0.32 [ 0.01, 7.84 ]
Sianni 2013 147/268 29/60 9.8 % 1.13 [ 0.85, 1.51 ]
Subtotal (95% CI) 694 485 100.0 % 0.99 [ 0.91, 1.08 ]
Total events: 342 (Higher omega 3), 233 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.78, df = 3 (P = 0.43); I2 =0.0%
Test for overall effect: Z = 0.24 (P = 0.81)
Test for subgroup differences: Chi2 = 8.71, df = 5 (P = 0.12), I2 =43%
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Analysis 1.73. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 73 Arrhythmia
- LCn3 - subgroup by intervention type.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)
Outcome: 73 Arrhythmia - LCn3 - subgroup by intervention type
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Dietary advice
DISAF 2003 154/201 157/206 9.4 % 1.01 [ 0.90, 1.12 ]
THIS DIET 2008 2/51 5/50 0.2 % 0.39 [ 0.08, 1.93 ]
Subtotal (95% CI) 252 256 9.6 % 0.87 [ 0.44, 1.72 ]
Total events: 156 (Higher omega 3), 162 (Lower omega 3)
Heterogeneity: Tau2 = 0.14; Chi2 = 1.41, df = 1 (P = 0.23); I2 =29%
Test for overall effect: Z = 0.39 (P = 0.70)
2 Supplemental foods
AlphaOmega - EPA+DHA 2010 67/2404 74/2433 3.8 % 0.92 [ 0.66, 1.27 ]
FOSTAR 2016 4/101 4/101 0.3 % 1.00 [ 0.26, 3.89 ]
Subtotal (95% CI) 2505 2534 4.1 % 0.92 [ 0.67, 1.26 ]
Total events: 71 (Higher omega 3), 78 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.02, df = 1 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 0.51 (P = 0.61)
3 Supplements (capsule)
AFFORD 2013 98/153 103/163 7.5 % 1.01 [ 0.86, 1.20 ]
Derosa 2016 1/128 3/130 0.1 % 0.34 [ 0.04, 3.21 ]
EPIC-1 2008 1/188 0/186 0.1 % 2.97 [ 0.12, 72.40 ]
EPOCH 2014 2/195 1/196 0.1 % 2.01 [ 0.18, 21.99 ]
Erdogan 2007 41/54 46/54 6.9 % 0.89 [ 0.74, 1.07 ]
FAAT 2005 60/200 79/202 4.8 % 0.77 [ 0.58, 1.01 ]
FORWARD 2013 68/289 56/297 4.0 % 1.25 [ 0.91, 1.71 ]
GISSI-HF 2008 76/278 98/284 5.3 % 0.79 [ 0.62, 1.02 ]
GISSI-HF 2008 444/2921 408/2914 8.9 % 1.09 [ 0.96, 1.23 ]
GISSI-P 1999 40/2836 46/2828 2.6 % 0.87 [ 0.57, 1.32 ]
Kumar 2012 61/91 78/87 7.7 % 0.75 [ 0.64, 0.88 ]
Nodari 2011 AF 37/100 56/99 4.1 % 0.65 [ 0.48, 0.89 ]
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Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Nodari 2011 HF 1/67 4/66 0.1 % 0.25 [ 0.03, 2.15 ]
OFAMI 2001 8/150 15/150 0.8 % 0.53 [ 0.23, 1.22 ]
OMEGA 2009 99/1919 84/1885 4.5 % 1.16 [ 0.87, 1.54 ]
ORIGIN 2012 288/6281 259/6255 7.6 % 1.11 [ 0.94, 1.30 ]
ORL 2013 0/171 1/165 0.1 % 0.32 [ 0.01, 7.84 ]
Proudman 2015 1/87 0/53 0.1 % 1.84 [ 0.08, 44.38 ]
Raitt 2005 (1) 65/100 59/100 6.0 % 1.10 [ 0.89, 1.37 ]
Risk % Prevention 2013 113/6239 92/6266 4.8 % 1.23 [ 0.94, 1.62 ]
Sianni 2013 147/268 29/60 4.5 % 1.13 [ 0.85, 1.51 ]
SOFA 2006 36/273 34/273 2.5 % 1.06 [ 0.68, 1.64 ]
SU.FOL.OM3 2010 33/1253 32/1248 2.1 % 1.03 [ 0.64, 1.66 ]
O¨zaydin 2011 9/23 9/24 1.0 % 1.04 [ 0.51, 2.16 ]
Subtotal (95% CI) 24264 23985 86.2 % 0.97 [ 0.88, 1.06 ]
Total events: 1729 (Higher omega 3), 1592 (Lower omega 3)
Heterogeneity: Tau2 = 0.02; Chi2 = 46.27, df = 23 (P = 0.003); I2 =50%
Test for overall effect: Z = 0.72 (P = 0.47)
4 Any combination
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 3), 0 (Lower omega 3)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 27021 26775 100.0 % 0.97 [ 0.90, 1.05 ]
Total events: 1956 (Higher omega 3), 1832 (Lower omega 3)
Heterogeneity: Tau2 = 0.01; Chi2 = 47.34, df = 27 (P = 0.01); I2 =43%
Test for overall effect: Z = 0.83 (P = 0.41)
Test for subgroup differences: Chi2 = 0.16, df = 2 (P = 0.92), I2 =0.0%
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Analysis 1.74. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 74 Arrhythmia
- LCn3 - subgroup by duration.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)
Outcome: 74 Arrhythmia - LCn3 - subgroup by duration
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Medium duration 1 to < 2 years in study
AFFORD 2013 98/153 103/163 7.5 % 1.01 [ 0.86, 1.20 ]
Derosa 2016 1/128 3/130 0.1 % 0.34 [ 0.04, 3.21 ]
DISAF 2003 154/201 157/206 9.3 % 1.01 [ 0.90, 1.12 ]
EPIC-1 2008 1/188 0/186 0.1 % 2.97 [ 0.12, 72.40 ]
EPOCH 2014 2/195 1/196 0.1 % 2.01 [ 0.18, 21.99 ]
Erdogan 2007 41/54 46/54 6.9 % 0.89 [ 0.74, 1.07 ]
FAAT 2005 57/200 78/202 4.6 % 0.74 [ 0.56, 0.98 ]
FORWARD 2013 68/289 56/297 4.0 % 1.25 [ 0.91, 1.71 ]
Kumar 2012 61/91 78/87 7.7 % 0.75 [ 0.64, 0.88 ]
Nodari 2011 AF 37/100 56/99 4.1 % 0.65 [ 0.48, 0.89 ]
Nodari 2011 HF 1/67 4/66 0.1 % 0.25 [ 0.03, 2.15 ]
OMEGA 2009 99/1919 84/1885 4.6 % 1.16 [ 0.87, 1.54 ]
ORL 2013 0/171 1/165 0.1 % 0.32 [ 0.01, 7.84 ]
Proudman 2015 1/87 0/53 0.1 % 1.84 [ 0.08, 44.38 ]
Sianni 2013 147/268 29/60 4.6 % 1.13 [ 0.85, 1.51 ]
SOFA 2006 36/273 34/273 2.5 % 1.06 [ 0.68, 1.64 ]
O¨zaydin 2011 9/23 9/24 1.1 % 1.04 [ 0.51, 2.16 ]
Subtotal (95% CI) 4407 4146 57.4 % 0.93 [ 0.84, 1.04 ]
Total events: 813 (Higher omega 3), 739 (Lower omega 3)
Heterogeneity: Tau2 = 0.02; Chi2 = 30.04, df = 16 (P = 0.02); I2 =47%
Test for overall effect: Z = 1.21 (P = 0.23)
2 Medium-long duration: 2 to < 4 years in study
AlphaOmega - EPA+DHA 2010 67/2404 74/2433 3.8 % 0.92 [ 0.66, 1.27 ]
FOSTAR 2016 4/101 4/101 0.3 % 1.00 [ 0.26, 3.89 ]
GISSI-HF 2008 76/278 98/284 5.3 % 0.79 [ 0.62, 1.02 ]
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Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
GISSI-HF 2008 444/2921 408/2914 8.8 % 1.09 [ 0.96, 1.23 ]
GISSI-P 1999 40/2836 46/2828 2.7 % 0.87 [ 0.57, 1.32 ]
OFAMI 2001 8/150 15/150 0.8 % 0.53 [ 0.23, 1.22 ]
Raitt 2005 (1) 65/100 59/100 6.1 % 1.10 [ 0.89, 1.37 ]
THIS DIET 2008 2/51 5/50 0.2 % 0.39 [ 0.08, 1.93 ]
Subtotal (95% CI) 8841 8860 28.1 % 0.96 [ 0.84, 1.10 ]
Total events: 706 (Higher omega 3), 709 (Lower omega 3)
Heterogeneity: Tau2 = 0.01; Chi2 = 10.05, df = 7 (P = 0.19); I2 =30%
Test for overall effect: Z = 0.58 (P = 0.56)
3 Long duration:≥ 4 years in study
ORIGIN 2012 288/6281 259/6255 7.6 % 1.11 [ 0.94, 1.30 ]
Risk % Prevention 2013 113/6239 92/6266 4.8 % 1.23 [ 0.94, 1.62 ]
SU.FOL.OM3 2010 33/1253 32/1248 2.2 % 1.03 [ 0.64, 1.66 ]
Subtotal (95% CI) 13773 13769 14.5 % 1.13 [ 0.99, 1.29 ]
Total events: 434 (Higher omega 3), 383 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.61, df = 2 (P = 0.74); I2 =0.0%
Test for overall effect: Z = 1.78 (P = 0.075)
Total (95% CI) 27021 26775 100.0 % 0.97 [ 0.89, 1.04 ]
Total events: 1953 (Higher omega 3), 1831 (Lower omega 3)
Heterogeneity: Tau2 = 0.01; Chi2 = 48.15, df = 27 (P = 0.01); I2 =44%
Test for overall effect: Z = 0.86 (P = 0.39)
Test for subgroup differences: Chi2 = 4.93, df = 2 (P = 0.08), I2 =59%
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Analysis 1.75. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 75 Arrhythmia
- LCn3 - subgroup by primary or secondary prevention3.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)
Outcome: 75 Arrhythmia - LCn3 - subgroup by primary or secondary prevention3
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Primary prevention
Derosa 2016 1/128 3/130 0.4 % 0.34 [ 0.04, 3.21 ]
EPIC-1 2008 1/188 0/186 0.2 % 2.97 [ 0.12, 72.40 ]
EPOCH 2014 2/195 1/196 0.3 % 2.01 [ 0.18, 21.99 ]
FOSTAR 2016 4/101 4/101 1.1 % 1.00 [ 0.26, 3.89 ]
ORIGIN 2012 288/6281 259/6255 73.1 % 1.11 [ 0.94, 1.30 ]
ORL 2013 0/171 1/165 0.2 % 0.32 [ 0.01, 7.84 ]
Proudman 2015 1/87 0/53 0.2 % 1.84 [ 0.08, 44.38 ]
Sianni 2013 147/268 29/60 24.5 % 1.13 [ 0.85, 1.51 ]
Subtotal (95% CI) 7419 7146 100.0 % 1.11 [ 0.97, 1.28 ]
Total events: 444 (Higher omega 3), 297 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.40, df = 7 (P = 0.93); I2 =0.0%
Test for overall effect: Z = 1.46 (P = 0.14)
2 Secondary prevention
AFFORD 2013 98/153 103/163 8.3 % 1.01 [ 0.86, 1.20 ]
AlphaOmega - EPA+DHA 2010 67/2404 74/2433 4.6 % 0.92 [ 0.66, 1.27 ]
DISAF 2003 154/201 157/206 10.0 % 1.01 [ 0.90, 1.12 ]
Erdogan 2007 41/54 46/54 7.8 % 0.89 [ 0.74, 1.07 ]
FAAT 2005 57/200 78/202 5.5 % 0.74 [ 0.56, 0.98 ]
FORWARD 2013 68/289 56/297 4.8 % 1.25 [ 0.91, 1.71 ]
GISSI-HF 2008 76/278 98/284 6.1 % 0.79 [ 0.62, 1.02 ]
GISSI-HF 2008 444/2921 408/2914 9.6 % 1.09 [ 0.96, 1.23 ]
GISSI-P 1999 40/2836 46/2828 3.3 % 0.87 [ 0.57, 1.32 ]
Kumar 2012 61/91 78/87 8.5 % 0.75 [ 0.64, 0.88 ]
Nodari 2011 AF 37/100 56/99 4.9 % 0.65 [ 0.48, 0.89 ]
Nodari 2011 HF 1/67 4/66 0.2 % 0.25 [ 0.03, 2.15 ]
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(. . . Continued)
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
OFAMI 2001 8/150 15/150 1.1 % 0.53 [ 0.23, 1.22 ]
OMEGA 2009 99/1919 84/1885 5.4 % 1.16 [ 0.87, 1.54 ]
Raitt 2005 (1) 65/100 59/100 6.9 % 1.10 [ 0.89, 1.37 ]
Risk % Prevention 2013 113/6239 92/6266 5.6 % 1.23 [ 0.94, 1.62 ]
SOFA 2006 36/273 34/273 3.1 % 1.06 [ 0.68, 1.64 ]
SU.FOL.OM3 2010 33/1253 32/1248 2.7 % 1.03 [ 0.64, 1.66 ]
THIS DIET 2008 2/51 5/50 0.3 % 0.39 [ 0.08, 1.93 ]
O¨zaydin 2011 9/23 9/24 1.3 % 1.04 [ 0.51, 2.16 ]
Subtotal (95% CI) 19602 19629 100.0 % 0.95 [ 0.86, 1.03 ]
Total events: 1509 (Higher omega 3), 1534 (Lower omega 3)
Heterogeneity: Tau2 = 0.02; Chi2 = 41.83, df = 19 (P = 0.002); I2 =55%
Test for overall effect: Z = 1.24 (P = 0.22)
Test for subgroup differences: Chi2 = 3.61, df = 1 (P = 0.06), I2 =72%
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Analysis 1.76. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 76 Arrhythmia
- LCn3 - subgroup by statin use.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)
Outcome: 76 Arrhythmia - LCn3 - subgroup by statin use
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 LCn3 -≥ 50% of control group on statins
AlphaOmega - EPA+DHA 2010 67/2404 74/2433 14.8 % 0.92 [ 0.66, 1.27 ]
OMEGA 2009 99/1919 84/1885 19.5 % 1.16 [ 0.87, 1.54 ]
ORIGIN 2012 288/6281 259/6255 58.3 % 1.11 [ 0.94, 1.30 ]
SU.FOL.OM3 2010 33/1253 32/1248 6.8 % 1.03 [ 0.64, 1.66 ]
THIS DIET 2008 2/51 5/50 0.6 % 0.39 [ 0.08, 1.93 ]
Subtotal (95% CI) 11908 11871 100.0 % 1.07 [ 0.95, 1.22 ]
Total events: 489 (Higher omega 3), 454 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.89, df = 4 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 1.11 (P = 0.27)
2 LCn3 - < 50% of control group on statins
AFFORD 2013 98/153 103/163 10.3 % 1.01 [ 0.86, 1.20 ]
DISAF 2003 154/201 157/206 12.2 % 1.01 [ 0.90, 1.12 ]
EPIC-1 2008 1/188 0/186 0.1 % 2.97 [ 0.12, 72.40 ]
FAAT 2005 57/200 78/202 6.9 % 0.74 [ 0.56, 0.98 ]
FORWARD 2013 68/289 56/297 6.1 % 1.25 [ 0.91, 1.71 ]
FOSTAR 2016 4/101 4/101 0.6 % 1.00 [ 0.26, 3.89 ]
GISSI-HF 2008 76/278 98/284 7.7 % 0.79 [ 0.62, 1.02 ]
GISSI-HF 2008 444/2921 408/2914 11.7 % 1.09 [ 0.96, 1.23 ]
GISSI-P 1999 40/2836 46/2828 4.2 % 0.87 [ 0.57, 1.32 ]
Kumar 2012 61/91 78/87 10.5 % 0.75 [ 0.64, 0.88 ]
Nodari 2011 AF 37/100 56/99 6.2 % 0.65 [ 0.48, 0.89 ]
Nodari 2011 HF 1/67 4/66 0.2 % 0.25 [ 0.03, 2.15 ]
OFAMI 2001 8/150 15/150 1.4 % 0.53 [ 0.23, 1.22 ]
ORL 2013 0/171 1/165 0.1 % 0.32 [ 0.01, 7.84 ]
Proudman 2015 1/87 0/53 0.1 % 1.84 [ 0.08, 44.38 ]
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Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Raitt 2005 (1) 65/100 59/100 8.7 % 1.10 [ 0.89, 1.37 ]
Risk % Prevention 2013 113/6239 92/6266 7.1 % 1.23 [ 0.94, 1.62 ]
SOFA 2006 36/273 34/273 4.0 % 1.06 [ 0.68, 1.64 ]
O¨zaydin 2011 9/23 9/24 1.8 % 1.04 [ 0.51, 2.16 ]
Subtotal (95% CI) 14468 14464 100.0 % 0.94 [ 0.85, 1.04 ]
Total events: 1273 (Higher omega 3), 1298 (Lower omega 3)
Heterogeneity: Tau2 = 0.02; Chi2 = 38.89, df = 18 (P = 0.003); I2 =54%
Test for overall effect: Z = 1.18 (P = 0.24)
3 LCn3 - use of statins unclear
Derosa 2016 1/128 3/130 0.8 % 0.34 [ 0.04, 3.21 ]
EPOCH 2014 2/195 1/196 0.7 % 2.01 [ 0.18, 21.99 ]
Erdogan 2007 41/54 46/54 62.3 % 0.89 [ 0.74, 1.07 ]
Sianni 2013 147/268 29/60 36.2 % 1.13 [ 0.85, 1.51 ]
Subtotal (95% CI) 645 440 100.0 % 0.97 [ 0.80, 1.18 ]
Total events: 191 (Higher omega 3), 79 (Lower omega 3)
Heterogeneity: Tau2 = 0.01; Chi2 = 3.50, df = 3 (P = 0.32); I2 =14%
Test for overall effect: Z = 0.29 (P = 0.77)
Test for subgroup differences: Chi2 = 2.62, df = 2 (P = 0.27), I2 =24%
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Analysis 2.1. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 1 MACCEs -
LCn3.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 2 High vs low LCn3 omega-3 fats (secondary outcomes)
Outcome: 1 MACCEs - LCn3
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
AREDS2 2014 116/2147 113/2056 4.8 % 0.98 [ 0.76, 1.26 ]
DART 1989 338/1015 332/1018 19.7 % 1.02 [ 0.90, 1.16 ]
OMEGA 2009 182/1752 149/1701 7.1 % 1.19 [ 0.97, 1.46 ]
ORIGIN 2012 1034/6281 1017/6255 48.2 % 1.01 [ 0.94, 1.10 ]
Risk % Prevention 2013 484/6239 467/6266 20.2 % 1.04 [ 0.92, 1.18 ]
Total (95% CI) 17434 17296 100.0 % 1.03 [ 0.97, 1.09 ]
Total events: 2154 (Higher omega 3), 2078 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.16, df = 4 (P = 0.71); I2 =0.0%
Test for overall effect: Z = 1.05 (P = 0.29)
Test for subgroup differences: Not applicable
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Analysis 2.2. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 2 Myocardial
infarction (overall) - LCn3.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 2 High vs low LCn3 omega-3 fats (secondary outcomes)
Outcome: 2 Myocardial infarction (overall) - LCn3
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
AlphaOmega - EPA+DHA 2010 89/2404 102/2433 8.4 % 0.88 [ 0.67, 1.17 ]
AREDS2 2014 28/2147 30/2056 2.5 % 0.89 [ 0.54, 1.49 ]
Baldassarre 2006 1/32 0/32 0.1 % 3.00 [ 0.13, 71.00 ]
Brox 2001 0/80 1/40 0.1 % 0.17 [ 0.01, 4.05 ]
DART 1989 207/1015 215/1018 22.5 % 0.97 [ 0.81, 1.14 ]
Derosa 2016 0/128 3/130 0.1 % 0.15 [ 0.01, 2.78 ]
DO IT 2010 11/282 9/281 0.9 % 1.22 [ 0.51, 2.89 ]
Doi 2014 1/119 0/119 0.1 % 3.00 [ 0.12, 72.91 ]
EPOCH 2014 1/195 0/196 0.1 % 3.02 [ 0.12, 73.57 ]
FORWARD 2013 1/289 1/297 0.1 % 1.03 [ 0.06, 16.35 ]
GISSI-HF 2008 107/3494 129/3481 10.2 % 0.83 [ 0.64, 1.06 ]
HARP 1995 1/41 3/39 0.1 % 0.32 [ 0.03, 2.92 ]
JELIS 2007 71/9326 93/9319 6.9 % 0.76 [ 0.56, 1.04 ]
OMEGA 2009 87/1919 78/1885 7.3 % 1.10 [ 0.81, 1.48 ]
ORIGIN 2012 344/6281 316/6255 29.4 % 1.08 [ 0.93, 1.26 ]
Proudman 2015 1/87 0/53 0.1 % 1.84 [ 0.08, 44.38 ]
Raitt 2005 1/100 3/100 0.1 % 0.33 [ 0.04, 3.15 ]
Risk % Prevention 2013 80/6239 90/6266 7.3 % 0.89 [ 0.66, 1.20 ]
SCIMO 1999 1/112 4/111 0.1 % 0.25 [ 0.03, 2.18 ]
SHOT 1996 7/317 12/293 0.8 % 0.54 [ 0.22, 1.35 ]
SOFA 2006 1/273 3/273 0.1 % 0.33 [ 0.03, 3.18 ]
SU.FOL.OM3 2010 32/1253 32/1248 2.8 % 1.00 [ 0.61, 1.62 ]
THIS DIET 2008 1/51 3/50 0.1 % 0.33 [ 0.04, 3.04 ]
Total (95% CI) 36184 35975 100.0 % 0.95 [ 0.88, 1.03 ]
Total events: 1073 (Higher omega 3), 1127 (Lower omega 3)
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(. . . Continued)
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Heterogeneity: Tau2 = 0.0; Chi2 = 18.70, df = 22 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 1.17 (P = 0.24)
Test for subgroup differences: Not applicable
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Analysis 2.3. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 3 Total MI -
sensitivity analysis (SA) by summary risk of bias.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 2 High vs low LCn3 omega-3 fats (secondary outcomes)
Outcome: 3 Total MI - sensitivity analysis (SA) by summary risk of bias
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Low summary risk of bias
AlphaOmega - EPA+DHA 2010 89/2404 102/2433 8.4 % 0.88 [ 0.67, 1.17 ]
AREDS2 2014 28/2147 30/2056 2.5 % 0.89 [ 0.54, 1.49 ]
Derosa 2016 0/128 3/130 0.1 % 0.15 [ 0.01, 2.78 ]
EPOCH 2014 1/195 0/196 0.1 % 3.02 [ 0.12, 73.57 ]
FORWARD 2013 1/289 1/297 0.1 % 1.03 [ 0.06, 16.35 ]
OMEGA 2009 87/1919 78/1885 7.3 % 1.10 [ 0.81, 1.48 ]
ORIGIN 2012 344/6281 316/6255 29.4 % 1.08 [ 0.93, 1.26 ]
Proudman 2015 1/87 0/53 0.1 % 1.84 [ 0.08, 44.38 ]
SCIMO 1999 1/112 4/111 0.1 % 0.25 [ 0.03, 2.18 ]
SOFA 2006 1/273 3/273 0.1 % 0.33 [ 0.03, 3.18 ]
SU.FOL.OM3 2010 32/1253 32/1248 2.8 % 1.00 [ 0.61, 1.62 ]
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Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Subtotal (95% CI) 15088 14937 50.9 % 1.03 [ 0.92, 1.15 ]
Total events: 585 (Higher omega 3), 569 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 6.97, df = 10 (P = 0.73); I2 =0.0%
Test for overall effect: Z = 0.46 (P = 0.65)
2 Moderate to high risk of bias
Baldassarre 2006 1/32 0/32 0.1 % 3.00 [ 0.13, 71.00 ]
Brox 2001 0/80 1/40 0.1 % 0.17 [ 0.01, 4.05 ]
DART 1989 207/1015 215/1018 22.5 % 0.97 [ 0.81, 1.14 ]
DO IT 2010 11/282 9/281 0.9 % 1.22 [ 0.51, 2.89 ]
Doi 2014 1/119 0/119 0.1 % 3.00 [ 0.12, 72.91 ]
GISSI-HF 2008 107/3494 129/3481 10.2 % 0.83 [ 0.64, 1.06 ]
HARP 1995 1/41 3/39 0.1 % 0.32 [ 0.03, 2.92 ]
JELIS 2007 71/9326 93/9319 6.9 % 0.76 [ 0.56, 1.04 ]
Raitt 2005 1/100 3/100 0.1 % 0.33 [ 0.04, 3.15 ]
Risk % Prevention 2013 80/6239 90/6266 7.3 % 0.89 [ 0.66, 1.20 ]
SHOT 1996 7/317 12/293 0.8 % 0.54 [ 0.22, 1.35 ]
THIS DIET 2008 1/51 3/50 0.1 % 0.33 [ 0.04, 3.04 ]
Subtotal (95% CI) 21096 21038 49.1 % 0.88 [ 0.79, 0.99 ]
Total events: 488 (Higher omega 3), 558 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 8.36, df = 11 (P = 0.68); I2 =0.0%
Test for overall effect: Z = 2.13 (P = 0.033)
Total (95% CI) 36184 35975 100.0 % 0.95 [ 0.88, 1.03 ]
Total events: 1073 (Higher omega 3), 1127 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 18.70, df = 22 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 1.17 (P = 0.24)
Test for subgroup differences: Chi2 = 3.39, df = 1 (P = 0.07), I2 =70%
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Analysis 2.4. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 4 Total MI -
LCn3 - SA by compliance and study size.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 2 High vs low LCn3 omega-3 fats (secondary outcomes)
Outcome: 4 Total MI - LCn3 - SA by compliance and study size
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 SA - low risk of compliance bias
AlphaOmega - EPA+DHA 2010 89/2404 102/2433 40.7 % 0.88 [ 0.67, 1.17 ]
Baldassarre 2006 1/32 0/32 0.3 % 3.00 [ 0.13, 71.00 ]
Brox 2001 0/80 1/40 0.3 % 0.17 [ 0.01, 4.05 ]
DO IT 2010 11/282 9/281 4.2 % 1.22 [ 0.51, 2.89 ]
HARP 1995 1/41 3/39 0.6 % 0.32 [ 0.03, 2.92 ]
OMEGA 2009 87/1919 78/1885 35.3 % 1.10 [ 0.81, 1.48 ]
Raitt 2005 1/100 3/100 0.6 % 0.33 [ 0.04, 3.15 ]
SCIMO 1999 1/112 4/111 0.7 % 0.25 [ 0.03, 2.18 ]
SHOT 1996 7/317 12/293 3.7 % 0.54 [ 0.22, 1.35 ]
SU.FOL.OM3 2010 32/1253 32/1248 13.5 % 1.00 [ 0.61, 1.62 ]
Subtotal (95% CI) 6540 6462 100.0 % 0.94 [ 0.79, 1.13 ]
Total events: 230 (Higher omega 3), 244 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 7.84, df = 9 (P = 0.55); I2 =0.0%
Test for overall effect: Z = 0.65 (P = 0.51)
2 SA - 100+ randomised
AlphaOmega - EPA+DHA 2010 89/2404 102/2433 8.4 % 0.88 [ 0.67, 1.17 ]
AREDS2 2014 28/2147 30/2056 2.5 % 0.89 [ 0.54, 1.49 ]
Brox 2001 0/80 1/40 0.1 % 0.17 [ 0.01, 4.05 ]
DART 1989 207/1015 215/1018 22.6 % 0.97 [ 0.81, 1.14 ]
Derosa 2016 0/128 3/130 0.1 % 0.15 [ 0.01, 2.78 ]
DO IT 2010 11/282 9/281 0.9 % 1.22 [ 0.51, 2.89 ]
Doi 2014 1/119 0/119 0.1 % 3.00 [ 0.12, 72.91 ]
EPOCH 2014 1/195 0/196 0.1 % 3.02 [ 0.12, 73.57 ]
FORWARD 2013 1/289 1/297 0.1 % 1.03 [ 0.06, 16.35 ]
GISSI-HF 2008 107/3494 129/3481 10.3 % 0.83 [ 0.64, 1.06 ]
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Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
JELIS 2007 71/9326 93/9319 6.9 % 0.76 [ 0.56, 1.04 ]
OMEGA 2009 87/1919 78/1885 7.3 % 1.10 [ 0.81, 1.48 ]
ORIGIN 2012 344/6281 316/6255 29.5 % 1.08 [ 0.93, 1.26 ]
Proudman 2015 1/87 0/53 0.1 % 1.84 [ 0.08, 44.38 ]
Raitt 2005 1/100 3/100 0.1 % 0.33 [ 0.04, 3.15 ]
Risk % Prevention 2013 80/6239 90/6266 7.3 % 0.89 [ 0.66, 1.20 ]
SCIMO 1999 1/112 4/111 0.1 % 0.25 [ 0.03, 2.18 ]
SHOT 1996 7/317 12/293 0.8 % 0.54 [ 0.22, 1.35 ]
SOFA 2006 1/273 3/273 0.1 % 0.33 [ 0.03, 3.18 ]
SU.FOL.OM3 2010 32/1253 32/1248 2.8 % 1.00 [ 0.61, 1.62 ]
THIS DIET 2008 1/51 3/50 0.1 % 0.33 [ 0.04, 3.04 ]
Subtotal (95% CI) 36111 35904 100.0 % 0.95 [ 0.88, 1.03 ]
Total events: 1071 (Higher omega 3), 1124 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 17.25, df = 20 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 1.15 (P = 0.25)
Test for subgroup differences: Chi2 = 0.01, df = 1 (P = 0.90), I2 =0.0%
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Analysis 2.5. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 5 Total MI -
LCn3 - subgroup by fatality.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 2 High vs low LCn3 omega-3 fats (secondary outcomes)
Outcome: 5 Total MI - LCn3 - subgroup by fatality
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Fatal MI
AlphaOmega - EPA+DHA 2010 36/2404 102/2433 14.4 % 0.36 [ 0.25, 0.52 ]
AREDS2 2014 3/2147 0/2056 1.4 % 6.70 [ 0.35, 129.70 ]
Brox 2001 0/80 1/40 1.2 % 0.17 [ 0.01, 4.05 ]
DART 1989 56/1015 84/1018 14.9 % 0.67 [ 0.48, 0.93 ]
DART2 2003 102/1571 76/1543 15.3 % 1.32 [ 0.99, 1.76 ]
Derosa 2016 0/128 1/130 1.2 % 0.34 [ 0.01, 8.23 ]
DO IT 2010 0/282 2/281 1.3 % 0.20 [ 0.01, 4.13 ]
GISSI-HF 2008 20/3494 25/3481 11.8 % 0.80 [ 0.44, 1.43 ]
HARP 1995 0/41 1/39 1.2 % 0.32 [ 0.01, 7.57 ]
JELIS 2007 11/9326 14/9319 9.5 % 0.79 [ 0.36, 1.73 ]
OMEGA 2009 13/1919 11/1885 9.4 % 1.16 [ 0.52, 2.58 ]
Risk % Prevention 2013 10/6239 13/6266 9.1 % 0.77 [ 0.34, 1.76 ]
SCIMO 1999 0/112 1/111 1.2 % 0.33 [ 0.01, 8.02 ]
SHOT 1996 7/317 4/293 5.9 % 1.62 [ 0.48, 5.47 ]
SU.FOL.OM3 2010 1/1253 2/1248 2.0 % 0.50 [ 0.05, 5.49 ]
Subtotal (95% CI) 30328 30143 100.0 % 0.76 [ 0.53, 1.10 ]
Total events: 259 (Higher omega 3), 337 (Lower omega 3)
Heterogeneity: Tau2 = 0.20; Chi2 = 37.23, df = 14 (P = 0.00068); I2 =62%
Test for overall effect: Z = 1.44 (P = 0.15)
2 Non-fatal MI
AlphaOmega - EPA+DHA 2010 53/2404 57/2433 7.4 % 0.94 [ 0.65, 1.36 ]
AREDS2 2014 25/2147 30/2433 3.6 % 0.94 [ 0.56, 1.60 ]
Baldassarre 2006 1/32 0/32 0.1 % 3.00 [ 0.13, 71.00 ]
DART 1989 49/1015 33/1018 5.4 % 1.49 [ 0.97, 2.30 ]
Derosa 2016 0/128 2/130 0.1 % 0.20 [ 0.01, 4.19 ]
0.1 0.2 0.5 1 2 5 10
Favours higher omega 3 Favours lower omega 3
(Continued . . . )
456Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(. . . Continued)
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
DO IT 2010 11/282 7/281 1.2 % 1.57 [ 0.62, 3.98 ]
Doi 2014 1/119 0/119 0.1 % 3.00 [ 0.12, 72.91 ]
EPOCH 2014 1/195 0/196 0.1 % 3.02 [ 0.12, 73.57 ]
GISSI-HF 2008 87/3494 104/3481 12.9 % 0.83 [ 0.63, 1.10 ]
GISSI-P 1999 223/5665 233/5658 31.4 % 0.96 [ 0.80, 1.14 ]
HARP 1995 1/41 2/39 0.2 % 0.48 [ 0.04, 5.04 ]
JELIS 2007 62/9326 83/9319 9.5 % 0.75 [ 0.54, 1.04 ]
OFAMI 2001 21/150 15/150 2.6 % 1.40 [ 0.75, 2.61 ]
OMEGA 2009 74/1662 67/1631 9.7 % 1.08 [ 0.78, 1.50 ]
OPAL 2010 5/376 9/372 0.9 % 0.55 [ 0.19, 1.62 ]
Proudman 2015 1/86 0/53 0.1 % 1.86 [ 0.08, 44.89 ]
Risk % Prevention 2013 70/6239 77/6266 9.8 % 0.91 [ 0.66, 1.26 ]
SCIMO 1999 1/112 3/111 0.2 % 0.33 [ 0.03, 3.13 ]
SHOT 1996 5/317 3/293 0.5 % 1.54 [ 0.37, 6.39 ]
SU.FOL.OM3 2010 32/1253 28/1248 4.0 % 1.14 [ 0.69, 1.88 ]
THIS DIET 2008 1/51 3/50 0.2 % 0.33 [ 0.04, 3.04 ]
Subtotal (95% CI) 35094 35313 100.0 % 0.96 [ 0.87, 1.06 ]
Total events: 724 (Higher omega 3), 756 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 16.96, df = 20 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 0.75 (P = 0.45)
Test for subgroup differences: Chi2 = 1.41, df = 1 (P = 0.23), I2 =29%
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Analysis 2.6. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 6 Sudden
cardiac death (overall) - LCn3.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 2 High vs low LCn3 omega-3 fats (secondary outcomes)
Outcome: 6 Sudden cardiac death (overall) - LCn3
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
AREDS2 2014 7/2147 9/2056 3.4 % 0.74 [ 0.28, 2.00 ]
Brox 2001 0/80 0/40 Not estimable
DART2 2003 73/1571 47/1543 14.5 % 1.53 [ 1.06, 2.19 ]
DO IT 2010 3/282 5/281 1.7 % 0.60 [ 0.14, 2.48 ]
Doi 2014 0/119 2/119 0.4 % 0.20 [ 0.01, 4.12 ]
FOSTAR 2016 0/101 1/101 0.4 % 0.33 [ 0.01, 8.09 ]
GISSI-HF 2008 307/3494 325/3481 25.1 % 0.94 [ 0.81, 1.09 ]
GISSI-P 1999 122/5666 164/5658 20.7 % 0.74 [ 0.59, 0.94 ]
JELIS 2007 18/9326 17/9319 6.6 % 1.06 [ 0.55, 2.05 ]
OMEGA 2009 28/1919 29/1885 9.5 % 0.95 [ 0.57, 1.59 ]
Raitt 2005 2/100 0/100 0.4 % 5.00 [ 0.24, 102.85 ]
Risk % Prevention 2013 49/6239 40/6266 12.4 % 1.23 [ 0.81, 1.87 ]
SHOT 1996 7/317 4/293 2.3 % 1.62 [ 0.48, 5.47 ]
SU.FOL.OM3 2010 4/1253 11/1248 2.6 % 0.36 [ 0.12, 1.13 ]
Total (95% CI) 32614 32390 100.0 % 0.97 [ 0.80, 1.18 ]
Total events: 620 (Higher omega 3), 654 (Lower omega 3)
Heterogeneity: Tau2 = 0.03; Chi2 = 19.29, df = 12 (P = 0.08); I2 =38%
Test for overall effect: Z = 0.29 (P = 0.77)
Test for subgroup differences: Not applicable
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Analysis 2.7. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 7 Angina -
LCn3.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 2 High vs low LCn3 omega-3 fats (secondary outcomes)
Outcome: 7 Angina - LCn3
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
AREDS2 2014 26/2147 25/2056 1.9 % 1.00 [ 0.58, 1.72 ]
EPE-A 2014 2/168 1/75 0.1 % 0.89 [ 0.08, 9.70 ]
FAAT 2005 (1) 0/200 4/202 0.1 % 0.11 [ 0.01, 2.07 ]
GISSI-P 1999 254/2836 249/2828 20.7 % 1.02 [ 0.86, 1.20 ]
Nye 1990 5/36 11/37 0.6 % 0.47 [ 0.18, 1.21 ]
OMEGA 2009 21/1661 25/1651 1.7 % 0.83 [ 0.47, 1.49 ]
ORIGIN 2012 724/6281 725/6255 61.4 % 0.99 [ 0.90, 1.10 ]
Raitt 2005 10/100 7/100 0.7 % 1.43 [ 0.57, 3.60 ]
Risk % Prevention 2013 143/6239 148/6266 11.2 % 0.97 [ 0.77, 1.22 ]
SCIMO 1999 9/112 11/111 0.8 % 0.81 [ 0.35, 1.88 ]
SOFA 2006 10/273 12/273 0.9 % 0.83 [ 0.37, 1.90 ]
Total (95% CI) 20053 19854 100.0 % 0.99 [ 0.91, 1.06 ]
Total events: 1204 (Higher omega 3), 1218 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 6.00, df = 10 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 0.35 (P = 0.72)
Test for subgroup differences: Not applicable
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Analysis 2.8. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 8 Heart
failure - LCn3.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 2 High vs low LCn3 omega-3 fats (secondary outcomes)
Outcome: 8 Heart failure - LCn3
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Low summary risk of bias
AREDS2 2014 55/2147 49/2056 5.8 % 1.07 [ 0.73, 1.57 ]
FORWARD 2013 5/289 6/297 0.7 % 0.86 [ 0.26, 2.78 ]
OMEGA 2009 467/1919 492/1885 24.5 % 0.93 [ 0.84, 1.04 ]
ORIGIN 2012 331/6281 320/6255 19.5 % 1.03 [ 0.89, 1.20 ]
SOFA 2006 22/273 19/273 2.7 % 1.16 [ 0.64, 2.09 ]
SU.FOL.OM3 2010 21/1253 22/1248 2.6 % 0.95 [ 0.53, 1.72 ]
Subtotal (95% CI) 12162 12014 55.8 % 0.97 [ 0.89, 1.06 ]
Total events: 901 (Higher omega 3), 908 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.81, df = 5 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 0.63 (P = 0.53)
2 Moderate to high risk of bias
DART 1989 5/1015 4/1018 0.6 % 1.25 [ 0.34, 4.66 ]
DART2 2003 1/1571 2/1543 0.2 % 0.49 [ 0.04, 5.41 ]
FAAT 2005 6/200 8/202 0.9 % 0.76 [ 0.27, 2.14 ]
GISSI-HF 2008 978/3494 995/3481 29.0 % 0.98 [ 0.91, 1.06 ]
HARP 1995 0/41 1/39 0.1 % 0.32 [ 0.01, 7.57 ]
Nodari 2011 HF 4/67 20/66 0.9 % 0.20 [ 0.07, 0.55 ]
Raitt 2005 14/100 12/100 1.8 % 1.17 [ 0.57, 2.40 ]
Risk % Prevention 2013 96/6239 142/6266 10.6 % 0.68 [ 0.53, 0.88 ]
Shinto 2014 1/13 0/13 0.1 % 3.00 [ 0.13, 67.51 ]
Subtotal (95% CI) 12740 12728 44.2 % 0.78 [ 0.57, 1.08 ]
Total events: 1105 (Higher omega 3), 1184 (Lower omega 3)
Heterogeneity: Tau2 = 0.07; Chi2 = 18.50, df = 8 (P = 0.02); I2 =57%
Test for overall effect: Z = 1.51 (P = 0.13)
Total (95% CI) 24902 24742 100.0 % 0.93 [ 0.85, 1.03 ]
Total events: 2006 (Higher omega 3), 2092 (Lower omega 3)
Heterogeneity: Tau2 = 0.01; Chi2 = 20.40, df = 14 (P = 0.12); I2 =31%
Test for overall effect: Z = 1.32 (P = 0.19)
Test for subgroup differences: Chi2 = 1.68, df = 1 (P = 0.19), I2 =41%
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Analysis 2.9. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 9
Revascularisation - LCn3.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 2 High vs low LCn3 omega-3 fats (secondary outcomes)
Outcome: 9 Revascularisation - LCn3
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 CABG - LCn3
Doi 2014 1/119 1/119 23.4 % 1.00 [ 0.06, 15.80 ]
EPOCH 2014 0/195 1/196 17.5 % 0.34 [ 0.01, 8.17 ]
Nye 1990 1/36 1/37 23.9 % 1.03 [ 0.07, 15.82 ]
SCIMO 1999 1/112 3/111 35.3 % 0.33 [ 0.03, 3.13 ]
SHOT 1996 0/317 0/293 Not estimable
Subtotal (95% CI) 779 756 100.0 % 0.56 [ 0.15, 2.14 ]
Total events: 3 (Higher omega 3), 6 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.67, df = 3 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 0.84 (P = 0.40)
2 Angioplasty - LCn3
EPOCH 2014 2/195 1/196 1.1 % 2.01 [ 0.18, 21.99 ]
HARP 1995 3/41 3/39 2.8 % 0.95 [ 0.20, 4.43 ]
SCIMO 1999 25/112 19/111 22.8 % 1.30 [ 0.76, 2.23 ]
SU.FOL.OM3 2010 75/1253 87/1248 73.3 % 0.86 [ 0.64, 1.16 ]
Subtotal (95% CI) 1601 1594 100.0 % 0.96 [ 0.74, 1.24 ]
Total events: 105 (Higher omega 3), 110 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.16, df = 3 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 0.34 (P = 0.73)
3 Any revascularisation - LCn3
AREDS2 2014 60/2147 53/2056 1.5 % 1.08 [ 0.75, 1.56 ]
Doi 2014 9/119 15/119 0.3 % 0.60 [ 0.27, 1.32 ]
GISSI-P 1999 1104/5666 1053/5658 33.8 % 1.05 [ 0.97, 1.13 ]
HARP 1995 3/41 3/39 0.1 % 0.95 [ 0.20, 4.43 ]
JELIS 2007 191/9326 222/9319 5.3 % 0.86 [ 0.71, 1.04 ]
OFAMI 2001 43/150 49/150 1.7 % 0.88 [ 0.62, 1.23 ]
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(. . . Continued)
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
OMEGA 2009 466/1686 482/1654 16.8 % 0.95 [ 0.85, 1.06 ]
ORIGIN 2012 866/6281 896/6255 26.0 % 0.96 [ 0.88, 1.05 ]
Raitt 2005 2/100 4/100 0.1 % 0.50 [ 0.09, 2.67 ]
Risk % Prevention 2013 334/6239 347/6266 9.1 % 0.97 [ 0.84, 1.12 ]
SCIMO 1999 26/112 22/111 0.8 % 1.17 [ 0.71, 1.94 ]
SU.FOL.OM3 2010 152/1253 156/1248 4.5 % 0.97 [ 0.79, 1.20 ]
Subtotal (95% CI) 33120 32975 100.0 % 0.98 [ 0.94, 1.03 ]
Total events: 3256 (Higher omega 3), 3302 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 8.56, df = 11 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 0.79 (P = 0.43)
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Analysis 2.10. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 10 Peripheral
arterial disease - LCn3.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 2 High vs low LCn3 omega-3 fats (secondary outcomes)
Outcome: 10 Peripheral arterial disease - LCn3
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
JELIS 2007 21/9326 29/9319 17.3 % 0.72 [ 0.41, 1.27 ]
ORIGIN 2012 52/6281 47/6255 35.2 % 1.10 [ 0.74, 1.63 ]
Risk % Prevention 2013 62/6239 68/6266 46.3 % 0.92 [ 0.65, 1.29 ]
FOSTAR 2016 1/101 1/101 0.7 % 1.00 [ 0.06, 15.77 ]
DART 1989 0/1015 1/1018 0.5 % 0.33 [ 0.01, 8.20 ]
DART2 2003 0/1571 0/1543 Not estimable
Total (95% CI) 24533 24502 100.0 % 0.93 [ 0.74, 1.18 ]
Total events: 136 (Higher omega 3), 146 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.89, df = 4 (P = 0.76); I2 =0.0%
Test for overall effect: Z = 0.57 (P = 0.57)
Test for subgroup differences: Not applicable
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Analysis 2.11. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 11 PAD -
LCn3 - SA by summary risk of bias.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 2 High vs low LCn3 omega-3 fats (secondary outcomes)
Outcome: 11 PAD - LCn3 - SA by summary risk of bias
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Low summary risk of bias
ORIGIN 2012 52/6281 47/6255 98.0 % 1.10 [ 0.74, 1.63 ]
FOSTAR 2016 1/101 1/101 2.0 % 1.00 [ 0.06, 15.77 ]
Subtotal (95% CI) 6382 6356 100.0 % 1.10 [ 0.75, 1.62 ]
Total events: 53 (Higher omega 3), 48 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 0.95); I2 =0.0%
Test for overall effect: Z = 0.48 (P = 0.63)
2 Moderate to high summary risk of bias
JELIS 2007 21/9326 29/9319 26.9 % 0.72 [ 0.41, 1.27 ]
Risk % Prevention 2013 62/6239 68/6266 72.2 % 0.92 [ 0.65, 1.29 ]
DART 1989 0/1015 1/1018 0.8 % 0.33 [ 0.01, 8.20 ]
DART2 2003 0/1571 0/1543 Not estimable
Subtotal (95% CI) 18151 18146 100.0 % 0.85 [ 0.64, 1.14 ]
Total events: 83 (Higher omega 3), 98 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.82, df = 2 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 1.08 (P = 0.28)
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Analysis 2.12. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 12 PAD -
LCn3 - SA compliance and study size.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 2 High vs low LCn3 omega-3 fats (secondary outcomes)
Outcome: 12 PAD - LCn3 - SA compliance and study size
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 SA compliance
FOSTAR 2016 1/101 1/101 100.0 % 1.00 [ 0.06, 15.77 ]
Subtotal (95% CI) 101 101 100.0 % 1.00 [ 0.06, 15.77 ]
Total events: 1 (Higher omega 3), 1 (Lower omega 3)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
2 SA study size 100+
JELIS 2007 21/9326 29/9319 17.3 % 0.72 [ 0.41, 1.27 ]
ORIGIN 2012 52/6281 47/6255 35.2 % 1.10 [ 0.74, 1.63 ]
Risk % Prevention 2013 62/6239 68/6266 46.3 % 0.92 [ 0.65, 1.29 ]
FOSTAR 2016 1/101 1/101 0.7 % 1.00 [ 0.06, 15.77 ]
DART 1989 0/1015 1/1018 0.5 % 0.33 [ 0.01, 8.20 ]
DART2 2003 0/1571 0/1543 Not estimable
Subtotal (95% CI) 24533 24502 100.0 % 0.93 [ 0.74, 1.18 ]
Total events: 136 (Higher omega 3), 146 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.89, df = 4 (P = 0.76); I2 =0.0%
Test for overall effect: Z = 0.57 (P = 0.57)
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Analysis 2.13. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 13 Acute
coronary syndrome - LCn3.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 2 High vs low LCn3 omega-3 fats (secondary outcomes)
Outcome: 13 Acute coronary syndrome - LCn3
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 LCn3
FOSTAR 2016 10/101 10/101 39.0 % 1.00 [ 0.44, 2.30 ]
SU.FOL.OM3 2010 20/1253 15/1248 61.0 % 1.33 [ 0.68, 2.58 ]
Subtotal (95% CI) 1354 1349 100.0 % 1.19 [ 0.71, 2.00 ]
Total events: 30 (Higher omega 3), 25 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.27, df = 1 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 0.65 (P = 0.51)
Test for subgroup differences: Not applicable
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Analysis 2.14. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 14 Body
weight, kg - LCn3.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 2 High vs low LCn3 omega-3 fats (secondary outcomes)
Outcome: 14 Body weight, kg - LCn3
Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Caldwell 2011 (1) 20 -1.5 (4.5) 21 -0.2 (3.7) 7.9 % -1.30 [ -3.83, 1.23 ]
Derosa 2016 128 78.7 (7.9) 130 81.4 (8.9) 10.5 % -2.70 [ -4.75, -0.65 ]
EPE-A 2014 (2) 64 0 (0) 55 -1 (0) Not estimable
FOSTAR 2016 101 1.8 (5.02) 101 0.3 (4.02) 17.6 % 1.50 [ 0.25, 2.75 ]
HARP 1995 31 82 (14) 28 80 (15) 1.2 % 2.00 [ -5.43, 9.43 ]
MARINA 2011 (3) 80 0.2 (1.8) 71 -0.3 (2.53) 24.2 % 0.50 [ -0.21, 1.21 ]
Norouzi 2014 54 71.37 (14.42) 50 70.77 (14.35) 2.1 % 0.60 [ -4.93, 6.13 ]
ORIGIN 2012 8281 83.9 (17.8) 6255 83.8 (17.6) 25.7 % 0.10 [ -0.48, 0.68 ]
SCIMO 1999 89 79.1 (12.5) 86 81 (12.3) 4.3 % -1.90 [ -5.57, 1.77 ]
SMART 2013 20 84.3 (11.7) 25 80.9 (12.7) 1.3 % 3.40 [ -3.75, 10.55 ]
Weinstock-Guttman 2005 13 -2.68 (6.21) 14 0.23 (5.08) 3.3 % -2.91 [ -7.21, 1.39 ]
WELCOME 2015 47 94.1 (13) 48 90.4 (16.3) 1.8 % 3.70 [ -2.22, 9.62 ]
Total (95% CI) 8928 6884 100.0 % -0.01 [ -0.84, 0.82 ]
Heterogeneity: Tau2 = 0.61; Chi2 = 19.57, df = 10 (P = 0.03); I2 =49%
Test for overall effect: Z = 0.01 (P = 0.99)
Test for subgroup differences: Not applicable
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(1) Unbalanced at baseline, change data used
(2) median change from baseline, highest EPA vs placebo
(3) 0.9g/d n3 vs placebo (as these arms were well balanced for weight at baseline)
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Analysis 2.15. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 15 Weight,
kg - LCn3 - SA by summary risk of bias.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 2 High vs low LCn3 omega-3 fats (secondary outcomes)
Outcome: 15 Weight, kg - LCn3 - SA by summary risk of bias
Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Low risk of bias
Caldwell 2011 (1) 20 -1.5 (4.5) 21 -0.2 (3.7) 7.9 % -1.30 [ -3.83, 1.23 ]
Derosa 2016 128 78.7 (7.9) 130 81.4 (8.9) 10.5 % -2.70 [ -4.75, -0.65 ]
FOSTAR 2016 101 1.8 (5.02) 101 0.3 (4.02) 17.6 % 1.50 [ 0.25, 2.75 ]
MARINA 2011 (2) 80 0.2 (1.8) 71 -0.3 (2.53) 24.2 % 0.50 [ -0.21, 1.21 ]
ORIGIN 2012 8281 83.9 (17.8) 6255 83.8 (17.6) 25.7 % 0.10 [ -0.48, 0.68 ]
SCIMO 1999 89 79.1 (12.5) 86 81 (12.3) 4.3 % -1.90 [ -5.57, 1.77 ]
WELCOME 2015 47 94.1 (13) 48 90.4 (16.3) 1.8 % 3.70 [ -2.22, 9.62 ]
Subtotal (95% CI) 8746 6712 92.1 % -0.01 [ -0.91, 0.90 ]
Heterogeneity: Tau2 = 0.70; Chi2 = 16.53, df = 6 (P = 0.01); I2 =64%
Test for overall effect: Z = 0.02 (P = 0.98)
2 Moderate/high risk of bias
EPE-A 2014 (3) 64 0 (0) 55 -1 (0) Not estimable
HARP 1995 31 82 (14) 28 80 (15) 1.2 % 2.00 [ -5.43, 9.43 ]
Norouzi 2014 54 71.37 (14.42) 50 70.77 (14.35) 2.1 % 0.60 [ -4.93, 6.13 ]
SMART 2013 20 84.3 (11.7) 25 80.9 (12.7) 1.3 % 3.40 [ -3.75, 10.55 ]
Weinstock-Guttman 2005 13 -2.68 (6.21) 14 0.23 (5.08) 3.3 % -2.91 [ -7.21, 1.39 ]
Subtotal (95% CI) 182 172 7.9 % -0.28 [ -3.12, 2.55 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 2.92, df = 3 (P = 0.40); I2 =0.0%
Test for overall effect: Z = 0.19 (P = 0.85)
Total (95% CI) 8928 6884 100.0 % -0.01 [ -0.84, 0.82 ]
Heterogeneity: Tau2 = 0.61; Chi2 = 19.57, df = 10 (P = 0.03); I2 =49%
Test for overall effect: Z = 0.01 (P = 0.99)
Test for subgroup differences: Chi2 = 0.03, df = 1 (P = 0.86), I2 =0.0%
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(1) Unbalanced at baseline, change data used
(2) 0.9g/d n3 vs placebo (as these arms were well balanced for weight at baseline)
(3) median change from baseline, highest EPA vs placebo
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Analysis 2.16. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 16 Weight,
kg - LCn3 - SA by compliance and study size.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 2 High vs low LCn3 omega-3 fats (secondary outcomes)
Outcome: 16 Weight, kg - LCn3 - SA by compliance and study size
Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 SA - low risk of compliance bias
EPE-A 2014 (1) 64 0 (0) 55 -1 (0) Not estimable
FOSTAR 2016 101 1.8 (5.02) 101 0.3 (4.02) 33.5 % 1.50 [ 0.25, 2.75 ]
HARP 1995 31 82 (14) 28 80 (15) 2.1 % 2.00 [ -5.43, 9.43 ]
MARINA 2011 (2) 80 0.2 (1.8) 71 -0.3 (2.53) 47.4 % 0.50 [ -0.21, 1.21 ]
SCIMO 1999 89 79.1 (12.5) 86 81 (12.3) 7.8 % -1.90 [ -5.57, 1.77 ]
Weinstock-Guttman 2005 13 -2.68 (6.21) 14 0.23 (5.08) 5.9 % -2.91 [ -7.21, 1.39 ]
WELCOME 2015 47 94.1 (13) 48 90.4 (16.3) 3.3 % 3.70 [ -2.22, 9.62 ]
Subtotal (95% CI) 425 403 100.0 % 0.58 [ -0.52, 1.69 ]
Heterogeneity: Tau2 = 0.54; Chi2 = 7.57, df = 5 (P = 0.18); I2 =34%
Test for overall effect: Z = 1.03 (P = 0.30)
2 SA - 100+ randomised
Derosa 2016 128 78.7 (7.9) 130 81.4 (8.9) 12.5 % -2.70 [ -4.75, -0.65 ]
EPE-A 2014 (3) 64 0 (0) 55 -1 (0) Not estimable
FOSTAR 2016 101 1.8 (5.02) 101 0.3 (4.02) 20.9 % 1.50 [ 0.25, 2.75 ]
MARINA 2011 (4) 80 0.2 (1.8) 71 -0.3 (2.53) 28.6 % 0.50 [ -0.21, 1.21 ]
Norouzi 2014 54 71.37 (14.42) 50 70.77 (14.35) 2.5 % 0.60 [ -4.93, 6.13 ]
ORIGIN 2012 8281 83.9 (17.8) 6255 83.8 (17.6) 30.4 % 0.10 [ -0.48, 0.68 ]
SCIMO 1999 89 79.1 (12.5) 86 81 (12.3) 5.2 % -1.90 [ -5.57, 1.77 ]
Subtotal (95% CI) 8797 6748 100.0 % 0.07 [ -0.84, 0.97 ]
Heterogeneity: Tau2 = 0.62; Chi2 = 13.81, df = 5 (P = 0.02); I2 =64%
Test for overall effect: Z = 0.14 (P = 0.89)
Test for subgroup differences: Chi2 = 0.50, df = 1 (P = 0.48), I2 =0.0%
-4 -2 0 2 4
Favours higher omega 3 Favours lower omega 3
(1) median change from baseline, highest EPA vs placebo
(2) 0.9g/d n3 vs placebo (as these arms were well balanced for weight at baseline)
(3) median change from baseline, highest EPA vs placebo
(4) 0.9g/d n3 vs placebo (as these arms were well balanced for weight at baseline)
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Analysis 2.17. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 17 Weight,
kg - LCn3 - subgroup by dose.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 2 High vs low LCn3 omega-3 fats (secondary outcomes)
Outcome: 17 Weight, kg - LCn3 - subgroup by dose
Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 LCn3≤ 150 mg/d
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
2 LCn3 > 150≤ 250 mg/d
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
3 LCn3 > 250≤ 400 mg/d
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
4 LCn3 > 400≤ 2400 mg/d
Caldwell 2011 (1) 20 -1.5 (4.5) 21 -0.2 (3.7) 9.3 % -1.30 [ -3.83, 1.23 ]
Derosa 2016 128 78.7 (7.9) 130 81.4 (8.9) 12.6 % -2.70 [ -4.75, -0.65 ]
EPE-A 2014 55 0.5 (0) 55 -1 (0) Not estimable
MARINA 2011 (2) 80 0.2 (1.8) 71 -0.3 (2.53) 33.4 % 0.50 [ -0.21, 1.21 ]
Norouzi 2014 54 71.37 (14.42) 50 70.77 (14.35) 2.3 % 0.60 [ -4.93, 6.13 ]
ORIGIN 2012 8281 83.9 (17.8) 6255 83.8 (17.6) 36.0 % 0.10 [ -0.48, 0.68 ]
SCIMO 1999 89 79.1 (12.5) 86 81 (12.3) 5.0 % -1.90 [ -5.57, 1.77 ]
SMART 2013 20 84.3 (11.7) 25 80.9 (12.7) 1.4 % 3.40 [ -3.75, 10.55 ]
Subtotal (95% CI) 8727 6693 100.0 % -0.29 [ -1.16, 0.58 ]
Heterogeneity: Tau2 = 0.46; Chi2 = 11.52, df = 6 (P = 0.07); I2 =48%
Test for overall effect: Z = 0.65 (P = 0.51)
5 LCn3 > 2.4≤ 4.4 g/d
EPE-A 2014 (3) 64 0 (0) 55 -1 (0) Not estimable
Weinstock-Guttman 2005 13 -2.68 (6.21) 14 0.23 (5.08) 54.9 % -2.91 [ -7.21, 1.39 ]
WELCOME 2015 47 94.1 (13) 48 90.4 (16.3) 45.1 % 3.70 [ -2.22, 9.62 ]
-20 -10 0 10 20
Favours higher omega 3 Favours lower omega 3
(Continued . . . )
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(. . . Continued)
Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Subtotal (95% CI) 124 117 100.0 % 0.07 [ -6.38, 6.51 ]
Heterogeneity: Tau2 = 14.88; Chi2 = 3.13, df = 1 (P = 0.08); I2 =68%
Test for overall effect: Z = 0.02 (P = 0.98)
6 LCn3 > 4.4 g/d
FOSTAR 2016 101 1.8 (5.02) 101 0.3 (4.02) 97.2 % 1.50 [ 0.25, 2.75 ]
HARP 1995 31 82 (14) 28 80 (15) 2.8 % 2.00 [ -5.43, 9.43 ]
Subtotal (95% CI) 132 129 100.0 % 1.51 [ 0.28, 2.75 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.02, df = 1 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 2.40 (P = 0.016)
Test for subgroup differences: Chi2 = 5.48, df = 2 (P = 0.06), I2 =63%
-20 -10 0 10 20
Favours higher omega 3 Favours lower omega 3
(1) Unbalanced at baseline, change data used
(2) 0.9g/d n3 vs placebo (as these arms were well balanced for weight at baseline)
(3) median change from baseline, highest EPA vs placebo
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Analysis 2.18. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 18 Weight,
kg - LCn3 - subgroup by replacement.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 2 High vs low LCn3 omega-3 fats (secondary outcomes)
Outcome: 18 Weight, kg - LCn3 - subgroup by replacement
Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 N-3 replacing SFA
Derosa 2016 128 78.7 (7.9) 130 81.4 (8.9) 76.2 % -2.70 [ -4.75, -0.65 ]
SCIMO 1999 89 79.1 (12.5) 86 81 (12.3) 23.8 % -1.90 [ -5.57, 1.77 ]
Subtotal (95% CI) 217 216 100.0 % -2.51 [ -4.30, -0.72 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.14, df = 1 (P = 0.71); I2 =0.0%
Test for overall effect: Z = 2.74 (P = 0.0061)
2 N-3 replacing MUFA
HARP 1995 31 82 (14) 28 80 (15) 0.5 % 2.00 [ -5.43, 9.43 ]
MARINA 2011 (1) 80 0.2 (1.8) 71 -0.3 (2.53) 40.5 % 0.50 [ -0.21, 1.21 ]
ORIGIN 2012 8281 83.9 (17.8) 6255 83.8 (17.6) 54.4 % 0.10 [ -0.48, 0.68 ]
SCIMO 1999 89 79.1 (12.5) 86 81 (12.3) 1.9 % -1.90 [ -5.57, 1.77 ]
SMART 2013 20 84.3 (11.7) 25 80.9 (12.7) 0.5 % 3.40 [ -3.75, 10.55 ]
Weinstock-Guttman 2005 13 -2.68 (6.21) 14 0.23 (5.08) 1.4 % -2.91 [ -7.21, 1.39 ]
WELCOME 2015 47 94.1 (13) 48 90.4 (16.3) 0.7 % 3.70 [ -2.22, 9.62 ]
Subtotal (95% CI) 8561 6527 100.0 % 0.23 [ -0.28, 0.75 ]
Heterogeneity: Tau2 = 0.04; Chi2 = 6.38, df = 6 (P = 0.38); I2 =6%
Test for overall effect: Z = 0.90 (P = 0.37)
3 N-3 replacing n-6
Caldwell 2011 (2) 20 -1.5 (4.5) 21 -0.2 (3.7) 100.0 % -1.30 [ -3.83, 1.23 ]
Subtotal (95% CI) 20 21 100.0 % -1.30 [ -3.83, 1.23 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.01 (P = 0.31)
4 N-3 replacing carbs/sugars
Derosa 2016 128 78.7 (7.9) 130 81.4 (8.9) 100.0 % -2.70 [ -4.75, -0.65 ]
Subtotal (95% CI) 128 130 100.0 % -2.70 [ -4.75, -0.65 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.58 (P = 0.0099)
5 N-3 replacing nil/low n-3 placebo
FOSTAR 2016 101 1.8 (5.02) 101 0.3 (4.02) 100.0 % 1.50 [ 0.25, 2.75 ]
-4 -2 0 2 4
Favours higher omega 3 Favours lower omega 3
(Continued . . . )
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(. . . Continued)
Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Subtotal (95% CI) 101 101 100.0 % 1.50 [ 0.25, 2.75 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.34 (P = 0.019)
6 Replacement unclear
EPE-A 2014 (3) 64 0 (0) 55 -1 (0) Not estimable
Norouzi 2014 54 71.37 (14.42) 50 70.77 (14.35) 100.0 % 0.60 [ -4.93, 6.13 ]
Subtotal (95% CI) 118 105 100.0 % 0.60 [ -4.93, 6.13 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.21 (P = 0.83)
Test for subgroup differences: Chi2 = 21.50, df = 5 (P = 0.00), I2 =77%
-4 -2 0 2 4
Favours higher omega 3 Favours lower omega 3
(1) 0.9g/d n3 vs placebo (as these arms were well balanced for weight at baseline)
(2) Unbalanced at baseline, change data used
(3) median change from baseline, highest EPA vs placebo
473Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 2.19. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 19 Weight,
kg - LCn3 - subgroup by intervention type.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 2 High vs low LCn3 omega-3 fats (secondary outcomes)
Outcome: 19 Weight, kg - LCn3 - subgroup by intervention type
Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Dietary advice
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Supplemental foods
FOSTAR 2016 101 1.8 (5.02) 101 0.3 (4.02) 17.6 % 1.50 [ 0.25, 2.75 ]
Subtotal (95% CI) 101 101 17.6 % 1.50 [ 0.25, 2.75 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.34 (P = 0.019)
3 Supplement (capsule)
Caldwell 2011 (1) 20 -1.5 (4.5) 21 -0.2 (3.7) 7.9 % -1.30 [ -3.83, 1.23 ]
Derosa 2016 128 78.7 (7.9) 130 81.4 (8.9) 10.5 % -2.70 [ -4.75, -0.65 ]
EPE-A 2014 (2) 64 0 (0) 55 -1 (0) Not estimable
HARP 1995 31 82 (14) 28 80 (15) 1.2 % 2.00 [ -5.43, 9.43 ]
MARINA 2011 (3) 80 0.2 (1.8) 71 -0.3 (2.53) 24.2 % 0.50 [ -0.21, 1.21 ]
Norouzi 2014 54 71.37 (14.42) 50 70.77 (14.35) 2.1 % 0.60 [ -4.93, 6.13 ]
ORIGIN 2012 8281 83.9 (17.8) 6255 83.8 (17.6) 25.7 % 0.10 [ -0.48, 0.68 ]
SCIMO 1999 89 79.1 (12.5) 86 81 (12.3) 4.3 % -1.90 [ -5.57, 1.77 ]
WELCOME 2015 47 94.1 (13) 48 90.4 (16.3) 1.8 % 3.70 [ -2.22, 9.62 ]
Subtotal (95% CI) 8794 6744 77.8 % -0.23 [ -1.08, 0.63 ]
Heterogeneity: Tau2 = 0.44; Chi2 = 12.39, df = 7 (P = 0.09); I2 =43%
Test for overall effect: Z = 0.52 (P = 0.60)
4 Any combination
SMART 2013 20 84.3 (11.7) 25 80.9 (12.7) 1.3 % 3.40 [ -3.75, 10.55 ]
Weinstock-Guttman 2005 13 -2.68 (6.21) 14 0.23 (5.08) 3.3 % -2.91 [ -7.21, 1.39 ]
Subtotal (95% CI) 33 39 4.6 % -0.43 [ -6.47, 5.61 ]
Heterogeneity: Tau2 = 10.86; Chi2 = 2.20, df = 1 (P = 0.14); I2 =55%
Test for overall effect: Z = 0.14 (P = 0.89)
Total (95% CI) 8928 6884 100.0 % -0.01 [ -0.84, 0.82 ]
-20 -10 0 10 20
Favours higher omega 3 Favours lower omega 3
(Continued . . . )
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(. . . Continued)
Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Heterogeneity: Tau2 = 0.61; Chi2 = 19.57, df = 10 (P = 0.03); I2 =49%
Test for overall effect: Z = 0.01 (P = 0.99)
Test for subgroup differences: Chi2 = 5.04, df = 2 (P = 0.08), I2 =60%
-20 -10 0 10 20
Favours higher omega 3 Favours lower omega 3
(1) Unbalanced at baseline, change data used
(2) median change from baseline, highest EPA vs placebo
(3) 0.9g/d n3 vs placebo (as these arms were well balanced for weight at baseline)
Analysis 2.20. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 20 Weight,
kg - LCn3 - subgroup by duration.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 2 High vs low LCn3 omega-3 fats (secondary outcomes)
Outcome: 20 Weight, kg - LCn3 - subgroup by duration
Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Medium duration 1 to < 2 years in study
Caldwell 2011 (1) 20 -1.5 (4.5) 21 -0.2 (3.7) 18.7 % -1.30 [ -3.83, 1.23 ]
Derosa 2016 128 78.7 (7.9) 130 81.4 (8.9) 21.9 % -2.70 [ -4.75, -0.65 ]
EPE-A 2014 (2) 64 0 (0) 55 -1 (0) Not estimable
MARINA 2011 (3) 80 0.2 (1.8) 71 -0.3 (2.53) 31.0 % 0.50 [ -0.21, 1.21 ]
Norouzi 2014 54 71.37 (14.42) 50 70.77 (14.35) 7.1 % 0.60 [ -4.93, 6.13 ]
SMART 2013 20 84.3 (11.7) 25 80.9 (12.7) 4.7 % 3.40 [ -3.75, 10.55 ]
Weinstock-Guttman 2005 13 -2.68 (6.21) 14 0.23 (5.08) 10.3 % -2.91 [ -7.21, 1.39 ]
WELCOME 2015 47 94.1 (13) 48 90.4 (16.3) 6.4 % 3.70 [ -2.22, 9.62 ]
Subtotal (95% CI) 426 414 100.0 % -0.54 [ -2.21, 1.12 ]
-20 -10 0 10 20
Favours higher omega 3 Favours lower omega 3
(Continued . . . )
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(. . . Continued)
Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Heterogeneity: Tau2 = 2.20; Chi2 = 13.70, df = 6 (P = 0.03); I2 =56%
Test for overall effect: Z = 0.64 (P = 0.52)
2 Medium-long duration: 2 to < 4 years in study
FOSTAR 2016 101 1.8 (5.02) 101 0.3 (4.02) 66.0 % 1.50 [ 0.25, 2.75 ]
HARP 1995 31 82 (14) 28 80 (15) 8.2 % 2.00 [ -5.43, 9.43 ]
SCIMO 1999 89 79.1 (12.5) 86 81 (12.3) 25.7 % -1.90 [ -5.57, 1.77 ]
Subtotal (95% CI) 221 215 100.0 % 0.67 [ -1.58, 2.91 ]
Heterogeneity: Tau2 = 1.57; Chi2 = 3.00, df = 2 (P = 0.22); I2 =33%
Test for overall effect: Z = 0.58 (P = 0.56)
3 Long duration≥ 4 years in study
ORIGIN 2012 8281 83.9 (17.8) 6255 83.8 (17.6) 100.0 % 0.10 [ -0.48, 0.68 ]
Subtotal (95% CI) 8281 6255 100.0 % 0.10 [ -0.48, 0.68 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.34 (P = 0.74)
Test for subgroup differences: Chi2 = 0.80, df = 2 (P = 0.67), I2 =0.0%
-20 -10 0 10 20
Favours higher omega 3 Favours lower omega 3
(1) Unbalanced at baseline, change data used
(2) median change from baseline, highest EPA vs placebo
(3) 0.9g/d n3 vs placebo (as these arms were well balanced for weight at baseline)
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Analysis 2.21. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 21 Weight,
kg - LCn3 - subgroup by primary or secondary prevention.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 2 High vs low LCn3 omega-3 fats (secondary outcomes)
Outcome: 21 Weight, kg - LCn3 - subgroup by primary or secondary prevention
Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Primary CVD prevention
Caldwell 2011 (1) 20 -1.5 (4.5) 21 -0.2 (3.7) 8.6 % -1.30 [ -3.83, 1.23 ]
Derosa 2016 128 78.7 (7.9) 130 81.4 (8.9) 11.4 % -2.70 [ -4.75, -0.65 ]
EPE-A 2014 (2) 64 0 (0) 55 -1 (0) Not estimable
FOSTAR 2016 101 1.8 (5.02) 101 0.3 (4.02) 18.7 % 1.50 [ 0.25, 2.75 ]
MARINA 2011 (3) 80 0.2 (1.8) 71 -0.3 (2.53) 25.2 % 0.50 [ -0.21, 1.21 ]
Norouzi 2014 54 71.37 (14.42) 50 70.77 (14.35) 2.3 % 0.60 [ -4.93, 6.13 ]
ORIGIN 2012 8281 83.9 (17.8) 6255 83.8 (17.6) 26.7 % 0.10 [ -0.48, 0.68 ]
SMART 2013 20 84.3 (11.7) 25 80.9 (12.7) 1.4 % 3.40 [ -3.75, 10.55 ]
Weinstock-Guttman 2005 13 -2.68 (6.21) 14 0.23 (5.08) 3.7 % -2.91 [ -7.21, 1.39 ]
WELCOME 2015 47 94.1 (13) 48 90.4 (16.3) 2.0 % 3.70 [ -2.22, 9.62 ]
Subtotal (95% CI) 8808 6770 100.0 % 0.05 [ -0.83, 0.92 ]
Heterogeneity: Tau2 = 0.66; Chi2 = 18.06, df = 8 (P = 0.02); I2 =56%
Test for overall effect: Z = 0.10 (P = 0.92)
2 Secondary CVD prevention
HARP 1995 31 82 (14) 28 80 (15) 19.7 % 2.00 [ -5.43, 9.43 ]
SCIMO 1999 89 79.1 (12.5) 86 81 (12.3) 80.3 % -1.90 [ -5.57, 1.77 ]
Subtotal (95% CI) 120 114 100.0 % -1.13 [ -4.43, 2.16 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.85, df = 1 (P = 0.36); I2 =0.0%
Test for overall effect: Z = 0.67 (P = 0.50)
Test for subgroup differences: Chi2 = 0.46, df = 1 (P = 0.50), I2 =0.0%
-20 -10 0 10 20
Favours higher omega 3 Favours lower omega 3
(1) Unbalanced at baseline, change data used
(2) median change from baseline, highest EPA vs placebo
(3) 0.9g/d n3 vs placebo (as these arms were well balanced for weight at baseline)
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Analysis 2.22. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 22 Weight,
kg - LCn3 - subgroup by statin use.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 2 High vs low LCn3 omega-3 fats (secondary outcomes)
Outcome: 22 Weight, kg - LCn3 - subgroup by statin use
Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 LCn3 -≥ 50% of control group on statins
ORIGIN 2012 8281 83.9 (17.8) 6255 83.8 (17.6) 84.9 % 0.10 [ -0.48, 0.68 ]
WELCOME 2015 47 94.1 (13) 48 90.4 (16.3) 15.1 % 3.70 [ -2.22, 9.62 ]
Subtotal (95% CI) 8328 6303 100.0 % 0.64 [ -1.88, 3.17 ]
Heterogeneity: Tau2 = 1.87; Chi2 = 1.41, df = 1 (P = 0.24); I2 =29%
Test for overall effect: Z = 0.50 (P = 0.62)
2 LCn3 - < 50% of control group on statins
FOSTAR 2016 101 1.8 (5.02) 101 0.3 (4.02) 34.6 % 1.50 [ 0.25, 2.75 ]
HARP 1995 31 82 (14) 28 80 (15) 2.2 % 2.00 [ -5.43, 9.43 ]
MARINA 2011 (1) 80 0.2 (1.8) 71 -0.3 (2.53) 48.8 % 0.50 [ -0.21, 1.21 ]
SCIMO 1999 89 79.1 (12.5) 86 81 (12.3) 8.2 % -1.90 [ -5.57, 1.77 ]
Weinstock-Guttman 2005 13 -2.68 (6.21) 14 0.23 (5.08) 6.2 % -2.91 [ -7.21, 1.39 ]
Subtotal (95% CI) 314 300 100.0 % 0.47 [ -0.66, 1.60 ]
Heterogeneity: Tau2 = 0.55; Chi2 = 6.53, df = 4 (P = 0.16); I2 =39%
Test for overall effect: Z = 0.82 (P = 0.41)
3 LCn3 - use of statins unclear
Caldwell 2011 (2) 20 -1.5 (4.5) 21 -0.2 (3.7) 36.2 % -1.30 [ -3.83, 1.23 ]
Derosa 2016 128 78.7 (7.9) 130 81.4 (8.9) 48.2 % -2.70 [ -4.75, -0.65 ]
EPE-A 2014 (3) 64 0 (0) 55 -1 (0) Not estimable
Norouzi 2014 54 71.37 (14.42) 50 70.77 (14.35) 9.6 % 0.60 [ -4.93, 6.13 ]
SMART 2013 20 84.3 (11.7) 25 80.9 (12.7) 6.0 % 3.40 [ -3.75, 10.55 ]
Subtotal (95% CI) 286 281 100.0 % -1.51 [ -3.30, 0.27 ]
Heterogeneity: Tau2 = 0.62; Chi2 = 3.63, df = 3 (P = 0.30); I2 =17%
Test for overall effect: Z = 1.66 (P = 0.097)
Test for subgroup differences: Chi2 = 3.67, df = 2 (P = 0.16), I2 =46%
-20 -10 0 10 20
Favours higher omega 3 Favours lower omega 3
(1) 0.9g/d n3 vs placebo (as these arms were well balanced for weight at baseline)
(2) Unbalanced at baseline, change data used
(3) median change from baseline, highest EPA vs placebo
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Analysis 2.23. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 23 Body
mass index, kg/m² - LCn3.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 2 High vs low LCn3 omega-3 fats (secondary outcomes)
Outcome: 23 Body mass index, kg/m2 - LCn3
Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
AlphaOmega - EPA+DHA 2010 (1) 630 0.02 (1.8) 630 -0.08 (1.8) 25.3 % 0.10 [ -0.10, 0.30 ]
Caldwell 2011 (2) 20 -0.5 (4.5) 21 -0.2 (3.7) 0.6 % -0.30 [ -2.83, 2.23 ]
Derosa 2016 128 28.6 (2.1) 130 29.2 (2.3) 9.6 % -0.60 [ -1.14, -0.06 ]
DO IT 2010 124 26.8 (3.5) 117 27 (3.9) 3.9 % -0.20 [ -1.14, 0.74 ]
EPE-A 2014 (3) 64 0 (0) 55 -0.3 (0) Not estimable
Mita 2007 30 25.1 (5.3) 30 24.1 (3) 0.8 % 1.00 [ -1.18, 3.18 ]
Nodari 2011 HF 67 26 (0.4) 66 26 (0.6) 26.9 % 0.0 [ -0.17, 0.17 ]
Norouzi 2014 54 24.8 (4.91) 50 24.22 (4.2) 1.2 % 0.58 [ -1.17, 2.33 ]
OFAMI 2001 115 26.6 (3.9) 116 26 (3.2) 4.0 % 0.60 [ -0.32, 1.52 ]
ORIGIN 2012 6281 30.3 (5.6) 6255 30.3 (5.6) 25.4 % 0.0 [ -0.20, 0.20 ]
SMART 2013 20 29.8 (3.5) 25 28.2 (3.4) 0.9 % 1.60 [ -0.43, 3.63 ]
Sofi 2010 (4) 6 -0.6 (0) 5 -0.1 (0) Not estimable
Tande 2016 50 0.6 (9.69) 50 -0.4 (12.13) 0.2 % 1.00 [ -3.30, 5.30 ]
WELCOME 2015 47 33.4 (4.9) 48 30.8 (4.5) 1.1 % 2.60 [ 0.71, 4.49 ]
Total (95% CI) 7636 7598 100.0 % 0.04 [ -0.16, 0.24 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 18.44, df = 11 (P = 0.07); I2 =40%
Test for overall effect: Z = 0.41 (P = 0.68)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
Favours higher omega 3 Favours lower omega 3
(1) Number of participants equally divided between groups
(2) Unbalanced at baseline, change data used
(3) median change from baseline, highest EPA vs placebo
(4) median change at 1 year
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Analysis 2.24. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 24 BMI,
kg/m²- LCn3 - SA by summary risk of bias.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 2 High vs low LCn3 omega-3 fats (secondary outcomes)
Outcome: 24 BMI, kg/m2- LCn3 - SA by summary risk of bias
Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Low risk of bias
AlphaOmega - EPA+DHA 2010 630 0.02 (1.8) 630 -0.08 (1.8) 25.3 % 0.10 [ -0.10, 0.30 ]
Caldwell 2011 (1) 20 -0.5 (4.5) 21 -0.2 (3.7) 0.6 % -0.30 [ -2.83, 2.23 ]
Derosa 2016 128 28.6 (2.1) 130 29.2 (2.3) 9.6 % -0.60 [ -1.14, -0.06 ]
ORIGIN 2012 6281 30.3 (5.6) 6255 30.3 (5.6) 25.4 % 0.0 [ -0.20, 0.20 ]
WELCOME 2015 47 33.4 (4.9) 48 30.8 (4.5) 1.1 % 2.60 [ 0.71, 4.49 ]
Subtotal (95% CI) 7106 7084 62.0 % -0.01 [ -0.36, 0.33 ]
Heterogeneity: Tau2 = 0.08; Chi2 = 12.98, df = 4 (P = 0.01); I2 =69%
Test for overall effect: Z = 0.07 (P = 0.94)
2 Moderate/high risk of bias
DO IT 2010 124 26.8 (3.5) 117 27 (3.9) 3.9 % -0.20 [ -1.14, 0.74 ]
EPE-A 2014 (2) 64 0 (0) 55 -0.3 (0) Not estimable
Mita 2007 30 25.1 (5.3) 30 24.1 (3) 0.8 % 1.00 [ -1.18, 3.18 ]
Nodari 2011 HF 67 26 (0.4) 66 26 (0.6) 26.9 % 0.0 [ -0.17, 0.17 ]
Norouzi 2014 54 24.8 (4.91) 50 24.22 (4.2) 1.2 % 0.58 [ -1.17, 2.33 ]
OFAMI 2001 115 26.6 (3.9) 116 26 (3.2) 4.0 % 0.60 [ -0.32, 1.52 ]
SMART 2013 20 29.8 (3.5) 25 28.2 (3.4) 0.9 % 1.60 [ -0.43, 3.63 ]
Sofi 2010 (3) 6 -0.6 (0) 5 -0.1 (0) Not estimable
Tande 2016 50 0.6 (9.69) 50 -0.4 (12.13) 0.2 % 1.00 [ -3.30, 5.30 ]
Subtotal (95% CI) 530 514 38.0 % 0.04 [ -0.13, 0.20 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 5.44, df = 6 (P = 0.49); I2 =0.0%
Test for overall effect: Z = 0.43 (P = 0.67)
Total (95% CI) 7636 7598 100.0 % 0.04 [ -0.16, 0.24 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 18.44, df = 11 (P = 0.07); I2 =40%
Test for overall effect: Z = 0.41 (P = 0.68)
Test for subgroup differences: Chi2 = 0.06, df = 1 (P = 0.80), I2 =0.0%
-4 -2 0 2 4
Favours higher omega 3 Favours lower omega 3
(1) Unbalanced at baseline, change data used
(2) median change from baseline, highest EPA vs placebo
(3) median change at 1 year
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Analysis 2.25. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 25 BMI,
kg/m²- LCn3 - SA by compliance and study size.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 2 High vs low LCn3 omega-3 fats (secondary outcomes)
Outcome: 25 BMI, kg/m2- LCn3 - SA by compliance and study size
Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 SA - low risk of compliance bias
AlphaOmega - EPA+DHA 2010 630 0.02 (1.8) 630 -0.08 (1.8) 43.6 % 0.10 [ -0.10, 0.30 ]
DO IT 2010 124 26.8 (3.5) 117 27 (3.9) 8.2 % -0.20 [ -1.14, 0.74 ]
EPE-A 2014 (1) 64 0 (0) 55 -0.3 (0) Not estimable
Nodari 2011 HF 67 26 (0.4) 66 26 (0.6) 45.8 % 0.0 [ -0.17, 0.17 ]
WELCOME 2015 47 33.4 (4.9) 48 30.8 (4.5) 2.3 % 2.60 [ 0.71, 4.49 ]
Subtotal (95% CI) 932 916 100.0 % 0.09 [ -0.21, 0.38 ]
Heterogeneity: Tau2 = 0.04; Chi2 = 7.81, df = 3 (P = 0.05); I2 =62%
Test for overall effect: Z = 0.58 (P = 0.56)
2 SA - 100+ randomised
AlphaOmega - EPA+DHA 2010 630 0.02 (1.8) 630 -0.08 (1.8) 28.1 % 0.10 [ -0.10, 0.30 ]
Derosa 2016 128 28.6 (2.1) 130 29.2 (2.3) 5.3 % -0.60 [ -1.14, -0.06 ]
DO IT 2010 124 26.8 (3.5) 117 27 (3.9) 1.8 % -0.20 [ -1.14, 0.74 ]
EPE-A 2014 (2) 64 0 (0) 55 -0.3 (0) Not estimable
Nodari 2011 HF 67 26 (0.4) 66 26 (0.6) 33.6 % 0.0 [ -0.17, 0.17 ]
Norouzi 2014 54 24.8 (4.91) 50 24.22 (4.2) 0.5 % 0.58 [ -1.17, 2.33 ]
OFAMI 2001 115 26.6 (3.9) 116 26 (3.2) 1.9 % 0.60 [ -0.32, 1.52 ]
ORIGIN 2012 6281 30.3 (5.6) 6255 30.3 (5.6) 28.7 % 0.0 [ -0.20, 0.20 ]
Tande 2016 50 0.6 (9.69) 50 -0.4 (12.13) 0.1 % 1.00 [ -3.30, 5.30 ]
Subtotal (95% CI) 7513 7469 100.0 % 0.01 [ -0.12, 0.14 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 8.14, df = 7 (P = 0.32); I2 =14%
Test for overall effect: Z = 0.12 (P = 0.90)
Test for subgroup differences: Chi2 = 0.23, df = 1 (P = 0.63), I2 =0.0%
-4 -2 0 2 4
Favours higher omega 3 Favours lower omega 3
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(1) median change from baseline, highest EPA vs placebo
(2) median change from baseline, highest EPA vs placebo
Analysis 2.26. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 26 BMI,
kg/m² - LCn3 - subgroup by dose.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 2 High vs low LCn3 omega-3 fats (secondary outcomes)
Outcome: 26 BMI, kg/m2 - LCn3 - subgroup by dose
Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 LCn3 > 150≤ 250 mg/d
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
2 LCn3≤ 150 mg/d
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
3 LCn3 > 250≤ 400 mg/d
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
4 LCn3 > 400≤ 2400 mg/d
AlphaOmega - EPA+DHA 2010 630 0.02 (1.8) 630 -0.08 (1.8) 28.4 % 0.10 [ -0.10, 0.30 ]
Caldwell 2011 (1) 20 -0.5 (4.5) 21 -0.2 (3.7) 0.2 % -0.30 [ -2.83, 2.23 ]
Derosa 2016 128 28.6 (2.1) 130 29.2 (2.3) 4.9 % -0.60 [ -1.14, -0.06 ]
DO IT 2010 124 26.8 (3.5) 117 27 (3.9) 1.6 % -0.20 [ -1.14, 0.74 ]
Mita 2007 30 25.1 (5.3) 30 24.1 (3) 0.3 % 1.00 [ -1.18, 3.18 ]
Nodari 2011 HF 67 26 (0.4) 66 26 (0.6) 34.7 % 0.0 [ -0.17, 0.17 ]
Norouzi 2014 54 24.8 (4.91) 50 24.22 (4.2) 0.5 % 0.58 [ -1.17, 2.33 ]
ORIGIN 2012 6281 30.3 (5.6) 6255 30.3 (5.6) 29.0 % 0.0 [ -0.20, 0.20 ]
SMART 2013 20 29.8 (3.5) 25 28.2 (3.4) 0.4 % 1.60 [ -0.43, 3.63 ]
Sofi 2010 (2) 6 -0.6 (0) 5 -0.1 (0) Not estimable
-20 -10 0 10 20
Favours higher omega 3 Favours lower omega 3
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(. . . Continued)
Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Tande 2016 50 0.6 (9.69) 50 -0.4 (12.13) 0.1 % 1.00 [ -3.30, 5.30 ]
Subtotal (95% CI) 7410 7379 100.0 % 0.01 [ -0.11, 0.13 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 9.77, df = 9 (P = 0.37); I2 =8%
Test for overall effect: Z = 0.12 (P = 0.90)
5 LCn3 > 2.4≤ 4.4 g/d
EPE-A 2014 (3) 64 0 (0) 55 -0.3 (0) Not estimable
OFAMI 2001 115 26.6 (3.9) 116 26 (3.2) 58.9 % 0.60 [ -0.32, 1.52 ]
WELCOME 2015 47 33.4 (4.9) 48 30.8 (4.5) 41.1 % 2.60 [ 0.71, 4.49 ]
Subtotal (95% CI) 226 219 100.0 % 1.42 [ -0.51, 3.35 ]
Heterogeneity: Tau2 = 1.42; Chi2 = 3.47, df = 1 (P = 0.06); I2 =71%
Test for overall effect: Z = 1.45 (P = 0.15)
6 LCn3 > 4.4 g/d
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Chi2 = 2.06, df = 1 (P = 0.15), I2 =51%
-20 -10 0 10 20
Favours higher omega 3 Favours lower omega 3
(1) Unbalanced at baseline, change data used
(2) median change at 1 year
(3) median change from baseline, highest EPA vs placebo
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Analysis 2.27. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 27 BMI,
kg/m² - LCn3 - subgroup by replacement.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 2 High vs low LCn3 omega-3 fats (secondary outcomes)
Outcome: 27 BMI, kg/m2 - LCn3 - subgroup by replacement
Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 N-3 replacing SFA
Derosa 2016 128 28.6 (2.1) 130 29.2 (2.3) 100.0 % -0.60 [ -1.14, -0.06 ]
Subtotal (95% CI) 128 130 100.0 % -0.60 [ -1.14, -0.06 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.19 (P = 0.029)
2 N-3 replacing MUFA
AlphaOmega - EPA+DHA 2010 630 0.02 (1.8) 630 -0.08 (1.8) 31.7 % 0.10 [ -0.10, 0.30 ]
Nodari 2011 HF 67 26 (0.4) 66 26 (0.6) 34.1 % 0.0 [ -0.17, 0.17 ]
ORIGIN 2012 6281 30.3 (5.6) 6255 30.3 (5.6) 31.9 % 0.0 [ -0.20, 0.20 ]
SMART 2013 20 29.8 (3.5) 25 28.2 (3.4) 1.0 % 1.60 [ -0.43, 3.63 ]
Sofi 2010 (1) 6 -0.6 (0) 5 -0.1 (0) Not estimable
Tande 2016 50 0.6 (9.69) 50 -0.4 (12.13) 0.2 % 1.00 [ -3.30, 5.30 ]
WELCOME 2015 47 33.4 (4.9) 48 30.8 (4.5) 1.1 % 2.60 [ 0.71, 4.49 ]
Subtotal (95% CI) 7101 7079 100.0 % 0.08 [ -0.12, 0.28 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 10.19, df = 5 (P = 0.07); I2 =51%
Test for overall effect: Z = 0.76 (P = 0.45)
3 N-3 replacing n-6
Caldwell 2011 (2) 20 -0.5 (4.5) 21 -0.2 (3.7) 6.3 % -0.30 [ -2.83, 2.23 ]
DO IT 2010 124 26.8 (3.5) 117 27 (3.9) 46.0 % -0.20 [ -1.14, 0.74 ]
OFAMI 2001 115 26.6 (3.9) 116 26 (3.2) 47.7 % 0.60 [ -0.32, 1.52 ]
Subtotal (95% CI) 259 254 100.0 % 0.18 [ -0.46, 0.81 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.57, df = 2 (P = 0.46); I2 =0.0%
Test for overall effect: Z = 0.54 (P = 0.59)
4 N-3 replacing carbs/sugars
Derosa 2016 128 28.6 (2.1) 130 29.2 (2.3) 100.0 % -0.60 [ -1.14, -0.06 ]
Subtotal (95% CI) 128 130 100.0 % -0.60 [ -1.14, -0.06 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.19 (P = 0.029)
5 N-3 replacing nil/low n-3 placebo
-0.5 -0.25 0 0.25 0.5
Favours higher omega 3 Favours lower omega 3
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(. . . Continued)
Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Mita 2007 30 25.1 (5.3) 30 24.1 (3) 100.0 % 1.00 [ -1.18, 3.18 ]
Subtotal (95% CI) 30 30 100.0 % 1.00 [ -1.18, 3.18 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.90 (P = 0.37)
6 Replacement unclear
EPE-A 2014 (3) 64 0 (0) 55 -0.3 (0) Not estimable
Norouzi 2014 54 24.8 (4.91) 50 24.22 (4.2) 100.0 % 0.58 [ -1.17, 2.33 ]
Subtotal (95% CI) 118 105 100.0 % 0.58 [ -1.17, 2.33 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.65 (P = 0.52)
Test for subgroup differences: Chi2 = 11.45, df = 5 (P = 0.04), I2 =56%
-0.5 -0.25 0 0.25 0.5
Favours higher omega 3 Favours lower omega 3
(1) median change at 1 year
(2) Unbalanced at baseline, change data used
(3) median change from baseline, highest EPA vs placebo
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Analysis 2.28. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 28 BMI,
kg/m² - LCn3 - subgroup by intervention type.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 2 High vs low LCn3 omega-3 fats (secondary outcomes)
Outcome: 28 BMI, kg/m2 - LCn3 - subgroup by intervention type
Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Dietary advice
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Supplemental foods
AlphaOmega - EPA+DHA 2010 630 0.02 (1.8) 630 -0.08 (1.8) 25.3 % 0.10 [ -0.10, 0.30 ]
Subtotal (95% CI) 630 630 25.3 % 0.10 [ -0.10, 0.30 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.99 (P = 0.32)
3 Supplement (capsule)
Caldwell 2011 (1) 20 -0.5 (4.5) 21 -0.2 (3.7) 0.6 % -0.30 [ -2.83, 2.23 ]
Derosa 2016 128 28.6 (2.1) 130 29.2 (2.3) 9.6 % -0.60 [ -1.14, -0.06 ]
DO IT 2010 124 26.8 (3.5) 117 27 (3.9) 3.9 % -0.20 [ -1.14, 0.74 ]
EPE-A 2014 (2) 64 0 (0) 55 -0.3 (0) Not estimable
Mita 2007 30 25.1 (5.3) 30 24.1 (3) 0.8 % 1.00 [ -1.18, 3.18 ]
Nodari 2011 HF 67 26 (0.4) 66 26 (0.6) 26.9 % 0.0 [ -0.17, 0.17 ]
Norouzi 2014 54 24.8 (4.91) 50 24.22 (4.2) 1.2 % 0.58 [ -1.17, 2.33 ]
OFAMI 2001 115 26.6 (3.9) 116 26 (3.2) 4.0 % 0.60 [ -0.32, 1.52 ]
ORIGIN 2012 6281 30.3 (5.6) 6255 30.3 (5.6) 25.4 % 0.0 [ -0.20, 0.20 ]
Sofi 2010 (3) 6 -0.6 (0) 5 -0.1 (0) Not estimable
Tande 2016 50 0.6 (9.69) 50 -0.4 (12.13) 0.2 % 1.00 [ -3.30, 5.30 ]
WELCOME 2015 47 33.4 (4.9) 48 30.8 (4.5) 1.1 % 2.60 [ 0.71, 4.49 ]
Subtotal (95% CI) 6986 6943 73.8 % 0.01 [ -0.25, 0.27 ]
Heterogeneity: Tau2 = 0.04; Chi2 = 15.32, df = 9 (P = 0.08); I2 =41%
Test for overall effect: Z = 0.08 (P = 0.94)
4 Any combination
SMART 2013 20 29.8 (3.5) 25 28.2 (3.4) 0.9 % 1.60 [ -0.43, 3.63 ]
Subtotal (95% CI) 20 25 0.9 % 1.60 [ -0.43, 3.63 ]
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(. . . Continued)
Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Heterogeneity: not applicable
Test for overall effect: Z = 1.54 (P = 0.12)
Total (95% CI) 7636 7598 100.0 % 0.04 [ -0.16, 0.24 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 18.44, df = 11 (P = 0.07); I2 =40%
Test for overall effect: Z = 0.41 (P = 0.68)
Test for subgroup differences: Chi2 = 2.47, df = 2 (P = 0.29), I2 =19%
-20 -10 0 10 20
Favours higher omega 3 Favours lower omega 3
(1) Unbalanced at baseline, change data used
(2) median change from baseline, highest EPA vs placebo
(3) median change at 1 year
Analysis 2.29. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 29 BMI,
kg/m² - LCn3 - subgroup by duration.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 2 High vs low LCn3 omega-3 fats (secondary outcomes)
Outcome: 29 BMI, kg/m2 - LCn3 - subgroup by duration
Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Medium duration 1 to < 2 years in study
Caldwell 2011 (1) 20 -0.5 (4.5) 21 -0.2 (3.7) 5.5 % -0.30 [ -2.83, 2.23 ]
Derosa 2016 128 28.6 (2.1) 130 29.2 (2.3) 29.6 % -0.60 [ -1.14, -0.06 ]
EPE-A 2014 (2) 64 0 (0) 55 -0.3 (0) Not estimable
Nodari 2011 HF 67 26 (0.4) 66 26 (0.6) 36.3 % 0.0 [ -0.17, 0.17 ]
Norouzi 2014 54 24.8 (4.91) 50 24.22 (4.2) 9.9 % 0.58 [ -1.17, 2.33 ]
SMART 2013 20 29.8 (3.5) 25 28.2 (3.4) 7.9 % 1.60 [ -0.43, 3.63 ]
Sofi 2010 (3) 6 -0.6 (0) 5 -0.1 (0) Not estimable
-20 -10 0 10 20
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(. . . Continued)
Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Tande 2016 50 0.6 (9.69) 50 -0.4 (12.13) 2.1 % 1.00 [ -3.30, 5.30 ]
WELCOME 2015 47 33.4 (4.9) 48 30.8 (4.5) 8.8 % 2.60 [ 0.71, 4.49 ]
Subtotal (95% CI) 456 450 100.0 % 0.24 [ -0.40, 0.88 ]
Heterogeneity: Tau2 = 0.29; Chi2 = 15.04, df = 6 (P = 0.02); I2 =60%
Test for overall effect: Z = 0.73 (P = 0.47)
2 Medium-long duration: 2 to < 4 years in study
AlphaOmega - EPA+DHA 2010 630 0.02 (1.8) 630 -0.08 (1.8) 90.9 % 0.10 [ -0.10, 0.30 ]
DO IT 2010 124 26.8 (3.5) 117 27 (3.9) 4.1 % -0.20 [ -1.14, 0.74 ]
Mita 2007 30 25.1 (5.3) 30 24.1 (3) 0.8 % 1.00 [ -1.18, 3.18 ]
OFAMI 2001 115 26.6 (3.9) 116 26 (3.2) 4.2 % 0.60 [ -0.32, 1.52 ]
Subtotal (95% CI) 899 893 100.0 % 0.12 [ -0.07, 0.31 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 2.16, df = 3 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 1.20 (P = 0.23)
3 Long duration≥ 4 years in study
ORIGIN 2012 6281 30.3 (5.6) 6255 30.3 (5.6) 100.0 % 0.0 [ -0.20, 0.20 ]
Subtotal (95% CI) 6281 6255 100.0 % 0.0 [ -0.20, 0.20 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Chi2 = 0.98, df = 2 (P = 0.61), I2 =0.0%
-20 -10 0 10 20
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(1) Unbalanced at baseline, change data used
(2) median change from baseline, highest EPA vs placebo
(3) median change at 1 year
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Analysis 2.30. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 30 BMI,
kg/m² - LCn3 - subgroup by primary or secondary prevention.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 2 High vs low LCn3 omega-3 fats (secondary outcomes)
Outcome: 30 BMI, kg/m2 - LCn3 - subgroup by primary or secondary prevention
Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Primary CVD prevention
Caldwell 2011 (1) 20 -0.5 (4.5) 21 -0.2 (3.7) 3.7 % -0.30 [ -2.83, 2.23 ]
Derosa 2016 128 28.6 (2.1) 130 29.2 (2.3) 24.5 % -0.60 [ -1.14, -0.06 ]
DO IT 2010 124 26.8 (3.5) 117 27 (3.9) 15.8 % -0.20 [ -1.14, 0.74 ]
EPE-A 2014 (2) 64 0 (0) 55 -0.3 (0) Not estimable
Mita 2007 30 25.1 (5.3) 30 24.1 (3) 4.7 % 1.00 [ -1.18, 3.18 ]
Norouzi 2014 54 24.8 (4.91) 50 24.22 (4.2) 6.8 % 0.58 [ -1.17, 2.33 ]
ORIGIN 2012 6281 30.3 (5.6) 6255 30.3 (5.6) 31.9 % 0.0 [ -0.20, 0.20 ]
SMART 2013 20 29.8 (3.5) 25 28.2 (3.4) 5.3 % 1.60 [ -0.43, 3.63 ]
Sofi 2010 (3) 6 -0.6 (0) 5 -0.1 (0) Not estimable
Tande 2016 50 0.6 (9.69) 50 -0.4 (12.13) 1.4 % 1.00 [ -3.30, 5.30 ]
WELCOME 2015 47 33.4 (4.9) 48 30.8 (4.5) 6.0 % 2.60 [ 0.71, 4.49 ]
Subtotal (95% CI) 6824 6786 100.0 % 0.15 [ -0.36, 0.66 ]
Heterogeneity: Tau2 = 0.20; Chi2 = 16.01, df = 8 (P = 0.04); I2 =50%
Test for overall effect: Z = 0.58 (P = 0.56)
2 Secondary CVD prevention
AlphaOmega - EPA+DHA 2010 630 0.02 (1.8) 630 -0.08 (1.8) 42.4 % 0.10 [ -0.10, 0.30 ]
Nodari 2011 HF 67 26 (0.4) 66 26 (0.6) 55.6 % 0.0 [ -0.17, 0.17 ]
OFAMI 2001 115 26.6 (3.9) 116 26 (3.2) 2.0 % 0.60 [ -0.32, 1.52 ]
Subtotal (95% CI) 812 812 100.0 % 0.05 [ -0.08, 0.18 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.93, df = 2 (P = 0.38); I2 =0.0%
Test for overall effect: Z = 0.82 (P = 0.41)
Test for subgroup differences: Chi2 = 0.13, df = 1 (P = 0.72), I2 =0.0%
-20 -10 0 10 20
Favours higher omega 3 Favours lower omega 3
(1) Unbalanced at baseline, change data used
(2) median change from baseline, highest EPA vs placebo
(3) median change at 1 year
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Analysis 2.31. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 31 BMI,
kg/m² - LCn3 - subgroup by statin use.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 2 High vs low LCn3 omega-3 fats (secondary outcomes)
Outcome: 31 BMI, kg/m2 - LCn3 - subgroup by statin use
Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 LCn3 -≥ 50% of control group on statins
AlphaOmega - EPA+DHA 2010 630 0.02 (1.8) 630 -0.08 (1.8) 48.3 % 0.10 [ -0.10, 0.30 ]
ORIGIN 2012 6281 30.3 (5.6) 6255 30.3 (5.6) 48.5 % 0.0 [ -0.20, 0.20 ]
WELCOME 2015 47 33.4 (4.9) 48 30.8 (4.5) 3.2 % 2.60 [ 0.71, 4.49 ]
Subtotal (95% CI) 6958 6933 100.0 % 0.13 [ -0.22, 0.48 ]
Heterogeneity: Tau2 = 0.05; Chi2 = 7.43, df = 2 (P = 0.02); I2 =73%
Test for overall effect: Z = 0.74 (P = 0.46)
2 LCn3 - < 50% of control group on statins
DO IT 2010 124 26.8 (3.5) 117 27 (3.9) 3.2 % -0.20 [ -1.14, 0.74 ]
Mita 2007 30 25.1 (5.3) 30 24.1 (3) 0.6 % 1.00 [ -1.18, 3.18 ]
Nodari 2011 HF 67 26 (0.4) 66 26 (0.6) 92.9 % 0.0 [ -0.17, 0.17 ]
OFAMI 2001 115 26.6 (3.9) 116 26 (3.2) 3.3 % 0.60 [ -0.32, 1.52 ]
Subtotal (95% CI) 336 329 100.0 % 0.02 [ -0.15, 0.19 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 2.56, df = 3 (P = 0.46); I2 =0.0%
Test for overall effect: Z = 0.23 (P = 0.82)
3 LCn3 - use of statins unclear
Caldwell 2011 (1) 20 -0.5 (4.5) 21 -0.2 (3.7) 10.7 % -0.30 [ -2.83, 2.23 ]
Derosa 2016 128 28.6 (2.1) 130 29.2 (2.3) 51.1 % -0.60 [ -1.14, -0.06 ]
EPE-A 2014 (2) 64 0 (0) 55 -0.3 (0) Not estimable
Norouzi 2014 54 24.8 (4.91) 50 24.22 (4.2) 18.8 % 0.58 [ -1.17, 2.33 ]
SMART 2013 20 29.8 (3.5) 25 28.2 (3.4) 15.2 % 1.60 [ -0.43, 3.63 ]
Sofi 2010 (3) 6 -0.6 (0) 5 -0.1 (0) Not estimable
Tande 2016 50 0.6 (9.69) 50 -0.4 (12.13) 4.2 % 1.00 [ -3.30, 5.30 ]
Subtotal (95% CI) 342 336 100.0 % 0.06 [ -0.86, 0.97 ]
Heterogeneity: Tau2 = 0.35; Chi2 = 5.83, df = 4 (P = 0.21); I2 =31%
Test for overall effect: Z = 0.12 (P = 0.90)
Test for subgroup differences: Chi2 = 0.32, df = 2 (P = 0.85), I2 =0.0%
-20 -10 0 10 20
Favours higher omega 3 Favours lower omega 3
(1) Unbalanced at baseline, change data used
(2) median change from baseline, highest EPA vs placebo
(3) median change at 1 year
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Analysis 2.32. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 32 Other
measures of adiposity - LCn3.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 2 High vs low LCn3 omega-3 fats (secondary outcomes)
Outcome: 32 Other measures of adiposity - LCn3
Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Percentage body fat
SMART 2013 16 34 (10.2) 16 37.4 (8.1) 46.3 % -3.40 [ -9.78, 2.98 ]
WELCOME 2015 47 33.5 (9.6) 48 29 (13.8) 53.7 % 4.50 [ -0.27, 9.27 ]
Subtotal (95% CI) 63 64 100.0 % 0.85 [ -6.87, 8.57 ]
Heterogeneity: Tau2 = 22.94; Chi2 = 3.78, df = 1 (P = 0.05); I2 =74%
Test for overall effect: Z = 0.21 (P = 0.83)
2 Percentage visceral fat
WELCOME 2015 47 15.9 (46) 48 17.7 (5.1) 100.0 % -1.80 [ -15.03, 11.43 ]
Subtotal (95% CI) 47 48 100.0 % -1.80 [ -15.03, 11.43 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.27 (P = 0.79)
3 Waist circumference, cm
Derosa 2016 (1) 128 89.5 (27.1529) 130 91.7 (38.766) 0.9 % -2.20 [ -10.36, 5.96 ]
ORL 2013 168 0.1 (2.9) 165 -0.6 (4.1) 97.4 % 0.70 [ -0.06, 1.46 ]
THIS DIET 2008 37 102.7 (12.8) 48 102.6 (13.6) 1.8 % 0.10 [ -5.54, 5.74 ]
Subtotal (95% CI) 333 343 100.0 % 0.66 [ -0.09, 1.42 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.52, df = 2 (P = 0.77); I2 =0.0%
Test for overall effect: Z = 1.73 (P = 0.084)
4 Waist-hip ratio
Tande 2016 50 0.01 (0.04) 50 0.01 (0.03) 100.0 % 0.0 [ -0.01, 0.01 ]
Subtotal (95% CI) 50 50 100.0 % 0.0 [ -0.01, 0.01 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
5 Abdominal circumference, cm
Derosa 2016 128 93.2 (29.4156) 128 93.9 (36.2039) 100.0 % -0.70 [ -8.78, 7.38 ]
Subtotal (95% CI) 128 128 100.0 % -0.70 [ -8.78, 7.38 ]
Heterogeneity: not applicable
-4 -2 0 2 4
Favours higher omega 3 Favours lower omega 3
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(. . . Continued)
Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Test for overall effect: Z = 0.17 (P = 0.87)
6 Hip circumference, cm
Derosa 2016 130 98.5 (22.8035) 128 100.9 (36.2039) 100.0 % -2.40 [ -9.80, 5.00 ]
Subtotal (95% CI) 130 128 100.0 % -2.40 [ -9.80, 5.00 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.64 (P = 0.52)
-4 -2 0 2 4
Favours higher omega 3 Favours lower omega 3
(1) SE assumed
Analysis 2.33. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 33 Total
cholesterol, serum, mmoL/L - LCn3.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 2 High vs low LCn3 omega-3 fats (secondary outcomes)
Outcome: 33 Total cholesterol, serum, mmoL/L - LCn3
Study or subgroup
Favours
higher
omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Ahn 2016 38 3.6 (0.74) 36 3.75 (0.67) 1.8 % -0.15 [ -0.47, 0.17 ]
AlphaOmega - EPA+DHA 2010 605 -0.26 (0.98) 605 -0.28 (0.98) 10.4 % 0.02 [ -0.09, 0.13 ]
Berson 2004 105 5.17 (0.82) 103 4.87 (0.91) 3.1 % 0.30 [ 0.06, 0.54 ]
Brox 2001 (1) 37 7.8 (0.9) 37 7.9 (0.8) 1.2 % -0.10 [ -0.49, 0.29 ]
Caldwell 2011 17 5.01 (1.18) 17 5.14 (0.97) 0.4 % -0.13 [ -0.86, 0.60 ]
DART 1989 868 6.47 (1.14) 847 6.37 (1.11) 10.9 % 0.10 [ -0.01, 0.21 ]
Derosa 2016 (2) 128 4.9 (3.4) 130 5.1 (3.4) 0.3 % -0.20 [ -1.03, 0.63 ]
Deslypere 1992 14 5.48 (0.89) 14 5.89 (1.03) 0.4 % -0.41 [ -1.12, 0.30 ]
DIPP 2015 (3) 91 5.52 (0.9) 75 5.4 (0.79) 2.7 % 0.12 [ -0.14, 0.38 ]
-0.2 -0.1 0 0.1 0.2
Favours higher omega 3 Favours lower omega 3
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Study or subgroup
Favours
higher
omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
DO IT 2010 124 6.3 (1.2) 117 6.3 (1.3) 1.8 % 0.0 [ -0.32, 0.32 ]
EPE-A 2014 (4) 64 0.1 (0) 55 0.21 (0) Not estimable
Franzen 1993 15 5.77 (1) 15 6.26 (1.1) 0.3 % -0.49 [ -1.24, 0.26 ]
HARP 1995 31 5.02 (0.96) 28 4.99 (0.62) 1.1 % 0.03 [ -0.38, 0.44 ]
JELIS 2007 9326 5.83 (0.8) 9319 5.88 (0.78) 28.0 % -0.05 [ -0.07, -0.03 ]
MARINA 2011 80 0.2 (0.8987) 71 0.1 (0.63) 2.9 % 0.10 [ -0.15, 0.35 ]
Mita 2007 30 5.15 (0.83) 30 5.27 (0.99) 0.9 % -0.12 [ -0.58, 0.34 ]
NAT2 2013 134 5.7 (1.18) 129 5.64 (1) 2.6 % 0.06 [ -0.20, 0.32 ]
Nodari 2011 HF 67 4.8 (0.62) 66 4.9 (0.62) 3.8 % -0.10 [ -0.31, 0.11 ]
Nye 1990 12 6.83 (1) 12 6.2 (1.31) 0.2 % 0.63 [ -0.30, 1.56 ]
OFAMI 2001 123 5.27 (1.09) 123 5.59 (1.18) 2.2 % -0.32 [ -0.60, -0.04 ]
ORIGIN 2012 6281 -0.406 (2.06) 6255 -0.38 (2.06) 16.7 % -0.03 [ -0.10, 0.04 ]
Rossing 1996 14 5.51 (1.12) 15 5.2 (1.16) 0.3 % 0.31 [ -0.52, 1.14 ]
Sandhu 2016 49 5.18 (0.89) 47 5.37 (0.94) 1.4 % -0.19 [ -0.56, 0.18 ]
SCIMO 1999 89 6.2 (1.55) 86 6.05 (1.64) 0.8 % 0.15 [ -0.32, 0.62 ]
SHOT 1996 289 7.01 (1.27) 267 7.03 (1.32) 3.7 % -0.02 [ -0.24, 0.20 ]
SMART 2013 21 5.4 (0.9) 24 5.2 (1) 0.6 % 0.20 [ -0.36, 0.76 ]
Sofi 2010 6 -0.02 (0.9624) 5 -0.12 (0.451) 0.3 % 0.10 [ -0.77, 0.97 ]
WELCOME 2015 47 4.7 (1.1) 48 4.8 (1) 1.1 % -0.10 [ -0.52, 0.32 ]
Total (95% CI) 18705 18576 100.0 % -0.01 [ -0.05, 0.04 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 32.20, df = 26 (P = 0.19); I2 =19%
Test for overall effect: Z = 0.34 (P = 0.73)
Test for subgroup differences: Not applicable
-0.2 -0.1 0 0.1 0.2
Favours higher omega 3 Favours lower omega 3
(1) 14 month data, cod liver oil vs control
(2) SDs unlikely so converted assuming they were SEs
(3) 2 year data
(4) median change from baseline, highest EPA vs placebo
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Analysis 2.34. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 34 TC,
mmoL/L - LCn3 - SA by summary risk of bias.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 2 High vs low LCn3 omega-3 fats (secondary outcomes)
Outcome: 34 TC, mmoL/L - LCn3 - SA by summary risk of bias
Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Low risk of bias
AlphaOmega - EPA+DHA 2010 605 -0.26 (0.98) 605 -0.28 (0.98) 10.1 % 0.02 [ -0.09, 0.13 ]
Berson 2004 105 5.17 (0.82) 103 4.87 (0.91) 2.9 % 0.30 [ 0.06, 0.54 ]
Caldwell 2011 17 5.01 (1.18) 17 5.14 (0.97) 0.3 % -0.13 [ -0.86, 0.60 ]
Derosa 2016 (1) 128 4.9 (3.4) 130 5.1 (3.4) 0.3 % -0.20 [ -1.03, 0.63 ]
MARINA 2011 80 5.6 (0.8987) 71 5.6 (0.4225) 3.3 % 0.0 [ -0.22, 0.22 ]
NAT2 2013 134 5.7 (1.18) 129 5.64 (1) 2.4 % 0.06 [ -0.20, 0.32 ]
ORIGIN 2012 6281 -0.406 (2.06) 6255 -0.38 (2.06) 16.9 % -0.03 [ -0.10, 0.04 ]
SCIMO 1999 89 6.2 (1.55) 86 6.05 (1.64) 0.8 % 0.15 [ -0.32, 0.62 ]
WELCOME 2015 47 4.7 (1.1) 48 4.8 (1) 1.0 % -0.10 [ -0.52, 0.32 ]
Subtotal (95% CI) 7486 7444 37.9 % 0.01 [ -0.05, 0.06 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 8.03, df = 8 (P = 0.43); I2 =0%
Test for overall effect: Z = 0.24 (P = 0.81)
2 Moderate/high risk of bias
Ahn 2016 38 3.6 (0.74) 36 3.75 (0.67) 1.6 % -0.15 [ -0.47, 0.17 ]
Brox 2001 (2) 37 7.8 (0.9) 37 7.9 (0.8) 1.1 % -0.10 [ -0.49, 0.29 ]
DART 1989 868 6.47 (1.14) 847 6.37 (1.11) 10.6 % 0.10 [ -0.01, 0.21 ]
Deslypere 1992 14 5.48 (0.89) 14 5.89 (1.03) 0.3 % -0.41 [ -1.12, 0.30 ]
DIPP 2015 (3) 91 5.52 (0.9) 75 5.4 (0.79) 2.5 % 0.12 [ -0.14, 0.38 ]
DO IT 2010 124 6.3 (1.2) 117 6.3 (1.3) 1.7 % 0.0 [ -0.32, 0.32 ]
EPE-A 2014 (4) 64 0.1 (0) 55 0.21 (0) Not estimable
Franzen 1993 15 5.77 (1) 15 6.26 (1.1) 0.3 % -0.49 [ -1.24, 0.26 ]
HARP 1995 31 5.02 (0.96) 28 4.99 (0.62) 1.0 % 0.03 [ -0.38, 0.44 ]
JELIS 2007 9326 5.83 (0.8) 9319 5.88 (0.78) 30.5 % -0.05 [ -0.07, -0.03 ]
Mita 2007 30 5.15 (0.83) 30 5.27 (0.99) 0.8 % -0.12 [ -0.58, 0.34 ]
Nodari 2011 HF 67 4.8 (0.62) 66 4.9 (0.62) 3.6 % -0.10 [ -0.31, 0.11 ]
-2 -1 0 1 2
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(. . . Continued)
Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Nye 1990 12 6.83 (1) 12 6.2 (1.31) 0.2 % 0.63 [ -0.30, 1.56 ]
OFAMI 2001 123 5.27 (1.09) 123 5.59 (1.18) 2.1 % -0.32 [ -0.60, -0.04 ]
Rossing 1996 14 5.51 (1.12) 15 5.2 (1.16) 0.3 % 0.31 [ -0.52, 1.14 ]
Sandhu 2016 49 5.18 (0.89) 47 5.37 (0.94) 1.3 % -0.19 [ -0.56, 0.18 ]
SHOT 1996 289 7.01 (1.27) 267 7.03 (1.32) 3.4 % -0.02 [ -0.24, 0.20 ]
SMART 2013 21 5.4 (0.9) 24 5.2 (1) 0.6 % 0.20 [ -0.36, 0.76 ]
Sofi 2010 6 -0.02 (0.9624) 5 -0.12 (0.451) 0.2 % 0.10 [ -0.77, 0.97 ]
Subtotal (95% CI) 11219 11132 62.1 % -0.03 [ -0.09, 0.03 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 20.13, df = 17 (P = 0.27); I2 =16%
Test for overall effect: Z = 0.98 (P = 0.33)
Total (95% CI) 18705 18576 100.0 % -0.01 [ -0.05, 0.03 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 31.10, df = 26 (P = 0.22); I2 =16%
Test for overall effect: Z = 0.56 (P = 0.58)
Test for subgroup differences: Chi2 = 0.78, df = 1 (P = 0.38), I2 =0.0%
-2 -1 0 1 2
Favours higher omega 3 Favours lower omega 3
(1) SDs unlikely, so converted assuming SEs
(2) 14 month data, cod liver oil gp int
(3) 2 year data
(4) median change from baseline, highest EPA vs placebo
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Analysis 2.35. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 35 TC,
mmoL/L - LCn3 - SA by compliance and study size.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 2 High vs low LCn3 omega-3 fats (secondary outcomes)
Outcome: 35 TC, mmoL/L - LCn3 - SA by compliance and study size
Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 SA - low risk of compliance bias
AlphaOmega - EPA+DHA 2010 605 -0.26 (0.98) 605 -0.28 (0.98) 38.1 % 0.02 [ -0.09, 0.13 ]
Berson 2004 105 5.17 (0.82) 103 4.87 (0.91) 8.4 % 0.30 [ 0.06, 0.54 ]
Brox 2001 (1) 37 7.8 (0.9) 37 7.9 (0.8) 3.1 % -0.10 [ -0.49, 0.29 ]
Deslypere 1992 14 5.48 (0.89) 14 5.89 (1.03) 0.9 % -0.41 [ -1.12, 0.30 ]
DO IT 2010 124 6.3 (1.2) 117 6.3 (1.3) 4.6 % 0.0 [ -0.32, 0.32 ]
EPE-A 2014 (2) 64 0.1 (0) 55 0.21 (0) Not estimable
HARP 1995 31 5.02 (0.96) 28 4.99 (0.62) 2.8 % 0.03 [ -0.38, 0.44 ]
MARINA 2011 80 5.6 (0.8987) 71 5.6 (0.4225) 9.6 % 0.0 [ -0.22, 0.22 ]
NAT2 2013 134 5.7 (1.18) 129 5.64 (1) 6.7 % 0.06 [ -0.20, 0.32 ]
Nodari 2011 HF 67 4.8 (0.62) 66 4.9 (0.62) 10.5 % -0.10 [ -0.31, 0.11 ]
Rossing 1996 14 5.51 (1.12) 15 5.2 (1.16) 0.7 % 0.31 [ -0.52, 1.14 ]
SCIMO 1999 89 6.2 (1.55) 86 6.05 (1.64) 2.1 % 0.15 [ -0.32, 0.62 ]
SHOT 1996 289 7.01 (1.27) 267 7.03 (1.32) 10.0 % -0.02 [ -0.24, 0.20 ]
WELCOME 2015 47 4.7 (1.1) 48 4.8 (1) 2.6 % -0.10 [ -0.52, 0.32 ]
Subtotal (95% CI) 1700 1641 100.0 % 0.02 [ -0.05, 0.09 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 9.78, df = 12 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 0.60 (P = 0.55)
2 SA - 100+ randomised
AlphaOmega - EPA+DHA 2010 605 -0.26 (0.98) 605 -0.28 (0.98) 12.2 % 0.02 [ -0.09, 0.13 ]
Berson 2004 105 5.17 (0.82) 103 4.87 (0.91) 4.4 % 0.30 [ 0.06, 0.54 ]
DART 1989 868 6.47 (1.14) 847 6.37 (1.11) 12.6 % 0.10 [ -0.01, 0.21 ]
Derosa 2016 (3) 128 4.9 (3.4) 130 5.1 (3.4) 0.4 % -0.20 [ -1.03, 0.63 ]
DIPP 2015 (4) 91 5.52 (0.9) 75 5.4 (0.79) 3.8 % 0.12 [ -0.14, 0.38 ]
DO IT 2010 124 6.3 (1.2) 117 6.3 (1.3) 2.6 % 0.0 [ -0.32, 0.32 ]
EPE-A 2014 (5) 64 0.1 (0) 55 0.21 (0) Not estimable
-2 -1 0 1 2
Favours higher omega 3 Favours lower omega 3
(Continued . . . )
496Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(. . . Continued)
Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
JELIS 2007 9326 5.83 (0.8) 9319 5.88 (0.78) 23.5 % -0.05 [ -0.07, -0.03 ]
MARINA 2011 80 5.6 (0.8987) 71 5.6 (0.4225) 4.9 % 0.0 [ -0.22, 0.22 ]
NAT2 2013 134 5.7 (1.18) 129 5.64 (1) 3.6 % 0.06 [ -0.20, 0.32 ]
Nodari 2011 HF 67 4.8 (0.62) 66 4.9 (0.62) 5.2 % -0.10 [ -0.31, 0.11 ]
OFAMI 2001 123 5.27 (1.09) 123 5.59 (1.18) 3.2 % -0.32 [ -0.60, -0.04 ]
ORIGIN 2012 6281 -0.406 (2.06) 6255 -0.38 (2.06) 17.1 % -0.03 [ -0.10, 0.04 ]
SCIMO 1999 89 6.2 (1.55) 86 6.05 (1.64) 1.3 % 0.15 [ -0.32, 0.62 ]
SHOT 1996 289 7.01 (1.27) 267 7.03 (1.32) 5.1 % -0.02 [ -0.24, 0.20 ]
Subtotal (95% CI) 18374 18248 100.0 % 0.00 [ -0.05, 0.06 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 23.61, df = 13 (P = 0.03); I2 =45%
Test for overall effect: Z = 0.11 (P = 0.92)
Test for subgroup differences: Chi2 = 0.16, df = 1 (P = 0.69), I2 =0.0%
-2 -1 0 1 2
Favours higher omega 3 Favours lower omega 3
(1) 14 month data, cod liver oil gp int
(2) median change from baseline, highest EPA vs placebo
(3) SDs unlikely, so converted assuming SEs
(4) 2 year data
(5) median change from baseline, highest EPA vs placebo
497Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 2.36. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 36 TC,
mmoL/L - LCn3 - subgroup by dose.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 2 High vs low LCn3 omega-3 fats (secondary outcomes)
Outcome: 36 TC, mmoL/L - LCn3 - subgroup by dose
Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 LCn3≤ 150 mg/d
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
2 LCn3 > 150≤ 250 mg/d
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
3 LCn3 > 250≤ 400 mg/d
DART 1989 868 6.47 (1.14) 847 6.37 (1.11) 100.0 % 0.10 [ -0.01, 0.21 ]
Subtotal (95% CI) 868 847 100.0 % 0.10 [ -0.01, 0.21 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.84 (P = 0.066)
4 LCn3 > 400≤ 2400 mg/d
Ahn 2016 38 3.6 (0.74) 36 3.75 (0.67) 0.9 % -0.15 [ -0.47, 0.17 ]
AlphaOmega - EPA+DHA 2010 605 -0.26 (0.98) 605 -0.28 (0.98) 7.5 % 0.02 [ -0.09, 0.13 ]
Berson 2004 105 5.17 (0.82) 103 4.87 (0.91) 1.7 % 0.30 [ 0.06, 0.54 ]
Caldwell 2011 17 5.01 (1.18) 17 5.14 (0.97) 0.2 % -0.13 [ -0.86, 0.60 ]
Derosa 2016 (1) 128 4.9 (3.4) 130 5.1 (3.4) 0.1 % -0.20 [ -1.03, 0.63 ]
Deslypere 1992 14 5.48 (0.89) 14 5.89 (1.03) 0.2 % -0.41 [ -1.12, 0.30 ]
DIPP 2015 91 5.52 (0.9) 75 5.4 (0.79) 1.5 % 0.12 [ -0.14, 0.38 ]
DO IT 2010 124 6.3 (1.2) 117 6.3 (1.3) 1.0 % 0.0 [ -0.32, 0.32 ]
JELIS 2007 9326 5.83 (0.8) 9319 5.88 (0.78) 64.0 % -0.05 [ -0.07, -0.03 ]
MARINA 2011 80 5.6 (0.8987) 71 5.6 (0.4225) 2.0 % 0.0 [ -0.22, 0.22 ]
Mita 2007 30 5.15 (0.83) 30 5.27 (0.99) 0.5 % -0.12 [ -0.58, 0.34 ]
NAT2 2013 134 5.7 (1.18) 129 5.64 (1) 1.4 % 0.06 [ -0.20, 0.32 ]
Nodari 2011 HF 67 4.8 (0.62) 66 4.9 (0.62) 2.2 % -0.10 [ -0.31, 0.11 ]
Nye 1990 12 6.83 (1) 12 6.2 (1.31) 0.1 % 0.63 [ -0.30, 1.56 ]
-2 -1 0 1 2
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(. . . Continued)
Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
ORIGIN 2012 6281 -0.406 (2.06) 6255 -0.38 (2.06) 15.9 % -0.03 [ -0.10, 0.04 ]
SCIMO 1999 89 6.2 (1.55) 86 6.05 (1.64) 0.4 % 0.15 [ -0.32, 0.62 ]
SMART 2013 21 5.4 (0.9) 24 5.2 (1) 0.3 % 0.20 [ -0.36, 0.76 ]
Sofi 2010 6 -0.02 (0.9624) 5 -0.12 (0.451) 0.1 % 0.10 [ -0.77, 0.97 ]
Subtotal (95% CI) 17168 17094 100.0 % -0.03 [ -0.06, 0.00 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 17.74, df = 17 (P = 0.41); I2 =4%
Test for overall effect: Z = 1.90 (P = 0.058)
5 LCn3 > 2.4≤ 4.4 g/d
Brox 2001 37 7.8 (0.9) 37 7.9 (0.8) 12.0 % -0.10 [ -0.49, 0.29 ]
EPE-A 2014 (2) 64 0.1 (0) 55 0.21 (0) Not estimable
Franzen 1993 15 5.77 (1) 15 6.26 (1.1) 3.2 % -0.49 [ -1.24, 0.26 ]
OFAMI 2001 123 5.27 (1.09) 123 5.59 (1.18) 22.4 % -0.32 [ -0.60, -0.04 ]
Sandhu 2016 49 5.18 (0.89) 47 5.37 (0.94) 13.5 % -0.19 [ -0.56, 0.18 ]
SHOT 1996 289 7.01 (1.27) 267 7.03 (1.32) 38.8 % -0.02 [ -0.24, 0.20 ]
WELCOME 2015 47 4.7 (1.1) 48 4.8 (1) 10.1 % -0.10 [ -0.52, 0.32 ]
Subtotal (95% CI) 624 592 100.0 % -0.14 [ -0.28, -0.01 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 3.71, df = 5 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 2.08 (P = 0.037)
6 LCn3 > 4.4 g/d
HARP 1995 31 5.02 (0.96) 28 4.99 (0.62) 80.5 % 0.03 [ -0.38, 0.44 ]
Rossing 1996 14 5.51 (1.12) 15 5.2 (1.16) 19.5 % 0.31 [ -0.52, 1.14 ]
Subtotal (95% CI) 45 43 100.0 % 0.08 [ -0.28, 0.45 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.35, df = 1 (P = 0.55); I2 =0.0%
Test for overall effect: Z = 0.45 (P = 0.65)
Test for subgroup differences: Chi2 = 8.70, df = 3 (P = 0.03), I2 =66%
-2 -1 0 1 2
Favours higher omega 3 Favours lower omega 3
(1) SDs unlikely so converted assuming SEs
(2) median change from baseline, highest EPA vs placebo
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Analysis 2.37. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 37 TC,
mmoL/L - LCn3 - subgroup by replacement.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 2 High vs low LCn3 omega-3 fats (secondary outcomes)
Outcome: 37 TC, mmoL/L - LCn3 - subgroup by replacement
Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 N-3 replacing SFA
DART 1989 868 6.47 (1.14) 847 6.37 (1.11) 93.7 % 0.10 [ -0.01, 0.21 ]
Derosa 2016 (1) 128 4.9 (3.4) 130 5.1 (3.4) 1.5 % -0.20 [ -1.03, 0.63 ]
SCIMO 1999 89 6.2 (1.55) 86 6.05 (1.64) 4.7 % 0.15 [ -0.32, 0.62 ]
Subtotal (95% CI) 1085 1063 100.0 % 0.10 [ -0.01, 0.20 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.54, df = 2 (P = 0.76); I2 =0.0%
Test for overall effect: Z = 1.86 (P = 0.063)
2 N-3 replacing MUFA
AlphaOmega - EPA+DHA 2010 605 -0.26 (0.98) 605 -0.28 (0.98) 18.3 % 0.02 [ -0.09, 0.13 ]
DART 1989 868 6.47 (1.14) 847 6.37 (1.11) 19.7 % 0.10 [ -0.01, 0.21 ]
Deslypere 1992 14 5.48 (0.89) 14 5.89 (1.03) 0.4 % -0.41 [ -1.12, 0.30 ]
Franzen 1993 15 5.77 (1) 15 6.26 (1.1) 0.4 % -0.49 [ -1.24, 0.26 ]
HARP 1995 31 5.02 (0.96) 28 4.99 (0.62) 1.3 % 0.03 [ -0.38, 0.44 ]
MARINA 2011 80 5.6 (0.8987) 71 5.6 (0.4225) 4.6 % 0.0 [ -0.22, 0.22 ]
NAT2 2013 134 5.7 (1.18) 129 5.64 (1) 3.2 % 0.06 [ -0.20, 0.32 ]
Nodari 2011 HF 67 4.8 (0.62) 66 4.9 (0.62) 5.0 % -0.10 [ -0.31, 0.11 ]
Nye 1990 12 6.83 (1) 12 6.2 (1.31) 0.3 % 0.63 [ -0.30, 1.56 ]
ORIGIN 2012 6281 -0.406 (2.06) 6255 -0.38 (2.06) 43.0 % -0.03 [ -0.10, 0.04 ]
Rossing 1996 14 5.51 (1.12) 15 5.2 (1.16) 0.3 % 0.31 [ -0.52, 1.14 ]
SCIMO 1999 89 6.2 (1.55) 86 6.05 (1.64) 1.0 % 0.15 [ -0.32, 0.62 ]
SMART 2013 21 5.4 (0.9) 24 5.2 (1) 0.7 % 0.20 [ -0.36, 0.76 ]
Sofi 2010 6 -0.02 (0.9624) 5 -0.12 (0.451) 0.3 % 0.10 [ -0.77, 0.97 ]
WELCOME 2015 47 4.7 (1.1) 48 4.8 (1) 1.3 % -0.10 [ -0.52, 0.32 ]
Subtotal (95% CI) 8284 8220 100.0 % 0.01 [ -0.04, 0.06 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 11.36, df = 14 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 0.40 (P = 0.69)
3 N-3 replacing n-6
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(. . . Continued)
Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Berson 2004 105 5.17 (0.82) 103 4.87 (0.91) 24.9 % 0.30 [ 0.06, 0.54 ]
Caldwell 2011 17 5.01 (1.18) 17 5.14 (0.97) 8.1 % -0.13 [ -0.86, 0.60 ]
DIPP 2015 91 5.52 (0.9) 75 5.4 (0.79) 23.8 % 0.12 [ -0.14, 0.38 ]
DO IT 2010 124 6.3 (1.2) 117 6.3 (1.3) 20.8 % 0.0 [ -0.32, 0.32 ]
OFAMI 2001 123 5.27 (1.09) 123 5.59 (1.18) 22.4 % -0.32 [ -0.60, -0.04 ]
Subtotal (95% CI) 460 435 100.0 % 0.02 [ -0.22, 0.26 ]
Heterogeneity: Tau2 = 0.04; Chi2 = 11.47, df = 4 (P = 0.02); I2 =65%
Test for overall effect: Z = 0.17 (P = 0.86)
4 N-3 replacing carbs/sugars
Derosa 2016 (2) 128 4.9 (3.4) 130 5.1 (3.4) 100.0 % -0.20 [ -1.03, 0.63 ]
Subtotal (95% CI) 128 130 100.0 % -0.20 [ -1.03, 0.63 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.47 (P = 0.64)
5 N-3 replacing nil/low n-3 placebo
Brox 2001 37 7.8 (0.9) 37 7.9 (0.8) 0.3 % -0.10 [ -0.49, 0.29 ]
JELIS 2007 9326 5.83 (0.8) 9319 5.88 (0.78) 98.0 % -0.05 [ -0.07, -0.03 ]
Mita 2007 30 5.15 (0.83) 30 5.27 (0.99) 0.2 % -0.12 [ -0.58, 0.34 ]
Sandhu 2016 49 5.18 (0.89) 47 5.37 (0.94) 0.4 % -0.19 [ -0.56, 0.18 ]
SHOT 1996 289 7.01 (1.27) 267 7.03 (1.32) 1.1 % -0.02 [ -0.24, 0.20 ]
Subtotal (95% CI) 9731 9700 100.0 % -0.05 [ -0.07, -0.03 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.78, df = 4 (P = 0.94); I2 =0.0%
Test for overall effect: Z = 4.41 (P = 0.000010)
6 Replacement unclear
Ahn 2016 38 3.6 (0.74) 36 3.75 (0.67) 100.0 % -0.15 [ -0.47, 0.17 ]
EPE-A 2014 (3) 64 0.1 (0) 55 0.21 (0) Not estimable
Subtotal (95% CI) 102 91 100.0 % -0.15 [ -0.47, 0.17 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.91 (P = 0.36)
Test for subgroup differences: Chi2 = 12.47, df = 5 (P = 0.03), I2 =60%
-2 -1 0 1 2
Favours higher omega 3 Favours lower omega 3
(1) SDs unlikely, so converted assuming SEs
(2) SDs unlikely, so converted assuming SEs
(3) median change from baseline, highest EPA vs placebo
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Analysis 2.38. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 38 TC,
mmoL/L - LCn3 - subgroup by intervention type.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 2 High vs low LCn3 omega-3 fats (secondary outcomes)
Outcome: 38 TC, mmoL/L - LCn3 - subgroup by intervention type
Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Dietary advice
DART 1989 868 6.47 (1.14) 847 6.37 (1.11) 100.0 % 0.10 [ -0.01, 0.21 ]
Subtotal (95% CI) 868 847 100.0 % 0.10 [ -0.01, 0.21 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.84 (P = 0.066)
2 Supplemental foods
AlphaOmega - EPA+DHA 2010 605 -0.26 (0.98) 605 -0.28 (0.98) 100.0 % 0.02 [ -0.09, 0.13 ]
Subtotal (95% CI) 605 605 100.0 % 0.02 [ -0.09, 0.13 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.35 (P = 0.72)
3 Supplement (capsule)
Ahn 2016 38 3.6 (0.74) 36 3.75 (0.67) 0.4 % -0.15 [ -0.47, 0.17 ]
Berson 2004 105 5.17 (0.82) 103 4.87 (0.91) 0.8 % 0.30 [ 0.06, 0.54 ]
Brox 2001 37 7.8 (0.9) 37 7.9 (0.8) 0.3 % -0.10 [ -0.49, 0.29 ]
Caldwell 2011 17 5.01 (1.18) 17 5.14 (0.97) 0.1 % -0.13 [ -0.86, 0.60 ]
Derosa 2016 (1) 128 4.9 (3.4) 130 5.1 (3.4) 0.1 % -0.20 [ -1.03, 0.63 ]
Deslypere 1992 14 5.48 (0.89) 14 5.89 (1.03) 0.1 % -0.41 [ -1.12, 0.30 ]
DO IT 2010 124 6.3 (1.2) 117 6.3 (1.3) 0.4 % 0.0 [ -0.32, 0.32 ]
EPE-A 2014 (2) 64 0.1 (0) 55 0.21 (0) Not estimable
Franzen 1993 15 5.77 (1) 15 6.26 (1.1) 0.1 % -0.49 [ -1.24, 0.26 ]
HARP 1995 31 5.02 (0.96) 28 4.99 (0.62) 0.3 % 0.03 [ -0.38, 0.44 ]
JELIS 2007 9326 5.83 (0.8) 9319 5.88 (0.78) 84.1 % -0.05 [ -0.07, -0.03 ]
MARINA 2011 80 5.6 (0.8987) 71 5.6 (0.4225) 0.9 % 0.0 [ -0.22, 0.22 ]
Mita 2007 30 5.15 (0.83) 30 5.27 (0.99) 0.2 % -0.12 [ -0.58, 0.34 ]
NAT2 2013 134 5.7 (1.18) 129 5.64 (1) 0.6 % 0.06 [ -0.20, 0.32 ]
Nodari 2011 HF 67 4.8 (0.62) 66 4.9 (0.62) 1.0 % -0.10 [ -0.31, 0.11 ]
Nye 1990 12 6.83 (1) 12 6.2 (1.31) 0.0 % 0.63 [ -0.30, 1.56 ]
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Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
OFAMI 2001 123 5.27 (1.09) 123 5.59 (1.18) 0.5 % -0.32 [ -0.60, -0.04 ]
ORIGIN 2012 6281 -0.406 (2.06) 6255 -0.38 (2.06) 8.3 % -0.03 [ -0.10, 0.04 ]
Rossing 1996 14 5.51 (1.12) 15 5.2 (1.16) 0.1 % 0.31 [ -0.52, 1.14 ]
Sandhu 2016 49 5.18 (0.89) 47 5.37 (0.94) 0.3 % -0.19 [ -0.56, 0.18 ]
SCIMO 1999 89 6.2 (1.55) 86 6.05 (1.64) 0.2 % 0.15 [ -0.32, 0.62 ]
SHOT 1996 289 7.01 (1.27) 267 7.03 (1.32) 0.9 % -0.02 [ -0.24, 0.20 ]
Sofi 2010 6 -0.02 (0.9624) 5 -0.12 (0.451) 0.1 % 0.10 [ -0.77, 0.97 ]
WELCOME 2015 47 4.7 (1.1) 48 4.8 (1) 0.2 % -0.10 [ -0.52, 0.32 ]
Subtotal (95% CI) 17120 17025 100.0 % -0.05 [ -0.07, -0.03 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 20.78, df = 22 (P = 0.53); I2 =0.0%
Test for overall effect: Z = 4.39 (P = 0.000011)
4 Any combination
DIPP 2015 91 5.52 (0.9) 75 5.4 (0.79) 82.3 % 0.12 [ -0.14, 0.38 ]
SMART 2013 21 5.4 (0.9) 24 5.2 (1) 17.7 % 0.20 [ -0.36, 0.76 ]
Subtotal (95% CI) 112 99 100.0 % 0.13 [ -0.10, 0.37 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.07, df = 1 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 1.13 (P = 0.26)
Test for subgroup differences: Chi2 = 10.26, df = 3 (P = 0.02), I2 =71%
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(1) SDs unlikely so converted assuming SEs
(2) median change from baseline, highest EPA vs placebo
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Analysis 2.39. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 39 TC,
mmoL/L - LCn3 - subgroup by duration.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 2 High vs low LCn3 omega-3 fats (secondary outcomes)
Outcome: 39 TC, mmoL/L - LCn3 - subgroup by duration
Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Medium duration 1 to < 2 years in study
Ahn 2016 38 3.6 (0.74) 36 3.75 (0.67) 9.6 % -0.15 [ -0.47, 0.17 ]
Brox 2001 37 7.8 (0.9) 37 7.9 (0.8) 6.6 % -0.10 [ -0.49, 0.29 ]
Caldwell 2011 17 5.01 (1.18) 17 5.14 (0.97) 1.9 % -0.13 [ -0.86, 0.60 ]
Derosa 2016 (1) 128 4.9 (3.4) 130 5.1 (3.4) 1.4 % -0.20 [ -1.03, 0.63 ]
Deslypere 1992 14 5.48 (0.89) 14 5.89 (1.03) 2.0 % -0.41 [ -1.12, 0.30 ]
EPE-A 2014 (2) 64 0.1 (0) 55 0.21 (0) Not estimable
Franzen 1993 15 5.77 (1) 15 6.26 (1.1) 1.8 % -0.49 [ -1.24, 0.26 ]
MARINA 2011 80 5.6 (0.8987) 71 5.6 (0.4225) 20.5 % 0.0 [ -0.22, 0.22 ]
Nodari 2011 HF 67 4.8 (0.62) 66 4.9 (0.62) 22.3 % -0.10 [ -0.31, 0.11 ]
Nye 1990 12 6.83 (1) 12 6.2 (1.31) 1.1 % 0.63 [ -0.30, 1.56 ]
Rossing 1996 14 5.51 (1.12) 15 5.2 (1.16) 1.4 % 0.31 [ -0.52, 1.14 ]
SHOT 1996 289 7.01 (1.27) 267 7.03 (1.32) 21.3 % -0.02 [ -0.24, 0.20 ]
SMART 2013 21 5.4 (0.9) 24 5.2 (1) 3.2 % 0.20 [ -0.36, 0.76 ]
Sofi 2010 6 -0.02 (0.9624) 5 -0.12 (0.451) 1.3 % 0.10 [ -0.77, 0.97 ]
WELCOME 2015 47 4.7 (1.1) 48 4.8 (1) 5.5 % -0.10 [ -0.52, 0.32 ]
Subtotal (95% CI) 849 812 100.0 % -0.06 [ -0.16, 0.04 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 7.09, df = 13 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 1.09 (P = 0.27)
2 Medium-long duration: 2 to < 4 years in study
AlphaOmega - EPA+DHA 2010 605 -0.26 (0.98) 605 -0.28 (0.98) 30.1 % 0.02 [ -0.09, 0.13 ]
DART 1989 868 6.47 (1.14) 847 6.37 (1.11) 31.5 % 0.10 [ -0.01, 0.21 ]
DIPP 2015 91 5.52 (0.9) 75 5.4 (0.79) 7.6 % 0.12 [ -0.14, 0.38 ]
DO IT 2010 124 6.3 (1.2) 117 6.3 (1.3) 5.2 % 0.0 [ -0.32, 0.32 ]
HARP 1995 31 5.02 (0.96) 28 4.99 (0.62) 3.2 % 0.03 [ -0.38, 0.44 ]
Mita 2007 30 5.15 (0.83) 30 5.27 (0.99) 2.5 % -0.12 [ -0.58, 0.34 ]
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(. . . Continued)
Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
NAT2 2013 134 5.7 (1.18) 129 5.64 (1) 7.3 % 0.06 [ -0.20, 0.32 ]
OFAMI 2001 123 5.27 (1.09) 123 5.59 (1.18) 6.3 % -0.32 [ -0.60, -0.04 ]
Sandhu 2016 49 5.18 (0.89) 47 5.37 (0.94) 3.9 % -0.19 [ -0.56, 0.18 ]
SCIMO 1999 89 6.2 (1.55) 86 6.05 (1.64) 2.4 % 0.15 [ -0.32, 0.62 ]
Subtotal (95% CI) 2144 2087 100.0 % 0.02 [ -0.05, 0.10 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 10.11, df = 9 (P = 0.34); I2 =11%
Test for overall effect: Z = 0.66 (P = 0.51)
3 Long duration≥ 4 years in study
Berson 2004 105 5.17 (0.82) 103 4.87 (0.91) 12.0 % 0.30 [ 0.06, 0.54 ]
JELIS 2007 9326 5.83 (0.8) 9319 5.88 (0.78) 49.1 % -0.05 [ -0.07, -0.03 ]
ORIGIN 2012 6281 -0.406 (2.06) 6255 -0.38 (2.06) 38.9 % -0.03 [ -0.10, 0.04 ]
Subtotal (95% CI) 15712 15677 100.0 % 0.00 [ -0.09, 0.09 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 8.64, df = 2 (P = 0.01); I2 =77%
Test for overall effect: Z = 0.01 (P = 0.99)
Test for subgroup differences: Chi2 = 1.62, df = 2 (P = 0.45), I2 =0.0%
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(1) SDs unlikely so converted assuming SEs
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Analysis 2.40. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 40 TC,
mmoL/L - LCn3 - subgroup by primary or secondary prevention.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 2 High vs low LCn3 omega-3 fats (secondary outcomes)
Outcome: 40 TC, mmoL/L - LCn3 - subgroup by primary or secondary prevention
Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Primary prevention
Berson 2004 105 5.17 (0.82) 103 4.87 (0.91) 0.8 % 0.30 [ 0.06, 0.54 ]
Brox 2001 37 7.8 (0.9) 37 7.9 (0.8) 0.3 % -0.10 [ -0.49, 0.29 ]
Caldwell 2011 17 5.01 (1.18) 17 5.14 (0.97) 0.1 % -0.13 [ -0.86, 0.60 ]
Derosa 2016 (1) 128 4.9 (3.4) 130 5.1 (3.4) 0.1 % -0.20 [ -1.03, 0.63 ]
Deslypere 1992 14 5.48 (0.89) 14 5.89 (1.03) 0.1 % -0.41 [ -1.12, 0.30 ]
DIPP 2015 91 5.52 (0.9) 75 5.4 (0.79) 0.7 % 0.12 [ -0.14, 0.38 ]
DO IT 2010 124 6.3 (1.2) 117 6.3 (1.3) 0.4 % 0.0 [ -0.32, 0.32 ]
EPE-A 2014 (2) 64 0.1 (0) 55 0.21 (0) Not estimable
JELIS 2007 9326 5.83 (0.8) 9319 5.88 (0.78) 87.0 % -0.05 [ -0.07, -0.03 ]
MARINA 2011 80 5.6 (0.8987) 71 5.6 (0.4225) 0.9 % 0.0 [ -0.22, 0.22 ]
Mita 2007 30 5.15 (0.83) 30 5.27 (0.99) 0.2 % -0.12 [ -0.58, 0.34 ]
ORIGIN 2012 6281 -0.406 (2.06) 6255 -0.38 (2.06) 8.6 % -0.03 [ -0.10, 0.04 ]
Rossing 1996 14 5.51 (1.12) 15 5.2 (1.16) 0.1 % 0.31 [ -0.52, 1.14 ]
Sandhu 2016 49 5.18 (0.89) 47 5.37 (0.94) 0.3 % -0.19 [ -0.56, 0.18 ]
SMART 2013 21 5.4 (0.9) 24 5.2 (1) 0.1 % 0.20 [ -0.36, 0.76 ]
Sofi 2010 6 -0.02 (0.9624) 5 -0.12 (0.451) 0.1 % 0.10 [ -0.77, 0.97 ]
WELCOME 2015 47 4.7 (1.1) 48 4.8 (1) 0.2 % -0.10 [ -0.52, 0.32 ]
Subtotal (95% CI) 16434 16362 100.0 % -0.04 [ -0.07, -0.02 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 14.05, df = 15 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 4.09 (P = 0.000043)
2 Secondary prevention
Ahn 2016 38 3.6 (0.74) 36 3.75 (0.67) 5.9 % -0.15 [ -0.47, 0.17 ]
AlphaOmega - EPA+DHA 2010 605 -0.26 (0.98) 605 -0.28 (0.98) 23.2 % 0.02 [ -0.09, 0.13 ]
DART 1989 868 6.47 (1.14) 847 6.37 (1.11) 23.9 % 0.10 [ -0.01, 0.21 ]
Franzen 1993 15 5.77 (1) 15 6.26 (1.1) 1.2 % -0.49 [ -1.24, 0.26 ]
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Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
HARP 1995 31 5.02 (0.96) 28 4.99 (0.62) 3.9 % 0.03 [ -0.38, 0.44 ]
NAT2 2013 134 5.7 (1.18) 129 5.64 (1) 8.2 % 0.06 [ -0.20, 0.32 ]
Nodari 2011 HF 67 4.8 (0.62) 66 4.9 (0.62) 11.4 % -0.10 [ -0.31, 0.11 ]
Nye 1990 12 6.83 (1) 12 6.2 (1.31) 0.8 % 0.63 [ -0.30, 1.56 ]
OFAMI 2001 123 5.27 (1.09) 123 5.59 (1.18) 7.3 % -0.32 [ -0.60, -0.04 ]
SCIMO 1999 89 6.2 (1.55) 86 6.05 (1.64) 3.0 % 0.15 [ -0.32, 0.62 ]
SHOT 1996 289 7.01 (1.27) 267 7.03 (1.32) 11.1 % -0.02 [ -0.24, 0.20 ]
Subtotal (95% CI) 2271 2214 100.0 % -0.01 [ -0.09, 0.08 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 13.89, df = 10 (P = 0.18); I2 =28%
Test for overall effect: Z = 0.18 (P = 0.86)
Test for subgroup differences: Chi2 = 0.66, df = 1 (P = 0.42), I2 =0.0%
-2 -1 0 1 2
Favours higher omega 3 Favours lower omega 3
(1) SDs unlikely so converted assuming SEs
(2) median change from baseline, highest EPA vs placebo
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Analysis 2.41. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 41 TC,
mmoL/L - LCn3 - subgroup by statin use.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 2 High vs low LCn3 omega-3 fats (secondary outcomes)
Outcome: 41 TC, mmoL/L - LCn3 - subgroup by statin use
Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 LCn3 -≥ 50% of control group on statins
Ahn 2016 38 3.6 (0.74) 36 3.75 (0.67) 0.4 % -0.15 [ -0.47, 0.17 ]
AlphaOmega - EPA+DHA 2010 605 -0.26 (0.98) 605 -0.28 (0.98) 3.6 % 0.02 [ -0.09, 0.13 ]
JELIS 2007 9326 5.83 (0.8) 9319 5.88 (0.78) 86.5 % -0.05 [ -0.07, -0.03 ]
NAT2 2013 134 5.7 (1.18) 129 5.64 (1) 0.6 % 0.06 [ -0.20, 0.32 ]
ORIGIN 2012 6281 -0.406 (2.06) 6255 -0.38 (2.06) 8.6 % -0.03 [ -0.10, 0.04 ]
WELCOME 2015 47 4.7 (1.1) 48 4.8 (1) 0.2 % -0.10 [ -0.52, 0.32 ]
Subtotal (95% CI) 16431 16392 100.0 % -0.05 [ -0.07, -0.02 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 2.81, df = 5 (P = 0.73); I2 =0.0%
Test for overall effect: Z = 4.22 (P = 0.000024)
2 LCn3 - < 50% of control group on statins
Berson 2004 105 5.17 (0.82) 103 4.87 (0.91) 9.3 % 0.30 [ 0.06, 0.54 ]
Brox 2001 37 7.8 (0.9) 37 7.9 (0.8) 4.4 % -0.10 [ -0.49, 0.29 ]
DART 1989 868 6.47 (1.14) 847 6.37 (1.11) 19.4 % 0.10 [ -0.01, 0.21 ]
Deslypere 1992 14 5.48 (0.89) 14 5.89 (1.03) 1.5 % -0.41 [ -1.12, 0.30 ]
DIPP 2015 91 5.52 (0.9) 75 5.4 (0.79) 8.2 % 0.12 [ -0.14, 0.38 ]
DO IT 2010 124 6.3 (1.2) 117 6.3 (1.3) 6.1 % 0.0 [ -0.32, 0.32 ]
Franzen 1993 15 5.77 (1) 15 6.26 (1.1) 1.3 % -0.49 [ -1.24, 0.26 ]
HARP 1995 31 5.02 (0.96) 28 4.99 (0.62) 4.0 % 0.03 [ -0.38, 0.44 ]
MARINA 2011 80 5.6 (0.8987) 71 5.6 (0.4225) 10.1 % 0.0 [ -0.22, 0.22 ]
Mita 2007 30 5.15 (0.83) 30 5.27 (0.99) 3.2 % -0.12 [ -0.58, 0.34 ]
Nodari 2011 HF 67 4.8 (0.62) 66 4.9 (0.62) 10.7 % -0.10 [ -0.31, 0.11 ]
OFAMI 2001 123 5.27 (1.09) 123 5.59 (1.18) 7.2 % -0.32 [ -0.60, -0.04 ]
Rossing 1996 14 5.51 (1.12) 15 5.2 (1.16) 1.1 % 0.31 [ -0.52, 1.14 ]
SCIMO 1999 89 6.2 (1.55) 86 6.05 (1.64) 3.1 % 0.15 [ -0.32, 0.62 ]
SHOT 1996 289 7.01 (1.27) 267 7.03 (1.32) 10.4 % -0.02 [ -0.24, 0.20 ]
-2 -1 0 1 2
Favours higher omega 3 Favours lower omega 3
(Continued . . . )
508Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(. . . Continued)
Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Subtotal (95% CI) 1977 1894 100.0 % 0.01 [ -0.08, 0.10 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 19.60, df = 14 (P = 0.14); I2 =29%
Test for overall effect: Z = 0.22 (P = 0.82)
3 LCn3 - use of statins unclear
Caldwell 2011 17 5.01 (1.18) 17 5.14 (0.97) 11.5 % -0.13 [ -0.86, 0.60 ]
Derosa 2016 (1) 128 4.9 (3.4) 130 5.1 (3.4) 8.8 % -0.20 [ -1.03, 0.63 ]
EPE-A 2014 (2) 64 0.1 (0) 55 0.21 (0) Not estimable
Nye 1990 12 6.83 (1) 12 6.2 (1.31) 7.0 % 0.63 [ -0.30, 1.56 ]
Sandhu 2016 49 5.18 (0.89) 47 5.37 (0.94) 45.1 % -0.19 [ -0.56, 0.18 ]
SMART 2013 21 5.4 (0.9) 24 5.2 (1) 19.6 % 0.20 [ -0.36, 0.76 ]
Sofi 2010 6 -0.02 (0.9624) 5 -0.12 (0.451) 8.1 % 0.10 [ -0.77, 0.97 ]
Subtotal (95% CI) 297 290 100.0 % -0.03 [ -0.27, 0.22 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 3.64, df = 5 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 0.21 (P = 0.83)
Test for subgroup differences: Chi2 = 1.44, df = 2 (P = 0.49), I2 =0.0%
-2 -1 0 1 2
Favours higher omega 3 Favours lower omega 3
(1) SDs unlikely to converted assuming SEs
(2) median change from baseline, highest EPA vs placebo
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Analysis 2.42. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 42
Triglycerides, fasting, serum, mmoL/L - LCn3.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 2 High vs low LCn3 omega-3 fats (secondary outcomes)
Outcome: 42 Triglycerides, fasting, serum, mmoL/L - LCn3
Study or subgroup
Favours
higher
omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
AlphaOmega - EPA+DHA 2010 605 -0.08 (1.2) 605 -0.05 (0.98) 8.5 % -0.03 [ -0.15, 0.09 ]
Berson 2004 105 1.06 (0.72) 103 1.39 (1.22) 4.4 % -0.33 [ -0.60, -0.06 ]
Derosa 2016 (1) 128 1.4 (3.4) 130 1.9 (4.6) 0.5 % -0.50 [ -1.49, 0.49 ]
Deslypere 1992 14 0.75 (0.35) 14 1.18 (0.79) 2.2 % -0.43 [ -0.88, 0.02 ]
DIPP 2015 90 1.45 (1.05) 71 1.44 (0.81) 4.2 % 0.01 [ -0.28, 0.30 ]
DO IT 2010 124 1.44 (0.8) 117 1.6 (0.9) 5.7 % -0.16 [ -0.38, 0.06 ]
EPE-A 2014 (2) 64 -0.07 (0) 55 0.14 (0) Not estimable
HARP 1995 31 1.14 (0.56) 28 1.61 (0.76) 3.3 % -0.47 [ -0.81, -0.13 ]
JELIS 2007 (3) 2303 1.61 (0) 2262 1.73 (0) Not estimable
JELIS 2007 (4) 7023 1.43 (0) 7057 1.54 (0) Not estimable
Lorenz-Meyer 1996 13 -0.42 (0.65) 12 -0.1 (0.45) 2.3 % -0.32 [ -0.76, 0.12 ]
MARINA 2011 80 -0.2 (0.45) 71 0.1 (0.63) 6.8 % -0.30 [ -0.48, -0.12 ]
Mita 2007 30 1.77 (1.07) 30 1.51 (0.9) 1.8 % 0.26 [ -0.24, 0.76 ]
Nodari 2011 HF 67 1.61 (0.51) 66 1.75 (0.78) 5.5 % -0.14 [ -0.36, 0.08 ]
Nye 1990 12 1.4 (0.58) 12 1.8 (0.55) 2.2 % -0.40 [ -0.85, 0.05 ]
OFAMI 2001 120 1.31 (0.6) 121 1.82 (1.05) 5.7 % -0.51 [ -0.73, -0.29 ]
ORIGIN 2012 6281 -0.265 (2.69) 6255 -0.1 (2.69) 9.4 % -0.16 [ -0.26, -0.07 ]
ORL 2013 170 -0.78 (0.9) 165 -0.4 (0.87) 6.4 % -0.38 [ -0.57, -0.19 ]
Sandhu 2016 49 1.08 (0.56) 47 1.24 (0.5) 5.8 % -0.16 [ -0.37, 0.05 ]
SCIMO 1999 87 -0.16 (0.98) 84 0.09 (1.19) 3.5 % -0.25 [ -0.58, 0.08 ]
SHOT 1996 289 1.6 (1) 267 2.05 (1.24) 6.5 % -0.45 [ -0.64, -0.26 ]
SMART 2013 21 1.12 (0.57) 24 1.19 (0.46) 3.8 % -0.07 [ -0.38, 0.24 ]
Sofi 2010 6 -0.36 (0.75) 5 0.23 (0.2497) 1.2 % -0.59 [ -1.23, 0.05 ]
Tande 2016 50 -0.04 (0.7) 50 0.17 (0.65) 4.6 % -0.21 [ -0.47, 0.05 ]
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Study or subgroup
Favours
higher
omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
THIS DIET 2008 37 1.45 (0.76) 34 1.43 (0.85) 2.9 % 0.02 [ -0.36, 0.40 ]
WELCOME 2015 47 1.5 (1.2) 48 1.8 (0.6) 2.8 % -0.30 [ -0.68, 0.08 ]
Total (95% CI) 17846 17733 100.0 % -0.24 [ -0.31, -0.16 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 42.25, df = 22 (P = 0.01); I2 =48%
Test for overall effect: Z = 6.24 (P < 0.00001)
Test for subgroup differences: Not applicable
-0.5 -0.25 0 0.25 0.5
Favours higher omega 3 Favours lower omega 3
(1) SDs unlikely so converted assuming SEs
(2) median change from baseline, highest EPA vs placebo
(3) Medians, in participants with impaired glucose metabolism
(4) medians in normoglycaemic participants
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Analysis 2.43. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 43 TG,
fasting, mmoL/L - LCn3 - SA by summary risk of bias.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 2 High vs low LCn3 omega-3 fats (secondary outcomes)
Outcome: 43 TG, fasting, mmoL/L - LCn3 - SA by summary risk of bias
Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Low risk of bias
AlphaOmega - EPA+DHA 2010 605 -0.08 (1.2) 605 -0.05 (0.98) 8.6 % -0.03 [ -0.15, 0.09 ]
Berson 2004 105 1.06 (0.72) 103 1.39 (1.22) 4.4 % -0.33 [ -0.60, -0.06 ]
Derosa 2016 (1) 128 1.4 (3.4) 130 1.9 (4.6) 0.5 % -0.50 [ -1.49, 0.49 ]
Lorenz-Meyer 1996 13 -0.42 (0.65) 12 -0.1 (0.45) 2.2 % -0.32 [ -0.76, 0.12 ]
MARINA 2011 80 0.96 (0.4044) 71 1.19 (0.507) 7.7 % -0.23 [ -0.38, -0.08 ]
ORIGIN 2012 6281 -0.265 (2.69) 6255 -0.1 (2.69) 9.6 % -0.16 [ -0.26, -0.07 ]
SCIMO 1999 87 -0.16 (0.98) 84 0.09 (1.19) 3.4 % -0.25 [ -0.58, 0.08 ]
WELCOME 2015 47 1.5 (1.2) 48 1.8 (0.6) 2.7 % -0.30 [ -0.68, 0.08 ]
Subtotal (95% CI) 7346 7308 39.1 % -0.17 [ -0.25, -0.09 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 8.40, df = 7 (P = 0.30); I2 =17%
Test for overall effect: Z = 4.39 (P = 0.000011)
2 Moderate/high risk of bias
Deslypere 1992 14 0.75 (0.35) 14 1.18 (0.79) 2.1 % -0.43 [ -0.88, 0.02 ]
DIPP 2015 90 1.45 (1.05) 71 1.44 (0.81) 4.1 % 0.01 [ -0.28, 0.30 ]
DO IT 2010 124 1.44 (0.8) 117 1.6 (0.9) 5.7 % -0.16 [ -0.38, 0.06 ]
EPE-A 2014 (2) 64 -0.07 (0) 55 0.14 (0) Not estimable
HARP 1995 31 1.14 (0.56) 28 1.61 (0.76) 3.2 % -0.47 [ -0.81, -0.13 ]
JELIS 2007 (3) 7023 1.43 (0) 7057 1.54 (0) Not estimable
JELIS 2007 (4) 2303 1.61 (0) 2262 1.73 (0) Not estimable
Mita 2007 30 1.77 (1.07) 30 1.51 (0.9) 1.8 % 0.26 [ -0.24, 0.76 ]
Nodari 2011 HF 67 1.61 (0.51) 66 1.75 (0.78) 5.4 % -0.14 [ -0.36, 0.08 ]
Nye 1990 12 1.4 (0.58) 12 1.8 (0.55) 2.1 % -0.40 [ -0.85, 0.05 ]
OFAMI 2001 120 1.31 (0.6) 121 1.82 (1.05) 5.7 % -0.51 [ -0.73, -0.29 ]
ORL 2013 170 -0.78 (0.9) 165 -0.4 (0.87) 6.4 % -0.38 [ -0.57, -0.19 ]
Sandhu 2016 49 1.08 (0.56) 47 1.24 (0.5) 5.8 % -0.16 [ -0.37, 0.05 ]
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Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
SHOT 1996 289 1.6 (1) 267 2.05 (1.24) 6.4 % -0.45 [ -0.64, -0.26 ]
SMART 2013 21 1.12 (0.57) 24 1.19 (0.46) 3.8 % -0.07 [ -0.38, 0.24 ]
Sofi 2010 6 -0.36 (0.75) 5 0.23 (0.2497) 1.2 % -0.59 [ -1.23, 0.05 ]
Tande 2016 50 -0.04 (0.7) 50 0.17 (0.65) 4.5 % -0.21 [ -0.47, 0.05 ]
THIS DIET 2008 37 1.45 (0.76) 34 1.43 (0.85) 2.8 % 0.02 [ -0.36, 0.40 ]
Subtotal (95% CI) 10500 10425 60.9 % -0.25 [ -0.35, -0.15 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 28.02, df = 14 (P = 0.01); I2 =50%
Test for overall effect: Z = 4.72 (P < 0.00001)
Total (95% CI) 17846 17733 100.0 % -0.23 [ -0.30, -0.16 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 41.33, df = 22 (P = 0.01); I2 =47%
Test for overall effect: Z = 6.25 (P < 0.00001)
Test for subgroup differences: Chi2 = 1.45, df = 1 (P = 0.23), I2 =31%
-0.5 -0.25 0 0.25 0.5
Favours higher omega 3 Favours lower omega 3
(1) SDs unlikely, converted assuming SEs
(2) median change from baseline, highest EPA vs placebo
(3) medians in normoglycaemic participants
(4) Medians, in participants with impaired glucose metabolism
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Analysis 2.44. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 44 TG,
fasting, mmoL/L - LCn3 - SA by compliance and study size.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 2 High vs low LCn3 omega-3 fats (secondary outcomes)
Outcome: 44 TG, fasting, mmoL/L - LCn3 - SA by compliance and study size
Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 SA - low risk of compliance bias
AlphaOmega - EPA+DHA 2010 605 -0.08 (1.2) 605 -0.05 (0.98) 14.6 % -0.03 [ -0.15, 0.09 ]
Berson 2004 105 1.06 (0.72) 103 1.39 (1.22) 8.0 % -0.33 [ -0.60, -0.06 ]
Deslypere 1992 14 0.75 (0.35) 14 1.18 (0.79) 4.0 % -0.43 [ -0.88, 0.02 ]
DO IT 2010 124 1.44 (0.8) 117 1.6 (0.9) 10.1 % -0.16 [ -0.38, 0.06 ]
EPE-A 2014 (1) 64 -0.07 (0) 55 0.14 (0) Not estimable
HARP 1995 31 1.14 (0.56) 28 1.61 (0.76) 6.0 % -0.47 [ -0.81, -0.13 ]
MARINA 2011 80 0.96 (0.4044) 71 1.19 (0.507) 13.4 % -0.23 [ -0.38, -0.08 ]
Nodari 2011 HF 67 1.61 (0.51) 66 1.75 (0.78) 9.8 % -0.14 [ -0.36, 0.08 ]
ORL 2013 170 -0.78 (0.9) 165 -0.4 (0.87) 11.3 % -0.38 [ -0.57, -0.19 ]
SCIMO 1999 87 -0.16 (0.98) 84 0.09 (1.19) 6.4 % -0.25 [ -0.58, 0.08 ]
SHOT 1996 289 1.6 (1) 267 2.05 (1.24) 11.4 % -0.45 [ -0.64, -0.26 ]
WELCOME 2015 47 1.5 (1.2) 48 1.8 (0.6) 5.1 % -0.30 [ -0.68, 0.08 ]
Subtotal (95% CI) 1683 1623 100.0 % -0.26 [ -0.36, -0.16 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 22.03, df = 10 (P = 0.01); I2 =55%
Test for overall effect: Z = 5.04 (P < 0.00001)
2 SA - 100+ randomised
AlphaOmega - EPA+DHA 2010 605 -0.08 (1.2) 605 -0.05 (0.98) 10.3 % -0.03 [ -0.15, 0.09 ]
Berson 2004 105 1.06 (0.72) 103 1.39 (1.22) 5.4 % -0.33 [ -0.60, -0.06 ]
Derosa 2016 (2) 128 1.4 (3.4) 130 1.9 (4.6) 0.7 % -0.50 [ -1.49, 0.49 ]
Deslypere 1992 14 0.75 (0.35) 14 1.18 (0.79) 2.7 % -0.43 [ -0.88, 0.02 ]
DIPP 2015 90 1.45 (1.05) 71 1.44 (0.81) 5.1 % 0.01 [ -0.28, 0.30 ]
DO IT 2010 124 1.44 (0.8) 117 1.6 (0.9) 7.0 % -0.16 [ -0.38, 0.06 ]
EPE-A 2014 (3) 64 -0.07 (0) 55 0.14 (0) Not estimable
HARP 1995 31 1.14 (0.56) 28 1.61 (0.76) 4.0 % -0.47 [ -0.81, -0.13 ]
JELIS 2007 (4) 2303 1.61 (0) 2262 1.73 (0) Not estimable
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Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
JELIS 2007 (5) 7023 1.43 (0) 7057 1.54 (0) Not estimable
MARINA 2011 80 0.96 (0.4044) 71 1.19 (0.507) 9.3 % -0.23 [ -0.38, -0.08 ]
Nodari 2011 HF 67 1.61 (0.51) 66 1.75 (0.78) 6.7 % -0.14 [ -0.36, 0.08 ]
OFAMI 2001 120 1.31 (0.6) 121 1.82 (1.05) 7.0 % -0.51 [ -0.73, -0.29 ]
ORIGIN 2012 6281 -0.265 (2.69) 6255 -0.1 (2.69) 11.3 % -0.16 [ -0.26, -0.07 ]
ORL 2013 170 -0.78 (0.9) 165 -0.4 (0.87) 7.8 % -0.38 [ -0.57, -0.19 ]
SCIMO 1999 87 -0.16 (0.98) 84 0.09 (1.19) 4.3 % -0.25 [ -0.58, 0.08 ]
SHOT 1996 289 1.6 (1) 267 2.05 (1.24) 7.9 % -0.45 [ -0.64, -0.26 ]
SMART 2013 21 1.12 (0.57) 24 1.19 (0.46) 4.7 % -0.07 [ -0.38, 0.24 ]
Tande 2016 50 -0.04 (0.7) 50 0.17 (0.65) 5.6 % -0.21 [ -0.47, 0.05 ]
Subtotal (95% CI) 17652 17545 100.0 % -0.24 [ -0.32, -0.16 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 33.80, df = 15 (P = 0.004); I2 =56%
Test for overall effect: Z = 5.72 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.09, df = 1 (P = 0.76), I2 =0.0%
-0.5 -0.25 0 0.25 0.5
Favours higher omega 3 Favours lower omega 3
(1) median change from baseline, highest EPA vs placebo
(2) SDs unlikely, converted assuming SEs
(3) median change from baseline, highest EPA vs placebo
(4) Medians, in participants with impaired glucose metabolism
(5) medians in normoglycaemic participants
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Analysis 2.45. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 45 TG,
fasting, mmoL/L - LCn3 - subgroup by dose.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 2 High vs low LCn3 omega-3 fats (secondary outcomes)
Outcome: 45 TG, fasting, mmoL/L - LCn3 - subgroup by dose
Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 LCn3≤ 150 mg/d
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
2 LCn3 > 150≤ 250 mg/d
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
3 LCn3 > 250≤ 400 mg/d
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
4 LCn3 > 400≤ 2400 mg/d
AlphaOmega - EPA+DHA 2010 605 -0.08 (1.2) 605 -0.05 (0.98) 14.0 % -0.03 [ -0.15, 0.09 ]
Berson 2004 105 1.06 (0.72) 103 1.39 (1.22) 5.1 % -0.33 [ -0.60, -0.06 ]
Derosa 2016 (1) 128 1.4 (3.4) 130 1.9 (4.6) 0.5 % -0.50 [ -1.49, 0.49 ]
Deslypere 1992 14 0.75 (0.35) 14 1.18 (0.79) 2.1 % -0.43 [ -0.88, 0.02 ]
DIPP 2015 90 1.45 (1.05) 71 1.44 (0.81) 4.7 % 0.01 [ -0.28, 0.30 ]
DO IT 2010 124 1.44 (0.8) 117 1.6 (0.9) 7.3 % -0.16 [ -0.38, 0.06 ]
JELIS 2007 (2) 2303 1.61 (0) 2262 1.73 (0) Not estimable
JELIS 2007 (3) 7023 1.43 (0) 7057 1.54 (0) Not estimable
MARINA 2011 80 0.96 (0.4044) 71 1.19 (0.507) 11.8 % -0.23 [ -0.38, -0.08 ]
Mita 2007 30 1.77 (1.07) 30 1.51 (0.9) 1.8 % 0.26 [ -0.24, 0.76 ]
Nodari 2011 HF 67 1.61 (0.51) 66 1.75 (0.78) 6.9 % -0.14 [ -0.36, 0.08 ]
Nye 1990 12 1.4 (0.58) 12 1.8 (0.55) 2.1 % -0.40 [ -0.85, 0.05 ]
ORIGIN 2012 6281 -0.265 (2.69) 6255 -0.1 (2.69) 17.2 % -0.16 [ -0.26, -0.07 ]
ORL 2013 170 -0.78 (0.9) 165 -0.4 (0.87) 8.7 % -0.38 [ -0.57, -0.19 ]
SCIMO 1999 87 -0.16 (0.98) 84 0.09 (1.19) 3.8 % -0.25 [ -0.58, 0.08 ]
-1 -0.5 0 0.5 1
Favours higher omega 3 Favours lower omega 3
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Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
SMART 2013 21 1.12 (0.57) 24 1.19 (0.46) 4.3 % -0.07 [ -0.38, 0.24 ]
Sofi 2010 6 -0.36 (0.75) 5 0.23 (0.2497) 1.1 % -0.59 [ -1.23, 0.05 ]
Tande 2016 50 -0.04 (0.7) 50 0.17 (0.65) 5.4 % -0.21 [ -0.47, 0.05 ]
THIS DIET 2008 37 1.45 (0.76) 34 1.43 (0.85) 3.0 % 0.02 [ -0.36, 0.40 ]
Subtotal (95% CI) 17233 17155 100.0 % -0.18 [ -0.25, -0.11 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 22.10, df = 16 (P = 0.14); I2 =28%
Test for overall effect: Z = 4.98 (P < 0.00001)
5 LCn3 > 2.4≤ 4.4 g/d
EPE-A 2014 (4) 64 -0.07 (0) 55 0.14 (0) Not estimable
OFAMI 2001 120 1.31 (0.6) 121 1.82 (1.05) 27.4 % -0.51 [ -0.73, -0.29 ]
Sandhu 2016 49 1.08 (0.56) 47 1.24 (0.5) 27.8 % -0.16 [ -0.37, 0.05 ]
SHOT 1996 289 1.6 (1) 267 2.05 (1.24) 30.7 % -0.45 [ -0.64, -0.26 ]
WELCOME 2015 47 1.5 (1.2) 48 1.8 (0.6) 14.0 % -0.30 [ -0.68, 0.08 ]
Subtotal (95% CI) 569 538 100.0 % -0.36 [ -0.53, -0.20 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 6.20, df = 3 (P = 0.10); I2 =52%
Test for overall effect: Z = 4.24 (P = 0.000023)
6 LCn3 > 4.4 g/d
HARP 1995 31 1.14 (0.56) 28 1.61 (0.76) 61.6 % -0.47 [ -0.81, -0.13 ]
Lorenz-Meyer 1996 13 -0.42 (0.65) 12 -0.1 (0.45) 38.4 % -0.32 [ -0.76, 0.12 ]
Subtotal (95% CI) 44 40 100.0 % -0.41 [ -0.68, -0.14 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.28, df = 1 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 3.00 (P = 0.0027)
Test for subgroup differences: Chi2 = 6.29, df = 2 (P = 0.04), I2 =68%
-1 -0.5 0 0.5 1
Favours higher omega 3 Favours lower omega 3
(1) SDs unlikely, converted assuming SEs
(2) Medians, in participants with impaired glucose metabolism
(3) medians in normoglycaemic participants
(4) median change from baseline, highest EPA vs placebo
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Analysis 2.46. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 46 TG,
fasting, mmoL/L - LCn3 - subgroup by replacement.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 2 High vs low LCn3 omega-3 fats (secondary outcomes)
Outcome: 46 TG, fasting, mmoL/L - LCn3 - subgroup by replacement
Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 N-3 replacing SFA
Derosa 2016 (1) 128 1.4 (3.4) 130 1.9 (4.6) 9.9 % -0.50 [ -1.49, 0.49 ]
SCIMO 1999 87 -0.16 (0.98) 84 0.09 (1.19) 90.1 % -0.25 [ -0.58, 0.08 ]
Subtotal (95% CI) 215 214 100.0 % -0.27 [ -0.59, 0.04 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.22, df = 1 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 1.73 (P = 0.083)
2 N-3 replacing MUFA
AlphaOmega - EPA+DHA 2010 605 -0.08 (1.2) 605 -0.05 (0.98) 19.3 % -0.03 [ -0.15, 0.09 ]
Deslypere 1992 14 0.75 (0.35) 14 1.18 (0.79) 2.3 % -0.43 [ -0.88, 0.02 ]
HARP 1995 31 1.14 (0.56) 28 1.61 (0.76) 3.9 % -0.47 [ -0.81, -0.13 ]
MARINA 2011 80 0.96 (0.4044) 71 1.19 (0.507) 15.4 % -0.23 [ -0.38, -0.08 ]
Nodari 2011 HF 67 1.61 (0.51) 66 1.75 (0.78) 8.2 % -0.14 [ -0.36, 0.08 ]
Nye 1990 12 1.4 (0.58) 12 1.8 (0.55) 2.3 % -0.40 [ -0.85, 0.05 ]
ORIGIN 2012 6281 -0.265 (2.69) 6255 -0.1 (2.69) 25.7 % -0.16 [ -0.26, -0.07 ]
SCIMO 1999 87 -0.16 (0.98) 84 0.09 (1.19) 4.2 % -0.25 [ -0.58, 0.08 ]
SMART 2013 21 1.12 (0.57) 24 1.19 (0.46) 4.8 % -0.07 [ -0.38, 0.24 ]
Sofi 2010 6 -0.36 (0.75) 5 0.23 (0.2497) 1.2 % -0.59 [ -1.23, 0.05 ]
Tande 2016 50 -0.04 (0.7) 50 0.17 (0.65) 6.2 % -0.21 [ -0.47, 0.05 ]
THIS DIET 2008 37 1.45 (0.76) 34 1.43 (0.85) 3.3 % 0.02 [ -0.36, 0.40 ]
WELCOME 2015 47 1.5 (1.2) 48 1.8 (0.6) 3.2 % -0.30 [ -0.68, 0.08 ]
Subtotal (95% CI) 7338 7296 100.0 % -0.18 [ -0.25, -0.10 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 14.61, df = 12 (P = 0.26); I2 =18%
Test for overall effect: Z = 4.86 (P < 0.00001)
3 N-3 replacing n-6
Berson 2004 105 1.06 (0.72) 103 1.39 (1.22) 20.2 % -0.33 [ -0.60, -0.06 ]
DIPP 2015 90 1.45 (1.05) 71 1.44 (0.81) 19.3 % 0.01 [ -0.28, 0.30 ]
DO IT 2010 124 1.44 (0.8) 117 1.6 (0.9) 24.1 % -0.16 [ -0.38, 0.06 ]
-0.5 -0.25 0 0.25 0.5
Favours higher omega 3 Favours lower omega 3
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Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Lorenz-Meyer 1996 13 -0.42 (0.65) 12 -0.1 (0.45) 12.2 % -0.32 [ -0.76, 0.12 ]
OFAMI 2001 120 1.31 (0.6) 121 1.82 (1.05) 24.1 % -0.51 [ -0.73, -0.29 ]
Subtotal (95% CI) 452 424 100.0 % -0.27 [ -0.45, -0.08 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 9.63, df = 4 (P = 0.05); I2 =58%
Test for overall effect: Z = 2.77 (P = 0.0056)
4 N-3 replacing carbs/sugars
Derosa 2016 (2) 128 1.4 (3.4) 130 1.9 (4.6) 100.0 % -0.50 [ -1.49, 0.49 ]
Subtotal (95% CI) 128 130 100.0 % -0.50 [ -1.49, 0.49 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.99 (P = 0.32)
5 N-3 replacing nil/low n-3 placebo
JELIS 2007 (3) 2303 1.61 (0) 2262 1.73 (0) Not estimable
JELIS 2007 (4) 7023 1.43 (0) 7057 1.54 (0) Not estimable
Mita 2007 30 1.77 (1.07) 30 1.51 (0.9) 21.8 % 0.26 [ -0.24, 0.76 ]
Sandhu 2016 49 1.08 (0.56) 47 1.24 (0.5) 38.4 % -0.16 [ -0.37, 0.05 ]
SHOT 1996 289 1.6 (1) 267 2.05 (1.24) 39.8 % -0.45 [ -0.64, -0.26 ]
Subtotal (95% CI) 9694 9663 100.0 % -0.18 [ -0.51, 0.14 ]
Heterogeneity: Tau2 = 0.06; Chi2 = 8.84, df = 2 (P = 0.01); I2 =77%
Test for overall effect: Z = 1.12 (P = 0.26)
6 Replacement unclear
EPE-A 2014 (5) 64 -0.07 (0) 55 0.14 (0) Not estimable
ORL 2013 170 -0.78 (0.9) 165 -0.4 (0.87) 100.0 % -0.38 [ -0.57, -0.19 ]
Subtotal (95% CI) 234 220 100.0 % -0.38 [ -0.57, -0.19 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.93 (P = 0.000085)
Test for subgroup differences: Chi2 = 4.89, df = 5 (P = 0.43), I2 =0.0%
-0.5 -0.25 0 0.25 0.5
Favours higher omega 3 Favours lower omega 3
(1) SDs unlikely, converted assuming SEs
(2) SDs unlikely, converted assuming SEs
(3) Medians, in participants with impaired glucose metabolism
(4) medians in normoglycaemic participants
(5) median change from baseline, highest EPA vs placebo
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Analysis 2.47. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 47 TG,
fasting, mmoL/L - LCn3 - subgroup by intervention type.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 2 High vs low LCn3 omega-3 fats (secondary outcomes)
Outcome: 47 TG, fasting, mmoL/L - LCn3 - subgroup by intervention type
Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Dietary advice
THIS DIET 2008 37 1.45 (0.76) 34 1.43 (0.85) 100.0 % 0.02 [ -0.36, 0.40 ]
Subtotal (95% CI) 37 34 100.0 % 0.02 [ -0.36, 0.40 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.10 (P = 0.92)
2 Supplemental foods
AlphaOmega - EPA+DHA 2010 605 -0.08 (1.2) 605 -0.05 (0.98) 100.0 % -0.03 [ -0.15, 0.09 ]
Subtotal (95% CI) 605 605 100.0 % -0.03 [ -0.15, 0.09 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.48 (P = 0.63)
3 Supplement (capsule)
Berson 2004 105 1.06 (0.72) 103 1.39 (1.22) 5.3 % -0.33 [ -0.60, -0.06 ]
Derosa 2016 (1) 128 1.4 (3.4) 130 1.9 (4.6) 2.3 % -0.50 [ -1.49, 0.49 ]
Deslypere 1992 14 0.75 (0.35) 14 1.18 (0.79) 4.5 % -0.43 [ -0.88, 0.02 ]
DO IT 2010 124 1.44 (0.8) 117 1.6 (0.9) 5.6 % -0.16 [ -0.38, 0.06 ]
EPE-A 2014 (2) 64 -0.07 (0) 55 0.14 (0) Not estimable
HARP 1995 31 1.14 (0.56) 28 1.61 (0.76) 5.0 % -0.47 [ -0.81, -0.13 ]
JELIS 2007 (3) 2303 1.61 (0) 2262 1.73 (0) Not estimable
JELIS 2007 (4) 7023 1.43 (0) 7057 1.54 (0) Not estimable
Lorenz-Meyer 1996 13 -0.42 (0.65) 12 -0.1 (0.45) 4.6 % -0.32 [ -0.76, 0.12 ]
MARINA 2011 80 0.96 (0.4044) 71 1.19 (0.507) 5.8 % -0.23 [ -0.38, -0.08 ]
Mita 2007 30 1.77 (1.07) 30 1.51 (0.9) 4.3 % 0.26 [ -0.24, 0.76 ]
Nodari 2011 HF 67 1.61 (0.51) 66 1.75 (0.78) 5.5 % -0.14 [ -0.36, 0.08 ]
Nye 1990 12 1.4 (0.58) 12 1.8 (0.55) 4.5 % -0.40 [ -0.85, 0.05 ]
OFAMI 2001 120 1.31 (0.6) 121 1.82 (1.05) 5.6 % -0.51 [ -0.73, -0.29 ]
ORIGIN 2012 6281 -0.265 (2.69) 6255 -0.1 (2.69) 5.9 % -0.16 [ -0.26, -0.07 ]
ORL 2013 170 0.78 (0.9) 165 -0.4 (0.87) 5.7 % 1.18 [ 0.99, 1.37 ]
-0.2 -0.1 0 0.1 0.2
Favours higher omega 3 Favours lower omega 3
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Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Sandhu 2016 49 1.08 (0.56) 47 1.24 (0.5) 5.6 % -0.16 [ -0.37, 0.05 ]
SCIMO 1999 87 -0.16 (0.98) 84 0.09 (1.19) 5.1 % -0.25 [ -0.58, 0.08 ]
SHOT 1996 289 1.6 (1) 267 2.05 (1.24) 5.7 % -0.45 [ -0.64, -0.26 ]
SMART 2013 21 1.12 (0.57) 24 1.19 (0.46) 5.2 % -0.07 [ -0.38, 0.24 ]
Sofi 2010 6 -0.36 (0.75) 5 0.23 (0.2497) 3.6 % -0.59 [ -1.23, 0.05 ]
Tande 2016 50 -0.04 (0.7) 50 0.17 (0.65) 5.4 % -0.21 [ -0.47, 0.05 ]
WELCOME 2015 47 1.5 (1.2) 48 1.8 (0.6) 4.8 % -0.30 [ -0.68, 0.08 ]
Subtotal (95% CI) 17114 17023 100.0 % -0.19 [ -0.38, 0.00 ]
Heterogeneity: Tau2 = 0.16; Chi2 = 225.13, df = 19 (P<0.00001); I2 =92%
Test for overall effect: Z = 1.97 (P = 0.049)
4 Any combination
DIPP 2015 90 1.45 (1.05) 71 1.44 (0.81) 100.0 % 0.01 [ -0.28, 0.30 ]
Subtotal (95% CI) 90 71 100.0 % 0.01 [ -0.28, 0.30 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.07 (P = 0.95)
Test for subgroup differences: Chi2 = 2.47, df = 3 (P = 0.48), I2 =0.0%
-0.2 -0.1 0 0.1 0.2
Favours higher omega 3 Favours lower omega 3
(1) SDs unlikely, converted assuming SEs
(2) median change from baseline, highest EPA vs placebo
(3) Medians, in participants with impaired glucose metabolism
(4) medians in normoglycaemic participants
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Analysis 2.48. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 48 TG,
fasting, mmoL/L - LCn3 - subgroup by duration.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 2 High vs low LCn3 omega-3 fats (secondary outcomes)
Outcome: 48 TG, fasting, mmoL/L - LCn3 - subgroup by duration
Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Medium duration 1 to < 2 years in study
Derosa 2016 (1) 128 1.4 (3.4) 130 1.9 (4.6) 0.7 % -0.50 [ -1.49, 0.49 ]
Deslypere 1992 14 0.75 (0.35) 14 1.18 (0.79) 3.4 % -0.43 [ -0.88, 0.02 ]
EPE-A 2014 (2) 64 -0.07 (0) 55 0.14 (0) Not estimable
Lorenz-Meyer 1996 13 -0.42 (0.65) 12 -0.1 (0.45) 3.7 % -0.32 [ -0.76, 0.12 ]
MARINA 2011 80 0.96 (0.4044) 71 1.19 (0.507) 31.8 % -0.23 [ -0.38, -0.08 ]
Nodari 2011 HF 67 1.61 (0.51) 66 1.75 (0.78) 13.8 % -0.14 [ -0.36, 0.08 ]
Nye 1990 12 1.4 (0.58) 12 1.8 (0.55) 3.4 % -0.40 [ -0.85, 0.05 ]
ORL 2013 (3) 170 -0.29 (0) 165 -0.16 (0) Not estimable
SHOT 1996 289 1.6 (1) 267 2.05 (1.24) 19.6 % -0.45 [ -0.64, -0.26 ]
SMART 2013 21 1.12 (0.57) 24 1.19 (0.46) 7.4 % -0.07 [ -0.38, 0.24 ]
Sofi 2010 6 -0.36 (0.75) 5 0.23 (0.2497) 1.7 % -0.59 [ -1.23, 0.05 ]
Tande 2016 50 -0.04 (0.7) 50 0.17 (0.65) 9.9 % -0.21 [ -0.47, 0.05 ]
WELCOME 2015 47 1.5 (1.2) 48 1.8 (0.6) 4.7 % -0.30 [ -0.68, 0.08 ]
Subtotal (95% CI) 961 919 100.0 % -0.27 [ -0.36, -0.19 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 8.97, df = 10 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 6.45 (P < 0.00001)
2 Medium-long duration: 2 to < 4 years in study
AlphaOmega - EPA+DHA 2010 605 -0.08 (1.2) 605 -0.05 (0.98) 16.7 % -0.03 [ -0.15, 0.09 ]
DIPP 2015 90 1.45 (1.05) 71 1.44 (0.81) 10.8 % 0.01 [ -0.28, 0.30 ]
DO IT 2010 124 1.44 (0.8) 117 1.6 (0.9) 13.3 % -0.16 [ -0.38, 0.06 ]
HARP 1995 31 1.14 (0.56) 28 1.61 (0.76) 9.1 % -0.47 [ -0.81, -0.13 ]
Mita 2007 30 1.77 (1.07) 30 1.51 (0.9) 5.7 % 0.26 [ -0.24, 0.76 ]
OFAMI 2001 120 1.31 (0.6) 121 1.82 (1.05) 13.3 % -0.51 [ -0.73, -0.29 ]
Sandhu 2016 49 1.08 (0.56) 47 1.24 (0.5) 13.4 % -0.16 [ -0.37, 0.05 ]
SCIMO 1999 87 -0.16 (0.98) 84 0.09 (1.19) 9.5 % -0.25 [ -0.58, 0.08 ]
-0.5 -0.25 0 0.25 0.5
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Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
THIS DIET 2008 37 1.45 (0.76) 34 1.43 (0.85) 8.2 % 0.02 [ -0.36, 0.40 ]
Subtotal (95% CI) 1173 1137 100.0 % -0.16 [ -0.31, -0.02 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 22.58, df = 8 (P = 0.004); I2 =65%
Test for overall effect: Z = 2.26 (P = 0.024)
3 Long duration≥ 4 years in study
Berson 2004 105 1.06 (0.72) 103 1.39 (1.22) 19.0 % -0.33 [ -0.60, -0.06 ]
JELIS 2007 (4) 2303 1.61 (0) 2262 1.73 (0) Not estimable
JELIS 2007 (5) 7023 1.43 (0) 7057 1.54 (0) Not estimable
ORIGIN 2012 6281 -0.265 (2.69) 6255 -0.1 (2.69) 81.0 % -0.16 [ -0.26, -0.07 ]
Subtotal (95% CI) 15712 15677 100.0 % -0.20 [ -0.32, -0.07 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 1.27, df = 1 (P = 0.26); I2 =21%
Test for overall effect: Z = 3.00 (P = 0.0027)
Test for subgroup differences: Chi2 = 2.14, df = 2 (P = 0.34), I2 =7%
-0.5 -0.25 0 0.25 0.5
Favours higher omega 3 Favours lower omega 3
(1) SDs unlikely, converted assuming SEs
(2) median change from baseline, highest EPA vs placebo
(3) data provided as % change from baseline only (no baseline)
(4) Medians, in participants with impaired glucose metabolism
(5) medians in normoglycaemic participants
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Analysis 2.49. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 49 TG,
fasting, mmoL/L - LCn3 - subgroup by primary or secondary prevention.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 2 High vs low LCn3 omega-3 fats (secondary outcomes)
Outcome: 49 TG, fasting, mmoL/L - LCn3 - subgroup by primary or secondary prevention
Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Primary prevention
Berson 2004 105 1.06 (0.72) 103 1.39 (1.22) 4.8 % -0.33 [ -0.60, -0.06 ]
Derosa 2016 (1) 128 1.4 (3.4) 130 1.9 (4.6) 0.4 % -0.50 [ -1.49, 0.49 ]
Deslypere 1992 14 0.75 (0.35) 14 1.18 (0.79) 1.8 % -0.43 [ -0.88, 0.02 ]
DIPP 2015 90 1.45 (1.05) 71 1.44 (0.81) 4.4 % 0.01 [ -0.28, 0.30 ]
DO IT 2010 124 1.44 (0.8) 117 1.6 (0.9) 7.6 % -0.16 [ -0.38, 0.06 ]
EPE-A 2014 (2) 64 -0.07 (0) 55 0.14 (0) Not estimable
JELIS 2007 (3) 7023 1.43 (0) 7057 1.54 (0) Not estimable
JELIS 2007 (4) 2303 1.61 (0) 2262 1.73 (0) Not estimable
Lorenz-Meyer 1996 13 -0.42 (0.65) 12 -0.1 (0.45) 1.9 % -0.32 [ -0.76, 0.12 ]
MARINA 2011 80 0.96 (0.4044) 71 1.19 (0.507) 15.3 % -0.23 [ -0.38, -0.08 ]
Mita 2007 30 1.77 (1.07) 30 1.51 (0.9) 1.5 % 0.26 [ -0.24, 0.76 ]
ORIGIN 2012 6281 -0.265 (2.69) 6255 -0.1 (2.69) 32.4 % -0.16 [ -0.26, -0.07 ]
ORL 2013 170 -0.78 (0.9) 165 -0.4 (0.87) 9.7 % -0.38 [ -0.57, -0.19 ]
Sandhu 2016 49 1.08 (0.56) 47 1.24 (0.5) 7.8 % -0.16 [ -0.37, 0.05 ]
SMART 2013 21 1.12 (0.57) 24 1.19 (0.46) 3.9 % -0.07 [ -0.38, 0.24 ]
Sofi 2010 6 -0.36 (0.75) 5 0.23 (0.2497) 0.9 % -0.59 [ -1.23, 0.05 ]
Tande 2016 50 -0.04 (0.7) 50 0.17 (0.65) 5.1 % -0.21 [ -0.47, 0.05 ]
WELCOME 2015 47 1.5 (1.2) 48 1.8 (0.6) 2.5 % -0.30 [ -0.68, 0.08 ]
Subtotal (95% CI) 16598 16516 100.0 % -0.20 [ -0.26, -0.14 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 14.66, df = 14 (P = 0.40); I2 =4%
Test for overall effect: Z = 6.53 (P < 0.00001)
2 Secondary prevention
AlphaOmega - EPA+DHA 2010 605 -0.08 (1.2) 605 -0.05 (0.98) 17.0 % -0.03 [ -0.15, 0.09 ]
HARP 1995 31 1.14 (0.56) 28 1.61 (0.76) 10.6 % -0.47 [ -0.81, -0.13 ]
Nodari 2011 HF 67 1.61 (0.51) 66 1.75 (0.78) 14.1 % -0.14 [ -0.36, 0.08 ]
-0.5 -0.25 0 0.25 0.5
Favours higher omega 3 Favours lower omega 3
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(. . . Continued)
Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Nye 1990 12 1.4 (0.58) 12 1.8 (0.55) 8.0 % -0.40 [ -0.85, 0.05 ]
OFAMI 2001 120 1.31 (0.6) 121 1.82 (1.05) 14.4 % -0.51 [ -0.73, -0.29 ]
SCIMO 1999 87 -0.16 (0.98) 84 0.09 (1.19) 11.0 % -0.25 [ -0.58, 0.08 ]
SHOT 1996 289 1.6 (1) 267 2.05 (1.24) 15.2 % -0.45 [ -0.64, -0.26 ]
THIS DIET 2008 37 1.45 (0.76) 34 1.43 (0.85) 9.7 % 0.02 [ -0.36, 0.40 ]
Subtotal (95% CI) 1248 1217 100.0 % -0.27 [ -0.44, -0.10 ]
Heterogeneity: Tau2 = 0.04; Chi2 = 26.50, df = 7 (P = 0.00041); I2 =74%
Test for overall effect: Z = 3.17 (P = 0.0015)
Test for subgroup differences: Chi2 = 0.58, df = 1 (P = 0.44), I2 =0.0%
-0.5 -0.25 0 0.25 0.5
Favours higher omega 3 Favours lower omega 3
(1) SDs unlikely, converted assuming SEs
(2) median change from baseline, highest EPA vs placebo
(3) medians in normoglycaemic participants
(4) Medians, in participants with impaired glucose metabolism
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Analysis 2.50. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 50 TG,
fasting, mmoL/L - LCn3 - subgroup by statin use.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 2 High vs low LCn3 omega-3 fats (secondary outcomes)
Outcome: 50 TG, fasting, mmoL/L - LCn3 - subgroup by statin use
Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 LCn3 -≥ 50% of control group on statins
AlphaOmega - EPA+DHA 2010 605 -0.08 (1.2) 605 -0.05 (0.98) 37.7 % -0.03 [ -0.15, 0.09 ]
JELIS 2007 (1) 2303 1.61 (0) 2262 1.73 (0) Not estimable
JELIS 2007 (2) 7023 1.43 (0) 7057 1.54 (0) Not estimable
ORIGIN 2012 6281 -0.265 (2.69) 6255 -0.1 (2.69) 49.1 % -0.16 [ -0.26, -0.07 ]
THIS DIET 2008 37 1.45 (0.76) 34 1.43 (0.85) 6.7 % 0.02 [ -0.36, 0.40 ]
WELCOME 2015 47 1.5 (1.2) 48 1.8 (0.6) 6.5 % -0.30 [ -0.68, 0.08 ]
Subtotal (95% CI) 16296 16261 100.0 % -0.11 [ -0.21, -0.01 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 4.25, df = 3 (P = 0.24); I2 =29%
Test for overall effect: Z = 2.12 (P = 0.034)
2 LCn3 - < 50% of control group on statins
Berson 2004 105 1.06 (0.72) 103 1.39 (1.22) 7.0 % -0.33 [ -0.60, -0.06 ]
Deslypere 1992 14 0.75 (0.35) 14 1.18 (0.79) 3.5 % -0.43 [ -0.88, 0.02 ]
DIPP 2015 90 1.45 (1.05) 71 1.44 (0.81) 6.6 % 0.01 [ -0.28, 0.30 ]
DO IT 2010 124 1.44 (0.8) 117 1.6 (0.9) 9.1 % -0.16 [ -0.38, 0.06 ]
HARP 1995 31 1.14 (0.56) 28 1.61 (0.76) 5.2 % -0.47 [ -0.81, -0.13 ]
Lorenz-Meyer 1996 13 -0.42 (0.65) 12 -0.1 (0.45) 3.7 % -0.32 [ -0.76, 0.12 ]
MARINA 2011 80 0.96 (0.4044) 71 1.19 (0.507) 12.1 % -0.23 [ -0.38, -0.08 ]
Mita 2007 30 1.77 (1.07) 30 1.51 (0.9) 2.9 % 0.26 [ -0.24, 0.76 ]
Nodari 2011 HF 67 1.61 (0.51) 66 1.75 (0.78) 8.7 % -0.14 [ -0.36, 0.08 ]
OFAMI 2001 120 1.31 (0.6) 121 1.82 (1.05) 9.1 % -0.51 [ -0.73, -0.29 ]
ORL 2013 170 -0.78 (0.9) 165 -0.4 (0.87) 10.2 % -0.38 [ -0.57, -0.19 ]
SCIMO 1999 87 -0.16 (0.98) 84 0.09 (1.19) 5.6 % -0.25 [ -0.58, 0.08 ]
SHOT 1996 289 1.6 (1) 267 2.05 (1.24) 10.2 % -0.45 [ -0.64, -0.26 ]
SMART 2013 21 1.12 (0.57) 24 1.19 (0.46) 6.1 % -0.07 [ -0.38, 0.24 ]
Subtotal (95% CI) 1241 1173 100.0 % -0.27 [ -0.36, -0.18 ]
-0.2 -0.1 0 0.1 0.2
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(. . . Continued)
Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Heterogeneity: Tau2 = 0.01; Chi2 = 23.69, df = 13 (P = 0.03); I2 =45%
Test for overall effect: Z = 5.62 (P < 0.00001)
3 LCn3 - use of statins unclear
Derosa 2016 (3) 128 1.4 (3.4) 130 1.9 (4.6) 2.3 % -0.50 [ -1.49, 0.49 ]
EPE-A 2014 (4) 64 -0.07 (0) 55 0.14 (0) Not estimable
Nye 1990 12 1.4 (0.58) 12 1.8 (0.55) 10.9 % -0.40 [ -0.85, 0.05 ]
Sandhu 2016 49 1.08 (0.56) 47 1.24 (0.5) 49.5 % -0.16 [ -0.37, 0.05 ]
Sofi 2010 6 -0.36 (0.75) 5 0.23 (0.2497) 5.5 % -0.59 [ -1.23, 0.05 ]
Tande 2016 50 -0.04 (0.7) 50 0.17 (0.65) 31.8 % -0.21 [ -0.47, 0.05 ]
Subtotal (95% CI) 309 299 100.0 % -0.23 [ -0.38, -0.08 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 2.49, df = 4 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 3.06 (P = 0.0022)
Test for subgroup differences: Chi2 = 5.31, df = 2 (P = 0.07), I2 =62%
-0.2 -0.1 0 0.1 0.2
Favours higher omega 3 Favours lower omega 3
(1) Medians, in participants with impaired glucose metabolism
(2) medians in normoglycaemic participants
(3) SDs unlikely, converted assuming SEs
(4) median change from baseline, highest EPA vs placebo
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Analysis 2.51. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 51 High-
density lipoprotein, serum, mmoL/L - LCn3.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 2 High vs low LCn3 omega-3 fats (secondary outcomes)
Outcome: 51 High-density lipoprotein, serum, mmoL/L - LCn3
Study or subgroup
Favours
lower
omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Ahn 2016 38 1.19 (0.31) 36 1.14 (0.33) 1.7 % 0.05 [ -0.10, 0.20 ]
AlphaOmega - EPA+DHA 2010 605 0.18 (0.25) 605 0.15 (0.25) 11.9 % 0.03 [ 0.00, 0.06 ]
Berson 2004 105 1.51 (0.41) 103 1.43 (0.41) 2.7 % 0.08 [ -0.03, 0.19 ]
Brox 2001 (1) 37 1.3 (0.4) 37 1.3 (0.4) 1.1 % 0.0 [ -0.18, 0.18 ]
DART 1989 867 1.05 (0.29) 847 1.04 (0.28) 12.1 % 0.01 [ -0.02, 0.04 ]
Derosa 2016 (2) 128 1.2 (1.1) 130 1.1 (1.1) 0.5 % 0.10 [ -0.17, 0.37 ]
Deslypere 1992 14 1.25 (0.21) 14 1.28 (0.35) 0.8 % -0.03 [ -0.24, 0.18 ]
DIPP 2015 89 1.43 (0.36) 73 1.46 (0.33) 2.9 % -0.03 [ -0.14, 0.08 ]
DO IT 2010 124 1.5 (0.39) 117 1.44 (0.35) 3.5 % 0.06 [ -0.03, 0.15 ]
EPE-A 2014 (3) 64 0.01 (0) 55 0.03 (0) Not estimable
HARP 1995 31 1.09 (0.28) 28 1.09 (0.34) 1.4 % 0.0 [ -0.16, 0.16 ]
JELIS 2007 9326 1.54 (0.42) 9319 1.54 (0.39) 14.8 % 0.0 [ -0.01, 0.01 ]
MARINA 2011 80 0 (0.45) 71 0 (0.21) 2.7 % 0.0 [ -0.11, 0.11 ]
Mita 2007 30 1.51 (0.59) 30 1.44 (0.37) 0.6 % 0.07 [ -0.18, 0.32 ]
NAT2 2013 134 1.95 (0.57) 129 1.8 (0.54) 1.9 % 0.15 [ 0.02, 0.28 ]
Nye 1990 12 1.38 (0.43) 12 1.45 (0.38) 0.4 % -0.07 [ -0.39, 0.25 ]
OFAMI 2001 119 1.28 (0.33) 120 1.24 (0.33) 4.2 % 0.04 [ -0.04, 0.12 ]
ORIGIN 2012 6281 -0.003 (0.63) 6255 -0.01 (0.63) 13.1 % 0.00 [ -0.02, 0.02 ]
Sandhu 2016 49 1.81 (0.5) 47 1.8 (0.5) 0.9 % 0.01 [ -0.19, 0.21 ]
SCIMO 1999 87 0 (0.25) 84 0.09 (0.31) 4.1 % -0.09 [ -0.17, -0.01 ]
SHOT 1996 289 1.16 (0.31) 267 1.06 (0.28) 8.0 % 0.10 [ 0.05, 0.15 ]
SMART 2013 21 1.5 (0.4) 24 1.4 (0.4) 0.7 % 0.10 [ -0.13, 0.33 ]
Sofi 2010 6 0.41 (0.34) 5 -0.67 (0.69) 0.1 % 1.08 [ 0.42, 1.74 ]
Tande 2016 50 0.03 (0.19) 50 0.02 (0.23) 4.2 % 0.01 [ -0.07, 0.09 ]
-0.5 -0.25 0 0.25 0.5
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Study or subgroup
Favours
lower
omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
THIS DIET 2008 37 1.03 (0.21) 34 1.03 (0.31) 2.2 % 0.0 [ -0.12, 0.12 ]
Weinstock-Guttman 2005 13 0.05 (0.19) 14 -0.29 (0.51) 0.5 % 0.34 [ 0.05, 0.63 ]
WELCOME 2015 47 1.1 (0.3) 48 1.1 (0.2) 3.0 % 0.0 [ -0.10, 0.10 ]
Total (95% CI) 18683 18554 100.0 % 0.02 [ 0.00, 0.04 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 48.46, df = 25 (P = 0.003); I2 =48%
Test for overall effect: Z = 2.20 (P = 0.028)
Test for subgroup differences: Not applicable
-0.5 -0.25 0 0.25 0.5
Favours lower omega 3 Favours higher omega 3
(1) 14 month data for cod liver oil vs control
(2) SDs unlikely, converted assuming SEs
(3) median change from baseline, highest EPA vs placebo
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Analysis 2.52. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 52 HDL,
mmoL/L - LCn3 - SA by summary risk of bias.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 2 High vs low LCn3 omega-3 fats (secondary outcomes)
Outcome: 52 HDL, mmoL/L - LCn3 - SA by summary risk of bias
Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Low risk of bias
AlphaOmega - EPA+DHA 2010 605 0.18 (0.25) 605 0.15 (0.25) 11.3 % 0.03 [ 0.00, 0.06 ]
Berson 2004 105 1.51 (0.41) 103 1.43 (0.41) 3.0 % 0.08 [ -0.03, 0.19 ]
Derosa 2016 (1) 128 1.2 (1.1) 130 1.1 (1.1) 0.6 % 0.10 [ -0.17, 0.37 ]
MARINA 2011 80 1.7 (0.45) 71 1.5 (0.42) 2.1 % 0.20 [ 0.06, 0.34 ]
NAT2 2013 134 1.95 (0.57) 129 1.8 (0.54) 2.2 % 0.15 [ 0.02, 0.28 ]
ORIGIN 2012 6281 -0.003 (0.63) 6255 -0.01 (0.63) 12.2 % 0.00 [ -0.02, 0.02 ]
SCIMO 1999 87 0 (0.25) 84 0.09 (0.31) 4.4 % -0.09 [ -0.17, -0.01 ]
WELCOME 2015 47 1.1 (0.3) 48 1.1 (0.2) 3.4 % 0.0 [ -0.10, 0.10 ]
Subtotal (95% CI) 7467 7425 39.0 % 0.03 [ -0.01, 0.07 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 20.83, df = 7 (P = 0.004); I2 =66%
Test for overall effect: Z = 1.43 (P = 0.15)
2 Moderate/high risk of bias
Ahn 2016 38 1.19 (0.31) 36 1.14 (0.33) 1.9 % 0.05 [ -0.10, 0.20 ]
Brox 2001 (2) 37 1.3 (0.4) 37 1.3 (0.4) 1.3 % 0.0 [ -0.18, 0.18 ]
DART 1989 867 1.05 (0.29) 847 1.04 (0.28) 11.4 % 0.01 [ -0.02, 0.04 ]
Deslypere 1992 14 1.25 (0.21) 14 1.28 (0.35) 1.0 % -0.03 [ -0.24, 0.18 ]
DIPP 2015 89 1.43 (0.36) 73 1.46 (0.33) 3.2 % -0.03 [ -0.14, 0.08 ]
DO IT 2010 124 1.5 (0.39) 117 1.44 (0.35) 3.9 % 0.06 [ -0.03, 0.15 ]
EPE-A 2014 (3) 64 0.01 (0) 55 0.03 (0) Not estimable
HARP 1995 31 1.09 (0.28) 28 1.09 (0.34) 1.6 % 0.0 [ -0.16, 0.16 ]
JELIS 2007 9326 1.54 (0.42) 9319 1.54 (0.39) 13.4 % 0.0 [ -0.01, 0.01 ]
Mita 2007 30 1.51 (0.59) 30 1.44 (0.37) 0.7 % 0.07 [ -0.18, 0.32 ]
Nye 1990 12 1.38 (0.43) 12 1.45 (0.38) 0.4 % -0.07 [ -0.39, 0.25 ]
OFAMI 2001 119 1.28 (0.33) 120 1.24 (0.33) 4.5 % 0.04 [ -0.04, 0.12 ]
Sandhu 2016 49 1.81 (0.5) 47 1.8 (0.5) 1.1 % 0.01 [ -0.19, 0.21 ]
-0.2 -0.1 0 0.1 0.2
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Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
SHOT 1996 289 1.16 (0.31) 267 1.06 (0.28) 8.1 % 0.10 [ 0.05, 0.15 ]
SMART 2013 21 1.5 (0.4) 24 1.4 (0.4) 0.8 % 0.10 [ -0.13, 0.33 ]
Sofi 2010 6 0.41 (0.34) 5 -0.67 (0.69) 0.1 % 1.08 [ 0.42, 1.74 ]
Tande 2016 50 0.03 (0.19) 50 0.02 (0.23) 4.6 % 0.01 [ -0.07, 0.09 ]
THIS DIET 2008 37 1.03 (0.21) 34 1.03 (0.31) 2.5 % 0.0 [ -0.12, 0.12 ]
Weinstock-Guttman 2005 13 0.05 (0.19) 14 -0.29 (0.51) 0.5 % 0.34 [ 0.05, 0.63 ]
Subtotal (95% CI) 11216 11129 61.0 % 0.03 [ 0.00, 0.06 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 34.32, df = 17 (P = 0.01); I2 =50%
Test for overall effect: Z = 1.99 (P = 0.046)
Total (95% CI) 18683 18554 100.0 % 0.03 [ 0.01, 0.05 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 55.68, df = 25 (P = 0.00040); I2 =55%
Test for overall effect: Z = 2.51 (P = 0.012)
Test for subgroup differences: Chi2 = 0.00, df = 1 (P = 0.97), I2 =0.0%
-0.2 -0.1 0 0.1 0.2
Favours lower omega 3 Favours higher omega 3
(1) SDs unlikely, converted assuming SEs
(2) 14 month data, cod liver oil arm vs control
(3) median change from baseline, highest EPA vs placebo
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Analysis 2.53. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 53 HDL,
mmoL/L - LCn3 - SA by compliance and study size.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 2 High vs low LCn3 omega-3 fats (secondary outcomes)
Outcome: 53 HDL, mmoL/L - LCn3 - SA by compliance and study size
Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 SA - low risk of compliance bias
AlphaOmega - EPA+DHA 2010 605 0.18 (0.25) 605 0.15 (0.25) 16.5 % 0.03 [ 0.00, 0.06 ]
Berson 2004 105 1.51 (0.41) 103 1.43 (0.41) 8.6 % 0.08 [ -0.03, 0.19 ]
Brox 2001 (1) 37 1.3 (0.4) 37 1.3 (0.4) 4.6 % 0.0 [ -0.18, 0.18 ]
Deslypere 1992 14 1.25 (0.21) 14 1.28 (0.35) 3.6 % -0.03 [ -0.24, 0.18 ]
DO IT 2010 124 1.5 (0.39) 117 1.44 (0.35) 10.1 % 0.06 [ -0.03, 0.15 ]
EPE-A 2014 (2) 64 0.01 (0) 55 0.03 (0) Not estimable
HARP 1995 31 1.09 (0.28) 28 1.09 (0.34) 5.6 % 0.0 [ -0.16, 0.16 ]
MARINA 2011 80 1.7 (0.45) 71 1.5 (0.42) 6.7 % 0.20 [ 0.06, 0.34 ]
NAT2 2013 134 1.95 (0.57) 129 1.8 (0.54) 7.0 % 0.15 [ 0.02, 0.28 ]
SCIMO 1999 87 0 (0.25) 84 0.09 (0.31) 11.0 % -0.09 [ -0.17, -0.01 ]
SHOT 1996 289 1.16 (0.31) 267 1.06 (0.28) 14.7 % 0.10 [ 0.05, 0.15 ]
Weinstock-Guttman 2005 13 0.05 (0.19) 14 -0.29 (0.51) 2.2 % 0.34 [ 0.05, 0.63 ]
WELCOME 2015 47 1.1 (0.3) 48 1.1 (0.2) 9.3 % 0.0 [ -0.10, 0.10 ]
Subtotal (95% CI) 1630 1572 100.0 % 0.05 [ 0.01, 0.10 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 29.14, df = 11 (P = 0.002); I2 =62%
Test for overall effect: Z = 2.28 (P = 0.023)
2 SA - 100+ randomised
AlphaOmega - EPA+DHA 2010 605 0.18 (0.25) 605 0.15 (0.25) 13.5 % 0.03 [ 0.00, 0.06 ]
Berson 2004 105 1.51 (0.41) 103 1.43 (0.41) 3.3 % 0.08 [ -0.03, 0.19 ]
DART 1989 867 1.05 (0.29) 847 1.04 (0.28) 13.8 % 0.01 [ -0.02, 0.04 ]
Derosa 2016 (3) 128 1.2 (1.1) 130 1.1 (1.1) 0.7 % 0.10 [ -0.17, 0.37 ]
DIPP 2015 89 1.43 (0.36) 73 1.46 (0.33) 3.6 % -0.03 [ -0.14, 0.08 ]
DO IT 2010 124 1.5 (0.39) 117 1.44 (0.35) 4.4 % 0.06 [ -0.03, 0.15 ]
EPE-A 2014 (4) 64 0.01 (0) 55 0.03 (0) Not estimable
JELIS 2007 9326 1.54 (0.42) 9319 1.54 (0.39) 16.3 % 0.0 [ -0.01, 0.01 ]
-0.2 -0.1 0 0.1 0.2
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Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
MARINA 2011 80 1.7 (0.45) 71 1.5 (0.42) 2.3 % 0.20 [ 0.06, 0.34 ]
NAT2 2013 134 1.95 (0.57) 129 1.8 (0.54) 2.4 % 0.15 [ 0.02, 0.28 ]
OFAMI 2001 119 1.28 (0.33) 120 1.24 (0.33) 5.1 % 0.04 [ -0.04, 0.12 ]
ORIGIN 2012 6281 -0.003 (0.63) 6255 -0.01 (0.63) 14.7 % 0.00 [ -0.02, 0.02 ]
SCIMO 1999 87 0 (0.25) 84 0.09 (0.31) 5.1 % -0.09 [ -0.17, -0.01 ]
SHOT 1996 289 1.16 (0.31) 267 1.06 (0.28) 9.5 % 0.10 [ 0.05, 0.15 ]
Tande 2016 50 0.03 (0.19) 50 0.02 (0.23) 5.2 % 0.01 [ -0.07, 0.09 ]
Subtotal (95% CI) 18348 18225 100.0 % 0.03 [ 0.00, 0.05 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 39.02, df = 13 (P = 0.00020); I2 =67%
Test for overall effect: Z = 2.28 (P = 0.022)
Test for subgroup differences: Chi2 = 1.05, df = 1 (P = 0.31), I2 =4%
-0.2 -0.1 0 0.1 0.2
Favours lower omega 3 Favours higher omega 3
(1) 14 month data, cod liver oil arm vs control
(2) median change from baseline, highest EPA vs placebo
(3) SDs unlikely, converted assuming SEs
(4) median change from baseline, highest EPA vs placebo
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Analysis 2.54. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 54 HDL,
mmoL/L - LCn3 - subgroup by dose.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 2 High vs low LCn3 omega-3 fats (secondary outcomes)
Outcome: 54 HDL, mmoL/L - LCn3 - subgroup by dose
Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 LCn3≤ 150 mg/d
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
2 LCn3 > 150≤ 250 mg/d
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
3 LCn3 > 250≤ 400 mg/d
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
4 LCn3 > 400≤ 2400 mg/d
Ahn 2016 38 1.19 (0.31) 36 1.14 (0.33) 2.0 % 0.05 [ -0.10, 0.20 ]
AlphaOmega - EPA+DHA 2010 605 0.18 (0.25) 605 0.15 (0.25) 15.1 % 0.03 [ 0.00, 0.06 ]
Berson 2004 105 1.51 (0.41) 103 1.43 (0.41) 3.1 % 0.08 [ -0.03, 0.19 ]
DART 1989 867 1.05 (0.29) 847 1.04 (0.28) 15.4 % 0.01 [ -0.02, 0.04 ]
Derosa 2016 (1) 128 1.2 (1.1) 130 1.1 (1.1) 0.6 % 0.10 [ -0.17, 0.37 ]
Deslypere 1992 14 1.25 (0.21) 14 1.28 (0.35) 1.0 % -0.03 [ -0.24, 0.18 ]
DIPP 2015 89 1.43 (0.36) 73 1.46 (0.33) 3.4 % -0.03 [ -0.14, 0.08 ]
DO IT 2010 124 1.5 (0.39) 117 1.44 (0.35) 4.2 % 0.06 [ -0.03, 0.15 ]
JELIS 2007 9326 1.54 (0.42) 9319 1.54 (0.39) 19.3 % 0.0 [ -0.01, 0.01 ]
MARINA 2011 80 1.7 (0.45) 71 1.5 (0.42) 2.1 % 0.20 [ 0.06, 0.34 ]
Mita 2007 30 1.51 (0.59) 30 1.44 (0.37) 0.7 % 0.07 [ -0.18, 0.32 ]
NAT2 2013 134 1.95 (0.57) 129 1.8 (0.54) 2.3 % 0.15 [ 0.02, 0.28 ]
Nye 1990 12 1.38 (0.43) 12 1.45 (0.38) 0.4 % -0.07 [ -0.39, 0.25 ]
ORIGIN 2012 6281 -0.003 (0.63) 6255 -0.01 (0.63) 16.8 % 0.00 [ -0.02, 0.02 ]
SCIMO 1999 87 0 (0.25) 84 0.09 (0.31) 4.9 % -0.09 [ -0.17, -0.01 ]
-1 -0.5 0 0.5 1
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Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
SMART 2013 21 1.5 (0.4) 24 1.4 (0.4) 0.8 % 0.10 [ -0.13, 0.33 ]
Sofi 2010 6 0.41 (0.34) 5 -0.67 (0.69) 0.1 % 1.08 [ 0.42, 1.74 ]
Tande 2016 50 0.03 (0.19) 50 0.02 (0.23) 5.1 % 0.01 [ -0.07, 0.09 ]
THIS DIET 2008 37 1.03 (0.21) 34 1.03 (0.31) 2.6 % 0.0 [ -0.12, 0.12 ]
Subtotal (95% CI) 18034 17938 100.0 % 0.02 [ 0.00, 0.04 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 36.41, df = 18 (P = 0.01); I2 =51%
Test for overall effect: Z = 1.61 (P = 0.11)
5 LCn3 > 2.4≤ 4.4 g/d
Brox 2001 37 1.3 (0.4) 37 1.3 (0.4) 8.5 % 0.0 [ -0.18, 0.18 ]
EPE-A 2014 (2) 64 0.01 (0) 55 0.03 (0) Not estimable
OFAMI 2001 119 1.28 (0.33) 120 1.24 (0.33) 24.5 % 0.04 [ -0.04, 0.12 ]
Sandhu 2016 49 1.81 (0.5) 47 1.8 (0.5) 7.3 % 0.01 [ -0.19, 0.21 ]
SHOT 1996 289 1.16 (0.31) 267 1.06 (0.28) 36.5 % 0.10 [ 0.05, 0.15 ]
Weinstock-Guttman 2005 13 0.05 (0.19) 14 -0.29 (0.51) 3.8 % 0.34 [ 0.05, 0.63 ]
WELCOME 2015 47 1.1 (0.3) 48 1.1 (0.2) 19.5 % 0.0 [ -0.10, 0.10 ]
Subtotal (95% CI) 618 588 100.0 % 0.06 [ 0.00, 0.12 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 8.03, df = 5 (P = 0.15); I2 =38%
Test for overall effect: Z = 2.02 (P = 0.044)
6 LCn3 > 4.4 g/d
HARP 1995 31 1.09 (0.28) 28 1.09 (0.34) 100.0 % 0.0 [ -0.16, 0.16 ]
Subtotal (95% CI) 31 28 100.0 % 0.0 [ -0.16, 0.16 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Chi2 = 1.86, df = 2 (P = 0.40), I2 =0.0%
-1 -0.5 0 0.5 1
Favours higher omega 3 Favours lower omega 3
(1) SDs unlikely, converted assuming SEs
(2) median change from baseline, highest EPA vs placebo
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Analysis 2.55. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 55 HDL,
mmoL/L - LCn3 - subgroup by replacement.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 2 High vs low LCn3 omega-3 fats (secondary outcomes)
Outcome: 55 HDL, mmoL/L - LCn3 - subgroup by replacement
Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 N-3 replacing SFA
DART 1989 867 1.05 (0.29) 847 1.04 (0.28) 54.9 % 0.01 [ -0.02, 0.04 ]
Derosa 2016 (1) 128 1.2 (1.1) 130 1.1 (1.1) 8.4 % 0.10 [ -0.17, 0.37 ]
SCIMO 1999 87 0 (0.25) 84 0.09 (0.31) 36.7 % -0.09 [ -0.17, -0.01 ]
Subtotal (95% CI) 1082 1061 100.0 % -0.02 [ -0.10, 0.07 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 5.39, df = 2 (P = 0.07); I2 =63%
Test for overall effect: Z = 0.44 (P = 0.66)
2 N-3 replacing MUFA
AlphaOmega - EPA+DHA 2010 605 0.18 (0.25) 605 0.15 (0.25) 17.1 % 0.03 [ 0.00, 0.06 ]
DART 1989 867 1.05 (0.29) 847 1.04 (0.28) 17.3 % 0.01 [ -0.02, 0.04 ]
Deslypere 1992 14 1.25 (0.21) 14 1.28 (0.35) 2.1 % -0.03 [ -0.24, 0.18 ]
HARP 1995 31 1.09 (0.28) 28 1.09 (0.34) 3.4 % 0.0 [ -0.16, 0.16 ]
MARINA 2011 80 1.7 (0.45) 71 1.5 (0.42) 4.3 % 0.20 [ 0.06, 0.34 ]
NAT2 2013 134 1.95 (0.57) 129 1.8 (0.54) 4.5 % 0.15 [ 0.02, 0.28 ]
Nye 1990 12 1.38 (0.43) 12 1.45 (0.38) 1.0 % -0.07 [ -0.39, 0.25 ]
ORIGIN 2012 6281 -0.003 (0.63) 6255 -0.01 (0.63) 18.0 % 0.00 [ -0.02, 0.02 ]
SCIMO 1999 87 0 (0.25) 84 0.09 (0.31) 8.5 % -0.09 [ -0.17, -0.01 ]
SMART 2013 21 1.5 (0.4) 24 1.4 (0.4) 1.8 % 0.10 [ -0.13, 0.33 ]
Sofi 2010 6 0.41 (0.34) 5 -0.67 (0.69) 0.2 % 1.08 [ 0.42, 1.74 ]
Tande 2016 50 0.03 (0.19) 50 0.02 (0.23) 8.7 % 0.01 [ -0.07, 0.09 ]
THIS DIET 2008 37 1.03 (0.21) 34 1.03 (0.31) 5.1 % 0.0 [ -0.12, 0.12 ]
Weinstock-Guttman 2005 13 0.05 (0.19) 14 -0.29 (0.51) 1.2 % 0.34 [ 0.05, 0.63 ]
WELCOME 2015 47 1.1 (0.3) 48 1.1 (0.2) 6.7 % 0.0 [ -0.10, 0.10 ]
Subtotal (95% CI) 8285 8220 100.0 % 0.02 [ -0.01, 0.06 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 35.10, df = 14 (P = 0.001); I2 =60%
Test for overall effect: Z = 1.39 (P = 0.16)
3 N-3 replacing n-6
-0.5 -0.25 0 0.25 0.5
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Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Berson 2004 105 1.51 (0.41) 103 1.43 (0.41) 18.9 % 0.08 [ -0.03, 0.19 ]
DIPP 2015 89 1.43 (0.36) 73 1.46 (0.33) 20.7 % -0.03 [ -0.14, 0.08 ]
DO IT 2010 124 1.5 (0.39) 117 1.44 (0.35) 26.9 % 0.06 [ -0.03, 0.15 ]
OFAMI 2001 119 1.28 (0.33) 120 1.24 (0.33) 33.5 % 0.04 [ -0.04, 0.12 ]
Subtotal (95% CI) 437 413 100.0 % 0.04 [ -0.01, 0.09 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 2.33, df = 3 (P = 0.51); I2 =0.0%
Test for overall effect: Z = 1.55 (P = 0.12)
4 N-3 replacing carbs/sugars
Derosa 2016 (2) 128 1.2 (1.1) 130 1.1 (1.1) 100.0 % 0.10 [ -0.17, 0.37 ]
Subtotal (95% CI) 128 130 100.0 % 0.10 [ -0.17, 0.37 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.73 (P = 0.47)
5 N-3 replacing nil/low n-3 placebo
Brox 2001 37 1.3 (0.4) 37 1.3 (0.4) 10.8 % 0.0 [ -0.18, 0.18 ]
JELIS 2007 9326 1.54 (0.42) 9319 1.54 (0.39) 39.6 % 0.0 [ -0.01, 0.01 ]
Mita 2007 30 1.51 (0.59) 30 1.44 (0.37) 6.6 % 0.07 [ -0.18, 0.32 ]
Sandhu 2016 49 1.81 (0.5) 47 1.8 (0.5) 9.4 % 0.01 [ -0.19, 0.21 ]
SHOT 1996 289 1.16 (0.31) 267 1.06 (0.28) 33.5 % 0.10 [ 0.05, 0.15 ]
Subtotal (95% CI) 9731 9700 100.0 % 0.04 [ -0.03, 0.11 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 15.38, df = 4 (P = 0.004); I2 =74%
Test for overall effect: Z = 1.09 (P = 0.28)
6 Replacement unclear
Ahn 2016 38 1.19 (0.31) 36 1.14 (0.33) 100.0 % 0.05 [ -0.10, 0.20 ]
EPE-A 2014 (3) 64 0.01 (0) 55 0.03 (0) Not estimable
Subtotal (95% CI) 102 91 100.0 % 0.05 [ -0.10, 0.20 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.67 (P = 0.50)
Test for subgroup differences: Chi2 = 1.91, df = 5 (P = 0.86), I2 =0.0%
-0.5 -0.25 0 0.25 0.5
Favours higher omega 3 Favours lower omega 3
(1) SDs unlikely, converted assuming SEs
(2) SDs unlikely, converted assuming SEs
(3) median change from baseline, highest EPA vs placebo
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Analysis 2.56. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 56 HDL,
mmoL/L - LCn3 - subgroup by intervention type.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 2 High vs low LCn3 omega-3 fats (secondary outcomes)
Outcome: 56 HDL, mmoL/L - LCn3 - subgroup by intervention type
Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Dietary advice
DART 1989 867 1.05 (0.29) 847 1.04 (0.28) 95.5 % 0.01 [ -0.02, 0.04 ]
THIS DIET 2008 37 1.03 (0.21) 34 1.03 (0.31) 4.5 % 0.0 [ -0.12, 0.12 ]
Subtotal (95% CI) 904 881 100.0 % 0.01 [ -0.02, 0.04 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.02, df = 1 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 0.71 (P = 0.48)
2 Supplemental foods
AlphaOmega - EPA+DHA 2010 605 0.18 (0.25) 605 0.15 (0.25) 100.0 % 0.03 [ 0.00, 0.06 ]
Subtotal (95% CI) 605 605 100.0 % 0.03 [ 0.00, 0.06 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.09 (P = 0.037)
3 Supplement (capsule)
Ahn 2016 38 1.19 (0.31) 36 1.14 (0.33) 3.1 % 0.05 [ -0.10, 0.20 ]
Berson 2004 105 1.51 (0.41) 103 1.43 (0.41) 4.7 % 0.08 [ -0.03, 0.19 ]
Brox 2001 37 1.3 (0.4) 37 1.3 (0.4) 2.2 % 0.0 [ -0.18, 0.18 ]
Derosa 2016 (1) 128 1.2 (1.1) 130 1.1 (1.1) 1.1 % 0.10 [ -0.17, 0.37 ]
Deslypere 1992 14 1.25 (0.21) 14 1.28 (0.35) 1.6 % -0.03 [ -0.24, 0.18 ]
DO IT 2010 124 1.5 (0.39) 117 1.44 (0.35) 6.0 % 0.06 [ -0.03, 0.15 ]
EPE-A 2014 (2) 64 0.01 (0) 55 0.03 (0) Not estimable
HARP 1995 31 1.09 (0.28) 28 1.09 (0.34) 2.7 % 0.0 [ -0.16, 0.16 ]
JELIS 2007 9326 1.54 (0.42) 9319 1.54 (0.39) 15.8 % 0.0 [ -0.01, 0.01 ]
MARINA 2011 80 1.7 (0.45) 71 1.5 (0.42) 3.4 % 0.20 [ 0.06, 0.34 ]
Mita 2007 30 1.51 (0.59) 30 1.44 (0.37) 1.2 % 0.07 [ -0.18, 0.32 ]
NAT2 2013 134 1.95 (0.57) 129 1.8 (0.54) 3.6 % 0.15 [ 0.02, 0.28 ]
Nye 1990 12 1.38 (0.43) 12 1.45 (0.38) 0.8 % -0.07 [ -0.39, 0.25 ]
OFAMI 2001 119 1.28 (0.33) 120 1.24 (0.33) 6.9 % 0.04 [ -0.04, 0.12 ]
ORIGIN 2012 6281 -0.003 (0.63) 6255 -0.01 (0.63) 14.8 % 0.00 [ -0.02, 0.02 ]
-0.2 -0.1 0 0.1 0.2
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Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Sandhu 2016 49 1.81 (0.5) 47 1.8 (0.5) 1.8 % 0.01 [ -0.19, 0.21 ]
SCIMO 1999 87 0 (0.25) 84 0.09 (0.31) 6.8 % -0.09 [ -0.17, -0.01 ]
SHOT 1996 289 1.16 (0.31) 267 1.06 (0.28) 11.0 % 0.10 [ 0.05, 0.15 ]
Sofi 2010 6 0.41 (0.34) 5 -0.67 (0.69) 0.2 % 1.08 [ 0.42, 1.74 ]
Tande 2016 50 0.03 (0.19) 50 0.02 (0.23) 7.0 % 0.01 [ -0.07, 0.09 ]
WELCOME 2015 47 1.1 (0.3) 48 1.1 (0.2) 5.3 % 0.0 [ -0.10, 0.10 ]
Subtotal (95% CI) 17051 16957 100.0 % 0.03 [ 0.00, 0.06 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 47.19, df = 19 (P = 0.00034); I2 =60%
Test for overall effect: Z = 2.24 (P = 0.025)
4 Any combination
DIPP 2015 89 1.43 (0.36) 73 1.46 (0.33) 44.3 % -0.03 [ -0.14, 0.08 ]
SMART 2013 21 1.5 (0.4) 24 1.4 (0.4) 30.3 % 0.10 [ -0.13, 0.33 ]
Weinstock-Guttman 2005 13 0.05 (0.19) 14 -0.29 (0.51) 25.3 % 0.34 [ 0.05, 0.63 ]
Subtotal (95% CI) 123 111 100.0 % 0.10 [ -0.10, 0.31 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 6.06, df = 2 (P = 0.05); I2 =67%
Test for overall effect: Z = 0.99 (P = 0.32)
Test for subgroup differences: Chi2 = 2.28, df = 3 (P = 0.52), I2 =0.0%
-0.2 -0.1 0 0.1 0.2
Favours higher omega 3 Favours lower omega 3
(1) SDs unlikely, converted assuming SEs
(2) median change from baseline, highest EPA vs placebo
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Analysis 2.57. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 57 HDL,
mmoL/L - LCn3 - subgroup by duration.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 2 High vs low LCn3 omega-3 fats (secondary outcomes)
Outcome: 57 HDL, mmoL/L - LCn3 - subgroup by duration
Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Medium duration 1 to < 2 years in study
Ahn 2016 38 1.19 (0.31) 36 1.14 (0.33) 10.0 % 0.05 [ -0.10, 0.20 ]
Brox 2001 37 1.3 (0.4) 37 1.3 (0.4) 7.7 % 0.0 [ -0.18, 0.18 ]
Derosa 2016 (1) 128 1.2 (1.1) 130 1.1 (1.1) 4.5 % 0.10 [ -0.17, 0.37 ]
Deslypere 1992 14 1.25 (0.21) 14 1.28 (0.35) 6.2 % -0.03 [ -0.24, 0.18 ]
EPE-A 2014 (2) 64 0.01 (0) 55 0.03 (0) Not estimable
MARINA 2011 80 1.7 (0.45) 71 1.5 (0.42) 10.5 % 0.20 [ 0.06, 0.34 ]
Nye 1990 12 1.38 (0.43) 12 1.45 (0.38) 3.3 % -0.07 [ -0.39, 0.25 ]
SHOT 1996 289 1.16 (0.31) 267 1.06 (0.28) 18.5 % 0.10 [ 0.05, 0.15 ]
SMART 2013 21 1.5 (0.4) 24 1.4 (0.4) 5.5 % 0.10 [ -0.13, 0.33 ]
Sofi 2010 6 0.41 (0.34) 5 -0.67 (0.69) 0.9 % 1.08 [ 0.42, 1.74 ]
Tande 2016 50 0.03 (0.19) 50 0.02 (0.23) 15.4 % 0.01 [ -0.07, 0.09 ]
Weinstock-Guttman 2005 13 0.05 (0.19) 14 -0.29 (0.51) 4.0 % 0.34 [ 0.05, 0.63 ]
WELCOME 2015 47 1.1 (0.3) 48 1.1 (0.2) 13.5 % 0.0 [ -0.10, 0.10 ]
Subtotal (95% CI) 799 763 100.0 % 0.08 [ 0.01, 0.14 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 23.18, df = 11 (P = 0.02); I2 =53%
Test for overall effect: Z = 2.30 (P = 0.021)
2 Medium-long duration: 2 to < 4 years in study
AlphaOmega - EPA+DHA 2010 605 0.18 (0.25) 605 0.15 (0.25) 29.9 % 0.03 [ 0.00, 0.06 ]
DART 1989 867 1.05 (0.29) 847 1.04 (0.28) 30.8 % 0.01 [ -0.02, 0.04 ]
DIPP 2015 89 1.43 (0.36) 73 1.46 (0.33) 5.1 % -0.03 [ -0.14, 0.08 ]
DO IT 2010 124 1.5 (0.39) 117 1.44 (0.35) 6.5 % 0.06 [ -0.03, 0.15 ]
HARP 1995 31 1.09 (0.28) 28 1.09 (0.34) 2.4 % 0.0 [ -0.16, 0.16 ]
Mita 2007 30 1.51 (0.59) 30 1.44 (0.37) 1.0 % 0.07 [ -0.18, 0.32 ]
NAT2 2013 134 1.95 (0.57) 129 1.8 (0.54) 3.4 % 0.15 [ 0.02, 0.28 ]
OFAMI 2001 119 1.28 (0.33) 120 1.24 (0.33) 7.8 % 0.04 [ -0.04, 0.12 ]
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Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Sandhu 2016 49 1.81 (0.5) 47 1.8 (0.5) 1.6 % 0.01 [ -0.19, 0.21 ]
SCIMO 1999 87 0 (0.25) 84 0.09 (0.31) 7.6 % -0.09 [ -0.17, -0.01 ]
THIS DIET 2008 37 1.03 (0.21) 34 1.03 (0.31) 3.9 % 0.0 [ -0.12, 0.12 ]
Subtotal (95% CI) 2172 2114 100.0 % 0.02 [ -0.01, 0.04 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 13.14, df = 10 (P = 0.22); I2 =24%
Test for overall effect: Z = 1.27 (P = 0.20)
3 Long duration≥ 4 years in study
Berson 2004 105 1.51 (0.41) 103 1.43 (0.41) 0.8 % 0.08 [ -0.03, 0.19 ]
JELIS 2007 9326 1.54 (0.42) 9319 1.54 (0.39) 77.6 % 0.0 [ -0.01, 0.01 ]
ORIGIN 2012 6281 -0.003 (0.63) 6255 -0.01 (0.63) 21.6 % 0.00 [ -0.02, 0.02 ]
Subtotal (95% CI) 15712 15677 100.0 % 0.00 [ -0.01, 0.01 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.97, df = 2 (P = 0.37); I2 =0.0%
Test for overall effect: Z = 0.21 (P = 0.83)
Test for subgroup differences: Chi2 = 5.95, df = 2 (P = 0.05), I2 =66%
-1 -0.5 0 0.5 1
Favours higher omega 3 Favours lower omega 3
(1) SDs unlikely, converted assuming SEs
(2) median change from baseline, highest EPA vs placebo
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Analysis 2.58. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 58 HDL,
mmoL/L - LCn3 - subgroup by primary or secondary prevention.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 2 High vs low LCn3 omega-3 fats (secondary outcomes)
Outcome: 58 HDL, mmoL/L - LCn3 - subgroup by primary or secondary prevention
Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Primary prevention
Berson 2004 105 1.51 (0.41) 103 1.43 (0.41) 5.6 % 0.08 [ -0.03, 0.19 ]
Brox 2001 37 1.3 (0.4) 37 1.3 (0.4) 2.4 % 0.0 [ -0.18, 0.18 ]
Derosa 2016 (1) 128 1.2 (1.1) 130 1.1 (1.1) 1.2 % 0.10 [ -0.17, 0.37 ]
Deslypere 1992 14 1.25 (0.21) 14 1.28 (0.35) 1.8 % -0.03 [ -0.24, 0.18 ]
DIPP 2015 89 1.43 (0.36) 73 1.46 (0.33) 6.0 % -0.03 [ -0.14, 0.08 ]
DO IT 2010 124 1.5 (0.39) 117 1.44 (0.35) 7.3 % 0.06 [ -0.03, 0.15 ]
EPE-A 2014 (2) 64 0.01 (0) 55 0.03 (0) Not estimable
JELIS 2007 9326 1.54 (0.42) 9319 1.54 (0.39) 26.7 % 0.0 [ -0.01, 0.01 ]
MARINA 2011 80 1.7 (0.45) 71 1.5 (0.42) 3.9 % 0.20 [ 0.06, 0.34 ]
Mita 2007 30 1.51 (0.59) 30 1.44 (0.37) 1.3 % 0.07 [ -0.18, 0.32 ]
ORIGIN 2012 6281 -0.003 (0.63) 6255 -0.01 (0.63) 24.1 % 0.00 [ -0.02, 0.02 ]
Sandhu 2016 49 1.81 (0.5) 47 1.8 (0.5) 2.0 % 0.01 [ -0.19, 0.21 ]
SMART 2013 21 1.5 (0.4) 24 1.4 (0.4) 1.5 % 0.10 [ -0.13, 0.33 ]
Sofi 2010 6 0.41 (0.34) 5 -0.67 (0.69) 0.2 % 1.08 [ 0.42, 1.74 ]
Tande 2016 50 0.03 (0.19) 50 0.02 (0.23) 8.7 % 0.01 [ -0.07, 0.09 ]
Weinstock-Guttman 2005 13 0.05 (0.19) 14 -0.29 (0.51) 1.0 % 0.34 [ 0.05, 0.63 ]
WELCOME 2015 47 1.1 (0.3) 48 1.1 (0.2) 6.4 % 0.0 [ -0.10, 0.10 ]
Subtotal (95% CI) 16464 16392 100.0 % 0.03 [ 0.00, 0.05 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 28.63, df = 15 (P = 0.02); I2 =48%
Test for overall effect: Z = 1.66 (P = 0.096)
2 Secondary prevention
AlphaOmega - EPA+DHA 2010 605 0.18 (0.25) 605 0.15 (0.25) 21.6 % 0.03 [ 0.00, 0.06 ]
DART 1989 867 1.05 (0.29) 847 1.04 (0.28) 21.8 % 0.01 [ -0.02, 0.04 ]
HARP 1995 31 1.09 (0.28) 28 1.09 (0.34) 4.4 % 0.0 [ -0.16, 0.16 ]
NAT2 2013 134 1.95 (0.57) 129 1.8 (0.54) 5.8 % 0.15 [ 0.02, 0.28 ]
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Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Nye 1990 12 1.38 (0.43) 12 1.45 (0.38) 1.2 % -0.07 [ -0.39, 0.25 ]
OFAMI 2001 119 1.28 (0.33) 120 1.24 (0.33) 10.9 % 0.04 [ -0.04, 0.12 ]
SCIMO 1999 87 0 (0.25) 84 0.09 (0.31) 10.7 % -0.09 [ -0.17, -0.01 ]
SHOT 1996 289 1.16 (0.31) 267 1.06 (0.28) 17.2 % 0.10 [ 0.05, 0.15 ]
THIS DIET 2008 37 1.03 (0.21) 34 1.03 (0.31) 6.5 % 0.0 [ -0.12, 0.12 ]
Subtotal (95% CI) 2181 2126 100.0 % 0.03 [ -0.01, 0.07 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 21.38, df = 8 (P = 0.01); I2 =63%
Test for overall effect: Z = 1.51 (P = 0.13)
Test for subgroup differences: Chi2 = 0.02, df = 1 (P = 0.89), I2 =0.0%
-0.5 -0.25 0 0.25 0.5
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(1) SDs unlikely, converted assuming SEs
(2) median change from baseline, highest EPA vs placebo
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Analysis 2.59. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 59 HDL,
mmoL/L - LCn3 - subgroup by statin use.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 2 High vs low LCn3 omega-3 fats (secondary outcomes)
Outcome: 59 HDL, mmoL/L - LCn3 - subgroup by statin use
Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 LCn3 -≥ 50% of control group on statins
Ahn 2016 38 1.19 (0.31) 36 1.14 (0.33) 1.3 % 0.05 [ -0.10, 0.20 ]
AlphaOmega - EPA+DHA 2010 605 0.18 (0.25) 605 0.15 (0.25) 21.3 % 0.03 [ 0.00, 0.06 ]
JELIS 2007 9326 1.54 (0.42) 9319 1.54 (0.39) 43.8 % 0.0 [ -0.01, 0.01 ]
NAT2 2013 134 1.95 (0.57) 129 1.8 (0.54) 1.5 % 0.15 [ 0.02, 0.28 ]
ORIGIN 2012 6281 -0.003 (0.63) 6255 -0.01 (0.63) 28.0 % 0.00 [ -0.02, 0.02 ]
THIS DIET 2008 37 1.03 (0.21) 34 1.03 (0.31) 1.7 % 0.0 [ -0.12, 0.12 ]
WELCOME 2015 47 1.1 (0.3) 48 1.1 (0.2) 2.5 % 0.0 [ -0.10, 0.10 ]
Subtotal (95% CI) 16468 16426 100.0 % 0.01 [ -0.01, 0.03 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 8.67, df = 6 (P = 0.19); I2 =31%
Test for overall effect: Z = 1.16 (P = 0.25)
2 LCn3 - < 50% of control group on statins
Berson 2004 105 1.51 (0.41) 103 1.43 (0.41) 8.0 % 0.08 [ -0.03, 0.19 ]
Brox 2001 37 1.3 (0.4) 37 1.3 (0.4) 4.3 % 0.0 [ -0.18, 0.18 ]
DART 1989 867 1.05 (0.29) 847 1.04 (0.28) 15.8 % 0.01 [ -0.02, 0.04 ]
Deslypere 1992 14 1.25 (0.21) 14 1.28 (0.35) 3.3 % -0.03 [ -0.24, 0.18 ]
DIPP 2015 89 1.43 (0.36) 73 1.46 (0.33) 8.4 % -0.03 [ -0.14, 0.08 ]
DO IT 2010 124 1.5 (0.39) 117 1.44 (0.35) 9.5 % 0.06 [ -0.03, 0.15 ]
HARP 1995 31 1.09 (0.28) 28 1.09 (0.34) 5.2 % 0.0 [ -0.16, 0.16 ]
MARINA 2011 80 1.7 (0.45) 71 1.5 (0.42) 6.2 % 0.20 [ 0.06, 0.34 ]
Mita 2007 30 1.51 (0.59) 30 1.44 (0.37) 2.6 % 0.07 [ -0.18, 0.32 ]
OFAMI 2001 119 1.28 (0.33) 120 1.24 (0.33) 10.4 % 0.04 [ -0.04, 0.12 ]
SCIMO 1999 87 0 (0.25) 84 0.09 (0.31) 10.3 % -0.09 [ -0.17, -0.01 ]
SHOT 1996 289 1.16 (0.31) 267 1.06 (0.28) 13.9 % 0.10 [ 0.05, 0.15 ]
Weinstock-Guttman 2005 13 0.05 (0.19) 14 -0.29 (0.51) 2.0 % 0.34 [ 0.05, 0.63 ]
Subtotal (95% CI) 1885 1805 100.0 % 0.04 [ 0.00, 0.08 ]
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(. . . Continued)
Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Heterogeneity: Tau2 = 0.00; Chi2 = 31.01, df = 12 (P = 0.002); I2 =61%
Test for overall effect: Z = 1.80 (P = 0.071)
3 LCn3 - use of statins unclear
Derosa 2016 (1) 128 1.2 (1.1) 130 1.1 (1.1) 15.1 % 0.10 [ -0.17, 0.37 ]
EPE-A 2014 (2) 64 0.01 (0) 55 0.03 (0) Not estimable
Nye 1990 12 1.38 (0.43) 12 1.45 (0.38) 11.9 % -0.07 [ -0.39, 0.25 ]
Sandhu 2016 49 1.81 (0.5) 47 1.8 (0.5) 20.3 % 0.01 [ -0.19, 0.21 ]
SMART 2013 21 1.5 (0.4) 24 1.4 (0.4) 17.5 % 0.10 [ -0.13, 0.33 ]
Sofi 2010 6 0.41 (0.34) 5 -0.67 (0.69) 3.8 % 1.08 [ 0.42, 1.74 ]
Tande 2016 50 0.03 (0.19) 50 0.02 (0.23) 31.4 % 0.01 [ -0.07, 0.09 ]
Subtotal (95% CI) 330 323 100.0 % 0.07 [ -0.07, 0.21 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 10.86, df = 5 (P = 0.05); I2 =54%
Test for overall effect: Z = 1.01 (P = 0.31)
Test for subgroup differences: Chi2 = 2.28, df = 2 (P = 0.32), I2 =12%
-1 -0.5 0 0.5 1
Favours higher omega 3 Favours lower omega 3
(1) SDs unlikely, converted assuming SEs
(2) median change from baseline, highest EPA vs placebo
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Analysis 2.60. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 60 Low-
density lipoprotein, serum, mmoL/L - LCn3.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 2 High vs low LCn3 omega-3 fats (secondary outcomes)
Outcome: 60 Low-density lipoprotein, serum, mmoL/L - LCn3
Study or subgroup
Favours
higher
omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Ahn 2016 38 2.23 (1.33) 36 2.07 (0.13) 0.2 % 0.16 [ -0.26, 0.58 ]
AlphaOmega - EPA+DHA 2010 562 -0.41 (0.71) 562 -0.39 (0.71) 5.1 % -0.02 [ -0.10, 0.06 ]
Berson 2004 105 3.18 (0.92) 103 2.87 (0.81) 0.6 % 0.31 [ 0.07, 0.55 ]
Caldwell 2011 17 3.18 (0.93) 17 3.29 (0.13) 0.2 % -0.11 [ -0.56, 0.34 ]
Derosa 2016 (1) 128 3.3 (3.4) 130 3.1 (2.3) 0.1 % 0.20 [ -0.51, 0.91 ]
Deslypere 1992 14 3.88 (0.87) 14 4.08 (0.89) 0.1 % -0.20 [ -0.85, 0.45 ]
EPE-A 2014 (2) 64 0.21 (0) 55 0.1 (0) Not estimable
HARP 1995 31 3.41 (0.78) 28 3.16 (0.62) 0.3 % 0.25 [ -0.11, 0.61 ]
JELIS 2007 9326 3.53 (0.77) 9319 3.53 (0.73) 76.5 % 0.0 [ -0.02, 0.02 ]
MARINA 2011 80 0.2 (0.8987) 71 0.2 (0.4225) 0.7 % 0.0 [ -0.22, 0.22 ]
NAT2 2013 134 3.65 (1.06) 129 3.71 (0.89) 0.6 % -0.06 [ -0.30, 0.18 ]
ORIGIN 2012 6281 -0.305 (1.66) 6255 -0.32 (1.66) 10.5 % 0.02 [ -0.04, 0.07 ]
ORL 2013 170 0.08 (0.68) 165 -0.01 (0.6) 1.9 % 0.09 [ -0.04, 0.23 ]
Rossing 1996 14 3.52 (0.9) 15 3.4 (0.97) 0.1 % 0.12 [ -0.56, 0.80 ]
Sandhu 2016 49 2.83 (0.75) 47 2.96 (0.75) 0.4 % -0.13 [ -0.43, 0.17 ]
SCIMO 1999 87 -0.25 (1.2) 84 -0.41 (1.03) 0.3 % 0.16 [ -0.17, 0.49 ]
SHOT 1996 289 5.12 (1.16) 267 5.04 (1.24) 0.9 % 0.08 [ -0.12, 0.28 ]
SMART 2013 21 3.4 (0.9) 24 3.2 (0.9) 0.1 % 0.20 [ -0.33, 0.73 ]
Sofi 2010 6 -0.05 (1.0101) 5 -0.15 (0.4349) 0.0 % 0.10 [ -0.79, 0.99 ]
Tande 2016 50 -0.04 (0.69) 50 -0.05 (0.5) 0.6 % 0.01 [ -0.23, 0.25 ]
THIS DIET 2008 37 2.59 (0.69) 34 2.51 (0.59) 0.4 % 0.08 [ -0.22, 0.38 ]
Weinstock-Guttman 2005 13 0.11 (0.59) 14 0.64 (2.39) 0.0 % -0.53 [ -1.82, 0.76 ]
WELCOME 2015 47 2.8 (0.9) 48 2.8 (0.8) 0.3 % 0.0 [ -0.34, 0.34 ]
Total (95% CI) 17563 17472 100.0 % 0.01 [ -0.01, 0.03 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 15.99, df = 21 (P = 0.77); I2 =0.0%
Test for overall effect: Z = 0.64 (P = 0.52)
Test for subgroup differences: Not applicable
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(1) SDs unlikely, converted assuming SEs
(2) median change from baseline, highest EPA vs placebo
Analysis 2.61. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 61 LDL,
mmoL/L - LCn3 - SA by summary risk of bias.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 2 High vs low LCn3 omega-3 fats (secondary outcomes)
Outcome: 61 LDL, mmoL/L - LCn3 - SA by summary risk of bias
Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Low risk of bias
AlphaOmega - EPA+DHA 2010 562 -0.41 (0.71) 562 -0.39 (0.71) 5.2 % -0.02 [ -0.10, 0.06 ]
Berson 2004 105 3.18 (0.92) 103 2.87 (0.81) 0.6 % 0.31 [ 0.07, 0.55 ]
Caldwell 2011 17 3.18 (0.93) 17 3.29 (0.13) 0.2 % -0.11 [ -0.56, 0.34 ]
Derosa 2016 (1) 128 3.3 (3.4) 130 3.1 (2.3) 0.1 % 0.20 [ -0.51, 0.91 ]
MARINA 2011 80 3.4 (0.8987) 71 3.4 (0.845) 0.5 % 0.0 [ -0.28, 0.28 ]
NAT2 2013 134 3.65 (1.06) 129 3.71 (0.89) 0.6 % -0.06 [ -0.30, 0.18 ]
ORIGIN 2012 6281 -0.305 (1.66) 6255 -0.32 (1.66) 10.5 % 0.02 [ -0.04, 0.07 ]
SCIMO 1999 87 -0.25 (1.2) 84 -0.41 (1.03) 0.3 % 0.16 [ -0.17, 0.49 ]
WELCOME 2015 47 2.8 (0.9) 48 2.8 (0.8) 0.3 % 0.0 [ -0.34, 0.34 ]
Subtotal (95% CI) 7441 7399 18.3 % 0.02 [ -0.03, 0.07 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 8.40, df = 8 (P = 0.40); I2 =5%
Test for overall effect: Z = 0.65 (P = 0.52)
2 Moderate/high risk of bias
Ahn 2016 38 2.23 (1.33) 36 2.07 (0.13) 0.2 % 0.16 [ -0.26, 0.58 ]
Deslypere 1992 14 3.88 (0.87) 14 4.08 (0.89) 0.1 % -0.20 [ -0.85, 0.45 ]
EPE-A 2014 (2) 64 0.21 (0) 55 0.1 (0) Not estimable
HARP 1995 31 3.41 (0.78) 28 3.16 (0.62) 0.3 % 0.25 [ -0.11, 0.61 ]
JELIS 2007 9326 3.53 (0.77) 9319 3.53 (0.73) 76.7 % 0.0 [ -0.02, 0.02 ]
ORL 2013 170 0.08 (0.68) 165 -0.01 (0.6) 1.9 % 0.09 [ -0.04, 0.23 ]
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Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Rossing 1996 14 3.52 (0.9) 15 3.4 (0.97) 0.1 % 0.12 [ -0.56, 0.80 ]
Sandhu 2016 49 2.83 (0.75) 47 2.96 (0.75) 0.4 % -0.13 [ -0.43, 0.17 ]
SHOT 1996 289 5.12 (1.16) 267 5.04 (1.24) 0.9 % 0.08 [ -0.12, 0.28 ]
SMART 2013 21 3.4 (0.9) 24 3.2 (0.9) 0.1 % 0.20 [ -0.33, 0.73 ]
Sofi 2010 6 -0.05 (1.0101) 5 -0.15 (0.4349) 0.0 % 0.10 [ -0.79, 0.99 ]
Tande 2016 50 -0.04 (0.69) 50 -0.05 (0.5) 0.6 % 0.01 [ -0.23, 0.25 ]
THIS DIET 2008 37 2.59 (0.69) 34 2.51 (0.59) 0.4 % 0.08 [ -0.22, 0.38 ]
Weinstock-Guttman 2005 13 0.11 (0.59) 14 0.64 (2.39) 0.0 % -0.53 [ -1.82, 0.76 ]
Subtotal (95% CI) 10122 10073 81.7 % 0.00 [ -0.02, 0.03 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 7.41, df = 12 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 0.40 (P = 0.69)
Total (95% CI) 17563 17472 100.0 % 0.01 [ -0.01, 0.03 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 15.99, df = 21 (P = 0.77); I2 =0.0%
Test for overall effect: Z = 0.64 (P = 0.52)
Test for subgroup differences: Chi2 = 0.19, df = 1 (P = 0.66), I2 =0.0%
-0.5 -0.25 0 0.25 0.5
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Analysis 2.62. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 62 LDL,
mmoL/L - LCn3 - SA by compliance and study size.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 2 High vs low LCn3 omega-3 fats (secondary outcomes)
Outcome: 62 LDL, mmoL/L - LCn3 - SA by compliance and study size
Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 SA - low risk of compliance bias
AlphaOmega - EPA+DHA 2010 562 -0.41 (0.71) 562 -0.39 (0.71) 8.8 % -0.02 [ -0.10, 0.06 ]
Berson 2004 105 3.18 (0.92) 103 2.87 (0.81) 1.2 % 0.31 [ 0.07, 0.55 ]
Deslypere 1992 14 3.88 (0.87) 14 4.08 (0.89) 0.2 % -0.20 [ -0.85, 0.45 ]
EPE-A 2014 (1) 64 0.21 (0) 55 0.1 (0) Not estimable
HARP 1995 31 3.41 (0.78) 28 3.16 (0.62) 0.5 % 0.25 [ -0.11, 0.61 ]
MARINA 2011 80 3.4 (0.8987) 71 3.4 (0.845) 0.9 % 0.0 [ -0.28, 0.28 ]
NAT2 2013 134 3.65 (1.06) 129 3.71 (0.89) 1.2 % -0.06 [ -0.30, 0.18 ]
ORL 2013 170 0.08 (0.68) 165 -0.01 (0.6) 3.5 % 0.09 [ -0.04, 0.23 ]
Rossing 1996 14 3.52 (0.9) 15 3.4 (0.97) 0.2 % 0.12 [ -0.56, 0.80 ]
SCIMO 1999 87 -0.25 (1.2) 84 -0.41 (1.03) 0.6 % 0.16 [ -0.17, 0.49 ]
SHOT 1996 289 5.12 (1.16) 267 5.04 (1.24) 1.7 % 0.08 [ -0.12, 0.28 ]
Weinstock-Guttman 2005 13 0.11 (0.59) 14 0.64 (2.39) 0.0 % -0.53 [ -1.82, 0.76 ]
WELCOME 2015 47 2.8 (0.9) 48 2.8 (0.8) 0.6 % 0.0 [ -0.34, 0.34 ]
Subtotal (95% CI) 1610 1555 19.6 % 0.05 [ -0.02, 0.11 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 11.76, df = 11 (P = 0.38); I2 =6%
Test for overall effect: Z = 1.41 (P = 0.16)
2 SA - 100+ randomised
AlphaOmega - EPA+DHA 2010 562 -0.41 (0.71) 562 -0.39 (0.71) 8.8 % -0.02 [ -0.10, 0.06 ]
Berson 2004 105 3.18 (0.92) 103 2.87 (0.81) 1.2 % 0.31 [ 0.07, 0.55 ]
Derosa 2016 (2) 128 3.3 (3.4) 130 3.1 (2.3) 0.1 % 0.20 [ -0.51, 0.91 ]
Deslypere 1992 14 3.88 (0.87) 14 4.08 (0.89) 0.2 % -0.20 [ -0.85, 0.45 ]
EPE-A 2014 (3) 64 0.21 (0) 55 0.1 (0) Not estimable
HARP 1995 31 3.41 (0.78) 28 3.16 (0.62) 0.5 % 0.25 [ -0.11, 0.61 ]
JELIS 2007 9326 3.53 (0.77) 9319 3.53 (0.73) 44.5 % 0.0 [ -0.02, 0.02 ]
MARINA 2011 80 3.4 (0.8987) 71 3.4 (0.845) 0.9 % 0.0 [ -0.28, 0.28 ]
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Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
NAT2 2013 134 3.65 (1.06) 129 3.71 (0.89) 1.2 % -0.06 [ -0.30, 0.18 ]
ORIGIN 2012 6281 -0.305 (1.66) 6255 -0.32 (1.66) 15.7 % 0.02 [ -0.04, 0.07 ]
ORL 2013 170 0.08 (0.68) 165 -0.01 (0.6) 3.5 % 0.09 [ -0.04, 0.23 ]
SCIMO 1999 87 -0.25 (1.2) 84 -0.41 (1.03) 0.6 % 0.16 [ -0.17, 0.49 ]
SHOT 1996 289 5.12 (1.16) 267 5.04 (1.24) 1.7 % 0.08 [ -0.12, 0.28 ]
Tande 2016 50 -0.04 (0.69) 50 -0.05 (0.5) 1.2 % 0.01 [ -0.23, 0.25 ]
Subtotal (95% CI) 17321 17232 80.4 % 0.01 [ -0.02, 0.04 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 12.87, df = 12 (P = 0.38); I2 =7%
Test for overall effect: Z = 0.86 (P = 0.39)
Total (95% CI) 18931 18787 100.0 % 0.02 [ -0.01, 0.05 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 25.69, df = 24 (P = 0.37); I2 =7%
Test for overall effect: Z = 1.41 (P = 0.16)
Test for subgroup differences: Chi2 = 0.91, df = 1 (P = 0.34), I2 =0.0%
-0.5 -0.25 0 0.25 0.5
Favours higher omega 3 Favours lower omega 3
(1) median change from baseline, highest EPA vs placebo
(2) SDs unlikely, converted assuming SEs
(3) median change from baseline, highest EPA vs placebo
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Analysis 2.63. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 63 LDL,
mmoL/L - LCn3 - subgroup by dose.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 2 High vs low LCn3 omega-3 fats (secondary outcomes)
Outcome: 63 LDL, mmoL/L - LCn3 - subgroup by dose
Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 LCn3≤ 150 mg/d
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
2 LCn3 > 150≤ 250 mg/d
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
3 LCn3 > 250≤ 400 mg/d
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
4 LCn3 > 400≤ 2400 mg/d
Ahn 2016 38 2.23 (1.33) 36 2.07 (0.13) 0.2 % 0.16 [ -0.26, 0.58 ]
AlphaOmega - EPA+DHA 2010 562 -0.41 (0.71) 562 -0.39 (0.71) 5.3 % -0.02 [ -0.10, 0.06 ]
Berson 2004 105 3.18 (0.92) 103 2.87 (0.81) 0.7 % 0.31 [ 0.07, 0.55 ]
Caldwell 2011 17 3.18 (0.93) 17 3.29 (0.13) 0.2 % -0.11 [ -0.56, 0.34 ]
Derosa 2016 (1) 128 3.3 (3.4) 130 3.1 (2.3) 0.1 % 0.20 [ -0.51, 0.91 ]
Deslypere 1992 14 3.88 (0.87) 14 4.08 (0.89) 0.1 % -0.20 [ -0.85, 0.45 ]
JELIS 2007 9326 3.53 (0.77) 9319 3.53 (0.73) 78.2 % 0.0 [ -0.02, 0.02 ]
MARINA 2011 80 3.4 (0.8987) 71 3.4 (0.845) 0.5 % 0.0 [ -0.28, 0.28 ]
NAT2 2013 134 3.65 (1.06) 129 3.71 (0.89) 0.7 % -0.06 [ -0.30, 0.18 ]
ORIGIN 2012 6281 -0.305 (1.66) 6255 -0.32 (1.66) 10.7 % 0.02 [ -0.04, 0.07 ]
ORL 2013 170 0.08 (0.68) 165 -0.01 (0.6) 1.9 % 0.09 [ -0.04, 0.23 ]
SCIMO 1999 87 -0.25 (1.2) 84 -0.41 (1.03) 0.3 % 0.16 [ -0.17, 0.49 ]
SMART 2013 21 3.4 (0.9) 24 3.2 (0.9) 0.1 % 0.20 [ -0.33, 0.73 ]
Sofi 2010 6 -0.05 (1.0101) 5 -0.15 (0.4349) 0.0 % 0.10 [ -0.79, 0.99 ]
Tande 2016 50 -0.04 (0.69) 50 -0.05 (0.5) 0.7 % 0.01 [ -0.23, 0.25 ]
-2 -1 0 1 2
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Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
THIS DIET 2008 37 2.59 (0.69) 34 2.51 (0.59) 0.4 % 0.08 [ -0.22, 0.38 ]
Subtotal (95% CI) 17056 16998 100.0 % 0.01 [ -0.01, 0.02 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 12.12, df = 15 (P = 0.67); I2 =0.0%
Test for overall effect: Z = 0.56 (P = 0.58)
5 LCn3 > 2.4≤ 4.4 g/d
EPE-A 2014 (2) 64 0.21 (0) 55 0.1 (0) Not estimable
Sandhu 2016 49 2.83 (0.75) 47 2.96 (0.75) 24.6 % -0.13 [ -0.43, 0.17 ]
SHOT 1996 289 5.12 (1.16) 267 5.04 (1.24) 55.3 % 0.08 [ -0.12, 0.28 ]
Weinstock-Guttman 2005 13 0.11 (0.59) 14 0.64 (2.39) 1.3 % -0.53 [ -1.82, 0.76 ]
WELCOME 2015 47 2.8 (0.9) 48 2.8 (0.8) 18.8 % 0.0 [ -0.34, 0.34 ]
Subtotal (95% CI) 462 431 100.0 % 0.01 [ -0.14, 0.15 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.98, df = 3 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 0.07 (P = 0.94)
6 LCn3 > 4.4 g/d
HARP 1995 31 3.41 (0.78) 28 3.16 (0.62) 78.3 % 0.25 [ -0.11, 0.61 ]
Rossing 1996 14 3.52 (0.9) 15 3.4 (0.97) 21.7 % 0.12 [ -0.56, 0.80 ]
Subtotal (95% CI) 45 43 100.0 % 0.22 [ -0.09, 0.54 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.11, df = 1 (P = 0.74); I2 =0.0%
Test for overall effect: Z = 1.37 (P = 0.17)
Test for subgroup differences: Chi2 = 1.79, df = 2 (P = 0.41), I2 =0.0%
-2 -1 0 1 2
Favours higher omega 3 Favours lower omega 3
(1) SDs unlikely, converted assuming SEs
(2) median change from baseline, highest EPA vs placebo
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Analysis 2.64. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 64 LDL,
mmoL/L - LCn3 - subgroup by replacement.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 2 High vs low LCn3 omega-3 fats (secondary outcomes)
Outcome: 64 LDL, mmoL/L - LCn3 - subgroup by replacement
Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 N-3 replacing SFA
Derosa 2016 (1) 128 3.3 (3.4) 130 3.1 (2.3) 18.2 % 0.20 [ -0.51, 0.91 ]
SCIMO 1999 87 -0.25 (1.2) 84 -0.41 (1.03) 81.8 % 0.16 [ -0.17, 0.49 ]
Subtotal (95% CI) 215 214 100.0 % 0.17 [ -0.14, 0.47 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.01, df = 1 (P = 0.92); I2 =0.0%
Test for overall effect: Z = 1.08 (P = 0.28)
2 N-3 replacing MUFA
AlphaOmega - EPA+DHA 2010 562 -0.41 (0.71) 562 -0.39 (0.71) 27.1 % -0.02 [ -0.10, 0.06 ]
Deslypere 1992 14 3.88 (0.87) 14 4.08 (0.89) 0.4 % -0.20 [ -0.85, 0.45 ]
HARP 1995 31 3.41 (0.78) 28 3.16 (0.62) 1.5 % 0.25 [ -0.11, 0.61 ]
MARINA 2011 80 3.4 (0.8987) 71 3.4 (0.845) 2.4 % 0.0 [ -0.28, 0.28 ]
NAT2 2013 134 3.65 (1.06) 129 3.71 (0.89) 3.3 % -0.06 [ -0.30, 0.18 ]
ORIGIN 2012 6281 -0.305 (1.66) 6255 -0.32 (1.66) 55.2 % 0.02 [ -0.04, 0.07 ]
Rossing 1996 14 3.52 (0.9) 15 3.4 (0.97) 0.4 % 0.12 [ -0.56, 0.80 ]
SCIMO 1999 87 -0.25 (1.2) 84 -0.41 (1.03) 1.7 % 0.16 [ -0.17, 0.49 ]
SMART 2013 21 3.4 (0.9) 24 3.2 (0.9) 0.7 % 0.20 [ -0.33, 0.73 ]
Sofi 2010 6 -0.05 (1.0101) 5 -0.15 (0.4349) 0.2 % 0.10 [ -0.79, 0.99 ]
Tande 2016 50 -0.04 (0.69) 50 -0.05 (0.5) 3.3 % 0.01 [ -0.23, 0.25 ]
THIS DIET 2008 37 2.59 (0.69) 34 2.51 (0.59) 2.1 % 0.08 [ -0.22, 0.38 ]
Weinstock-Guttman 2005 13 0.11 (0.59) 14 0.64 (2.39) 0.1 % -0.53 [ -1.82, 0.76 ]
WELCOME 2015 47 2.8 (0.9) 48 2.8 (0.8) 1.6 % 0.0 [ -0.34, 0.34 ]
Subtotal (95% CI) 7377 7333 100.0 % 0.01 [ -0.03, 0.05 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 5.31, df = 13 (P = 0.97); I2 =0.0%
Test for overall effect: Z = 0.47 (P = 0.64)
3 N-3 replacing n-6
Berson 2004 105 3.18 (0.92) 103 2.87 (0.81) 60.6 % 0.31 [ 0.07, 0.55 ]
Caldwell 2011 17 3.18 (0.93) 17 3.29 (0.13) 39.4 % -0.11 [ -0.56, 0.34 ]
-2 -1 0 1 2
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Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Subtotal (95% CI) 122 120 100.0 % 0.14 [ -0.26, 0.55 ]
Heterogeneity: Tau2 = 0.06; Chi2 = 2.66, df = 1 (P = 0.10); I2 =62%
Test for overall effect: Z = 0.70 (P = 0.48)
4 N-3 replacing carbs/sugars
Derosa 2016 (2) 128 3.3 (3.4) 130 3.1 (2.3) 100.0 % 0.20 [ -0.51, 0.91 ]
Subtotal (95% CI) 128 130 100.0 % 0.20 [ -0.51, 0.91 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.55 (P = 0.58)
5 N-3 replacing nil/low n-3 placebo
JELIS 2007 9326 3.53 (0.77) 9319 3.53 (0.73) 98.4 % 0.0 [ -0.02, 0.02 ]
Sandhu 2016 49 2.83 (0.75) 47 2.96 (0.75) 0.5 % -0.13 [ -0.43, 0.17 ]
SHOT 1996 289 5.12 (1.16) 267 5.04 (1.24) 1.1 % 0.08 [ -0.12, 0.28 ]
Subtotal (95% CI) 9664 9633 100.0 % 0.00 [ -0.02, 0.02 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.33, df = 2 (P = 0.51); I2 =0.0%
Test for overall effect: Z = 0.02 (P = 0.98)
6 Replacement unclear
Ahn 2016 38 2.23 (1.33) 36 2.07 (0.13) 9.4 % 0.16 [ -0.26, 0.58 ]
EPE-A 2014 (3) 64 0.21 (0) 55 0.1 (0) Not estimable
ORL 2013 170 0.08 (0.68) 165 -0.01 (0.6) 90.6 % 0.09 [ -0.04, 0.23 ]
Subtotal (95% CI) 272 256 100.0 % 0.10 [ -0.03, 0.23 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.08, df = 1 (P = 0.77); I2 =0.0%
Test for overall effect: Z = 1.50 (P = 0.13)
Test for subgroup differences: Chi2 = 4.15, df = 5 (P = 0.53), I2 =0.0%
-2 -1 0 1 2
Favours higher omega 3 Favours lower omega 3
(1) SDs unlikely, converted assuming SEs
(2) SDs unlikely, converted assuming SEs
(3) median change from baseline, highest EPA vs placebo
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Analysis 2.65. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 65 LDL,
mmoL/L - LCn3 - subgroup by intervention type.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 2 High vs low LCn3 omega-3 fats (secondary outcomes)
Outcome: 65 LDL, mmoL/L - LCn3 - subgroup by intervention type
Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Dietary advice
THIS DIET 2008 37 2.59 (0.69) 34 2.51 (0.59) 100.0 % 0.08 [ -0.22, 0.38 ]
Subtotal (95% CI) 37 34 100.0 % 0.08 [ -0.22, 0.38 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.53 (P = 0.60)
2 Supplemental foods
AlphaOmega - EPA+DHA 2010 562 -0.41 (0.71) 562 -0.39 (0.71) 100.0 % -0.02 [ -0.10, 0.06 ]
Subtotal (95% CI) 562 562 100.0 % -0.02 [ -0.10, 0.06 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.47 (P = 0.64)
3 Supplement (capsule)
Ahn 2016 38 2.23 (1.33) 36 2.07 (0.13) 0.2 % 0.16 [ -0.26, 0.58 ]
Berson 2004 105 3.18 (0.92) 103 2.87 (0.81) 0.7 % 0.31 [ 0.07, 0.55 ]
Caldwell 2011 17 3.18 (0.93) 17 3.29 (0.13) 0.2 % -0.11 [ -0.56, 0.34 ]
Derosa 2016 (1) 128 3.3 (3.4) 130 3.1 (2.3) 0.1 % 0.20 [ -0.51, 0.91 ]
Deslypere 1992 14 3.88 (0.87) 14 4.08 (0.89) 0.1 % -0.20 [ -0.85, 0.45 ]
EPE-A 2014 (2) 64 0.21 (0) 55 0.1 (0) Not estimable
HARP 1995 31 3.41 (0.78) 28 3.16 (0.62) 0.3 % 0.25 [ -0.11, 0.61 ]
JELIS 2007 9326 3.53 (0.77) 9319 3.53 (0.73) 81.3 % 0.0 [ -0.02, 0.02 ]
MARINA 2011 80 3.4 (0.8987) 71 3.4 (0.845) 0.5 % 0.0 [ -0.28, 0.28 ]
NAT2 2013 134 3.65 (1.06) 129 3.71 (0.89) 0.7 % -0.06 [ -0.30, 0.18 ]
ORIGIN 2012 6281 -0.305 (1.66) 6255 -0.32 (1.66) 11.2 % 0.02 [ -0.04, 0.07 ]
ORL 2013 170 0.08 (0.68) 165 -0.01 (0.6) 2.0 % 0.09 [ -0.04, 0.23 ]
Rossing 1996 14 3.52 (0.9) 15 3.4 (0.97) 0.1 % 0.12 [ -0.56, 0.80 ]
Sandhu 2016 49 2.83 (0.75) 47 2.96 (0.75) 0.4 % -0.13 [ -0.43, 0.17 ]
SCIMO 1999 87 -0.25 (1.2) 84 -0.41 (1.03) 0.3 % 0.16 [ -0.17, 0.49 ]
SHOT 1996 289 5.12 (1.16) 267 5.04 (1.24) 0.9 % 0.08 [ -0.12, 0.28 ]
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Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Sofi 2010 6 -0.05 (1.0101) 5 -0.15 (0.4349) 0.0 % 0.10 [ -0.79, 0.99 ]
Tande 2016 50 -0.04 (0.69) 50 -0.05 (0.5) 0.7 % 0.01 [ -0.23, 0.25 ]
WELCOME 2015 47 2.8 (0.9) 48 2.8 (0.8) 0.3 % 0.0 [ -0.34, 0.34 ]
Subtotal (95% CI) 16930 16838 100.0 % 0.01 [ -0.01, 0.03 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 14.18, df = 17 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 0.72 (P = 0.47)
4 Any combination
SMART 2013 21 3.4 (0.9) 24 3.2 (0.9) 84.0 % 0.20 [ -0.33, 0.73 ]
Weinstock-Guttman 2005 13 0.11 (0.59) 14 0.64 (2.39) 16.0 % -0.53 [ -1.82, 0.76 ]
Subtotal (95% CI) 34 38 100.0 % 0.08 [ -0.44, 0.61 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 1.05, df = 1 (P = 0.31); I2 =5%
Test for overall effect: Z = 0.31 (P = 0.76)
Test for subgroup differences: Chi2 = 0.71, df = 3 (P = 0.87), I2 =0.0%
-2 -1 0 1 2
Favours higher omega 3 Favours lower omega 3
(1) SDs unlikely, converted assuming SEs
(2) median change from baseline, highest EPA vs placebo
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Analysis 2.66. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 66 LDL,
mmoL/L - LCn3 - subgroup by duration.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 2 High vs low LCn3 omega-3 fats (secondary outcomes)
Outcome: 66 LDL, mmoL/L - LCn3 - subgroup by duration
Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Medium duration 1 to < 2 years in study
Ahn 2016 38 2.23 (1.33) 36 2.07 (0.13) 4.0 % 0.16 [ -0.26, 0.58 ]
Caldwell 2011 17 3.18 (0.93) 17 3.29 (0.13) 3.6 % -0.11 [ -0.56, 0.34 ]
Derosa 2016 (1) 128 3.3 (3.4) 130 3.1 (2.3) 1.4 % 0.20 [ -0.51, 0.91 ]
Deslypere 1992 14 3.88 (0.87) 14 4.08 (0.89) 1.7 % -0.20 [ -0.85, 0.45 ]
EPE-A 2014 (2) 64 0.21 (0) 55 0.1 (0) Not estimable
MARINA 2011 80 3.4 (0.8987) 71 3.4 (0.845) 9.2 % 0.0 [ -0.28, 0.28 ]
ORL 2013 170 0.08 (0.68) 165 -0.01 (0.6) 37.9 % 0.09 [ -0.04, 0.23 ]
Rossing 1996 14 3.52 (0.9) 15 3.4 (0.97) 1.5 % 0.12 [ -0.56, 0.80 ]
SHOT 1996 289 5.12 (1.16) 267 5.04 (1.24) 17.9 % 0.08 [ -0.12, 0.28 ]
SMART 2013 21 3.4 (0.9) 24 3.2 (0.9) 2.6 % 0.20 [ -0.33, 0.73 ]
Sofi 2010 6 -0.05 (1.0101) 5 -0.15 (0.4349) 0.9 % 0.10 [ -0.79, 0.99 ]
Tande 2016 50 -0.04 (0.69) 50 -0.05 (0.5) 12.8 % 0.01 [ -0.23, 0.25 ]
Weinstock-Guttman 2005 13 0.11 (0.59) 14 0.64 (2.39) 0.4 % -0.53 [ -1.82, 0.76 ]
WELCOME 2015 47 2.8 (0.9) 48 2.8 (0.8) 6.1 % 0.0 [ -0.34, 0.34 ]
Subtotal (95% CI) 951 911 100.0 % 0.06 [ -0.03, 0.14 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 3.38, df = 12 (P = 0.99); I2 =0.0%
Test for overall effect: Z = 1.36 (P = 0.17)
2 Medium-long duration: 2 to < 4 years in study
AlphaOmega - EPA+DHA 2010 562 -0.41 (0.71) 562 -0.39 (0.71) 71.8 % -0.02 [ -0.10, 0.06 ]
HARP 1995 31 3.41 (0.78) 28 3.16 (0.62) 3.9 % 0.25 [ -0.11, 0.61 ]
NAT2 2013 134 3.65 (1.06) 129 3.71 (0.89) 8.9 % -0.06 [ -0.30, 0.18 ]
Sandhu 2016 49 2.83 (0.75) 47 2.96 (0.75) 5.5 % -0.13 [ -0.43, 0.17 ]
SCIMO 1999 87 -0.25 (1.2) 84 -0.41 (1.03) 4.4 % 0.16 [ -0.17, 0.49 ]
THIS DIET 2008 37 2.59 (0.69) 34 2.51 (0.59) 5.6 % 0.08 [ -0.22, 0.38 ]
Subtotal (95% CI) 900 884 100.0 % -0.01 [ -0.08, 0.06 ]
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Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Heterogeneity: Tau2 = 0.0; Chi2 = 4.19, df = 5 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 0.16 (P = 0.88)
3 Long duration≥ 4 years in study
Berson 2004 105 3.18 (0.92) 103 2.87 (0.81) 7.5 % 0.31 [ 0.07, 0.55 ]
JELIS 2007 9326 3.53 (0.77) 9319 3.53 (0.73) 52.6 % 0.0 [ -0.02, 0.02 ]
ORIGIN 2012 6281 -0.305 (1.66) 6255 -0.32 (1.66) 39.9 % 0.02 [ -0.04, 0.07 ]
Subtotal (95% CI) 15712 15677 100.0 % 0.03 [ -0.04, 0.10 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 6.78, df = 2 (P = 0.03); I2 =71%
Test for overall effect: Z = 0.84 (P = 0.40)
Test for subgroup differences: Chi2 = 1.36, df = 2 (P = 0.51), I2 =0.0%
-1 -0.5 0 0.5 1
Favours higher omega 3 Favours lower omega 3
(1) SDs unlikely, converted assuming SEs
(2) median change from baseline, highest EPA vs placebo
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Analysis 2.67. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 67 LDL,
mmoL/L - LCn3 - subgroup by primary or secondary prevention.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 2 High vs low LCn3 omega-3 fats (secondary outcomes)
Outcome: 67 LDL, mmoL/L - LCn3 - subgroup by primary or secondary prevention
Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Primary prevention
Berson 2004 105 3.18 (0.92) 103 2.87 (0.81) 0.7 % 0.31 [ 0.07, 0.55 ]
Caldwell 2011 17 3.18 (0.93) 17 3.29 (0.13) 0.2 % -0.11 [ -0.56, 0.34 ]
Derosa 2016 (1) 128 3.3 (3.4) 130 3.1 (2.3) 0.1 % 0.20 [ -0.51, 0.91 ]
Deslypere 1992 14 3.88 (0.87) 14 4.08 (0.89) 0.1 % -0.20 [ -0.85, 0.45 ]
EPE-A 2014 (2) 64 0.21 (0) 55 0.1 (0) Not estimable
JELIS 2007 9326 3.53 (0.77) 9319 3.53 (0.73) 83.2 % 0.0 [ -0.02, 0.02 ]
MARINA 2011 80 3.4 (0.8987) 71 3.4 (0.845) 0.5 % 0.0 [ -0.28, 0.28 ]
ORIGIN 2012 6281 -0.305 (1.66) 6255 -0.32 (1.66) 11.4 % 0.02 [ -0.04, 0.07 ]
ORL 2013 170 0.08 (0.68) 165 -0.01 (0.6) 2.1 % 0.09 [ -0.04, 0.23 ]
Rossing 1996 14 3.52 (0.9) 15 3.4 (0.97) 0.1 % 0.12 [ -0.56, 0.80 ]
Sandhu 2016 49 2.83 (0.75) 47 2.96 (0.75) 0.4 % -0.13 [ -0.43, 0.17 ]
SMART 2013 21 3.4 (0.9) 24 3.2 (0.9) 0.1 % 0.20 [ -0.33, 0.73 ]
Sofi 2010 6 -0.05 (1.0101) 5 -0.15 (0.4349) 0.0 % 0.10 [ -0.79, 0.99 ]
Tande 2016 50 -0.04 (0.69) 50 -0.05 (0.5) 0.7 % 0.01 [ -0.23, 0.25 ]
Weinstock-Guttman 2005 13 0.11 (0.59) 14 0.64 (2.39) 0.0 % -0.53 [ -1.82, 0.76 ]
WELCOME 2015 47 2.8 (0.9) 48 2.8 (0.8) 0.3 % 0.0 [ -0.34, 0.34 ]
Subtotal (95% CI) 16385 16332 100.0 % 0.01 [ -0.01, 0.03 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 11.45, df = 14 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 0.55 (P = 0.58)
2 Secondary prevention
Ahn 2016 38 2.23 (1.33) 36 2.07 (0.13) 2.5 % 0.16 [ -0.26, 0.58 ]
AlphaOmega - EPA+DHA 2010 562 -0.41 (0.71) 562 -0.39 (0.71) 65.5 % -0.02 [ -0.10, 0.06 ]
HARP 1995 31 3.41 (0.78) 28 3.16 (0.62) 3.5 % 0.25 [ -0.11, 0.61 ]
NAT2 2013 134 3.65 (1.06) 129 3.71 (0.89) 8.1 % -0.06 [ -0.30, 0.18 ]
SCIMO 1999 87 -0.25 (1.2) 84 -0.41 (1.03) 4.0 % 0.16 [ -0.17, 0.49 ]
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Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
SHOT 1996 289 5.12 (1.16) 267 5.04 (1.24) 11.3 % 0.08 [ -0.12, 0.28 ]
THIS DIET 2008 37 2.59 (0.69) 34 2.51 (0.59) 5.1 % 0.08 [ -0.22, 0.38 ]
Subtotal (95% CI) 1178 1140 100.0 % 0.01 [ -0.05, 0.08 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 4.48, df = 6 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 0.42 (P = 0.67)
Test for subgroup differences: Chi2 = 0.06, df = 1 (P = 0.80), I2 =0.0%
-1 -0.5 0 0.5 1
Favours higher omega 3 Favours lower omega 3
(1) SDs unlikely, converted assuming SEs
(2) median change from baseline, highest EPA vs placebo
Analysis 2.68. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 68 LDL,
mmoL/L - LCn3 - subgroup by statin use.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 2 High vs low LCn3 omega-3 fats (secondary outcomes)
Outcome: 68 LDL, mmoL/L - LCn3 - subgroup by statin use
Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 LCn3 -≥ 50% of control group on statins
Ahn 2016 38 2.23 (1.33) 36 2.07 (0.13) 0.2 % 0.16 [ -0.26, 0.58 ]
AlphaOmega - EPA+DHA 2010 562 -0.41 (0.71) 562 -0.39 (0.71) 5.5 % -0.02 [ -0.10, 0.06 ]
JELIS 2007 9326 3.53 (0.77) 9319 3.53 (0.73) 81.7 % 0.0 [ -0.02, 0.02 ]
NAT2 2013 134 3.65 (1.06) 129 3.71 (0.89) 0.7 % -0.06 [ -0.30, 0.18 ]
ORIGIN 2012 6281 -0.305 (1.66) 6255 -0.32 (1.66) 11.2 % 0.02 [ -0.04, 0.07 ]
THIS DIET 2008 37 2.59 (0.69) 34 2.51 (0.59) 0.4 % 0.08 [ -0.22, 0.38 ]
WELCOME 2015 47 2.8 (0.9) 48 2.8 (0.8) 0.3 % 0.0 [ -0.34, 0.34 ]
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Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Subtotal (95% CI) 16425 16383 100.0 % 0.00 [ -0.02, 0.02 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.57, df = 6 (P = 0.95); I2 =0.0%
Test for overall effect: Z = 0.10 (P = 0.92)
2 LCn3 - < 50% of control group on statins
Berson 2004 105 3.18 (0.92) 103 2.87 (0.81) 13.8 % 0.31 [ 0.07, 0.55 ]
Deslypere 1992 14 3.88 (0.87) 14 4.08 (0.89) 1.8 % -0.20 [ -0.85, 0.45 ]
HARP 1995 31 3.41 (0.78) 28 3.16 (0.62) 6.0 % 0.25 [ -0.11, 0.61 ]
MARINA 2011 80 3.4 (0.8987) 71 3.4 (0.845) 9.9 % 0.0 [ -0.28, 0.28 ]
ORL 2013 170 0.08 (0.68) 165 -0.01 (0.6) 40.6 % 0.09 [ -0.04, 0.23 ]
Rossing 1996 14 3.52 (0.9) 15 3.4 (0.97) 1.6 % 0.12 [ -0.56, 0.80 ]
SCIMO 1999 87 -0.25 (1.2) 84 -0.41 (1.03) 6.8 % 0.16 [ -0.17, 0.49 ]
SHOT 1996 289 5.12 (1.16) 267 5.04 (1.24) 19.1 % 0.08 [ -0.12, 0.28 ]
Weinstock-Guttman 2005 13 0.11 (0.59) 14 0.64 (2.39) 0.5 % -0.53 [ -1.82, 0.76 ]
Subtotal (95% CI) 803 761 100.0 % 0.12 [ 0.03, 0.21 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 5.96, df = 8 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 2.64 (P = 0.0082)
3 LCn3 - use of statins unclear
Caldwell 2011 17 3.18 (0.93) 17 3.29 (0.13) 12.3 % -0.11 [ -0.56, 0.34 ]
Derosa 2016 (1) 128 3.3 (3.4) 130 3.1 (2.3) 4.9 % 0.20 [ -0.51, 0.91 ]
EPE-A 2014 (2) 64 0.21 (0) 55 0.1 (0) Not estimable
Sandhu 2016 49 2.83 (0.75) 47 2.96 (0.75) 27.2 % -0.13 [ -0.43, 0.17 ]
SMART 2013 21 3.4 (0.9) 24 3.2 (0.9) 8.8 % 0.20 [ -0.33, 0.73 ]
Sofi 2010 6 -0.05 (1.0101) 5 -0.15 (0.4349) 3.1 % 0.10 [ -0.79, 0.99 ]
Tande 2016 50 -0.04 (0.69) 50 -0.05 (0.5) 43.8 % 0.01 [ -0.23, 0.25 ]
Subtotal (95% CI) 335 328 100.0 % -0.01 [ -0.17, 0.14 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.84, df = 5 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 0.18 (P = 0.86)
Test for subgroup differences: Chi2 = 6.62, df = 2 (P = 0.04), I2 =70%
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Analysis 3.1. Comparison 3 High vs low LCn3 omega-3 fats (tertiary outcomes), Outcome 1 Blood
pressure, mmHg - LCn3.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 3 High vs low LCn3 omega-3 fats (tertiary outcomes)
Outcome: 1 Blood pressure, mmHg - LCn3
Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Systolic BP - LCn3
AlphaOmega - EPA+DHA 2010 632 -0.64 (20) 632 -2.29 (21.3) 2.2 % 1.65 [ -0.63, 3.93 ]
DART 1989 871 138.06 (21.89) 852 137.73 (21.2) 2.7 % 0.33 [ -1.70, 2.36 ]
Deslypere 1992 14 118 (21) 14 119 (18) 0.1 % -1.00 [ -15.49, 13.49 ]
DO IT 2010 124 143 (16) 117 143 (22) 0.5 % 0.0 [ -4.88, 4.88 ]
HARP 1995 31 129 (16) 28 137 (29) 0.1 % -8.00 [ -20.13, 4.13 ]
JELIS 2007 9326 133.25 (14) 9319 133.25 (13) 74.3 % 0.0 [ -0.39, 0.39 ]
MARINA 2011 80 118.3 (12.1) 71 122.1 (12.7) 0.7 % -3.80 [ -7.77, 0.17 ]
OFAMI 2001 127 132.2 (24.4) 130 136 (19.3) 0.4 % -3.80 [ -9.19, 1.59 ]
ORIGIN 2012 6281 -4.37 (22.5) 5255 -4.51 (22.5) 16.4 % 0.14 [ -0.68, 0.96 ]
Rossing 1996 14 142 (18.7) 15 144 (15.5) 0.1 % -2.00 [ -14.55, 10.55 ]
SCIMO 1999 87 8.3 (19.1) 84 8.3 (24.2) 0.3 % 0.0 [ -6.55, 6.55 ]
SMART 2013 20 120 (13) 23 128 (17) 0.1 % -8.00 [ -16.98, 0.98 ]
Tande 2016 50 2.68 (6.32) 50 1.95 (7.1) 1.6 % 0.73 [ -1.90, 3.36 ]
THIS DIET 2008 37 123 (16) 34 123 (12) 0.3 % 0.0 [ -6.55, 6.55 ]
WELCOME 2015 47 133.3 (13.7) 48 133.9 (11.3) 0.4 % -0.60 [ -5.66, 4.46 ]
Subtotal (95% CI) 17741 16672 100.0 % 0.02 [ -0.32, 0.35 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 12.83, df = 14 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 0.09 (P = 0.93)
2 Diastolic BP - LCn3
AlphaOmega - EPA+DHA 2010 632 -3.17 (10.5) 632 -2.75 (10.3) 2.9 % -0.42 [ -1.57, 0.73 ]
DART 1989 870 81.37 (12.5) 852 81.55 (11.86) 2.9 % -0.18 [ -1.33, 0.97 ]
Deslypere 1992 14 72 (13) 14 75 (11) 0.0 % -3.00 [ -11.92, 5.92 ]
DO IT 2010 124 79 (11) 117 79 (12) 0.4 % 0.0 [ -2.91, 2.91 ]
HARP 1995 31 77 (7) 28 77 (7) 0.3 % 0.0 [ -3.58, 3.58 ]
JELIS 2007 9326 78 (8) 9319 78 (8) 71.9 % 0.0 [ -0.23, 0.23 ]
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Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
MARINA 2011 80 71.2 (6.1652) 71 72.9 (6.3372) 0.9 % -1.70 [ -3.70, 0.30 ]
OFAMI 2001 127 80.8 (9.3) 130 81.1 (12.6) 0.5 % -0.30 [ -3.00, 2.40 ]
ORIGIN 2012 6281 -4.93 (12.8) 6255 -4.96 (13.1) 18.5 % 0.03 [ -0.42, 0.48 ]
SCIMO 1999 87 4.2 (11.5) 84 3.4 (14.6) 0.2 % 0.80 [ -3.15, 4.75 ]
SMART 2013 20 74 (9) 23 77 (10) 0.1 % -3.00 [ -8.68, 2.68 ]
Tande 2016 50 -0.92 (7.24) 50 -2.4 (6.04) 0.6 % 1.48 [ -1.13, 4.09 ]
THIS DIET 2008 37 74 (9) 37 72 (8) 0.3 % 2.00 [ -1.88, 5.88 ]
WELCOME 2015 47 81.7 (8.2) 48 82.9 (6.5) 0.4 % -1.20 [ -4.18, 1.78 ]
Subtotal (95% CI) 17726 17660 100.0 % -0.02 [ -0.22, 0.17 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 7.93, df = 13 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 0.24 (P = 0.81)
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Analysis 3.2. Comparison 3 High vs low LCn3 omega-3 fats (tertiary outcomes), Outcome 2 Serious
adverse events - LCn3.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 3 High vs low LCn3 omega-3 fats (tertiary outcomes)
Outcome: 2 Serious adverse events - LCn3
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Any serious adverse events
ADCS 2010 76/238 50/164 100.0 % 1.05 [ 0.78, 1.41 ]
Subtotal (95% CI) 238 164 100.0 % 1.05 [ 0.78, 1.41 ]
Total events: 76 (Higher omega 3), 50 (Lower omega 3)
Heterogeneity: not applicable
Test for overall effect: Z = 0.31 (P = 0.76)
2 Bleeding
AFFORD 2013 10/153 14/163 13.1 % 0.76 [ 0.35, 1.66 ]
EPIC-1 2008 0/187 2/184 1.4 % 0.20 [ 0.01, 4.07 ]
EPIC-2 2008 9/189 10/188 11.4 % 0.90 [ 0.37, 2.15 ]
FOSTAR 2016 1/101 4/101 2.6 % 0.25 [ 0.03, 2.20 ]
JELIS 2007 105/9326 60/9319 26.3 % 1.75 [ 1.28, 2.40 ]
ORIGIN 2012 57/6281 65/6255 25.0 % 0.87 [ 0.61, 1.24 ]
Risk % Prevention 2013 16/6239 12/6266 13.8 % 1.34 [ 0.63, 2.83 ]
SHOT 1996 5/317 4/293 6.4 % 1.16 [ 0.31, 4.26 ]
Subtotal (95% CI) 22793 22769 100.0 % 1.06 [ 0.73, 1.52 ]
Total events: 203 (Higher omega 3), 171 (Lower omega 3)
Heterogeneity: Tau2 = 0.11; Chi2 = 13.73, df = 7 (P = 0.06); I2 =49%
Test for overall effect: Z = 0.29 (P = 0.77)
3 GI hospitalisation
Raitt 2005 7/100 4/100 100.0 % 1.75 [ 0.53, 5.79 ]
Subtotal (95% CI) 100 100 100.0 % 1.75 [ 0.53, 5.79 ]
Total events: 7 (Higher omega 3), 4 (Lower omega 3)
Heterogeneity: not applicable
Test for overall effect: Z = 0.92 (P = 0.36)
4 Pulmonary embolus or DVT - LCn3
ADCS 2010 8/214 2/164 41.7 % 3.07 [ 0.66, 14.24 ]
DART 1989 2/1015 4/1018 35.5 % 0.50 [ 0.09, 2.73 ]
NAT2 2013 1/150 0/150 11.4 % 3.00 [ 0.12, 73.06 ]
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Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
OFAMI 2001 0/150 1/150 11.4 % 0.33 [ 0.01, 8.12 ]
Subtotal (95% CI) 1529 1482 100.0 % 1.25 [ 0.41, 3.78 ]
Total events: 11 (Higher omega 3), 7 (Lower omega 3)
Heterogeneity: Tau2 = 0.15; Chi2 = 3.38, df = 3 (P = 0.34); I2 =11%
Test for overall effect: Z = 0.39 (P = 0.69)
5 Progression to advanced AMD (age-related macular degeneration)
AREDS2 2014 1025/2147 1024/2056 100.0 % 0.96 [ 0.90, 1.02 ]
Subtotal (95% CI) 2147 2056 100.0 % 0.96 [ 0.90, 1.02 ]
Total events: 1025 (Higher omega 3), 1024 (Lower omega 3)
Heterogeneity: not applicable
Test for overall effect: Z = 1.34 (P = 0.18)
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Analysis 3.3. Comparison 3 High vs low LCn3 omega-3 fats (tertiary outcomes), Outcome 3 Side effects -
LCn3.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 3 High vs low LCn3 omega-3 fats (tertiary outcomes)
Outcome: 3 Side effects - LCn3
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Dropouts due to side effects
ADCS 2010 14/238 10/167 4.0 % 0.98 [ 0.45, 2.16 ]
AFFORD 2013 10/153 7/163 2.8 % 1.52 [ 0.59, 3.90 ]
AlphaOmega - EPA+DHA 2010 32/1192 21/1236 8.4 % 1.58 [ 0.92, 2.72 ]
EPE-A 2014 7/168 7/75 2.4 % 0.45 [ 0.16, 1.23 ]
EPIC-1 2008 9/187 7/185 2.7 % 1.27 [ 0.48, 3.34 ]
EPIC-2 2008 9/189 5/188 2.2 % 1.79 [ 0.61, 5.24 ]
FORWARD 2013 6/289 8/297 2.3 % 0.77 [ 0.27, 2.19 ]
FOSTAR 2016 17/101 6/101 3.2 % 2.83 [ 1.16, 6.89 ]
GISSI-HF 2008 102/3494 104/3481 33.1 % 0.98 [ 0.75, 1.28 ]
HARP 1995 3/41 0/39 0.3 % 6.67 [ 0.36, 125.02 ]
HERO 2009 1/26 0/24 0.3 % 2.78 [ 0.12, 65.08 ]
Kumar 2012 4/91 0/87 0.3 % 8.61 [ 0.47, 157.57 ]
Kumar 2013 1/39 0/39 0.2 % 3.00 [ 0.13, 71.46 ]
MAPT 2017 48/820 51/832 16.8 % 0.95 [ 0.65, 1.40 ]
NAT2 2013 12/150 7/150 3.1 % 1.71 [ 0.69, 4.23 ]
Nodari 2011 AF 2/100 3/99 0.8 % 0.66 [ 0.11, 3.87 ]
OPAL 2010 17/434 18/433 5.9 % 0.94 [ 0.49, 1.80 ]
ORL 2013 9/171 4/165 1.9 % 2.17 [ 0.68, 6.91 ]
Puri 2005 3/67 1/68 0.5 % 3.04 [ 0.32, 28.54 ]
Rossing 1996 3/18 1/18 0.5 % 3.00 [ 0.34, 26.19 ]
Sandhu 2016 1/54 0/53 0.2 % 2.95 [ 0.12, 70.72 ]
SCIMO 1999 4/112 3/111 1.2 % 1.32 [ 0.30, 5.77 ]
SHOT 1996 27/317 16/293 7.0 % 1.56 [ 0.86, 2.84 ]
Subtotal (95% CI) 8451 8304 100.0 % 1.16 [ 0.99, 1.36 ]
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Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Total events: 341 (Higher omega 3), 279 (Lower omega 3)
Heterogeneity: Tau2 = 0.00; Chi2 = 22.11, df = 22 (P = 0.45); I2 =1%
Test for overall effect: Z = 1.86 (P = 0.064)
2 Abdominal pain or discomfort
EPE-A 2014 3/68 0/75 0.8 % 7.71 [ 0.41, 146.61 ]
EPIC-1 2008 45/187 41/184 29.4 % 1.08 [ 0.75, 1.57 ]
EPIC-2 2008 65/189 62/188 38.1 % 1.04 [ 0.79, 1.38 ]
Lorenz-Meyer 1996 0/70 2/63 0.8 % 0.18 [ 0.01, 3.69 ]
OPAL 2010 11/434 17/433 11.0 % 0.65 [ 0.31, 1.36 ]
ORIGIN 2012 32/6281 18/6255 16.6 % 1.77 [ 0.99, 3.15 ]
SCIMO 1999 4/112 3/111 3.2 % 1.32 [ 0.30, 5.77 ]
Subtotal (95% CI) 7341 7309 100.0 % 1.10 [ 0.84, 1.45 ]
Total events: 160 (Higher omega 3), 143 (Lower omega 3)
Heterogeneity: Tau2 = 0.03; Chi2 = 7.86, df = 6 (P = 0.25); I2 =24%
Test for overall effect: Z = 0.70 (P = 0.48)
3 Diarrhoea
ADCS 2010 18/238 10/167 8.4 % 1.26 [ 0.60, 2.67 ]
EPE-A 2014 17/168 13/75 10.5 % 0.58 [ 0.30, 1.14 ]
EPIC-1 2008 35/187 21/184 18.8 % 1.64 [ 0.99, 2.71 ]
EPIC-2 2008 44/189 37/188 31.4 % 1.18 [ 0.80, 1.74 ]
FOSTAR 2016 8/101 5/101 4.0 % 1.60 [ 0.54, 4.72 ]
Lorenz-Meyer 1996 1/70 1/63 0.6 % 0.90 [ 0.06, 14.09 ]
ORL 2013 9/171 8/165 5.5 % 1.09 [ 0.43, 2.75 ]
Puri 2005 17/67 14/68 12.2 % 1.23 [ 0.66, 2.29 ]
Raitt 2005 11/100 12/100 8.0 % 0.92 [ 0.42, 1.98 ]
Shinto 2014 0/13 3/13 0.6 % 0.14 [ 0.01, 2.52 ]
Subtotal (95% CI) 1304 1124 100.0 % 1.15 [ 0.92, 1.43 ]
Total events: 160 (Higher omega 3), 124 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 8.77, df = 9 (P = 0.46); I2 =0.0%
Test for overall effect: Z = 1.25 (P = 0.21)
4 Nausea
EPE-A 2014 24/168 7/75 18.6 % 1.53 [ 0.69, 3.40 ]
EPIC-1 2008 17/188 4/186 10.3 % 4.20 [ 1.44, 12.26 ]
EPIC-2 2008 30/189 19/190 40.7 % 1.59 [ 0.93, 2.72 ]
FOSTAR 2016 19/101 13/101 28.0 % 1.46 [ 0.76, 2.80 ]
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Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Rossing 1996 3/18 1/18 2.5 % 3.00 [ 0.34, 26.19 ]
Subtotal (95% CI) 664 570 100.0 % 1.73 [ 1.23, 2.44 ]
Total events: 93 (Higher omega 3), 44 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.39, df = 4 (P = 0.50); I2 =0.0%
Test for overall effect: Z = 3.13 (P = 0.0017)
5 Any gastrointestinal side effect - LCn3 fats
ADCS 2010 (1) 18/238 10/167 3.2 % 1.26 [ 0.60, 2.67 ]
AFFORD 2013 6/153 5/163 1.8 % 1.28 [ 0.40, 4.10 ]
AlphaOmega - EPA+DHA 2010 18/1192 10/1236 3.1 % 1.87 [ 0.87, 4.03 ]
AREDS2 2014 119/2147 145/2056 6.4 % 0.79 [ 0.62, 0.99 ]
EPE-A 2014 67/168 40/75 6.1 % 0.75 [ 0.56, 0.99 ]
EPIC-1 2008 (2) 45/187 41/184 5.5 % 1.08 [ 0.75, 1.57 ]
EPIC-2 2008 (3) 65/189 62/188 6.1 % 1.04 [ 0.79, 1.38 ]
FORWARD 2013 6/289 8/297 2.1 % 0.77 [ 0.27, 2.19 ]
FOSTAR 2016 67/101 62/101 6.6 % 1.08 [ 0.88, 1.33 ]
GISSI-HF 2008 96/3494 92/3481 6.1 % 1.04 [ 0.78, 1.38 ]
JELIS 2007 352/9326 155/9319 6.7 % 2.27 [ 1.88, 2.74 ]
Kumar 2012 4/91 0/87 0.4 % 8.61 [ 0.47, 157.57 ]
Kumar 2013 14/39 0/39 0.4 % 29.00 [ 1.79, 469.76 ]
Lorenz-Meyer 1996 (4) 10/70 2/63 1.2 % 4.50 [ 1.02, 19.76 ]
MAPT 2017 175/820 164/832 6.7 % 1.08 [ 0.90, 1.31 ]
OPAL 2010 0/434 4/433 0.4 % 0.11 [ 0.01, 2.05 ]
ORIGIN 2012 14/6281 24/6255 3.6 % 0.58 [ 0.30, 1.12 ]
ORL 2013 27/171 24/165 4.6 % 1.09 [ 0.65, 1.80 ]
Proudman 2015 1/86 1/53 0.4 % 0.62 [ 0.04, 9.65 ]
Puri 2005 (5) 17/67 14/68 3.8 % 1.23 [ 0.66, 2.29 ]
Raitt 2005 11/100 12/100 3.1 % 0.92 [ 0.42, 1.98 ]
Risk % Prevention 2013 200/6239 186/6266 6.6 % 1.08 [ 0.89, 1.31 ]
Rossing 1996 (6) 3/18 1/18 0.6 % 3.00 [ 0.34, 26.19 ]
Sandhu 2016 2/54 1/53 0.5 % 1.96 [ 0.18, 21.01 ]
SCIMO 1999 (7) 4/112 3/111 1.2 % 1.32 [ 0.30, 5.77 ]
Shinto 2014 (8) 0/13 3/13 0.4 % 0.14 [ 0.01, 2.52 ]
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Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
SHOT 1996 40/317 20/293 4.5 % 1.85 [ 1.11, 3.09 ]
SOFA 2006 17/273 12/273 3.3 % 1.42 [ 0.69, 2.91 ]
Tande 2016 18/64 28/63 4.7 % 0.63 [ 0.39, 1.02 ]
Subtotal (95% CI) 32733 32452 100.0 % 1.12 [ 0.94, 1.34 ]
Total events: 1416 (Higher omega 3), 1129 (Lower omega 3)
Heterogeneity: Tau2 = 0.12; Chi2 = 106.35, df = 28 (P<0.00001); I2 =74%
Test for overall effect: Z = 1.26 (P = 0.21)
6 Skin problems (itching, rashes)
AREDS2 2014 8/2147 7/2056 16.5 % 1.09 [ 0.40, 3.01 ]
EPE-A 2014 4/168 3/75 12.7 % 0.60 [ 0.14, 2.59 ]
JELIS 2007 160/9326 65/9319 21.9 % 2.46 [ 1.85, 3.28 ]
Lorenz-Meyer 1996 2/70 4/63 11.4 % 0.45 [ 0.09, 2.37 ]
Risk % Prevention 2013 8/6239 17/6266 18.0 % 0.47 [ 0.20, 1.09 ]
Sandhu 2016 0/54 3/53 5.5 % 0.14 [ 0.01, 2.65 ]
SCIMO 1999 1/112 0/111 4.9 % 2.97 [ 0.12, 72.21 ]
Tande 2016 7/64 1/63 9.0 % 6.89 [ 0.87, 54.40 ]
Subtotal (95% CI) 18180 18006 100.0 % 1.04 [ 0.47, 2.30 ]
Total events: 190 (Higher omega 3), 100 (Lower omega 3)
Heterogeneity: Tau2 = 0.73; Chi2 = 24.63, df = 7 (P = 0.00088); I2 =72%
Test for overall effect: Z = 0.09 (P = 0.93)
7 Headache or worsening migraine
EPE-A 2014 1/168 0/75 2.6 % 1.35 [ 0.06, 32.74 ]
EPIC-1 2008 12/187 10/184 40.5 % 1.18 [ 0.52, 2.67 ]
EPIC-2 2008 12/189 20/188 56.9 % 0.60 [ 0.30, 1.19 ]
Subtotal (95% CI) 544 447 100.0 % 0.80 [ 0.48, 1.35 ]
Total events: 25 (Higher omega 3), 30 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.68, df = 2 (P = 0.43); I2 =0.0%
Test for overall effect: Z = 0.83 (P = 0.41)
8 Reflux
FOSTAR 2016 17/101 12/101 100.0 % 1.42 [ 0.71, 2.81 ]
Subtotal (95% CI) 101 101 100.0 % 1.42 [ 0.71, 2.81 ]
Total events: 17 (Higher omega 3), 12 (Lower omega 3)
Heterogeneity: not applicable
Test for overall effect: Z = 1.00 (P = 0.32)
9 Pain (joint, lumbar, muscle pain)
JELIS 2007 144/9326 180/9319 100.0 % 0.80 [ 0.64, 0.99 ]
Subtotal (95% CI) 9326 9319 100.0 % 0.80 [ 0.64, 0.99 ]
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(. . . Continued)
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Total events: 144 (Higher omega 3), 180 (Lower omega 3)
Heterogeneity: not applicable
Test for overall effect: Z = 2.02 (P = 0.043)
10 All side effects combined
ADCS 2010 214/238 144/167 11.6 % 1.04 [ 0.97, 1.12 ]
AREDS2 2014 1024/2147 963/2056 12.1 % 1.02 [ 0.96, 1.09 ]
EPE-A 2014 139/168 71/75 11.0 % 0.87 [ 0.80, 0.95 ]
HARP 1995 3/41 0/39 0.1 % 6.67 [ 0.36, 125.02 ]
JELIS 2007 2334/9326 2004/9319 12.5 % 1.16 [ 1.10, 1.23 ]
Lorenz-Meyer 1996 17/70 15/63 1.1 % 1.02 [ 0.56, 1.87 ]
MAPT 2017 702/820 712/832 13.0 % 1.00 [ 0.96, 1.04 ]
NAT2 2013 125/134 115/129 11.6 % 1.05 [ 0.97, 1.13 ]
ORL 2013 216/336 109/167 8.6 % 0.98 [ 0.86, 1.13 ]
Proudman 2015 74/86 49/53 9.7 % 0.93 [ 0.83, 1.04 ]
Risk % Prevention 2013 240/6239 218/6266 6.8 % 1.11 [ 0.92, 1.32 ]
Sandhu 2016 16/54 16/53 1.2 % 0.98 [ 0.55, 1.75 ]
Shinto 2014 5/13 9/13 0.7 % 0.56 [ 0.26, 1.21 ]
Subtotal (95% CI) 19672 19232 100.0 % 1.01 [ 0.95, 1.08 ]
Total events: 5109 (Higher omega 3), 4425 (Lower omega 3)
Heterogeneity: Tau2 = 0.01; Chi2 = 62.03, df = 12 (P<0.00001); I2 =81%
Test for overall effect: Z = 0.36 (P = 0.72)
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Analysis 3.4. Comparison 3 High vs low LCn3 omega-3 fats (tertiary outcomes), Outcome 4 Dropouts -
LCn3.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 3 High vs low LCn3 omega-3 fats (tertiary outcomes)
Outcome: 4 Dropouts - LCn3
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
ADCS 2010 67/238 40/164 3.6 % 1.15 [ 0.82, 1.62 ]
AFFORD 2013 21/165 19/172 1.3 % 1.15 [ 0.64, 2.06 ]
AlphaOmega - EPA+DHA 2010 214/1192 191/1236 10.2 % 1.16 [ 0.97, 1.39 ]
Bates 1989 10/155 10/157 0.6 % 1.01 [ 0.43, 2.37 ]
Berson 2004 6/105 8/103 0.4 % 0.74 [ 0.26, 2.05 ]
Brox 2001 13/80 3/40 0.3 % 2.17 [ 0.65, 7.17 ]
DIPP 2015 3/104 5/101 0.2 % 0.58 [ 0.14, 2.37 ]
DISAF 2003 26/201 31/206 1.8 % 0.86 [ 0.53, 1.39 ]
EPE-A 2014 49/168 20/75 2.2 % 1.09 [ 0.70, 1.70 ]
EPIC-1 2008 80/188 91/186 7.3 % 0.87 [ 0.70, 1.09 ]
EPIC-2 2008 114/189 112/190 11.3 % 1.02 [ 0.87, 1.21 ]
FAAT 2005 73/200 69/202 5.5 % 1.07 [ 0.82, 1.39 ]
FORWARD 2013 20/289 25/297 1.4 % 0.82 [ 0.47, 1.45 ]
FOSTAR 2016 18/101 16/101 1.2 % 1.13 [ 0.61, 2.08 ]
HARP 1995 10/41 11/39 0.8 % 0.86 [ 0.41, 1.80 ]
JELIS 2007 1766/9326 1582/9319 27.8 % 1.12 [ 1.05, 1.19 ]
MARINA 2011 38/279 17/88 1.6 % 0.71 [ 0.42, 1.19 ]
Mita 2007 10/40 11/41 0.8 % 0.93 [ 0.45, 1.95 ]
NAT2 2013 29/150 34/150 2.2 % 0.85 [ 0.55, 1.33 ]
Nodari 2011 AF 6/100 5/99 0.3 % 1.19 [ 0.37, 3.77 ]
Norouzi 2014 1/55 5/55 0.1 % 0.20 [ 0.02, 1.66 ]
OPAL 2010 67/434 78/433 4.5 % 0.86 [ 0.64, 1.15 ]
ORL 2013 22/336 21/167 1.3 % 0.52 [ 0.29, 0.92 ]
Raitt 2005 17/100 26/100 1.5 % 0.65 [ 0.38, 1.13 ]
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(. . . Continued)
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Rossing 1996 4/18 3/18 0.2 % 1.33 [ 0.35, 5.13 ]
Sandhu 2016 5/54 6/53 0.4 % 0.82 [ 0.27, 2.52 ]
Shinto 2014 2/13 2/13 0.1 % 1.00 [ 0.16, 6.07 ]
SHOT 1996 41/317 25/293 1.9 % 1.52 [ 0.95, 2.43 ]
SMART 2013 20/41 18/43 1.9 % 1.17 [ 0.73, 1.87 ]
SU.FOL.OM3 2010 134/1253 145/1248 7.3 % 0.92 [ 0.74, 1.15 ]
Total (95% CI) 15932 15389 100.0 % 1.02 [ 0.95, 1.09 ]
Total events: 2886 (Higher omega 3), 2629 (Lower omega 3)
Heterogeneity: Tau2 = 0.00; Chi2 = 32.74, df = 29 (P = 0.29); I2 =11%
Test for overall effect: Z = 0.51 (P = 0.61)
Test for subgroup differences: Not applicable
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Analysis 4.1. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 1 All-cause
mortality (overall) - ALA.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 4 High vs low ALA omega-3 fat (primary outcomes)
Outcome: 1 All-cause mortality (overall) - ALA
Study or subgroup
Favours
higher
omega 3 Lower omega 3 fats Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
AlphaOmega - ALA 2010 182/2409 188/2428 81.7 % 0.98 [ 0.80, 1.19 ]
FLAX-PAD 2013 1/58 0/52 0.3 % 2.69 [ 0.11, 64.74 ]
MARGARIN 2002 (1) 3/109 1/157 0.6 % 4.32 [ 0.46, 41.00 ]
Norwegian 1968 43/6716 40/6690 17.0 % 1.07 [ 0.70, 1.64 ]
WAHA 2016 1/362 0/346 0.3 % 2.87 [ 0.12, 70.16 ]
Total (95% CI) 9654 9673 100.0 % 1.01 [ 0.84, 1.20 ]
Total events: 230 (Favours higher omega 3), 229 (Lower omega 3 fats)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.57, df = 4 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 0.08 (P = 0.94)
Test for subgroup differences: Not applicable
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Analysis 4.2. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 2 All-cause
mortality - ALA - sensitivity analysis (SA) fixed-effect.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 4 High vs low ALA omega-3 fat (primary outcomes)
Outcome: 2 All-cause mortality - ALA - sensitivity analysis (SA) fixed-effect
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
AlphaOmega - ALA 2010 91/1197 93/1236 68.6 % 1.01 [ 0.77, 1.33 ]
FLAX-PAD 2013 1/58 0/52 0.4 % 2.69 [ 0.11, 64.74 ]
MARGARIN 2002 (1) 3/109 1/157 0.6 % 4.32 [ 0.46, 41.00 ]
Norwegian 1968 43/6716 40/6690 30.0 % 1.07 [ 0.70, 1.64 ]
WAHA 2016 1/362 0/346 0.4 % 2.87 [ 0.12, 70.16 ]
Total (95% CI) 8442 8481 100.0 % 1.06 [ 0.84, 1.34 ]
Total events: 139 (Higher omega 3), 134 (Lower omega 3)
Heterogeneity: Chi2 = 2.32, df = 4 (P = 0.68); I2 =0.0%
Test for overall effect: Z = 0.52 (P = 0.60)
Test for subgroup differences: Not applicable
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Analysis 4.3. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 3 All-cause
mortality - ALA - SA by summary risk of bias.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 4 High vs low ALA omega-3 fat (primary outcomes)
Outcome: 3 All-cause mortality - ALA - SA by summary risk of bias
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Low risk of bias
AlphaOmega - ALA 2010 182/2409 188/2428 81.7 % 0.98 [ 0.80, 1.19 ]
FLAX-PAD 2013 1/58 0/52 0.3 % 2.69 [ 0.11, 64.74 ]
MARGARIN 2002 (1) 3/109 1/157 0.6 % 4.32 [ 0.46, 41.00 ]
Subtotal (95% CI) 2576 2637 82.7 % 1.02 [ 0.72, 1.45 ]
Total events: 186 (Higher omega 3), 189 (Lower omega 3)
Heterogeneity: Tau2 = 0.02; Chi2 = 2.05, df = 2 (P = 0.36); I2 =3%
Test for overall effect: Z = 0.13 (P = 0.90)
2 Moderate/high risk of bias
Norwegian 1968 43/6716 40/6690 17.0 % 1.07 [ 0.70, 1.64 ]
WAHA 2016 1/362 0/346 0.3 % 2.87 [ 0.12, 70.16 ]
Subtotal (95% CI) 7078 7036 17.3 % 1.09 [ 0.71, 1.67 ]
Total events: 44 (Higher omega 3), 40 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.36, df = 1 (P = 0.55); I2 =0.0%
Test for overall effect: Z = 0.40 (P = 0.69)
Total (95% CI) 9654 9673 100.0 % 1.01 [ 0.84, 1.20 ]
Total events: 230 (Higher omega 3), 229 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.57, df = 4 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 0.08 (P = 0.94)
Test for subgroup differences: Chi2 = 0.05, df = 1 (P = 0.82), I2 =0.0%
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Analysis 4.4. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 4 All-cause
mortality - ALA - SA by compliance and study size.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 4 High vs low ALA omega-3 fat (primary outcomes)
Outcome: 4 All-cause mortality - ALA - SA by compliance and study size
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 SA - low risk of compliance bias
AlphaOmega - ALA 2010 182/2409 188/2428 94.5 % 0.98 [ 0.80, 1.19 ]
MARGARIN 2002 (1) 3/109 1/157 3.7 % 4.32 [ 0.46, 41.00 ]
WAHA 2016 1/362 0/346 1.8 % 2.87 [ 0.12, 70.16 ]
Subtotal (95% CI) 2880 2931 100.0 % 1.05 [ 0.68, 1.63 ]
Total events: 186 (Higher omega 3), 189 (Lower omega 3)
Heterogeneity: Tau2 = 0.04; Chi2 = 2.10, df = 2 (P = 0.35); I2 =5%
Test for overall effect: Z = 0.22 (P = 0.82)
2 SA - 100+ randomised
AlphaOmega - ALA 2010 182/2409 188/2428 81.7 % 0.98 [ 0.80, 1.19 ]
FLAX-PAD 2013 1/58 0/52 0.3 % 2.69 [ 0.11, 64.74 ]
MARGARIN 2002 (2) 3/109 1/157 0.6 % 4.32 [ 0.46, 41.00 ]
Norwegian 1968 43/6716 40/6690 17.0 % 1.07 [ 0.70, 1.64 ]
WAHA 2016 1/362 0/346 0.3 % 2.87 [ 0.12, 70.16 ]
Subtotal (95% CI) 9654 9673 100.0 % 1.01 [ 0.84, 1.20 ]
Total events: 230 (Higher omega 3), 229 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.57, df = 4 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 0.08 (P = 0.94)
Test for subgroup differences: Chi2 = 0.03, df = 1 (P = 0.86), I2 =0.0%
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576Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 4.5. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 5 All-cause
mortality - ALA - subgroup by dose.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 4 High vs low ALA omega-3 fat (primary outcomes)
Outcome: 5 All-cause mortality - ALA - subgroup by dose
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 ALA low < 5 g/d
AlphaOmega - ALA 2010 182/2409 188/2428 81.7 % 0.98 [ 0.80, 1.19 ]
Subtotal (95% CI) 2409 2428 81.7 % 0.98 [ 0.80, 1.19 ]
Total events: 182 (Higher omega 3), 188 (Lower omega 3)
Heterogeneity: not applicable
Test for overall effect: Z = 0.25 (P = 0.81)
2 ALA high≥ 5 g/d
FLAX-PAD 2013 1/58 0/52 0.3 % 2.69 [ 0.11, 64.74 ]
MARGARIN 2002 (1) 3/109 1/157 0.6 % 4.32 [ 0.46, 41.00 ]
Norwegian 1968 43/6716 40/6690 17.0 % 1.07 [ 0.70, 1.64 ]
WAHA 2016 1/362 0/346 0.3 % 2.87 [ 0.12, 70.16 ]
Subtotal (95% CI) 7245 7245 18.3 % 1.16 [ 0.77, 1.75 ]
Total events: 48 (Higher omega 3), 41 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.03, df = 3 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 0.70 (P = 0.48)
Total (95% CI) 9654 9673 100.0 % 1.01 [ 0.84, 1.20 ]
Total events: 230 (Higher omega 3), 229 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.57, df = 4 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 0.08 (P = 0.94)
Test for subgroup differences: Chi2 = 0.54, df = 1 (P = 0.46), I2 =0.0%
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Analysis 4.6. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 6 All-cause
mortality - ALA - subgroup by replacement.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 4 High vs low ALA omega-3 fat (primary outcomes)
Outcome: 6 All-cause mortality - ALA - subgroup by replacement
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 ALA replacing SFA
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 3), 0 (Lower omega 3)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 ALA replacing MUFA
AlphaOmega - ALA 2010 182/2409 188/2428 100.0 % 0.98 [ 0.80, 1.19 ]
Subtotal (95% CI) 2409 2428 100.0 % 0.98 [ 0.80, 1.19 ]
Total events: 182 (Higher omega 3), 188 (Lower omega 3)
Heterogeneity: not applicable
Test for overall effect: Z = 0.25 (P = 0.81)
3 ALA replacing n-6
MARGARIN 2002 (1) 3/109 1/157 17.4 % 4.32 [ 0.46, 41.00 ]
Norwegian 1968 43/6716 40/6690 82.6 % 1.07 [ 0.70, 1.64 ]
Subtotal (95% CI) 6825 6847 100.0 % 1.37 [ 0.48, 3.86 ]
Total events: 46 (Higher omega 3), 41 (Lower omega 3)
Heterogeneity: Tau2 = 0.29; Chi2 = 1.43, df = 1 (P = 0.23); I2 =30%
Test for overall effect: Z = 0.59 (P = 0.56)
4 ALA replacing CHO
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 3), 0 (Lower omega 3)
Heterogeneity: not applicable
Test for overall effect: not applicable
5 ALA replacing nil/low n-3 placebo
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 3), 0 (Lower omega 3)
Heterogeneity: not applicable
Test for overall effect: not applicable
6 ALA replacement unclear
FLAX-PAD 2013 1/58 0/52 50.3 % 2.69 [ 0.11, 64.74 ]
WAHA 2016 1/362 0/346 49.7 % 2.87 [ 0.12, 70.16 ]
Subtotal (95% CI) 420 398 100.0 % 2.78 [ 0.29, 26.49 ]
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(. . . Continued)
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Total events: 2 (Higher omega 3), 0 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 0.89 (P = 0.37)
Test for subgroup differences: Chi2 = 1.19, df = 2 (P = 0.55), I2 =0.0%
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(1) MARGARIN study - comparing ALA EPA+DHA with no ALA EPA+DHA
Analysis 4.7. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 7 All cause
mortality - ALA - subgroup by intervention type.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 4 High vs low ALA omega-3 fat (primary outcomes)
Outcome: 7 All cause mortality - ALA - subgroup by intervention type
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Dietary advice
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 3), 0 (Lower omega 3)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Supplemental foods
AlphaOmega - ALA 2010 182/2409 188/2428 81.7 % 0.98 [ 0.80, 1.19 ]
FLAX-PAD 2013 1/58 0/52 0.3 % 2.69 [ 0.11, 64.74 ]
MARGARIN 2002 (1) 3/109 1/157 0.6 % 4.32 [ 0.46, 41.00 ]
WAHA 2016 1/362 0/346 0.3 % 2.87 [ 0.12, 70.16 ]
Subtotal (95% CI) 2938 2983 83.0 % 0.99 [ 0.82, 1.21 ]
Total events: 187 (Higher omega 3), 189 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.48, df = 3 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 0.06 (P = 0.95)
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(. . . Continued)
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
3 Supplements (capsule)
Norwegian 1968 43/6716 40/6690 17.0 % 1.07 [ 0.70, 1.64 ]
Subtotal (95% CI) 6716 6690 17.0 % 1.07 [ 0.70, 1.64 ]
Total events: 43 (Higher omega 3), 40 (Lower omega 3)
Heterogeneity: not applicable
Test for overall effect: Z = 0.31 (P = 0.75)
4 Any combination
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 3), 0 (Lower omega 3)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 9654 9673 100.0 % 1.01 [ 0.84, 1.20 ]
Total events: 230 (Higher omega 3), 229 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.57, df = 4 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 0.08 (P = 0.94)
Test for subgroup differences: Chi2 = 0.10, df = 1 (P = 0.76), I2 =0.0%
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Analysis 4.8. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 8 All-cause
mortality - ALA - subgroup by duration.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 4 High vs low ALA omega-3 fat (primary outcomes)
Outcome: 8 All-cause mortality - ALA - subgroup by duration
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Medium duration 1 to < 2 years in study
FLAX-PAD 2013 1/58 0/52 0.3 % 2.69 [ 0.11, 64.74 ]
Norwegian 1968 43/6716 40/6690 17.0 % 1.07 [ 0.70, 1.64 ]
Subtotal (95% CI) 6774 6742 17.3 % 1.09 [ 0.71, 1.67 ]
Total events: 44 (Higher omega 3), 40 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.32, df = 1 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 0.39 (P = 0.70)
2 Medium-long duration: 2 to < 4 years in study
AlphaOmega - ALA 2010 182/2409 188/2428 81.7 % 0.98 [ 0.80, 1.19 ]
MARGARIN 2002 (1) 3/109 1/157 0.6 % 4.32 [ 0.46, 41.00 ]
WAHA 2016 1/362 0/346 0.3 % 2.87 [ 0.12, 70.16 ]
Subtotal (95% CI) 2880 2931 82.7 % 1.05 [ 0.68, 1.63 ]
Total events: 186 (Higher omega 3), 189 (Lower omega 3)
Heterogeneity: Tau2 = 0.04; Chi2 = 2.10, df = 2 (P = 0.35); I2 =5%
Test for overall effect: Z = 0.22 (P = 0.82)
3 Long duration:≥ 4 years in study
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 3), 0 (Lower omega 3)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 9654 9673 100.0 % 1.01 [ 0.84, 1.20 ]
Total events: 230 (Higher omega 3), 229 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.57, df = 4 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 0.08 (P = 0.94)
Test for subgroup differences: Chi2 = 0.01, df = 1 (P = 0.91), I2 =0.0%
0.01 0.1 1 10 100
Favours [high ALA] Favours low ALA
(1) MARGARIN study - comparing ALA EPA+DHA with no ALA EPA+DHA
581Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 4.9. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 9 All-cause
mortality - ALA - subgroup by primary or secondary prevention.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 4 High vs low ALA omega-3 fat (primary outcomes)
Outcome: 9 All-cause mortality - ALA - subgroup by primary or secondary prevention
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Primary CVD prevention
MARGARIN 2002 (1) 3/109 1/157 0.6 % 4.32 [ 0.46, 41.00 ]
Norwegian 1968 43/6716 40/6690 17.0 % 1.07 [ 0.70, 1.64 ]
WAHA 2016 1/362 0/346 0.3 % 2.87 [ 0.12, 70.16 ]
Subtotal (95% CI) 7187 7193 17.9 % 1.14 [ 0.75, 1.74 ]
Total events: 47 (Higher omega 3), 41 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.75, df = 2 (P = 0.42); I2 =0.0%
Test for overall effect: Z = 0.63 (P = 0.53)
2 Secondary CVD prevention
AlphaOmega - ALA 2010 182/2409 188/2428 81.7 % 0.98 [ 0.80, 1.19 ]
FLAX-PAD 2013 1/58 0/52 0.3 % 2.69 [ 0.11, 64.74 ]
Subtotal (95% CI) 2467 2480 82.1 % 0.98 [ 0.81, 1.19 ]
Total events: 183 (Higher omega 3), 188 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.39, df = 1 (P = 0.53); I2 =0.0%
Test for overall effect: Z = 0.21 (P = 0.84)
Total (95% CI) 9654 9673 100.0 % 1.01 [ 0.84, 1.20 ]
Total events: 230 (Higher omega 3), 229 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.57, df = 4 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 0.08 (P = 0.94)
Test for subgroup differences: Chi2 = 0.43, df = 1 (P = 0.51), I2 =0.0%
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Analysis 4.10. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 10 All-cause
mortality - ALA - subgroup by statin use.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 4 High vs low ALA omega-3 fat (primary outcomes)
Outcome: 10 All-cause mortality - ALA - subgroup by statin use
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 ALA -≥ 50% of control group on statins
AlphaOmega - ALA 2010 91/1197 93/1236 69.0 % 1.01 [ 0.77, 1.33 ]
FLAX-PAD 2013 1/58 0/52 0.5 % 2.69 [ 0.11, 64.74 ]
Subtotal (95% CI) 1255 1288 69.5 % 1.02 [ 0.77, 1.34 ]
Total events: 92 (Higher omega 3), 93 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.36, df = 1 (P = 0.55); I2 =0.0%
Test for overall effect: Z = 0.13 (P = 0.90)
2 ALA - < 50% of control group on statins
MARGARIN 2002 (1) 3/109 1/157 1.1 % 4.32 [ 0.46, 41.00 ]
Norwegian 1968 43/6716 40/6690 28.9 % 1.07 [ 0.70, 1.64 ]
WAHA 2016 1/362 0/346 0.5 % 2.87 [ 0.12, 70.16 ]
Subtotal (95% CI) 7187 7193 30.5 % 1.14 [ 0.75, 1.74 ]
Total events: 47 (Higher omega 3), 41 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.75, df = 2 (P = 0.42); I2 =0.0%
Test for overall effect: Z = 0.63 (P = 0.53)
Total (95% CI) 8442 8481 100.0 % 1.05 [ 0.84, 1.33 ]
Total events: 139 (Higher omega 3), 134 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.32, df = 4 (P = 0.68); I2 =0.0%
Test for overall effect: Z = 0.45 (P = 0.65)
Test for subgroup differences: Chi2 = 0.20, df = 1 (P = 0.65), I2 =0.0%
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Analysis 4.11. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 11
Cardiovascular mortality (overall) - ALA.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 4 High vs low ALA omega-3 fat (primary outcomes)
Outcome: 11 Cardiovascular mortality (overall) - ALA
Study or subgroup
Favours
higher
omega 3 Lower omega 3 fats Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
AlphaOmega - ALA 2010 78/2409 84/2428 74.3 % 0.94 [ 0.69, 1.27 ]
FLAX-PAD 2013 1/58 0/52 0.7 % 2.69 [ 0.11, 64.74 ]
MARGARIN 2002 1/109 1/157 0.9 % 1.44 [ 0.09, 22.78 ]
Norwegian 1968 27/6716 27/6690 24.1 % 1.00 [ 0.58, 1.70 ]
Total (95% CI) 9292 9327 100.0 % 0.96 [ 0.74, 1.25 ]
Total events: 107 (Favours higher omega 3), 112 (Lower omega 3 fats)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.53, df = 3 (P = 0.91); I2 =0.0%
Test for overall effect: Z = 0.30 (P = 0.76)
Test for subgroup differences: Not applicable
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Analysis 4.12. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 12 CVD
mortality - ALA - SA fixed-effect.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 4 High vs low ALA omega-3 fat (primary outcomes)
Outcome: 12 CVD mortality - ALA - SA fixed-effect
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
AlphaOmega - ALA 2010 78/2409 84/2428 74.7 % 0.94 [ 0.69, 1.27 ]
FLAX-PAD 2013 1/58 0/52 0.5 % 2.69 [ 0.11, 64.74 ]
MARGARIN 2002 1/109 1/157 0.7 % 1.44 [ 0.09, 22.78 ]
Norwegian 1968 27/6716 27/6690 24.1 % 1.00 [ 0.58, 1.70 ]
Total (95% CI) 9292 9327 100.0 % 0.96 [ 0.74, 1.25 ]
Total events: 107 (Higher omega 3), 112 (Lower omega 3)
Heterogeneity: Chi2 = 0.53, df = 3 (P = 0.91); I2 =0.0%
Test for overall effect: Z = 0.29 (P = 0.77)
Test for subgroup differences: Not applicable
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Analysis 4.13. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 13 CVD
mortality - ALA - SA by summary risk of bias.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 4 High vs low ALA omega-3 fat (primary outcomes)
Outcome: 13 CVD mortality - ALA - SA by summary risk of bias
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Low risk of bias
AlphaOmega - ALA 2010 78/2409 84/2428 74.3 % 0.94 [ 0.69, 1.27 ]
FLAX-PAD 2013 1/58 0/52 0.7 % 2.69 [ 0.11, 64.74 ]
MARGARIN 2002 1/109 1/157 0.9 % 1.44 [ 0.09, 22.78 ]
Subtotal (95% CI) 2576 2637 75.9 % 0.95 [ 0.70, 1.28 ]
Total events: 80 (Higher omega 3), 85 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.51, df = 2 (P = 0.77); I2 =0.0%
Test for overall effect: Z = 0.34 (P = 0.74)
2 Moderate/high risk of bias
Norwegian 1968 27/6716 27/6690 24.1 % 1.00 [ 0.58, 1.70 ]
Subtotal (95% CI) 6716 6690 24.1 % 1.00 [ 0.58, 1.70 ]
Total events: 27 (Higher omega 3), 27 (Lower omega 3)
Heterogeneity: not applicable
Test for overall effect: Z = 0.01 (P = 0.99)
Total (95% CI) 9292 9327 100.0 % 0.96 [ 0.74, 1.25 ]
Total events: 107 (Higher omega 3), 112 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.53, df = 3 (P = 0.91); I2 =0.0%
Test for overall effect: Z = 0.30 (P = 0.76)
Test for subgroup differences: Chi2 = 0.02, df = 1 (P = 0.88), I2 =0.0%
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Analysis 4.14. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 14 CVD
mortality - ALA - SA by compliance and study size.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 4 High vs low ALA omega-3 fat (primary outcomes)
Outcome: 14 CVD mortality - ALA - SA by compliance and study size
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 SA - low risk of compliance bias
AlphaOmega - ALA 2010 78/2409 84/2428 42.4 % 0.94 [ 0.69, 1.27 ]
MARGARIN 2002 1/109 1/157 0.5 % 1.44 [ 0.09, 22.78 ]
Subtotal (95% CI) 2518 2585 42.9 % 0.94 [ 0.70, 1.27 ]
Total events: 79 (Higher omega 3), 85 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.09, df = 1 (P = 0.76); I2 =0.0%
Test for overall effect: Z = 0.40 (P = 0.69)
2 SA - 100+ randomised
AlphaOmega - ALA 2010 78/2409 84/2428 42.4 % 0.94 [ 0.69, 1.27 ]
FLAX-PAD 2013 1/58 0/52 0.4 % 2.69 [ 0.11, 64.74 ]
MARGARIN 2002 1/109 1/157 0.5 % 1.44 [ 0.09, 22.78 ]
Norwegian 1968 27/6716 27/6690 13.7 % 1.00 [ 0.58, 1.70 ]
Subtotal (95% CI) 9292 9327 57.1 % 0.96 [ 0.74, 1.25 ]
Total events: 107 (Higher omega 3), 112 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.53, df = 3 (P = 0.91); I2 =0.0%
Test for overall effect: Z = 0.30 (P = 0.76)
Total (95% CI) 11810 11912 100.0 % 0.95 [ 0.78, 1.16 ]
Total events: 186 (Higher omega 3), 197 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.64, df = 5 (P = 0.99); I2 =0.0%
Test for overall effect: Z = 0.49 (P = 0.63)
Test for subgroup differences: Chi2 = 0.01, df = 1 (P = 0.92), I2 =0.0%
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Analysis 4.15. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 15 CVD
mortality - ALA - subgroup by dose.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 4 High vs low ALA omega-3 fat (primary outcomes)
Outcome: 15 CVD mortality - ALA - subgroup by dose
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 ALA low < 5 g/d
AlphaOmega - ALA 2010 78/2409 84/2428 74.3 % 0.94 [ 0.69, 1.27 ]
Subtotal (95% CI) 2409 2428 74.3 % 0.94 [ 0.69, 1.27 ]
Total events: 78 (Higher omega 3), 84 (Lower omega 3)
Heterogeneity: not applicable
Test for overall effect: Z = 0.43 (P = 0.67)
2 ALA high≥ 5 g/d
FLAX-PAD 2013 1/58 0/52 0.7 % 2.69 [ 0.11, 64.74 ]
MARGARIN 2002 1/109 1/157 0.9 % 1.44 [ 0.09, 22.78 ]
Norwegian 1968 27/6716 27/6690 24.1 % 1.00 [ 0.58, 1.70 ]
Subtotal (95% CI) 6883 6899 25.7 % 1.04 [ 0.62, 1.73 ]
Total events: 29 (Higher omega 3), 28 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.42, df = 2 (P = 0.81); I2 =0.0%
Test for overall effect: Z = 0.13 (P = 0.89)
Total (95% CI) 9292 9327 100.0 % 0.96 [ 0.74, 1.25 ]
Total events: 107 (Higher omega 3), 112 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.53, df = 3 (P = 0.91); I2 =0.0%
Test for overall effect: Z = 0.30 (P = 0.76)
Test for subgroup differences: Chi2 = 0.11, df = 1 (P = 0.74), I2 =0.0%
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Analysis 4.16. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 16 CVD
mortality - ALA - subgroup by replacement.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 4 High vs low ALA omega-3 fat (primary outcomes)
Outcome: 16 CVD mortality - ALA - subgroup by replacement
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 N-3 replacing SFA
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 3), 0 (Lower omega 3)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 N-3 replacing MUFA
AlphaOmega - ALA 2010 78/2409 84/2428 100.0 % 0.94 [ 0.69, 1.27 ]
Subtotal (95% CI) 2409 2428 100.0 % 0.94 [ 0.69, 1.27 ]
Total events: 78 (Higher omega 3), 84 (Lower omega 3)
Heterogeneity: not applicable
Test for overall effect: Z = 0.43 (P = 0.67)
3 N-3 replacing n-6
MARGARIN 2002 1/109 1/157 3.6 % 1.44 [ 0.09, 22.78 ]
Norwegian 1968 27/6716 27/6690 96.4 % 1.00 [ 0.58, 1.70 ]
Subtotal (95% CI) 6825 6847 100.0 % 1.01 [ 0.60, 1.70 ]
Total events: 28 (Higher omega 3), 28 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.07, df = 1 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 0.04 (P = 0.97)
4 N-3 replacing carbohydrates/sugars
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 3), 0 (Lower omega 3)
Heterogeneity: not applicable
Test for overall effect: not applicable
5 N-3 replacing nil/low n-3 placebo
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 3), 0 (Lower omega 3)
Heterogeneity: not applicable
Test for overall effect: not applicable
6 Replacement unclear
FLAX-PAD 2013 1/58 0/52 100.0 % 2.69 [ 0.11, 64.74 ]
Subtotal (95% CI) 58 52 100.0 % 2.69 [ 0.11, 64.74 ]
Total events: 1 (Higher omega 3), 0 (Lower omega 3)
Heterogeneity: not applicable
Test for overall effect: Z = 0.61 (P = 0.54)
Test for subgroup differences: Chi2 = 0.47, df = 2 (P = 0.79), I2 =0.0%
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Analysis 4.17. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 17 CVD
mortality - ALA - subgroup by intervention type.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 4 High vs low ALA omega-3 fat (primary outcomes)
Outcome: 17 CVD mortality - ALA - subgroup by intervention type
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Dietary advice
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 3), 0 (Lower omega 3)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Supplemental foods
AlphaOmega - ALA 2010 78/2409 84/2428 74.3 % 0.94 [ 0.69, 1.27 ]
FLAX-PAD 2013 1/58 0/52 0.7 % 2.69 [ 0.11, 64.74 ]
MARGARIN 2002 1/109 1/157 0.9 % 1.44 [ 0.09, 22.78 ]
Subtotal (95% CI) 2576 2637 75.9 % 0.95 [ 0.70, 1.28 ]
Total events: 80 (Higher omega 3), 85 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.51, df = 2 (P = 0.77); I2 =0.0%
Test for overall effect: Z = 0.34 (P = 0.74)
3 Supplements (capsule)
Norwegian 1968 27/6716 27/6690 24.1 % 1.00 [ 0.58, 1.70 ]
Subtotal (95% CI) 6716 6690 24.1 % 1.00 [ 0.58, 1.70 ]
Total events: 27 (Higher omega 3), 27 (Lower omega 3)
Heterogeneity: not applicable
Test for overall effect: Z = 0.01 (P = 0.99)
4 Any combination
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 3), 0 (Lower omega 3)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 9292 9327 100.0 % 0.96 [ 0.74, 1.25 ]
Total events: 107 (Higher omega 3), 112 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.53, df = 3 (P = 0.91); I2 =0.0%
Test for overall effect: Z = 0.30 (P = 0.76)
Test for subgroup differences: Chi2 = 0.02, df = 1 (P = 0.88), I2 =0.0%
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Analysis 4.18. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 18 CVD
mortality - ALA - subgroup by duration.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 4 High vs low ALA omega-3 fat (primary outcomes)
Outcome: 18 CVD mortality - ALA - subgroup by duration
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Medium duration 1 to < 2 years in study
FLAX-PAD 2013 1/58 0/52 0.7 % 2.69 [ 0.11, 64.74 ]
Norwegian 1968 27/6716 27/6690 24.1 % 1.00 [ 0.58, 1.70 ]
Subtotal (95% CI) 6774 6742 24.8 % 1.02 [ 0.61, 1.73 ]
Total events: 28 (Higher omega 3), 27 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.37, df = 1 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 0.09 (P = 0.93)
2 Medium-long duration: 2 to < 4 years in study
AlphaOmega - ALA 2010 78/2409 84/2428 74.3 % 0.94 [ 0.69, 1.27 ]
MARGARIN 2002 1/109 1/157 0.9 % 1.44 [ 0.09, 22.78 ]
Subtotal (95% CI) 2518 2585 75.2 % 0.94 [ 0.70, 1.27 ]
Total events: 79 (Higher omega 3), 85 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.09, df = 1 (P = 0.76); I2 =0.0%
Test for overall effect: Z = 0.40 (P = 0.69)
3 Long duration:≥ 4 years in study
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 3), 0 (Lower omega 3)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 9292 9327 100.0 % 0.96 [ 0.74, 1.25 ]
Total events: 107 (Higher omega 3), 112 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.53, df = 3 (P = 0.91); I2 =0.0%
Test for overall effect: Z = 0.30 (P = 0.76)
Test for subgroup differences: Chi2 = 0.07, df = 1 (P = 0.78), I2 =0.0%
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Analysis 4.19. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 19 CVD
mortality - ALA - subgroup by primary or secondary prevention.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 4 High vs low ALA omega-3 fat (primary outcomes)
Outcome: 19 CVD mortality - ALA - subgroup by primary or secondary prevention
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Primary prevention
Norwegian 1968 27/6716 27/6690 24.1 % 1.00 [ 0.58, 1.70 ]
Subtotal (95% CI) 6716 6690 24.1 % 1.00 [ 0.58, 1.70 ]
Total events: 27 (Higher omega 3), 27 (Lower omega 3)
Heterogeneity: not applicable
Test for overall effect: Z = 0.01 (P = 0.99)
2 Secondary prevention
AlphaOmega - ALA 2010 78/2409 84/2428 74.3 % 0.94 [ 0.69, 1.27 ]
FLAX-PAD 2013 1/58 0/52 0.7 % 2.69 [ 0.11, 64.74 ]
MARGARIN 2002 1/109 1/157 0.9 % 1.44 [ 0.09, 22.78 ]
Subtotal (95% CI) 2576 2637 75.9 % 0.95 [ 0.70, 1.28 ]
Total events: 80 (Higher omega 3), 85 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.51, df = 2 (P = 0.77); I2 =0.0%
Test for overall effect: Z = 0.34 (P = 0.74)
Total (95% CI) 9292 9327 100.0 % 0.96 [ 0.74, 1.25 ]
Total events: 107 (Higher omega 3), 112 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.53, df = 3 (P = 0.91); I2 =0.0%
Test for overall effect: Z = 0.30 (P = 0.76)
Test for subgroup differences: Chi2 = 0.02, df = 1 (P = 0.88), I2 =0.0%
0.01 0.1 1 10 100
Favours [high ALA] Favours low ALA
592Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 4.20. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 20 CVD
mortality - ALA - subgroup by statin uses.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 4 High vs low ALA omega-3 fat (primary outcomes)
Outcome: 20 CVD mortality - ALA - subgroup by statin uses
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 ALA -≥ 50% of control group on statins
AlphaOmega - ALA 2010 78/2409 84/2428 74.3 % 0.94 [ 0.69, 1.27 ]
FLAX-PAD 2013 1/58 0/52 0.7 % 2.69 [ 0.11, 64.74 ]
Subtotal (95% CI) 2467 2480 75.0 % 0.94 [ 0.70, 1.28 ]
Total events: 79 (Higher omega 3), 84 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.42, df = 1 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 0.37 (P = 0.71)
2 ALA - < 50% of control group on statins
MARGARIN 2002 1/109 1/157 0.9 % 1.44 [ 0.09, 22.78 ]
Norwegian 1968 27/6716 27/6690 24.1 % 1.00 [ 0.58, 1.70 ]
Subtotal (95% CI) 6825 6847 25.0 % 1.01 [ 0.60, 1.70 ]
Total events: 28 (Higher omega 3), 28 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.07, df = 1 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 0.04 (P = 0.97)
Total (95% CI) 9292 9327 100.0 % 0.96 [ 0.74, 1.25 ]
Total events: 107 (Higher omega 3), 112 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.53, df = 3 (P = 0.91); I2 =0.0%
Test for overall effect: Z = 0.30 (P = 0.76)
Test for subgroup differences: Chi2 = 0.05, df = 1 (P = 0.83), I2 =0.0%
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Analysis 4.21. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 21
Cardiovascular events (overall) - ALA.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 4 High vs low ALA omega-3 fat (primary outcomes)
Outcome: 21 Cardiovascular events (overall) - ALA
Study or subgroup
Favours
higher
omega 3 Lower omega 3 fats Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
AlphaOmega - ALA 2010 319/2409 352/2428 78.6 % 0.91 [ 0.79, 1.05 ]
FLAX-PAD 2013 5/58 4/52 1.0 % 1.12 [ 0.32, 3.95 ]
MARGARIN 2002 (1) 2/109 9/157 0.7 % 0.32 [ 0.07, 1.45 ]
Norwegian 1968 99/6716 87/6690 19.0 % 1.13 [ 0.85, 1.51 ]
WAHA 2016 3/362 4/346 0.7 % 0.72 [ 0.16, 3.18 ]
Total (95% CI) 9654 9673 100.0 % 0.95 [ 0.83, 1.07 ]
Total events: 428 (Favours higher omega 3), 456 (Lower omega 3 fats)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.95, df = 4 (P = 0.41); I2 =0.0%
Test for overall effect: Z = 0.89 (P = 0.38)
Test for subgroup differences: Not applicable
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Analysis 4.22. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 22 CVD events -
ALA - SA fixed-effect.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 4 High vs low ALA omega-3 fat (primary outcomes)
Outcome: 22 CVD events - ALA - SA fixed-effect
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
AlphaOmega - ALA 2010 319/2409 352/2428 77.3 % 0.91 [ 0.79, 1.05 ]
FLAX-PAD 2013 5/58 4/52 0.9 % 1.12 [ 0.32, 3.95 ]
MARGARIN 2002 (1) 2/109 9/157 1.6 % 0.32 [ 0.07, 1.45 ]
Norwegian 1968 99/6716 87/6690 19.2 % 1.13 [ 0.85, 1.51 ]
WAHA 2016 3/362 4/346 0.9 % 0.72 [ 0.16, 3.18 ]
Total (95% CI) 9654 9673 100.0 % 0.95 [ 0.84, 1.07 ]
Total events: 428 (Higher omega 3), 456 (Lower omega 3)
Heterogeneity: Chi2 = 3.95, df = 4 (P = 0.41); I2 =0.0%
Test for overall effect: Z = 0.87 (P = 0.38)
Test for subgroup differences: Not applicable
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Analysis 4.23. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 23 CVD events -
ALA - SA by summary risk of bias.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 4 High vs low ALA omega-3 fat (primary outcomes)
Outcome: 23 CVD events - ALA - SA by summary risk of bias
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Low risk of bias
AlphaOmega - ALA 2010 319/2409 352/2428 78.6 % 0.91 [ 0.79, 1.05 ]
FLAX-PAD 2013 5/58 4/52 1.0 % 1.12 [ 0.32, 3.95 ]
MARGARIN 2002 (1) 2/109 9/157 0.7 % 0.32 [ 0.07, 1.45 ]
Subtotal (95% CI) 2576 2637 80.3 % 0.91 [ 0.79, 1.04 ]
Total events: 326 (Higher omega 3), 365 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.94, df = 2 (P = 0.38); I2 =0.0%
Test for overall effect: Z = 1.37 (P = 0.17)
2 Moderate/high risk of bias
Norwegian 1968 99/6716 87/6690 19.0 % 1.13 [ 0.85, 1.51 ]
WAHA 2016 3/362 4/346 0.7 % 0.72 [ 0.16, 3.18 ]
Subtotal (95% CI) 7078 7036 19.7 % 1.12 [ 0.84, 1.48 ]
Total events: 102 (Higher omega 3), 91 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.35, df = 1 (P = 0.55); I2 =0.0%
Test for overall effect: Z = 0.76 (P = 0.45)
Total (95% CI) 9654 9673 100.0 % 0.95 [ 0.83, 1.07 ]
Total events: 428 (Higher omega 3), 456 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.95, df = 4 (P = 0.41); I2 =0.0%
Test for overall effect: Z = 0.89 (P = 0.38)
Test for subgroup differences: Chi2 = 1.66, df = 1 (P = 0.20), I2 =40%
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Analysis 4.24. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 24 CVD events -
ALA - SA by compliance and study size.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 4 High vs low ALA omega-3 fat (primary outcomes)
Outcome: 24 CVD events - ALA - SA by compliance and study size
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 SA - low risk of compliance bias
AlphaOmega - ALA 2010 319/2409 352/2428 98.3 % 0.91 [ 0.79, 1.05 ]
MARGARIN 2002 (1) 2/109 9/157 0.8 % 0.32 [ 0.07, 1.45 ]
WAHA 2016 3/362 4/346 0.9 % 0.72 [ 0.16, 3.18 ]
Subtotal (95% CI) 2880 2931 100.0 % 0.90 [ 0.79, 1.04 ]
Total events: 324 (Higher omega 3), 365 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.93, df = 2 (P = 0.38); I2 =0.0%
Test for overall effect: Z = 1.43 (P = 0.15)
2 SA - 100+ randomised
AlphaOmega - ALA 2010 319/2409 352/2428 78.6 % 0.91 [ 0.79, 1.05 ]
FLAX-PAD 2013 5/58 4/52 1.0 % 1.12 [ 0.32, 3.95 ]
MARGARIN 2002 (2) 2/109 9/157 0.7 % 0.32 [ 0.07, 1.45 ]
Norwegian 1968 99/6716 87/6690 19.0 % 1.13 [ 0.85, 1.51 ]
WAHA 2016 3/362 4/346 0.7 % 0.72 [ 0.16, 3.18 ]
Subtotal (95% CI) 9654 9673 100.0 % 0.95 [ 0.83, 1.07 ]
Total events: 428 (Higher omega 3), 456 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.95, df = 4 (P = 0.41); I2 =0.0%
Test for overall effect: Z = 0.89 (P = 0.38)
Test for subgroup differences: Chi2 = 0.22, df = 1 (P = 0.64), I2 =0.0%
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Analysis 4.25. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 25 CVD events -
ALA - subgroup by dose.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 4 High vs low ALA omega-3 fat (primary outcomes)
Outcome: 25 CVD events - ALA - subgroup by dose
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 ALA low < 5 g/d
AlphaOmega - ALA 2010 319/2409 352/2428 78.6 % 0.91 [ 0.79, 1.05 ]
Subtotal (95% CI) 2409 2428 78.6 % 0.91 [ 0.79, 1.05 ]
Total events: 319 (Higher omega 3), 352 (Lower omega 3)
Heterogeneity: not applicable
Test for overall effect: Z = 1.26 (P = 0.21)
2 ALA high≥ 5 g/d
FLAX-PAD 2013 5/58 4/52 1.0 % 1.12 [ 0.32, 3.95 ]
MARGARIN 2002 (1) 2/109 9/157 0.7 % 0.32 [ 0.07, 1.45 ]
Norwegian 1968 99/6716 87/6690 19.0 % 1.13 [ 0.85, 1.51 ]
WAHA 2016 3/362 4/346 0.7 % 0.72 [ 0.16, 3.18 ]
Subtotal (95% CI) 7245 7245 21.4 % 1.07 [ 0.82, 1.40 ]
Total events: 109 (Higher omega 3), 104 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.89, df = 3 (P = 0.41); I2 =0.0%
Test for overall effect: Z = 0.51 (P = 0.61)
Total (95% CI) 9654 9673 100.0 % 0.95 [ 0.83, 1.07 ]
Total events: 428 (Higher omega 3), 456 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.95, df = 4 (P = 0.41); I2 =0.0%
Test for overall effect: Z = 0.89 (P = 0.38)
Test for subgroup differences: Chi2 = 1.06, df = 1 (P = 0.30), I2 =6%
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Analysis 4.26. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 26 CVD events -
ALA - subgroup by replacement.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 4 High vs low ALA omega-3 fat (primary outcomes)
Outcome: 26 CVD events - ALA - subgroup by replacement
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 N-3 replacing SFA
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 3), 0 (Lower omega 3)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 N-3 replacing MUFA
AlphaOmega - ALA 2010 319/2409 352/2428 100.0 % 0.91 [ 0.79, 1.05 ]
Subtotal (95% CI) 2409 2428 100.0 % 0.91 [ 0.79, 1.05 ]
Total events: 319 (Higher omega 3), 352 (Lower omega 3)
Heterogeneity: not applicable
Test for overall effect: Z = 1.26 (P = 0.21)
3 N-3 replacing n-6
MARGARIN 2002 (1) 2/109 9/157 32.1 % 0.32 [ 0.07, 1.45 ]
Norwegian 1968 99/6716 87/6690 67.9 % 1.13 [ 0.85, 1.51 ]
Subtotal (95% CI) 6825 6847 100.0 % 0.76 [ 0.24, 2.41 ]
Total events: 101 (Higher omega 3), 96 (Lower omega 3)
Heterogeneity: Tau2 = 0.49; Chi2 = 2.60, df = 1 (P = 0.11); I2 =62%
Test for overall effect: Z = 0.47 (P = 0.64)
4 N-3 replacing carbohydrates/sugars
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 3), 0 (Lower omega 3)
Heterogeneity: not applicable
Test for overall effect: not applicable
5 N-3 replacing nil/low n-3 placebo
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 3), 0 (Lower omega 3)
Heterogeneity: not applicable
Test for overall effect: not applicable
6 Replacement unclear
FLAX-PAD 2013 5/58 4/52 58.3 % 1.12 [ 0.32, 3.95 ]
WAHA 2016 3/362 4/346 41.7 % 0.72 [ 0.16, 3.18 ]
Subtotal (95% CI) 420 398 100.0 % 0.93 [ 0.36, 2.43 ]
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(. . . Continued)
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Total events: 8 (Higher omega 3), 8 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.20, df = 1 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 0.15 (P = 0.88)
Test for subgroup differences: Chi2 = 0.10, df = 2 (P = 0.95), I2 =0.0%
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Analysis 4.27. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 27 CVD events -
ALA - subgroup by intervention type.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 4 High vs low ALA omega-3 fat (primary outcomes)
Outcome: 27 CVD events - ALA - subgroup by intervention type
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Dietary advice
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 3), 0 (Lower omega 3)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Supplemental foods
AlphaOmega - ALA 2010 319/2409 352/2428 78.6 % 0.91 [ 0.79, 1.05 ]
Dodin 2005 0/101 0/98 Not estimable
FLAX-PAD 2013 5/58 4/52 1.0 % 1.12 [ 0.32, 3.95 ]
MARGARIN 2002 (1) 2/109 9/157 0.7 % 0.32 [ 0.07, 1.45 ]
WAHA 2016 3/362 4/346 0.7 % 0.72 [ 0.16, 3.18 ]
Subtotal (95% CI) 3039 3081 81.0 % 0.91 [ 0.79, 1.04 ]
Total events: 329 (Higher omega 3), 369 (Lower omega 3)
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(. . . Continued)
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Heterogeneity: Tau2 = 0.0; Chi2 = 2.04, df = 3 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 1.40 (P = 0.16)
3 Supplements (capsule)
Norwegian 1968 99/6716 87/6690 19.0 % 1.13 [ 0.85, 1.51 ]
Subtotal (95% CI) 6716 6690 19.0 % 1.13 [ 0.85, 1.51 ]
Total events: 99 (Higher omega 3), 87 (Lower omega 3)
Heterogeneity: not applicable
Test for overall effect: Z = 0.86 (P = 0.39)
4 Any combination
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 3), 0 (Lower omega 3)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 9755 9771 100.0 % 0.95 [ 0.83, 1.07 ]
Total events: 428 (Higher omega 3), 456 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.95, df = 4 (P = 0.41); I2 =0.0%
Test for overall effect: Z = 0.89 (P = 0.38)
Test for subgroup differences: Chi2 = 1.91, df = 1 (P = 0.17), I2 =48%
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Analysis 4.28. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 28 CVD events -
ALA - subgroup by duration.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 4 High vs low ALA omega-3 fat (primary outcomes)
Outcome: 28 CVD events - ALA - subgroup by duration
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Medium duration 1 to < 2 years in study
FLAX-PAD 2013 5/58 4/52 1.0 % 1.12 [ 0.32, 3.95 ]
Norwegian 1968 99/6716 87/6690 19.0 % 1.13 [ 0.85, 1.51 ]
Subtotal (95% CI) 6774 6742 20.0 % 1.13 [ 0.86, 1.50 ]
Total events: 104 (Higher omega 3), 91 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 0.99); I2 =0.0%
Test for overall effect: Z = 0.88 (P = 0.38)
2 Medium-long duration: 2 to < 4 years in study
AlphaOmega - ALA 2010 319/2409 352/2428 78.6 % 0.91 [ 0.79, 1.05 ]
MARGARIN 2002 (1) 2/109 9/157 0.7 % 0.32 [ 0.07, 1.45 ]
WAHA 2016 3/362 4/346 0.7 % 0.72 [ 0.16, 3.18 ]
Subtotal (95% CI) 2880 2931 80.0 % 0.90 [ 0.79, 1.04 ]
Total events: 324 (Higher omega 3), 365 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.93, df = 2 (P = 0.38); I2 =0.0%
Test for overall effect: Z = 1.43 (P = 0.15)
3 Long duration:≥ 4 years in study
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 3), 0 (Lower omega 3)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 9654 9673 100.0 % 0.95 [ 0.83, 1.07 ]
Total events: 428 (Higher omega 3), 456 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.95, df = 4 (P = 0.41); I2 =0.0%
Test for overall effect: Z = 0.89 (P = 0.38)
Test for subgroup differences: Chi2 = 2.02, df = 1 (P = 0.15), I2 =51%
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Analysis 4.29. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 29 CVD events -
ALA - subgroup by primary or secondary prevention.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 4 High vs low ALA omega-3 fat (primary outcomes)
Outcome: 29 CVD events - ALA - subgroup by primary or secondary prevention
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Primary prevention
MARGARIN 2002 (1) 2/109 9/157 0.7 % 0.32 [ 0.07, 1.45 ]
Norwegian 1968 99/6716 87/6690 19.0 % 1.13 [ 0.85, 1.51 ]
WAHA 2016 3/362 4/346 0.7 % 0.72 [ 0.16, 3.18 ]
Subtotal (95% CI) 7187 7193 20.4 % 0.87 [ 0.46, 1.67 ]
Total events: 104 (Higher omega 3), 100 (Lower omega 3)
Heterogeneity: Tau2 = 0.14; Chi2 = 2.89, df = 2 (P = 0.24); I2 =31%
Test for overall effect: Z = 0.41 (P = 0.68)
2 Secondary prevention
AlphaOmega - ALA 2010 319/2409 352/2428 78.6 % 0.91 [ 0.79, 1.05 ]
FLAX-PAD 2013 5/58 4/52 1.0 % 1.12 [ 0.32, 3.95 ]
Subtotal (95% CI) 2467 2480 79.6 % 0.92 [ 0.80, 1.05 ]
Total events: 324 (Higher omega 3), 356 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.10, df = 1 (P = 0.75); I2 =0.0%
Test for overall effect: Z = 1.23 (P = 0.22)
Total (95% CI) 9654 9673 100.0 % 0.95 [ 0.83, 1.07 ]
Total events: 428 (Higher omega 3), 456 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.95, df = 4 (P = 0.41); I2 =0.0%
Test for overall effect: Z = 0.89 (P = 0.38)
Test for subgroup differences: Chi2 = 0.02, df = 1 (P = 0.89), I2 =0.0%
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Analysis 4.30. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 30 CVD events -
ALA - subgroup by statin use.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 4 High vs low ALA omega-3 fat (primary outcomes)
Outcome: 30 CVD events - ALA - subgroup by statin use
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 ALA -≥ 50% of control group on statins
AlphaOmega - ALA 2010 319/2409 352/2428 78.6 % 0.91 [ 0.79, 1.05 ]
FLAX-PAD 2013 5/58 4/52 1.0 % 1.12 [ 0.32, 3.95 ]
Subtotal (95% CI) 2467 2480 79.6 % 0.92 [ 0.80, 1.05 ]
Total events: 324 (Higher omega 3), 356 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.10, df = 1 (P = 0.75); I2 =0.0%
Test for overall effect: Z = 1.23 (P = 0.22)
2 ALA - < 50% of control group on statins
MARGARIN 2002 (1) 2/109 9/157 0.7 % 0.32 [ 0.07, 1.45 ]
Norwegian 1968 99/6716 87/6690 19.0 % 1.13 [ 0.85, 1.51 ]
WAHA 2016 3/362 4/346 0.7 % 0.72 [ 0.16, 3.18 ]
Subtotal (95% CI) 7187 7193 20.4 % 0.87 [ 0.46, 1.67 ]
Total events: 104 (Higher omega 3), 100 (Lower omega 3)
Heterogeneity: Tau2 = 0.14; Chi2 = 2.89, df = 2 (P = 0.24); I2 =31%
Test for overall effect: Z = 0.41 (P = 0.68)
Total (95% CI) 9654 9673 100.0 % 0.95 [ 0.83, 1.07 ]
Total events: 428 (Higher omega 3), 456 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.95, df = 4 (P = 0.41); I2 =0.0%
Test for overall effect: Z = 0.89 (P = 0.38)
Test for subgroup differences: Chi2 = 0.02, df = 1 (P = 0.89), I2 =0.0%
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Analysis 4.31. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 31 Coronary
heart disease mortality (overall) - ALA.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 4 High vs low ALA omega-3 fat (primary outcomes)
Outcome: 31 Coronary heart disease mortality (overall) - ALA
Study or subgroup
Favours
higher
omega 3 Lower omega 3 fats Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
AlphaOmega - ALA 2010 66/2409 72/2428 71.8 % 0.92 [ 0.66, 1.28 ]
FLAX-PAD 2013 (1) 1/58 0/52 0.8 % 2.69 [ 0.11, 64.74 ]
Norwegian 1968 (2) 27/6716 27/6690 27.5 % 1.00 [ 0.58, 1.70 ]
Total (95% CI) 9183 9170 100.0 % 0.95 [ 0.72, 1.26 ]
Total events: 94 (Favours higher omega 3), 99 (Lower omega 3 fats)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.47, df = 2 (P = 0.79); I2 =0.0%
Test for overall effect: Z = 0.35 (P = 0.72)
Test for subgroup differences: Not applicable
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Analysis 4.32. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 32 CHD
mortality - ALA - SA fixed-effect.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 4 High vs low ALA omega-3 fat (primary outcomes)
Outcome: 32 CHD mortality - ALA - SA fixed-effect
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
AlphaOmega - ALA 2010 66/2409 72/2428 72.2 % 0.92 [ 0.66, 1.28 ]
FLAX-PAD 2013 (1) 1/58 0/52 0.5 % 2.69 [ 0.11, 64.74 ]
Norwegian 1968 (2) 27/6716 27/6690 27.2 % 1.00 [ 0.58, 1.70 ]
Total (95% CI) 9183 9170 100.0 % 0.95 [ 0.72, 1.26 ]
Total events: 94 (Higher omega 3), 99 (Lower omega 3)
Heterogeneity: Chi2 = 0.47, df = 2 (P = 0.79); I2 =0.0%
Test for overall effect: Z = 0.34 (P = 0.73)
Test for subgroup differences: Not applicable
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Analysis 4.33. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 33 CHD
mortality - ALA - SA by summary risk of bias.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 4 High vs low ALA omega-3 fat (primary outcomes)
Outcome: 33 CHD mortality - ALA - SA by summary risk of bias
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Low risk of bias
AlphaOmega - ALA 2010 66/2409 72/2428 71.8 % 0.92 [ 0.66, 1.28 ]
FLAX-PAD 2013 (1) 1/58 0/52 0.8 % 2.69 [ 0.11, 64.74 ]
Subtotal (95% CI) 2467 2480 72.5 % 0.93 [ 0.67, 1.30 ]
Total events: 67 (Higher omega 3), 72 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.43, df = 1 (P = 0.51); I2 =0.0%
Test for overall effect: Z = 0.41 (P = 0.68)
2 Moderate/high risk of bias
Norwegian 1968 (2) 27/6716 27/6690 27.5 % 1.00 [ 0.58, 1.70 ]
Subtotal (95% CI) 6716 6690 27.5 % 1.00 [ 0.58, 1.70 ]
Total events: 27 (Higher omega 3), 27 (Lower omega 3)
Heterogeneity: not applicable
Test for overall effect: Z = 0.01 (P = 0.99)
Total (95% CI) 9183 9170 100.0 % 0.95 [ 0.72, 1.26 ]
Total events: 94 (Higher omega 3), 99 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.47, df = 2 (P = 0.79); I2 =0.0%
Test for overall effect: Z = 0.35 (P = 0.72)
Test for subgroup differences: Chi2 = 0.04, df = 1 (P = 0.84), I2 =0.0%
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Analysis 4.34. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 34 CHD
mortality - ALA - SA by compliance and study size.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 4 High vs low ALA omega-3 fat (primary outcomes)
Outcome: 34 CHD mortality - ALA - SA by compliance and study size
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 SA - low risk of compliance bias
AlphaOmega - ALA 2010 66/2409 72/2428 100.0 % 0.92 [ 0.66, 1.28 ]
Subtotal (95% CI) 2409 2428 100.0 % 0.92 [ 0.66, 1.28 ]
Total events: 66 (Higher omega 3), 72 (Lower omega 3)
Heterogeneity: not applicable
Test for overall effect: Z = 0.47 (P = 0.64)
2 SA - 100+ randomised
AlphaOmega - ALA 2010 66/2409 72/2428 71.8 % 0.92 [ 0.66, 1.28 ]
FLAX-PAD 2013 (1) 1/58 0/52 0.8 % 2.69 [ 0.11, 64.74 ]
Norwegian 1968 (2) 27/6716 27/6690 27.5 % 1.00 [ 0.58, 1.70 ]
Subtotal (95% CI) 9183 9170 100.0 % 0.95 [ 0.72, 1.26 ]
Total events: 94 (Higher omega 3), 99 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.47, df = 2 (P = 0.79); I2 =0.0%
Test for overall effect: Z = 0.35 (P = 0.72)
Test for subgroup differences: Chi2 = 0.02, df = 1 (P = 0.90), I2 =0.0%
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Analysis 4.35. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 35 CHD
mortality - ALA - subgroup by dose.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 4 High vs low ALA omega-3 fat (primary outcomes)
Outcome: 35 CHD mortality - ALA - subgroup by dose
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 ALA low < 5 g/d
AlphaOmega - ALA 2010 66/2409 72/2428 71.8 % 0.92 [ 0.66, 1.28 ]
Subtotal (95% CI) 2409 2428 71.8 % 0.92 [ 0.66, 1.28 ]
Total events: 66 (Higher omega 3), 72 (Lower omega 3)
Heterogeneity: not applicable
Test for overall effect: Z = 0.47 (P = 0.64)
2 ALA high≥ 5 g/d
FLAX-PAD 2013 (1) 1/58 0/52 0.8 % 2.69 [ 0.11, 64.74 ]
Norwegian 1968 (2) 27/6716 27/6690 27.5 % 1.00 [ 0.58, 1.70 ]
Subtotal (95% CI) 6774 6742 28.2 % 1.02 [ 0.61, 1.73 ]
Total events: 28 (Higher omega 3), 27 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.37, df = 1 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 0.09 (P = 0.93)
Total (95% CI) 9183 9170 100.0 % 0.95 [ 0.72, 1.26 ]
Total events: 94 (Higher omega 3), 99 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.47, df = 2 (P = 0.79); I2 =0.0%
Test for overall effect: Z = 0.35 (P = 0.72)
Test for subgroup differences: Chi2 = 0.10, df = 1 (P = 0.75), I2 =0.0%
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Analysis 4.36. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 36 CHD
mortality - ALA - subgroup by replacement.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 4 High vs low ALA omega-3 fat (primary outcomes)
Outcome: 36 CHD mortality - ALA - subgroup by replacement
Study or subgroup High omega 3 Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 N-3 replacing SFA
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (High omega 3), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Coronary heart mortality- ALA
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (High omega 3), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 N-3 replacing MUFA
AlphaOmega - ALA 2010 66/2409 72/2428 100.0 % 0.92 [ 0.66, 1.28 ]
Subtotal (95% CI) 2409 2428 100.0 % 0.92 [ 0.66, 1.28 ]
Total events: 66 (High omega 3), 72 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.47 (P = 0.64)
4 N-3 replacing n-6
Norwegian 1968 (1) 27/6716 27/6690 100.0 % 1.00 [ 0.58, 1.70 ]
Subtotal (95% CI) 6716 6690 100.0 % 1.00 [ 0.58, 1.70 ]
Total events: 27 (High omega 3), 27 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.01 (P = 0.99)
5 N-3 replacing carbohydrates/sugars
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (High omega 3), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
6 N-3 replacing nil/low n-3 placebo
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (High omega 3), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
7 Replacement unclear
FLAX-PAD 2013 (2) 1/58 0/52 100.0 % 2.69 [ 0.11, 64.74 ]
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(. . . Continued)
Study or subgroup High omega 3 Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Subtotal (95% CI) 58 52 100.0 % 2.69 [ 0.11, 64.74 ]
Total events: 1 (High omega 3), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.61 (P = 0.54)
Test for subgroup differences: Chi2 = 0.47, df = 2 (P = 0.79), I2 =0.0%
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Favours high ALA Favours low ALA
(1) Coronary heart plus sudden death
(2) Fatal MI
Analysis 4.37. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 37 CHD
mortality - ALA - subgroup by intervention type.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 4 High vs low ALA omega-3 fat (primary outcomes)
Outcome: 37 CHD mortality - ALA - subgroup by intervention type
Study or subgroup High omega 3 Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Dietary advice
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (High omega 3), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Supplemental foods
AlphaOmega - ALA 2010 66/2409 72/2428 71.8 % 0.92 [ 0.66, 1.28 ]
FLAX-PAD 2013 (1) 1/58 0/52 0.8 % 2.69 [ 0.11, 64.74 ]
Subtotal (95% CI) 2467 2480 72.5 % 0.93 [ 0.67, 1.30 ]
Total events: 67 (High omega 3), 72 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.43, df = 1 (P = 0.51); I2 =0.0%
Test for overall effect: Z = 0.41 (P = 0.68)
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(. . . Continued)
Study or subgroup High omega 3 Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
3 Supplements (capsule)
Norwegian 1968 (2) 27/6716 27/6690 27.5 % 1.00 [ 0.58, 1.70 ]
Subtotal (95% CI) 6716 6690 27.5 % 1.00 [ 0.58, 1.70 ]
Total events: 27 (High omega 3), 27 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.01 (P = 0.99)
4 Any combination
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (High omega 3), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 9183 9170 100.0 % 0.95 [ 0.72, 1.26 ]
Total events: 94 (High omega 3), 99 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.47, df = 2 (P = 0.79); I2 =0.0%
Test for overall effect: Z = 0.35 (P = 0.72)
Test for subgroup differences: Chi2 = 0.04, df = 1 (P = 0.84), I2 =0.0%
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Analysis 4.38. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 38 CHD
mortality - ALA - subgroup by duration.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 4 High vs low ALA omega-3 fat (primary outcomes)
Outcome: 38 CHD mortality - ALA - subgroup by duration
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Medium duration 1 to < 2 years in study
FLAX-PAD 2013 (1) 1/58 0/52 0.8 % 2.69 [ 0.11, 64.74 ]
Norwegian 1968 (2) 27/6716 27/6690 27.5 % 1.00 [ 0.58, 1.70 ]
Subtotal (95% CI) 6774 6742 28.2 % 1.02 [ 0.61, 1.73 ]
Total events: 28 (Higher omega 3), 27 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.37, df = 1 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 0.09 (P = 0.93)
2 Medium-long duration: 2 to < 4 years in study
AlphaOmega - ALA 2010 66/2409 72/2428 71.8 % 0.92 [ 0.66, 1.28 ]
Subtotal (95% CI) 2409 2428 71.8 % 0.92 [ 0.66, 1.28 ]
Total events: 66 (Higher omega 3), 72 (Lower omega 3)
Heterogeneity: not applicable
Test for overall effect: Z = 0.47 (P = 0.64)
3 Long duration:≥ 4 years in study
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 3), 0 (Lower omega 3)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 9183 9170 100.0 % 0.95 [ 0.72, 1.26 ]
Total events: 94 (Higher omega 3), 99 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.47, df = 2 (P = 0.79); I2 =0.0%
Test for overall effect: Z = 0.35 (P = 0.72)
Test for subgroup differences: Chi2 = 0.10, df = 1 (P = 0.75), I2 =0.0%
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Analysis 4.39. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 39 CHD
mortality - ALA - subgroup by primary or secondary prevention.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 4 High vs low ALA omega-3 fat (primary outcomes)
Outcome: 39 CHD mortality - ALA - subgroup by primary or secondary prevention
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Primary prevention of CVD
Norwegian 1968 (1) 27/6716 27/6690 27.5 % 1.00 [ 0.58, 1.70 ]
Subtotal (95% CI) 6716 6690 27.5 % 1.00 [ 0.58, 1.70 ]
Total events: 27 (Higher omega 3), 27 (Lower omega 3)
Heterogeneity: not applicable
Test for overall effect: Z = 0.01 (P = 0.99)
2 Secondary prevention of CVD
AlphaOmega - ALA 2010 66/2409 72/2428 71.8 % 0.92 [ 0.66, 1.28 ]
FLAX-PAD 2013 (2) 1/58 0/52 0.8 % 2.69 [ 0.11, 64.74 ]
Subtotal (95% CI) 2467 2480 72.5 % 0.93 [ 0.67, 1.30 ]
Total events: 67 (Higher omega 3), 72 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.43, df = 1 (P = 0.51); I2 =0.0%
Test for overall effect: Z = 0.41 (P = 0.68)
Total (95% CI) 9183 9170 100.0 % 0.95 [ 0.72, 1.26 ]
Total events: 94 (Higher omega 3), 99 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.47, df = 2 (P = 0.79); I2 =0.0%
Test for overall effect: Z = 0.35 (P = 0.72)
Test for subgroup differences: Chi2 = 0.04, df = 1 (P = 0.84), I2 =0.0%
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Analysis 4.40. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 40 CHD
mortality - ALA - subgroup by statin use.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 4 High vs low ALA omega-3 fat (primary outcomes)
Outcome: 40 CHD mortality - ALA - subgroup by statin use
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 ALA -≥ 50% of control group on statins
AlphaOmega - ALA 2010 66/2409 72/2428 71.8 % 0.92 [ 0.66, 1.28 ]
FLAX-PAD 2013 (1) 1/58 0/52 0.8 % 2.69 [ 0.11, 64.74 ]
Subtotal (95% CI) 2467 2480 72.5 % 0.93 [ 0.67, 1.30 ]
Total events: 67 (Higher omega 3), 72 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.43, df = 1 (P = 0.51); I2 =0.0%
Test for overall effect: Z = 0.41 (P = 0.68)
2 ALA - < 50% of control group on statins
Norwegian 1968 (2) 27/6716 27/6690 27.5 % 1.00 [ 0.58, 1.70 ]
Subtotal (95% CI) 6716 6690 27.5 % 1.00 [ 0.58, 1.70 ]
Total events: 27 (Higher omega 3), 27 (Lower omega 3)
Heterogeneity: not applicable
Test for overall effect: Z = 0.01 (P = 0.99)
Total (95% CI) 9183 9170 100.0 % 0.95 [ 0.72, 1.26 ]
Total events: 94 (Higher omega 3), 99 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.47, df = 2 (P = 0.79); I2 =0.0%
Test for overall effect: Z = 0.35 (P = 0.72)
Test for subgroup differences: Chi2 = 0.04, df = 1 (P = 0.84), I2 =0.0%
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Analysis 4.41. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 41 CHD
mortality - ALA - subgroup by CAD history.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 4 High vs low ALA omega-3 fat (primary outcomes)
Outcome: 41 CHD mortality - ALA - subgroup by CAD history
Study or subgroup High omega 3 Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Previous CAD
AlphaOmega - ALA 2010 66/2409 72/2428 71.8 % 0.92 [ 0.66, 1.28 ]
Subtotal (95% CI) 2409 2428 71.8 % 0.92 [ 0.66, 1.28 ]
Total events: 66 (High omega 3), 72 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.47 (P = 0.64)
2 No previous CAD
FLAX-PAD 2013 (1) 1/58 0/52 0.8 % 2.69 [ 0.11, 64.74 ]
Norwegian 1968 (2) 27/6716 27/6690 27.5 % 1.00 [ 0.58, 1.70 ]
Subtotal (95% CI) 6774 6742 28.2 % 1.02 [ 0.61, 1.73 ]
Total events: 28 (High omega 3), 27 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.37, df = 1 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 0.09 (P = 0.93)
Total (95% CI) 9183 9170 100.0 % 0.95 [ 0.72, 1.26 ]
Total events: 94 (High omega 3), 99 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.47, df = 2 (P = 0.79); I2 =0.0%
Test for overall effect: Z = 0.35 (P = 0.72)
Test for subgroup differences: Chi2 = 0.10, df = 1 (P = 0.75), I2 =0.0%
0.01 0.1 1 10 100
Favours high ALA Favours low ALA
(1) Fatal MI
(2) Coronary heart plus sudden death
616Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 4.42. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 42 Coronary
heart disease events (overall) - ALA.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 4 High vs low ALA omega-3 fat (primary outcomes)
Outcome: 42 Coronary heart disease events (overall) - ALA
Study or subgroup
Favours
higher
omega 3 Lower omega 3 fats Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
AlphaOmega - ALA 2010 121/2409 133/2428 64.4 % 0.92 [ 0.72, 1.17 ]
FLAX-PAD 2013 (1) 1/58 3/52 0.8 % 0.30 [ 0.03, 2.78 ]
Norwegian 1968 (2) 75/6716 63/6690 34.4 % 1.19 [ 0.85, 1.65 ]
WAHA 2016 1/362 0/346 0.4 % 2.87 [ 0.12, 70.16 ]
Total (95% CI) 9545 9516 100.0 % 1.00 [ 0.82, 1.22 ]
Total events: 198 (Favours higher omega 3), 199 (Lower omega 3 fats)
Heterogeneity: Tau2 = 0.00; Chi2 = 3.05, df = 3 (P = 0.38); I2 =2%
Test for overall effect: Z = 0.03 (P = 0.98)
Test for subgroup differences: Not applicable
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Analysis 4.43. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 43 CHD events -
ALA - SA fixed-effect.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 4 High vs low ALA omega-3 fat (primary outcomes)
Outcome: 43 CHD events - ALA - SA fixed-effect
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
AlphaOmega - ALA 2010 121/2409 133/2428 66.5 % 0.92 [ 0.72, 1.17 ]
FLAX-PAD 2013 (1) 1/58 3/52 1.6 % 0.30 [ 0.03, 2.78 ]
Norwegian 1968 (2) 75/6716 63/6690 31.7 % 1.19 [ 0.85, 1.65 ]
WAHA 2016 1/362 0/346 0.3 % 2.87 [ 0.12, 70.16 ]
Total (95% CI) 9545 9516 100.0 % 1.00 [ 0.82, 1.21 ]
Total events: 198 (Higher omega 3), 199 (Lower omega 3)
Heterogeneity: Chi2 = 3.05, df = 3 (P = 0.38); I2 =2%
Test for overall effect: Z = 0.03 (P = 0.98)
Test for subgroup differences: Not applicable
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Analysis 4.44. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 44 CHD events -
ALA - SA by summary risk of bias.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 4 High vs low ALA omega-3 fat (primary outcomes)
Outcome: 44 CHD events - ALA - SA by summary risk of bias
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Low risk of bias
AlphaOmega - ALA 2010 121/2409 133/2428 64.4 % 0.92 [ 0.72, 1.17 ]
FLAX-PAD 2013 (1) 1/58 3/52 0.8 % 0.30 [ 0.03, 2.78 ]
Subtotal (95% CI) 2467 2480 65.2 % 0.91 [ 0.71, 1.15 ]
Total events: 122 (Higher omega 3), 136 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.96, df = 1 (P = 0.33); I2 =0.0%
Test for overall effect: Z = 0.82 (P = 0.41)
2 Moderate/high risk of bias
Norwegian 1968 (2) 75/6716 63/6690 34.4 % 1.19 [ 0.85, 1.65 ]
WAHA 2016 1/362 0/346 0.4 % 2.87 [ 0.12, 70.16 ]
Subtotal (95% CI) 7078 7036 34.8 % 1.20 [ 0.86, 1.67 ]
Total events: 76 (Higher omega 3), 63 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.29, df = 1 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 1.06 (P = 0.29)
Total (95% CI) 9545 9516 100.0 % 1.00 [ 0.82, 1.22 ]
Total events: 198 (Higher omega 3), 199 (Lower omega 3)
Heterogeneity: Tau2 = 0.00; Chi2 = 3.05, df = 3 (P = 0.38); I2 =2%
Test for overall effect: Z = 0.03 (P = 0.98)
Test for subgroup differences: Chi2 = 1.80, df = 1 (P = 0.18), I2 =44%
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Analysis 4.45. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 45 CHD events -
ALA - SA by compliance and study size.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 4 High vs low ALA omega-3 fat (primary outcomes)
Outcome: 45 CHD events - ALA - SA by compliance and study size
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 SA - low risk of compliance bias
AlphaOmega - ALA 2010 121/2409 133/2428 99.4 % 0.92 [ 0.72, 1.17 ]
WAHA 2016 1/362 0/346 0.6 % 2.87 [ 0.12, 70.16 ]
Subtotal (95% CI) 2771 2774 100.0 % 0.92 [ 0.73, 1.17 ]
Total events: 122 (Higher omega 3), 133 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.49, df = 1 (P = 0.49); I2 =0.0%
Test for overall effect: Z = 0.66 (P = 0.51)
2 SA - 100+ randomised
AlphaOmega - ALA 2010 121/2409 133/2428 64.4 % 0.92 [ 0.72, 1.17 ]
FLAX-PAD 2013 (1) 1/58 3/52 0.8 % 0.30 [ 0.03, 2.78 ]
Norwegian 1968 (2) 75/6716 63/6690 34.4 % 1.19 [ 0.85, 1.65 ]
WAHA 2016 1/362 0/346 0.4 % 2.87 [ 0.12, 70.16 ]
Subtotal (95% CI) 9545 9516 100.0 % 1.00 [ 0.82, 1.22 ]
Total events: 198 (Higher omega 3), 199 (Lower omega 3)
Heterogeneity: Tau2 = 0.00; Chi2 = 3.05, df = 3 (P = 0.38); I2 =2%
Test for overall effect: Z = 0.03 (P = 0.98)
Test for subgroup differences: Chi2 = 0.24, df = 1 (P = 0.62), I2 =0.0%
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Analysis 4.46. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 46 CHD events -
ALA - subgroup by dose.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 4 High vs low ALA omega-3 fat (primary outcomes)
Outcome: 46 CHD events - ALA - subgroup by dose
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 ALA low < 5 g/d
AlphaOmega - ALA 2010 121/2409 133/2428 64.4 % 0.92 [ 0.72, 1.17 ]
Subtotal (95% CI) 2409 2428 64.4 % 0.92 [ 0.72, 1.17 ]
Total events: 121 (Higher omega 3), 133 (Lower omega 3)
Heterogeneity: not applicable
Test for overall effect: Z = 0.71 (P = 0.48)
2 ALA high≥ 5 g/d
FLAX-PAD 2013 (1) 1/58 3/52 0.8 % 0.30 [ 0.03, 2.78 ]
Norwegian 1968 (2) 75/6716 63/6690 34.4 % 1.19 [ 0.85, 1.65 ]
WAHA 2016 1/362 0/346 0.4 % 2.87 [ 0.12, 70.16 ]
Subtotal (95% CI) 7136 7088 35.6 % 1.16 [ 0.84, 1.61 ]
Total events: 77 (Higher omega 3), 66 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.74, df = 2 (P = 0.42); I2 =0.0%
Test for overall effect: Z = 0.90 (P = 0.37)
Total (95% CI) 9545 9516 100.0 % 1.00 [ 0.82, 1.22 ]
Total events: 198 (Higher omega 3), 199 (Lower omega 3)
Heterogeneity: Tau2 = 0.00; Chi2 = 3.05, df = 3 (P = 0.38); I2 =2%
Test for overall effect: Z = 0.03 (P = 0.98)
Test for subgroup differences: Chi2 = 1.31, df = 1 (P = 0.25), I2 =23%
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Analysis 4.47. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 47 CHD events -
ALA - subgroup by replacement.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 4 High vs low ALA omega-3 fat (primary outcomes)
Outcome: 47 CHD events - ALA - subgroup by replacement
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 N-3 replacing SFA
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 3), 0 (Lower omega 3)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 N-3 replacing MUFA
AlphaOmega - ALA 2010 121/2409 133/2428 100.0 % 0.92 [ 0.72, 1.17 ]
Subtotal (95% CI) 2409 2428 100.0 % 0.92 [ 0.72, 1.17 ]
Total events: 121 (Higher omega 3), 133 (Lower omega 3)
Heterogeneity: not applicable
Test for overall effect: Z = 0.71 (P = 0.48)
3 N-3 replacing n-6
Norwegian 1968 (1) 75/6716 63/6690 100.0 % 1.19 [ 0.85, 1.65 ]
Subtotal (95% CI) 6716 6690 100.0 % 1.19 [ 0.85, 1.65 ]
Total events: 75 (Higher omega 3), 63 (Lower omega 3)
Heterogeneity: not applicable
Test for overall effect: Z = 1.00 (P = 0.32)
4 N-3 replacing carbohydrates/sugars
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 3), 0 (Lower omega 3)
Heterogeneity: not applicable
Test for overall effect: not applicable
5 N-3 replacing nil/low n-3 placebo
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 3), 0 (Lower omega 3)
Heterogeneity: not applicable
Test for overall effect: not applicable
6 Replacement unclear
FLAX-PAD 2013 (2) 1/58 3/52 63.3 % 0.30 [ 0.03, 2.78 ]
WAHA 2016 1/362 0/346 36.7 % 2.87 [ 0.12, 70.16 ]
Subtotal (95% CI) 420 398 100.0 % 0.69 [ 0.08, 5.81 ]
Total events: 2 (Higher omega 3), 3 (Lower omega 3)
Heterogeneity: Tau2 = 0.58; Chi2 = 1.29, df = 1 (P = 0.26); I2 =23%
Test for overall effect: Z = 0.35 (P = 0.73)
Test for subgroup differences: Chi2 = 1.63, df = 2 (P = 0.44), I2 =0.0%
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(1) Total MI
(2) Total MI
Analysis 4.48. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 48 CHD events -
ALA - subgroup by intervention type.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 4 High vs low ALA omega-3 fat (primary outcomes)
Outcome: 48 CHD events - ALA - subgroup by intervention type
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Dietary advice
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 3), 0 (Lower omega 3)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Supplemental foods
AlphaOmega - ALA 2010 121/2409 133/2428 64.4 % 0.92 [ 0.72, 1.17 ]
FLAX-PAD 2013 (1) 1/58 3/52 0.8 % 0.30 [ 0.03, 2.78 ]
WAHA 2016 1/362 0/346 0.4 % 2.87 [ 0.12, 70.16 ]
Subtotal (95% CI) 2829 2826 65.6 % 0.91 [ 0.72, 1.16 ]
Total events: 123 (Higher omega 3), 136 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.46, df = 2 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 0.77 (P = 0.44)
3 Supplements (capsule)
Norwegian 1968 (2) 75/6716 63/6690 34.4 % 1.19 [ 0.85, 1.65 ]
Subtotal (95% CI) 6716 6690 34.4 % 1.19 [ 0.85, 1.65 ]
Total events: 75 (Higher omega 3), 63 (Lower omega 3)
Heterogeneity: not applicable
Test for overall effect: Z = 1.00 (P = 0.32)
4 Any combination
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 3), 0 (Lower omega 3)
Heterogeneity: not applicable
Test for overall effect: not applicable
0.01 0.1 1 10 100
Favours high ALA Favours low ALA
(Continued . . . )
623Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(. . . Continued)
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Total (95% CI) 9545 9516 100.0 % 1.00 [ 0.82, 1.22 ]
Total events: 198 (Higher omega 3), 199 (Lower omega 3)
Heterogeneity: Tau2 = 0.00; Chi2 = 3.05, df = 3 (P = 0.38); I2 =2%
Test for overall effect: Z = 0.03 (P = 0.98)
Test for subgroup differences: Chi2 = 1.59, df = 1 (P = 0.21), I2 =37%
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Analysis 4.49. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 49 CHD events -
ALA - subgroup by duration.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 4 High vs low ALA omega-3 fat (primary outcomes)
Outcome: 49 CHD events - ALA - subgroup by duration
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Medium duration 1 to < 2 years in study
FLAX-PAD 2013 (1) 1/58 3/52 0.8 % 0.30 [ 0.03, 2.78 ]
Norwegian 1968 (2) 75/6716 63/6690 34.4 % 1.19 [ 0.85, 1.65 ]
Subtotal (95% CI) 6774 6742 35.2 % 0.94 [ 0.34, 2.58 ]
Total events: 76 (Higher omega 3), 66 (Lower omega 3)
Heterogeneity: Tau2 = 0.29; Chi2 = 1.43, df = 1 (P = 0.23); I2 =30%
Test for overall effect: Z = 0.12 (P = 0.91)
2 Medium-long duration: 2 to < 4 years in study
AlphaOmega - ALA 2010 121/2409 133/2428 64.4 % 0.92 [ 0.72, 1.17 ]
WAHA 2016 1/362 0/346 0.4 % 2.87 [ 0.12, 70.16 ]
Subtotal (95% CI) 2771 2774 64.8 % 0.92 [ 0.73, 1.17 ]
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(. . . Continued)
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Total events: 122 (Higher omega 3), 133 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.49, df = 1 (P = 0.49); I2 =0.0%
Test for overall effect: Z = 0.66 (P = 0.51)
3 Long duration:≥ 4 years in study
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 3), 0 (Lower omega 3)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 9545 9516 100.0 % 1.00 [ 0.82, 1.22 ]
Total events: 198 (Higher omega 3), 199 (Lower omega 3)
Heterogeneity: Tau2 = 0.00; Chi2 = 3.05, df = 3 (P = 0.38); I2 =2%
Test for overall effect: Z = 0.03 (P = 0.98)
Test for subgroup differences: Chi2 = 0.00, df = 1 (P = 0.97), I2 =0.0%
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Analysis 4.50. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 50 CHD events -
ALA - subgroup by primary or secondary prevention.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 4 High vs low ALA omega-3 fat (primary outcomes)
Outcome: 50 CHD events - ALA - subgroup by primary or secondary prevention
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Primary prevention
Norwegian 1968 (1) 75/6716 63/6690 34.4 % 1.19 [ 0.85, 1.65 ]
WAHA 2016 1/362 0/346 0.4 % 2.87 [ 0.12, 70.16 ]
Subtotal (95% CI) 7078 7036 34.8 % 1.20 [ 0.86, 1.67 ]
Total events: 76 (Higher omega 3), 63 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.29, df = 1 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 1.06 (P = 0.29)
2 Secondary prevention
AlphaOmega - ALA 2010 121/2409 133/2428 64.4 % 0.92 [ 0.72, 1.17 ]
FLAX-PAD 2013 (2) 1/58 3/52 0.8 % 0.30 [ 0.03, 2.78 ]
Subtotal (95% CI) 2467 2480 65.2 % 0.91 [ 0.71, 1.15 ]
Total events: 122 (Higher omega 3), 136 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.96, df = 1 (P = 0.33); I2 =0.0%
Test for overall effect: Z = 0.82 (P = 0.41)
Total (95% CI) 9545 9516 100.0 % 1.00 [ 0.82, 1.22 ]
Total events: 198 (Higher omega 3), 199 (Lower omega 3)
Heterogeneity: Tau2 = 0.00; Chi2 = 3.05, df = 3 (P = 0.38); I2 =2%
Test for overall effect: Z = 0.03 (P = 0.98)
Test for subgroup differences: Chi2 = 1.80, df = 1 (P = 0.18), I2 =44%
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Analysis 4.51. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 51 CHD events -
ALA - subgroup by statin use.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 4 High vs low ALA omega-3 fat (primary outcomes)
Outcome: 51 CHD events - ALA - subgroup by statin use
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 ALA -≥ 50% of control group on statins
AlphaOmega - ALA 2010 121/2409 133/2428 64.4 % 0.92 [ 0.72, 1.17 ]
FLAX-PAD 2013 (1) 1/58 3/52 0.8 % 0.30 [ 0.03, 2.78 ]
Subtotal (95% CI) 2467 2480 65.2 % 0.91 [ 0.71, 1.15 ]
Total events: 122 (Higher omega 3), 136 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.96, df = 1 (P = 0.33); I2 =0.0%
Test for overall effect: Z = 0.82 (P = 0.41)
2 ALA - < 50% of control group on statins
Norwegian 1968 (2) 75/6716 63/6690 34.4 % 1.19 [ 0.85, 1.65 ]
WAHA 2016 1/362 0/346 0.4 % 2.87 [ 0.12, 70.16 ]
Subtotal (95% CI) 7078 7036 34.8 % 1.20 [ 0.86, 1.67 ]
Total events: 76 (Higher omega 3), 63 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.29, df = 1 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 1.06 (P = 0.29)
Total (95% CI) 9545 9516 100.0 % 1.00 [ 0.82, 1.22 ]
Total events: 198 (Higher omega 3), 199 (Lower omega 3)
Heterogeneity: Tau2 = 0.00; Chi2 = 3.05, df = 3 (P = 0.38); I2 =2%
Test for overall effect: Z = 0.03 (P = 0.98)
Test for subgroup differences: Chi2 = 1.80, df = 1 (P = 0.18), I2 =44%
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Analysis 4.52. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 52 CHD events -
ALA - subgroup by CAD history.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 4 High vs low ALA omega-3 fat (primary outcomes)
Outcome: 52 CHD events - ALA - subgroup by CAD history
Study or subgroup High omega 3 Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Previous CAD
AlphaOmega - ALA 2010 121/2409 133/2428 64.4 % 0.92 [ 0.72, 1.17 ]
Subtotal (95% CI) 2409 2428 64.4 % 0.92 [ 0.72, 1.17 ]
Total events: 121 (High omega 3), 133 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.71 (P = 0.48)
2 No previous CAD
FLAX-PAD 2013 (1) 1/58 3/52 0.8 % 0.30 [ 0.03, 2.78 ]
Norwegian 1968 (2) 75/6716 63/6690 34.4 % 1.19 [ 0.85, 1.65 ]
WAHA 2016 1/362 0/346 0.4 % 2.87 [ 0.12, 70.16 ]
Subtotal (95% CI) 7136 7088 35.6 % 1.16 [ 0.84, 1.61 ]
Total events: 77 (High omega 3), 66 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.74, df = 2 (P = 0.42); I2 =0.0%
Test for overall effect: Z = 0.90 (P = 0.37)
Total (95% CI) 9545 9516 100.0 % 1.00 [ 0.82, 1.22 ]
Total events: 198 (High omega 3), 199 (Control)
Heterogeneity: Tau2 = 0.00; Chi2 = 3.05, df = 3 (P = 0.38); I2 =2%
Test for overall effect: Z = 0.03 (P = 0.98)
Test for subgroup differences: Chi2 = 1.31, df = 1 (P = 0.25), I2 =23%
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Analysis 4.53. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 53 Stroke
(overall) - ALA.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 4 High vs low ALA omega-3 fat (primary outcomes)
Outcome: 53 Stroke (overall) - ALA
Study or subgroup
Favours
higher
omega 3 Lower omega 3 fats Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
AlphaOmega - ALA 2010 10/2409 11/2428 42.8 % 0.92 [ 0.39, 2.15 ]
FLAX-PAD 2013 3/58 1/52 6.3 % 2.69 [ 0.29, 25.06 ]
MARGARIN 2002 0/109 2/157 3.4 % 0.29 [ 0.01, 5.93 ]
Norwegian 1968 13/6716 9/6690 43.4 % 1.44 [ 0.62, 3.36 ]
WAHA 2016 1/362 1/346 4.1 % 0.96 [ 0.06, 15.22 ]
Total (95% CI) 9654 9673 100.0 % 1.15 [ 0.66, 2.01 ]
Total events: 27 (Favours higher omega 3), 24 (Lower omega 3 fats)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.92, df = 4 (P = 0.75); I2 =0.0%
Test for overall effect: Z = 0.48 (P = 0.63)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours higher omega 3 Favours lower omega 3
629Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 4.54. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 54 Stroke - ALA
- SA fixed-effect.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 4 High vs low ALA omega-3 fat (primary outcomes)
Outcome: 54 Stroke - ALA - SA fixed-effect
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
AlphaOmega - EPA+DHA 2010 11/2404 10/2433 43.1 % 1.11 [ 0.47, 2.62 ]
FLAX-PAD 2013 3/58 1/52 4.6 % 2.69 [ 0.29, 25.06 ]
MARGARIN 2002 0/109 2/157 8.9 % 0.29 [ 0.01, 5.93 ]
Norwegian 1968 13/6716 9/6690 39.1 % 1.44 [ 0.62, 3.36 ]
WAHA 2016 1/362 1/346 4.4 % 0.96 [ 0.06, 15.22 ]
Total (95% CI) 9649 9678 100.0 % 1.23 [ 0.71, 2.13 ]
Total events: 28 (Higher omega 3), 23 (Lower omega 3)
Heterogeneity: Chi2 = 1.57, df = 4 (P = 0.81); I2 =0.0%
Test for overall effect: Z = 0.74 (P = 0.46)
Test for subgroup differences: Not applicable
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Analysis 4.55. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 55 Stroke - ALA
- SA by summary risk of bias.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 4 High vs low ALA omega-3 fat (primary outcomes)
Outcome: 55 Stroke - ALA - SA by summary risk of bias
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Low risk of bias
AlphaOmega - ALA 2010 10/2409 11/2428 42.8 % 0.92 [ 0.39, 2.15 ]
FLAX-PAD 2013 3/58 1/52 6.3 % 2.69 [ 0.29, 25.06 ]
MARGARIN 2002 0/109 2/157 3.4 % 0.29 [ 0.01, 5.93 ]
Subtotal (95% CI) 2576 2637 52.5 % 0.97 [ 0.45, 2.09 ]
Total events: 13 (Higher omega 3), 14 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.44, df = 2 (P = 0.49); I2 =0.0%
Test for overall effect: Z = 0.09 (P = 0.93)
2 Moderate/high risk of bias
Norwegian 1968 13/6716 9/6690 43.4 % 1.44 [ 0.62, 3.36 ]
WAHA 2016 1/362 1/346 4.1 % 0.96 [ 0.06, 15.22 ]
Subtotal (95% CI) 7078 7036 47.5 % 1.39 [ 0.62, 3.13 ]
Total events: 14 (Higher omega 3), 10 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.08, df = 1 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 0.79 (P = 0.43)
Total (95% CI) 9654 9673 100.0 % 1.15 [ 0.66, 2.01 ]
Total events: 27 (Higher omega 3), 24 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.92, df = 4 (P = 0.75); I2 =0.0%
Test for overall effect: Z = 0.48 (P = 0.63)
Test for subgroup differences: Chi2 = 0.40, df = 1 (P = 0.53), I2 =0.0%
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Analysis 4.56. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 56 Stroke - ALA
- SA by compliance and study size.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 4 High vs low ALA omega-3 fat (primary outcomes)
Outcome: 56 Stroke - ALA - SA by compliance and study size
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 SA - low risk of compliance bias
AlphaOmega - ALA 2010 10/2409 11/2428 28.5 % 0.92 [ 0.39, 2.15 ]
MARGARIN 2002 0/109 2/157 2.3 % 0.29 [ 0.01, 5.93 ]
WAHA 2016 1/362 1/346 2.7 % 0.96 [ 0.06, 15.22 ]
Subtotal (95% CI) 2880 2931 33.5 % 0.85 [ 0.39, 1.87 ]
Total events: 11 (Higher omega 3), 14 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.53, df = 2 (P = 0.77); I2 =0.0%
Test for overall effect: Z = 0.40 (P = 0.69)
2 SA - 100+ randomised
AlphaOmega - ALA 2010 10/2409 11/2428 28.5 % 0.92 [ 0.39, 2.15 ]
FLAX-PAD 2013 3/58 1/52 4.2 % 2.69 [ 0.29, 25.06 ]
MARGARIN 2002 0/109 2/157 2.3 % 0.29 [ 0.01, 5.93 ]
Norwegian 1968 13/6716 9/6690 28.9 % 1.44 [ 0.62, 3.36 ]
WAHA 2016 1/362 1/346 2.7 % 0.96 [ 0.06, 15.22 ]
Subtotal (95% CI) 9654 9673 66.5 % 1.15 [ 0.66, 2.01 ]
Total events: 27 (Higher omega 3), 24 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.92, df = 4 (P = 0.75); I2 =0.0%
Test for overall effect: Z = 0.48 (P = 0.63)
Total (95% CI) 12534 12604 100.0 % 1.04 [ 0.66, 1.64 ]
Total events: 38 (Higher omega 3), 38 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.83, df = 7 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 0.16 (P = 0.87)
Test for subgroup differences: Chi2 = 0.37, df = 1 (P = 0.54), I2 =0.0%
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Analysis 4.57. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 57 Stroke - ALA
- subgroup by dose.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 4 High vs low ALA omega-3 fat (primary outcomes)
Outcome: 57 Stroke - ALA - subgroup by dose
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 ALA low < 5 g/d
AlphaOmega - ALA 2010 10/2409 11/2428 100.0 % 0.92 [ 0.39, 2.15 ]
Subtotal (95% CI) 2409 2428 100.0 % 0.92 [ 0.39, 2.15 ]
Total events: 10 (Higher omega 3), 11 (Lower omega 3)
Heterogeneity: not applicable
Test for overall effect: Z = 0.20 (P = 0.84)
2 ALA high≥ 5 g/d
FLAX-PAD 2013 3/58 1/52 11.0 % 2.69 [ 0.29, 25.06 ]
MARGARIN 2002 0/109 2/157 6.0 % 0.29 [ 0.01, 5.93 ]
Norwegian 1968 13/6716 9/6690 75.9 % 1.44 [ 0.62, 3.36 ]
WAHA 2016 1/362 1/346 7.1 % 0.96 [ 0.06, 15.22 ]
Subtotal (95% CI) 7245 7245 100.0 % 1.36 [ 0.65, 2.85 ]
Total events: 17 (Higher omega 3), 13 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.46, df = 3 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 0.81 (P = 0.42)
Test for subgroup differences: Chi2 = 0.47, df = 1 (P = 0.49), I2 =0.0%
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Analysis 4.58. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 58 Stroke - ALA
- subgroup by replacement.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 4 High vs low ALA omega-3 fat (primary outcomes)
Outcome: 58 Stroke - ALA - subgroup by replacement
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 N-3 replacing SFA
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 3), 0 (Lower omega 3)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 N-3 replacing MUFA
AlphaOmega - ALA 2010 10/2409 11/2428 100.0 % 0.92 [ 0.39, 2.15 ]
Subtotal (95% CI) 2409 2428 100.0 % 0.92 [ 0.39, 2.15 ]
Total events: 10 (Higher omega 3), 11 (Lower omega 3)
Heterogeneity: not applicable
Test for overall effect: Z = 0.20 (P = 0.84)
3 N-3 replacing n-6
MARGARIN 2002 0/109 2/157 8.1 % 0.29 [ 0.01, 5.93 ]
Norwegian 1968 13/6716 9/6690 91.9 % 1.44 [ 0.62, 3.36 ]
Subtotal (95% CI) 6825 6847 100.0 % 1.26 [ 0.53, 3.01 ]
Total events: 13 (Higher omega 3), 11 (Lower omega 3)
Heterogeneity: Tau2 = 0.03; Chi2 = 1.02, df = 1 (P = 0.31); I2 =2%
Test for overall effect: Z = 0.53 (P = 0.60)
4 N-3 replacing carbohydrates/sugars
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 3), 0 (Lower omega 3)
Heterogeneity: not applicable
Test for overall effect: not applicable
5 N-3 replacing nil/low n-3 placebo
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 3), 0 (Lower omega 3)
Heterogeneity: not applicable
Test for overall effect: not applicable
6 Replacement unclear
FLAX-PAD 2013 3/58 1/52 60.6 % 2.69 [ 0.29, 25.06 ]
WAHA 2016 1/362 1/346 39.4 % 0.96 [ 0.06, 15.22 ]
Subtotal (95% CI) 420 398 100.0 % 1.79 [ 0.31, 10.17 ]
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(. . . Continued)
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Total events: 4 (Higher omega 3), 2 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.33, df = 1 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 0.66 (P = 0.51)
Test for subgroup differences: Chi2 = 0.56, df = 2 (P = 0.75), I2 =0.0%
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Analysis 4.59. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 59 Stroke - ALA
- subgroup by intervention type.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 4 High vs low ALA omega-3 fat (primary outcomes)
Outcome: 59 Stroke - ALA - subgroup by intervention type
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Dietary advice
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 3), 0 (Lower omega 3)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Supplemental foods
AlphaOmega - ALA 2010 10/2409 11/2428 42.8 % 0.92 [ 0.39, 2.15 ]
FLAX-PAD 2013 3/58 1/52 6.3 % 2.69 [ 0.29, 25.06 ]
MARGARIN 2002 0/109 2/157 3.4 % 0.29 [ 0.01, 5.93 ]
WAHA 2016 1/362 1/346 4.1 % 0.96 [ 0.06, 15.22 ]
Subtotal (95% CI) 2938 2983 56.6 % 0.97 [ 0.46, 2.03 ]
Total events: 14 (Higher omega 3), 15 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.44, df = 3 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 0.09 (P = 0.93)
3 Supplements (capsule)
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(. . . Continued)
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Norwegian 1968 13/6716 9/6690 43.4 % 1.44 [ 0.62, 3.36 ]
Subtotal (95% CI) 6716 6690 43.4 % 1.44 [ 0.62, 3.36 ]
Total events: 13 (Higher omega 3), 9 (Lower omega 3)
Heterogeneity: not applicable
Test for overall effect: Z = 0.84 (P = 0.40)
4 Any combination
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 3), 0 (Lower omega 3)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 9654 9673 100.0 % 1.15 [ 0.66, 2.01 ]
Total events: 27 (Higher omega 3), 24 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.92, df = 4 (P = 0.75); I2 =0.0%
Test for overall effect: Z = 0.48 (P = 0.63)
Test for subgroup differences: Chi2 = 0.48, df = 1 (P = 0.49), I2 =0.0%
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Analysis 4.60. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 60 Stroke - ALA
- subgroup by duration.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 4 High vs low ALA omega-3 fat (primary outcomes)
Outcome: 60 Stroke - ALA - subgroup by duration
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Medium duration 1 to < 2 years in study
FLAX-PAD 2013 3/58 1/52 6.3 % 2.69 [ 0.29, 25.06 ]
Norwegian 1968 13/6716 9/6690 43.4 % 1.44 [ 0.62, 3.36 ]
Subtotal (95% CI) 6774 6742 49.7 % 1.56 [ 0.70, 3.44 ]
Total events: 16 (Higher omega 3), 10 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.26, df = 1 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 1.09 (P = 0.27)
2 Medium-long duration: 2 to < 4 years in study
AlphaOmega - ALA 2010 10/2409 11/2428 42.8 % 0.92 [ 0.39, 2.15 ]
MARGARIN 2002 0/109 2/157 3.4 % 0.29 [ 0.01, 5.93 ]
WAHA 2016 1/362 1/346 4.1 % 0.96 [ 0.06, 15.22 ]
Subtotal (95% CI) 2880 2931 50.3 % 0.85 [ 0.39, 1.87 ]
Total events: 11 (Higher omega 3), 14 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.53, df = 2 (P = 0.77); I2 =0.0%
Test for overall effect: Z = 0.40 (P = 0.69)
3 Long duration:≥ 4 years in study
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 3), 0 (Lower omega 3)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 9654 9673 100.0 % 1.15 [ 0.66, 2.01 ]
Total events: 27 (Higher omega 3), 24 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.92, df = 4 (P = 0.75); I2 =0.0%
Test for overall effect: Z = 0.48 (P = 0.63)
Test for subgroup differences: Chi2 = 1.13, df = 1 (P = 0.29), I2 =11%
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Analysis 4.61. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 61 Stroke - ALA
- subgroup by primary or secondary prevention.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 4 High vs low ALA omega-3 fat (primary outcomes)
Outcome: 61 Stroke - ALA - subgroup by primary or secondary prevention
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Primary prevention
MARGARIN 2002 0/109 2/157 3.4 % 0.29 [ 0.01, 5.93 ]
Norwegian 1968 13/6716 9/6690 43.4 % 1.44 [ 0.62, 3.36 ]
WAHA 2016 1/362 1/346 4.1 % 0.96 [ 0.06, 15.22 ]
Subtotal (95% CI) 7187 7193 50.9 % 1.25 [ 0.57, 2.74 ]
Total events: 14 (Higher omega 3), 12 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.06, df = 2 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 0.56 (P = 0.58)
2 Secondary prevention
AlphaOmega - ALA 2010 10/2409 11/2428 42.8 % 0.92 [ 0.39, 2.15 ]
FLAX-PAD 2013 3/58 1/52 6.3 % 2.69 [ 0.29, 25.06 ]
Subtotal (95% CI) 2467 2480 49.1 % 1.05 [ 0.47, 2.34 ]
Total events: 13 (Higher omega 3), 12 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.78, df = 1 (P = 0.38); I2 =0.0%
Test for overall effect: Z = 0.12 (P = 0.90)
Total (95% CI) 9654 9673 100.0 % 1.15 [ 0.66, 2.01 ]
Total events: 27 (Higher omega 3), 24 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.92, df = 4 (P = 0.75); I2 =0.0%
Test for overall effect: Z = 0.48 (P = 0.63)
Test for subgroup differences: Chi2 = 0.09, df = 1 (P = 0.76), I2 =0.0%
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Analysis 4.62. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 62 Stroke - ALA
- subgroup by statin use.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 4 High vs low ALA omega-3 fat (primary outcomes)
Outcome: 62 Stroke - ALA - subgroup by statin use
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 ALA -≥ 50% of control group on statins
AlphaOmega - EPA+DHA 2010 11/2404 10/2433 42.8 % 1.11 [ 0.47, 2.62 ]
FLAX-PAD 2013 3/58 1/52 6.3 % 2.69 [ 0.29, 25.06 ]
Subtotal (95% CI) 2462 2485 49.1 % 1.25 [ 0.56, 2.77 ]
Total events: 14 (Higher omega 3), 11 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.52, df = 1 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 0.54 (P = 0.59)
2 ALA - < 50% of control group on statins
MARGARIN 2002 0/109 2/157 3.4 % 0.29 [ 0.01, 5.93 ]
Norwegian 1968 13/6716 9/6690 43.4 % 1.44 [ 0.62, 3.36 ]
WAHA 2016 1/362 1/346 4.1 % 0.96 [ 0.06, 15.22 ]
Subtotal (95% CI) 7187 7193 50.9 % 1.25 [ 0.57, 2.74 ]
Total events: 14 (Higher omega 3), 12 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.06, df = 2 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 0.56 (P = 0.58)
Total (95% CI) 9649 9678 100.0 % 1.25 [ 0.71, 2.18 ]
Total events: 28 (Higher omega 3), 23 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.57, df = 4 (P = 0.81); I2 =0.0%
Test for overall effect: Z = 0.78 (P = 0.44)
Test for subgroup differences: Chi2 = 0.00, df = 1 (P = 1.00), I2 =0.0%
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Analysis 4.63. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 63 Stroke - ALA
- subgroup by stroke type.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 4 High vs low ALA omega-3 fat (primary outcomes)
Outcome: 63 Stroke - ALA - subgroup by stroke type
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Ischaemic stroke - ALA
FLAX-PAD 2013 3/58 1/52 11.8 % 2.69 [ 0.29, 25.06 ]
MARGARIN 2002 0/109 2/157 6.4 % 0.29 [ 0.01, 5.93 ]
Norwegian 1968 13/6716 9/6690 81.7 % 1.44 [ 0.62, 3.36 ]
Subtotal (95% CI) 6883 6899 100.0 % 1.40 [ 0.65, 3.01 ]
Total events: 16 (Higher omega 3), 12 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.39, df = 2 (P = 0.50); I2 =0.0%
Test for overall effect: Z = 0.85 (P = 0.39)
2 Haemorrhagic stroke - ALA
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 3), 0 (Lower omega 3)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 6883 6899 100.0 % 1.40 [ 0.65, 3.01 ]
Total events: 16 (Higher omega 3), 12 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.39, df = 2 (P = 0.50); I2 =0.0%
Test for overall effect: Z = 0.85 (P = 0.39)
Test for subgroup differences: Not applicable
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Analysis 4.64. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 64 Arrythmia
(overall) - ALA.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 4 High vs low ALA omega-3 fat (primary outcomes)
Outcome: 64 Arrythmia (overall) - ALA
Study or subgroup
Favours
higher
omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 ALA - new arrhythmias
AlphaOmega - ALA 2010 62/2409 79/2428 100.0 % 0.79 [ 0.57, 1.10 ]
Subtotal (95% CI) 2409 2428 100.0 % 0.79 [ 0.57, 1.10 ]
Total events: 62 (Favours higher omega 3), 79 (Lower omega 3)
Heterogeneity: not applicable
Test for overall effect: Z = 1.40 (P = 0.16)
2 ALA - recurrent arrhythmias
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Favours higher omega 3), 0 (Lower omega 3)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 2409 2428 100.0 % 0.79 [ 0.57, 1.10 ]
Total events: 62 (Favours higher omega 3), 79 (Lower omega 3)
Heterogeneity: not applicable
Test for overall effect: Z = 1.40 (P = 0.16)
Test for subgroup differences: Not applicable
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Analysis 4.65. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 65 Arrhythmia -
ALA - SA by summary risk of bias.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 4 High vs low ALA omega-3 fat (primary outcomes)
Outcome: 65 Arrhythmia - ALA - SA by summary risk of bias
Study or subgroup
Favours
higher
omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Low risk of bias
AlphaOmega - ALA 2010 62/2409 79/2428 100.0 % 0.79 [ 0.57, 1.10 ]
Subtotal (95% CI) 2409 2428 100.0 % 0.79 [ 0.57, 1.10 ]
Total events: 62 (Favours higher omega 3), 79 (Lower omega 3)
Heterogeneity: not applicable
Test for overall effect: Z = 1.40 (P = 0.16)
2 Moderate/high risk of bias
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Favours higher omega 3), 0 (Lower omega 3)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 2409 2428 100.0 % 0.79 [ 0.57, 1.10 ]
Total events: 62 (Favours higher omega 3), 79 (Lower omega 3)
Heterogeneity: not applicable
Test for overall effect: Z = 1.40 (P = 0.16)
Test for subgroup differences: Not applicable
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Analysis 5.1. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 1 MACCEs -
ALA.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 5 High vs low ALA omega-3 fat (secondary outcomes)
Outcome: 1 MACCEs - ALA
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
FLAX-PAD 2013 5/58 4/52 100.0 % 1.12 [ 0.32, 3.95 ]
Total (95% CI) 58 52 100.0 % 1.12 [ 0.32, 3.95 ]
Total events: 5 (Higher omega 3), 4 (Lower omega 3)
Heterogeneity: not applicable
Test for overall effect: Z = 0.18 (P = 0.86)
Test for subgroup differences: Not applicable
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Analysis 5.2. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 2 Myocardial
infarction (overall) - ALA.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 5 High vs low ALA omega-3 fat (secondary outcomes)
Outcome: 2 Myocardial infarction (overall) - ALA
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
AlphaOmega - ALA 2010 90/2409 101/2428 54.4 % 0.90 [ 0.68, 1.19 ]
FLAX-PAD 2013 1/58 3/52 1.5 % 0.30 [ 0.03, 2.78 ]
Norwegian 1968 75/6716 63/6690 44.0 % 1.19 [ 0.85, 1.65 ]
Total (95% CI) 9183 9170 100.0 % 1.00 [ 0.76, 1.32 ]
Total events: 166 (Higher omega 3), 167 (Lower omega 3)
Heterogeneity: Tau2 = 0.02; Chi2 = 2.70, df = 2 (P = 0.26); I2 =26%
Test for overall effect: Z = 0.01 (P = 0.99)
Test for subgroup differences: Not applicable
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Analysis 5.3. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 3 Total MI -
ALA - subgroup by fatality.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 5 High vs low ALA omega-3 fat (secondary outcomes)
Outcome: 3 Total MI - ALA - subgroup by fatality
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Fatal MI
AlphaOmega - ALA 2010 39/2409 42/2428 98.2 % 0.94 [ 0.61, 1.44 ]
FLAX-PAD 2013 1/58 0/52 1.8 % 2.69 [ 0.11, 64.74 ]
Subtotal (95% CI) 2467 2480 100.0 % 0.95 [ 0.62, 1.46 ]
Total events: 40 (Higher omega 3), 42 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.42, df = 1 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 0.22 (P = 0.83)
2 Non-fatal MI
AlphaOmega - ALA 2010 51/2409 59/2428 71.5 % 0.87 [ 0.60, 1.26 ]
FLAX-PAD 2013 0/58 3/52 14.1 % 0.13 [ 0.01, 2.43 ]
MARGARIN 2002 0/109 4/157 14.4 % 0.16 [ 0.01, 2.93 ]
Subtotal (95% CI) 2576 2637 100.0 % 0.52 [ 0.15, 1.77 ]
Total events: 51 (Higher omega 3), 66 (Lower omega 3)
Heterogeneity: Tau2 = 0.51; Chi2 = 2.90, df = 2 (P = 0.24); I2 =31%
Test for overall effect: Z = 1.04 (P = 0.30)
Test for subgroup differences: Chi2 = 0.84, df = 1 (P = 0.36), I2 =0.0%
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Analysis 5.4. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 4 Angina - ALA.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 5 High vs low ALA omega-3 fat (secondary outcomes)
Outcome: 4 Angina - ALA
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
FLAX-PAD 2013 1/58 0/52 3.9 % 2.69 [ 0.11, 64.74 ]
Norwegian 1968 22/6716 16/6690 96.1 % 1.37 [ 0.72, 2.61 ]
Total (95% CI) 6774 6742 100.0 % 1.41 [ 0.75, 2.64 ]
Total events: 23 (Higher omega 3), 16 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.17, df = 1 (P = 0.68); I2 =0.0%
Test for overall effect: Z = 1.06 (P = 0.29)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours higher omega 3 Favours lower omega 3
645Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 5.5. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 5
Revascularisation - ALA.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 5 High vs low ALA omega-3 fat (secondary outcomes)
Outcome: 5 Revascularisation - ALA
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 CABG - ALA
MARGARIN 2002 0/109 2/157 100.0 % 0.29 [ 0.01, 5.93 ]
Subtotal (95% CI) 109 157 100.0 % 0.29 [ 0.01, 5.93 ]
Total events: 0 (Higher omega 3), 2 (Lower omega 3)
Heterogeneity: not applicable
Test for overall effect: Z = 0.81 (P = 0.42)
2 Angioplasty - ALA
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 3), 0 (Lower omega 3)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Any revascularisation - ALA
MARGARIN 2002 1/109 2/157 100.0 % 0.72 [ 0.07, 7.84 ]
Subtotal (95% CI) 109 157 100.0 % 0.72 [ 0.07, 7.84 ]
Total events: 1 (Higher omega 3), 2 (Lower omega 3)
Heterogeneity: not applicable
Test for overall effect: Z = 0.27 (P = 0.79)
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Analysis 5.6. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 6 Peripheral
arterial disease - ALA.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 5 High vs low ALA omega-3 fat (secondary outcomes)
Outcome: 6 Peripheral arterial disease - ALA
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Norwegian 1968 2/6716 8/6690 0.25 [ 0.05, 1.17 ]
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Analysis 5.7. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 7 Body weight,
kg - ALA.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 5 High vs low ALA omega-3 fat (secondary outcomes)
Outcome: 7 Body weight, kg - ALA
Study or subgroup
Favours
higher
omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Dodin 2005 85 65.3 (11.2) 94 69.5 (12.1) 21.2 % -4.20 [ -7.61, -0.79 ]
HERO 2009 18 92 (17.1) 17 92.3 (13.8) 5.6 % -0.30 [ -10.57, 9.97 ]
MENU 2016 (1) 35 -8.1 (7.0993) 37 -4.3 (6.0828) 22.7 % -3.80 [ -6.86, -0.74 ]
MENU 2016 (2) 34 -6.8 (8.1633) 32 -7 (7.9196) 19.2 % 0.20 [ -3.68, 4.08 ]
WAHA 2016 156 -0.29 (3.85) 156 -1.05 (3.85) 31.3 % 0.76 [ -0.09, 1.61 ]
Total (95% CI) 328 336 100.0 % -1.49 [ -4.17, 1.18 ]
Heterogeneity: Tau2 = 5.76; Chi2 = 14.60, df = 4 (P = 0.01); I2 =73%
Test for overall effect: Z = 1.09 (P = 0.27)
Test for subgroup differences: Not applicable
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(1) Insulin sensitive participants
(2) Insulin resistant participants
Analysis 5.8. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 8 Weight, kg -
ALA - sensitivity analysis (SA) fixed-effect.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 5 High vs low ALA omega-3 fat (secondary outcomes)
Outcome: 8 Weight, kg - ALA - sensitivity analysis (SA) fixed-effect
Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Dodin 2005 85 65.3 (11.2) 94 69.5 (12.1) 5.2 % -4.20 [ -7.61, -0.79 ]
HERO 2009 18 92 (17.1) 17 92.3 (13.8) 0.6 % -0.30 [ -10.57, 9.97 ]
MENU 2016 (1) 34 -6.8 (8.1633) 32 -7 (7.9196) 4.1 % 0.20 [ -3.68, 4.08 ]
MENU 2016 (2) 35 -8.1 (7.0993) 37 -4.3 (6.0828) 6.5 % -3.80 [ -6.86, -0.74 ]
WAHA 2016 156 -0.29 (3.85) 156 -1.05 (3.85) 83.6 % 0.76 [ -0.09, 1.61 ]
Total (95% CI) 328 336 100.0 % 0.17 [ -0.61, 0.96 ]
Heterogeneity: Chi2 = 14.60, df = 4 (P = 0.01); I2 =73%
Test for overall effect: Z = 0.44 (P = 0.66)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
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Analysis 5.9. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 9 Weight, kg -
ALA - SA by summary risk of bias.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 5 High vs low ALA omega-3 fat (secondary outcomes)
Outcome: 9 Weight, kg - ALA - SA by summary risk of bias
Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Low risk of bias
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Moderate/high risk of bias
Dodin 2005 85 65.3 (11.2) 94 69.5 (12.1) 21.2 % -4.20 [ -7.61, -0.79 ]
HERO 2009 18 92 (17.1) 17 92.3 (13.8) 5.6 % -0.30 [ -10.57, 9.97 ]
MENU 2016 (1) 35 -8.1 (7.0993) 37 -4.3 (6.0828) 22.7 % -3.80 [ -6.86, -0.74 ]
MENU 2016 (2) 34 -6.8 (8.1633) 32 -7 (7.9196) 19.2 % 0.20 [ -3.68, 4.08 ]
WAHA 2016 156 -0.29 (3.85) 156 -1.05 (3.85) 31.3 % 0.76 [ -0.09, 1.61 ]
Subtotal (95% CI) 328 336 100.0 % -1.49 [ -4.17, 1.18 ]
Heterogeneity: Tau2 = 5.76; Chi2 = 14.60, df = 4 (P = 0.01); I2 =73%
Test for overall effect: Z = 1.09 (P = 0.27)
-20 -10 0 10 20
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Analysis 5.10. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 10 Weight, kg
- ALA - SA by compliance and study size.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 5 High vs low ALA omega-3 fat (secondary outcomes)
Outcome: 10 Weight, kg - ALA - SA by compliance and study size
Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 SA - low risk of compliance bias
Dodin 2005 85 65.3 (11.2) 94 69.5 (12.1) 22.7 % -4.20 [ -7.61, -0.79 ]
MENU 2016 (1) 34 -6.8 (8.1633) 32 -7 (7.9196) 20.8 % 0.20 [ -3.68, 4.08 ]
MENU 2016 (2) 35 -8.1 (7.0993) 37 -4.3 (6.0828) 24.2 % -3.80 [ -6.86, -0.74 ]
WAHA 2016 156 -0.29 (3.85) 156 -1.05 (3.85) 32.3 % 0.76 [ -0.09, 1.61 ]
Subtotal (95% CI) 310 319 100.0 % -1.59 [ -4.47, 1.30 ]
Heterogeneity: Tau2 = 6.52; Chi2 = 14.59, df = 3 (P = 0.002); I2 =79%
Test for overall effect: Z = 1.08 (P = 0.28)
2 SA - 100+ randomised
Dodin 2005 85 65.3 (11.2) 94 69.5 (12.1) 22.7 % -4.20 [ -7.61, -0.79 ]
MENU 2016 (3) 35 -8.1 (7.0993) 37 -4.3 (6.0828) 24.2 % -3.80 [ -6.86, -0.74 ]
MENU 2016 (4) 34 -6.8 (8.1633) 32 -7 (7.9196) 20.8 % 0.20 [ -3.68, 4.08 ]
WAHA 2016 156 -0.29 (3.85) 156 -1.05 (3.85) 32.3 % 0.76 [ -0.09, 1.61 ]
Subtotal (95% CI) 310 319 100.0 % -1.59 [ -4.47, 1.30 ]
Heterogeneity: Tau2 = 6.52; Chi2 = 14.59, df = 3 (P = 0.002); I2 =79%
Test for overall effect: Z = 1.08 (P = 0.28)
-20 -10 0 10 20
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(3) Insulin sensitive participants
(4) Insulin resistant participants
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Analysis 5.11. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 11 Weight, kg
- ALA - subgroup by dose.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 5 High vs low ALA omega-3 fat (secondary outcomes)
Outcome: 11 Weight, kg - ALA - subgroup by dose
Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 ALA low < 5 g/d
HERO 2009 18 92 (17.1) 17 92.3 (13.8) 5.6 % -0.30 [ -10.57, 9.97 ]
MENU 2016 (1) 35 -8.1 (7.0993) 37 -4.3 (6.0828) 28.0 % -3.80 [ -6.86, -0.74 ]
MENU 2016 (2) 34 -6.8 (8.1633) 32 -7 (7.9196) 22.7 % 0.20 [ -3.68, 4.08 ]
WAHA 2016 156 -0.29 (3.85) 156 -1.05 (3.85) 43.6 % 0.76 [ -0.09, 1.61 ]
Subtotal (95% CI) 243 242 100.0 % -0.71 [ -3.31, 1.90 ]
Heterogeneity: Tau2 = 3.85; Chi2 = 7.94, df = 3 (P = 0.05); I2 =62%
Test for overall effect: Z = 0.53 (P = 0.60)
2 ALA high > 5 g/d
Dodin 2005 85 65.3 (11.2) 94 69.5 (12.1) 100.0 % -4.20 [ -7.61, -0.79 ]
Subtotal (95% CI) 85 94 100.0 % -4.20 [ -7.61, -0.79 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.41 (P = 0.016)
Test for subgroup differences: Chi2 = 2.55, df = 1 (P = 0.11), I2 =61%
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Analysis 5.12. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 12 Weight, kg
- ALA - subgroup by intervention type.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 5 High vs low ALA omega-3 fat (secondary outcomes)
Outcome: 12 Weight, kg - ALA - subgroup by intervention type
Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Dietary advice
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Supplemental foods
Dodin 2005 85 65.3 (11.2) 94 69.5 (12.1) 37.7 % -4.20 [ -7.61, -0.79 ]
HERO 2009 18 92 (17.1) 17 92.3 (13.8) 11.9 % -0.30 [ -10.57, 9.97 ]
WAHA 2016 156 -0.29 (3.85) 156 -1.05 (3.85) 50.4 % 0.76 [ -0.09, 1.61 ]
Subtotal (95% CI) 259 267 100.0 % -1.23 [ -5.27, 2.80 ]
Heterogeneity: Tau2 = 8.21; Chi2 = 7.65, df = 2 (P = 0.02); I2 =74%
Test for overall effect: Z = 0.60 (P = 0.55)
3 Supplement (capsule)
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
4 Any combination
MENU 2016 (1) 35 -8.1 (7.0993) 37 -4.3 (6.0828) 54.6 % -3.80 [ -6.86, -0.74 ]
MENU 2016 (2) 34 -6.8 (8.1633) 32 -7 (7.9196) 45.4 % 0.20 [ -3.68, 4.08 ]
Subtotal (95% CI) 69 69 100.0 % -1.98 [ -5.89, 1.92 ]
Heterogeneity: Tau2 = 4.82; Chi2 = 2.52, df = 1 (P = 0.11); I2 =60%
Test for overall effect: Z = 1.00 (P = 0.32)
Test for subgroup differences: Chi2 = 0.07, df = 1 (P = 0.79), I2 =0.0%
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Analysis 5.13. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 13 Weight, kg
- ALA - subgroup by replacement.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 5 High vs low ALA omega-3 fat (secondary outcomes)
Outcome: 13 Weight, kg - ALA - subgroup by replacement
Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 ALA replacing SFA
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
2 ALA replacing MUFA
MENU 2016 (1) 35 -8.1 (7.0993) 37 -4.3 (6.0828) 54.6 % -3.80 [ -6.86, -0.74 ]
MENU 2016 (2) 34 -6.8 (8.1633) 32 -7 (7.9196) 45.4 % 0.20 [ -3.68, 4.08 ]
Subtotal (95% CI) 69 69 100.0 % -1.98 [ -5.89, 1.92 ]
Heterogeneity: Tau2 = 4.82; Chi2 = 2.52, df = 1 (P = 0.11); I2 =60%
Test for overall effect: Z = 1.00 (P = 0.32)
3 ALA replacing n-6
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
4 ALA replacing carbs/sugars
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
5 ALA replacing nil/low n-3 placebo
HERO 2009 18 92 (17.1) 17 92.3 (13.8) 100.0 % -0.30 [ -10.57, 9.97 ]
Subtotal (95% CI) 18 17 100.0 % -0.30 [ -10.57, 9.97 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.06 (P = 0.95)
6 Replacement unclear
Dodin 2005 85 65.3 (11.2) 94 69.5 (12.1) 44.2 % -4.20 [ -7.61, -0.79 ]
WAHA 2016 156 -0.29 (3.85) 156 -1.05 (3.85) 55.8 % 0.76 [ -0.09, 1.61 ]
Subtotal (95% CI) 241 250 100.0 % -1.43 [ -6.26, 3.39 ]
Heterogeneity: Tau2 = 10.69; Chi2 = 7.63, df = 1 (P = 0.01); I2 =87%
Test for overall effect: Z = 0.58 (P = 0.56)
Test for subgroup differences: Chi2 = 0.10, df = 2 (P = 0.95), I2 =0.0%
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Analysis 5.14. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 14 Weight, kg
- ALA - subgroup by duration.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 5 High vs low ALA omega-3 fat (secondary outcomes)
Outcome: 14 Weight, kg - ALA - subgroup by duration
Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Medium duration 1 to < 2 years in study
Dodin 2005 85 65.3 (11.2) 94 69.5 (12.1) 21.2 % -4.20 [ -7.61, -0.79 ]
HERO 2009 18 92 (17.1) 17 92.3 (13.8) 5.6 % -0.30 [ -10.57, 9.97 ]
MENU 2016 (1) 34 -6.8 (8.1633) 32 -7 (7.9196) 19.2 % 0.20 [ -3.68, 4.08 ]
MENU 2016 (2) 35 -8.1 (7.0993) 37 -4.3 (6.0828) 22.7 % -3.80 [ -6.86, -0.74 ]
WAHA 2016 156 -0.29 (3.85) 156 -1.05 (3.85) 31.3 % 0.76 [ -0.09, 1.61 ]
Subtotal (95% CI) 328 336 100.0 % -1.49 [ -4.17, 1.18 ]
Heterogeneity: Tau2 = 5.76; Chi2 = 14.60, df = 4 (P = 0.01); I2 =73%
Test for overall effect: Z = 1.09 (P = 0.27)
2 Medium-long duration: 2 to < 4 years in study
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Long duration≥ 4 years in study
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 5.15. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 15 Weight, kg
- ALA - subgroup by statin use.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 5 High vs low ALA omega-3 fat (secondary outcomes)
Outcome: 15 Weight, kg - ALA - subgroup by statin use
Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 ALA -≥ 50% of control group on statins
HERO 2009 18 92 (17.1) 17 92.3 (13.8) 100.0 % -0.30 [ -10.57, 9.97 ]
Subtotal (95% CI) 18 17 100.0 % -0.30 [ -10.57, 9.97 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.06 (P = 0.95)
2 ALA - < 50% of control group on statins
MENU 2016 (1) 34 -6.8 (8.1633) 32 -7 (7.9196) 45.4 % 0.20 [ -3.68, 4.08 ]
MENU 2016 (2) 35 -8.1 (7.0993) 37 -4.3 (6.0828) 54.6 % -3.80 [ -6.86, -0.74 ]
Subtotal (95% CI) 69 69 100.0 % -1.98 [ -5.89, 1.92 ]
Heterogeneity: Tau2 = 4.82; Chi2 = 2.52, df = 1 (P = 0.11); I2 =60%
Test for overall effect: Z = 1.00 (P = 0.32)
3 ALA - use of statins unclear
Dodin 2005 85 65.3 (11.2) 94 69.5 (12.1) 44.2 % -4.20 [ -7.61, -0.79 ]
WAHA 2016 156 -0.29 (3.85) 156 -1.05 (3.85) 55.8 % 0.76 [ -0.09, 1.61 ]
Subtotal (95% CI) 241 250 100.0 % -1.43 [ -6.26, 3.39 ]
Heterogeneity: Tau2 = 10.69; Chi2 = 7.63, df = 1 (P = 0.01); I2 =87%
Test for overall effect: Z = 0.58 (P = 0.56)
Test for subgroup differences: Chi2 = 0.10, df = 2 (P = 0.95), I2 =0.0%
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Analysis 5.16. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 16 Weight, kg
- ALA - subgroup by primary or secondary prevention.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 5 High vs low ALA omega-3 fat (secondary outcomes)
Outcome: 16 Weight, kg - ALA - subgroup by primary or secondary prevention
Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Low CVD risk
Dodin 2005 85 65.3 (11.2) 94 69.5 (12.1) 22.7 % -4.20 [ -7.61, -0.79 ]
MENU 2016 (1) 34 -6.8 (8.1633) 32 -7 (7.9196) 20.8 % 0.20 [ -3.68, 4.08 ]
MENU 2016 (2) 35 -8.1 (7.0993) 37 -4.3 (6.0828) 24.2 % -3.80 [ -6.86, -0.74 ]
WAHA 2016 156 -0.29 (3.85) 156 -1.05 (3.85) 32.3 % 0.76 [ -0.09, 1.61 ]
Subtotal (95% CI) 310 319 100.0 % -1.59 [ -4.47, 1.30 ]
Heterogeneity: Tau2 = 6.52; Chi2 = 14.59, df = 3 (P = 0.002); I2 =79%
Test for overall effect: Z = 1.08 (P = 0.28)
2 Moderate CVD risk
HERO 2009 18 92 (17.1) 17 92.3 (13.8) 100.0 % -0.30 [ -10.57, 9.97 ]
Subtotal (95% CI) 18 17 100.0 % -0.30 [ -10.57, 9.97 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.06 (P = 0.95)
3 High CVD risk
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Chi2 = 0.06, df = 1 (P = 0.81), I2 =0.0%
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Analysis 5.17. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 17 Body mass
index, kg/m² - ALA.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 5 High vs low ALA omega-3 fat (secondary outcomes)
Outcome: 17 Body mass index, kg/m2 - ALA
Study or subgroup
Favours
higher
omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
AlphaOmega - ALA 2010 (1) 630 0.07 (1.5) 630 -0.08 (1.8) 51.2 % 0.15 [ -0.03, 0.33 ]
Dodin 2005 85 25.9 (4.5) 94 27.4 (4.8) 29.2 % -1.50 [ -2.86, -0.14 ]
MARGARIN 2002 49 0.2 (1.4) 93 0.5 (9.6) 19.5 % -0.30 [ -2.29, 1.69 ]
Total (95% CI) 764 817 100.0 % -0.42 [ -1.53, 0.69 ]
Heterogeneity: Tau2 = 0.62; Chi2 = 5.70, df = 2 (P = 0.06); I2 =65%
Test for overall effect: Z = 0.74 (P = 0.46)
Test for subgroup differences: Not applicable
-0.5 -0.25 0 0.25 0.5
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(1) Numer of participants equally divided between groups
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Analysis 5.18. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 18 BMI, kg/m²
- ALA - SA fixed-effect.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 5 High vs low ALA omega-3 fat (secondary outcomes)
Outcome: 18 BMI, kg/m2 - ALA - SA fixed-effect
Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
AlphaOmega - ALA 2010 630 0.07 (1.5) 630 -0.08 (1.8) 97.4 % 0.15 [ -0.03, 0.33 ]
Dodin 2005 85 25.9 (4.5) 94 27.4 (4.8) 1.8 % -1.50 [ -2.86, -0.14 ]
MARGARIN 2002 49 0.2 (1.4) 93 0.5 (9.6) 0.8 % -0.30 [ -2.29, 1.69 ]
Total (95% CI) 764 817 100.0 % 0.12 [ -0.06, 0.30 ]
Heterogeneity: Chi2 = 5.70, df = 2 (P = 0.06); I2 =65%
Test for overall effect: Z = 1.27 (P = 0.20)
Test for subgroup differences: Not applicable
-0.5 -0.25 0 0.25 0.5
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Analysis 5.19. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 19 BMI, kg/m²
- ALA - SA by summary risk of bias.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 5 High vs low ALA omega-3 fat (secondary outcomes)
Outcome: 19 BMI, kg/m2 - ALA - SA by summary risk of bias
Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Low risk of bias
AlphaOmega - ALA 2010 630 0.07 (1.5) 630 -0.08 (1.8) 99.2 % 0.15 [ -0.03, 0.33 ]
MARGARIN 2002 49 0.2 (1.4) 93 0.5 (9.6) 0.8 % -0.30 [ -2.29, 1.69 ]
Subtotal (95% CI) 679 723 100.0 % 0.15 [ -0.04, 0.33 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.19, df = 1 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 1.57 (P = 0.12)
2 Moderate/high risk of bias
Dodin 2005 85 25.9 (4.5) 94 27.4 (4.8) 100.0 % -1.50 [ -2.86, -0.14 ]
Subtotal (95% CI) 85 94 100.0 % -1.50 [ -2.86, -0.14 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.16 (P = 0.031)
Test for subgroup differences: Chi2 = 5.51, df = 1 (P = 0.02), I2 =82%
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Analysis 5.20. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 20 BMI, kg/m²
- ALA - SA by compliance and study size.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 5 High vs low ALA omega-3 fat (secondary outcomes)
Outcome: 20 BMI, kg/m2 - ALA - SA by compliance and study size
Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 SA - low risk of compliance bias
AlphaOmega - ALA 2010 630 0.07 (1.5) 630 -0.08 (1.8) 51.2 % 0.15 [ -0.03, 0.33 ]
Dodin 2005 85 25.9 (4.5) 94 27.4 (4.8) 29.2 % -1.50 [ -2.86, -0.14 ]
MARGARIN 2002 49 0.2 (1.4) 93 0.5 (9.6) 19.5 % -0.30 [ -2.29, 1.69 ]
Subtotal (95% CI) 764 817 100.0 % -0.42 [ -1.53, 0.69 ]
Heterogeneity: Tau2 = 0.62; Chi2 = 5.70, df = 2 (P = 0.06); I2 =65%
Test for overall effect: Z = 0.74 (P = 0.46)
2 SA - 100+ randomised
AlphaOmega - ALA 2010 630 0.07 (1.5) 630 -0.08 (1.8) 51.2 % 0.15 [ -0.03, 0.33 ]
Dodin 2005 85 25.9 (4.5) 94 27.4 (4.8) 29.2 % -1.50 [ -2.86, -0.14 ]
MARGARIN 2002 49 0.2 (1.4) 93 0.5 (9.6) 19.5 % -0.30 [ -2.29, 1.69 ]
Subtotal (95% CI) 764 817 100.0 % -0.42 [ -1.53, 0.69 ]
Heterogeneity: Tau2 = 0.62; Chi2 = 5.70, df = 2 (P = 0.06); I2 =65%
Test for overall effect: Z = 0.74 (P = 0.46)
Test for subgroup differences: Chi2 = 0.0, df = 1 (P = 1.00), I2 =0.0%
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Analysis 5.21. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 21 BMI, kg/m²
- ALA - subgroup by dose.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 5 High vs low ALA omega-3 fat (secondary outcomes)
Outcome: 21 BMI, kg/m2 - ALA - subgroup by dose
Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 ALA low < 5 g/d
AlphaOmega - ALA 2010 630 0.07 (1.5) 630 -0.08 (1.8) 100.0 % 0.15 [ -0.03, 0.33 ]
Subtotal (95% CI) 630 630 100.0 % 0.15 [ -0.03, 0.33 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.61 (P = 0.11)
2 ALA high > 5 g/d
Dodin 2005 85 25.9 (4.5) 94 27.4 (4.8) 68.1 % -1.50 [ -2.86, -0.14 ]
MARGARIN 2002 49 0.2 (1.4) 93 0.5 (9.6) 31.9 % -0.30 [ -2.29, 1.69 ]
Subtotal (95% CI) 134 187 100.0 % -1.12 [ -2.24, 0.01 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.95, df = 1 (P = 0.33); I2 =0.0%
Test for overall effect: Z = 1.95 (P = 0.052)
Test for subgroup differences: Chi2 = 4.75, df = 1 (P = 0.03), I2 =79%
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Analysis 5.22. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 22 BMI, kg/m²
- ALA - subgroup by intervention type.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 5 High vs low ALA omega-3 fat (secondary outcomes)
Outcome: 22 BMI, kg/m2 - ALA - subgroup by intervention type
Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Dietary advice
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Supplemental foods
AlphaOmega - ALA 2010 630 0.07 (1.5) 630 -0.08 (1.8) 51.2 % 0.15 [ -0.03, 0.33 ]
Dodin 2005 85 25.9 (4.5) 94 27.4 (4.8) 29.2 % -1.50 [ -2.86, -0.14 ]
MARGARIN 2002 49 0.2 (1.4) 93 0.5 (9.6) 19.5 % -0.30 [ -2.29, 1.69 ]
Subtotal (95% CI) 764 817 100.0 % -0.42 [ -1.53, 0.69 ]
Heterogeneity: Tau2 = 0.62; Chi2 = 5.70, df = 2 (P = 0.06); I2 =65%
Test for overall effect: Z = 0.74 (P = 0.46)
3 Supplement (capsule)
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
4 Any combination
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 5.23. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 23 BMI, kg/m²
- ALA - subgroup by replacement.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 5 High vs low ALA omega-3 fat (secondary outcomes)
Outcome: 23 BMI, kg/m2 - ALA - subgroup by replacement
Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 ALA replacing SFA
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
2 ALA replacing MUFA
AlphaOmega - ALA 2010 630 0.07 (1.5) 630 -0.08 (1.8) 51.2 % 0.15 [ -0.03, 0.33 ]
Subtotal (95% CI) 630 630 51.2 % 0.15 [ -0.03, 0.33 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.61 (P = 0.11)
3 ALA replacing n-6
MARGARIN 2002 49 0.2 (1.4) 93 0.5 (9.6) 19.5 % -0.30 [ -2.29, 1.69 ]
Subtotal (95% CI) 49 93 19.5 % -0.30 [ -2.29, 1.69 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.30 (P = 0.77)
4 ALA replacing carbs/sugars
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
5 ALA replacing nil/low n-3 placebo
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
6 Replacement unclear
Dodin 2005 85 25.9 (4.5) 94 27.4 (4.8) 29.2 % -1.50 [ -2.86, -0.14 ]
Subtotal (95% CI) 85 94 29.2 % -1.50 [ -2.86, -0.14 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.16 (P = 0.031)
Total (95% CI) 764 817 100.0 % -0.42 [ -1.53, 0.69 ]
Heterogeneity: Tau2 = 0.62; Chi2 = 5.70, df = 2 (P = 0.06); I2 =65%
Test for overall effect: Z = 0.74 (P = 0.46)
Test for subgroup differences: Chi2 = 5.70, df = 2 (P = 0.06), I2 =65%
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Analysis 5.24. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 24 BMI, kg/m²
- ALA - subgroup by duration.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 5 High vs low ALA omega-3 fat (secondary outcomes)
Outcome: 24 BMI, kg/m2 - ALA - subgroup by duration
Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Medium duration 1 to < 2 years in study
Dodin 2005 85 25.9 (4.5) 94 27.4 (4.8) 100.0 % -1.50 [ -2.86, -0.14 ]
Subtotal (95% CI) 85 94 100.0 % -1.50 [ -2.86, -0.14 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.16 (P = 0.031)
2 Medium-long duration: 2 to < 4 years in study
AlphaOmega - ALA 2010 630 0.07 (1.5) 630 -0.08 (1.8) 99.2 % 0.15 [ -0.03, 0.33 ]
MARGARIN 2002 49 0.2 (1.4) 93 0.5 (9.6) 0.8 % -0.30 [ -2.29, 1.69 ]
Subtotal (95% CI) 679 723 100.0 % 0.15 [ -0.04, 0.33 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.19, df = 1 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 1.57 (P = 0.12)
3 Long duration≥ 4 years in study
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Chi2 = 5.51, df = 1 (P = 0.02), I2 =82%
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Analysis 5.25. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 25 BMI, kg/m²
- ALA - subgroup by statin use.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 5 High vs low ALA omega-3 fat (secondary outcomes)
Outcome: 25 BMI, kg/m2 - ALA - subgroup by statin use
Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 ALA -≥ 50% of control group on statins
AlphaOmega - ALA 2010 630 0.07 (1.5) 630 -0.08 (1.8) 100.0 % 0.15 [ -0.03, 0.33 ]
Subtotal (95% CI) 630 630 100.0 % 0.15 [ -0.03, 0.33 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.61 (P = 0.11)
2 ALA - < 50% of control group on statins
MARGARIN 2002 49 0.2 (1.4) 93 0.5 (9.6) 100.0 % -0.30 [ -2.29, 1.69 ]
Subtotal (95% CI) 49 93 100.0 % -0.30 [ -2.29, 1.69 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.30 (P = 0.77)
3 ALA - use of statins unclear
Dodin 2005 85 25.9 (4.5) 94 27.4 (4.8) 100.0 % -1.50 [ -2.86, -0.14 ]
Subtotal (95% CI) 85 94 100.0 % -1.50 [ -2.86, -0.14 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.16 (P = 0.031)
Test for subgroup differences: Chi2 = 5.70, df = 2 (P = 0.06), I2 =65%
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Analysis 5.26. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 26 BMI, kg/m²
- ALA - subgroup by primary or secondary preventionA.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 5 High vs low ALA omega-3 fat (secondary outcomes)
Outcome: 26 BMI, kg/m2 - ALA - subgroup by primary or secondary preventionA
Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Primary prevention of CVD
Dodin 2005 85 25.9 (4.5) 94 27.4 (4.8) 68.1 % -1.50 [ -2.86, -0.14 ]
MARGARIN 2002 49 0.2 (1.4) 93 0.5 (9.6) 31.9 % -0.30 [ -2.29, 1.69 ]
Subtotal (95% CI) 134 187 100.0 % -1.12 [ -2.24, 0.01 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.95, df = 1 (P = 0.33); I2 =0.0%
Test for overall effect: Z = 1.95 (P = 0.052)
2 Secondary prevention of CVD
AlphaOmega - ALA 2010 630 0.07 (1.5) 630 -0.08 (1.8) 100.0 % 0.15 [ -0.03, 0.33 ]
Subtotal (95% CI) 630 630 100.0 % 0.15 [ -0.03, 0.33 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.61 (P = 0.11)
Test for subgroup differences: Chi2 = 4.75, df = 1 (P = 0.03), I2 =79%
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Analysis 5.27. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 27 Other
measures of adiposity - ALA.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 5 High vs low ALA omega-3 fat (secondary outcomes)
Outcome: 27 Other measures of adiposity - ALA
Study or subgroup
Favours
higher
omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Visceral adipose tissue, cm2
HERO 2009 18 194.6 (73.5) 17 167.6 (72.2) 100.0 % 27.00 [ -21.28, 75.28 ]
Subtotal (95% CI) 18 17 100.0 % 27.00 [ -21.28, 75.28 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.10 (P = 0.27)
2 Subcutaneous adipose tissue, cm2
HERO 2009 (1) 18 7.5 (0) 17 -28.1 (0) Not estimable
Subtotal (95% CI) 18 17 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Waist circumference, cm
Dodin 2005 85 1.7 (6.8) 94 3.4 (6.2) 62.7 % -1.70 [ -3.61, 0.21 ]
MENU 2016 (2) 35 -6 (5.9161) 37 -4 (6.0828) 29.9 % -2.00 [ -4.77, 0.77 ]
MENU 2016 (3) 34 -7 (11.6619) 32 -8 (11.3137) 7.5 % 1.00 [ -4.54, 6.54 ]
WAHA 2016 156 2.25 (0) 156 1.94 (0) Not estimable
Subtotal (95% CI) 310 319 100.0 % -1.59 [ -3.10, -0.07 ]
Heterogeneity: Chi2 = 0.94, df = 2 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 2.05 (P = 0.040)
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Analysis 5.28. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 28 Total
cholesterol, serum, mmoL/L - ALA.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 5 High vs low ALA omega-3 fat (secondary outcomes)
Outcome: 28 Total cholesterol, serum, mmoL/L - ALA
Study or subgroup
Favours
higher
omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
AlphaOmega - ALA 2010 605 -0.3 (0.98) 605 -0.28 (0.98) 27.3 % -0.02 [ -0.13, 0.09 ]
Dodin 2005 85 5.66 (0.72) 94 5.96 (0.72) 18.8 % -0.30 [ -0.51, -0.09 ]
FLAX-PAD 2013 43 4.2 (1.3) 41 4.5 (1.3) 5.3 % -0.30 [ -0.86, 0.26 ]
HERO 2009 18 4.9 (0.8) 17 4.6 (1) 4.7 % 0.30 [ -0.30, 0.90 ]
MARGARIN 2002 49 -0.25 (0.7) 93 -0.39 (0.7) 16.6 % 0.14 [ -0.10, 0.38 ]
WAHA 2016 260 -0.19 (0.65) 254 -0.01 (0.64) 27.2 % -0.18 [ -0.29, -0.07 ]
Total (95% CI) 1060 1104 100.0 % -0.09 [ -0.23, 0.05 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 13.40, df = 5 (P = 0.02); I2 =63%
Test for overall effect: Z = 1.25 (P = 0.21)
Test for subgroup differences: Not applicable
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Analysis 5.29. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 29 TC,
mmoL/L - ALA - SA fixed-effect.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 5 High vs low ALA omega-3 fat (secondary outcomes)
Outcome: 29 TC, mmoL/L - ALA - SA fixed-effect
Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
AlphaOmega - ALA 2010 605 -0.3 (0.98) 605 -0.28 (0.98) 39.4 % -0.02 [ -0.13, 0.09 ]
Dodin 2005 85 5.66 (0.72) 94 5.96 (0.72) 10.8 % -0.30 [ -0.51, -0.09 ]
FLAX-PAD 2013 43 4.2 (1.3) 41 4.5 (1.3) 1.6 % -0.30 [ -0.86, 0.26 ]
HERO 2009 18 4.9 (0.8) 17 4.6 (1) 1.3 % 0.30 [ -0.30, 0.90 ]
MARGARIN 2002 49 -0.25 (0.7) 93 -0.39 (0.7) 8.2 % 0.14 [ -0.10, 0.38 ]
WAHA 2016 260 -0.19 (0.65) 254 -0.01 (0.64) 38.7 % -0.18 [ -0.29, -0.07 ]
Total (95% CI) 1060 1104 100.0 % -0.10 [ -0.17, -0.03 ]
Heterogeneity: Chi2 = 13.40, df = 5 (P = 0.02); I2 =63%
Test for overall effect: Z = 2.80 (P = 0.0051)
Test for subgroup differences: Not applicable
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Analysis 5.30. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 30 TC,
mmoL/L - ALA - SA by summary risk of bias.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 5 High vs low ALA omega-3 fat (secondary outcomes)
Outcome: 30 TC, mmoL/L - ALA - SA by summary risk of bias
Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Low risk of bias
AlphaOmega - ALA 2010 605 -0.3 (0.98) 605 -0.28 (0.98) 68.5 % -0.02 [ -0.13, 0.09 ]
FLAX-PAD 2013 43 4.2 (1.3) 41 4.5 (1.3) 5.9 % -0.30 [ -0.86, 0.26 ]
MARGARIN 2002 49 -0.25 (0.7) 93 -0.39 (0.7) 25.7 % 0.14 [ -0.10, 0.38 ]
Subtotal (95% CI) 697 739 100.0 % 0.00 [ -0.13, 0.14 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 2.53, df = 2 (P = 0.28); I2 =21%
Test for overall effect: Z = 0.07 (P = 0.95)
2 Moderate/high risk of bias
Dodin 2005 85 5.66 (0.72) 94 5.96 (0.72) 35.5 % -0.30 [ -0.51, -0.09 ]
HERO 2009 18 4.9 (0.8) 17 4.6 (1) 7.5 % 0.30 [ -0.30, 0.90 ]
WAHA 2016 260 -0.19 (0.65) 254 -0.01 (0.64) 57.0 % -0.18 [ -0.29, -0.07 ]
Subtotal (95% CI) 363 365 100.0 % -0.19 [ -0.36, -0.01 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 3.61, df = 2 (P = 0.16); I2 =45%
Test for overall effect: Z = 2.10 (P = 0.036)
Test for subgroup differences: Chi2 = 2.84, df = 1 (P = 0.09), I2 =65%
-2 -1 0 1 2
Favours higher omega 3 Favours lower omega 3
670Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 5.31. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 31 TC,
mmoL/L - ALA - SA by compliance and study size.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 5 High vs low ALA omega-3 fat (secondary outcomes)
Outcome: 31 TC, mmoL/L - ALA - SA by compliance and study size
Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 SA - low risk of compliance bias
AlphaOmega - ALA 2010 605 -0.3 (0.98) 605 -0.28 (0.98) 30.2 % -0.02 [ -0.13, 0.09 ]
Dodin 2005 85 5.66 (0.72) 94 5.96 (0.72) 21.0 % -0.30 [ -0.51, -0.09 ]
MARGARIN 2002 49 -0.25 (0.7) 93 -0.39 (0.7) 18.6 % 0.14 [ -0.10, 0.38 ]
WAHA 2016 260 -0.19 (0.65) 254 -0.01 (0.64) 30.1 % -0.18 [ -0.29, -0.07 ]
Subtotal (95% CI) 999 1046 100.0 % -0.10 [ -0.25, 0.05 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 11.21, df = 3 (P = 0.01); I2 =73%
Test for overall effect: Z = 1.28 (P = 0.20)
2 SA - 100+ randomised
AlphaOmega - ALA 2010 605 -0.3 (0.98) 605 -0.28 (0.98) 30.2 % -0.02 [ -0.13, 0.09 ]
Dodin 2005 85 5.66 (0.72) 94 5.96 (0.72) 21.0 % -0.30 [ -0.51, -0.09 ]
MARGARIN 2002 49 -0.25 (0.7) 93 -0.39 (0.7) 18.6 % 0.14 [ -0.10, 0.38 ]
WAHA 2016 260 -0.19 (0.65) 254 -0.01 (0.64) 30.1 % -0.18 [ -0.29, -0.07 ]
Subtotal (95% CI) 999 1046 100.0 % -0.10 [ -0.25, 0.05 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 11.21, df = 3 (P = 0.01); I2 =73%
Test for overall effect: Z = 1.28 (P = 0.20)
Test for subgroup differences: Chi2 = 0.00, df = 1 (P = 1.00), I2 =0.0%
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Analysis 5.32. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 32 TC,
mmoL/L - ALA - subgroup by dose.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 5 High vs low ALA omega-3 fat (secondary outcomes)
Outcome: 32 TC, mmoL/L - ALA - subgroup by dose
Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 ALA low < 5 g/d
AlphaOmega - ALA 2010 605 -0.3 (0.98) 605 -0.28 (0.98) 46.9 % -0.02 [ -0.13, 0.09 ]
HERO 2009 18 4.9 (0.8) 17 4.6 (1) 6.4 % 0.30 [ -0.30, 0.90 ]
WAHA 2016 260 -0.19 (0.65) 254 -0.01 (0.64) 46.7 % -0.18 [ -0.29, -0.07 ]
Subtotal (95% CI) 883 876 100.0 % -0.07 [ -0.24, 0.09 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 5.65, df = 2 (P = 0.06); I2 =65%
Test for overall effect: Z = 0.91 (P = 0.36)
2 ALA high > 5 g/d
Dodin 2005 85 5.66 (0.72) 94 5.96 (0.72) 40.5 % -0.30 [ -0.51, -0.09 ]
FLAX-PAD 2013 43 4.2 (1.3) 41 4.5 (1.3) 20.8 % -0.30 [ -0.86, 0.26 ]
MARGARIN 2002 49 -0.25 (0.7) 93 -0.39 (0.7) 38.6 % 0.14 [ -0.10, 0.38 ]
Subtotal (95% CI) 177 228 100.0 % -0.13 [ -0.47, 0.21 ]
Heterogeneity: Tau2 = 0.06; Chi2 = 7.62, df = 2 (P = 0.02); I2 =74%
Test for overall effect: Z = 0.76 (P = 0.45)
Test for subgroup differences: Chi2 = 0.09, df = 1 (P = 0.77), I2 =0.0%
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Analysis 5.33. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 33 TC,
mmoL/L - ALA - subgroup by intervention type.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 5 High vs low ALA omega-3 fat (secondary outcomes)
Outcome: 33 TC, mmoL/L - ALA - subgroup by intervention type
Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Dietary advice
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Supplemental foods
AlphaOmega - ALA 2010 605 -0.3 (0.98) 605 -0.28 (0.98) 27.3 % -0.02 [ -0.13, 0.09 ]
Dodin 2005 85 5.66 (0.72) 94 5.96 (0.72) 18.8 % -0.30 [ -0.51, -0.09 ]
FLAX-PAD 2013 43 4.2 (1.3) 41 4.5 (1.3) 5.3 % -0.30 [ -0.86, 0.26 ]
HERO 2009 18 4.9 (0.8) 17 4.6 (1) 4.7 % 0.30 [ -0.30, 0.90 ]
MARGARIN 2002 49 -0.25 (0.7) 93 -0.39 (0.7) 16.6 % 0.14 [ -0.10, 0.38 ]
WAHA 2016 260 -0.19 (0.65) 254 -0.01 (0.64) 27.2 % -0.18 [ -0.29, -0.07 ]
Subtotal (95% CI) 1060 1104 100.0 % -0.09 [ -0.23, 0.05 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 13.40, df = 5 (P = 0.02); I2 =63%
Test for overall effect: Z = 1.25 (P = 0.21)
3 Supplement (capsule)
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
4 Any combination
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 5.34. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 34 TC,
mmoL/L - ALA - subgroup by replacement.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 5 High vs low ALA omega-3 fat (secondary outcomes)
Outcome: 34 TC, mmoL/L - ALA - subgroup by replacement
Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 ALA replacing SFA
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
2 ALA replacing MUFA
AlphaOmega - ALA 2010 605 -0.3 (0.98) 605 -0.28 (0.98) 100.0 % -0.02 [ -0.13, 0.09 ]
Subtotal (95% CI) 605 605 100.0 % -0.02 [ -0.13, 0.09 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.35 (P = 0.72)
3 ALA replacing n-6
MARGARIN 2002 49 -0.25 (0.7) 93 -0.39 (0.7) 100.0 % 0.14 [ -0.10, 0.38 ]
Subtotal (95% CI) 49 93 100.0 % 0.14 [ -0.10, 0.38 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.13 (P = 0.26)
4 ALA replacing carbs/sugars
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
5 ALA replacing nil/low n-3 placebo
HERO 2009 18 4.9 (0.8) 17 4.6 (1) 100.0 % 0.30 [ -0.30, 0.90 ]
Subtotal (95% CI) 18 17 100.0 % 0.30 [ -0.30, 0.90 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.98 (P = 0.33)
6 Replacement unclear
Dodin 2005 85 5.66 (0.72) 94 5.96 (0.72) 21.1 % -0.30 [ -0.51, -0.09 ]
FLAX-PAD 2013 43 4.2 (1.3) 41 4.5 (1.3) 3.0 % -0.30 [ -0.86, 0.26 ]
WAHA 2016 260 -0.19 (0.65) 254 -0.01 (0.64) 75.8 % -0.18 [ -0.29, -0.07 ]
Subtotal (95% CI) 388 389 100.0 % -0.21 [ -0.31, -0.11 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.08, df = 2 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 4.22 (P = 0.000025)
Test for subgroup differences: Chi2 = 12.32, df = 3 (P = 0.01), I2 =76%
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Analysis 5.35. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 35 TC,
mmoL/L - ALA - subgroup by duration.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 5 High vs low ALA omega-3 fat (secondary outcomes)
Outcome: 35 TC, mmoL/L - ALA - subgroup by duration
Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Medium duration 1 to < 2 years in study
Dodin 2005 85 5.66 (0.72) 94 5.96 (0.72) 29.0 % -0.30 [ -0.51, -0.09 ]
FLAX-PAD 2013 43 4.2 (1.3) 41 4.5 (1.3) 5.5 % -0.30 [ -0.86, 0.26 ]
HERO 2009 18 4.9 (0.8) 17 4.6 (1) 4.7 % 0.30 [ -0.30, 0.90 ]
WAHA 2016 260 -0.19 (0.65) 254 -0.01 (0.64) 60.9 % -0.18 [ -0.29, -0.07 ]
Subtotal (95% CI) 406 406 100.0 % -0.20 [ -0.33, -0.07 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 3.75, df = 3 (P = 0.29); I2 =20%
Test for overall effect: Z = 2.92 (P = 0.0035)
2 Medium-long duration: 2 to < 4 years in study
AlphaOmega - ALA 2010 605 -0.3 (0.98) 605 -0.28 (0.98) 73.6 % -0.02 [ -0.13, 0.09 ]
MARGARIN 2002 49 -0.25 (0.7) 93 -0.39 (0.7) 26.4 % 0.14 [ -0.10, 0.38 ]
Subtotal (95% CI) 654 698 100.0 % 0.02 [ -0.12, 0.16 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 1.39, df = 1 (P = 0.24); I2 =28%
Test for overall effect: Z = 0.31 (P = 0.75)
3 Long duration≥ 4 years in study
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Chi2 = 5.08, df = 1 (P = 0.02), I2 =80%
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Analysis 5.36. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 36 TC,
mmoL/L - ALA - subgroup by statin use.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 5 High vs low ALA omega-3 fat (secondary outcomes)
Outcome: 36 TC, mmoL/L - ALA - subgroup by statin use
Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 ALA -≥ 50% of control group on statins
AlphaOmega - ALA 2010 605 -0.3 (0.98) 605 -0.28 (0.98) 90.7 % -0.02 [ -0.13, 0.09 ]
FLAX-PAD 2013 43 4.2 (1.3) 41 4.5 (1.3) 5.0 % -0.30 [ -0.86, 0.26 ]
HERO 2009 18 4.9 (0.8) 17 4.6 (1) 4.3 % 0.30 [ -0.30, 0.90 ]
Subtotal (95% CI) 666 663 100.0 % -0.02 [ -0.15, 0.11 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 2.06, df = 2 (P = 0.36); I2 =3%
Test for overall effect: Z = 0.32 (P = 0.75)
2 ALA - < 50% of control group on statins
MARGARIN 2002 49 -0.25 (0.7) 93 -0.39 (0.7) 100.0 % 0.14 [ -0.10, 0.38 ]
Subtotal (95% CI) 49 93 100.0 % 0.14 [ -0.10, 0.38 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.13 (P = 0.26)
3 ALA - use of statins unclear
Dodin 2005 85 5.66 (0.72) 94 5.96 (0.72) 21.8 % -0.30 [ -0.51, -0.09 ]
WAHA 2016 260 -0.19 (0.65) 254 -0.01 (0.64) 78.2 % -0.18 [ -0.29, -0.07 ]
Subtotal (95% CI) 345 348 100.0 % -0.21 [ -0.30, -0.11 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.97, df = 1 (P = 0.32); I2 =0.0%
Test for overall effect: Z = 4.10 (P = 0.000042)
Test for subgroup differences: Chi2 = 9.71, df = 2 (P = 0.01), I2 =79%
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Analysis 5.37. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 37 TC,
mmoL/L - ALA - subgroup by primary or secondary preventionA.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 5 High vs low ALA omega-3 fat (secondary outcomes)
Outcome: 37 TC, mmoL/L - ALA - subgroup by primary or secondary preventionA
Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Primary prevention of CVD
Dodin 2005 85 5.66 (0.72) 94 5.96 (0.72) 28.5 % -0.30 [ -0.51, -0.09 ]
HERO 2009 18 4.9 (0.8) 17 4.6 (1) 9.3 % 0.30 [ -0.30, 0.90 ]
MARGARIN 2002 49 -0.25 (0.7) 93 -0.39 (0.7) 26.1 % 0.14 [ -0.10, 0.38 ]
WAHA 2016 260 -0.19 (0.65) 254 -0.01 (0.64) 36.1 % -0.18 [ -0.29, -0.07 ]
Subtotal (95% CI) 412 458 100.0 % -0.09 [ -0.30, 0.12 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 9.86, df = 3 (P = 0.02); I2 =70%
Test for overall effect: Z = 0.81 (P = 0.42)
2 Secondary prevention of CVD
AlphaOmega - ALA 2010 605 -0.3 (0.98) 605 -0.28 (0.98) 96.2 % -0.02 [ -0.13, 0.09 ]
FLAX-PAD 2013 43 4.2 (1.3) 41 4.5 (1.3) 3.8 % -0.30 [ -0.86, 0.26 ]
Subtotal (95% CI) 648 646 100.0 % -0.03 [ -0.14, 0.08 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.94, df = 1 (P = 0.33); I2 =0.0%
Test for overall effect: Z = 0.55 (P = 0.58)
Test for subgroup differences: Chi2 = 0.21, df = 1 (P = 0.64), I2 =0.0%
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Analysis 5.38. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 38
Triglycerides, fasting, serum, mmoL/L - ALA.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 5 High vs low ALA omega-3 fat (secondary outcomes)
Outcome: 38 Triglycerides, fasting, serum, mmoL/L - ALA
Study or subgroup
Favours
higher
omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
AlphaOmega - ALA 2010 605 -0.11 (0.98) 605 -0.05 (0.98) 52.2 % -0.06 [ -0.17, 0.05 ]
Dodin 2005 85 1.15 (0.53) 94 1.17 (0.72) 18.8 % -0.02 [ -0.20, 0.16 ]
FLAX-PAD 2013 43 1.9 (0.9) 41 1.7 (0.7) 5.4 % 0.20 [ -0.14, 0.54 ]
HERO 2009 18 2.1 (1.3) 17 1.8 (0.7) 1.4 % 0.30 [ -0.39, 0.99 ]
MARGARIN 2002 49 0.18 (0.8) 93 0.05 (0.9) 7.6 % 0.13 [ -0.16, 0.42 ]
MENU 2016 65 1.14 (0.5644) 61 1.26 (0.6248) 14.7 % -0.12 [ -0.33, 0.09 ]
Total (95% CI) 865 911 100.0 % -0.03 [ -0.11, 0.05 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 4.79, df = 5 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 0.69 (P = 0.49)
Test for subgroup differences: Not applicable
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Analysis 5.39. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 39 TG, fasting,
mmoL/L - ALA - SA fixed-effect.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 5 High vs low ALA omega-3 fat (secondary outcomes)
Outcome: 39 TG, fasting, mmoL/L - ALA - SA fixed-effect
Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
AlphaOmega - ALA 2010 605 -0.11 (0.98) 605 -0.05 (0.98) 52.2 % -0.06 [ -0.17, 0.05 ]
Dodin 2005 85 1.15 (0.53) 94 1.17 (0.72) 18.8 % -0.02 [ -0.20, 0.16 ]
FLAX-PAD 2013 43 1.9 (0.9) 41 1.7 (0.7) 5.4 % 0.20 [ -0.14, 0.54 ]
HERO 2009 18 2.1 (1.3) 17 1.8 (0.7) 1.4 % 0.30 [ -0.39, 0.99 ]
MARGARIN 2002 49 0.18 (0.8) 93 0.05 (0.9) 7.6 % 0.13 [ -0.16, 0.42 ]
MENU 2016 65 1.14 (0.5644) 61 1.26 (0.6248) 14.7 % -0.12 [ -0.33, 0.09 ]
Total (95% CI) 865 911 100.0 % -0.03 [ -0.11, 0.05 ]
Heterogeneity: Chi2 = 4.79, df = 5 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 0.69 (P = 0.49)
Test for subgroup differences: Not applicable
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Analysis 5.40. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 40 TG, fasting,
mmoL/L- ALA - SA by summary risk of bias.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 5 High vs low ALA omega-3 fat (secondary outcomes)
Outcome: 40 TG, fasting, mmoL/L- ALA - SA by summary risk of bias
Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Low risk of bias
AlphaOmega - ALA 2010 605 -0.11 (0.98) 605 -0.05 (0.98) 59.7 % -0.06 [ -0.17, 0.05 ]
FLAX-PAD 2013 43 1.9 (0.9) 41 1.7 (0.7) 17.5 % 0.20 [ -0.14, 0.54 ]
MARGARIN 2002 49 0.18 (0.8) 93 0.05 (0.9) 22.8 % 0.13 [ -0.16, 0.42 ]
Subtotal (95% CI) 697 739 100.0 % 0.03 [ -0.13, 0.19 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 3.10, df = 2 (P = 0.21); I2 =36%
Test for overall effect: Z = 0.35 (P = 0.73)
2 Moderate/high risk of bias
Dodin 2005 85 1.15 (0.53) 94 1.17 (0.72) 54.0 % -0.02 [ -0.20, 0.16 ]
HERO 2009 18 2.1 (1.3) 17 1.8 (0.7) 3.9 % 0.30 [ -0.39, 0.99 ]
MENU 2016 65 1.14 (0.5644) 61 1.26 (0.6248) 42.1 % -0.12 [ -0.33, 0.09 ]
Subtotal (95% CI) 168 172 100.0 % -0.05 [ -0.18, 0.09 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.53, df = 2 (P = 0.46); I2 =0.0%
Test for overall effect: Z = 0.72 (P = 0.47)
Test for subgroup differences: Chi2 = 0.53, df = 1 (P = 0.47), I2 =0.0%
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Analysis 5.41. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 41 TG, fasting,
mmoL/L- ALA - SA by compliance and study size.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 5 High vs low ALA omega-3 fat (secondary outcomes)
Outcome: 41 TG, fasting, mmoL/L- ALA - SA by compliance and study size
Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 SA - low risk of compliance bias
AlphaOmega - ALA 2010 605 -0.11 (0.98) 605 -0.05 (0.98) 56.0 % -0.06 [ -0.17, 0.05 ]
Dodin 2005 85 1.15 (0.53) 94 1.17 (0.72) 20.1 % -0.02 [ -0.20, 0.16 ]
MARGARIN 2002 49 0.18 (0.8) 93 0.05 (0.9) 8.2 % 0.13 [ -0.16, 0.42 ]
MENU 2016 65 1.14 (0.5644) 61 1.26 (0.6248) 15.7 % -0.12 [ -0.33, 0.09 ]
Subtotal (95% CI) 804 853 100.0 % -0.05 [ -0.13, 0.04 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 2.05, df = 3 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 1.09 (P = 0.28)
2 SA - 100+ randomised
AlphaOmega - ALA 2010 605 -0.11 (0.98) 605 -0.05 (0.98) 56.0 % -0.06 [ -0.17, 0.05 ]
Dodin 2005 85 1.15 (0.53) 94 1.17 (0.72) 20.1 % -0.02 [ -0.20, 0.16 ]
MARGARIN 2002 49 0.18 (0.8) 93 0.05 (0.9) 8.2 % 0.13 [ -0.16, 0.42 ]
MENU 2016 65 1.14 (0.5644) 61 1.26 (0.6248) 15.7 % -0.12 [ -0.33, 0.09 ]
Subtotal (95% CI) 804 853 100.0 % -0.05 [ -0.13, 0.04 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 2.05, df = 3 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 1.09 (P = 0.28)
Test for subgroup differences: Chi2 = 0.00, df = 1 (P = 1.00), I2 =0.0%
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Analysis 5.42. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 42 TG, fasting,
mmoL/L - ALA - subgroup by dose.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 5 High vs low ALA omega-3 fat (secondary outcomes)
Outcome: 42 TG, fasting, mmoL/L - ALA - subgroup by dose
Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 ALA low < 5 g/d
AlphaOmega - ALA 2010 605 -0.11 (0.98) 605 -0.05 (0.98) 76.5 % -0.06 [ -0.17, 0.05 ]
HERO 2009 18 2.1 (1.3) 17 1.8 (0.7) 2.0 % 0.30 [ -0.39, 0.99 ]
MENU 2016 65 1.14 (0.5644) 61 1.26 (0.6248) 21.5 % -0.12 [ -0.33, 0.09 ]
Subtotal (95% CI) 688 683 100.0 % -0.07 [ -0.16, 0.03 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.36, df = 2 (P = 0.51); I2 =0.0%
Test for overall effect: Z = 1.33 (P = 0.18)
2 ALA high > 5 g/d
Dodin 2005 85 1.15 (0.53) 94 1.17 (0.72) 59.1 % -0.02 [ -0.20, 0.16 ]
FLAX-PAD 2013 43 1.9 (0.9) 41 1.7 (0.7) 16.9 % 0.20 [ -0.14, 0.54 ]
MARGARIN 2002 49 0.18 (0.8) 93 0.05 (0.9) 23.9 % 0.13 [ -0.16, 0.42 ]
Subtotal (95% CI) 177 228 100.0 % 0.05 [ -0.09, 0.19 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.58, df = 2 (P = 0.45); I2 =0.0%
Test for overall effect: Z = 0.74 (P = 0.46)
Test for subgroup differences: Chi2 = 1.85, df = 1 (P = 0.17), I2 =46%
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Analysis 5.43. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 43 TG, fasting,
mmoL/L- ALA - subgroup by intervention type.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 5 High vs low ALA omega-3 fat (secondary outcomes)
Outcome: 43 TG, fasting, mmoL/L- ALA - subgroup by intervention type
Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Dietary advice
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Supplemental foods
AlphaOmega - ALA 2010 605 -0.11 (0.98) 605 -0.05 (0.98) 61.2 % -0.06 [ -0.17, 0.05 ]
Dodin 2005 85 1.15 (0.53) 94 1.17 (0.72) 22.0 % -0.02 [ -0.20, 0.16 ]
FLAX-PAD 2013 43 1.9 (0.9) 41 1.7 (0.7) 6.3 % 0.20 [ -0.14, 0.54 ]
HERO 2009 18 2.1 (1.3) 17 1.8 (0.7) 1.6 % 0.30 [ -0.39, 0.99 ]
MARGARIN 2002 49 0.18 (0.8) 93 0.05 (0.9) 8.9 % 0.13 [ -0.16, 0.42 ]
Subtotal (95% CI) 800 850 100.0 % -0.01 [ -0.10, 0.07 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 3.91, df = 4 (P = 0.42); I2 =0.0%
Test for overall effect: Z = 0.28 (P = 0.78)
3 Supplement (capsule)
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
4 Any combination
MENU 2016 65 1.14 (0.5644) 61 1.26 (0.6248) 100.0 % -0.12 [ -0.33, 0.09 ]
Subtotal (95% CI) 65 61 100.0 % -0.12 [ -0.33, 0.09 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.13 (P = 0.26)
Test for subgroup differences: Chi2 = 0.88, df = 1 (P = 0.35), I2 =0.0%
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Analysis 5.44. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 44 TG, fasting,
mmoL/L-AL - subgroup by replacementA.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 5 High vs low ALA omega-3 fat (secondary outcomes)
Outcome: 44 TG, fasting, mmoL/L-AL - subgroup by replacementA
Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 ALA replacing SFA
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
2 ALA replacing MUFA
AlphaOmega - ALA 2010 605 -0.11 (0.98) 605 -0.05 (0.98) 78.1 % -0.06 [ -0.17, 0.05 ]
MENU 2016 65 1.14 (0.5644) 61 1.26 (0.6248) 21.9 % -0.12 [ -0.33, 0.09 ]
Subtotal (95% CI) 670 666 100.0 % -0.07 [ -0.17, 0.02 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.25, df = 1 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 1.47 (P = 0.14)
3 ALA replacing n-6
MARGARIN 2002 49 0.18 (0.8) 93 0.05 (0.9) 100.0 % 0.13 [ -0.16, 0.42 ]
Subtotal (95% CI) 49 93 100.0 % 0.13 [ -0.16, 0.42 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.88 (P = 0.38)
4 ALA replacing carbs/sugars
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
5 ALA replacing nil/low n-3 placebo
HERO 2009 18 2.1 (1.3) 17 1.8 (0.7) 100.0 % 0.30 [ -0.39, 0.99 ]
Subtotal (95% CI) 18 17 100.0 % 0.30 [ -0.39, 0.99 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.86 (P = 0.39)
6 Replacement unclear
Dodin 2005 85 1.15 (0.53) 94 1.17 (0.72) 72.7 % -0.02 [ -0.20, 0.16 ]
FLAX-PAD 2013 43 1.9 (0.9) 41 1.7 (0.7) 27.3 % 0.20 [ -0.14, 0.54 ]
Subtotal (95% CI) 128 135 100.0 % 0.04 [ -0.15, 0.23 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 1.22, df = 1 (P = 0.27); I2 =18%
Test for overall effect: Z = 0.41 (P = 0.68)
Test for subgroup differences: Chi2 = 3.33, df = 3 (P = 0.34), I2 =10%
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Analysis 5.45. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 45 TG, fasting,
mmoL/L- ALA - subgroup by duration.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 5 High vs low ALA omega-3 fat (secondary outcomes)
Outcome: 45 TG, fasting, mmoL/L- ALA - subgroup by duration
Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Medium duration 1 to < 2 years in study
Dodin 2005 85 1.15 (0.53) 94 1.17 (0.72) 44.9 % -0.02 [ -0.20, 0.16 ]
FLAX-PAD 2013 43 1.9 (0.9) 41 1.7 (0.7) 14.7 % 0.20 [ -0.14, 0.54 ]
HERO 2009 18 2.1 (1.3) 17 1.8 (0.7) 3.9 % 0.30 [ -0.39, 0.99 ]
MENU 2016 65 1.14 (0.5644) 61 1.26 (0.6248) 36.5 % -0.12 [ -0.33, 0.09 ]
Subtotal (95% CI) 211 213 100.0 % -0.01 [ -0.15, 0.12 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 3.29, df = 3 (P = 0.35); I2 =9%
Test for overall effect: Z = 0.17 (P = 0.87)
2 Medium-long duration: 2 to < 4 years in study
AlphaOmega - ALA 2010 605 -0.11 (0.98) 605 -0.05 (0.98) 75.8 % -0.06 [ -0.17, 0.05 ]
MARGARIN 2002 49 0.18 (0.8) 93 0.05 (0.9) 24.2 % 0.13 [ -0.16, 0.42 ]
Subtotal (95% CI) 654 698 100.0 % -0.01 [ -0.17, 0.15 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 1.45, df = 1 (P = 0.23); I2 =31%
Test for overall effect: Z = 0.17 (P = 0.86)
3 Long duration≥ 4 years in study
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Chi2 = 0.00, df = 1 (P = 0.98), I2 =0.0%
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Analysis 5.46. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 46 TG, fasting,
mmoL/L - ALA - subgroup by statin use.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 5 High vs low ALA omega-3 fat (secondary outcomes)
Outcome: 46 TG, fasting, mmoL/L - ALA - subgroup by statin use
Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 ALA -≥ 50% of control group on statins
AlphaOmega - ALA 2010 605 -0.11 (0.98) 605 -0.05 (0.98) 68.1 % -0.06 [ -0.17, 0.05 ]
FLAX-PAD 2013 43 1.9 (0.9) 41 1.7 (0.7) 24.2 % 0.20 [ -0.14, 0.54 ]
HERO 2009 18 2.1 (1.3) 17 1.8 (0.7) 7.7 % 0.30 [ -0.39, 0.99 ]
Subtotal (95% CI) 666 663 100.0 % 0.03 [ -0.17, 0.23 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 2.89, df = 2 (P = 0.24); I2 =31%
Test for overall effect: Z = 0.30 (P = 0.76)
2 ALA - < 50% of control group on statins
MARGARIN 2002 49 0.18 (0.8) 93 0.05 (0.9) 41.6 % 0.13 [ -0.16, 0.42 ]
MENU 2016 65 1.14 (0.5644) 61 1.26 (0.6248) 58.4 % -0.12 [ -0.33, 0.09 ]
Subtotal (95% CI) 114 154 100.0 % -0.02 [ -0.26, 0.23 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 1.89, df = 1 (P = 0.17); I2 =47%
Test for overall effect: Z = 0.13 (P = 0.90)
3 ALA - use of statins unclear
Dodin 2005 85 1.15 (0.53) 94 1.17 (0.72) 100.0 % -0.02 [ -0.20, 0.16 ]
Subtotal (95% CI) 85 94 100.0 % -0.02 [ -0.20, 0.16 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.21 (P = 0.83)
Test for subgroup differences: Chi2 = 0.15, df = 2 (P = 0.93), I2 =0.0%
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Analysis 5.47. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 47 TG, fasting,
mmoL/L- ALA - subgroup by primary or secondary prevention.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 5 High vs low ALA omega-3 fat (secondary outcomes)
Outcome: 47 TG, fasting, mmoL/L- ALA - subgroup by primary or secondary prevention
Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Primary prevention
Dodin 2005 85 1.15 (0.53) 94 1.17 (0.72) 44.3 % -0.02 [ -0.20, 0.16 ]
HERO 2009 18 2.1 (1.3) 17 1.8 (0.7) 3.2 % 0.30 [ -0.39, 0.99 ]
MARGARIN 2002 49 0.18 (0.8) 93 0.05 (0.9) 17.9 % 0.13 [ -0.16, 0.42 ]
MENU 2016 65 1.14 (0.5644) 61 1.26 (0.6248) 34.6 % -0.12 [ -0.33, 0.09 ]
Subtotal (95% CI) 217 265 100.0 % -0.02 [ -0.14, 0.11 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 2.75, df = 3 (P = 0.43); I2 =0.0%
Test for overall effect: Z = 0.28 (P = 0.78)
2 Secondary prevention
AlphaOmega - ALA 2010 605 -0.11 (0.98) 605 -0.05 (0.98) 70.4 % -0.06 [ -0.17, 0.05 ]
FLAX-PAD 2013 43 1.9 (0.9) 41 1.7 (0.7) 29.6 % 0.20 [ -0.14, 0.54 ]
Subtotal (95% CI) 648 646 100.0 % 0.02 [ -0.22, 0.25 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 1.99, df = 1 (P = 0.16); I2 =50%
Test for overall effect: Z = 0.14 (P = 0.89)
Test for subgroup differences: Chi2 = 0.07, df = 1 (P = 0.80), I2 =0.0%
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Analysis 5.48. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 48 High-
density lipoprotein, serum, mmoL/L - ALA.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 5 High vs low ALA omega-3 fat (secondary outcomes)
Outcome: 48 High-density lipoprotein, serum, mmoL/L - ALA
Study or subgroup
Favours
lower
omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
AlphaOmega - ALA 2010 605 0.13 (0.25) 605 0.15 (0.25) 33.7 % -0.02 [ -0.05, 0.01 ]
Dodin 2005 85 1.68 (0.35) 94 1.77 (0.38) 14.8 % -0.09 [ -0.20, 0.02 ]
FLAX-PAD 2013 43 1.12 (0.25) 41 1.22 (0.25) 14.7 % -0.10 [ -0.21, 0.01 ]
HERO 2009 18 1.5 (0.4) 17 1.4 (0.4) 3.6 % 0.10 [ -0.17, 0.37 ]
MARGARIN 2002 49 0.09 (0.2) 93 0.13 (0.2) 22.7 % -0.04 [ -0.11, 0.03 ]
MENU 2016 65 1.73 (0.4031) 61 1.58 (0.3905) 10.5 % 0.15 [ 0.01, 0.29 ]
Total (95% CI) 865 911 100.0 % -0.02 [ -0.08, 0.03 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 10.58, df = 5 (P = 0.06); I2 =53%
Test for overall effect: Z = 0.91 (P = 0.36)
Test for subgroup differences: Not applicable
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Analysis 5.49. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 49 HDL,
mmoL/L - ALA - SA fixed-effect.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 5 High vs low ALA omega-3 fat (secondary outcomes)
Outcome: 49 HDL, mmoL/L - ALA - SA fixed-effect
Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
AlphaOmega - ALA 2010 605 0.13 (0.25) 605 0.15 (0.25) 73.7 % -0.02 [ -0.05, 0.01 ]
Dodin 2005 85 1.68 (0.35) 94 1.77 (0.38) 5.1 % -0.09 [ -0.20, 0.02 ]
FLAX-PAD 2013 43 1.12 (0.25) 41 1.22 (0.25) 5.1 % -0.10 [ -0.21, 0.01 ]
HERO 2009 18 1.5 (0.4) 17 1.4 (0.4) 0.8 % 0.10 [ -0.17, 0.37 ]
MARGARIN 2002 49 0.09 (0.2) 93 0.13 (0.2) 12.2 % -0.04 [ -0.11, 0.03 ]
MENU 2016 65 1.73 (0.4031) 61 1.58 (0.3905) 3.0 % 0.15 [ 0.01, 0.29 ]
Total (95% CI) 865 911 100.0 % -0.02 [ -0.05, 0.00 ]
Heterogeneity: Chi2 = 10.58, df = 5 (P = 0.06); I2 =53%
Test for overall effect: Z = 1.94 (P = 0.052)
Test for subgroup differences: Not applicable
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Analysis 5.50. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 50 HDL,
mmoL/L - ALA - SA by summary risk of bias.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 5 High vs low ALA omega-3 fat (secondary outcomes)
Outcome: 50 HDL, mmoL/L - ALA - SA by summary risk of bias
Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Low risk of bias
AlphaOmega - ALA 2010 605 0.13 (0.25) 605 0.15 (0.25) 76.1 % -0.02 [ -0.05, 0.01 ]
FLAX-PAD 2013 43 1.12 (0.25) 41 1.22 (0.25) 7.2 % -0.10 [ -0.21, 0.01 ]
MARGARIN 2002 49 0.09 (0.2) 93 0.13 (0.2) 16.6 % -0.04 [ -0.11, 0.03 ]
Subtotal (95% CI) 697 739 100.0 % -0.03 [ -0.06, 0.00 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 2.16, df = 2 (P = 0.34); I2 =7%
Test for overall effect: Z = 1.96 (P = 0.050)
2 Moderate/high risk of bias
Dodin 2005 85 1.68 (0.35) 94 1.77 (0.38) 40.3 % -0.09 [ -0.20, 0.02 ]
HERO 2009 18 1.5 (0.4) 17 1.4 (0.4) 23.0 % 0.10 [ -0.17, 0.37 ]
MENU 2016 65 1.73 (0.4031) 61 1.58 (0.3905) 36.7 % 0.15 [ 0.01, 0.29 ]
Subtotal (95% CI) 168 172 100.0 % 0.04 [ -0.14, 0.22 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 7.72, df = 2 (P = 0.02); I2 =74%
Test for overall effect: Z = 0.46 (P = 0.65)
Test for subgroup differences: Chi2 = 0.59, df = 1 (P = 0.44), I2 =0.0%
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Analysis 5.51. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 51 HDL,
mmoL/L - ALA - SA by compliance and study size.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 5 High vs low ALA omega-3 fat (secondary outcomes)
Outcome: 51 HDL, mmoL/L - ALA - SA by compliance and study size
Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 SA - low risk of compliance bias
AlphaOmega - ALA 2010 605 0.13 (0.25) 605 0.15 (0.25) 40.5 % -0.02 [ -0.05, 0.01 ]
Dodin 2005 85 1.68 (0.35) 94 1.77 (0.38) 18.4 % -0.09 [ -0.20, 0.02 ]
MARGARIN 2002 49 0.09 (0.2) 93 0.13 (0.2) 27.9 % -0.04 [ -0.11, 0.03 ]
MENU 2016 65 1.73 (0.4031) 61 1.58 (0.3905) 13.2 % 0.15 [ 0.01, 0.29 ]
Subtotal (95% CI) 804 853 100.0 % -0.02 [ -0.08, 0.04 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 7.74, df = 3 (P = 0.05); I2 =61%
Test for overall effect: Z = 0.53 (P = 0.60)
2 SA - 100+ randomised
AlphaOmega - ALA 2010 605 0.13 (0.25) 605 0.15 (0.25) 40.5 % -0.02 [ -0.05, 0.01 ]
Dodin 2005 85 1.68 (0.35) 94 1.77 (0.38) 18.4 % -0.09 [ -0.20, 0.02 ]
MARGARIN 2002 49 0.09 (0.2) 93 0.13 (0.2) 27.9 % -0.04 [ -0.11, 0.03 ]
MENU 2016 65 1.73 (0.4031) 61 1.58 (0.3905) 13.2 % 0.15 [ 0.01, 0.29 ]
Subtotal (95% CI) 804 853 100.0 % -0.02 [ -0.08, 0.04 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 7.74, df = 3 (P = 0.05); I2 =61%
Test for overall effect: Z = 0.53 (P = 0.60)
Test for subgroup differences: Chi2 = 0.00, df = 1 (P = 1.00), I2 =0.0%
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Analysis 5.52. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 52 HDL,
mmoL/L - ALA - subgroup by dose.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 5 High vs low ALA omega-3 fat (secondary outcomes)
Outcome: 52 HDL, mmoL/L - ALA - subgroup by dose
Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 ALA low < 5 g/d
AlphaOmega - ALA 2010 605 0.13 (0.25) 605 0.15 (0.25) 50.5 % -0.02 [ -0.05, 0.01 ]
HERO 2009 18 1.5 (0.4) 17 1.4 (0.4) 16.7 % 0.10 [ -0.17, 0.37 ]
MENU 2016 65 1.73 (0.4031) 61 1.58 (0.3905) 32.8 % 0.15 [ 0.01, 0.29 ]
Subtotal (95% CI) 688 683 100.0 % 0.06 [ -0.08, 0.19 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 6.24, df = 2 (P = 0.04); I2 =68%
Test for overall effect: Z = 0.83 (P = 0.41)
2 ALA high > 5 g/d
Dodin 2005 85 1.68 (0.35) 94 1.77 (0.38) 22.8 % -0.09 [ -0.20, 0.02 ]
FLAX-PAD 2013 43 1.12 (0.25) 41 1.22 (0.25) 22.8 % -0.10 [ -0.21, 0.01 ]
MARGARIN 2002 49 0.09 (0.2) 93 0.13 (0.2) 54.4 % -0.04 [ -0.11, 0.03 ]
Subtotal (95% CI) 177 228 100.0 % -0.07 [ -0.12, -0.01 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.12, df = 2 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 2.50 (P = 0.012)
Test for subgroup differences: Chi2 = 2.82, df = 1 (P = 0.09), I2 =65%
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Analysis 5.53. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 53 HDL,
mmoL/L - ALA - subgroup by intervention type.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 5 High vs low ALA omega-3 fat (secondary outcomes)
Outcome: 53 HDL, mmoL/L - ALA - subgroup by intervention type
Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Dietary advice
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Supplemental foods
AlphaOmega - ALA 2010 605 0.13 (0.25) 605 0.15 (0.25) 67.4 % -0.02 [ -0.05, 0.01 ]
Dodin 2005 85 1.68 (0.35) 94 1.77 (0.38) 7.4 % -0.09 [ -0.20, 0.02 ]
FLAX-PAD 2013 43 1.12 (0.25) 41 1.22 (0.25) 7.4 % -0.10 [ -0.21, 0.01 ]
HERO 2009 18 1.5 (0.4) 17 1.4 (0.4) 1.2 % 0.10 [ -0.17, 0.37 ]
MARGARIN 2002 49 0.09 (0.2) 93 0.13 (0.2) 16.6 % -0.04 [ -0.11, 0.03 ]
Subtotal (95% CI) 800 850 100.0 % -0.03 [ -0.06, 0.00 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 4.34, df = 4 (P = 0.36); I2 =8%
Test for overall effect: Z = 2.17 (P = 0.030)
3 Supplement (capsule)
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
4 Any combination
MENU 2016 65 1.73 (0.4031) 61 1.58 (0.3905) 100.0 % 0.15 [ 0.01, 0.29 ]
Subtotal (95% CI) 65 61 100.0 % 0.15 [ 0.01, 0.29 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.12 (P = 0.034)
Test for subgroup differences: Chi2 = 6.40, df = 1 (P = 0.01), I2 =84%
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Analysis 5.54. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 54 HDL,
mmoL/L - ALA - subgroup by replacement.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 5 High vs low ALA omega-3 fat (secondary outcomes)
Outcome: 54 HDL, mmoL/L - ALA - subgroup by replacement
Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 ALA replacing SFA
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
2 ALA replacing MUFA
AlphaOmega - ALA 2010 605 0.13 (0.25) 605 0.15 (0.25) 58.3 % -0.02 [ -0.05, 0.01 ]
MENU 2016 65 1.73 (0.4031) 61 1.58 (0.3905) 41.7 % 0.15 [ 0.01, 0.29 ]
Subtotal (95% CI) 670 666 100.0 % 0.05 [ -0.11, 0.22 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 5.55, df = 1 (P = 0.02); I2 =82%
Test for overall effect: Z = 0.61 (P = 0.54)
3 ALA replacing n-6
MARGARIN 2002 49 0.09 (0.2) 93 0.13 (0.2) 100.0 % -0.04 [ -0.11, 0.03 ]
Subtotal (95% CI) 49 93 100.0 % -0.04 [ -0.11, 0.03 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.13 (P = 0.26)
4 ALA replacing carbs/sugars
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
5 ALA replacing nil/low n-3 placebo
HERO 2009 18 1.5 (0.4) 17 1.4 (0.4) 100.0 % 0.10 [ -0.17, 0.37 ]
Subtotal (95% CI) 18 17 100.0 % 0.10 [ -0.17, 0.37 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.74 (P = 0.46)
6 Replacement unclear
Dodin 2005 85 1.68 (0.35) 94 1.77 (0.38) 50.0 % -0.09 [ -0.20, 0.02 ]
FLAX-PAD 2013 43 1.12 (0.25) 41 1.22 (0.25) 50.0 % -0.10 [ -0.21, 0.01 ]
Subtotal (95% CI) 128 135 100.0 % -0.09 [ -0.17, -0.02 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.02, df = 1 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 2.46 (P = 0.014)
Test for subgroup differences: Chi2 = 4.12, df = 3 (P = 0.25), I2 =27%
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Analysis 5.55. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 55 HDL,
mmoL/L - ALA - subgroup by duration.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 5 High vs low ALA omega-3 fat (secondary outcomes)
Outcome: 55 HDL, mmoL/L - ALA - subgroup by duration
Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Medium duration 1 to < 2 years in study
Dodin 2005 85 1.68 (0.35) 94 1.77 (0.38) 29.8 % -0.09 [ -0.20, 0.02 ]
FLAX-PAD 2013 43 1.12 (0.25) 41 1.22 (0.25) 29.8 % -0.10 [ -0.21, 0.01 ]
HERO 2009 18 1.5 (0.4) 17 1.4 (0.4) 14.4 % 0.10 [ -0.17, 0.37 ]
MENU 2016 65 1.73 (0.4031) 61 1.58 (0.3905) 26.1 % 0.15 [ 0.01, 0.29 ]
Subtotal (95% CI) 211 213 100.0 % 0.00 [ -0.13, 0.13 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 10.26, df = 3 (P = 0.02); I2 =71%
Test for overall effect: Z = 0.05 (P = 0.96)
2 Medium-long duration: 2 to < 4 years in study
AlphaOmega - ALA 2010 605 0.13 (0.25) 605 0.15 (0.25) 85.8 % -0.02 [ -0.05, 0.01 ]
MARGARIN 2002 49 0.09 (0.2) 93 0.13 (0.2) 14.2 % -0.04 [ -0.11, 0.03 ]
Subtotal (95% CI) 654 698 100.0 % -0.02 [ -0.05, 0.00 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.28, df = 1 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 1.72 (P = 0.086)
3 Long duration≥ 4 years in study
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Chi2 = 0.09, df = 1 (P = 0.77), I2 =0.0%
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Analysis 5.56. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 56 HDL,
mmoL/L - ALA - subgroup by statin use.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 5 High vs low ALA omega-3 fat (secondary outcomes)
Outcome: 56 HDL, mmoL/L - ALA - subgroup by statin use
Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 ALA -≥ 50% of control group on statins
AlphaOmega - ALA 2010 605 0.13 (0.25) 605 0.15 (0.25) 71.2 % -0.02 [ -0.05, 0.01 ]
FLAX-PAD 2013 43 1.12 (0.25) 41 1.22 (0.25) 23.7 % -0.10 [ -0.21, 0.01 ]
HERO 2009 18 1.5 (0.4) 17 1.4 (0.4) 5.1 % 0.10 [ -0.17, 0.37 ]
Subtotal (95% CI) 666 663 100.0 % -0.03 [ -0.09, 0.03 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 2.86, df = 2 (P = 0.24); I2 =30%
Test for overall effect: Z = 1.05 (P = 0.29)
2 ALA - < 50% of control group on statins
MARGARIN 2002 49 0.09 (0.2) 93 0.13 (0.2) 55.2 % -0.04 [ -0.11, 0.03 ]
MENU 2016 65 1.73 (0.4031) 61 1.58 (0.3905) 44.8 % 0.15 [ 0.01, 0.29 ]
Subtotal (95% CI) 114 154 100.0 % 0.05 [ -0.14, 0.23 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 5.78, df = 1 (P = 0.02); I2 =83%
Test for overall effect: Z = 0.48 (P = 0.63)
3 ALA - use of statins unclear
Dodin 2005 85 1.68 (0.35) 94 1.77 (0.38) 100.0 % -0.09 [ -0.20, 0.02 ]
Subtotal (95% CI) 85 94 100.0 % -0.09 [ -0.20, 0.02 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.65 (P = 0.099)
Test for subgroup differences: Chi2 = 1.70, df = 2 (P = 0.43), I2 =0.0%
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Analysis 5.57. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 57 HDL,
mmoL/L - ALA - subgroup by primary or secondary prevention.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 5 High vs low ALA omega-3 fat (secondary outcomes)
Outcome: 57 HDL, mmoL/L - ALA - subgroup by primary or secondary prevention
Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Low CVD risk
Dodin 2005 85 1.68 (0.35) 94 1.77 (0.38) 51.8 % -0.09 [ -0.20, 0.02 ]
MENU 2016 65 1.73 (0.4031) 61 1.58 (0.3905) 48.2 % 0.15 [ 0.01, 0.29 ]
Subtotal (95% CI) 150 155 100.0 % 0.03 [ -0.21, 0.26 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 7.22, df = 1 (P = 0.01); I2 =86%
Test for overall effect: Z = 0.22 (P = 0.83)
2 Moderate CVD risk
HERO 2009 18 1.5 (0.4) 17 1.4 (0.4) 6.5 % 0.10 [ -0.17, 0.37 ]
MARGARIN 2002 49 0.09 (0.2) 93 0.13 (0.2) 93.5 % -0.04 [ -0.11, 0.03 ]
Subtotal (95% CI) 67 110 100.0 % -0.03 [ -0.10, 0.04 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 1.00, df = 1 (P = 0.32); I2 =0%
Test for overall effect: Z = 0.90 (P = 0.37)
3 High CVD risk
Ahn 2016 38 1.19 (0.31) 36 1.14 (0.33) 12.6 % 0.05 [ -0.10, 0.20 ]
AlphaOmega - ALA 2010 605 0.13 (0.25) 605 0.15 (0.25) 66.7 % -0.02 [ -0.05, 0.01 ]
FLAX-PAD 2013 43 1.12 (0.25) 41 1.22 (0.25) 20.7 % -0.10 [ -0.21, 0.01 ]
Subtotal (95% CI) 686 682 100.0 % -0.03 [ -0.08, 0.03 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 2.99, df = 2 (P = 0.22); I2 =33%
Test for overall effect: Z = 0.96 (P = 0.34)
Test for subgroup differences: Chi2 = 0.21, df = 2 (P = 0.90), I2 =0.0%
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Analysis 5.58. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 58 Low-density
lipoprotein, serum, mmoL/L - ALA.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 5 High vs low ALA omega-3 fat (secondary outcomes)
Outcome: 58 Low-density lipoprotein, serum, mmoL/L - ALA
Study or subgroup
Favours
higher
omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
AlphaOmega - ALA 2010 562 -0.38 (0.71) 562 -0.39 (0.71) 29.1 % 0.01 [ -0.07, 0.09 ]
Dodin 2005 85 3.45 (0.67) 94 3.64 (0.67) 14.2 % -0.19 [ -0.39, 0.01 ]
FLAX-PAD 2013 43 2.3 (1.1) 41 2.4 (0.9) 4.2 % -0.10 [ -0.53, 0.33 ]
HERO 2009 16 2.4 (0.6) 16 2.5 (0.8) 3.3 % -0.10 [ -0.59, 0.39 ]
MARGARIN 2002 49 -0.39 (0.6) 93 -0.53 (0.7) 12.2 % 0.14 [ -0.08, 0.36 ]
MENU 2016 65 2.97 (0.8062) 61 2.97 (0.6248) 10.2 % 0.0 [ -0.25, 0.25 ]
WAHA 2016 (1) 260 -0.18 (0.48) 254 -0.03 (0.64) 26.7 % -0.15 [ -0.25, -0.05 ]
Total (95% CI) 1080 1121 100.0 % -0.05 [ -0.15, 0.04 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 11.05, df = 6 (P = 0.09); I2 =46%
Test for overall effect: Z = 1.14 (P = 0.25)
Test for subgroup differences: Not applicable
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Analysis 5.59. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 59 LDL,
mmoL/L - ALA - SA fixed-effect.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 5 High vs low ALA omega-3 fat (secondary outcomes)
Outcome: 59 LDL, mmoL/L - ALA - SA fixed-effect
Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
AlphaOmega - ALA 2010 562 -0.38 (0.71) 562 -0.39 (0.71) 45.2 % 0.01 [ -0.07, 0.09 ]
Dodin 2005 85 3.45 (0.67) 94 3.64 (0.67) 8.1 % -0.19 [ -0.39, 0.01 ]
FLAX-PAD 2013 43 2.3 (1.1) 41 2.4 (0.9) 1.7 % -0.10 [ -0.53, 0.33 ]
HERO 2009 16 2.4 (0.6) 16 2.5 (0.8) 1.3 % -0.10 [ -0.59, 0.39 ]
MARGARIN 2002 49 -0.39 (0.6) 93 -0.53 (0.7) 6.4 % 0.14 [ -0.08, 0.36 ]
MENU 2016 65 2.97 (0.8062) 61 2.97 (0.6248) 4.9 % 0.0 [ -0.25, 0.25 ]
WAHA 2016 (1) 260 -0.18 (0.48) 254 -0.03 (0.64) 32.4 % -0.15 [ -0.25, -0.05 ]
Total (95% CI) 1080 1121 100.0 % -0.05 [ -0.11, 0.00 ]
Heterogeneity: Chi2 = 11.05, df = 6 (P = 0.09); I2 =46%
Test for overall effect: Z = 1.88 (P = 0.061)
Test for subgroup differences: Not applicable
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Analysis 5.60. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 60 LDL,
mmoL/L - ALA - SA by summary risk of bias.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 5 High vs low ALA omega-3 fat (secondary outcomes)
Outcome: 60 LDL, mmoL/L - ALA - SA by summary risk of bias
Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Low risk of bias
AlphaOmega - ALA 2010 562 -0.38 (0.71) 562 -0.39 (0.71) 84.8 % 0.01 [ -0.07, 0.09 ]
FLAX-PAD 2013 43 2.3 (1.1) 41 2.4 (0.9) 3.2 % -0.10 [ -0.53, 0.33 ]
MARGARIN 2002 49 -0.39 (0.6) 93 -0.53 (0.7) 12.1 % 0.14 [ -0.08, 0.36 ]
Subtotal (95% CI) 654 696 100.0 % 0.02 [ -0.05, 0.10 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.49, df = 2 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 0.57 (P = 0.57)
2 Moderate/high risk of bias
Dodin 2005 85 3.45 (0.67) 94 3.64 (0.67) 17.2 % -0.19 [ -0.39, 0.01 ]
HERO 2009 16 2.4 (0.6) 16 2.5 (0.8) 2.8 % -0.10 [ -0.59, 0.39 ]
MENU 2016 65 2.97 (0.8062) 61 2.97 (0.6248) 10.6 % 0.0 [ -0.25, 0.25 ]
WAHA 2016 (1) 260 -0.18 (0.48) 254 -0.03 (0.64) 69.4 % -0.15 [ -0.25, -0.05 ]
Subtotal (95% CI) 426 425 100.0 % -0.14 [ -0.22, -0.06 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.51, df = 3 (P = 0.68); I2 =0.0%
Test for overall effect: Z = 3.35 (P = 0.00080)
Test for subgroup differences: Chi2 = 8.05, df = 1 (P = 0.00), I2 =88%
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Analysis 5.61. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 61 LDL,
mmoL/L - ALA - SA by compliance and study size.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 5 High vs low ALA omega-3 fat (secondary outcomes)
Outcome: 61 LDL, mmoL/L - ALA - SA by compliance and study size
Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 SA - low risk of compliance bias
AlphaOmega - ALA 2010 562 -0.38 (0.71) 562 -0.39 (0.71) 29.3 % 0.01 [ -0.07, 0.09 ]
Dodin 2005 85 3.45 (0.67) 94 3.64 (0.67) 16.5 % -0.19 [ -0.39, 0.01 ]
MARGARIN 2002 49 -0.39 (0.6) 93 -0.53 (0.7) 14.5 % 0.14 [ -0.08, 0.36 ]
MENU 2016 65 2.97 (0.8062) 61 2.97 (0.6248) 12.3 % 0.0 [ -0.25, 0.25 ]
WAHA 2016 (1) 260 -0.18 (0.48) 254 -0.03 (0.64) 27.4 % -0.15 [ -0.25, -0.05 ]
Subtotal (95% CI) 1021 1064 100.0 % -0.05 [ -0.16, 0.06 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 10.97, df = 4 (P = 0.03); I2 =64%
Test for overall effect: Z = 0.88 (P = 0.38)
2 SA - 100+ randomised
AlphaOmega - ALA 2010 562 -0.38 (0.71) 562 -0.39 (0.71) 29.3 % 0.01 [ -0.07, 0.09 ]
Dodin 2005 85 3.45 (0.67) 94 3.64 (0.67) 16.5 % -0.19 [ -0.39, 0.01 ]
MARGARIN 2002 49 -0.39 (0.6) 93 -0.53 (0.7) 14.5 % 0.14 [ -0.08, 0.36 ]
MENU 2016 65 2.97 (0.8062) 61 2.97 (0.6248) 12.3 % 0.0 [ -0.25, 0.25 ]
WAHA 2016 (2) 260 -0.18 (0.48) 254 -0.03 (0.64) 27.4 % -0.15 [ -0.25, -0.05 ]
Subtotal (95% CI) 1021 1064 100.0 % -0.05 [ -0.16, 0.06 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 10.97, df = 4 (P = 0.03); I2 =64%
Test for overall effect: Z = 0.88 (P = 0.38)
Test for subgroup differences: Chi2 = 0.00, df = 1 (P = 1.00), I2 =0.0%
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Analysis 5.62. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 62 LDL,
mmoL/L - ALA - subgroup by dose.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 5 High vs low ALA omega-3 fat (secondary outcomes)
Outcome: 62 LDL, mmoL/L - ALA - subgroup by dose
Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 ALA low < 5 g/d
AlphaOmega - ALA 2010 562 -0.38 (0.71) 562 -0.39 (0.71) 42.5 % 0.01 [ -0.07, 0.09 ]
HERO 2009 16 2.4 (0.6) 16 2.5 (0.8) 4.6 % -0.10 [ -0.59, 0.39 ]
MENU 2016 65 2.97 (0.8062) 61 2.97 (0.6248) 14.2 % 0.0 [ -0.25, 0.25 ]
WAHA 2016 (1) 260 -0.18 (0.48) 254 -0.03 (0.64) 38.8 % -0.15 [ -0.25, -0.05 ]
Subtotal (95% CI) 903 893 100.0 % -0.06 [ -0.17, 0.05 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 6.18, df = 3 (P = 0.10); I2 =51%
Test for overall effect: Z = 1.05 (P = 0.29)
2 ALA high > 5 g/d
Dodin 2005 85 3.45 (0.67) 94 3.64 (0.67) 41.5 % -0.19 [ -0.39, 0.01 ]
FLAX-PAD 2013 43 2.3 (1.1) 41 2.4 (0.9) 19.8 % -0.10 [ -0.53, 0.33 ]
MARGARIN 2002 49 -0.39 (0.6) 93 -0.53 (0.7) 38.7 % 0.14 [ -0.08, 0.36 ]
Subtotal (95% CI) 177 228 100.0 % -0.04 [ -0.28, 0.19 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 4.86, df = 2 (P = 0.09); I2 =59%
Test for overall effect: Z = 0.37 (P = 0.71)
Test for subgroup differences: Chi2 = 0.01, df = 1 (P = 0.92), I2 =0.0%
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Analysis 5.63. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 63 LDL,
mmoL/L - ALA - subgroup by intervention type.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 5 High vs low ALA omega-3 fat (secondary outcomes)
Outcome: 63 LDL, mmoL/L - ALA - subgroup by intervention type
Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Dietary advice
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Supplemental foods
AlphaOmega - ALA 2010 562 -0.38 (0.71) 562 -0.39 (0.71) 30.8 % 0.01 [ -0.07, 0.09 ]
Dodin 2005 85 3.45 (0.67) 94 3.64 (0.67) 16.5 % -0.19 [ -0.39, 0.01 ]
FLAX-PAD 2013 43 2.3 (1.1) 41 2.4 (0.9) 5.3 % -0.10 [ -0.53, 0.33 ]
HERO 2009 16 2.4 (0.6) 16 2.5 (0.8) 4.2 % -0.10 [ -0.59, 0.39 ]
MARGARIN 2002 49 -0.39 (0.6) 93 -0.53 (0.7) 14.4 % 0.14 [ -0.08, 0.36 ]
WAHA 2016 (1) 260 -0.18 (0.48) 254 -0.03 (0.64) 28.7 % -0.15 [ -0.25, -0.05 ]
Subtotal (95% CI) 1015 1060 100.0 % -0.06 [ -0.17, 0.05 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 10.87, df = 5 (P = 0.05); I2 =54%
Test for overall effect: Z = 1.12 (P = 0.26)
3 Supplement (capsule)
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
4 Any combination
MENU 2016 65 2.97 (0.8062) 61 2.97 (0.6248) 100.0 % 0.0 [ -0.25, 0.25 ]
Subtotal (95% CI) 65 61 100.0 % 0.0 [ -0.25, 0.25 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Chi2 = 0.19, df = 1 (P = 0.66), I2 =0.0%
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Analysis 5.64. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 64 LDL,
mmoL/L - ALA - subgroup by replacement.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 5 High vs low ALA omega-3 fat (secondary outcomes)
Outcome: 64 LDL, mmoL/L - ALA - subgroup by replacement
Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 ALA replacing SFA
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
2 ALA replacing MUFA
AlphaOmega - ALA 2010 562 -0.38 (0.71) 562 -0.39 (0.71) 90.1 % 0.01 [ -0.07, 0.09 ]
MENU 2016 65 2.97 (0.8062) 61 2.97 (0.6248) 9.9 % 0.0 [ -0.25, 0.25 ]
Subtotal (95% CI) 627 623 100.0 % 0.01 [ -0.07, 0.09 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.01, df = 1 (P = 0.94); I2 =0.0%
Test for overall effect: Z = 0.22 (P = 0.82)
3 ALA replacing n-6
MARGARIN 2002 49 -0.39 (0.6) 93 -0.53 (0.7) 100.0 % 0.14 [ -0.08, 0.36 ]
Subtotal (95% CI) 49 93 100.0 % 0.14 [ -0.08, 0.36 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.25 (P = 0.21)
4 ALA replacing carbs/sugars
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
5 ALA replacing nil/low n-3 placebo
HERO 2009 16 2.4 (0.6) 16 2.5 (0.8) 100.0 % -0.10 [ -0.59, 0.39 ]
Subtotal (95% CI) 16 16 100.0 % -0.10 [ -0.59, 0.39 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.40 (P = 0.69)
6 Replacement unclear
Dodin 2005 85 3.45 (0.67) 94 3.64 (0.67) 19.1 % -0.19 [ -0.39, 0.01 ]
FLAX-PAD 2013 43 2.3 (1.1) 41 2.4 (0.9) 4.0 % -0.10 [ -0.53, 0.33 ]
WAHA 2016 (1) 260 -0.18 (0.48) 254 -0.03 (0.64) 76.9 % -0.15 [ -0.25, -0.05 ]
Subtotal (95% CI) 388 389 100.0 % -0.16 [ -0.24, -0.07 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.19, df = 2 (P = 0.91); I2 =0.0%
Test for overall effect: Z = 3.55 (P = 0.00038)
Test for subgroup differences: Chi2 = 10.85, df = 3 (P = 0.01), I2 =72%
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(1) change from baseline
Analysis 5.65. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 65 LDL,
mmoL/L - ALA - subgroup by duration.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 5 High vs low ALA omega-3 fat (secondary outcomes)
Outcome: 65 LDL, mmoL/L - ALA - subgroup by duration
Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Medium duration 1 to < 2 years in study
Dodin 2005 85 3.45 (0.67) 94 3.64 (0.67) 16.6 % -0.19 [ -0.39, 0.01 ]
FLAX-PAD 2013 43 2.3 (1.1) 41 2.4 (0.9) 3.5 % -0.10 [ -0.53, 0.33 ]
HERO 2009 16 2.4 (0.6) 16 2.5 (0.8) 2.7 % -0.10 [ -0.59, 0.39 ]
MENU 2016 65 2.97 (0.8062) 61 2.97 (0.6248) 10.2 % 0.0 [ -0.25, 0.25 ]
WAHA 2016 (1) 260 -0.18 (0.48) 254 -0.03 (0.64) 67.0 % -0.15 [ -0.25, -0.05 ]
Subtotal (95% CI) 469 466 100.0 % -0.14 [ -0.22, -0.06 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.54, df = 4 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 3.38 (P = 0.00073)
2 Medium-long duration: 2 to < 4 years in study
AlphaOmega - ALA 2010 562 -0.38 (0.71) 562 -0.39 (0.71) 82.0 % 0.01 [ -0.07, 0.09 ]
MARGARIN 2002 49 -0.39 (0.6) 93 -0.53 (0.7) 18.0 % 0.14 [ -0.08, 0.36 ]
Subtotal (95% CI) 611 655 100.0 % 0.03 [ -0.06, 0.13 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 1.17, df = 1 (P = 0.28); I2 =15%
Test for overall effect: Z = 0.67 (P = 0.50)
3 Long duration≥ 4 years in study
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Chi2 = 7.07, df = 1 (P = 0.01), I2 =86%
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Analysis 5.66. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 66 LDL,
mmoL/L - ALA - subgroup by statin use.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 5 High vs low ALA omega-3 fat (secondary outcomes)
Outcome: 66 LDL, mmoL/L - ALA - subgroup by statin use
Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 ALA -≥ 50% of control group on statins
AlphaOmega - ALA 2010 562 -0.38 (0.71) 562 -0.39 (0.71) 93.8 % 0.01 [ -0.07, 0.09 ]
FLAX-PAD 2013 43 2.3 (1.1) 41 2.4 (0.9) 3.5 % -0.10 [ -0.53, 0.33 ]
HERO 2009 16 2.4 (0.6) 16 2.5 (0.8) 2.7 % -0.10 [ -0.59, 0.39 ]
Subtotal (95% CI) 621 619 100.0 % 0.00 [ -0.08, 0.08 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.42, df = 2 (P = 0.81); I2 =0.0%
Test for overall effect: Z = 0.08 (P = 0.94)
2 ALA - < 50% of control group on statins
MARGARIN 2002 49 -0.39 (0.6) 93 -0.53 (0.7) 56.5 % 0.14 [ -0.08, 0.36 ]
MENU 2016 65 2.97 (0.8062) 61 2.97 (0.6248) 43.5 % 0.0 [ -0.25, 0.25 ]
Subtotal (95% CI) 114 154 100.0 % 0.08 [ -0.09, 0.24 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.68, df = 1 (P = 0.41); I2 =0.0%
Test for overall effect: Z = 0.94 (P = 0.35)
3 ALA - use of statins unclear
Dodin 2005 85 3.45 (0.67) 94 3.64 (0.67) 19.9 % -0.19 [ -0.39, 0.01 ]
WAHA 2016 (1) 260 -0.18 (0.48) 254 -0.03 (0.64) 80.1 % -0.15 [ -0.25, -0.05 ]
Subtotal (95% CI) 345 348 100.0 % -0.16 [ -0.25, -0.07 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.13, df = 1 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 3.53 (P = 0.00041)
Test for subgroup differences: Chi2 = 9.83, df = 2 (P = 0.01), I2 =80%
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Analysis 5.67. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 67 LDL,
mmoL/L - ALA - subgroup by primary or secondary prevention.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 5 High vs low ALA omega-3 fat (secondary outcomes)
Outcome: 67 LDL, mmoL/L - ALA - subgroup by primary or secondary prevention
Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Primary prevention of CVD
Dodin 2005 85 3.45 (0.67) 94 3.64 (0.67) 21.7 % -0.19 [ -0.39, 0.01 ]
HERO 2009 16 2.4 (0.6) 16 2.5 (0.8) 5.5 % -0.10 [ -0.59, 0.39 ]
MARGARIN 2002 49 -0.39 (0.6) 93 -0.53 (0.7) 19.0 % 0.14 [ -0.08, 0.36 ]
MENU 2016 65 2.97 (0.8062) 61 2.97 (0.6248) 16.0 % 0.0 [ -0.25, 0.25 ]
WAHA 2016 (1) 260 -0.18 (0.48) 254 -0.03 (0.64) 37.7 % -0.15 [ -0.25, -0.05 ]
Subtotal (95% CI) 475 518 100.0 % -0.08 [ -0.20, 0.05 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 6.96, df = 4 (P = 0.14); I2 =43%
Test for overall effect: Z = 1.23 (P = 0.22)
2 Secondary prevention of CVD
AlphaOmega - ALA 2010 562 -0.38 (0.71) 562 -0.39 (0.71) 96.4 % 0.01 [ -0.07, 0.09 ]
FLAX-PAD 2013 43 2.3 (1.1) 41 2.4 (0.9) 3.6 % -0.10 [ -0.53, 0.33 ]
Subtotal (95% CI) 605 603 100.0 % 0.01 [ -0.08, 0.09 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.24, df = 1 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 0.14 (P = 0.88)
Test for subgroup differences: Chi2 = 1.22, df = 1 (P = 0.27), I2 =18%
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Analysis 6.1. Comparison 6 High vs low ALA omega-3 fats (tertiary outcomes), Outcome 1 Blood pressure,
mmHg - ALA.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 6 High vs low ALA omega-3 fats (tertiary outcomes)
Outcome: 1 Blood pressure, mmHg - ALA
Study or subgroup Higher omega 3 Lower omega 3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Systolic BP - ALA
AlphaOmega - ALA 2010 632 -0.24 (20) 632 -2.29 (21.3) 39.1 % 2.05 [ -0.23, 4.33 ]
Dodin 2005 85 120.6 (14.4) 94 120.8 (17.1) 26.4 % -0.20 [ -4.82, 4.42 ]
FLAX-PAD 2013 45 136.2 (25.4912) 41 145.6 (21.7706) 10.2 % -9.40 [ -19.39, 0.59 ]
MARGARIN 2002 49 -2.9 (14.7) 93 -0.2 (14.5) 24.3 % -2.70 [ -7.76, 2.36 ]
Subtotal (95% CI) 811 860 100.0 % -0.87 [ -4.48, 2.75 ]
Heterogeneity: Tau2 = 7.36; Chi2 = 7.15, df = 3 (P = 0.07); I2 =58%
Test for overall effect: Z = 0.47 (P = 0.64)
2 Diastolic BP - ALA
AlphaOmega - ALA 2010 632 -1.79 (10.3) 632 -2.75 (10.3) 33.9 % 0.96 [ -0.18, 2.10 ]
Dodin 2005 85 75.5 (10.9) 94 76.1 (11.9) 24.7 % -0.60 [ -3.94, 2.74 ]
FLAX-PAD 2013 45 71.8 (11.4039) 41 78.5 (9.6047) 19.9 % -6.70 [ -11.14, -2.26 ]
MARGARIN 2002 49 0.7 (11.9) 93 1.9 (11.6) 21.4 % -1.20 [ -5.28, 2.88 ]
Subtotal (95% CI) 811 860 100.0 % -1.42 [ -4.40, 1.57 ]
Heterogeneity: Tau2 = 6.51; Chi2 = 11.63, df = 3 (P = 0.01); I2 =74%
Test for overall effect: Z = 0.93 (P = 0.35)
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Analysis 6.2. Comparison 6 High vs low ALA omega-3 fats (tertiary outcomes), Outcome 2 Serious adverse
events - ALA.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 6 High vs low ALA omega-3 fats (tertiary outcomes)
Outcome: 2 Serious adverse events - ALA
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Any serious adverse events
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 3), 0 (Lower omega 3)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Bleeding
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 3), 0 (Lower omega 3)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 GI hospitalisation
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 3), 0 (Lower omega 3)
Heterogeneity: not applicable
Test for overall effect: not applicable
4 Pulmonary embolus or DVT
WAHA 2016 0/362 1/346 100.0 % 0.32 [ 0.01, 7.80 ]
Subtotal (95% CI) 362 346 100.0 % 0.32 [ 0.01, 7.80 ]
Total events: 0 (Higher omega 3), 1 (Lower omega 3)
Heterogeneity: not applicable
Test for overall effect: Z = 0.70 (P = 0.48)
5 Thrombophleibitis
Norwegian 1968 16/6716 10/6690 100.0 % 1.59 [ 0.72, 3.51 ]
Subtotal (95% CI) 6716 6690 100.0 % 1.59 [ 0.72, 3.51 ]
Total events: 16 (Higher omega 3), 10 (Lower omega 3)
Heterogeneity: not applicable
Test for overall effect: Z = 1.16 (P = 0.25)
6 Urolithiasis
Norwegian 1968 24/6716 30/6690 100.0 % 0.80 [ 0.47, 1.36 ]
Subtotal (95% CI) 6716 6690 100.0 % 0.80 [ 0.47, 1.36 ]
Total events: 24 (Higher omega 3), 30 (Lower omega 3)
Heterogeneity: not applicable
Test for overall effect: Z = 0.83 (P = 0.41)
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Analysis 6.3. Comparison 6 High vs low ALA omega-3 fats (tertiary outcomes), Outcome 3 Side effects -
ALA.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 6 High vs low ALA omega-3 fats (tertiary outcomes)
Outcome: 3 Side effects - ALA
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Dropouts due to side effects
AlphaOmega - ALA 2010 18/1197 21/1236 42.1 % 0.89 [ 0.47, 1.65 ]
Dodin 2005 10/85 5/94 34.8 % 2.21 [ 0.79, 6.21 ]
FLAX-PAD 2013 0/58 0/52 Not estimable
HERO 2009 1/26 0/24 10.6 % 2.78 [ 0.12, 65.08 ]
WAHA 2016 13/362 0/346 12.6 % 25.81 [ 1.54, 432.50 ]
Subtotal (95% CI) 1728 1752 100.0 % 2.10 [ 0.66, 6.71 ]
Total events: 42 (Higher omega 3), 26 (Lower omega 3)
Heterogeneity: Tau2 = 0.73; Chi2 = 7.86, df = 3 (P = 0.05); I2 =62%
Test for overall effect: Z = 1.25 (P = 0.21)
2 Abdominal pain or discomfort
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 3), 0 (Lower omega 3)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Diarrhoea
WAHA 2016 8/362 2/346 100.0 % 3.82 [ 0.82, 17.88 ]
Subtotal (95% CI) 362 346 100.0 % 3.82 [ 0.82, 17.88 ]
Total events: 8 (Higher omega 3), 2 (Lower omega 3)
Heterogeneity: not applicable
Test for overall effect: Z = 1.70 (P = 0.088)
4 Nausea
FLAX-PAD 2013 3/58 0/52 100.0 % 6.29 [ 0.33, 118.93 ]
Subtotal (95% CI) 58 52 100.0 % 6.29 [ 0.33, 118.93 ]
Total events: 3 (Higher omega 3), 0 (Lower omega 3)
Heterogeneity: not applicable
Test for overall effect: Z = 1.23 (P = 0.22)
5 Any gastrointestinal side effect - ALA
AlphaOmega - ALA 2010 9/1197 10/1236 38.4 % 0.93 [ 0.38, 2.28 ]
Dodin 2005 8/101 6/98 36.1 % 1.29 [ 0.47, 3.59 ]
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(. . . Continued)
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
FLAX-PAD 2013 (1) 3/58 0/52 12.4 % 6.29 [ 0.33, 118.93 ]
WAHA 2016 13/362 0/346 13.2 % 25.81 [ 1.54, 432.50 ]
Subtotal (95% CI) 1718 1732 100.0 % 2.06 [ 0.62, 6.80 ]
Total events: 33 (Higher omega 3), 16 (Lower omega 3)
Heterogeneity: Tau2 = 0.76; Chi2 = 7.17, df = 3 (P = 0.07); I2 =58%
Test for overall effect: Z = 1.18 (P = 0.24)
6 Pain (joint, lumbar, muscle pain)
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 3), 0 (Lower omega 3)
Heterogeneity: not applicable
Test for overall effect: not applicable
7 All side effects combined
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 3), 0 (Lower omega 3)
Heterogeneity: not applicable
Test for overall effect: not applicable
0.1 0.2 0.5 1 2 5 10
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Analysis 6.4. Comparison 6 High vs low ALA omega-3 fats (tertiary outcomes), Outcome 4 Dropouts - ALA.
Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 6 High vs low ALA omega-3 fats (tertiary outcomes)
Outcome: 4 Dropouts - ALA
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
AlphaOmega - ALA 2010 189/1197 191/1236 68.3 % 1.02 [ 0.85, 1.23 ]
Dodin 2005 26/101 17/98 7.9 % 1.48 [ 0.86, 2.56 ]
FLAX-PAD 2013 15/58 11/52 5.0 % 1.22 [ 0.62, 2.42 ]
HERO 2009 7/26 5/24 2.3 % 1.29 [ 0.47, 3.53 ]
MENU 2016 13/82 12/81 4.5 % 1.07 [ 0.52, 2.20 ]
WAHA 2016 38/362 34/346 12.1 % 1.07 [ 0.69, 1.66 ]
Total (95% CI) 1826 1837 100.0 % 1.08 [ 0.92, 1.25 ]
Total events: 288 (Higher omega 3), 270 (Lower omega 3)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.90, df = 5 (P = 0.86); I2 =0.0%
Test for overall effect: Z = 0.93 (P = 0.35)
Test for subgroup differences: Not applicable
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A D D I T I O N A L T A B L E S
Table 1. Risk of bias assessment methods in greater detail
Risk of bias element Criteria for low risk of bias Criteria for unclear Criteria for high risk of bias
Selection bias: random se-
quence generation
The study authors needed to
have described themethod used
to generate the allocation se-
quence in sufficient detail to al-
low an assessment of whether
it should produce comparable
groups. For example “the ran-
domisation sequence was com-
puter generated”. We allowed
that a goodmethodof randomi-
sation was strongly implied if
the authors discussed stratifi-
cation and/or blocking. There-
The study authors have not de-
scribed their method in suffi-
cient detail for the assessment
of whether it would produce
comparable groups. For exam-
ple, the authors state “the trial
was randomised” and provide
no further information
The randomisationmethodwas
assessed as not truly random,
and may not produce compara-
ble groups
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Table 1. Risk of bias assessment methods in greater detail (Continued)
fore, if the authors were not
explicit about their randomisa-
tion method but did describe
stratification or blocking we as-
sessed this as corresponding to
low risk
Selection bias: allocation con-
cealment
The study authors needed to
have described themethod used
to conceal allocation sequence
in sufficient detail to determine
whether the allocations could
have been foreseen in advance
of, or during, enrolment. Good
methods included putting allo-
cation codes in opaque sealed
envelopes (ideally prepared by
someone outside the treatment
or assessment teams and se-
quentially numbered), using a
telephone allocation system af-
ter the participants had con-
sented to participate or provid-
ing a random number that links
to a specific set of capsules pre-
pared and distributed centrally
or by an arms-length pharma-
cist
The authors gave insufficient
detail as to method.
The allocation was known in
advance of participants con-
senting to take part in the study
Performance bias: blinding of
participants and personnel
The study authors needed to
have described all measures
used, if any, to blind study par-
ticipants and personnel from
knowledge of which interven-
tion a participant received. Ide-
ally, they should also have pro-
vided information relating to
whether the intended blinding
was effective. For example, the
authors could say “both the in-
tervention and placebo capsules
looked and tasted the same.”
However, if the study authors
did not provide information on
whether the blinding was ef-
fective, but sufficient detail was
given on a good method of
blinding, then it was assumed
that the blinding was effective
and the risk of bias was low
Insufficient methodological de-
tails were provided e.g. “the
study was blinded.”
The study was unblinded or
where blinding was broken, e.
g. “the capsules were visually
identical but the participants re-
ported a strong fishy flavour in
the intervention group only.”
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Table 1. Risk of bias assessment methods in greater detail (Continued)
Detection bias: blinding of
outcome assessment
Study authors needed to have
described measures used, if
any, to blind outcome asses-
sors from knowledge of which
intervention a participant re-
ceived. Ideally, they should also
have provided information re-
lating to whether the intended
blinding was effective. For ex-
ample, the authors could say
“the outcome assessors had no
knowledge of the group alloca-
tion, and both the intervention
and placebo capsules looked
and tasted the same so the
self-assessment scales were also
blinded.” However if the study
authors did not provide infor-
mation onwhether the blinding
was effective, but sufficient de-
tail was given on a goodmethod
of blinding of the assessors, then
it was assumed that the blind-
ing was effective and the risk of
bias is low. All biochemical as-
sessment (lipids, glucose, CRP,
insulin, PSA, etc.) were consid-
ered at low risk of detection bias
if outcome assessor blinding or
double blinding was stated
Insufficient methodological de-
tails were provided e.g. “the
study was blinded.”
The study was unblinded or
blinding was broken, e.g. for
a self-assessment measure “the
capsules were visually identical
but the participants reported a
strong fishy flavour in the inter-
vention group only.”
Because the level of blinding
could vary by outcome assess-
ment of risk of bias was based
on blinding of the review’s pri-
mary outcome(s). Where pri-
mary outcomes had different
assessments we opted for the
higher risk of bias but noted
that that risk of bias was lower
for other outcomes
Attrition bias: incomplete
outcome data
The study authors needed tode-
scribe the completeness of out-
come data for each main out-
come, including attrition and
exclusions from the analysis.
They needed to report the num-
ber of attrition/exclusions, the
numbers in each group at each
time point, reasons for attri-
tion/exclusion and any re-inclu-
sions in analyses. Ideally, they
would report how they imputed
any missing data e.g. last obser-
vation carried forward. There
needed to be a reasonable bal-
ance of attrition/exclusions be-
tween study arms and≤ 20%of
the sample should be lost over a
The authors didn’t state reasons
for attrition/exclusion, or were
unclear about the numbers lost
to attrition/exclusion in each
study arm
The authors demonstrated a
substantial difference in the
rates of attrition/exclusions be-
tween the study arms and/or >
20% of the baseline sample was
lost over a year (> 10% over 6
months)
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Table 1. Risk of bias assessment methods in greater detail (Continued)
year
Reporting bias: selective out-
come reporting
The study authors needed to
have published their trial proto-
col or trials registry entry before
the end of the study’s recruit-
ment period i.e. prospectively.
They needed to have reported
on all of the primary and sec-
ondary outcomes listed in the
protocol/registry entry. Report-
ing additional secondary out-
comes in the results paper(s), al-
though not ideal, was deemed
to still be low risk
No trial protocol or trials reg-
istry entry was found, it was
registered retrospectively, or the
dates of registration and partic-
ipant recruitment were unclear
The study authors did not re-
port at least one primary or sec-
ondary outcome listed in the
protocol/registry entry or the re-
sults paper(s) reported a pri-
mary outcome that was not
listed at all in the protocol or
not listed as a primary outcome
in the protocol
Other sources of bias: atten-
tion bias
The study authors needed to
have reported that participants
in all study arms received the
same amount of attention and
time from researchers and clin-
ical teams. For example, “All
participants attended the clinic
for a baseline assessment which
took 2 hours. They were then
followed with monthly tele-
phone calls, and finally at-
tended for a 6 month assess-
ment at the clinic which took
1 hour.” If the study only dif-
fered by the content of the cap-
sules, and the assessment sched-
ule was not stated to differ be-
tween the two arms, it was as-
sumed to be at low risk
The authors did not state the
attention each arm received.
Participants in different arms
received different amounts of
attention. For example “the in-
tervention group only attended
for additional assessments at
months 2, 4, and6” or “the rates
of relapse differed substantially
between the groupswhich led to
differing amounts of treatment
time and attention,” or “the in-
tervention group received a 40
minute dietary education ses-
sion.”
Other sources of bias: limited
compliance
The study authors needed to
have reported on the level
of compliance in all arms in
sufficient detail to determine
whether the study results were
robust. We followed a flow
chart to make this determi-
nation. A statistically signifi-
cant difference between the in-
tervention and control groups
in a body measure of at least
50% of the text fatty acids.
Where no body measures were
Compliance not reported or not
in a way that could be inter-
preted
Measures of compliance were
reported but fell below the ap-
propriate thresholds
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Table 1. Risk of bias assessment methods in greater detail (Continued)
reported then estimated com-
pliance needed to be greater
than 64% (proportion comply-
ing multiplied by compliance
threshold)
Other sources of bias: other In the absence of any additional
issues this item was coded “low
risk of bias”
- If fraud concerns had been
raised and the paper had been
withdrawn, or the author had
been found guilty of fraud by a
legal or medical entity the paper
was excluded from the review.
However if fraud concerns were
raised, but the journal had not
withdrawn the paper, and the
author had not been formally
sanctioned; then the study was
included in the review, but con-
cerns were raised here, and the
risk of bias for this item was
high
CRP: C-reactive protein; PSA: prostate specific antigen.
Table 2. Meta-regression results for cardiovascular mortalitya
Variable assessed P value
LCn3 dose 0.61
ALA dose 0.91
Omega-6 dose 0.81
Total PUFA dose 0.82
Duration, months 0.68
Primary or secondary CVD prevention 0.88
Food or capsule 0.54
Risk of bias 0.94
Food or capsule
+ LCn3 dose
+ duration
0.70
0.96
0.69
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ALA: alpha-linolenic acid; CVD: cardiovascular disease; LCn3: long-chain omega-3 fatty acids; PUFA: poly-unsaturated fatty acids.
aRandom-effects meta-regression exploring effects of LCn3 dose, ALA dose, omega-6 dose, total PUFA dose, study duration, primary
or secondary prevention, food or capsule intervention, and summary risk of bias (low or moderate to high) on cardiovascular mortality.
We ran the meta-regression using all included trials that reported this outcome in this review, and its sister reviews (update of Hooper
2018, and Abdelhamid 2018). For each variable the P value presented represents probability that the relationship was due to chance (as
we had limited power we assumed a true relationship when P < 0.10). Meta-regression was of each variable singly, plus a multivariate
meta-regression of the 3 single variables with lowest P values. See methods for further information.
Table 3. Meta-regression results for cardiovascular eventsa
Variable assessed P value
LCn3 dose 0.91
ALA dose 0.70
omega-6 dose 0.34
Total PUFA dose 0.34
Duration, months 0.62
Primary or secondary CVD prevention 0.78
Food or capsule 0.83
Risk of bias 0.24
Risk of bias
+ PUFA dose
+ Omega-6 dose
0.25
0.87
0.83
ALA: alpha-linolenic acid; CVD: cardiovascular disease; LCn3: long-chain omega-3 fatty acids; PUFA: poly-unsaturated fatty acids.
aRandom-effects meta-regression exploring effects of LCn3 dose, ALA dose, omega-6 dose, total PUFA dose, study duration, primary
or secondary prevention, food or capsule intervention, and summary risk of bias (low or moderate to high) on cardiovascular events.
We ran the meta-regression using all included trials that reported this outcome in this review, and its sister reviews (update of Hooper
2018, and Abdelhamid 2018). For each variable the P value presented represents probability that the relationship was due to chance (as
we had limited power we assumed a true relationship when P < 0.10). Meta-regression was of each variable singly, plus a multivariate
meta-regression of the 3 single variables with lowest P values. See methods for further information.
Table 4. Meta-regression results for CHD deathsa
Variable assessed P value
LCn3 dose 0.94
ALA dose 0.93
Omega-6 dose 0.66
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Table 4. Meta-regression results for CHD deathsa (Continued)
Total PUFA dose 0.64
Duration, months 0.41
Primary or secondary CVD prevention 0.63
Food or capsule 0.78
Risk of bias 0.89
Duration
+ Primary or secondary prevention
+ PUFA dose
0.73
0.90
0.76
ALA: alpha-linolenic acid; CVD: cardiovascular disease; LCn3: long-chain omega-3 fatty acids; PUFA: poly-unsaturated fatty acids.
aRandom-effects meta-regression exploring effects of LCn3 dose, ALA dose, omega-6 dose, total PUFA dose, study duration, primary
or secondary prevention, food or capsule intervention, and summary risk of bias (low or moderate to high) on CHD mortality. We ran
the meta-regression using all included trials that reported this outcome in this review, and its sister reviews (update of Hooper 2018,
and Abdelhamid 2018). For each variable the P value presented represents probability that the relationship was due to chance (as we
had limited power we assumed a true relationship when P < 0.10). Meta-regression was of each variable singly, plus a multivariate meta-
regression of the 3 single variables with lowest P values. See methods for further information.
Table 5. Metaregression results for CHD eventsa
Variable assessed P value
LCn3 dose 0.68
ALA dose 0.23
Omega-6 dose 0.84
Total PUFA dose 0.79
Duration, months 0.87
Primary or secondary CVD prevention 0.42
Food or capsule 0.91
Risk of bias 0.98
ALA dose
+ Prim or sec prev
+ LCn3 dose
0.32
0.46
0.86
ALA: alpha-linolenic acid; CVD: cardiovascular disease; LCn3: long-chain omega-3 fatty acids; PUFA: poly-unsaturated fatty acids.
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aRandom-effects meta-regression exploring effects of LCn3 dose, ALA dose, omega-6 dose, total PUFA dose, study duration, primary
or secondary prevention, food or capsule intervention, and summary risk of bias (low or moderate to high) on CHD events. We ran the
meta-regression using all included trials that reported this outcome in this review, and its sister reviews (update of Hooper 2018, and
Abdelhamid 2018). For each variable the P value presented represents probability that the relationship was due to chance (as we had
limited power we assumed a true relationship when P < 0.10). Meta-regression was of each variable singly, plus a multivariate meta-
regression of the 3 single variables with lowest P values. See methods for further information.
Table 6. Metaregression results for strokea
Variable assessed P value Coefficient sign where P < 0.10
LCn3 dose 0.42 -
ALA dose 0.81 -
Omega-6 dose 0.19 -
Total PUFA dose 0.21 -
Duration, months 0.012 Negative (greater effect with shorter duration)
Primary or secondary CVD prevention 0.04 Positive (greater effect with secondary prevention)
Food or capsule 0.21 -
Risk of bias 0.25 -
Duration
+ primary or secondary prevention
+ omega-6
0.21
0.67
0.38
-
ALA: alpha-linolenic acid; CVD: cardiovascular disease; LCn3: long-chain omega-3 fatty acids; PUFA: poly-unsaturated fatty acids.
aRandom-effects meta-regression exploring effects of LCn3 dose, ALA dose, omega-6 dose, total PUFA dose, study duration, primary
or secondary prevention, food or capsule intervention, and summary risk of bias (low or moderate to high) on stroke. We ran the
meta-regression using all included trials that reported this outcome in this review, and its sister reviews (update of Hooper 2018, and
Abdelhamid 2018). For each variable the P value presented represents probability that the relationship was due to chance (as we had
limited power we assumed a true relationship when P < 0.10). Meta-regression was of each variable singly, plus a multivariate meta-
regression of the 3 single variables with lowest P values. See methods for further information.
Table 7. Meta-regression results for arrhythmiasa
Variable assessed P value Coefficient sign where P < 0.10
LCn3 dose 0.06 Negative (greater effect at lower dose)
ALA dose 0.67 -
Omega-6 dose 0.59 -
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Table 7. Meta-regression results for arrhythmiasa (Continued)
Total PUFA dose 0.54 -
Duration, months 0.16 -
Primary or secondary CVD prevention 0.07 Negative (greater effect with primary prevention)
Food or capsule 0.82 -
Risk of bias 0.51 -
LCn3 dose
+ Primary secondary prevention
+ duration
0.09
0.12
0.46
-
ALA: alpha-linolenic acid; CVD: cardiovascular disease; LCn3: long-chain omega-3 fatty acids; PUFA: poly-unsaturated fatty acids.
aRandom-effects meta-regression exploring effects of LCn3 dose, ALA dose, omega-6 dose, total PUFA dose, study duration, primary
or secondary prevention, food or capsule intervention, and summary risk of bias (low or moderate to high) on arrhythmia. We ran the
meta-regression using all included trials that reported this outcome in this review, and its sister reviews (update of Hooper 2018, and
Abdelhamid 2018). For each variable the P value presented represents probability that the relationship was due to chance (as we had
limited power we assumed a true relationship when P < 0.10). Meta-regression was of each variable singly, plus a multivariate meta-
regression of the 3 single variables with lowest P values. See methods for further information.
Table 8. Comparison of the results of this review with Balk 2016 and Aung 2018a
Balk 2016 Aung 2018 This review
Number of peo-
ple experienc-
ing events
RR (95% CI) Number of peo-
ple experienc-
ing events
RR (95% CI) No
of people expe-
riencing events
RR (95% CI)
All-cause
mortality
8480 0.97 (0.92 to 1.
03)
- Not assessed 8647 0.98 (0.93 to 1.
03)
Cardiovascular
deaths
3799 0.92 (0.82 to 1.
02)
- Not assessed 4763 0.95 (0.87 to 1.
03)
CVD events
(MACCEs in
Balk 2016)
8085 0.96 (0.91 to 1.
02)
12001 0.97 (0.93 to 1.
01)
15614 0.99 (0.94 to 1.
04)
CHD deaths - Not pooled 2695 0.93, (0.83 to 1.
03)
1791 0.93 (0.79 to 1.
09)
CHD events - Not assessed 6273 0.96, (0.90 to 1.
01)
5865 0.93 (0.88 to 0.
97)
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Table 8. Comparison of the results of this review with Balk 2016 and Aung 2018a (Continued)
Stroke 1467 0.98 (0.88 to 1.
09)
1713 1.03 (0.93 to 1.
13)
1871 1.06 (0.96, 1.16)
Arrhythmia - Not pooled - Not assessed 3788 0.97 (0.90 to 1.
05)
CHD: coronary heart disease; CI: confidence interval; CVD: cardiovascular disease; MACCE: major adverse cerebrovascular or car-
diovascular event; RR: risk ratio.
aMeta-analysis of effects of LCn3 in Balk 2016 and Aung 2018 systematic reviews, comparing their findings with our findings for our
primary outcomes.
A P P E N D I C E S
Appendix 1. Medline (Ovid) search strategy run in 2002 for the previous version of this review.
1 exp Fish Oils/
2 exp Linseed Oil/
3 linolenic acids/ or exp alpha-linolenic acid/
4 exp Fatty Acids, Omega-3/
5 (fish adj5 (diet$ or nutrit$ or oil$ or supplement$)).tw.
6 (oil$ adj3 (cod$ or marin$ or rapeseed$ or canola$)).tw.
7 (omega-3 or omega3).tw.
8 (eicosapentaen$ or icosapentaen$).tw.
9 docosahexaen$.tw.
10 (Linolen$ or alpha-linolen$ or alphalinolen$).tw.
11 (maxepa$ or omacor$).tw.
12 (trout or kipper$ or salmon or mackerel$ or tuna or tunafish or sardine$ or pilchard$ or herring$).tw.
13 flax$.tw.
14 rapeseed$.tw.
15 canola$.tw.
16 alphalinolen$.tw.
17 perilla$.tw.
18 linolen$.tw.
19 linseed$.tw.
20 maxepa$.tw.
21 (oil$ adj3 colza).tw.
22 (marin$ adj3 (lipid$ or oil$)).tw.
23 naudicelle$.tw.
24 sild.tw.
25 (clupe$ adj3 hareng$).tw.
26 whitebait$.tw.
27 sprat$.tw.
28 brisling$.tw.
29 (salmo adj3 trut$).tw.
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30 bloater.tw.
31 scomb$.tw.
32 conger$.tw.
33 tunny.tw.
34 tuna-fish.tw.
35 thunnus$.tw.
36 swordfish$.tw.
37 xiphias$.tw.
38 dogfish.tw.
39 scyliorhinus$.tw.
40 (crab or crabs).tw.
41 (cancer adj3 pagurus).tw.
42 (laks or lax).tw.
43 exp Flax/
44 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or
25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39 or 40 or 41 or 42 or 43
45 randomized controlled trial.pt.
46 controlled clinical trial.pt.
47 randomized.ab.
48 placebo.ab.
49 clinical trials as topic.sh.
50 randomly.ab.
51 trial.ti.
52 50 or 47 or 51 or 46 or 45 or 48 or 49
53 (animals not (human and animals)).sh.
54 52 not 53
55 44 and 54
56 (20$ not (2000$ or 2001$)).ed.
57 55 and 56
Appendix 2. Searches run in July 2016 to update the omega-3 review
CENTRAL
#1 MeSH descriptor: [Fish Oils] explode all trees
#2 MeSH descriptor: [Linseed Oil] this term only
#3 MeSH descriptor: [Linolenic Acids] this term only
#4 MeSH descriptor: [Fatty Acids, Omega-3] explode all trees
#5 (fish near/3 oil*)
#6 (oil* near/3 (cod* or marin*))
#7 (omega-3 or omega3 or (omega* near/5 fat*))
#8 eicosapentaen*
#9 docosahexaen*
#10 (oil* near/3 (flax* or rapeseed* or canola*))
#11 (Linolen* or alpha-linolen* or alphalinolen*)
#12 (perilla* or linseed* or maxepa*)
#13 (oil* near/3 (rape or colza))
#14 (marin* near/3 lipid*)
#15 (naudicelle* or herring* or sild)
#16 (clupe* near/3 hareng*)
#17 (whitebait or sardine* or sardina* or pilchard* or sprat* or brisling*)
#18 (salmo* near/3 trut*)
#19 (trout or bloater or kipper* or salmon or mackerel* or scomb* or conger* or tuna or tunny or tunafish or tuna-fish)
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#20 (thunnus* or swordfish* or xiphias* or dogfish or scyliorrhinus*)
#21 (crab or crabs or (cancer pagarus))
#22 (DHA or EPA)
#23 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #
20 or #21 or #22 Publication Year from 2002 to 2016
#24 MeSH descriptor: [Salmoniformes] explode all trees
#25 MeSH descriptor: [Tuna] this term only
#26 MeSH descriptor: [alpha-Linolenic Acid] this term only
#27 MeSH descriptor: [Flax] this term only
#28 (fish near/3 (diet* or capsul* or nutrit* or supplement*))
#29 (icosapentaen* or docosapentaen*)
#30 (oil* near/3 (purslane or mustard* or candlenut* or stillingia or walnut*))
#31 (laks or lax)
#32 (ALA or DPA)
#33 (algal near oil*)
#34 #24 or #25 or #26 or #27 or #28 or #29 or #30 or #31 or #32 or #33
#35 #23 or #34
MEDLINE Ovid
1. exp Fish Oils/
2. Linseed Oil/
3. linolenic acids/ or alpha-linolenic acid/
4. Flax/
5. exp Fatty Acids, Omega-3/
6. (fish adj3 (diet* or nutrit* or oil* or supplement*)).ti,ab.
7. (oil* adj3 (cod* or marin*)).ti,ab.
8. (omega-3 or omega3 or (omega* adj5 fat*)).ti,ab.
9. eicosapentaen*.ti,ab.
10. docosahexaen*.ti,ab.
11. (oil* adj3 (flax* or rapeseed* or canola*)).ti,ab.
12. (Linolen* or alpha-linolen* or alphalinolen*).ti,ab.
13. (perilla* or linseed* or maxepa*).ti,ab.
14. (oil* adj3 (rape or colza)).ti,ab.
15. (marin* adj3 lipid*).ti,ab.
16. (naudicelle* or herring* or sild).ti,ab.
17. (clupe* adj3 hareng*).ti,ab.
18. (whitebait or sardine* or sardina* or pilchard* or sprat* or brisling*).ti,ab.
19. (salmo* adj3 trut*).ti,ab.
20. (trout or bloater or kipper* or salmon or mackerel* or scomb* or conger* or tuna or tunny or tunafish or tuna-fish).ti,ab.
21. (thunnus* or swordfish* or xiphias* or dogfish or scyliorrhinus* or laks or lax).ti,ab.
22. (crab or crabs or cancer pagarus).ti,ab.
23. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22
24. randomized controlled trial.pt.
25. controlled clinical trial.pt.
26. randomized.ab.
27. placebo.ab.
28. clinical trials as topic.sh.
29. randomly.ab.
30. trial.ti.
31. 24 or 25 or 26 or 27 or 28 or 29 or 30
32. exp animals/ not humans.sh.
33. 31 not 32
34. 23 and 33
35. limit 34 to ed=20020201-20160721
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36. exp salmoniformes/ or tuna/
37. (fish adj3 capsul*).ti,ab.
38. icosapentaen*.ti,ab.
39. docosapentaen*.ti,ab.
40. (oil* adj3 (purslane or mustard* or candlenut* or stillingia or walnut*)).ti,ab.
41. 36 or 37 or 38 or 39 or 40
42. 33 and 41
43. 35 or 42
Embase Ovid
1. exp salmoniformes/ or tuna/
2. fish oil/
3. linseed oil/
4. linolenic acid/
5. Flax/
6. omega 3 fatty acid/
7. (fish adj3 (diet* or nutrit* or oil* or supplement*)).ti,ab.
8. (oil* adj3 (cod* or marin*)).ti,ab.
9. (omega-3 or omega3 or (omega* adj5 fat*)).ti,ab.
10. (eicosapentaen* or icosapentaen*).ti,ab.
11. docosahexaen*.ti,ab.
12. (oil* adj3 (flax* or rapeseed* or canola*)).ti,ab.
13. (Linolen* or alpha-linolen* or alphalinolen*).ti,ab.
14. (perilla* or linseed* or maxepa*).ti,ab.
15. (marin* adj3 lipid*).ti,ab.
16. (naudicelle* or herring* or sild).ti,ab.
17. (clupe* adj3 hareng*).ti,ab.
18. (whitebait or sardine* or sardina* or pilchard* or sprat* or brisling*).ti,ab.
19. (salmo* adj3 trut*).ti,ab.
20. (trout or bloater or kipper* or salmon or mackerel* or scomb* or conger* or tuna or tunny or tunafish or tuna-fish).ti,ab.
21. (thunnus* or swordfish* or xiphias* or dogfish or scyliorrhinus* or laks or lax).ti,ab.
22. (crab or crabs or (cancer adj3 pagarus)).ti,ab.
23. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22
24. random$.tw.
25. placebo$.tw.
26. (doubl$ adj blind$).tw.
27. (singl$ adj blind$).tw.
28. double blind procedure/
29. randomized controlled trial/
30. single blind procedure/
31. 24 or 25 or 26 or 27 or 28 or 29 or 30
32. (animal/ or nonhuman/) not human/
33. 31 not 32
34. 23 and 33
35. (2002* or 2003* or 2004* or 2005* or 2006* or 2007* or 2008* or 2009* or 2010* or 2011* or 2012* or 2013* or 2014* or
2015* or 2016*).dd,em.
36. 34 and 35
37. exp salmonine/
38. (fish adj3 capsul*).ti,ab.
39. docosapentaen*.ti,ab.
40. (ALA or DHA or DPA or EPA).ti,ab.
41. (algal adj oil*).ti,ab.
42. 37 or 38 or 39 or 40 or 41
43. 33 and 42
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44. 36 or 43
Appendix 3. Searches run in April 2017 for allied reviews
These searches were developed and run to collect relevant trials for the systematic reviews on omega-6 fats (the update of Hooper
2018) and on total PUFA fats (Abdelhamid 2018) on health. They are shown here as these searches were run with the searches for
this review, the identified titles and abstracts de-duplicated and combined, so that we assessed titles and abstracts for all three reviews
together. These searches were each run from database inception, due to the widening of the inclusion criteria, then de-duplicated with
each other. The RCT filter for MEDLINE is the Cochrane sensitivity and precision-maximising RCT filter, and for Embase, terms as
recommended in the Cochrane Handbook have been applied (Lefebvre 2011).
CENTRAL
#1 MeSH descriptor: [Fatty Acids, Essential] explode all trees
#2 MeSH descriptor: [Fatty Acids, Unsaturated] this term only
#3 ((polyunsaturat* or poly-unsaturat*) near/3 fat*)
#4 (poly* adj4 unsat* near/4 fatty acid*)
#5 PUFA
#6 MeSH descriptor: [Fatty Acids, Omega-6] explode all trees
#7 omega-6
#8 (n-6 near/4 acid*) or (“n 6” near/4 acid*)
#9 linoleic acid*
#10 MeSH descriptor: [Corn Oil] this term only
#11 MeSH descriptor: [Cottonseed Oil] this term only
#12 MeSH descriptor: [Olive Oil] this term only
#13 MeSH descriptor: [Safflower Oil] this term only
#14 MeSH descriptor: [Sesame Oil] this term only
#15 MeSH descriptor: [Soybean Oil] this term only
#16 ((corn or maize or mazola) near/4 oil*)
#17 (cottonseed* or (cotton next seed*))
#18 (olive near/4 oil*)
#19 (safflower near/4 oil*)
#20 (sesame near/4 oil*)
#21 ((soy bean or soybean) near/4 (oil* or fat*))
#22 (so?a near/4 oil*)
#23 so?aoil*
#24 (soy near/4 oil*)
#25 (sunflower near/4 oil*)
#26 helianth*
#27 (grapeseed near/4 oil*)
#28 (canola near/4 oil*)
#29 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #
20 or #21 or #22 or #23 or #24 or #25 or #26 or #27 or #28
MEDLINE Ovid
1. exp fatty acids, essential/
2. fatty acids, unsaturated/
3. ((polyunsaturat* or poly-unsaturat*) adj3 fat*).ti,ab.
4. (poly* adj4 unsat* adj4 fatty acid*).ti,ab.
5. PUFA.ti,ab.
6. exp fatty acids, omega-6/
7. omega-6.ti,ab.
8. (n-6 adj4 acid*).ti,ab.
9. linoleic acid*.ti,ab.
10. corn oil/ or cottonseed oil/ or olive oil/ or safflower oil/ or sesame oil/ or soybean oil/
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11. ((corn or maize or mazola) adj4 oil*).ti,ab.
12. (cottonseed* or (cotton adj seed*)).ti,ab.
13. (olive adj4 oil*).ti,ab.
14. (safflower adj4 oil*).ti,ab.
15. (sesame adj4 oil*).ti,ab.
16. ((soy bean or soybean) adj4 (oil* or fat*)).ti,ab.
17. (so?a adj4 oil*).ti,ab.
18. so?aoil*.ti,ab.
19. (soy adj4 oil*).ti,ab.
20. (sunflower adj4 oil*).ti,ab.
21. helianth*.ti,ab.
22. (grapeseed adj4 oil*).ti,ab.
23. (canola adj4 oil*).ti,ab.
24. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23
25. randomized controlled trial.pt.
26. controlled clinical trial.pt.
27. randomized.ab.
28. placebo.ab.
29. clinical trials as topic.sh.
30. randomly.ab.
31. trial.ti.
32. 25 or 26 or 27 or 28 or 29 or 30 or 31
33. exp animals/ not humans.sh.
34. 32 not 33
35. 24 and 34
Embase Ovid
1. exp essential fatty acid/
2. unsaturated fatty acid/ or docosapentaenoic acid/ or omega 6 fatty acid/ or polyunsaturated fatty acid/
3. ((polyunsaturat* or poly-unsaturat*) adj3 fat*).ti,ab.
4. (poly* adj4 unsat* adj4 fatty acid*).ti,ab.
5. PUFA.ti,ab.
6. omega-6.ti,ab.
7. (n-6 adj4 acid*).ti,ab.
8. linoleic acid*.ti,ab.
9. edible oil/ or canola oil/ or corn oil/ or cotton seed oil/ or olive oil/ or safflower oil/ or safflower oil plus soybean oil/ or sesame seed
oil/ or soybean oil/ or sunflower oil/
10. ((corn or maize or mazola) adj4 oil*).ti,ab.
11. (cottonseed* or (cotton adj seed*)).ti,ab.
12. (olive adj4 oil*).ti,ab.
13. (safflower adj4 oil*).ti,ab.
14. (sesame adj4 oil*).ti,ab.
15. ((soy bean or soybean) adj4 (oil* or fat*)).ti,ab.
16. (so?a adj4 oil*).ti,ab.
17. so?aoil*.ti,ab.
18. (soy adj4 oil*).ti,ab.
19. (sunflower adj4 oil*).ti,ab.
20. helianth*.ti,ab.
21. (grapeseed adj4 oil*).ti,ab.
22. (canola adj4 oil*).ti,ab.
23. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22
24. double blind procedure/
25. single blind procedure/
26. randomized controlled trial/
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27. ((double* or single*) adj blind*).ti,ab.
28. (random* or placebo*).ti,ab.
29. 24 or 25 or 26 or 27 or 28
30. (animal/ or nonhuman/) not human/
31. 29 not 30
32. 23 and 31
WH A T ’ S N E W
Last assessed as up-to-date: 27 April 2017.
Date Event Description
13 March 2018 New citation required and conclusions have changed This update now reports arrhythmia (atrial fibrillation)
and cardiovascular mortality data. Data now included
from 79 RCTs (112,059 participants) lasting at least one
year, of which 25 were at low summary risk of bias
We added the following outcomes to the list of primary
outcomes upon the request of World Health Organiza-
tion (WHO) Nutrition Guidance Expert Advisory Group
(NUGAG) Subgroup on Diet and Health
1. Cardiovascular mortality.
2. Arrhyhtmia (new and recurrent).
We altered inclusion criteria to include only RCTs of at
least 12 months’ duration (rather than 6 months as previ-
ously), and we excluded cohort studies
We are assessing effects of long-chain omega-3 fats sepa-
rately from effects of alpha-linolenic acid (as planned in
the previously published version)
27 April 2017 New search has been performed Electronic searches updated to 27 April 2017
H I S T O R Y
Protocol first published: Issue 2, 1999
Review first published: Issue 4, 2004
Date Event Description
14 March 2012 Amended Additional tables re-numbered
16 October 2011 New search has been performed Searches updated to July 2011.
Cohort studies not included in this update, and previ-
ously included cohort studies and related text have been
removed
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(Continued)
Previously included trials where we know that no deaths
or primary or secondary health events occurred were
removed
New secondary outcomes added (fatal and non-fatal
arrhythmias, and diabetes)
Cardiovascular mortality added as a primary outcome.
9 September 2008 Amended Converted to new review format.
1 August 2004 New citation required and conclusions have changed Substantive amendment
C O N T R I B U T I O N S O F A U T H O R S
LH and CDS conceived and led the original version of this review; LH, CDS, HM and HVW were authors of the original version of
this review. LH designed the searches, and CB developed, refined, ran and de-duplicated them. ASA, TJB, JSB, PB, GCT, KHOD,
HVW, FS and LH screened titles and abstracts; ASA, JSB, PB, GCT and LH assessed full-text papers for inclusion; LH, PB and JSB
searched trials registers and assessed entries for inclusion; LH and ASA located full texts, managed assessment and collection of titles,
abstracts and full texts, data extraction and risk of bias assessment. All authors carried out data extraction and assessed risk of bias. LH,
KHOD and JSB designed risk of bias assessment; JSB, KHOD, TJB, ASA and LH wrote to study authors; LH, KHOD, JSB, TJB and
ASA carried out data checks; JSB, TJB, LH and ASA tabulated intake and status data. FS, KHOD, JSB, HVW, CDS and LH provided
methodological support. ASA, FKA and LH entered data into RevMan and ran meta-analyses, ASA and LH carried out sensitivity
and subgroup analyses, and LH the meta-regression. ASA wrote the first draft of the review and LH the WHO NUGAG Subgroup
on Diet and Health report; both carried out GRADE assessment and interpretation. All authors critically read and commented on the
final draft and agreed on it for submission.
D E C L A R A T I O N S O F I N T E R E S T
ASA: none known.
TJB: none known.
JSB: none known.
PB: none known.
GCT: none known.
HJM: none known.
KHOD: none known.
FKA: none known.
CDS: none known.
HVW: none known.
FS: none known.
LH: none known.
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S O U R C E S O F S U P P O R T
Internal sources
• University of East Anglia, UK.
• Cochrane Heart Group, UK.
This project was supported by the National Institute for Health Research, via Cochrane Infrastructure funding to the Heart Group.
The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the Systematic Reviews
Programme, NIHR, NHS or the Department of Health, UK
External sources
• World Health Organization nutrition guidance expert advisory group (NUGAG), Not specified.
WHO NUGAG Subgroup on Diet and Health requested and funded the update and extension of this review.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Differences between the previous version of this review (2004) and this update (2018):
• Authors altered. The Acknowledgments recognise authors of the previous version who chose not to participate in this update.
• Background updated.
• Objectives: primary objective altered from ’Do dietary or supplemental omega-3 fatty acids alter total mortality, cardiovascular
events, cancers or other adverse events?’ to ’Do long-chain omega-3 (LCn3, fish-based omega-3 fats) or ALA (plant-based omega-3
fats) fats alter risk of all-cause mortality, cardiovascular deaths, cardiovascular events, coronary heart disease deaths, coronary heart
disease events, stroke, arrhythmia, adiposity and lipids?’ This change in emphasis, which we anticipated in the original review, focuses
on long-chain omega-3 fats (EPA, DHA, DPA) and ALA separately. We discuss changes in outcomes assessed below.
• Secondary questions: we added assessment of effects of omega-3 fats (including both LCn3 and ALA) as a secondary question.
• Types of studies included: included RCTs had to be at least one year in duration in the update (the limit was six months in the
original review). We excluded cohort studies from the update.
• Types of outcomes: primary outcomes assessed were updated, removing cancers and adverse events as primary outcomes and
adding cardiovascular deaths, coronary heart disease deaths and events, stroke and arrhythmia (atrial fibrillation) as primary
outcomes. Adiposity and lipids were added as key secondary outcomes. Cancer outcomes and other non-cardiovascular outcomes,
including diabetes, were assessed in separate reviews (Abdelhamid 2018; Abdelhamid 2017; Brown 2017; Hanson 2017a; Hanson
2017b; Jimoh 2017; Thorpe 2017).
• Secondary outcomes: we added new secondary outcomes (major adverse cardiac or cerebrovascular events (MACCEs),
myocardial infarction, sudden cardiac death, angina, heart failure, peripheral arterial disease, re-vascularisation and acute coronary
syndrome). Blood pressure (a secondary outcome in the original review) became a tertiary outcome in the update. We dropped
urinary thromboxane and participant fatty acid data as secondary outcomes but collected fatty acid data to help assess compliance.
• Risk of bias: we updated this review to incorporate the Cochrane ’Risk of bias’ tool (for all included studies). We slightly
updated our assessment of summary risk of bias from low summary risk when “allocation concealment was adequate, and participant,
provider and outcome assessor blinding were all coded ’yes”’ to low summary risk for a supplement or capsule type trial where “we
judged randomisation, allocation concealment, blinding of participants and personnel, and blinding of outcome assessors to be
adequate” and for a dietary advice or all-food provided type trial where “we judged randomisation, allocation concealment, and
blinding of outcome assessors to be adequate”.
• Subgroup analyses: in the update we carried out separate subgroup analyses for LCn3 and ALA studies. Subgrouping in the
update was as in the original review (by dose, dietary or supplemental source and trial duration), with the addition of some new
subgroups. We added new subgroup analyses at the request of the WHO NUGAG Subgroup on Diet and Health.
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◦ Replacement of SFA, MUFA, omega-6 fats, fat mixture, carbohydrates or sugars, non-fat or no placebo (or unclear) by
LCn3 or ALA.
◦ Primary prevention versus secondary prevention of CVD.
◦ Statin use (< 50% of control group on statins, ≥ 50% of control group on statins, use of statins unclear).
◦ Baseline LCn3 or ALA intake.
• Sensitivity analyses: updated for this review. Limiting analyses to studies at low summary risk of bias was continued in the
update from the original review, and we added sensitivity analyses by study size (retaining only trials that randomised at least 100
participants across all study arms), fixed-effect meta-analysis and compliance (retaining only studies at low risk of compliance bias,
this latter at the request of WHO NUGAG Subgroup on Diet and Health).
• Heterogeneity: the original review used Cochran’s test while the update used I2. This reflects current best methodology.
I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Dietary Supplements; Cardiovascular Diseases [∗diet therapy; mortality; prevention & control]; Fatty Acids, Omega-3 [∗therapeutic
use]; Randomized Controlled Trials as Topic
MeSH check words
Humans
730Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
